{"doc_id": "10048291_1", "wnd_id": "10048291_1_1", "text": "Immobilization , while Paget 's bone disease was present , and perhaps enhanced activation of dihydrotachysterol by rifampicin , could have led to increased calcium - release into the circulation .", "tokens": ["Immobilization", ",", "while", "Paget", "'s", "bone", "disease", "was", "present", ",", "and", "perhaps", "enhanced", "activation", "of", "dihydrotachysterol", "by", "rifampicin", ",", "could", "have", "led", "to", "increased", "calcium", "-", "release", "into", "the", "circulation", "."], "event_mentions": [{"id": "10048291_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "led", "start": 21, "end": 22}, "arguments": [{"entity_id": "10048291_1_Ent1", "role": "Treatment", "text": "dihydrotachysterol", "start": 15, "end": 16}, {"entity_id": "10048291_1_Ent2", "role": "Treatment_Drug", "text": "dihydrotachysterol", "start": 15, "end": 16}, {"entity_id": "10048291_1_Ent0", "role": "Effect", "text": "increased calcium - release", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "10048291_1_Ent1", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10048291_1_Ent2", "text": "dihydrotachysterol", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10048291_1_Ent0", "text": "increased calcium - release", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "10084639_1", "wnd_id": "10084639_1_1", "text": "BACKGROUND : How to best treat psychotic patients who have had past clozapine - induced agranulocytosis or granulocytopenia remains a problem .", "tokens": ["BACKGROUND", ":", "How", "to", "best", "treat", "psychotic", "patients", "who", "have", "had", "past", "clozapine", "-", "induced", "agranulocytosis", "or", "granulocytopenia", "remains", "a", "problem", "."], "event_mentions": [{"id": "10084639_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "10084639_1_Ent4", "role": "Treatment_Disorder", "text": "psychotic", "start": 6, "end": 7}, {"entity_id": "10084639_1_Ent0", "role": "Subject", "text": "psychotic patients", "start": 6, "end": 8}, {"entity_id": "10084639_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "10084639_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "10084639_1_Ent1", "role": "Effect", "text": "agranulocytosis or granulocytopenia", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "10084639_1_Ent4", "text": "psychotic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10084639_1_Ent0", "text": "psychotic patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10084639_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10084639_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10084639_1_Ent1", "text": "agranulocytosis or granulocytopenia", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "10102531_1", "wnd_id": "10102531_1_1", "text": "This case suggests that BH - AC , a derivative of cytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible encephalopathy syndrome .", "tokens": ["This", "case", "suggests", "that", "BH", "-", "AC", ",", "a", "derivative", "of", "cytosine", "arabinoside", "(", "1", "-", "beta", "-", "D", "-", "arabinofuranosylcytosine", ")", "could", "be", "a", "cause", "of", "reversible", "encephalopathy", "syndrome", "."], "event_mentions": [{"id": "10102531_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 25, "end": 26}, "arguments": [{"entity_id": "10102531_1_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "10102531_1_Ent3", "role": "Treatment_Drug", "text": "BH - AC", "start": 4, "end": 7}, {"entity_id": "10102531_1_Ent2", "role": "Treatment", "text": "BH - AC , a derivative of cytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine )", "start": 4, "end": 22}, {"entity_id": "10102531_1_Ent1", "role": "Effect", "text": "reversible encephalopathy syndrome", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "10102531_1_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10102531_1_Ent3", "text": "BH - AC", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "10102531_1_Ent2", "text": "BH - AC , a derivative of cytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine )", "entity_type": "Entity", "start": 4, "end": 22}, {"id": "10102531_1_Ent1", "text": "reversible encephalopathy syndrome", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "10190739_2", "wnd_id": "10190739_2_1", "text": "We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks , respectively .", "tokens": ["We", "report", "the", "cases", "of", "two", "patients", "who", "developed", "acute", "hepatitis", "after", "taking", "riluzole", "at", "the", "recommended", "dose", "(", "100", "mg", "daily", ")", "for", "7", "and", "4", "weeks", ",", "respectively", "."], "event_mentions": [{"id": "10190739_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 12, "end": 13}, "arguments": [{"entity_id": "10190739_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "10190739_2_Ent0", "role": "Subject", "text": "two patients", "start": 5, "end": 7}, {"entity_id": "10190739_2_Ent2", "role": "Effect", "text": "acute hepatitis", "start": 9, "end": 11}, {"entity_id": "10190739_2_Ent4", "role": "Treatment_Drug", "text": "riluzole", "start": 13, "end": 14}, {"entity_id": "10190739_2_Ent3", "role": "Treatment", "text": "riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks", "start": 13, "end": 28}, {"entity_id": "10190739_2_Ent6", "role": "Treatment_Dosage", "text": "100 mg", "start": 19, "end": 21}, {"entity_id": "10190739_2_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 21, "end": 22}, {"entity_id": "10190739_2_Ent5", "role": "Treatment_Duration", "text": "7 and 4 weeks", "start": 24, "end": 28}]}], "entity_mentions": [{"id": "10190739_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10190739_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10190739_2_Ent2", "text": "acute hepatitis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10190739_2_Ent4", "text": "riluzole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10190739_2_Ent3", "text": "riluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks", "entity_type": "Entity", "start": 13, "end": 28}, {"id": "10190739_2_Ent6", "text": "100 mg", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "10190739_2_Ent7", "text": "daily", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10190739_2_Ent5", "text": "7 and 4 weeks", "entity_type": "Entity", "start": 24, "end": 28}], "lang": "en"}
{"doc_id": "10225085_2", "wnd_id": "10225085_2_1", "text": "Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field .", "tokens": ["Methemoglobinemia", "after", "axillary", "block", "with", "bupivacaine", "and", "additional", "injection", "of", "lidocaine", "in", "the", "operative", "field", "."], "event_mentions": [{"id": "10225085_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 1, "end": 2}, "arguments": [{"entity_id": "10225085_2_Ent0", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "10225085_2_Ent1", "role": "Treatment", "text": "axillary block with bupivacaine and additional injection of lidocaine in the operative field", "start": 2, "end": 15}, {"entity_id": "10225085_2_Ent3", "role": "Treatment_Drug", "text": "bupivacaine", "start": 5, "end": 6}, {"entity_id": "10225085_2_Ent6", "role": "Combination_Drug", "text": "bupivacaine", "start": 5, "end": 6}, {"entity_id": "10225085_2_Ent2", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}, {"entity_id": "10225085_2_Ent4", "role": "Treatment_Drug", "text": "lidocaine", "start": 10, "end": 11}, {"entity_id": "10225085_2_Ent5", "role": "Combination_Drug", "text": "lidocaine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10225085_2_Ent0", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10225085_2_Ent1", "text": "axillary block with bupivacaine and additional injection of lidocaine in the operative field", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "10225085_2_Ent3", "text": "bupivacaine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10225085_2_Ent6", "text": "bupivacaine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10225085_2_Ent2", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10225085_2_Ent4", "text": "lidocaine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10225085_2_Ent5", "text": "lidocaine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10332990_1", "wnd_id": "10332990_1_1", "text": "Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma .", "tokens": ["Pulmonary", "edema", "during", "acute", "infusion", "of", "epoprostenol", "in", "a", "patient", "with", "pulmonary", "hypertension", "and", "limited", "scleroderma", "."], "event_mentions": [{"id": "10332990_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "10332990_1_Ent3", "role": "Treatment_Route", "text": "acute infusion", "start": 3, "end": 5}, {"entity_id": "10332990_1_Ent1", "role": "Treatment", "text": "acute infusion of epoprostenol", "start": 3, "end": 7}, {"entity_id": "10332990_1_Ent2", "role": "Treatment_Drug", "text": "epoprostenol", "start": 6, "end": 7}, {"entity_id": "10332990_1_Ent0", "role": "Subject", "text": "a patient with pulmonary hypertension and limited scleroderma", "start": 8, "end": 16}, {"entity_id": "10332990_1_Ent4", "role": "Treatment_Disorder", "text": "pulmonary hypertension and limited scleroderma", "start": 11, "end": 16}]}], "entity_mentions": [{"id": "10332990_1_Ent3", "text": "acute infusion", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10332990_1_Ent1", "text": "acute infusion of epoprostenol", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "10332990_1_Ent2", "text": "epoprostenol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10332990_1_Ent0", "text": "a patient with pulmonary hypertension and limited scleroderma", "entity_type": "Entity", "start": 8, "end": 16}, {"id": "10332990_1_Ent4", "text": "pulmonary hypertension and limited scleroderma", "entity_type": "Entity", "start": 11, "end": 16}], "lang": "en"}
{"doc_id": "10332990_2", "wnd_id": "10332990_2_1", "text": "Epoprostenol ( prostacyclin ) is currently approved for treatment of primary pulmonary hypertension ; however , it is being evaluated in other forms of pulmonary hypertension , particularly scleroderma .", "tokens": ["Epoprostenol", "(", "prostacyclin", ")", "is", "currently", "approved", "for", "treatment", "of", "primary", "pulmonary", "hypertension", ";", "however", ",", "it", "is", "being", "evaluated", "in", "other", "forms", "of", "pulmonary", "hypertension", ",", "particularly", "scleroderma", "."], "event_mentions": [{"id": "10332990_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "10332990_2_Ent1", "role": "Treatment_Drug", "text": "Epoprostenol", "start": 0, "end": 1}, {"entity_id": "10332990_2_Ent0", "role": "Treatment", "text": "Epoprostenol ( prostacyclin )", "start": 0, "end": 4}, {"entity_id": "10332990_2_Ent2", "role": "Treatment_Drug", "text": "prostacyclin", "start": 2, "end": 3}, {"entity_id": "10332990_2_Ent3", "role": "Treatment_Disorder", "text": "primary pulmonary hypertension", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "10332990_2_Ent1", "text": "Epoprostenol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10332990_2_Ent0", "text": "Epoprostenol ( prostacyclin )", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10332990_2_Ent2", "text": "prostacyclin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10332990_2_Ent3", "text": "primary pulmonary hypertension", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "10357715_3", "wnd_id": "10357715_3_1", "text": "The present observation suggests , that a batch of different testing doses , including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol .", "tokens": ["The", "present", "observation", "suggests", ",", "that", "a", "batch", "of", "different", "testing", "doses", ",", "including", "lower", "testing", "doses", "may", "help", "to", "differentiate", "between", "an", "allergic", "type", "of", "contact", "dermatitis", "and", "an", "irritant", "type", "of", "reaction", "after", "treatment", "with", "calcipotriol", "."], "event_mentions": [{"id": "10357715_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after treatment", "start": 34, "end": 36}, "arguments": [{"entity_id": "10357715_3_Ent0", "role": "Effect", "text": "an allergic type of contact dermatitis", "start": 22, "end": 28}, {"entity_id": "10357715_3_Ent1", "role": "Effect", "text": "an irritant type of reaction", "start": 29, "end": 34}, {"entity_id": "10357715_3_Ent2", "role": "Treatment", "text": "calcipotriol", "start": 37, "end": 38}, {"entity_id": "10357715_3_Ent3", "role": "Treatment_Drug", "text": "calcipotriol", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "10357715_3_Ent0", "text": "an allergic type of contact dermatitis", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "10357715_3_Ent1", "text": "an irritant type of reaction", "entity_type": "Entity", "start": 29, "end": 34}, {"id": "10357715_3_Ent2", "text": "calcipotriol", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "10357715_3_Ent3", "text": "calcipotriol", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "10395123_3", "wnd_id": "10395123_3_1", "text": "The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment .", "tokens": ["The", "objective", "of", "this", "report", "is", "to", "describe", "a", "case", "of", "fixed", "drug", "eruption", "that", "occurred", "during", "omeprazole", "treatment", "."], "event_mentions": [{"id": "10395123_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 15, "end": 16}, "arguments": [{"entity_id": "10395123_3_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 11, "end": 14}, {"entity_id": "10395123_3_Ent1", "role": "Treatment", "text": "during omeprazole treatment", "start": 16, "end": 19}, {"entity_id": "10395123_3_Ent2", "role": "Treatment_Drug", "text": "omeprazole", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10395123_3_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10395123_3_Ent1", "text": "during omeprazole treatment", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "10395123_3_Ent2", "text": "omeprazole", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10431414_3", "wnd_id": "10431414_3_1", "text": "The association between heparin and priapism is often recognized ; abnormal platelet aggregation could play a role in the pathogenesis of this side effect .", "tokens": ["The", "association", "between", "heparin", "and", "priapism", "is", "often", "recognized", ";", "abnormal", "platelet", "aggregation", "could", "play", "a", "role", "in", "the", "pathogenesis", "of", "this", "side", "effect", "."], "event_mentions": [{"id": "10431414_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "10431414_3_Ent1", "role": "Treatment", "text": "heparin", "start": 3, "end": 4}, {"entity_id": "10431414_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 3, "end": 4}, {"entity_id": "10431414_3_Ent0", "role": "Effect", "text": "priapism", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "10431414_3_Ent1", "text": "heparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10431414_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10431414_3_Ent0", "text": "priapism", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "10435399_1", "wnd_id": "10435399_1_1", "text": "It carries a well - known risk of neutropenia and agranulocytosis , which necessitates the immediate discontinuation of clozapine .", "tokens": ["It", "carries", "a", "well", "-", "known", "risk", "of", "neutropenia", "and", "agranulocytosis", ",", "which", "necessitates", "the", "immediate", "discontinuation", "of", "clozapine", "."], "event_mentions": [{"id": "10435399_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 6, "end": 7}, "arguments": [{"entity_id": "10435399_1_Ent0", "role": "Effect", "text": "neutropenia and agranulocytosis", "start": 8, "end": 11}, {"entity_id": "10435399_1_Ent1", "role": "Treatment", "text": "clozapine", "start": 18, "end": 19}, {"entity_id": "10435399_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10435399_1_Ent0", "text": "neutropenia and agranulocytosis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10435399_1_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10435399_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10442258_1", "wnd_id": "10442258_1_1", "text": "Hair loss associated with paroxetine treatment : a case report .", "tokens": ["Hair", "loss", "associated", "with", "paroxetine", "treatment", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10442258_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10442258_1_Ent1", "role": "Effect", "text": "Hair loss", "start": 0, "end": 2}, {"entity_id": "10442258_1_Ent2", "role": "Treatment", "text": "paroxetine", "start": 4, "end": 5}, {"entity_id": "10442258_1_Ent3", "role": "Treatment_Drug", "text": "paroxetine", "start": 4, "end": 5}, {"entity_id": "10442258_1_Ent0", "role": "Subject", "text": "a case", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "10442258_1_Ent1", "text": "Hair loss", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10442258_1_Ent2", "text": "paroxetine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10442258_1_Ent3", "text": "paroxetine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10442258_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "10442258_5", "wnd_id": "10442258_5_1", "text": "Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine .", "tokens": ["Findings", "on", "discontinuation", "and", "rechallenge", "supported", "the", "assumption", "that", "the", "hair", "loss", "was", "a", "side", "effect", "of", "the", "paroxetine", "."], "event_mentions": [{"id": "10442258_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effect", "start": 14, "end": 16}, "arguments": [{"entity_id": "10442258_5_Ent0", "role": "Effect", "text": "hair loss", "start": 10, "end": 12}, {"entity_id": "10442258_5_Ent2", "role": "Treatment_Drug", "text": "paroxetine", "start": 18, "end": 19}, {"entity_id": "10442258_5_Ent1", "role": "Treatment", "text": "paroxetine .", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "10442258_5_Ent0", "text": "hair loss", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10442258_5_Ent2", "text": "paroxetine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "10442258_5_Ent1", "text": "paroxetine .", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "10452772_4", "wnd_id": "10452772_4_1", "text": "Patients receiving neutral protamine Hagedorn ( NPH ) insulin are at increased risk for the development of protamine hypersensitivity .", "tokens": ["Patients", "receiving", "neutral", "protamine", "Hagedorn", "(", "NPH", ")", "insulin", "are", "at", "increased", "risk", "for", "the", "development", "of", "protamine", "hypersensitivity", "."], "event_mentions": [{"id": "10452772_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "10452772_4_Ent0", "role": "Subject", "text": "Patients", "start": 0, "end": 1}, {"entity_id": "10452772_4_Ent2", "role": "Treatment", "text": "neutral protamine Hagedorn ( NPH ) insulin", "start": 2, "end": 9}, {"entity_id": "10452772_4_Ent3", "role": "Treatment_Drug", "text": "neutral protamine Hagedorn ( NPH ) insulin", "start": 2, "end": 9}, {"entity_id": "10452772_4_Ent1", "role": "Effect", "text": "protamine hypersensitivity", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "10452772_4_Ent0", "text": "Patients", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10452772_4_Ent2", "text": "neutral protamine Hagedorn ( NPH ) insulin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "10452772_4_Ent3", "text": "neutral protamine Hagedorn ( NPH ) insulin", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "10452772_4_Ent1", "text": "protamine hypersensitivity", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "10452772_5", "wnd_id": "10452772_5_1", "text": "Protamine allergy as a complication of insulin hypersensitivity : A case report .", "tokens": ["Protamine", "allergy", "as", "a", "complication", "of", "insulin", "hypersensitivity", ":", "A", "case", "report", "."], "event_mentions": [{"id": "10452772_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "10452772_5_Ent1", "role": "Effect", "text": "Protamine allergy", "start": 0, "end": 2}, {"entity_id": "10452772_5_Ent2", "role": "Treatment", "text": "insulin", "start": 6, "end": 7}, {"entity_id": "10452772_5_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 6, "end": 7}, {"entity_id": "10452772_5_Ent0", "role": "Effect", "text": "hypersensitivity", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "10452772_5_Ent1", "text": "Protamine allergy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10452772_5_Ent2", "text": "insulin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10452772_5_Ent3", "text": "insulin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10452772_5_Ent0", "text": "hypersensitivity", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "10456487_15", "wnd_id": "10456487_15_1", "text": "Whether concomitant fluvoxamine treatment reduces tacrine - induced hepatotoxicity needs further study .", "tokens": ["Whether", "concomitant", "fluvoxamine", "treatment", "reduces", "tacrine", "-", "induced", "hepatotoxicity", "needs", "further", "study", "."], "event_mentions": [{"id": "10456487_15_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "reduces", "start": 4, "end": 5}, "arguments": [{"entity_id": "10456487_15_Ent3", "role": "Treatment", "text": "concomitant fluvoxamine", "start": 1, "end": 3}, {"entity_id": "10456487_15_Ent5", "role": "Treatment_Drug", "text": "fluvoxamine", "start": 2, "end": 3}, {"entity_id": "10456487_15_Ent4", "role": "Treatment_Disorder", "text": "tacrine - induced hepatotoxicity", "start": 5, "end": 9}]}, {"id": "10456487_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "10456487_15_Ent1", "role": "Treatment", "text": "tacrine", "start": 5, "end": 6}, {"entity_id": "10456487_15_Ent2", "role": "Treatment_Drug", "text": "tacrine", "start": 5, "end": 6}, {"entity_id": "10456487_15_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "10456487_15_Ent3", "text": "concomitant fluvoxamine", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10456487_15_Ent5", "text": "fluvoxamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10456487_15_Ent1", "text": "tacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10456487_15_Ent2", "text": "tacrine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10456487_15_Ent4", "text": "tacrine - induced hepatotoxicity", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10456487_15_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "10456487_3", "wnd_id": "10456487_3_1", "text": "One of the monohydroxy - metabolites has been incriminated with tacrine - induced hepatotoxicity .", "tokens": ["One", "of", "the", "monohydroxy", "-", "metabolites", "has", "been", "incriminated", "with", "tacrine", "-", "induced", "hepatotoxicity", "."], "event_mentions": [{"id": "10456487_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "10456487_3_Ent1", "role": "Treatment", "text": "tacrine", "start": 10, "end": 11}, {"entity_id": "10456487_3_Ent2", "role": "Treatment_Drug", "text": "tacrine", "start": 10, "end": 11}, {"entity_id": "10456487_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10456487_3_Ent1", "text": "tacrine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10456487_3_Ent2", "text": "tacrine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10456487_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10458196_2", "wnd_id": "10458196_2_1", "text": "An 11 - day - old infant became lethargic and apneic after a single drop of brimonidine .", "tokens": ["An", "11", "-", "day", "-", "old", "infant", "became", "lethargic", "and", "apneic", "after", "a", "single", "drop", "of", "brimonidine", "."], "event_mentions": [{"id": "10458196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 7, "end": 8}, "arguments": [{"entity_id": "10458196_2_Ent0", "role": "Subject", "text": "An 11 - day - old infant", "start": 0, "end": 7}, {"entity_id": "10458196_2_Ent1", "role": "Subject_Age", "text": "11 - day - old", "start": 1, "end": 6}, {"entity_id": "10458196_2_Ent2", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}, {"entity_id": "10458196_2_Ent3", "role": "Effect", "text": "lethargic and apneic", "start": 8, "end": 11}, {"entity_id": "10458196_2_Ent4", "role": "Treatment", "text": "a single drop of brimonidine", "start": 12, "end": 17}, {"entity_id": "10458196_2_Ent5", "role": "Treatment_Dosage", "text": "single drop", "start": 13, "end": 15}, {"entity_id": "10458196_2_Ent6", "role": "Treatment_Drug", "text": "brimonidine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "10458196_2_Ent0", "text": "An 11 - day - old infant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10458196_2_Ent1", "text": "11 - day - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10458196_2_Ent2", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10458196_2_Ent3", "text": "lethargic and apneic", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10458196_2_Ent4", "text": "a single drop of brimonidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "10458196_2_Ent5", "text": "single drop", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "10458196_2_Ent6", "text": "brimonidine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "10458196_4", "wnd_id": "10458196_4_1", "text": "CONCLUSIONS : Topical brimonidine may be associated with central nervous system depression in infants .", "tokens": ["CONCLUSIONS", ":", "Topical", "brimonidine", "may", "be", "associated", "with", "central", "nervous", "system", "depression", "in", "infants", "."], "event_mentions": [{"id": "10458196_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "10458196_4_Ent5", "role": "Treatment_Route", "text": "Topical", "start": 2, "end": 3}, {"entity_id": "10458196_4_Ent3", "role": "Treatment", "text": "Topical brimonidine", "start": 2, "end": 4}, {"entity_id": "10458196_4_Ent4", "role": "Treatment_Drug", "text": "brimonidine", "start": 3, "end": 4}, {"entity_id": "10458196_4_Ent2", "role": "Effect", "text": "central nervous system depression", "start": 8, "end": 12}, {"entity_id": "10458196_4_Ent0", "role": "Subject", "text": "infants", "start": 13, "end": 14}, {"entity_id": "10458196_4_Ent1", "role": "Subject_Age", "text": "infants", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10458196_4_Ent5", "text": "Topical", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10458196_4_Ent3", "text": "Topical brimonidine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10458196_4_Ent4", "text": "brimonidine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10458196_4_Ent2", "text": "central nervous system depression", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "10458196_4_Ent0", "text": "infants", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10458196_4_Ent1", "text": "infants", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10458196_5", "wnd_id": "10458196_5_1", "text": "PURPOSE : To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant .", "tokens": ["PURPOSE", ":", "To", "report", "two", "cases", "in", "which", "topical", "brimonidine", "resulted", "in", "apparent", "central", "nervous", "system", "depression", "and", "unresponsiveness", "in", "an", "infant", "."], "event_mentions": [{"id": "10458196_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 10, "end": 11}, "arguments": [{"entity_id": "10458196_5_Ent4", "role": "Treatment_Route", "text": "topical", "start": 8, "end": 9}, {"entity_id": "10458196_5_Ent3", "role": "Treatment", "text": "topical brimonidine", "start": 8, "end": 10}, {"entity_id": "10458196_5_Ent5", "role": "Treatment_Drug", "text": "brimonidine", "start": 9, "end": 10}, {"entity_id": "10458196_5_Ent2", "role": "Effect", "text": "apparent central nervous system depression and unresponsiveness", "start": 12, "end": 19}, {"entity_id": "10458196_5_Ent0", "role": "Subject", "text": "an infant", "start": 20, "end": 22}, {"entity_id": "10458196_5_Ent1", "role": "Subject_Age", "text": "infant", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10458196_5_Ent4", "text": "topical", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10458196_5_Ent3", "text": "topical brimonidine", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "10458196_5_Ent5", "text": "brimonidine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10458196_5_Ent2", "text": "apparent central nervous system depression and unresponsiveness", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "10458196_5_Ent0", "text": "an infant", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "10458196_5_Ent1", "text": "infant", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10461415_2", "wnd_id": "10461415_2_1", "text": "Hepato - biliary abnormalities secondary to ceftriaxone use : a case report .", "tokens": ["Hepato", "-", "biliary", "abnormalities", "secondary", "to", "ceftriaxone", "use", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10461415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 4, "end": 6}, "arguments": [{"entity_id": "10461415_2_Ent0", "role": "Effect", "text": "Hepato - biliary abnormalities", "start": 0, "end": 4}, {"entity_id": "10461415_2_Ent2", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 6, "end": 7}, {"entity_id": "10461415_2_Ent1", "role": "Treatment", "text": "ceftriaxone use", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10461415_2_Ent0", "text": "Hepato - biliary abnormalities", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10461415_2_Ent2", "text": "ceftriaxone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10461415_2_Ent1", "text": "ceftriaxone use", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10465148_4", "wnd_id": "10465148_4_1", "text": "Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery .", "tokens": ["Reported", "are", "three", "children", "who", "developed", "progressive", "paraparesis", "after", "intrathecal", "methotrexate", "administration", "followed", "by", "complete", "or", "partial", "recovery", "."], "event_mentions": [{"id": "10465148_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "10465148_4_Ent1", "role": "Subject_Population", "text": "three", "start": 2, "end": 3}, {"entity_id": "10465148_4_Ent0", "role": "Subject", "text": "three children", "start": 2, "end": 4}, {"entity_id": "10465148_4_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "10465148_4_Ent3", "role": "Effect", "text": "paraparesis", "start": 7, "end": 8}, {"entity_id": "10465148_4_Ent6", "role": "Treatment_Route", "text": "intrathecal", "start": 9, "end": 10}, {"entity_id": "10465148_4_Ent4", "role": "Treatment", "text": "intrathecal methotrexate", "start": 9, "end": 11}, {"entity_id": "10465148_4_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "10465148_4_Ent1", "text": "three", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10465148_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10465148_4_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10465148_4_Ent3", "text": "paraparesis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10465148_4_Ent6", "text": "intrathecal", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10465148_4_Ent4", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10465148_4_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "10465148_6", "wnd_id": "10465148_6_1", "text": "The clinical data suggest that anterior lumbosacral radiculopathy is also a type of neurologic complication associated with intrathecal methotrexate treatment .", "tokens": ["The", "clinical", "data", "suggest", "that", "anterior", "lumbosacral", "radiculopathy", "is", "also", "a", "type", "of", "neurologic", "complication", "associated", "with", "intrathecal", "methotrexate", "treatment", "."], "event_mentions": [{"id": "10465148_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "10465148_6_Ent0", "role": "Effect", "text": "anterior lumbosacral radiculopathy", "start": 5, "end": 8}, {"entity_id": "10465148_6_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 17, "end": 18}, {"entity_id": "10465148_6_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 17, "end": 19}, {"entity_id": "10465148_6_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10465148_6_Ent0", "text": "anterior lumbosacral radiculopathy", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10465148_6_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10465148_6_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10465148_6_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10466445_7", "wnd_id": "10466445_7_1", "text": "These data confirm the therapeutic value of arsenic trioxide in relapsed / resistant APL .", "tokens": ["These", "data", "confirm", "the", "therapeutic", "value", "of", "arsenic", "trioxide", "in", "relapsed", "/", "resistant", "APL", "."], "event_mentions": [{"id": "10466445_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapeutic value", "start": 4, "end": 6}, "arguments": [{"entity_id": "10466445_7_Ent0", "role": "Treatment", "text": "arsenic trioxide", "start": 7, "end": 9}, {"entity_id": "10466445_7_Ent1", "role": "Treatment_Disorder", "text": "relapsed / resistant APL", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "10466445_7_Ent0", "text": "arsenic trioxide", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "10466445_7_Ent1", "text": "relapsed / resistant APL", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "10467499_2", "wnd_id": "10467499_2_1", "text": "With the negative viral serologies , the clinical picture was most consistent with an infectious mononucleosis - like syndrome produced by the minocycline ingestion .", "tokens": ["With", "the", "negative", "viral", "serologies", ",", "the", "clinical", "picture", "was", "most", "consistent", "with", "an", "infectious", "mononucleosis", "-", "like", "syndrome", "produced", "by", "the", "minocycline", "ingestion", "."], "event_mentions": [{"id": "10467499_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "produced", "start": 19, "end": 20}, "arguments": [{"entity_id": "10467499_2_Ent0", "role": "Effect", "text": "infectious mononucleosis - like syndrome", "start": 14, "end": 19}, {"entity_id": "10467499_2_Ent3", "role": "Treatment_Drug", "text": "minocycline", "start": 22, "end": 23}, {"entity_id": "10467499_2_Ent1", "role": "Treatment", "text": "minocycline ingestion", "start": 22, "end": 24}, {"entity_id": "10467499_2_Ent2", "role": "Treatment_Route", "text": "ingestion", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10467499_2_Ent0", "text": "infectious mononucleosis - like syndrome", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10467499_2_Ent3", "text": "minocycline", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "10467499_2_Ent1", "text": "minocycline ingestion", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10467499_2_Ent2", "text": "ingestion", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10473079_2", "wnd_id": "10473079_2_1", "text": "We now report the first known cancer patient who developed life - threatening complications after treatment with topical 5 - FU and was shown subsequently to have profound DPD deficiency .", "tokens": ["We", "now", "report", "the", "first", "known", "cancer", "patient", "who", "developed", "life", "-", "threatening", "complications", "after", "treatment", "with", "topical", "5", "-", "FU", "and", "was", "shown", "subsequently", "to", "have", "profound", "DPD", "deficiency", "."], "event_mentions": [{"id": "10473079_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "10473079_2_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 6, "end": 7}, {"entity_id": "10473079_2_Ent0", "role": "Subject", "text": "cancer patient", "start": 6, "end": 8}, {"entity_id": "10473079_2_Ent1", "role": "Effect", "text": "life - threatening complications", "start": 10, "end": 14}, {"entity_id": "10473079_2_Ent6", "role": "Treatment_Route", "text": "topical", "start": 17, "end": 18}, {"entity_id": "10473079_2_Ent3", "role": "Treatment", "text": "topical 5 - FU", "start": 17, "end": 21}, {"entity_id": "10473079_2_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 18, "end": 21}, {"entity_id": "10473079_2_Ent2", "role": "Effect", "text": "have profound DPD deficiency", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "10473079_2_Ent4", "text": "cancer", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10473079_2_Ent0", "text": "cancer patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10473079_2_Ent1", "text": "life - threatening complications", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "10473079_2_Ent6", "text": "topical", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10473079_2_Ent3", "text": "topical 5 - FU", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "10473079_2_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "10473079_2_Ent2", "text": "have profound DPD deficiency", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "10475726_1", "wnd_id": "10475726_1_1", "text": "An acute ischaemic event associated with the use of venlafaxine : a case report and proposed pathophysiological mechanisms .", "tokens": ["An", "acute", "ischaemic", "event", "associated", "with", "the", "use", "of", "venlafaxine", ":", "a", "case", "report", "and", "proposed", "pathophysiological", "mechanisms", "."], "event_mentions": [{"id": "10475726_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10475726_1_Ent1", "role": "Effect", "text": "An acute ischaemic event", "start": 0, "end": 4}, {"entity_id": "10475726_1_Ent2", "role": "Treatment", "text": "venlafaxine", "start": 9, "end": 10}, {"entity_id": "10475726_1_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 9, "end": 10}, {"entity_id": "10475726_1_Ent0", "role": "Subject", "text": "a case", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "10475726_1_Ent1", "text": "An acute ischaemic event", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10475726_1_Ent2", "text": "venlafaxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10475726_1_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10475726_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "10485779_10", "wnd_id": "10485779_10_1", "text": "Ritonavir can inhibit the metabolism of fentanyl significantly , so caution should be exercised if fentanyl is given to patients receiving ritonavir medication .", "tokens": ["Ritonavir", "can", "inhibit", "the", "metabolism", "of", "fentanyl", "significantly", ",", "so", "caution", "should", "be", "exercised", "if", "fentanyl", "is", "given", "to", "patients", "receiving", "ritonavir", "medication", "."], "event_mentions": [{"id": "10485779_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caution", "start": 10, "end": 11}, "arguments": [{"entity_id": "10485779_10_Ent4", "role": "Treatment_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "10485779_10_Ent6", "role": "Combination_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "10485779_10_Ent1", "role": "Effect", "text": "metabolism of fentanyl significantly", "start": 4, "end": 8}, {"entity_id": "10485779_10_Ent2", "role": "Treatment", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent3", "role": "Treatment_Drug", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent5", "role": "Combination_Drug", "text": "fentanyl", "start": 15, "end": 16}, {"entity_id": "10485779_10_Ent0", "role": "Subject", "text": "patients receiving ritonavir medication", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "10485779_10_Ent4", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10485779_10_Ent6", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10485779_10_Ent1", "text": "metabolism of fentanyl significantly", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10485779_10_Ent2", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent3", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent5", "text": "fentanyl", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "10485779_10_Ent0", "text": "patients receiving ritonavir medication", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "10494874_1", "wnd_id": "10494874_1_1", "text": "We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis .", "tokens": ["We", "report", "the", "case", "of", "a", "female", "acromegalic", "patient", "in", "whom", "multiple", "hepatic", "adenomas", "appeared", "soon", "after", "danazol", "treatment", "for", "uterine", "fibromatosis", "."], "event_mentions": [{"id": "10494874_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared", "start": 14, "end": 15}, "arguments": [{"entity_id": "10494874_1_Ent0", "role": "Subject", "text": "a female acromegalic patient", "start": 5, "end": 9}, {"entity_id": "10494874_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 6, "end": 7}, {"entity_id": "10494874_1_Ent1", "role": "Subject_Disorder", "text": "acromegalic", "start": 7, "end": 8}, {"entity_id": "10494874_1_Ent3", "role": "Effect", "text": "hepatic adenomas", "start": 12, "end": 14}, {"entity_id": "10494874_1_Ent6", "role": "Treatment_Drug", "text": "danazol", "start": 17, "end": 18}, {"entity_id": "10494874_1_Ent4", "role": "Treatment", "text": "danazol treatment", "start": 17, "end": 19}, {"entity_id": "10494874_1_Ent5", "role": "Treatment_Disorder", "text": "uterine fibromatosis .", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "10494874_1_Ent0", "text": "a female acromegalic patient", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10494874_1_Ent2", "text": "female", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10494874_1_Ent1", "text": "acromegalic", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10494874_1_Ent3", "text": "hepatic adenomas", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10494874_1_Ent6", "text": "danazol", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10494874_1_Ent4", "text": "danazol treatment", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10494874_1_Ent5", "text": "uterine fibromatosis .", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "10513720_2", "wnd_id": "10513720_2_1", "text": "We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer .", "tokens": ["We", "report", "a", "case", "of", "glaucoma", "induced", "by", "doxetaxel", "therapy", "for", "metastatic", "breast", "cancer", "."], "event_mentions": [{"id": "10513720_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "10513720_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "10513720_2_Ent1", "role": "Effect", "text": "glaucoma", "start": 5, "end": 6}, {"entity_id": "10513720_2_Ent3", "role": "Treatment_Drug", "text": "doxetaxel", "start": 8, "end": 9}, {"entity_id": "10513720_2_Ent2", "role": "Treatment", "text": "doxetaxel therapy for metastatic breast cancer", "start": 8, "end": 14}, {"entity_id": "10513720_2_Ent4", "role": "Treatment_Disorder", "text": "metastatic breast cancer", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "10513720_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10513720_2_Ent1", "text": "glaucoma", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10513720_2_Ent3", "text": "doxetaxel", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10513720_2_Ent2", "text": "doxetaxel therapy for metastatic breast cancer", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "10513720_2_Ent4", "text": "metastatic breast cancer", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "10516999_1", "wnd_id": "10516999_1_1", "text": "Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure .", "tokens": ["Acute", "hyperphosphatemia", "caused", "by", "sodium", "phosphate", "enema", "in", "a", "patient", "with", "liver", "dysfunction", "and", "chronic", "renal", "failure", "."], "event_mentions": [{"id": "10516999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "10516999_1_Ent2", "role": "Effect", "text": "Acute hyperphosphatemia", "start": 0, "end": 2}, {"entity_id": "10516999_1_Ent4", "role": "Treatment_Drug", "text": "sodium phosphate", "start": 4, "end": 6}, {"entity_id": "10516999_1_Ent3", "role": "Treatment", "text": "sodium phosphate enema", "start": 4, "end": 7}, {"entity_id": "10516999_1_Ent5", "role": "Treatment_Route", "text": "enema", "start": 6, "end": 7}, {"entity_id": "10516999_1_Ent0", "role": "Subject", "text": "a patient with liver dysfunction and chronic renal failure", "start": 8, "end": 17}, {"entity_id": "10516999_1_Ent1", "role": "Subject_Disorder", "text": "liver dysfunction and chronic renal failure", "start": 11, "end": 17}]}], "entity_mentions": [{"id": "10516999_1_Ent2", "text": "Acute hyperphosphatemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10516999_1_Ent4", "text": "sodium phosphate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10516999_1_Ent3", "text": "sodium phosphate enema", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "10516999_1_Ent5", "text": "enema", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10516999_1_Ent0", "text": "a patient with liver dysfunction and chronic renal failure", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "10516999_1_Ent1", "text": "liver dysfunction and chronic renal failure", "entity_type": "Entity", "start": 11, "end": 17}], "lang": "en"}
{"doc_id": "10530201_9", "wnd_id": "10530201_9_1", "text": "Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned .", "tokens": ["Emphasis", "is", "given", "to", "the", "differentiation", "of", "diphenylhydantoin", "induced", "gingival", "hyperplasia", "from", "the", "angiomatous", "enlargement", "of", "the", "gingiva", "before", "any", "treatment", "is", "planned", "."], "event_mentions": [{"id": "10530201_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "10530201_9_Ent2", "role": "Treatment", "text": "diphenylhydantoin", "start": 7, "end": 8}, {"entity_id": "10530201_9_Ent3", "role": "Treatment_Drug", "text": "diphenylhydantoin", "start": 7, "end": 8}, {"entity_id": "10530201_9_Ent0", "role": "Effect", "text": "gingival hyperplasia", "start": 9, "end": 11}, {"entity_id": "10530201_9_Ent1", "role": "Effect", "text": "the angiomatous enlargement of the gingiva", "start": 12, "end": 18}]}], "entity_mentions": [{"id": "10530201_9_Ent2", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10530201_9_Ent3", "text": "diphenylhydantoin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10530201_9_Ent0", "text": "gingival hyperplasia", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "10530201_9_Ent1", "text": "the angiomatous enlargement of the gingiva", "entity_type": "Entity", "start": 12, "end": 18}], "lang": "en"}
{"doc_id": "10560960_1", "wnd_id": "10560960_1_1", "text": "A 48 - year - old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis .", "tokens": ["A", "48", "-", "year", "-", "old", "woman", "who", "was", "treated", "for", "thyrotoxicosis", "with", "methimazole", "developed", "agranulocytosis", "."], "event_mentions": [{"id": "10560960_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "10560960_1_Ent0", "role": "Subject", "text": "A 48 - year - old woman", "start": 0, "end": 7}, {"entity_id": "10560960_1_Ent1", "role": "Subject_Age", "text": "48 - year - old", "start": 1, "end": 6}, {"entity_id": "10560960_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10560960_1_Ent5", "role": "Treatment_Disorder", "text": "thyrotoxicosis", "start": 11, "end": 12}, {"entity_id": "10560960_1_Ent4", "role": "Treatment", "text": "methimazole", "start": 13, "end": 14}, {"entity_id": "10560960_1_Ent6", "role": "Treatment_Drug", "text": "methimazole", "start": 13, "end": 14}, {"entity_id": "10560960_1_Ent3", "role": "Effect", "text": "agranulocytosis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "10560960_1_Ent0", "text": "A 48 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "10560960_1_Ent1", "text": "48 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10560960_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10560960_1_Ent5", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10560960_1_Ent4", "text": "methimazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10560960_1_Ent6", "text": "methimazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10560960_1_Ent3", "text": "agranulocytosis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "10566542_1", "wnd_id": "10566542_1_1", "text": "Postoperative hypocalcemic tetany caused by fleet phospho - soda preparation in a patient taking alendronate sodium : report of a case .", "tokens": ["Postoperative", "hypocalcemic", "tetany", "caused", "by", "fleet", "phospho", "-", "soda", "preparation", "in", "a", "patient", "taking", "alendronate", "sodium", ":", "report", "of", "a", "case", "."], "event_mentions": [{"id": "10566542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 3, "end": 4}, "arguments": [{"entity_id": "10566542_1_Ent1", "role": "Effect", "text": "hypocalcemic tetany", "start": 1, "end": 3}, {"entity_id": "10566542_1_Ent2", "role": "Treatment", "text": "fleet phospho - soda", "start": 5, "end": 9}, {"entity_id": "10566542_1_Ent4", "role": "Treatment_Drug", "text": "fleet phospho - soda", "start": 5, "end": 9}, {"entity_id": "10566542_1_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "10566542_1_Ent3", "role": "Treatment", "text": "alendronate sodium", "start": 14, "end": 16}, {"entity_id": "10566542_1_Ent5", "role": "Treatment_Drug", "text": "alendronate sodium", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "10566542_1_Ent1", "text": "hypocalcemic tetany", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10566542_1_Ent2", "text": "fleet phospho - soda", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10566542_1_Ent4", "text": "fleet phospho - soda", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "10566542_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "10566542_1_Ent3", "text": "alendronate sodium", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "10566542_1_Ent5", "text": "alendronate sodium", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "10579985_3", "wnd_id": "10579985_3_1", "text": "The second is a 29 - year - old man with CD in whom nodular sclerosing Hodgkin 's lymphoma was diagnosed 3 weeks after infusion with infliximab .", "tokens": ["The", "second", "is", "a", "29", "-", "year", "-", "old", "man", "with", "CD", "in", "whom", "nodular", "sclerosing", "Hodgkin", "'s", "lymphoma", "was", "diagnosed", "3", "weeks", "after", "infusion", "with", "infliximab", "."], "event_mentions": [{"id": "10579985_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosed", "start": 20, "end": 21}, "arguments": [{"entity_id": "10579985_3_Ent0", "role": "Subject", "text": "a 29 - year - old man with CD", "start": 3, "end": 12}, {"entity_id": "10579985_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 4, "end": 9}, {"entity_id": "10579985_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 9, "end": 10}, {"entity_id": "10579985_3_Ent5", "role": "Treatment_Disorder", "text": "CD", "start": 11, "end": 12}, {"entity_id": "10579985_3_Ent3", "role": "Effect", "text": "nodular sclerosing Hodgkin 's lymphoma", "start": 14, "end": 19}, {"entity_id": "10579985_3_Ent6", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 21, "end": 23}, {"entity_id": "10579985_3_Ent4", "role": "Treatment", "text": "3 weeks after infusion with infliximab", "start": 21, "end": 27}, {"entity_id": "10579985_3_Ent7", "role": "Treatment_Route", "text": "infusion", "start": 24, "end": 25}, {"entity_id": "10579985_3_Ent8", "role": "Treatment_Drug", "text": "infliximab", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "10579985_3_Ent0", "text": "a 29 - year - old man with CD", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "10579985_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10579985_3_Ent2", "text": "man", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10579985_3_Ent5", "text": "CD", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10579985_3_Ent3", "text": "nodular sclerosing Hodgkin 's lymphoma", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "10579985_3_Ent6", "text": "3 weeks", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "10579985_3_Ent4", "text": "3 weeks after infusion with infliximab", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "10579985_3_Ent7", "text": "infusion", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "10579985_3_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "10586009_2", "wnd_id": "10586009_2_1", "text": "We report a case of codeine intoxication in the neonate , in which the drug was prescribed for cough control during an emergency department visit .", "tokens": ["We", "report", "a", "case", "of", "codeine", "intoxication", "in", "the", "neonate", ",", "in", "which", "the", "drug", "was", "prescribed", "for", "cough", "control", "during", "an", "emergency", "department", "visit", "."], "event_mentions": [{"id": "10586009_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "prescribed", "start": 16, "end": 17}, "arguments": [{"entity_id": "10586009_2_Ent4", "role": "Treatment", "text": "codeine", "start": 5, "end": 6}, {"entity_id": "10586009_2_Ent5", "role": "Treatment_Drug", "text": "codeine", "start": 5, "end": 6}, {"entity_id": "10586009_2_Ent3", "role": "Effect", "text": "intoxication", "start": 6, "end": 7}, {"entity_id": "10586009_2_Ent0", "role": "Subject", "text": "in the neonate", "start": 7, "end": 10}, {"entity_id": "10586009_2_Ent2", "role": "Subject_Age", "text": "neonate", "start": 9, "end": 10}, {"entity_id": "10586009_2_Ent1", "role": "Subject", "text": "for cough control during an emergency department visit", "start": 17, "end": 25}, {"entity_id": "10586009_2_Ent6", "role": "Treatment_Disorder", "text": "cough", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "10586009_2_Ent4", "text": "codeine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10586009_2_Ent5", "text": "codeine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10586009_2_Ent3", "text": "intoxication", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10586009_2_Ent0", "text": "in the neonate", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "10586009_2_Ent2", "text": "neonate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10586009_2_Ent1", "text": "for cough control during an emergency department visit", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "10586009_2_Ent6", "text": "cough", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "10589077_5", "wnd_id": "10589077_5_1", "text": "We conclude that low - dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions .", "tokens": ["We", "conclude", "that", "low", "-", "dose", "HU", "therapy", "in", "patients", "with", "thalassemia", "intermedia", "may", "increase", "total", "Hb", "levels", "sufficiently", "to", "eliminate", "the", "need", "for", "transfusions", "."], "event_mentions": [{"id": "10589077_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 7, "end": 8}, "arguments": [{"entity_id": "10589077_5_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 3, "end": 6}, {"entity_id": "10589077_5_Ent2", "role": "Treatment", "text": "low - dose HU therapy", "start": 3, "end": 8}, {"entity_id": "10589077_5_Ent4", "role": "Treatment_Drug", "text": "HU", "start": 6, "end": 7}, {"entity_id": "10589077_5_Ent0", "role": "Subject", "text": "in patients with thalassemia intermedia", "start": 8, "end": 13}, {"entity_id": "10589077_5_Ent3", "role": "Treatment_Disorder", "text": "thalassemia intermedia", "start": 11, "end": 13}, {"entity_id": "10589077_5_Ent1", "role": "Effect", "text": "increase total Hb levels", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "10589077_5_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "10589077_5_Ent2", "text": "low - dose HU therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "10589077_5_Ent4", "text": "HU", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10589077_5_Ent0", "text": "in patients with thalassemia intermedia", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "10589077_5_Ent3", "text": "thalassemia intermedia", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "10589077_5_Ent1", "text": "increase total Hb levels", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "10592946_1", "wnd_id": "10592946_1_1", "text": "A 36 - y - o patient with schizophrenia , who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day , became delirious and was admitted to a psychiatric hospital .", "tokens": ["A", "36", "-", "y", "-", "o", "patient", "with", "schizophrenia", ",", "who", "had", "consumed", "gradually", "increasing", "quantities", "of", "oolong", "tea", "that", "eventually", "reached", "15", "L", "each", "day", ",", "became", "delirious", "and", "was", "admitted", "to", "a", "psychiatric", "hospital", "."], "event_mentions": [{"id": "10592946_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 27, "end": 28}, "arguments": [{"entity_id": "10592946_1_Ent0", "role": "Subject", "text": "A 36 - y - o patient with schizophrenia", "start": 0, "end": 9}, {"entity_id": "10592946_1_Ent1", "role": "Subject_Age", "text": "36 - y - o", "start": 1, "end": 6}, {"entity_id": "10592946_1_Ent2", "role": "Subject_Disorder", "text": "schizophrenia", "start": 8, "end": 9}, {"entity_id": "10592946_1_Ent4", "role": "Treatment", "text": "gradually increasing quantities of oolong tea that eventually reached 15 L each day", "start": 13, "end": 26}, {"entity_id": "10592946_1_Ent7", "role": "Treatment_Drug", "text": "oolong tea", "start": 17, "end": 19}, {"entity_id": "10592946_1_Ent5", "role": "Treatment_Dosage", "text": "15 L", "start": 22, "end": 24}, {"entity_id": "10592946_1_Ent6", "role": "Treatment_Freq", "text": "each day", "start": 24, "end": 26}, {"entity_id": "10592946_1_Ent3", "role": "Effect", "text": "delirious", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "10592946_1_Ent0", "text": "A 36 - y - o patient with schizophrenia", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "10592946_1_Ent1", "text": "36 - y - o", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10592946_1_Ent2", "text": "schizophrenia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10592946_1_Ent4", "text": "gradually increasing quantities of oolong tea that eventually reached 15 L each day", "entity_type": "Entity", "start": 13, "end": 26}, {"id": "10592946_1_Ent7", "text": "oolong tea", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10592946_1_Ent5", "text": "15 L", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "10592946_1_Ent6", "text": "each day", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "10592946_1_Ent3", "text": "delirious", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "10592946_6", "wnd_id": "10592946_6_1", "text": "We hypothesize that caffeine toxicity injured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis .", "tokens": ["We", "hypothesize", "that", "caffeine", "toxicity", "injured", "the", "muscle", "cells", ",", "which", "were", "fragile", "due", "to", "the", "potassium", "depletion", "induced", "by", "the", "coexisting", "hyponatremia", ",", "to", "result", "in", "unusually", "severe", "rhabdomyolysis", "."], "event_mentions": [{"id": "10592946_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "injured", "start": 5, "end": 6}, "arguments": [{"entity_id": "10592946_6_Ent2", "role": "Treatment_Drug", "text": "caffeine", "start": 3, "end": 4}, {"entity_id": "10592946_6_Ent1", "role": "Treatment", "text": "caffeine toxicity", "start": 3, "end": 5}, {"entity_id": "10592946_6_Ent0", "role": "Effect", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "start": 7, "end": 30}]}], "entity_mentions": [{"id": "10592946_6_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10592946_6_Ent1", "text": "caffeine toxicity", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "10592946_6_Ent0", "text": "muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia , to result in unusually severe rhabdomyolysis", "entity_type": "Entity", "start": 7, "end": 30}], "lang": "en"}
{"doc_id": "10599932_5", "wnd_id": "10599932_5_1", "text": "After the addition of citalopram , a desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease were observed .", "tokens": ["After", "the", "addition", "of", "citalopram", ",", "a", "desmethylclomipramine", "plasma", "level", "increase", "and", "an", "8", "-", "hydroacy", "-", "desmethylclomipramine", "plasma", "level", "decrease", "were", "observed", "."], "event_mentions": [{"id": "10599932_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "10599932_5_Ent1", "role": "Treatment", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "10599932_5_Ent2", "role": "Treatment_Drug", "text": "citalopram", "start": 4, "end": 5}, {"entity_id": "10599932_5_Ent0", "role": "Effect", "text": "desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease", "start": 7, "end": 21}]}], "entity_mentions": [{"id": "10599932_5_Ent1", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10599932_5_Ent2", "text": "citalopram", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10599932_5_Ent0", "text": "desmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease", "entity_type": "Entity", "start": 7, "end": 21}], "lang": "en"}
{"doc_id": "10607332_1", "wnd_id": "10607332_1_1", "text": "We report 3 cases of HIV - 1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir .", "tokens": ["We", "report", "3", "cases", "of", "HIV", "-", "1", "infected", "patients", "who", "experienced", "symptomatic", "angiolipomas", "shortly", "after", "starting", "antiretroviral", "therapy", "including", "the", "protease", "inhibitor", "indinavir", "."], "event_mentions": [{"id": "10607332_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 11, "end": 12}, "arguments": [{"entity_id": "10607332_1_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "10607332_1_Ent0", "role": "Subject", "text": "3 cases of HIV - 1 infected patients", "start": 2, "end": 10}, {"entity_id": "10607332_1_Ent4", "role": "Treatment_Disorder", "text": "HIV - 1", "start": 5, "end": 8}, {"entity_id": "10607332_1_Ent2", "role": "Effect", "text": "symptomatic angiolipomas", "start": 12, "end": 14}, {"entity_id": "10607332_1_Ent3", "role": "Treatment", "text": "antiretroviral therapy including the protease inhibitor indinavir", "start": 17, "end": 24}, {"entity_id": "10607332_1_Ent5", "role": "Treatment_Drug", "text": "indinavir", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "10607332_1_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10607332_1_Ent0", "text": "3 cases of HIV - 1 infected patients", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "10607332_1_Ent4", "text": "HIV - 1", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10607332_1_Ent2", "text": "symptomatic angiolipomas", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "10607332_1_Ent3", "text": "antiretroviral therapy including the protease inhibitor indinavir", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "10607332_1_Ent5", "text": "indinavir", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "10614572_1", "wnd_id": "10614572_1_1", "text": "Intravenous valproate associated with significant hypotension in the treatment of status epilepticus .", "tokens": ["Intravenous", "valproate", "associated", "with", "significant", "hypotension", "in", "the", "treatment", "of", "status", "epilepticus", "."], "event_mentions": [{"id": "10614572_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10614572_1_Ent3", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10614572_1_Ent1", "role": "Treatment", "text": "Intravenous valproate", "start": 0, "end": 2}, {"entity_id": "10614572_1_Ent4", "role": "Treatment_Drug", "text": "valproate", "start": 1, "end": 2}, {"entity_id": "10614572_1_Ent0", "role": "Effect", "text": "significant hypotension", "start": 4, "end": 6}, {"entity_id": "10614572_1_Ent2", "role": "Treatment_Disorder", "text": "status epilepticus", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "10614572_1_Ent3", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10614572_1_Ent1", "text": "Intravenous valproate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10614572_1_Ent4", "text": "valproate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10614572_1_Ent0", "text": "significant hypotension", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "10614572_1_Ent2", "text": "status epilepticus", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "10660641_2", "wnd_id": "10660641_2_1", "text": "A patient treated with itraconazole ( ITCZ ) under the diagnosis of Aspergillus flavus - induced chronic hypertrophic pachymeningitis is presented .", "tokens": ["A", "patient", "treated", "with", "itraconazole", "(", "ITCZ", ")", "under", "the", "diagnosis", "of", "Aspergillus", "flavus", "-", "induced", "chronic", "hypertrophic", "pachymeningitis", "is", "presented", "."], "event_mentions": [{"id": "10660641_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 2, "end": 3}, "arguments": [{"entity_id": "10660641_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "10660641_2_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "10660641_2_Ent1", "role": "Treatment", "text": "itraconazole ( ITCZ )", "start": 4, "end": 8}, {"entity_id": "10660641_2_Ent3", "role": "Treatment_Disorder", "text": "Aspergillus flavus - induced chronic hypertrophic pachymeningitis", "start": 12, "end": 19}]}], "entity_mentions": [{"id": "10660641_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "10660641_2_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "10660641_2_Ent1", "text": "itraconazole ( ITCZ )", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "10660641_2_Ent3", "text": "Aspergillus flavus - induced chronic hypertrophic pachymeningitis", "entity_type": "Entity", "start": 12, "end": 19}], "lang": "en"}
{"doc_id": "10660641_8", "wnd_id": "10660641_8_1", "text": "Since renal insufficiency was induced by AMPH and the other antifungal drugs were ineffective , daily administration of 200 mg of ITCZ was initiated , and the inflammatory signs and symptoms gradually subsided .", "tokens": ["Since", "renal", "insufficiency", "was", "induced", "by", "AMPH", "and", "the", "other", "antifungal", "drugs", "were", "ineffective", ",", "daily", "administration", "of", "200", "mg", "of", "ITCZ", "was", "initiated", ",", "and", "the", "inflammatory", "signs", "and", "symptoms", "gradually", "subsided", "."], "event_mentions": [{"id": "10660641_8_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "10660641_8_Ent6", "role": "Effect", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "10660641_8_Ent7", "role": "Treatment", "text": "AMPH", "start": 6, "end": 7}, {"entity_id": "10660641_8_Ent8", "role": "Treatment_Drug", "text": "AMPH", "start": 6, "end": 7}]}, {"id": "10660641_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "initiated", "start": 23, "end": 24}, "arguments": [{"entity_id": "10660641_8_Ent2", "role": "Treatment_Disorder", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "10660641_8_Ent4", "role": "Treatment_Freq", "text": "daily administration", "start": 15, "end": 17}, {"entity_id": "10660641_8_Ent1", "role": "Treatment", "text": "daily administration of 200 mg of ITCZ", "start": 15, "end": 22}, {"entity_id": "10660641_8_Ent3", "role": "Treatment_Dosage", "text": "200 mg", "start": 18, "end": 20}, {"entity_id": "10660641_8_Ent5", "role": "Treatment_Drug", "text": "ITCZ", "start": 21, "end": 22}, {"entity_id": "10660641_8_Ent0", "role": "Effect", "text": "the inflammatory signs and symptoms gradually subsided .", "start": 26, "end": 34}]}], "entity_mentions": [{"id": "10660641_8_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_8_Ent6", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "10660641_8_Ent7", "text": "AMPH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10660641_8_Ent8", "text": "AMPH", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10660641_8_Ent4", "text": "daily administration", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "10660641_8_Ent1", "text": "daily administration of 200 mg of ITCZ", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "10660641_8_Ent3", "text": "200 mg", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "10660641_8_Ent5", "text": "ITCZ", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "10660641_8_Ent0", "text": "the inflammatory signs and symptoms gradually subsided .", "entity_type": "Entity", "start": 26, "end": 34}], "lang": "en"}
{"doc_id": "10679548_3", "wnd_id": "10679548_3_1", "text": "The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia ( BOOP ) , a rare but recognised form of drug induced injury .", "tokens": ["The", "case", "histories", "are", "presented", "of", "two", "patients", "who", "developed", "lung", "disease", "associated", "with", "the", "use", "of", "nitrofurantoin", "with", "histological", "features", "of", "bronchiolitis", "obliterans", "organising", "pneumonia", "(", "BOOP", ")", ",", "a", "rare", "but", "recognised", "form", "of", "drug", "induced", "injury", "."], "event_mentions": [{"id": "10679548_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "10679548_3_Ent1", "role": "Subject_Population", "text": "two", "start": 6, "end": 7}, {"entity_id": "10679548_3_Ent0", "role": "Subject", "text": "two patients", "start": 6, "end": 8}, {"entity_id": "10679548_3_Ent2", "role": "Effect", "text": "lung disease", "start": 10, "end": 12}, {"entity_id": "10679548_3_Ent4", "role": "Treatment", "text": "the use of nitrofurantoin", "start": 14, "end": 18}, {"entity_id": "10679548_3_Ent5", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 17, "end": 18}, {"entity_id": "10679548_3_Ent3", "role": "Effect", "text": "with histological features of bronchiolitis obliterans organising pneumonia ( BOOP )", "start": 18, "end": 29}]}], "entity_mentions": [{"id": "10679548_3_Ent1", "text": "two", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10679548_3_Ent0", "text": "two patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10679548_3_Ent2", "text": "lung disease", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10679548_3_Ent4", "text": "the use of nitrofurantoin", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "10679548_3_Ent5", "text": "nitrofurantoin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "10679548_3_Ent3", "text": "with histological features of bronchiolitis obliterans organising pneumonia ( BOOP )", "entity_type": "Entity", "start": 18, "end": 29}], "lang": "en"}
{"doc_id": "10679548_4", "wnd_id": "10679548_4_1", "text": "The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP .", "tokens": ["The", "favourable", "outcome", "in", "these", "two", "patients", "contrasts", "with", "the", "fatal", "outcome", "of", "the", "two", "other", "reported", "cases", "of", "nitrofurantoin", "induced", "BOOP", "."], "event_mentions": [{"id": "10679548_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 20, "end": 21}, "arguments": [{"entity_id": "10679548_4_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "10679548_4_Ent0", "role": "Subject", "text": "two patients", "start": 5, "end": 7}, {"entity_id": "10679548_4_Ent3", "role": "Treatment", "text": "nitrofurantoin", "start": 19, "end": 20}, {"entity_id": "10679548_4_Ent4", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 19, "end": 20}, {"entity_id": "10679548_4_Ent2", "role": "Effect", "text": "BOOP", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "10679548_4_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10679548_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "10679548_4_Ent3", "text": "nitrofurantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10679548_4_Ent4", "text": "nitrofurantoin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "10679548_4_Ent2", "text": "BOOP", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "10682234_1", "wnd_id": "10682234_1_1", "text": "Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon - alpha .", "tokens": ["Intravenous", "administration", "of", "levodopa", "ameliorated", "a", "refractory", "akathisia", "case", "induced", "by", "interferon", "-", "alpha", "."], "event_mentions": [{"id": "10682234_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_1_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_1_Ent0", "role": "Treatment", "text": "Intravenous administration of levodopa", "start": 0, "end": 4}, {"entity_id": "10682234_1_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 3, "end": 4}, {"entity_id": "10682234_1_Ent1", "role": "Treatment_Disorder", "text": "a refractory akathisia case induced by interferon - alpha", "start": 5, "end": 14}]}, {"id": "10682234_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "10682234_1_Ent4", "role": "Effect", "text": "refractory akathisia", "start": 6, "end": 8}, {"entity_id": "10682234_1_Ent6", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 11, "end": 14}, {"entity_id": "10682234_1_Ent5", "role": "Treatment", "text": "interferon - alpha .", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "10682234_1_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_1_Ent0", "text": "Intravenous administration of levodopa", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_1_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "10682234_1_Ent1", "text": "a refractory akathisia case induced by interferon - alpha", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "10682234_1_Ent4", "text": "refractory akathisia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "10682234_1_Ent6", "text": "interferon - alpha", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10682234_1_Ent5", "text": "interferon - alpha .", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "10682234_7", "wnd_id": "10682234_7_1", "text": "Intravenous levodopa 25 mg ameliorated his akathisia symptoms drastically .", "tokens": ["Intravenous", "levodopa", "25", "mg", "ameliorated", "his", "akathisia", "symptoms", "drastically", "."], "event_mentions": [{"id": "10682234_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorated", "start": 4, "end": 5}, "arguments": [{"entity_id": "10682234_7_Ent2", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "10682234_7_Ent0", "role": "Treatment", "text": "Intravenous levodopa 25 mg", "start": 0, "end": 4}, {"entity_id": "10682234_7_Ent3", "role": "Treatment_Drug", "text": "levodopa", "start": 1, "end": 2}, {"entity_id": "10682234_7_Ent1", "role": "Treatment_Disorder", "text": "akathisia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10682234_7_Ent2", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10682234_7_Ent0", "text": "Intravenous levodopa 25 mg", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "10682234_7_Ent3", "text": "levodopa", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "10682234_7_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1068531_2", "wnd_id": "1068531_2_1", "text": "The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy .", "tokens": ["The", "development", "of", "erythroid", "leukemia", "plus", "carcinoma", "in", "these", "two", "men", "suggests", "mutagenic", "change", "secondary", "to", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "1068531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suggests", "start": 11, "end": 12}, "arguments": [{"entity_id": "1068531_2_Ent3", "role": "Effect", "text": "development of erythroid leukemia plus carcinoma", "start": 1, "end": 7}, {"entity_id": "1068531_2_Ent1", "role": "Subject_Population", "text": "two", "start": 9, "end": 10}, {"entity_id": "1068531_2_Ent0", "role": "Subject", "text": "two men", "start": 9, "end": 11}, {"entity_id": "1068531_2_Ent2", "role": "Subject_Gender", "text": "men", "start": 10, "end": 11}, {"entity_id": "1068531_2_Ent4", "role": "Effect", "text": "mutagenic change", "start": 12, "end": 14}, {"entity_id": "1068531_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 16, "end": 17}, {"entity_id": "1068531_2_Ent5", "role": "Treatment", "text": "cyclophosphamide therapy", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "1068531_2_Ent3", "text": "development of erythroid leukemia plus carcinoma", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "1068531_2_Ent1", "text": "two", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1068531_2_Ent0", "text": "two men", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "1068531_2_Ent2", "text": "men", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1068531_2_Ent4", "text": "mutagenic change", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1068531_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "1068531_2_Ent5", "text": "cyclophosphamide therapy", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "10688731_3", "wnd_id": "10688731_3_1", "text": "We report a case of a scleroderma - like reaction induced by long - term administration of UFT .", "tokens": ["We", "report", "a", "case", "of", "a", "scleroderma", "-", "like", "reaction", "induced", "by", "long", "-", "term", "administration", "of", "UFT", "."], "event_mentions": [{"id": "10688731_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "10688731_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "10688731_3_Ent1", "role": "Effect", "text": "a scleroderma - like reaction", "start": 5, "end": 10}, {"entity_id": "10688731_3_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 12, "end": 15}, {"entity_id": "10688731_3_Ent2", "role": "Treatment", "text": "long - term administration of UFT", "start": 12, "end": 18}, {"entity_id": "10688731_3_Ent4", "role": "Treatment_Drug", "text": "UFT", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "10688731_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "10688731_3_Ent1", "text": "a scleroderma - like reaction", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "10688731_3_Ent3", "text": "long - term", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10688731_3_Ent2", "text": "long - term administration of UFT", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "10688731_3_Ent4", "text": "UFT", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "10707759_2", "wnd_id": "10707759_2_1", "text": "Flecainide is a rare cause of hypersensitivity pneumonitis , and few cases have been reported .", "tokens": ["Flecainide", "is", "a", "rare", "cause", "of", "hypersensitivity", "pneumonitis", ",", "and", "few", "cases", "have", "been", "reported", "."], "event_mentions": [{"id": "10707759_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "10707759_2_Ent1", "role": "Treatment", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_2_Ent2", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "10707759_2_Ent0", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "10707759_2_Ent1", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_2_Ent2", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10707759_2_Ent0", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "10715308_1", "wnd_id": "10715308_1_1", "text": "Tirapazamine plus cisplatin versus cisplatin in advanced non - small - cell lung cancer : A report of the international CATAPULT I study group .", "tokens": ["Tirapazamine", "plus", "cisplatin", "versus", "cisplatin", "in", "advanced", "non", "-", "small", "-", "cell", "lung", "cancer", ":", "A", "report", "of", "the", "international", "CATAPULT", "I", "study", "group", "."], "event_mentions": [{"id": "10715308_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "10715308_1_Ent3", "role": "Treatment_Drug", "text": "Tirapazamine", "start": 0, "end": 1}, {"entity_id": "10715308_1_Ent5", "role": "Combination_Drug", "text": "Tirapazamine", "start": 0, "end": 1}, {"entity_id": "10715308_1_Ent0", "role": "Treatment", "text": "Tirapazamine plus cisplatin", "start": 0, "end": 3}, {"entity_id": "10715308_1_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "10715308_1_Ent4", "role": "Combination_Drug", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "10715308_1_Ent1", "role": "Treatment_Disorder", "text": "advanced non - small - cell lung cancer", "start": 6, "end": 14}]}], "entity_mentions": [{"id": "10715308_1_Ent3", "text": "Tirapazamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10715308_1_Ent5", "text": "Tirapazamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "10715308_1_Ent0", "text": "Tirapazamine plus cisplatin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10715308_1_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10715308_1_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "10715308_1_Ent1", "text": "advanced non - small - cell lung cancer", "entity_type": "Entity", "start": 6, "end": 14}], "lang": "en"}
{"doc_id": "10717401_2", "wnd_id": "10717401_2_1", "text": "We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L - asparaginase .", "tokens": ["We", "report", "the", "case", "of", "an", "adult", "patient", "with", "acute", "lymphoblastic", "leukemia", "who", "presented", "with", "repeated", "transient", "ischemic", "attacks", "followed", "by", "a", "seizure", "during", "consolidation", "treatment", "with", "L", "-", "asparaginase", "."], "event_mentions": [{"id": "10717401_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 13, "end": 14}, "arguments": [{"entity_id": "10717401_2_Ent0", "role": "Subject", "text": "an adult patient with acute lymphoblastic leukemia", "start": 5, "end": 12}, {"entity_id": "10717401_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 6, "end": 7}, {"entity_id": "10717401_2_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 9, "end": 12}, {"entity_id": "10717401_2_Ent2", "role": "Effect", "text": "repeated transient ischemic attacks followed by a seizure", "start": 15, "end": 23}, {"entity_id": "10717401_2_Ent3", "role": "Treatment", "text": "consolidation treatment with L - asparaginase", "start": 24, "end": 30}, {"entity_id": "10717401_2_Ent5", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "10717401_2_Ent0", "text": "an adult patient with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "10717401_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10717401_2_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "10717401_2_Ent2", "text": "repeated transient ischemic attacks followed by a seizure", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "10717401_2_Ent3", "text": "consolidation treatment with L - asparaginase", "entity_type": "Entity", "start": 24, "end": 30}, {"id": "10717401_2_Ent5", "text": "L - asparaginase", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "10752888_2", "wnd_id": "10752888_2_1", "text": "We present two cases of nitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established fibrosis .", "tokens": ["We", "present", "two", "cases", "of", "nitrofurantoin", "-", "induced", "pulmonary", "toxicity", "in", "which", "the", "initial", "HRCT", "showed", "a", "widespread", "reticular", "pattern", "and", "associated", "distortion", "of", "the", "lung", "parenchyma", ",", "thought", "to", "represent", "established", "fibrosis", "."], "event_mentions": [{"id": "10752888_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "10752888_2_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 5, "end": 6}, {"entity_id": "10752888_2_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 5, "end": 6}, {"entity_id": "10752888_2_Ent0", "role": "Effect", "text": "pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established fibrosis", "start": 8, "end": 33}]}], "entity_mentions": [{"id": "10752888_2_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10752888_2_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10752888_2_Ent0", "text": "pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma , thought to represent established fibrosis", "entity_type": "Entity", "start": 8, "end": 33}], "lang": "en"}
{"doc_id": "10759907_1", "wnd_id": "10759907_1_1", "text": "A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods , developed a spinal cord lesion following the use of zolmitriptan .", "tokens": ["A", "50", "-", "year", "-", "old", "woman", "with", "a", "history", "of", "migraine", "without", "aura", ",", "predominantly", "occurring", "around", "her", "menstrual", "periods", ",", "developed", "a", "spinal", "cord", "lesion", "following", "the", "use", "of", "zolmitriptan", "."], "event_mentions": [{"id": "10759907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "10759907_1_Ent0", "role": "Subject", "text": "A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods", "start": 0, "end": 21}, {"entity_id": "10759907_1_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "10759907_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "10759907_1_Ent6", "role": "Treatment_Disorder", "text": "migraine without aura", "start": 11, "end": 14}, {"entity_id": "10759907_1_Ent3", "role": "Effect", "text": "a spinal cord lesion", "start": 23, "end": 27}, {"entity_id": "10759907_1_Ent4", "role": "Treatment", "text": "zolmitriptan", "start": 31, "end": 32}, {"entity_id": "10759907_1_Ent5", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "10759907_1_Ent0", "text": "A 50 - year - old woman with a history of migraine without aura , predominantly occurring around her menstrual periods", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "10759907_1_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "10759907_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "10759907_1_Ent6", "text": "migraine without aura", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "10759907_1_Ent3", "text": "a spinal cord lesion", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "10759907_1_Ent4", "text": "zolmitriptan", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "10759907_1_Ent5", "text": "zolmitriptan", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "10759907_2", "wnd_id": "10759907_2_1", "text": "Spinal cord infarction during use of zolmitriptan : a case report .", "tokens": ["Spinal", "cord", "infarction", "during", "use", "of", "zolmitriptan", ":", "a", "case", "report", "."], "event_mentions": [{"id": "10759907_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "10759907_2_Ent0", "role": "Effect", "text": "Spinal cord infarction", "start": 0, "end": 3}, {"entity_id": "10759907_2_Ent1", "role": "Treatment", "text": "use of zolmitriptan", "start": 4, "end": 7}, {"entity_id": "10759907_2_Ent2", "role": "Treatment_Drug", "text": "zolmitriptan", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "10759907_2_Ent0", "text": "Spinal cord infarction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "10759907_2_Ent1", "text": "use of zolmitriptan", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "10759907_2_Ent2", "text": "zolmitriptan", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "10772434_1", "wnd_id": "10772434_1_1", "text": "CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses .", "tokens": ["CASE", "SUMMARY", ":", "A", "10", "-", "year", "-", "old", "white", "girl", "with", "bilateral", "optic", "glioma", "developed", "a", "hypersensitivity", "reaction", "to", "carboplatin", "after", "nine", "courses", "."], "event_mentions": [{"id": "10772434_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "10772434_1_Ent0", "role": "Subject", "text": "A 10 - year - old white girl with bilateral optic glioma", "start": 3, "end": 15}, {"entity_id": "10772434_1_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 4, "end": 9}, {"entity_id": "10772434_1_Ent3", "role": "Subject_Race", "text": "white", "start": 9, "end": 10}, {"entity_id": "10772434_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 10, "end": 11}, {"entity_id": "10772434_1_Ent6", "role": "Treatment_Disorder", "text": "bilateral optic glioma", "start": 12, "end": 15}, {"entity_id": "10772434_1_Ent4", "role": "Effect", "text": "hypersensitivity reaction", "start": 17, "end": 19}, {"entity_id": "10772434_1_Ent7", "role": "Treatment_Drug", "text": "carboplatin", "start": 20, "end": 21}, {"entity_id": "10772434_1_Ent5", "role": "Treatment", "text": "carboplatin after nine courses", "start": 20, "end": 24}, {"entity_id": "10772434_1_Ent8", "role": "Treatment_Duration", "text": "nine courses", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "10772434_1_Ent0", "text": "A 10 - year - old white girl with bilateral optic glioma", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "10772434_1_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "10772434_1_Ent3", "text": "white", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10772434_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "10772434_1_Ent6", "text": "bilateral optic glioma", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "10772434_1_Ent4", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "10772434_1_Ent7", "text": "carboplatin", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10772434_1_Ent5", "text": "carboplatin after nine courses", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "10772434_1_Ent8", "text": "nine courses", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "10772434_2", "wnd_id": "10772434_2_1", "text": "This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue .", "tokens": ["This", "regimen", "could", "prove", "useful", "for", "other", "patients", "who", "develop", "hypersensitivity", "reactions", "to", "carboplatin", "and", "allow", "therapy", "to", "continue", "."], "event_mentions": [{"id": "10772434_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 9, "end": 10}, "arguments": [{"entity_id": "10772434_2_Ent0", "role": "Subject", "text": "patients", "start": 7, "end": 8}, {"entity_id": "10772434_2_Ent1", "role": "Effect", "text": "hypersensitivity reactions", "start": 10, "end": 12}, {"entity_id": "10772434_2_Ent2", "role": "Treatment", "text": "carboplatin", "start": 13, "end": 14}, {"entity_id": "10772434_2_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "10772434_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10772434_2_Ent1", "text": "hypersensitivity reactions", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "10772434_2_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "10772434_2_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "10840527_1", "wnd_id": "10840527_1_1", "text": "Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials , case reports , and chart reviews , it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( EPS ) .", "tokens": ["Although", "the", "literature", "on", "the", "use", "of", "risperidone", "in", "elderly", "patients", "with", "dementia", "consists", "largely", "of", "uncontrolled", "trials", ",", "case", "reports", ",", "and", "chart", "reviews", ",", "it", "appears", "that", "this", "agent", "is", "effective", "for", "managing", "agitation", "in", "this", "population", "and", "does", "so", "with", "a", "low", "frequency", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "."], "event_mentions": [{"id": "10840527_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "is", "start": 31, "end": 32}, "arguments": [{"entity_id": "10840527_1_Ent2", "role": "Treatment", "text": "use of risperidone", "start": 5, "end": 8}, {"entity_id": "10840527_1_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 7, "end": 8}, {"entity_id": "10840527_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 9, "end": 10}, {"entity_id": "10840527_1_Ent0", "role": "Subject", "text": "elderly patients with dementia", "start": 9, "end": 13}, {"entity_id": "10840527_1_Ent4", "role": "Treatment_Disorder", "text": "dementia", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "10840527_1_Ent2", "text": "use of risperidone", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "10840527_1_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "10840527_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "10840527_1_Ent0", "text": "elderly patients with dementia", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "10840527_1_Ent4", "text": "dementia", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1087773_1", "wnd_id": "1087773_1_1", "text": "After seven months ' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine - year - old boy developed polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor .", "tokens": ["After", "seven", "months", "'", "continuous", "treatment", "for", "suspected", "tuberculosis", "with", "rifampicin", "and", "ethambutol", "a", "nine", "-", "year", "-", "old", "boy", "developed", "polyarthritis", ",", "rash", "and", "hepatitis", "in", "association", "with", "anti", "-", "native", "DNA", "antibodies", "and", "positive", "antinuclear", "factor", "."], "event_mentions": [{"id": "1087773_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "1087773_1_Ent9", "role": "Treatment_Time_elapsed", "text": "seven months", "start": 1, "end": 3}, {"entity_id": "1087773_1_Ent4", "role": "Treatment", "text": "seven months ' continuous treatment", "start": 1, "end": 6}, {"entity_id": "1087773_1_Ent8", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "1087773_1_Ent5", "role": "Treatment", "text": "with rifampicin and ethambutol", "start": 9, "end": 13}, {"entity_id": "1087773_1_Ent6", "role": "Treatment_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent11", "role": "Combination_Drug", "text": "rifampicin", "start": 10, "end": 11}, {"entity_id": "1087773_1_Ent7", "role": "Treatment_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent10", "role": "Combination_Drug", "text": "ethambutol", "start": 12, "end": 13}, {"entity_id": "1087773_1_Ent0", "role": "Subject", "text": "a nine - year - old boy", "start": 13, "end": 20}, {"entity_id": "1087773_1_Ent1", "role": "Subject_Age", "text": "nine - year - old", "start": 14, "end": 19}, {"entity_id": "1087773_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 19, "end": 20}, {"entity_id": "1087773_1_Ent3", "role": "Effect", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "start": 21, "end": 38}]}], "entity_mentions": [{"id": "1087773_1_Ent9", "text": "seven months", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "1087773_1_Ent4", "text": "seven months ' continuous treatment", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1087773_1_Ent8", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1087773_1_Ent5", "text": "with rifampicin and ethambutol", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "1087773_1_Ent6", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent11", "text": "rifampicin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1087773_1_Ent7", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent10", "text": "ethambutol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1087773_1_Ent0", "text": "a nine - year - old boy", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "1087773_1_Ent1", "text": "nine - year - old", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "1087773_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1087773_1_Ent3", "text": "polyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor", "entity_type": "Entity", "start": 21, "end": 38}], "lang": "en"}
{"doc_id": "10885900_3", "wnd_id": "10885900_3_1", "text": "We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine , and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow - up .", "tokens": ["We", "present", "a", "case", "of", "HUS", "in", "an", "advanced", "ovarian", "cancer", "patient", "treated", "with", "carboplatin", "and", "gemcitabine", ",", "and", "described", "its", "favorable", "outcome", "after", "chemotherapy", "interruption", "and", "supportive", "care", "with", "a", "1", "year", "follow", "-", "up", "."], "event_mentions": [{"id": "10885900_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "10885900_3_Ent0", "role": "Effect", "text": "HUS", "start": 5, "end": 6}, {"entity_id": "10885900_3_Ent2", "role": "Treatment_Disorder", "text": "advanced ovarian cancer", "start": 8, "end": 11}, {"entity_id": "10885900_3_Ent3", "role": "Treatment_Drug", "text": "carboplatin", "start": 14, "end": 15}, {"entity_id": "10885900_3_Ent5", "role": "Combination_Drug", "text": "carboplatin", "start": 14, "end": 15}, {"entity_id": "10885900_3_Ent1", "role": "Treatment", "text": "carboplatin and gemcitabine", "start": 14, "end": 17}, {"entity_id": "10885900_3_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 16, "end": 17}, {"entity_id": "10885900_3_Ent6", "role": "Combination_Drug", "text": "gemcitabine", "start": 16, "end": 17}]}, {"id": "10885900_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "10885900_3_Ent10", "role": "Treatment_Disorder", "text": "HUS", "start": 5, "end": 6}, {"entity_id": "10885900_3_Ent7", "role": "Subject", "text": "an advanced ovarian cancer patient", "start": 7, "end": 12}, {"entity_id": "10885900_3_Ent8", "role": "Effect", "text": "favorable outcome", "start": 21, "end": 23}, {"entity_id": "10885900_3_Ent9", "role": "Treatment", "text": "chemotherapy interruption and supportive care with a 1 year follow - up", "start": 24, "end": 36}]}], "entity_mentions": [{"id": "10885900_3_Ent0", "text": "HUS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10885900_3_Ent10", "text": "HUS", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10885900_3_Ent7", "text": "an advanced ovarian cancer patient", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "10885900_3_Ent2", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "10885900_3_Ent3", "text": "carboplatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10885900_3_Ent5", "text": "carboplatin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "10885900_3_Ent1", "text": "carboplatin and gemcitabine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "10885900_3_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10885900_3_Ent6", "text": "gemcitabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10885900_3_Ent8", "text": "favorable outcome", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "10885900_3_Ent9", "text": "chemotherapy interruption and supportive care with a 1 year follow - up", "entity_type": "Entity", "start": 24, "end": 36}], "lang": "en"}
{"doc_id": "10891991_2", "wnd_id": "10891991_2_1", "text": "BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy .", "tokens": ["BACKGROUND", ":", "Reproductive", "endocrine", "disorders", "characterized", "by", "menstrual", "disorders", ",", "polycystic", "ovaries", ",", "and", "hyperandrogenism", "seem", "to", "be", "common", "among", "women", "treated", "with", "sodium", "valproate", "for", "epilepsy", "."], "event_mentions": [{"id": "10891991_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "10891991_2_Ent2", "role": "Effect", "text": "Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism", "start": 2, "end": 15}, {"entity_id": "10891991_2_Ent0", "role": "Subject", "text": "women", "start": 20, "end": 21}, {"entity_id": "10891991_2_Ent1", "role": "Subject_Gender", "text": "women", "start": 20, "end": 21}, {"entity_id": "10891991_2_Ent4", "role": "Treatment_Drug", "text": "sodium valproate", "start": 23, "end": 25}, {"entity_id": "10891991_2_Ent3", "role": "Treatment", "text": "sodium valproate for epilepsy", "start": 23, "end": 27}, {"entity_id": "10891991_2_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "10891991_2_Ent2", "text": "Reproductive endocrine disorders characterized by menstrual disorders , polycystic ovaries , and hyperandrogenism", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "10891991_2_Ent0", "text": "women", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_2_Ent1", "text": "women", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "10891991_2_Ent4", "text": "sodium valproate", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "10891991_2_Ent3", "text": "sodium valproate for epilepsy", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "10891991_2_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "10897389_1", "wnd_id": "10897389_1_1", "text": "However , recurrent staphylococcus aureus sepsis developed during CyA therapy .", "tokens": ["However", ",", "recurrent", "staphylococcus", "aureus", "sepsis", "developed", "during", "CyA", "therapy", "."], "event_mentions": [{"id": "10897389_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "10897389_1_Ent0", "role": "Effect", "text": "staphylococcus aureus sepsis", "start": 3, "end": 6}, {"entity_id": "10897389_1_Ent2", "role": "Treatment_Drug", "text": "CyA", "start": 8, "end": 9}, {"entity_id": "10897389_1_Ent1", "role": "Treatment", "text": "CyA therapy", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "10897389_1_Ent0", "text": "staphylococcus aureus sepsis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "10897389_1_Ent2", "text": "CyA", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "10897389_1_Ent1", "text": "CyA therapy", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "10904571_3", "wnd_id": "10904571_3_1", "text": "Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine - induced myopathy .", "tokens": ["Muscle", "biopsy", "revealed", "variation", "in", "muscle", "fiber", "size", "and", "few", "vacuolated", "fibers", "which", "were", "features", "of", "colchicine", "-", "induced", "myopathy", "."], "event_mentions": [{"id": "10904571_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 18, "end": 19}, "arguments": [{"entity_id": "10904571_3_Ent0", "role": "Effect", "text": "variation in muscle fiber size and few vacuolated fibers", "start": 3, "end": 12}, {"entity_id": "10904571_3_Ent2", "role": "Treatment", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "10904571_3_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "10904571_3_Ent1", "role": "Effect", "text": "myopathy", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "10904571_3_Ent0", "text": "variation in muscle fiber size and few vacuolated fibers", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "10904571_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10904571_3_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "10904571_3_Ent1", "text": "myopathy", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "10907391_3", "wnd_id": "10907391_3_1", "text": "Physicians should be aware that PLP can occur after initiation of paclitaxel .", "tokens": ["Physicians", "should", "be", "aware", "that", "PLP", "can", "occur", "after", "initiation", "of", "paclitaxel", "."], "event_mentions": [{"id": "10907391_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 7, "end": 8}, "arguments": [{"entity_id": "10907391_3_Ent0", "role": "Effect", "text": "PLP", "start": 5, "end": 6}, {"entity_id": "10907391_3_Ent1", "role": "Treatment", "text": "paclitaxel", "start": 11, "end": 12}, {"entity_id": "10907391_3_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "10907391_3_Ent0", "text": "PLP", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "10907391_3_Ent1", "text": "paclitaxel", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "10907391_3_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "10923593_2", "wnd_id": "10923593_2_1", "text": "Serum sickness consists of a systemic reaction resulting from the formation of soluble circulating immunocomplexes after the introduction of a foreign substance into the body We studied a 38 - year - old woman diagnosed with anxiety , depression and right sacroileitis who was treated with phenylbutazone , ranitidine , clomipramine and levomepromazine .", "tokens": ["Serum", "sickness", "consists", "of", "a", "systemic", "reaction", "resulting", "from", "the", "formation", "of", "soluble", "circulating", "immunocomplexes", "after", "the", "introduction", "of", "a", "foreign", "substance", "into", "the", "body", "We", "studied", "a", "38", "-", "year", "-", "old", "woman", "diagnosed", "with", "anxiety", ",", "depression", "and", "right", "sacroileitis", "who", "was", "treated", "with", "phenylbutazone", ",", "ranitidine", ",", "clomipramine", "and", "levomepromazine", "."], "event_mentions": [{"id": "10923593_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 44, "end": 45}, "arguments": [{"entity_id": "10923593_2_Ent0", "role": "Subject", "text": "a 38 - year - old woman diagnosed with anxiety , depression and right sacroileitis", "start": 27, "end": 42}, {"entity_id": "10923593_2_Ent1", "role": "Subject_Age", "text": "38 - year - old", "start": 28, "end": 33}, {"entity_id": "10923593_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 33, "end": 34}, {"entity_id": "10923593_2_Ent8", "role": "Treatment_Disorder", "text": "anxiety , depression and right sacroileitis", "start": 36, "end": 42}, {"entity_id": "10923593_2_Ent4", "role": "Treatment_Drug", "text": "phenylbutazone", "start": 46, "end": 47}, {"entity_id": "10923593_2_Ent12", "role": "Combination_Drug", "text": "phenylbutazone", "start": 46, "end": 47}, {"entity_id": "10923593_2_Ent3", "role": "Treatment", "text": "phenylbutazone , ranitidine , clomipramine and levomepromazine", "start": 46, "end": 53}, {"entity_id": "10923593_2_Ent7", "role": "Treatment_Drug", "text": "ranitidine", "start": 48, "end": 49}, {"entity_id": "10923593_2_Ent11", "role": "Combination_Drug", "text": "ranitidine", "start": 48, "end": 49}, {"entity_id": "10923593_2_Ent5", "role": "Treatment_Drug", "text": "clomipramine", "start": 50, "end": 51}, {"entity_id": "10923593_2_Ent10", "role": "Combination_Drug", "text": "clomipramine", "start": 50, "end": 51}, {"entity_id": "10923593_2_Ent6", "role": "Treatment_Drug", "text": "levomepromazine", "start": 52, "end": 53}, {"entity_id": "10923593_2_Ent9", "role": "Combination_Drug", "text": "levomepromazine", "start": 52, "end": 53}]}], "entity_mentions": [{"id": "10923593_2_Ent0", "text": "a 38 - year - old woman diagnosed with anxiety , depression and right sacroileitis", "entity_type": "Entity", "start": 27, "end": 42}, {"id": "10923593_2_Ent1", "text": "38 - year - old", "entity_type": "Entity", "start": 28, "end": 33}, {"id": "10923593_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "10923593_2_Ent8", "text": "anxiety , depression and right sacroileitis", "entity_type": "Entity", "start": 36, "end": 42}, {"id": "10923593_2_Ent4", "text": "phenylbutazone", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "10923593_2_Ent12", "text": "phenylbutazone", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "10923593_2_Ent3", "text": "phenylbutazone , ranitidine , clomipramine and levomepromazine", "entity_type": "Entity", "start": 46, "end": 53}, {"id": "10923593_2_Ent7", "text": "ranitidine", "entity_type": "Entity", "start": 48, "end": 49}, {"id": "10923593_2_Ent11", "text": "ranitidine", "entity_type": "Entity", "start": 48, "end": 49}, {"id": "10923593_2_Ent5", "text": "clomipramine", "entity_type": "Entity", "start": 50, "end": 51}, {"id": "10923593_2_Ent10", "text": "clomipramine", "entity_type": "Entity", "start": 50, "end": 51}, {"id": "10923593_2_Ent6", "text": "levomepromazine", "entity_type": "Entity", "start": 52, "end": 53}, {"id": "10923593_2_Ent9", "text": "levomepromazine", "entity_type": "Entity", "start": 52, "end": 53}], "lang": "en"}
{"doc_id": "11020127_3", "wnd_id": "11020127_3_1", "text": "Ritonavir acted as a CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity .", "tokens": ["Ritonavir", "acted", "as", "a", "CYP3A4", "inhibitor", ",", "diminishing", "carbamazepine", "metabolism", "and", "provoking", "an", "increase", "in", "serum", "levels", "and", "clinical", "toxicity", "."], "event_mentions": [{"id": "11020127_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "acted", "start": 1, "end": 2}, "arguments": [{"entity_id": "11020127_3_Ent1", "role": "Treatment", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "11020127_3_Ent2", "role": "Treatment_Drug", "text": "Ritonavir", "start": 0, "end": 1}, {"entity_id": "11020127_3_Ent0", "role": "Effect", "text": "CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity", "start": 4, "end": 20}]}], "entity_mentions": [{"id": "11020127_3_Ent1", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11020127_3_Ent2", "text": "Ritonavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11020127_3_Ent0", "text": "CYP3A4 inhibitor , diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity", "entity_type": "Entity", "start": 4, "end": 20}], "lang": "en"}
{"doc_id": "11022272_2", "wnd_id": "11022272_2_1", "text": "CONCLUSION : We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction .", "tokens": ["CONCLUSION", ":", "We", "have", "introduced", "a", "case", "of", "anaphylaxis", "by", "calcitonin", "that", "suggest", "an", "IgE", "mediated", "hypersensitivity", "reaction", "."], "event_mentions": [{"id": "11022272_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 9, "end": 10}, "arguments": [{"entity_id": "11022272_2_Ent0", "role": "Subject", "text": "a case", "start": 5, "end": 7}, {"entity_id": "11022272_2_Ent1", "role": "Effect", "text": "anaphylaxis", "start": 8, "end": 9}, {"entity_id": "11022272_2_Ent2", "role": "Treatment", "text": "calcitonin", "start": 10, "end": 11}, {"entity_id": "11022272_2_Ent3", "role": "Treatment_Drug", "text": "calcitonin", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11022272_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11022272_2_Ent1", "text": "anaphylaxis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11022272_2_Ent2", "text": "calcitonin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11022272_2_Ent3", "text": "calcitonin", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11059196_2", "wnd_id": "11059196_2_1", "text": "We describe a 10 - year - old boy with ulcerative colitis who developed acute pancreatitis while on long - term treatment with 5 - aminosalicylic acid .", "tokens": ["We", "describe", "a", "10", "-", "year", "-", "old", "boy", "with", "ulcerative", "colitis", "who", "developed", "acute", "pancreatitis", "while", "on", "long", "-", "term", "treatment", "with", "5", "-", "aminosalicylic", "acid", "."], "event_mentions": [{"id": "11059196_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "11059196_2_Ent0", "role": "Subject", "text": "a 10 - year - old boy with ulcerative colitis", "start": 2, "end": 12}, {"entity_id": "11059196_2_Ent1", "role": "Subject_Age", "text": "10 - year - old", "start": 3, "end": 8}, {"entity_id": "11059196_2_Ent2", "role": "Subject_Gender", "text": "boy", "start": 8, "end": 9}, {"entity_id": "11059196_2_Ent7", "role": "Treatment_Disorder", "text": "ulcerative colitis", "start": 10, "end": 12}, {"entity_id": "11059196_2_Ent3", "role": "Effect", "text": "acute pancreatitis", "start": 14, "end": 16}, {"entity_id": "11059196_2_Ent5", "role": "Treatment_Freq", "text": "long - term treatment", "start": 18, "end": 22}, {"entity_id": "11059196_2_Ent4", "role": "Treatment", "text": "long - term treatment with 5 - aminosalicylic acid", "start": 18, "end": 27}, {"entity_id": "11059196_2_Ent6", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "11059196_2_Ent0", "text": "a 10 - year - old boy with ulcerative colitis", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "11059196_2_Ent1", "text": "10 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "11059196_2_Ent2", "text": "boy", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11059196_2_Ent7", "text": "ulcerative colitis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "11059196_2_Ent3", "text": "acute pancreatitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11059196_2_Ent5", "text": "long - term treatment", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "11059196_2_Ent4", "text": "long - term treatment with 5 - aminosalicylic acid", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "11059196_2_Ent6", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "11077455_3", "wnd_id": "11077455_3_1", "text": "PURPOSE : Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .", "tokens": ["PURPOSE", ":", "Symptomatic", "visual", "field", "constriction", "thought", "to", "be", "associated", "with", "vigabatrin", "has", "been", "reported", "."], "event_mentions": [{"id": "11077455_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "11077455_3_Ent0", "role": "Effect", "text": "Symptomatic visual field constriction", "start": 2, "end": 6}, {"entity_id": "11077455_3_Ent1", "role": "Treatment", "text": "vigabatrin", "start": 11, "end": 12}, {"entity_id": "11077455_3_Ent2", "role": "Treatment_Drug", "text": "vigabatrin", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "11077455_3_Ent0", "text": "Symptomatic visual field constriction", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "11077455_3_Ent1", "text": "vigabatrin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11077455_3_Ent2", "text": "vigabatrin", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "11105373_1", "wnd_id": "11105373_1_1", "text": "A 33 - year - old male presented with brown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months .", "tokens": ["A", "33", "-", "year", "-", "old", "male", "presented", "with", "brown", "discolouration", "of", "the", "fingernails", "following", "the", "application", "of", "4", "%", "hydroquinone", "in", "sorbolene", "cream", "and", "0.1", "%", "tretinoin", "cream", "to", "the", "face", "intermittently", "for", "9", "months", "."], "event_mentions": [{"id": "11105373_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "application", "start": 16, "end": 17}, "arguments": [{"entity_id": "11105373_1_Ent0", "role": "Subject", "text": "A 33 - year - old male", "start": 0, "end": 7}, {"entity_id": "11105373_1_Ent1", "role": "Subject_Age", "text": "33 - year - old", "start": 1, "end": 6}, {"entity_id": "11105373_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "11105373_1_Ent3", "role": "Effect", "text": "brown discolouration of the fingernails", "start": 9, "end": 14}, {"entity_id": "11105373_1_Ent7", "role": "Treatment_Dosage", "text": "4 %", "start": 18, "end": 20}, {"entity_id": "11105373_1_Ent4", "role": "Treatment", "text": "4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months", "start": 18, "end": 36}, {"entity_id": "11105373_1_Ent5", "role": "Treatment_Drug", "text": "hydroquinone", "start": 20, "end": 21}, {"entity_id": "11105373_1_Ent9", "role": "Treatment_Route", "text": "cream", "start": 23, "end": 24}, {"entity_id": "11105373_1_Ent8", "role": "Treatment_Dosage", "text": "0.1 %", "start": 25, "end": 27}, {"entity_id": "11105373_1_Ent6", "role": "Treatment_Drug", "text": "tretinoin", "start": 27, "end": 28}, {"entity_id": "11105373_1_Ent10", "role": "Treatment_Route", "text": "cream", "start": 28, "end": 29}, {"entity_id": "11105373_1_Ent11", "role": "Treatment_Route", "text": "face", "start": 31, "end": 32}, {"entity_id": "11105373_1_Ent12", "role": "Treatment_Freq", "text": "intermittently", "start": 32, "end": 33}, {"entity_id": "11105373_1_Ent13", "role": "Treatment_Duration", "text": "9 months", "start": 34, "end": 36}]}], "entity_mentions": [{"id": "11105373_1_Ent0", "text": "A 33 - year - old male", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11105373_1_Ent1", "text": "33 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11105373_1_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11105373_1_Ent3", "text": "brown discolouration of the fingernails", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "11105373_1_Ent7", "text": "4 %", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "11105373_1_Ent4", "text": "4 % hydroquinone in sorbolene cream and 0.1 % tretinoin cream to the face intermittently for 9 months", "entity_type": "Entity", "start": 18, "end": 36}, {"id": "11105373_1_Ent5", "text": "hydroquinone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11105373_1_Ent9", "text": "cream", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11105373_1_Ent8", "text": "0.1 %", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11105373_1_Ent6", "text": "tretinoin", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "11105373_1_Ent10", "text": "cream", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11105373_1_Ent11", "text": "face", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "11105373_1_Ent12", "text": "intermittently", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "11105373_1_Ent13", "text": "9 months", "entity_type": "Entity", "start": 34, "end": 36}], "lang": "en"}
{"doc_id": "11111942_2", "wnd_id": "11111942_2_1", "text": "We present a case of significant over - anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy .", "tokens": ["We", "present", "a", "case", "of", "significant", "over", "-", "anticoagulation", "temporally", "associated", "with", "a", "bout", "of", "protracted", "diarrhea", "in", "a", "patient", "on", "warfarin", "therapy", "."], "event_mentions": [{"id": "11111942_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "over - anticoagulation", "start": 6, "end": 9}, "arguments": [{"entity_id": "11111942_2_Ent0", "role": "Effect", "text": "protracted diarrhea", "start": 15, "end": 17}, {"entity_id": "11111942_2_Ent1", "role": "Treatment", "text": "warfarin", "start": 21, "end": 22}, {"entity_id": "11111942_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "11111942_2_Ent0", "text": "protracted diarrhea", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "11111942_2_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11111942_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "11122162_1", "wnd_id": "11122162_1_1", "text": "MI related to the use of activated and non - activated PCCs predominantly affects young patients who often have no preceding history of , or risk factors for , MI and tends to be associated with large cumulative doses of concentrate .", "tokens": ["MI", "related", "to", "the", "use", "of", "activated", "and", "non", "-", "activated", "PCCs", "predominantly", "affects", "young", "patients", "who", "often", "have", "no", "preceding", "history", "of", ",", "or", "risk", "factors", "for", ",", "MI", "and", "tends", "to", "be", "associated", "with", "large", "cumulative", "doses", "of", "concentrate", "."], "event_mentions": [{"id": "11122162_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "11122162_1_Ent2", "role": "Effect", "text": "MI", "start": 0, "end": 1}, {"entity_id": "11122162_1_Ent6", "role": "Treatment_Drug", "text": "activated", "start": 6, "end": 7}, {"entity_id": "11122162_1_Ent3", "role": "Treatment", "text": "activated and non - activated PCCs", "start": 6, "end": 12}, {"entity_id": "11122162_1_Ent5", "role": "Treatment_Drug", "text": "non - activated PCCs", "start": 8, "end": 12}, {"entity_id": "11122162_1_Ent7", "role": "Treatment_Drug", "text": "PCCs", "start": 11, "end": 12}, {"entity_id": "11122162_1_Ent1", "role": "Subject_Age", "text": "young", "start": 14, "end": 15}, {"entity_id": "11122162_1_Ent0", "role": "Subject", "text": "young patients who often have no preceding history of , or risk factors for , MI", "start": 14, "end": 30}, {"entity_id": "11122162_1_Ent8", "role": "Treatment_Dosage", "text": "large cumulative doses", "start": 36, "end": 39}, {"entity_id": "11122162_1_Ent4", "role": "Treatment", "text": "large cumulative doses of concentrate", "start": 36, "end": 41}]}], "entity_mentions": [{"id": "11122162_1_Ent2", "text": "MI", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11122162_1_Ent6", "text": "activated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11122162_1_Ent3", "text": "activated and non - activated PCCs", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11122162_1_Ent5", "text": "non - activated PCCs", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "11122162_1_Ent7", "text": "PCCs", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11122162_1_Ent1", "text": "young", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11122162_1_Ent0", "text": "young patients who often have no preceding history of , or risk factors for , MI", "entity_type": "Entity", "start": 14, "end": 30}, {"id": "11122162_1_Ent8", "text": "large cumulative doses", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "11122162_1_Ent4", "text": "large cumulative doses of concentrate", "entity_type": "Entity", "start": 36, "end": 41}], "lang": "en"}
{"doc_id": "11126885_7", "wnd_id": "11126885_7_1", "text": "Only after three subsequent episodes of severe , symptomatic thrombocytopenia over the next four weeks did he say , upon repeat questioning , that he had continued to take quinine for night leg cramps .", "tokens": ["Only", "after", "three", "subsequent", "episodes", "of", "severe", ",", "symptomatic", "thrombocytopenia", "over", "the", "next", "four", "weeks", "did", "he", "say", ",", "upon", "repeat", "questioning", ",", "that", "he", "had", "continued", "to", "take", "quinine", "for", "night", "leg", "cramps", "."], "event_mentions": [{"id": "11126885_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "take", "start": 28, "end": 29}, "arguments": [{"entity_id": "11126885_7_Ent3", "role": "Effect", "text": "symptomatic thrombocytopenia", "start": 8, "end": 10}, {"entity_id": "11126885_7_Ent7", "role": "Treatment_Time_elapsed", "text": "over the next four weeks", "start": 10, "end": 15}, {"entity_id": "11126885_7_Ent0", "role": "Subject", "text": "he", "start": 24, "end": 25}, {"entity_id": "11126885_7_Ent2", "role": "Subject_Gender", "text": "he", "start": 24, "end": 25}, {"entity_id": "11126885_7_Ent4", "role": "Treatment", "text": "continued to take quinine", "start": 26, "end": 30}, {"entity_id": "11126885_7_Ent5", "role": "Treatment_Drug", "text": "quinine", "start": 29, "end": 30}, {"entity_id": "11126885_7_Ent1", "role": "Subject", "text": "night leg cramps", "start": 31, "end": 34}, {"entity_id": "11126885_7_Ent6", "role": "Treatment_Disorder", "text": "night leg cramps", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11126885_7_Ent3", "text": "symptomatic thrombocytopenia", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "11126885_7_Ent7", "text": "over the next four weeks", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11126885_7_Ent0", "text": "he", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11126885_7_Ent2", "text": "he", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11126885_7_Ent4", "text": "continued to take quinine", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "11126885_7_Ent5", "text": "quinine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11126885_7_Ent1", "text": "night leg cramps", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "11126885_7_Ent6", "text": "night leg cramps", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11131346_3", "wnd_id": "11131346_3_1", "text": "An 8 - year - old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug .", "tokens": ["An", "8", "-", "year", "-", "old", "child", "with", "familial", "Mediterranean", "fever", "exhibited", "signs", "of", "colchicine", "intoxication", "while", "receiving", "prophylactic", "doses", "of", "the", "drug", "."], "event_mentions": [{"id": "11131346_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibited", "start": 11, "end": 12}, "arguments": [{"entity_id": "11131346_3_Ent0", "role": "Subject", "text": "An 8 - year - old child", "start": 0, "end": 7}, {"entity_id": "11131346_3_Ent1", "role": "Subject_Age", "text": "8 - year - old", "start": 1, "end": 6}, {"entity_id": "11131346_3_Ent2", "role": "Subject_Age", "text": "child", "start": 6, "end": 7}, {"entity_id": "11131346_3_Ent6", "role": "Treatment_Disorder", "text": "familial Mediterranean fever", "start": 8, "end": 11}, {"entity_id": "11131346_3_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 14, "end": 15}, {"entity_id": "11131346_3_Ent3", "role": "Effect", "text": "colchicine intoxication", "start": 14, "end": 16}, {"entity_id": "11131346_3_Ent5", "role": "Treatment_Dosage", "text": "prophylactic doses", "start": 18, "end": 20}, {"entity_id": "11131346_3_Ent4", "role": "Treatment", "text": "prophylactic doses of the drug", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "11131346_3_Ent0", "text": "An 8 - year - old child", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "11131346_3_Ent1", "text": "8 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11131346_3_Ent2", "text": "child", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "11131346_3_Ent6", "text": "familial Mediterranean fever", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11131346_3_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11131346_3_Ent3", "text": "colchicine intoxication", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11131346_3_Ent5", "text": "prophylactic doses", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "11131346_3_Ent4", "text": "prophylactic doses of the drug", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "11142491_1", "wnd_id": "11142491_1_1", "text": "Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem - cell transplantation .", "tokens": ["Acute", "myeloid", "leukemia", "and", "lung", "cancer", "occurring", "in", "a", "chronic", "lymphocytic", "leukemia", "patient", "treated", "with", "fludarabine", "and", "autologous", "peripheral", "blood", "stem", "-", "cell", "transplantation", "."], "event_mentions": [{"id": "11142491_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "11142491_1_Ent1", "role": "Effect", "text": "Acute myeloid leukemia and lung cancer", "start": 0, "end": 6}, {"entity_id": "11142491_1_Ent0", "role": "Subject", "text": "a chronic lymphocytic leukemia patient", "start": 8, "end": 13}, {"entity_id": "11142491_1_Ent4", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukemia", "start": 9, "end": 12}, {"entity_id": "11142491_1_Ent3", "role": "Treatment_Drug", "text": "fludarabine", "start": 15, "end": 16}, {"entity_id": "11142491_1_Ent2", "role": "Treatment", "text": "fludarabine and autologous peripheral blood stem - cell transplantation", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "11142491_1_Ent1", "text": "Acute myeloid leukemia and lung cancer", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "11142491_1_Ent0", "text": "a chronic lymphocytic leukemia patient", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "11142491_1_Ent4", "text": "chronic lymphocytic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "11142491_1_Ent3", "text": "fludarabine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11142491_1_Ent2", "text": "fludarabine and autologous peripheral blood stem - cell transplantation", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "11144696_9", "wnd_id": "11144696_9_1", "text": "Both venlafaxine and trimipramine have been associated with seizures , mainly after overdose .", "tokens": ["Both", "venlafaxine", "and", "trimipramine", "have", "been", "associated", "with", "seizures", ",", "mainly", "after", "overdose", "."], "event_mentions": [{"id": "11144696_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "11144696_9_Ent3", "role": "Treatment_Drug", "text": "venlafaxine", "start": 1, "end": 2}, {"entity_id": "11144696_9_Ent2", "role": "Treatment", "text": "venlafaxine and trimipramine", "start": 1, "end": 4}, {"entity_id": "11144696_9_Ent4", "role": "Treatment_Drug", "text": "trimipramine", "start": 3, "end": 4}, {"entity_id": "11144696_9_Ent0", "role": "Effect", "text": "seizures", "start": 8, "end": 9}, {"entity_id": "11144696_9_Ent1", "role": "Treatment", "text": "overdose", "start": 12, "end": 13}, {"entity_id": "11144696_9_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "11144696_9_Ent3", "text": "venlafaxine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11144696_9_Ent2", "text": "venlafaxine and trimipramine", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "11144696_9_Ent4", "text": "trimipramine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11144696_9_Ent0", "text": "seizures", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11144696_9_Ent1", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11144696_9_Ent5", "text": "overdose", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11147747_3", "wnd_id": "11147747_3_1", "text": "This concerns 2 male patients who experienced incontinence while taking venlafaxine .", "tokens": ["This", "concerns", "2", "male", "patients", "who", "experienced", "incontinence", "while", "taking", "venlafaxine", "."], "event_mentions": [{"id": "11147747_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11147747_3_Ent1", "role": "Subject_Population", "text": "2", "start": 2, "end": 3}, {"entity_id": "11147747_3_Ent0", "role": "Subject", "text": "2 male patients", "start": 2, "end": 5}, {"entity_id": "11147747_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 3, "end": 4}, {"entity_id": "11147747_3_Ent3", "role": "Effect", "text": "incontinence", "start": 7, "end": 8}, {"entity_id": "11147747_3_Ent4", "role": "Treatment", "text": "venlafaxine", "start": 10, "end": 11}, {"entity_id": "11147747_3_Ent5", "role": "Treatment_Drug", "text": "venlafaxine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11147747_3_Ent1", "text": "2", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11147747_3_Ent0", "text": "2 male patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11147747_3_Ent2", "text": "male", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11147747_3_Ent3", "text": "incontinence", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11147747_3_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11147747_3_Ent5", "text": "venlafaxine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11155197_3", "wnd_id": "11155197_3_1", "text": "Type II heparin - induced thrombocytopenia ( HIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications .", "tokens": ["Type", "II", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "is", "an", "immunological", "disorder", "characterized", "by", "antibodies", "to", "heparin", "-", "platelet", "factor", "4", "complexes", "and", "a", "high", "risk", "of", "thrombotic", "complications", "."], "event_mentions": [{"id": "11155197_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "11155197_3_Ent1", "role": "Treatment", "text": "Type II heparin", "start": 0, "end": 3}, {"entity_id": "11155197_3_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 2, "end": 3}, {"entity_id": "11155197_3_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "11155197_3_Ent1", "text": "Type II heparin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11155197_3_Ent2", "text": "heparin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11155197_3_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "11171531_2", "wnd_id": "11171531_2_1", "text": "It also highlights a current major etiologic question , that is , whether and to what degree lead exposure contributes to the development of hypertension , and raises the issue of whether lead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium .", "tokens": ["It", "also", "highlights", "a", "current", "major", "etiologic", "question", ",", "that", "is", ",", "whether", "and", "to", "what", "degree", "lead", "exposure", "contributes", "to", "the", "development", "of", "hypertension", ",", "and", "raises", "the", "issue", "of", "whether", "lead", "-", "induced", "hypertension", "constitutes", "a", "subset", "of", "hypertension", "that", "is", "especially", "amenable", "to", "therapy", "with", "dietary", "calcium", "."], "event_mentions": [{"id": "11171531_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributes", "start": 19, "end": 20}, "arguments": [{"entity_id": "11171531_2_Ent2", "role": "Treatment_Drug", "text": "lead", "start": 17, "end": 18}, {"entity_id": "11171531_2_Ent1", "role": "Treatment", "text": "lead exposure", "start": 17, "end": 19}, {"entity_id": "11171531_2_Ent3", "role": "Treatment_Route", "text": "exposure", "start": 18, "end": 19}, {"entity_id": "11171531_2_Ent0", "role": "Effect", "text": "hypertension", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "11171531_2_Ent2", "text": "lead", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11171531_2_Ent1", "text": "lead exposure", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11171531_2_Ent3", "text": "exposure", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11171531_2_Ent0", "text": "hypertension", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "11174414_1", "wnd_id": "11174414_1_1", "text": "Stevens - Johnson syndrome caused by the antiretroviral drug nevirapine .", "tokens": ["Stevens", "-", "Johnson", "syndrome", "caused", "by", "the", "antiretroviral", "drug", "nevirapine", "."], "event_mentions": [{"id": "11174414_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused by", "start": 4, "end": 6}, "arguments": [{"entity_id": "11174414_1_Ent0", "role": "Effect", "text": "Stevens - Johnson syndrome", "start": 0, "end": 4}, {"entity_id": "11174414_1_Ent1", "role": "Treatment", "text": "antiretroviral drug nevirapine", "start": 7, "end": 10}, {"entity_id": "11174414_1_Ent2", "role": "Treatment_Drug", "text": "nevirapine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11174414_1_Ent0", "text": "Stevens - Johnson syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "11174414_1_Ent1", "text": "antiretroviral drug nevirapine", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "11174414_1_Ent2", "text": "nevirapine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11197767_1", "wnd_id": "11197767_1_1", "text": "Toxicity of cadmium and zinc to encystment and in vitro excystment of Parorchis acanthus ( Digenea : Philophthalmidae ) .", "tokens": ["Toxicity", "of", "cadmium", "and", "zinc", "to", "encystment", "and", "in", "vitro", "excystment", "of", "Parorchis", "acanthus", "(", "Digenea", ":", "Philophthalmidae", ")", "."], "event_mentions": [{"id": "11197767_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Toxicity", "start": 0, "end": 1}, "arguments": [{"entity_id": "11197767_1_Ent0", "role": "Effect", "text": "Toxicity", "start": 0, "end": 1}, {"entity_id": "11197767_1_Ent2", "role": "Treatment_Drug", "text": "cadmium", "start": 2, "end": 3}, {"entity_id": "11197767_1_Ent1", "role": "Treatment", "text": "cadmium and zinc", "start": 2, "end": 5}, {"entity_id": "11197767_1_Ent3", "role": "Treatment_Drug", "text": "zinc", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "11197767_1_Ent0", "text": "Toxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11197767_1_Ent2", "text": "cadmium", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "11197767_1_Ent1", "text": "cadmium and zinc", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "11197767_1_Ent3", "text": "zinc", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "11206417_2", "wnd_id": "11206417_2_1", "text": "AIMS / HYPOTHESIS : There is evidence that insulin and glucose cause renal and ocular vasodilation .", "tokens": ["AIMS", "/", "HYPOTHESIS", ":", "There", "is", "evidence", "that", "insulin", "and", "glucose", "cause", "renal", "and", "ocular", "vasodilation", "."], "event_mentions": [{"id": "11206417_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "11206417_2_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 8, "end": 9}, {"entity_id": "11206417_2_Ent4", "role": "Combination_Drug", "text": "insulin", "start": 8, "end": 9}, {"entity_id": "11206417_2_Ent1", "role": "Treatment", "text": "insulin and glucose", "start": 8, "end": 11}, {"entity_id": "11206417_2_Ent2", "role": "Treatment_Drug", "text": "glucose", "start": 10, "end": 11}, {"entity_id": "11206417_2_Ent5", "role": "Combination_Drug", "text": "glucose", "start": 10, "end": 11}, {"entity_id": "11206417_2_Ent0", "role": "Effect", "text": "renal and ocular vasodilation", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "11206417_2_Ent3", "text": "insulin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11206417_2_Ent4", "text": "insulin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11206417_2_Ent1", "text": "insulin and glucose", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11206417_2_Ent2", "text": "glucose", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11206417_2_Ent5", "text": "glucose", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11206417_2_Ent0", "text": "renal and ocular vasodilation", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "11207969_4", "wnd_id": "11207969_4_1", "text": "We report a fatal case of toxic epidermal necrolysis ( TEN ) resulting from a high dose of cytosine arabinoside ( ARA - C ) .", "tokens": ["We", "report", "a", "fatal", "case", "of", "toxic", "epidermal", "necrolysis", "(", "TEN", ")", "resulting", "from", "a", "high", "dose", "of", "cytosine", "arabinoside", "(", "ARA", "-", "C", ")", "."], "event_mentions": [{"id": "11207969_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting from", "start": 12, "end": 14}, "arguments": [{"entity_id": "11207969_4_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis ( TEN )", "start": 6, "end": 12}, {"entity_id": "11207969_4_Ent3", "role": "Treatment_Dosage", "text": "high dose", "start": 15, "end": 17}, {"entity_id": "11207969_4_Ent1", "role": "Treatment", "text": "high dose of cytosine arabinoside ( ARA - C )", "start": 15, "end": 25}, {"entity_id": "11207969_4_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside ( ARA - C )", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "11207969_4_Ent0", "text": "toxic epidermal necrolysis ( TEN )", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11207969_4_Ent3", "text": "high dose", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "11207969_4_Ent1", "text": "high dose of cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "11207969_4_Ent2", "text": "cytosine arabinoside ( ARA - C )", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "11283125_2", "wnd_id": "11283125_2_1", "text": "The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX ) to reduce the incidence of CNS and systemic relapses in children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma treated with a Berlin - Frankfurt - Munster ( BFM) - based regimen .", "tokens": ["The", "European", "Organization", "for", "Research", "and", "Treatment", "of", "Cancer", "58881", "study", "was", "designed", "to", "test", "in", "a", "prospective", "multicentric", "randomized", "trial", "the", "value", "of", "high", "-", "dose", "(", "HD", ")", "intravenous", "(", "IV", ")", "cytarabine", "(", "Ara", "-", "C", ")", "added", "to", "HD", "IV", "methotrexate", "(", "MTX", ")", "to", "reduce", "the", "incidence", "of", "CNS", "and", "systemic", "relapses", "in", "children", "with", "increased", "-", "risk", "acute", "lymphoblastic", "leukemia", "(", "ALL", ")", "or", "stage", "III", "and", "IV", "lymphoblastic", "lymphoma", "treated", "with", "a", "Berlin", "-", "Frankfurt", "-", "Munster", "(", "BFM)", "-", "based", "regimen", "."], "event_mentions": [{"id": "11283125_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 48, "end": 49}, "arguments": [{"entity_id": "11283125_2_Ent4", "role": "Treatment_Dosage", "text": "high - dose", "start": 24, "end": 27}, {"entity_id": "11283125_2_Ent3", "role": "Treatment", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "start": 24, "end": 48}, {"entity_id": "11283125_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 30, "end": 31}, {"entity_id": "11283125_2_Ent6", "role": "Treatment_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent10", "role": "Combination_Drug", "text": "cytarabine", "start": 34, "end": 35}, {"entity_id": "11283125_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent11", "role": "Combination_Drug", "text": "methotrexate", "start": 44, "end": 45}, {"entity_id": "11283125_2_Ent2", "role": "Effect", "text": "reduce the incidence of CNS and systemic relapses", "start": 49, "end": 57}, {"entity_id": "11283125_2_Ent1", "role": "Subject_Age", "text": "children", "start": 58, "end": 59}, {"entity_id": "11283125_2_Ent0", "role": "Subject", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "start": 58, "end": 76}, {"entity_id": "11283125_2_Ent8", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 63, "end": 66}, {"entity_id": "11283125_2_Ent9", "role": "Treatment_Disorder", "text": "stage III and IV lymphoblastic lymphoma", "start": 70, "end": 76}]}], "entity_mentions": [{"id": "11283125_2_Ent4", "text": "high - dose", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "11283125_2_Ent3", "text": "high - dose ( HD ) intravenous ( IV ) cytarabine ( Ara - C ) added to HD IV methotrexate ( MTX )", "entity_type": "Entity", "start": 24, "end": 48}, {"id": "11283125_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11283125_2_Ent6", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent10", "text": "cytarabine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "11283125_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent11", "text": "methotrexate", "entity_type": "Entity", "start": 44, "end": 45}, {"id": "11283125_2_Ent2", "text": "reduce the incidence of CNS and systemic relapses", "entity_type": "Entity", "start": 49, "end": 57}, {"id": "11283125_2_Ent1", "text": "children", "entity_type": "Entity", "start": 58, "end": 59}, {"id": "11283125_2_Ent0", "text": "children with increased - risk acute lymphoblastic leukemia ( ALL ) or stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 58, "end": 76}, {"id": "11283125_2_Ent8", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 63, "end": 66}, {"id": "11283125_2_Ent9", "text": "stage III and IV lymphoblastic lymphoma", "entity_type": "Entity", "start": 70, "end": 76}], "lang": "en"}
{"doc_id": "11292139_1", "wnd_id": "11292139_1_1", "text": "We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin .", "tokens": ["We", "report", "a", "patient", "with", "advanced", "colonic", "carcinoma", "who", "was", "treated", "with", "concomitant", "chemoirradiation", "with", "oxaliplatin", "and", "developed", "a", "peculiar", "dermnatitis", "in", "the", "irradiated", "field", "after", "being", "exposed", "to", "subsequent", "chemotherapy", "with", "oxaliplatin", "."], "event_mentions": [{"id": "11292139_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "11292139_1_Ent0", "role": "Subject", "text": "a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin", "start": 2, "end": 16}, {"entity_id": "11292139_1_Ent3", "role": "Treatment_Disorder", "text": "advanced colonic carcinoma", "start": 5, "end": 8}, {"entity_id": "11292139_1_Ent4", "role": "Treatment_Drug", "text": "concomitant chemoirradiation", "start": 12, "end": 14}, {"entity_id": "11292139_1_Ent5", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 15, "end": 16}, {"entity_id": "11292139_1_Ent1", "role": "Effect", "text": "a peculiar dermnatitis in the irradiated field", "start": 18, "end": 25}, {"entity_id": "11292139_1_Ent2", "role": "Treatment", "text": "exposed to subsequent chemotherapy with oxaliplatin", "start": 27, "end": 33}, {"entity_id": "11292139_1_Ent6", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "11292139_1_Ent0", "text": "a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin", "entity_type": "Entity", "start": 2, "end": 16}, {"id": "11292139_1_Ent3", "text": "advanced colonic carcinoma", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11292139_1_Ent4", "text": "concomitant chemoirradiation", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "11292139_1_Ent5", "text": "oxaliplatin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11292139_1_Ent1", "text": "a peculiar dermnatitis in the irradiated field", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "11292139_1_Ent2", "text": "exposed to subsequent chemotherapy with oxaliplatin", "entity_type": "Entity", "start": 27, "end": 33}, {"id": "11292139_1_Ent6", "text": "oxaliplatin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "11335880_3", "wnd_id": "11335880_3_1", "text": "Hashimoto 's disease during interferon - alpha therapy in a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease .", "tokens": ["Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "therapy", "in", "a", "patient", "with", "pre", "-", "treatment", "negative", "anti", "-", "thyroid", "autoantibodies", "and", "with", "the", "specific", "genetic", "susceptibility", "to", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "11335880_3_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 0, "end": 3}, {"entity_id": "11335880_3_Ent3", "role": "Treatment", "text": "interferon - alpha", "start": 4, "end": 7}, {"entity_id": "11335880_3_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 4, "end": 7}, {"entity_id": "11335880_3_Ent0", "role": "Subject", "text": "a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "start": 9, "end": 30}, {"entity_id": "11335880_3_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility to the thyroid disease", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "11335880_3_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11335880_3_Ent3", "text": "interferon - alpha", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11335880_3_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11335880_3_Ent0", "text": "a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease", "entity_type": "Entity", "start": 9, "end": 30}, {"id": "11335880_3_Ent1", "text": "specific genetic susceptibility to the thyroid disease", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "11335880_4", "wnd_id": "11335880_4_1", "text": "OBJECTIVES : The authors described a case of Hashimoto 's disease during interferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease .", "tokens": ["OBJECTIVES", ":", "The", "authors", "described", "a", "case", "of", "Hashimoto", "'s", "disease", "during", "interferon", "-", "alpha", "(", "IFN", "-", "alpha", ")", "treatment", "for", "chronic", "viral", "C", "hepatitis", "in", "a", "patient", "with", "the", "specific", "genetic", "susceptibility", "associated", "with", "the", "thyroid", "disease", "."], "event_mentions": [{"id": "11335880_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 11, "end": 12}, "arguments": [{"entity_id": "11335880_4_Ent2", "role": "Effect", "text": "Hashimoto 's disease", "start": 8, "end": 11}, {"entity_id": "11335880_4_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 12, "end": 15}, {"entity_id": "11335880_4_Ent3", "role": "Treatment", "text": "interferon - alpha ( IFN - alpha ) treatment", "start": 12, "end": 21}, {"entity_id": "11335880_4_Ent5", "role": "Treatment_Disorder", "text": "chronic viral C hepatitis", "start": 22, "end": 26}, {"entity_id": "11335880_4_Ent0", "role": "Subject", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "start": 27, "end": 39}, {"entity_id": "11335880_4_Ent1", "role": "Subject_Disorder", "text": "specific genetic susceptibility", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11335880_4_Ent2", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "11335880_4_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "11335880_4_Ent3", "text": "interferon - alpha ( IFN - alpha ) treatment", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "11335880_4_Ent5", "text": "chronic viral C hepatitis", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "11335880_4_Ent0", "text": "a patient with the specific genetic susceptibility associated with the thyroid disease", "entity_type": "Entity", "start": 27, "end": 39}, {"id": "11335880_4_Ent1", "text": "specific genetic susceptibility", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11341670_1", "wnd_id": "11341670_1_1", "text": "During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole , three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid .", "tokens": ["During", "dose", "-", "finding", "studies", "for", "intravenous", "proton", "pump", "inhibitors", "omeprazole", "and", "pantoprazole", ",", "three", "of", "six", "young", "female", "volunteers", "receiving", "omeprazole", "and", "two", "young", "female", "volunteers", "receiving", "pantoprazole", "developed", "peripheral", "edema", "within", "8", "hr", "when", "high", "doses", "of", "the", "proton", "pump", "inhibitors", "were", "applied", "by", "continuous", "infusion", "together", "with", "large", "volumes", "of", "fluid", "."], "event_mentions": [{"id": "11341670_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "11341670_1_Ent1", "role": "Subject_Population", "text": "three", "start": 14, "end": 15}, {"entity_id": "11341670_1_Ent0", "role": "Subject", "text": "three of six young female volunteers", "start": 14, "end": 20}, {"entity_id": "11341670_1_Ent2", "role": "Subject_Age", "text": "young", "start": 17, "end": 18}, {"entity_id": "11341670_1_Ent3", "role": "Subject_Gender", "text": "female", "start": 18, "end": 19}, {"entity_id": "11341670_1_Ent5", "role": "Treatment", "text": "omeprazole", "start": 21, "end": 22}, {"entity_id": "11341670_1_Ent7", "role": "Treatment_Drug", "text": "omeprazole", "start": 21, "end": 22}, {"entity_id": "11341670_1_Ent4", "role": "Effect", "text": "peripheral edema within 8 hr", "start": 30, "end": 35}, {"entity_id": "11341670_1_Ent6", "role": "Treatment", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "start": 36, "end": 54}]}, {"id": "11341670_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "11341670_1_Ent9", "role": "Subject_Population", "text": "two", "start": 23, "end": 24}, {"entity_id": "11341670_1_Ent8", "role": "Subject", "text": "two young female volunteers", "start": 23, "end": 27}, {"entity_id": "11341670_1_Ent10", "role": "Subject_Age", "text": "young", "start": 24, "end": 25}, {"entity_id": "11341670_1_Ent11", "role": "Subject_Gender", "text": "female", "start": 25, "end": 26}, {"entity_id": "11341670_1_Ent13", "role": "Treatment", "text": "pantoprazole", "start": 28, "end": 29}, {"entity_id": "11341670_1_Ent15", "role": "Treatment_Drug", "text": "pantoprazole", "start": 28, "end": 29}, {"entity_id": "11341670_1_Ent12", "role": "Effect", "text": "peripheral edema within 8 hr", "start": 30, "end": 35}, {"entity_id": "11341670_1_Ent14", "role": "Treatment", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "start": 36, "end": 54}]}], "entity_mentions": [{"id": "11341670_1_Ent1", "text": "three", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11341670_1_Ent0", "text": "three of six young female volunteers", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "11341670_1_Ent2", "text": "young", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11341670_1_Ent3", "text": "female", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11341670_1_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11341670_1_Ent7", "text": "omeprazole", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11341670_1_Ent9", "text": "two", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11341670_1_Ent8", "text": "two young female volunteers", "entity_type": "Entity", "start": 23, "end": 27}, {"id": "11341670_1_Ent10", "text": "young", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11341670_1_Ent11", "text": "female", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11341670_1_Ent13", "text": "pantoprazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11341670_1_Ent15", "text": "pantoprazole", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11341670_1_Ent4", "text": "peripheral edema within 8 hr", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "11341670_1_Ent12", "text": "peripheral edema within 8 hr", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "11341670_1_Ent6", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "entity_type": "Entity", "start": 36, "end": 54}, {"id": "11341670_1_Ent14", "text": "high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid", "entity_type": "Entity", "start": 36, "end": 54}], "lang": "en"}
{"doc_id": "11399735_2", "wnd_id": "11399735_2_1", "text": "Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment .", "tokens": ["Special", "care", "should", "be", "taken", "when", "pulmonary", "symptoms", "appear", "in", "association", "with", "ticlopidine", "treatment", "."], "event_mentions": [{"id": "11399735_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 8, "end": 9}, "arguments": [{"entity_id": "11399735_2_Ent0", "role": "Effect", "text": "pulmonary symptoms", "start": 6, "end": 8}, {"entity_id": "11399735_2_Ent2", "role": "Treatment_Drug", "text": "ticlopidine", "start": 12, "end": 13}, {"entity_id": "11399735_2_Ent1", "role": "Treatment", "text": "ticlopidine treatment", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "11399735_2_Ent0", "text": "pulmonary symptoms", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11399735_2_Ent2", "text": "ticlopidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11399735_2_Ent1", "text": "ticlopidine treatment", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "11428480_1", "wnd_id": "11428480_1_1", "text": "Adenosine - induced ventricular fibrillation .", "tokens": ["Adenosine", "-", "induced", "ventricular", "fibrillation", "."], "event_mentions": [{"id": "11428480_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "11428480_1_Ent1", "role": "Treatment", "text": "Adenosine", "start": 0, "end": 1}, {"entity_id": "11428480_1_Ent2", "role": "Treatment_Drug", "text": "Adenosine", "start": 0, "end": 1}, {"entity_id": "11428480_1_Ent0", "role": "Effect", "text": "ventricular fibrillation", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "11428480_1_Ent1", "text": "Adenosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11428480_1_Ent2", "text": "Adenosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11428480_1_Ent0", "text": "ventricular fibrillation", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "11443640_1", "wnd_id": "11443640_1_1", "text": "Massive plasmocytosis due to methimazole - induced bone marrow toxicity .", "tokens": ["Massive", "plasmocytosis", "due", "to", "methimazole", "-", "induced", "bone", "marrow", "toxicity", "."], "event_mentions": [{"id": "11443640_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "11443640_1_Ent1", "role": "Effect", "text": "Massive plasmocytosis", "start": 0, "end": 2}, {"entity_id": "11443640_1_Ent2", "role": "Treatment", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "11443640_1_Ent3", "role": "Treatment_Drug", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "11443640_1_Ent0", "role": "Effect", "text": "bone marrow toxicity", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "11443640_1_Ent1", "text": "Massive plasmocytosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11443640_1_Ent2", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11443640_1_Ent3", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11443640_1_Ent0", "text": "bone marrow toxicity", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "11452688_1", "wnd_id": "11452688_1_1", "text": "This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving ' standard ' doses of dexamethasone as part of the antiemetic regimen used in cisplatin - based combination chemotherapy .", "tokens": ["This", "report", "details", "a", "case", "of", "bilateral", "avascular", "necrosis", "of", "the", "femoral", "heads", "in", "a", "patient", "receiving", "'", "standard", "'", "doses", "of", "dexamethasone", "as", "part", "of", "the", "antiemetic", "regimen", "used", "in", "cisplatin", "-", "based", "combination", "chemotherapy", "."], "event_mentions": [{"id": "11452688_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 16, "end": 17}, "arguments": [{"entity_id": "11452688_1_Ent1", "role": "Effect", "text": "bilateral avascular necrosis of the femoral heads", "start": 6, "end": 13}, {"entity_id": "11452688_1_Ent0", "role": "Subject", "text": "a patient", "start": 14, "end": 16}, {"entity_id": "11452688_1_Ent3", "role": "Treatment_Dosage", "text": "' standard ' doses", "start": 17, "end": 21}, {"entity_id": "11452688_1_Ent2", "role": "Treatment", "text": "' standard ' doses of dexamethasone", "start": 17, "end": 23}, {"entity_id": "11452688_1_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11452688_1_Ent1", "text": "bilateral avascular necrosis of the femoral heads", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "11452688_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "11452688_1_Ent3", "text": "' standard ' doses", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11452688_1_Ent2", "text": "' standard ' doses of dexamethasone", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "11452688_1_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11485141_3", "wnd_id": "11485141_3_1", "text": "Linear immunoglobulin A bullous dermatosis induced by gemcitabine .", "tokens": ["Linear", "immunoglobulin", "A", "bullous", "dermatosis", "induced", "by", "gemcitabine", "."], "event_mentions": [{"id": "11485141_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "11485141_3_Ent0", "role": "Effect", "text": "Linear immunoglobulin A bullous dermatosis", "start": 0, "end": 5}, {"entity_id": "11485141_3_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 7, "end": 8}, {"entity_id": "11485141_3_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11485141_3_Ent0", "text": "Linear immunoglobulin A bullous dermatosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11485141_3_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11485141_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11487721_3", "wnd_id": "11487721_3_1", "text": "We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol ( 80 mg / m(2)x3 ) .", "tokens": ["We", "describe", "a", "case", "of", "advanced", "ovarian", "carcinoma", "who", "developed", "difficulty", "walking", "because", "of", "marked", "pain", "in", "the", "lower", "extremities", "and", "loss", "of", "proprioception", "25", "days", "after", "treatment", "with", "weekly", "taxol", "(", "80", "mg", "/", "m(2)x3", ")", "."], "event_mentions": [{"id": "11487721_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "11487721_3_Ent0", "role": "Subject", "text": "a case of advanced ovarian carcinoma", "start": 2, "end": 8}, {"entity_id": "11487721_3_Ent7", "role": "Treatment_Disorder", "text": "advanced ovarian carcinoma", "start": 5, "end": 8}, {"entity_id": "11487721_3_Ent1", "role": "Effect", "text": "difficulty walking because of marked pain in the lower extremities and loss of proprioception", "start": 10, "end": 24}, {"entity_id": "11487721_3_Ent3", "role": "Treatment_Time_elapsed", "text": "25 days", "start": 24, "end": 26}, {"entity_id": "11487721_3_Ent2", "role": "Treatment", "text": "25 days after treatment with weekly taxol ( 80 mg / m(2)x3 )", "start": 24, "end": 37}, {"entity_id": "11487721_3_Ent5", "role": "Treatment_Freq", "text": "weekly", "start": 29, "end": 30}, {"entity_id": "11487721_3_Ent4", "role": "Treatment_Drug", "text": "taxol", "start": 30, "end": 31}, {"entity_id": "11487721_3_Ent6", "role": "Treatment_Dosage", "text": "80 mg / m(2)x3", "start": 32, "end": 36}]}], "entity_mentions": [{"id": "11487721_3_Ent0", "text": "a case of advanced ovarian carcinoma", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "11487721_3_Ent7", "text": "advanced ovarian carcinoma", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "11487721_3_Ent1", "text": "difficulty walking because of marked pain in the lower extremities and loss of proprioception", "entity_type": "Entity", "start": 10, "end": 24}, {"id": "11487721_3_Ent3", "text": "25 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "11487721_3_Ent2", "text": "25 days after treatment with weekly taxol ( 80 mg / m(2)x3 )", "entity_type": "Entity", "start": 24, "end": 37}, {"id": "11487721_3_Ent5", "text": "weekly", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11487721_3_Ent4", "text": "taxol", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11487721_3_Ent6", "text": "80 mg / m(2)x3", "entity_type": "Entity", "start": 32, "end": 36}], "lang": "en"}
{"doc_id": "11510798_2", "wnd_id": "11510798_2_1", "text": "Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age , who was treated with oxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma .", "tokens": ["Diarrhoea", ",", "T", "-", "CD4", "+", "lymphopenia", "and", "bilateral", "patchy", "pulmonary", "infiltrates", "developed", "in", "a", "male", "60", "yrs", "of", "age", ",", "who", "was", "treated", "with", "oxaliplatinum", "and", "5", "-", "fluorouracil", "for", "unresectable", "rectum", "carcinoma", "."], "event_mentions": [{"id": "11510798_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "11510798_2_Ent3", "role": "Effect", "text": "Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates", "start": 0, "end": 12}, {"entity_id": "11510798_2_Ent1", "role": "Subject_Gender", "text": "male", "start": 15, "end": 16}, {"entity_id": "11510798_2_Ent0", "role": "Subject", "text": "male 60 yrs of age", "start": 15, "end": 20}, {"entity_id": "11510798_2_Ent2", "role": "Subject_Age", "text": "60 yrs of age", "start": 16, "end": 20}, {"entity_id": "11510798_2_Ent5", "role": "Treatment_Drug", "text": "oxaliplatinum", "start": 25, "end": 26}, {"entity_id": "11510798_2_Ent8", "role": "Combination_Drug", "text": "oxaliplatinum", "start": 25, "end": 26}, {"entity_id": "11510798_2_Ent4", "role": "Treatment", "text": "oxaliplatinum and 5 - fluorouracil", "start": 25, "end": 30}, {"entity_id": "11510798_2_Ent6", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 27, "end": 30}, {"entity_id": "11510798_2_Ent9", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 27, "end": 30}, {"entity_id": "11510798_2_Ent7", "role": "Treatment_Disorder", "text": "unresectable rectum carcinoma", "start": 31, "end": 34}]}], "entity_mentions": [{"id": "11510798_2_Ent3", "text": "Diarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "11510798_2_Ent1", "text": "male", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11510798_2_Ent0", "text": "male 60 yrs of age", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "11510798_2_Ent2", "text": "60 yrs of age", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "11510798_2_Ent5", "text": "oxaliplatinum", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11510798_2_Ent8", "text": "oxaliplatinum", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "11510798_2_Ent4", "text": "oxaliplatinum and 5 - fluorouracil", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "11510798_2_Ent6", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "11510798_2_Ent9", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "11510798_2_Ent7", "text": "unresectable rectum carcinoma", "entity_type": "Entity", "start": 31, "end": 34}], "lang": "en"}
{"doc_id": "11545487_2", "wnd_id": "11545487_2_1", "text": "Indinavir - associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient .", "tokens": ["Indinavir", "-", "associated", "nephrolithiasis", "and", "chronic", "interstitial", "nephritis", "were", "the", "only", "possible", "causes", "identified", "in", "this", "patient", "."], "event_mentions": [{"id": "11545487_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "11545487_2_Ent1", "role": "Treatment", "text": "Indinavir", "start": 0, "end": 1}, {"entity_id": "11545487_2_Ent2", "role": "Treatment_Drug", "text": "Indinavir", "start": 0, "end": 1}, {"entity_id": "11545487_2_Ent0", "role": "Effect", "text": "nephrolithiasis and chronic interstitial nephritis", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "11545487_2_Ent1", "text": "Indinavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11545487_2_Ent2", "text": "Indinavir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11545487_2_Ent0", "text": "nephrolithiasis and chronic interstitial nephritis", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "11576059_1", "wnd_id": "11576059_1_1", "text": "Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine .", "tokens": ["Vocal", "cord", "paralysis", "as", "a", "consequence", "of", "peritonsillar", "infiltration", "with", "bupivacaine", "."], "event_mentions": [{"id": "11576059_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 5, "end": 6}, "arguments": [{"entity_id": "11576059_1_Ent0", "role": "Effect", "text": "Vocal cord paralysis", "start": 0, "end": 3}, {"entity_id": "11576059_1_Ent2", "role": "Treatment_Route", "text": "peritonsillar infiltration", "start": 7, "end": 9}, {"entity_id": "11576059_1_Ent1", "role": "Treatment", "text": "peritonsillar infiltration with bupivacaine", "start": 7, "end": 11}, {"entity_id": "11576059_1_Ent3", "role": "Treatment_Drug", "text": "bupivacaine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11576059_1_Ent0", "text": "Vocal cord paralysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11576059_1_Ent2", "text": "peritonsillar infiltration", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11576059_1_Ent1", "text": "peritonsillar infiltration with bupivacaine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "11576059_1_Ent3", "text": "bupivacaine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11597289_2", "wnd_id": "11597289_2_1", "text": "High - dose antithrombin III in severe sepsis : a randomized controlled trial .", "tokens": ["High", "-", "dose", "antithrombin", "III", "in", "severe", "sepsis", ":", "a", "randomized", "controlled", "trial", "."], "event_mentions": [{"id": "11597289_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 5, "end": 6}, "arguments": [{"entity_id": "11597289_2_Ent2", "role": "Treatment_Dosage", "text": "High - dose", "start": 0, "end": 3}, {"entity_id": "11597289_2_Ent0", "role": "Treatment", "text": "High - dose antithrombin III", "start": 0, "end": 5}, {"entity_id": "11597289_2_Ent3", "role": "Treatment_Drug", "text": "antithrombin III", "start": 3, "end": 5}, {"entity_id": "11597289_2_Ent1", "role": "Treatment_Disorder", "text": "severe sepsis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "11597289_2_Ent2", "text": "High - dose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11597289_2_Ent0", "text": "High - dose antithrombin III", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "11597289_2_Ent3", "text": "antithrombin III", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11597289_2_Ent1", "text": "severe sepsis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "11688826_3", "wnd_id": "11688826_3_1", "text": "We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS ) .", "tokens": ["We", "report", "a", "patient", "with", "pulmonary", "adenocarcinoma", "complicated", "by", "the", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "(", "SIADH", ")", "following", "systemic", "chemotherapy", "with", "cisplatin", "(", "CDDP", ")", "and", "vindesine", "(", "VDS", ")", "."], "event_mentions": [{"id": "11688826_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 20, "end": 21}, "arguments": [{"entity_id": "11688826_3_Ent0", "role": "Subject", "text": "a patient with pulmonary adenocarcinoma", "start": 2, "end": 7}, {"entity_id": "11688826_3_Ent3", "role": "Treatment_Disorder", "text": "pulmonary adenocarcinoma", "start": 5, "end": 7}, {"entity_id": "11688826_3_Ent1", "role": "Effect", "text": "the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "start": 9, "end": 20}, {"entity_id": "11688826_3_Ent2", "role": "Treatment", "text": "systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS )", "start": 21, "end": 33}, {"entity_id": "11688826_3_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 24, "end": 25}, {"entity_id": "11688826_3_Ent7", "role": "Combination_Drug", "text": "cisplatin", "start": 24, "end": 25}, {"entity_id": "11688826_3_Ent5", "role": "Treatment_Drug", "text": "vindesine", "start": 29, "end": 30}, {"entity_id": "11688826_3_Ent6", "role": "Combination_Drug", "text": "vindesine", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "11688826_3_Ent0", "text": "a patient with pulmonary adenocarcinoma", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "11688826_3_Ent3", "text": "pulmonary adenocarcinoma", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "11688826_3_Ent1", "text": "the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "11688826_3_Ent2", "text": "systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( VDS )", "entity_type": "Entity", "start": 21, "end": 33}, {"id": "11688826_3_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11688826_3_Ent7", "text": "cisplatin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11688826_3_Ent5", "text": "vindesine", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "11688826_3_Ent6", "text": "vindesine", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "11696132_2", "wnd_id": "11696132_2_1", "text": "Anisocoria from transdermal scopolamine .", "tokens": ["Anisocoria", "from", "transdermal", "scopolamine", "."], "event_mentions": [{"id": "11696132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 1, "end": 2}, "arguments": [{"entity_id": "11696132_2_Ent0", "role": "Effect", "text": "Anisocoria", "start": 0, "end": 1}, {"entity_id": "11696132_2_Ent1", "role": "Treatment", "text": "transdermal scopolamine", "start": 2, "end": 4}, {"entity_id": "11696132_2_Ent2", "role": "Treatment_Drug", "text": "transdermal scopolamine", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "11696132_2_Ent0", "text": "Anisocoria", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11696132_2_Ent1", "text": "transdermal scopolamine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "11696132_2_Ent2", "text": "transdermal scopolamine", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "11706664_2", "wnd_id": "11706664_2_1", "text": "This report describes an unexpected drug - induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate .", "tokens": ["This", "report", "describes", "an", "unexpected", "drug", "-", "induced", "hepatitis", "in", "a", "previously", "healthy", "young", "woman", "exposed", "to", "2", "doses", "of", "amodiaquine", "and", "artesunate", "."], "event_mentions": [{"id": "11706664_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 15, "end": 16}, "arguments": [{"entity_id": "11706664_2_Ent3", "role": "Effect", "text": "hepatitis", "start": 8, "end": 9}, {"entity_id": "11706664_2_Ent0", "role": "Subject", "text": "a previously healthy young woman", "start": 10, "end": 15}, {"entity_id": "11706664_2_Ent1", "role": "Subject_Gender", "text": "young", "start": 13, "end": 14}, {"entity_id": "11706664_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 14, "end": 15}, {"entity_id": "11706664_2_Ent5", "role": "Treatment_Dosage", "text": "2 doses", "start": 17, "end": 19}, {"entity_id": "11706664_2_Ent4", "role": "Treatment", "text": "2 doses of amodiaquine and artesunate", "start": 17, "end": 23}, {"entity_id": "11706664_2_Ent6", "role": "Treatment_Drug", "text": "amodiaquine", "start": 20, "end": 21}, {"entity_id": "11706664_2_Ent8", "role": "Combination_Drug", "text": "amodiaquine", "start": 20, "end": 21}, {"entity_id": "11706664_2_Ent7", "role": "Treatment_Drug", "text": "artesunate", "start": 22, "end": 23}, {"entity_id": "11706664_2_Ent9", "role": "Combination_Drug", "text": "artesunate", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11706664_2_Ent3", "text": "hepatitis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11706664_2_Ent0", "text": "a previously healthy young woman", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "11706664_2_Ent1", "text": "young", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11706664_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "11706664_2_Ent5", "text": "2 doses", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11706664_2_Ent4", "text": "2 doses of amodiaquine and artesunate", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "11706664_2_Ent6", "text": "amodiaquine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11706664_2_Ent8", "text": "amodiaquine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11706664_2_Ent7", "text": "artesunate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11706664_2_Ent9", "text": "artesunate", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11724089_1", "wnd_id": "11724089_1_1", "text": "CONCLUSIONS : There is very little published information regarding ofloxacin - induced toxic epidermal necrolysis .", "tokens": ["CONCLUSIONS", ":", "There", "is", "very", "little", "published", "information", "regarding", "ofloxacin", "-", "induced", "toxic", "epidermal", "necrolysis", "."], "event_mentions": [{"id": "11724089_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "11724089_1_Ent1", "role": "Treatment", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "11724089_1_Ent2", "role": "Treatment_Drug", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "11724089_1_Ent0", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "11724089_1_Ent1", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_1_Ent2", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11724089_1_Ent0", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "11737689_2", "wnd_id": "11737689_2_1", "text": "A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G - CSF .", "tokens": ["A", "girl", "with", "cystic", "fibrosis", "and", "cyclic", "neutropenia", "developed", "an", "erythematous", "papular", "eruption", "without", "fever", "or", "neutrophilia", "7", "months", "after", "commencing", "therapy", "with", "G", "-", "CSF", "."], "event_mentions": [{"id": "11737689_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "11737689_2_Ent0", "role": "Subject", "text": "A girl with cystic fibrosis and cyclic neutropenia", "start": 0, "end": 8}, {"entity_id": "11737689_2_Ent1", "role": "Subject_Gender", "text": "girl", "start": 1, "end": 2}, {"entity_id": "11737689_2_Ent2", "role": "Subject_Disorder", "text": "cystic fibrosis", "start": 3, "end": 5}, {"entity_id": "11737689_2_Ent5", "role": "Treatment_Disorder", "text": "cyclic neutropenia", "start": 6, "end": 8}, {"entity_id": "11737689_2_Ent3", "role": "Effect", "text": "erythematous papular eruption without fever or neutrophilia", "start": 10, "end": 17}, {"entity_id": "11737689_2_Ent7", "role": "Treatment_Time_elapsed", "text": "7 months", "start": 17, "end": 19}, {"entity_id": "11737689_2_Ent4", "role": "Treatment", "text": "7 months after commencing therapy with G - CSF .", "start": 17, "end": 27}, {"entity_id": "11737689_2_Ent6", "role": "Treatment_Drug", "text": "G - CSF", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "11737689_2_Ent0", "text": "A girl with cystic fibrosis and cyclic neutropenia", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "11737689_2_Ent1", "text": "girl", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11737689_2_Ent2", "text": "cystic fibrosis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11737689_2_Ent5", "text": "cyclic neutropenia", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "11737689_2_Ent3", "text": "erythematous papular eruption without fever or neutrophilia", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "11737689_2_Ent7", "text": "7 months", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "11737689_2_Ent4", "text": "7 months after commencing therapy with G - CSF .", "entity_type": "Entity", "start": 17, "end": 27}, {"id": "11737689_2_Ent6", "text": "G - CSF", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "1174301_1", "wnd_id": "1174301_1_1", "text": "There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism .", "tokens": ["There", "is", "a", "putative", "role", "of", "liothyronine", "administration", "in", "precipitating", "or", "activating", "hyperthyroidism", "."], "event_mentions": [{"id": "1174301_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitating or activating", "start": 9, "end": 12}, "arguments": [{"entity_id": "1174301_1_Ent1", "role": "Treatment", "text": "liothyronine", "start": 6, "end": 7}, {"entity_id": "1174301_1_Ent2", "role": "Treatment_Drug", "text": "liothyronine", "start": 6, "end": 7}, {"entity_id": "1174301_1_Ent0", "role": "Effect", "text": "hyperthyroidism", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1174301_1_Ent1", "text": "liothyronine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1174301_1_Ent2", "text": "liothyronine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1174301_1_Ent0", "text": "hyperthyroidism", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "11757641_1", "wnd_id": "11757641_1_1", "text": "Pulmonary toxicity with mefloquine .", "tokens": ["Pulmonary", "toxicity", "with", "mefloquine", "."], "event_mentions": [{"id": "11757641_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "11757641_1_Ent0", "role": "Effect", "text": "Pulmonary toxicity", "start": 0, "end": 2}, {"entity_id": "11757641_1_Ent1", "role": "Treatment", "text": "mefloquine", "start": 3, "end": 4}, {"entity_id": "11757641_1_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11757641_1_Ent0", "text": "Pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11757641_1_Ent1", "text": "mefloquine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11757641_1_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11757641_2", "wnd_id": "11757641_2_1", "text": "This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine .", "tokens": ["This", "is", "the", "second", "report", "of", "acute", "lung", "injury", "and", "diffuse", "alveolar", "damage", "caused", "by", "mefloquine", "."], "event_mentions": [{"id": "11757641_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "11757641_2_Ent0", "role": "Effect", "text": "acute lung injury and diffuse alveolar damage", "start": 6, "end": 13}, {"entity_id": "11757641_2_Ent1", "role": "Treatment", "text": "mefloquine", "start": 15, "end": 16}, {"entity_id": "11757641_2_Ent2", "role": "Treatment_Drug", "text": "mefloquine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "11757641_2_Ent0", "text": "acute lung injury and diffuse alveolar damage", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "11757641_2_Ent1", "text": "mefloquine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11757641_2_Ent2", "text": "mefloquine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "11788010_1", "wnd_id": "11788010_1_1", "text": "Extra caution should be taken in using octreotide or its long - acting analog in patients otherwise predisposed to intrahepatic bile stasis .", "tokens": ["Extra", "caution", "should", "be", "taken", "in", "using", "octreotide", "or", "its", "long", "-", "acting", "analog", "in", "patients", "otherwise", "predisposed", "to", "intrahepatic", "bile", "stasis", "."], "event_mentions": [{"id": "11788010_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "predisposed", "start": 17, "end": 18}, "arguments": [{"entity_id": "11788010_1_Ent3", "role": "Treatment_Drug", "text": "octreotide", "start": 7, "end": 8}, {"entity_id": "11788010_1_Ent2", "role": "Treatment", "text": "octreotide or its long - acting analog", "start": 7, "end": 14}, {"entity_id": "11788010_1_Ent4", "role": "Treatment_Drug", "text": "long - acting analog", "start": 10, "end": 14}, {"entity_id": "11788010_1_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}, {"entity_id": "11788010_1_Ent1", "role": "Effect", "text": "intrahepatic bile stasis", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "11788010_1_Ent3", "text": "octreotide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11788010_1_Ent2", "text": "octreotide or its long - acting analog", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "11788010_1_Ent4", "text": "long - acting analog", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "11788010_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "11788010_1_Ent1", "text": "intrahepatic bile stasis", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "11788010_4", "wnd_id": "11788010_4_1", "text": "In addition to its known effect on gallbladder stasis , octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation .", "tokens": ["In", "addition", "to", "its", "known", "effect", "on", "gallbladder", "stasis", ",", "octreotide", "alters", "bile", "acid", "composition", "and", "may", "thus", "hasten", "intrahepatic", "sludge", "and", "stone", "formation", "."], "event_mentions": [{"id": "11788010_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "effect on", "start": 5, "end": 7}, "arguments": [{"entity_id": "11788010_4_Ent0", "role": "Effect", "text": "gallbladder stasis", "start": 7, "end": 9}, {"entity_id": "11788010_4_Ent2", "role": "Treatment", "text": "octreotide", "start": 10, "end": 11}, {"entity_id": "11788010_4_Ent3", "role": "Treatment_Drug", "text": "octreotide", "start": 10, "end": 11}, {"entity_id": "11788010_4_Ent1", "role": "Effect", "text": "alters bile acid composition and may thus hasten intrahepatic sludge and stone formation", "start": 11, "end": 24}]}], "entity_mentions": [{"id": "11788010_4_Ent0", "text": "gallbladder stasis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "11788010_4_Ent2", "text": "octreotide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11788010_4_Ent3", "text": "octreotide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11788010_4_Ent1", "text": "alters bile acid composition and may thus hasten intrahepatic sludge and stone formation", "entity_type": "Entity", "start": 11, "end": 24}], "lang": "en"}
{"doc_id": "11804071_3", "wnd_id": "11804071_3_1", "text": "Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously .", "tokens": ["Such", "anagen", "effluvium", "with", "lichenoid", "eruption", "following", "INH", "therapy", "has", "not", "been", "observed", "previously", "."], "event_mentions": [{"id": "11804071_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "11804071_3_Ent0", "role": "Effect", "text": "anagen effluvium with lichenoid eruption", "start": 1, "end": 6}, {"entity_id": "11804071_3_Ent1", "role": "Treatment", "text": "INH", "start": 7, "end": 8}, {"entity_id": "11804071_3_Ent2", "role": "Treatment_Drug", "text": "INH", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "11804071_3_Ent0", "text": "anagen effluvium with lichenoid eruption", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "11804071_3_Ent1", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11804071_3_Ent2", "text": "INH", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "11816261_2", "wnd_id": "11816261_2_1", "text": "CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single , conventional dose .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "a", "risk", "of", "serotonin", "syndrome", "with", "serious", "extrapyramidal", "reactions", "in", "patients", "receiving", "sertraline", "or", "venlafaxine", "when", "metoclopramide", "is", "coadministered", "even", "in", "a", "single", ",", "conventional", "dose", "."], "event_mentions": [{"id": "11816261_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "11816261_2_Ent1", "role": "Effect", "text": "serotonin syndrome with serious extrapyramidal reactions", "start": 10, "end": 16}, {"entity_id": "11816261_2_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "11816261_2_Ent3", "role": "Treatment_Drug", "text": "sertraline", "start": 19, "end": 20}, {"entity_id": "11816261_2_Ent9", "role": "Combination_Drug", "text": "sertraline", "start": 19, "end": 20}, {"entity_id": "11816261_2_Ent2", "role": "Treatment", "text": "sertraline or venlafaxine when metoclopramide is coadministered even in a single , conventional dose", "start": 19, "end": 33}, {"entity_id": "11816261_2_Ent4", "role": "Treatment_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "11816261_2_Ent8", "role": "Combination_Drug", "text": "venlafaxine", "start": 21, "end": 22}, {"entity_id": "11816261_2_Ent5", "role": "Treatment_Drug", "text": "metoclopramide", "start": 23, "end": 24}, {"entity_id": "11816261_2_Ent7", "role": "Combination_Drug", "text": "metoclopramide", "start": 23, "end": 24}, {"entity_id": "11816261_2_Ent6", "role": "Treatment_Dosage", "text": "single , conventional dose", "start": 29, "end": 33}]}], "entity_mentions": [{"id": "11816261_2_Ent1", "text": "serotonin syndrome with serious extrapyramidal reactions", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "11816261_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "11816261_2_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11816261_2_Ent9", "text": "sertraline", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11816261_2_Ent2", "text": "sertraline or venlafaxine when metoclopramide is coadministered even in a single , conventional dose", "entity_type": "Entity", "start": 19, "end": 33}, {"id": "11816261_2_Ent4", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11816261_2_Ent8", "text": "venlafaxine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "11816261_2_Ent5", "text": "metoclopramide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11816261_2_Ent7", "text": "metoclopramide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11816261_2_Ent6", "text": "single , conventional dose", "entity_type": "Entity", "start": 29, "end": 33}], "lang": "en"}
{"doc_id": "11816261_3", "wnd_id": "11816261_3_1", "text": "OBJECTIVE : To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine .", "tokens": ["OBJECTIVE", ":", "To", "report", "2", "cases", "of", "serotonin", "syndrome", "with", "serious", "extrapyramidal", "movement", "disorders", "occurring", "when", "metoclopramide", "was", "coadministered", "with", "sertraline", "or", "venlafaxine", "."], "event_mentions": [{"id": "11816261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 14, "end": 15}, "arguments": [{"entity_id": "11816261_3_Ent1", "role": "Subject_Population", "text": "2", "start": 4, "end": 5}, {"entity_id": "11816261_3_Ent0", "role": "Subject", "text": "2 cases", "start": 4, "end": 6}, {"entity_id": "11816261_3_Ent2", "role": "Effect", "text": "serotonin syndrome with serious extrapyramidal movement disorders", "start": 7, "end": 14}, {"entity_id": "11816261_3_Ent4", "role": "Treatment_Drug", "text": "metoclopramide", "start": 16, "end": 17}, {"entity_id": "11816261_3_Ent7", "role": "Combination_Drug", "text": "metoclopramide", "start": 16, "end": 17}, {"entity_id": "11816261_3_Ent10", "role": "Combination_Drug", "text": "metoclopramide", "start": 16, "end": 17}, {"entity_id": "11816261_3_Ent3", "role": "Treatment", "text": "metoclopramide was coadministered with sertraline or venlafaxine", "start": 16, "end": 23}, {"entity_id": "11816261_3_Ent5", "role": "Treatment_Drug", "text": "sertraline", "start": 20, "end": 21}, {"entity_id": "11816261_3_Ent8", "role": "Combination_Drug", "text": "sertraline", "start": 20, "end": 21}, {"entity_id": "11816261_3_Ent6", "role": "Treatment_Drug", "text": "venlafaxine", "start": 22, "end": 23}, {"entity_id": "11816261_3_Ent9", "role": "Combination_Drug", "text": "venlafaxine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "11816261_3_Ent1", "text": "2", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "11816261_3_Ent0", "text": "2 cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "11816261_3_Ent2", "text": "serotonin syndrome with serious extrapyramidal movement disorders", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "11816261_3_Ent4", "text": "metoclopramide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11816261_3_Ent7", "text": "metoclopramide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11816261_3_Ent10", "text": "metoclopramide", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "11816261_3_Ent3", "text": "metoclopramide was coadministered with sertraline or venlafaxine", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "11816261_3_Ent5", "text": "sertraline", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11816261_3_Ent8", "text": "sertraline", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11816261_3_Ent6", "text": "venlafaxine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11816261_3_Ent9", "text": "venlafaxine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "11816261_4", "wnd_id": "11816261_4_1", "text": "Serotonin syndrome caused by selective serotonin reuptake - inhibitors - metoclopramide interaction .", "tokens": ["Serotonin", "syndrome", "caused", "by", "selective", "serotonin", "reuptake", "-", "inhibitors", "-", "metoclopramide", "interaction", "."], "event_mentions": [{"id": "11816261_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 2, "end": 3}, "arguments": [{"entity_id": "11816261_4_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "11816261_4_Ent3", "role": "Treatment_Drug", "text": "selective serotonin reuptake - inhibitors", "start": 4, "end": 9}, {"entity_id": "11816261_4_Ent5", "role": "Combination_Drug", "text": "selective serotonin reuptake - inhibitors", "start": 4, "end": 9}, {"entity_id": "11816261_4_Ent1", "role": "Treatment", "text": "selective serotonin reuptake - inhibitors - metoclopramide interaction", "start": 4, "end": 12}, {"entity_id": "11816261_4_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 10, "end": 11}, {"entity_id": "11816261_4_Ent4", "role": "Combination_Drug", "text": "metoclopramide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "11816261_4_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11816261_4_Ent3", "text": "selective serotonin reuptake - inhibitors", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11816261_4_Ent5", "text": "selective serotonin reuptake - inhibitors", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "11816261_4_Ent1", "text": "selective serotonin reuptake - inhibitors - metoclopramide interaction", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "11816261_4_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "11816261_4_Ent4", "text": "metoclopramide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "11834188_1", "wnd_id": "11834188_1_1", "text": "BACKGROUND : reports on delated cutaneous reactions to captopril have been seldom reported .", "tokens": ["BACKGROUND", ":", "reports", "on", "delated", "cutaneous", "reactions", "to", "captopril", "have", "been", "seldom", "reported", "."], "event_mentions": [{"id": "11834188_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 12, "end": 13}, "arguments": [{"entity_id": "11834188_1_Ent0", "role": "Effect", "text": "delated cutaneous reactions", "start": 4, "end": 7}, {"entity_id": "11834188_1_Ent1", "role": "Treatment", "text": "captopril", "start": 8, "end": 9}, {"entity_id": "11834188_1_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "11834188_1_Ent0", "text": "delated cutaneous reactions", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "11834188_1_Ent1", "text": "captopril", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "11834188_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "11834188_2", "wnd_id": "11834188_2_1", "text": "Captopril is an angiotensin - converting enzyme ( ACE ) inhibitor and their cutaneous side - effects are documented , but little has been published concerning the usefulness of patch test when they occur .", "tokens": ["Captopril", "is", "an", "angiotensin", "-", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "and", "their", "cutaneous", "side", "-", "effects", "are", "documented", ",", "but", "little", "has", "been", "published", "concerning", "the", "usefulness", "of", "patch", "test", "when", "they", "occur", "."], "event_mentions": [{"id": "11834188_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "documented", "start": 18, "end": 19}, "arguments": [{"entity_id": "11834188_2_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "11834188_2_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "11834188_2_Ent0", "role": "Effect", "text": "cutaneous side - effects", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "11834188_2_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11834188_2_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "11834188_2_Ent0", "text": "cutaneous side - effects", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "11850606_1", "wnd_id": "11850606_1_1", "text": "A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.", "tokens": ["A", "case", "of", "polymyositis", "with", "dilated", "cardiomyopathy", "associated", "with", "interferon", "alpha", "treatment", "for", "hepatitis", "B."], "event_mentions": [{"id": "11850606_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "11850606_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "11850606_1_Ent1", "role": "Effect", "text": "polymyositis with dilated cardiomyopathy", "start": 3, "end": 7}, {"entity_id": "11850606_1_Ent2", "role": "Treatment", "text": "interferon alpha", "start": 9, "end": 11}, {"entity_id": "11850606_1_Ent4", "role": "Treatment_Drug", "text": "interferon alpha", "start": 9, "end": 11}, {"entity_id": "11850606_1_Ent3", "role": "Treatment_Disorder", "text": "hepatitis B.", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "11850606_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "11850606_1_Ent1", "text": "polymyositis with dilated cardiomyopathy", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "11850606_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11850606_1_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "11850606_1_Ent3", "text": "hepatitis B.", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "11881322_1", "wnd_id": "11881322_1_1", "text": "Beginning ductopenia was present in two , suggesting that itraconazole might be responsible for the occurrence of prolonged drug - induced cholangiopathy .", "tokens": ["Beginning", "ductopenia", "was", "present", "in", "two", ",", "suggesting", "that", "itraconazole", "might", "be", "responsible", "for", "the", "occurrence", "of", "prolonged", "drug", "-", "induced", "cholangiopathy", "."], "event_mentions": [{"id": "11881322_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 12, "end": 13}, "arguments": [{"entity_id": "11881322_1_Ent1", "role": "Effect", "text": "ductopenia", "start": 1, "end": 2}, {"entity_id": "11881322_1_Ent0", "role": "Subject", "text": "two", "start": 5, "end": 6}, {"entity_id": "11881322_1_Ent2", "role": "Treatment", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "11881322_1_Ent4", "role": "Treatment_Drug", "text": "itraconazole", "start": 9, "end": 10}, {"entity_id": "11881322_1_Ent3", "role": "Treatment_Disorder", "text": "prolonged drug - induced cholangiopathy", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "11881322_1_Ent1", "text": "ductopenia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11881322_1_Ent0", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "11881322_1_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_1_Ent4", "text": "itraconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_1_Ent3", "text": "prolonged drug - induced cholangiopathy", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "11881322_5", "wnd_id": "11881322_5_1", "text": "The occurrence of acute hepatitis is best known for ketoconazole .", "tokens": ["The", "occurrence", "of", "acute", "hepatitis", "is", "best", "known", "for", "ketoconazole", "."], "event_mentions": [{"id": "11881322_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 8, "end": 9}, "arguments": [{"entity_id": "11881322_5_Ent0", "role": "Effect", "text": "acute hepatitis", "start": 3, "end": 5}, {"entity_id": "11881322_5_Ent1", "role": "Treatment", "text": "ketoconazole", "start": 9, "end": 10}, {"entity_id": "11881322_5_Ent2", "role": "Treatment_Drug", "text": "ketoconazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "11881322_5_Ent0", "text": "acute hepatitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "11881322_5_Ent1", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "11881322_5_Ent2", "text": "ketoconazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "11881322_7", "wnd_id": "11881322_7_1", "text": "We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug - induced vanishing bile duct syndrome .", "tokens": ["We", "suggest", "that", "itraconazole", "should", "be", "added", "to", "the", "list", "of", "drugs", "that", "may", "be", "responsible", "for", "a", "drug", "-", "induced", "vanishing", "bile", "duct", "syndrome", "."], "event_mentions": [{"id": "11881322_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 15, "end": 16}, "arguments": [{"entity_id": "11881322_7_Ent1", "role": "Treatment", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_7_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 3, "end": 4}, {"entity_id": "11881322_7_Ent0", "role": "Effect", "text": "drug - induced vanishing bile duct syndrome", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "11881322_7_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_7_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11881322_7_Ent0", "text": "drug - induced vanishing bile duct syndrome", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "11881322_8", "wnd_id": "11881322_8_1", "text": "With itraconazole , hepatotoxic reactions have only very rarely been reported , and histologic data are lacking .", "tokens": ["With", "itraconazole", ",", "hepatotoxic", "reactions", "have", "only", "very", "rarely", "been", "reported", ",", "and", "histologic", "data", "are", "lacking", "."], "event_mentions": [{"id": "11881322_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 10, "end": 11}, "arguments": [{"entity_id": "11881322_8_Ent1", "role": "Treatment", "text": "itraconazole", "start": 1, "end": 2}, {"entity_id": "11881322_8_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 1, "end": 2}, {"entity_id": "11881322_8_Ent0", "role": "Effect", "text": "hepatotoxic", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "11881322_8_Ent1", "text": "itraconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11881322_8_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11881322_8_Ent0", "text": "hepatotoxic", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "11886466_5", "wnd_id": "11886466_5_1", "text": "We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors .", "tokens": ["We", "speculate", "that", "platelet", "activation", "induced", "by", "pFVIII", "may", "have", "contributed", "to", "thrombosis", "and", "suggest", "that", "pFVIII", "be", "used", "with", "caution", "in", "elderly", "patients", "with", "pre", "-", "existing", "cardiovascular", "risk", "factors", "."], "event_mentions": [{"id": "11886466_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 10, "end": 11}, "arguments": [{"entity_id": "11886466_5_Ent1", "role": "Treatment", "text": "pFVIII", "start": 7, "end": 8}, {"entity_id": "11886466_5_Ent2", "role": "Treatment_Drug", "text": "pFVIII", "start": 7, "end": 8}, {"entity_id": "11886466_5_Ent0", "role": "Effect", "text": "thrombosis", "start": 12, "end": 13}, {"entity_id": "11886466_5_Ent3", "role": "Treatment_Disorder", "text": "cardiovascular", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11886466_5_Ent1", "text": "pFVIII", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11886466_5_Ent2", "text": "pFVIII", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "11886466_5_Ent0", "text": "thrombosis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "11886466_5_Ent3", "text": "cardiovascular", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11889149_3", "wnd_id": "11889149_3_1", "text": "This phase 3 , randomized , double - blind 1 - yr study assessed the effects of combined RLX and ALN in 331 postmenopausal women with osteoporosis ( femoral neck BMD T - score , less than -2 ) .", "tokens": ["This", "phase", "3", ",", "randomized", ",", "double", "-", "blind", "1", "-", "yr", "study", "assessed", "the", "effects", "of", "combined", "RLX", "and", "ALN", "in", "331", "postmenopausal", "women", "with", "osteoporosis", "(", "femoral", "neck", "BMD", "T", "-", "score", ",", "less", "than", "-2", ")", "."], "event_mentions": [{"id": "11889149_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effects", "start": 15, "end": 16}, "arguments": [{"entity_id": "11889149_3_Ent4", "role": "Treatment", "text": "combined RLX and ALN", "start": 17, "end": 21}, {"entity_id": "11889149_3_Ent6", "role": "Treatment_Drug", "text": "RLX", "start": 18, "end": 19}, {"entity_id": "11889149_3_Ent8", "role": "Combination_Drug", "text": "RLX", "start": 18, "end": 19}, {"entity_id": "11889149_3_Ent7", "role": "Treatment_Drug", "text": "ALN", "start": 20, "end": 21}, {"entity_id": "11889149_3_Ent9", "role": "Combination_Drug", "text": "ALN", "start": 20, "end": 21}, {"entity_id": "11889149_3_Ent1", "role": "Subject_Population", "text": "331", "start": 22, "end": 23}, {"entity_id": "11889149_3_Ent0", "role": "Subject", "text": "331 postmenopausal women with osteoporosis ( femoral neck BMD T - score , less than -2 )", "start": 22, "end": 39}, {"entity_id": "11889149_3_Ent3", "role": "Subject_Age", "text": "postmenopausal", "start": 23, "end": 24}, {"entity_id": "11889149_3_Ent2", "role": "Subject_Gender", "text": "women", "start": 24, "end": 25}, {"entity_id": "11889149_3_Ent5", "role": "Treatment_Disorder", "text": "osteoporosis", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "11889149_3_Ent4", "text": "combined RLX and ALN", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "11889149_3_Ent6", "text": "RLX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11889149_3_Ent8", "text": "RLX", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11889149_3_Ent7", "text": "ALN", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11889149_3_Ent9", "text": "ALN", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "11889149_3_Ent1", "text": "331", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "11889149_3_Ent0", "text": "331 postmenopausal women with osteoporosis ( femoral neck BMD T - score , less than -2 )", "entity_type": "Entity", "start": 22, "end": 39}, {"id": "11889149_3_Ent3", "text": "postmenopausal", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "11889149_3_Ent2", "text": "women", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "11889149_3_Ent5", "text": "osteoporosis", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "11903249_2", "wnd_id": "11903249_2_1", "text": "There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin .", "tokens": ["There", "have", "been", "more", "than", "20", "observations", "of", "the", "appearance", "or", "aggravation", "of", "this", "granulomatosis", "with", "interferon", "alfa", "and", "more", "recently", "with", "the", "combination", "of", "interferon", "alfa", "plus", "ribavirin", "."], "event_mentions": [{"id": "11903249_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 15, "end": 16}, "arguments": [{"entity_id": "11903249_2_Ent0", "role": "Effect", "text": "more than 20 observations of the appearance or aggravation of this granulomatosis", "start": 3, "end": 15}, {"entity_id": "11903249_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 16, "end": 18}, {"entity_id": "11903249_2_Ent1", "role": "Treatment", "text": "interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "start": 16, "end": 29}, {"entity_id": "11903249_2_Ent3", "role": "Treatment_Drug", "text": "interferon alfa", "start": 25, "end": 27}, {"entity_id": "11903249_2_Ent5", "role": "Combination_Drug", "text": "interferon alfa", "start": 25, "end": 27}, {"entity_id": "11903249_2_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 28, "end": 29}, {"entity_id": "11903249_2_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "11903249_2_Ent0", "text": "more than 20 observations of the appearance or aggravation of this granulomatosis", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "11903249_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "11903249_2_Ent1", "text": "interferon alfa and more recently with the combination of interferon alfa plus ribavirin", "entity_type": "Entity", "start": 16, "end": 29}, {"id": "11903249_2_Ent3", "text": "interferon alfa", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11903249_2_Ent5", "text": "interferon alfa", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "11903249_2_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "11903249_2_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "11918514_1", "wnd_id": "11918514_1_1", "text": "CONCLUSIONS : Although mirtazapine offers clinicians a combination of strong efficacy and good safety , we suggest bearing SS in mind when prescribing this drug , especially in frail , elderly patients with underlying chronic conditions .", "tokens": ["CONCLUSIONS", ":", "Although", "mirtazapine", "offers", "clinicians", "a", "combination", "of", "strong", "efficacy", "and", "good", "safety", ",", "we", "suggest", "bearing", "SS", "in", "mind", "when", "prescribing", "this", "drug", ",", "especially", "in", "frail", ",", "elderly", "patients", "with", "underlying", "chronic", "conditions", "."], "event_mentions": [{"id": "11918514_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "bearing", "start": 17, "end": 18}, "arguments": [{"entity_id": "11918514_1_Ent4", "role": "Treatment", "text": "mirtazapine", "start": 3, "end": 4}, {"entity_id": "11918514_1_Ent5", "role": "Treatment_Drug", "text": "mirtazapine", "start": 3, "end": 4}, {"entity_id": "11918514_1_Ent3", "role": "Effect", "text": "SS", "start": 18, "end": 19}, {"entity_id": "11918514_1_Ent0", "role": "Subject", "text": "frail , elderly patients with underlying chronic conditions", "start": 28, "end": 36}, {"entity_id": "11918514_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 30, "end": 31}, {"entity_id": "11918514_1_Ent2", "role": "Subject_Disorder", "text": "underlying chronic conditions", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "11918514_1_Ent4", "text": "mirtazapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11918514_1_Ent5", "text": "mirtazapine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "11918514_1_Ent3", "text": "SS", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "11918514_1_Ent0", "text": "frail , elderly patients with underlying chronic conditions", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "11918514_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "11918514_1_Ent2", "text": "underlying chronic conditions", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "11978156_1", "wnd_id": "11978156_1_1", "text": "CONCLUSIONS : Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "the", "possible", "association", "of", "thrombocytopenia", "with", "lansoprazole", "and", "discontinue", "the", "drug", "if", "thrombocytopenia", "becomes", "apparent", "."], "event_mentions": [{"id": "11978156_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 9, "end": 10}, "arguments": [{"entity_id": "11978156_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 11, "end": 12}, {"entity_id": "11978156_1_Ent1", "role": "Treatment", "text": "lansoprazole", "start": 13, "end": 14}, {"entity_id": "11978156_1_Ent2", "role": "Treatment_Drug", "text": "lansoprazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "11978156_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11978156_1_Ent1", "text": "lansoprazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "11978156_1_Ent2", "text": "lansoprazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "11999915_4", "wnd_id": "11999915_4_1", "text": "The male patient was treated with 225 - mg / day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks .", "tokens": ["The", "male", "patient", "was", "treated", "with", "225", "-", "mg", "/", "day", "clozapine", "and", "the", "time", "to", "the", "diagnosis", "of", "agranulocytosis", "was", "6", "weeks", "."], "event_mentions": [{"id": "11999915_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "diagnosis", "start": 17, "end": 18}, "arguments": [{"entity_id": "11999915_4_Ent0", "role": "Subject", "text": "The male patient", "start": 0, "end": 3}, {"entity_id": "11999915_4_Ent1", "role": "Subject_Gender", "text": "male", "start": 1, "end": 2}, {"entity_id": "11999915_4_Ent5", "role": "Treatment_Dosage", "text": "225 - mg / day", "start": 6, "end": 11}, {"entity_id": "11999915_4_Ent3", "role": "Treatment", "text": "225 - mg / day clozapine", "start": 6, "end": 12}, {"entity_id": "11999915_4_Ent4", "role": "Treatment_Drug", "text": "clozapine", "start": 11, "end": 12}, {"entity_id": "11999915_4_Ent2", "role": "Effect", "text": "agranulocytosis", "start": 19, "end": 20}, {"entity_id": "11999915_4_Ent6", "role": "Treatment_Duration", "text": "6 weeks", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "11999915_4_Ent0", "text": "The male patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "11999915_4_Ent1", "text": "male", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "11999915_4_Ent5", "text": "225 - mg / day", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "11999915_4_Ent3", "text": "225 - mg / day clozapine", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "11999915_4_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "11999915_4_Ent2", "text": "agranulocytosis", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "11999915_4_Ent6", "text": "6 weeks", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "12013364_2", "wnd_id": "12013364_2_1", "text": "Atypical neuroleptic malignant syndrome associated with olanzapine .", "tokens": ["Atypical", "neuroleptic", "malignant", "syndrome", "associated", "with", "olanzapine", "."], "event_mentions": [{"id": "12013364_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "12013364_2_Ent0", "role": "Effect", "text": "Atypical neuroleptic malignant syndrome", "start": 0, "end": 4}, {"entity_id": "12013364_2_Ent1", "role": "Treatment", "text": "olanzapine", "start": 6, "end": 7}, {"entity_id": "12013364_2_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "12013364_2_Ent0", "text": "Atypical neuroleptic malignant syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12013364_2_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12013364_2_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "12022905_5", "wnd_id": "12022905_5_1", "text": "Priapism associated with zuclopenthixol .", "tokens": ["Priapism", "associated", "with", "zuclopenthixol", "."], "event_mentions": [{"id": "12022905_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "12022905_5_Ent0", "role": "Effect", "text": "Priapism", "start": 0, "end": 1}, {"entity_id": "12022905_5_Ent1", "role": "Treatment", "text": "zuclopenthixol", "start": 3, "end": 4}, {"entity_id": "12022905_5_Ent2", "role": "Treatment_Drug", "text": "zuclopenthixol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12022905_5_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12022905_5_Ent1", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12022905_5_Ent2", "text": "zuclopenthixol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12042592_2", "wnd_id": "12042592_2_1", "text": "Metamizole , a nonsteroidal antiinflammatory agent , is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries .", "tokens": ["Metamizole", ",", "a", "nonsteroidal", "antiinflammatory", "agent", ",", "is", "prohibited", "in", "the", "United", "States", "because", "of", "the", "risk", "of", "agranulocytosis", "but", "is", "widely", "used", "in", "Mexico", "and", "other", "countries", "."], "event_mentions": [{"id": "12042592_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 16, "end": 17}, "arguments": [{"entity_id": "12042592_2_Ent1", "role": "Treatment", "text": "Metamizole", "start": 0, "end": 1}, {"entity_id": "12042592_2_Ent2", "role": "Treatment_Drug", "text": "Metamizole", "start": 0, "end": 1}, {"entity_id": "12042592_2_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "12042592_2_Ent1", "text": "Metamizole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12042592_2_Ent2", "text": "Metamizole", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12042592_2_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "12053072_2", "wnd_id": "12053072_2_1", "text": "We describe a patient who developed HUS after treatment with mitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "HUS", "after", "treatment", "with", "mitomycin", "C", "(", "total", "dose", "144", "mg", "/", "m2", ")", "due", "to", "a", "carcinoma", "of", "the", "ascending", "colon", "."], "event_mentions": [{"id": "12053072_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12053072_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12053072_2_Ent1", "role": "Effect", "text": "HUS", "start": 6, "end": 7}, {"entity_id": "12053072_2_Ent3", "role": "Treatment_Drug", "text": "mitomycin C", "start": 10, "end": 12}, {"entity_id": "12053072_2_Ent2", "role": "Treatment", "text": "mitomycin C ( total dose 144 mg / m2 )", "start": 10, "end": 20}, {"entity_id": "12053072_2_Ent4", "role": "Treatment_Dosage", "text": "144 mg / m2", "start": 15, "end": 19}, {"entity_id": "12053072_2_Ent5", "role": "Treatment_Disorder", "text": "carcinoma of the ascending colon", "start": 23, "end": 28}]}], "entity_mentions": [{"id": "12053072_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12053072_2_Ent1", "text": "HUS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12053072_2_Ent3", "text": "mitomycin C", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12053072_2_Ent2", "text": "mitomycin C ( total dose 144 mg / m2 )", "entity_type": "Entity", "start": 10, "end": 20}, {"id": "12053072_2_Ent4", "text": "144 mg / m2", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12053072_2_Ent5", "text": "carcinoma of the ascending colon", "entity_type": "Entity", "start": 23, "end": 28}], "lang": "en"}
{"doc_id": "12078977_2", "wnd_id": "12078977_2_1", "text": "Posterior leukoencephalopathy following cisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary .", "tokens": ["Posterior", "leukoencephalopathy", "following", "cisplatin", ",", "bleomycin", "and", "vinblastine", "therapy", "for", "germ", "cell", "tumor", "of", "the", "ovary", "."], "event_mentions": [{"id": "12078977_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "12078977_2_Ent0", "role": "Effect", "text": "Posterior leukoencephalopathy", "start": 0, "end": 2}, {"entity_id": "12078977_2_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 3, "end": 4}, {"entity_id": "12078977_2_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 3, "end": 4}, {"entity_id": "12078977_2_Ent1", "role": "Treatment", "text": "cisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary", "start": 3, "end": 16}, {"entity_id": "12078977_2_Ent4", "role": "Treatment_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "12078977_2_Ent7", "role": "Combination_Drug", "text": "bleomycin", "start": 5, "end": 6}, {"entity_id": "12078977_2_Ent5", "role": "Treatment_Drug", "text": "vinblastine", "start": 7, "end": 8}, {"entity_id": "12078977_2_Ent6", "role": "Combination_Drug", "text": "vinblastine", "start": 7, "end": 8}, {"entity_id": "12078977_2_Ent2", "role": "Treatment_Disorder", "text": "germ cell tumor of the ovary", "start": 10, "end": 16}]}], "entity_mentions": [{"id": "12078977_2_Ent0", "text": "Posterior leukoencephalopathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12078977_2_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12078977_2_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12078977_2_Ent1", "text": "cisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "12078977_2_Ent4", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12078977_2_Ent7", "text": "bleomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12078977_2_Ent5", "text": "vinblastine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12078977_2_Ent6", "text": "vinblastine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12078977_2_Ent2", "text": "germ cell tumor of the ovary", "entity_type": "Entity", "start": 10, "end": 16}], "lang": "en"}
{"doc_id": "12086549_4", "wnd_id": "12086549_4_1", "text": "Toxic epidermal necrolysis associated with interleukin - 2 .", "tokens": ["Toxic", "epidermal", "necrolysis", "associated", "with", "interleukin", "-", "2", "."], "event_mentions": [{"id": "12086549_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12086549_4_Ent0", "role": "Effect", "text": "Toxic epidermal necrolysis", "start": 0, "end": 3}, {"entity_id": "12086549_4_Ent1", "role": "Treatment", "text": "interleukin - 2", "start": 5, "end": 8}, {"entity_id": "12086549_4_Ent2", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "12086549_4_Ent0", "text": "Toxic epidermal necrolysis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12086549_4_Ent1", "text": "interleukin - 2", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12086549_4_Ent2", "text": "interleukin - 2", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "12111771_5", "wnd_id": "12111771_5_1", "text": "To our knowledge , four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature .", "tokens": ["To", "our", "knowledge", ",", "four", "cases", "of", "interstitial", "pneumonitis", "associated", "with", "fludarabine", "have", "been", "reported", "in", "medical", "literature", "."], "event_mentions": [{"id": "12111771_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "12111771_5_Ent0", "role": "Effect", "text": "interstitial pneumonitis", "start": 7, "end": 9}, {"entity_id": "12111771_5_Ent1", "role": "Treatment", "text": "fludarabine", "start": 11, "end": 12}, {"entity_id": "12111771_5_Ent2", "role": "Treatment_Drug", "text": "fludarabine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "12111771_5_Ent0", "text": "interstitial pneumonitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12111771_5_Ent1", "text": "fludarabine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12111771_5_Ent2", "text": "fludarabine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "12121061_2", "wnd_id": "12121061_2_1", "text": "A 50 - year - old diabetic and hypertensive male patient is reported who had ticlopidine - induced marrow aplasia partially responsive to colony - stimulating factors and corticosteroids , but experienced complete recovery with cyclosporine .", "tokens": ["A", "50", "-", "year", "-", "old", "diabetic", "and", "hypertensive", "male", "patient", "is", "reported", "who", "had", "ticlopidine", "-", "induced", "marrow", "aplasia", "partially", "responsive", "to", "colony", "-", "stimulating", "factors", "and", "corticosteroids", ",", "but", "experienced", "complete", "recovery", "with", "cyclosporine", "."], "event_mentions": [{"id": "12121061_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "12121061_2_Ent2", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent0", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent1", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent3", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent5", "role": "Treatment", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 15, "end": 16}, {"entity_id": "12121061_2_Ent4", "role": "Effect", "text": "marrow aplasia", "start": 18, "end": 20}]}, {"id": "12121061_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "with", "start": 34, "end": 35}, "arguments": [{"entity_id": "12121061_2_Ent9", "role": "Subject_Age", "text": "50 - year - old", "start": 1, "end": 6}, {"entity_id": "12121061_2_Ent7", "role": "Subject", "text": "50 - year - old diabetic and hypertensive male patient", "start": 1, "end": 11}, {"entity_id": "12121061_2_Ent8", "role": "Subject_Disorder", "text": "diabetic and hypertensive", "start": 6, "end": 9}, {"entity_id": "12121061_2_Ent10", "role": "Subject_Gender", "text": "male", "start": 9, "end": 10}, {"entity_id": "12121061_2_Ent13", "role": "Treatment_Disorder", "text": "ticlopidine - induced marrow aplasia", "start": 15, "end": 20}, {"entity_id": "12121061_2_Ent11", "role": "Effect", "text": "experienced complete recovery", "start": 31, "end": 34}, {"entity_id": "12121061_2_Ent12", "role": "Treatment", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "12121061_2_Ent14", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}]}], "entity_mentions": [{"id": "12121061_2_Ent2", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent9", "text": "50 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12121061_2_Ent0", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent7", "text": "50 - year - old diabetic and hypertensive male patient", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "12121061_2_Ent1", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent8", "text": "diabetic and hypertensive", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12121061_2_Ent3", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent10", "text": "male", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12121061_2_Ent5", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12121061_2_Ent13", "text": "ticlopidine - induced marrow aplasia", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "12121061_2_Ent4", "text": "marrow aplasia", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "12121061_2_Ent11", "text": "experienced complete recovery", "entity_type": "Entity", "start": 31, "end": 34}, {"id": "12121061_2_Ent12", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "12121061_2_Ent14", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}], "lang": "en"}
{"doc_id": "12121061_6", "wnd_id": "12121061_6_1", "text": "Alone or in combination with corticosteroids , cyclosporine is an effective drug of choice for the resistant patients .", "tokens": ["Alone", "or", "in", "combination", "with", "corticosteroids", ",", "cyclosporine", "is", "an", "effective", "drug", "of", "choice", "for", "the", "resistant", "patients", "."], "event_mentions": [{"id": "12121061_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "is", "start": 8, "end": 9}, "arguments": [{"entity_id": "12121061_6_Ent1", "role": "Treatment", "text": "Alone or in combination with corticosteroids , cyclosporine", "start": 0, "end": 8}, {"entity_id": "12121061_6_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 5, "end": 6}, {"entity_id": "12121061_6_Ent4", "role": "Combination_Drug", "text": "corticosteroids", "start": 5, "end": 6}, {"entity_id": "12121061_6_Ent3", "role": "Treatment_Drug", "text": "cyclosporine", "start": 7, "end": 8}, {"entity_id": "12121061_6_Ent5", "role": "Combination_Drug", "text": "cyclosporine", "start": 7, "end": 8}, {"entity_id": "12121061_6_Ent0", "role": "Subject", "text": "resistant patients", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12121061_6_Ent1", "text": "Alone or in combination with corticosteroids , cyclosporine", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12121061_6_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12121061_6_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12121061_6_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12121061_6_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12121061_6_Ent0", "text": "resistant patients", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12135176_2", "wnd_id": "12135176_2_1", "text": "Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia ( PSVT ) with little proarrhythmic effect .", "tokens": ["Verapamil", "is", "widely", "used", "for", "the", "termination", "of", "paroxysmal", "supraventricular", "tachycardia", "(", "PSVT", ")", "with", "little", "proarrhythmic", "effect", "."], "event_mentions": [{"id": "12135176_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 14, "end": 15}, "arguments": [{"entity_id": "12135176_2_Ent1", "role": "Treatment", "text": "Verapamil", "start": 0, "end": 1}, {"entity_id": "12135176_2_Ent2", "role": "Treatment_Drug", "text": "Verapamil", "start": 0, "end": 1}, {"entity_id": "12135176_2_Ent3", "role": "Treatment_Disorder", "text": "paroxysmal supraventricular tachycardia", "start": 8, "end": 11}, {"entity_id": "12135176_2_Ent0", "role": "Effect", "text": "proarrhythmic effect", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "12135176_2_Ent1", "text": "Verapamil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12135176_2_Ent2", "text": "Verapamil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12135176_2_Ent3", "text": "paroxysmal supraventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "12135176_2_Ent0", "text": "proarrhythmic effect", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "12149193_3", "wnd_id": "12149193_3_1", "text": "Thalidomide has proven activity in refractory multiple myeloma ( MM ) , and although single - agent thalidomide has minimal prothrombogenic activity , its combination with cytotoxic chemotherapy is associated with a significantly increased risk of DVT .", "tokens": ["Thalidomide", "has", "proven", "activity", "in", "refractory", "multiple", "myeloma", "(", "MM", ")", ",", "and", "although", "single", "-", "agent", "thalidomide", "has", "minimal", "prothrombogenic", "activity", ",", "its", "combination", "with", "cytotoxic", "chemotherapy", "is", "associated", "with", "a", "significantly", "increased", "risk", "of", "DVT", "."], "event_mentions": [{"id": "12149193_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 29, "end": 30}, "arguments": [{"entity_id": "12149193_3_Ent3", "role": "Treatment_Disorder", "text": "refractory multiple myeloma ( MM )", "start": 5, "end": 11}, {"entity_id": "12149193_3_Ent1", "role": "Treatment", "text": "single - agent thalidomide", "start": 14, "end": 18}, {"entity_id": "12149193_3_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_3_Ent7", "role": "Combination_Drug", "text": "thalidomide", "start": 17, "end": 18}, {"entity_id": "12149193_3_Ent2", "role": "Treatment", "text": "combination with cytotoxic chemotherapy", "start": 24, "end": 28}, {"entity_id": "12149193_3_Ent5", "role": "Treatment_Drug", "text": "cytotoxic", "start": 26, "end": 27}, {"entity_id": "12149193_3_Ent8", "role": "Combination_Drug", "text": "cytotoxic", "start": 26, "end": 27}, {"entity_id": "12149193_3_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 27, "end": 28}, {"entity_id": "12149193_3_Ent0", "role": "Effect", "text": "significantly increased risk of DVT", "start": 32, "end": 37}]}], "entity_mentions": [{"id": "12149193_3_Ent3", "text": "refractory multiple myeloma ( MM )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "12149193_3_Ent1", "text": "single - agent thalidomide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "12149193_3_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_3_Ent7", "text": "thalidomide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "12149193_3_Ent2", "text": "combination with cytotoxic chemotherapy", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "12149193_3_Ent5", "text": "cytotoxic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12149193_3_Ent8", "text": "cytotoxic", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12149193_3_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "12149193_3_Ent0", "text": "significantly increased risk of DVT", "entity_type": "Entity", "start": 32, "end": 37}], "lang": "en"}
{"doc_id": "12166705_1", "wnd_id": "12166705_1_1", "text": "Mitomycin - C induced hemolytic uremic syndrome : a case report .", "tokens": ["Mitomycin", "-", "C", "induced", "hemolytic", "uremic", "syndrome", ":", "a", "case", "report", "."], "event_mentions": [{"id": "12166705_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "12166705_1_Ent1", "role": "Treatment", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_1_Ent2", "role": "Treatment_Drug", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_1_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "12166705_1_Ent1", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_1_Ent2", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_1_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "12166705_2", "wnd_id": "12166705_2_1", "text": "Mitomycin - C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome .", "tokens": ["Mitomycin", "-", "C", "is", "used", "widely", "in", "the", "treatment", "of", "malignancies", "and", "is", "associated", "with", "serious", "dose", "related", "adverse", "effects", "including", "the", "occurrence", "of", "hemolytic", "uremic", "syndrome", "."], "event_mentions": [{"id": "12166705_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "12166705_2_Ent1", "role": "Treatment", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_2_Ent3", "role": "Treatment_Drug", "text": "Mitomycin - C", "start": 0, "end": 3}, {"entity_id": "12166705_2_Ent2", "role": "Treatment_Disorder", "text": "malignancies", "start": 10, "end": 11}, {"entity_id": "12166705_2_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "12166705_2_Ent1", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_2_Ent3", "text": "Mitomycin - C", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12166705_2_Ent2", "text": "malignancies", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12166705_2_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "12181031_1", "wnd_id": "12181031_1_1", "text": "Although vasculitis has been reported in the course of hairy cell leukaemia , it has only rarely been reported as the consequence of cladribine treatment .", "tokens": ["Although", "vasculitis", "has", "been", "reported", "in", "the", "course", "of", "hairy", "cell", "leukaemia", ",", "it", "has", "only", "rarely", "been", "reported", "as", "the", "consequence", "of", "cladribine", "treatment", "."], "event_mentions": [{"id": "12181031_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 21, "end": 22}, "arguments": [{"entity_id": "12181031_1_Ent0", "role": "Effect", "text": "vasculitis", "start": 1, "end": 2}, {"entity_id": "12181031_1_Ent2", "role": "Treatment_Disorder", "text": "hairy cell leukaemia", "start": 9, "end": 12}, {"entity_id": "12181031_1_Ent1", "role": "Treatment", "text": "cladribine", "start": 23, "end": 24}, {"entity_id": "12181031_1_Ent3", "role": "Treatment_Drug", "text": "cladribine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12181031_1_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12181031_1_Ent2", "text": "hairy cell leukaemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12181031_1_Ent1", "text": "cladribine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12181031_1_Ent3", "text": "cladribine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12181031_3", "wnd_id": "12181031_3_1", "text": "We describe a 73 - year - old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine .", "tokens": ["We", "describe", "a", "73", "-", "year", "-", "old", "woman", "who", "developed", "serious", "systemic", "vasculitis", "with", "associated", "thrombocytopenia", "in", "the", "course", "of", "treatment", "with", "cladribine", "."], "event_mentions": [{"id": "12181031_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "12181031_3_Ent0", "role": "Subject", "text": "a 73 - year - old woman", "start": 2, "end": 9}, {"entity_id": "12181031_3_Ent1", "role": "Subject_Age", "text": "73 - year - old", "start": 3, "end": 8}, {"entity_id": "12181031_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "12181031_3_Ent3", "role": "Effect", "text": "systemic vasculitis with associated thrombocytopenia", "start": 12, "end": 17}, {"entity_id": "12181031_3_Ent4", "role": "Treatment", "text": "cladribine", "start": 23, "end": 24}, {"entity_id": "12181031_3_Ent5", "role": "Treatment_Drug", "text": "cladribine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12181031_3_Ent0", "text": "a 73 - year - old woman", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "12181031_3_Ent1", "text": "73 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12181031_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12181031_3_Ent3", "text": "systemic vasculitis with associated thrombocytopenia", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "12181031_3_Ent4", "text": "cladribine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12181031_3_Ent5", "text": "cladribine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12187348_1", "wnd_id": "12187348_1_1", "text": "Gigantomastia induced by bucillamine .", "tokens": ["Gigantomastia", "induced", "by", "bucillamine", "."], "event_mentions": [{"id": "12187348_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "12187348_1_Ent0", "role": "Effect", "text": "Gigantomastia", "start": 0, "end": 1}, {"entity_id": "12187348_1_Ent1", "role": "Treatment", "text": "bucillamine", "start": 3, "end": 4}, {"entity_id": "12187348_1_Ent2", "role": "Treatment_Drug", "text": "bucillamine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12187348_1_Ent0", "text": "Gigantomastia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12187348_1_Ent1", "text": "bucillamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12187348_1_Ent2", "text": "bucillamine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12196060_2", "wnd_id": "12196060_2_1", "text": "To report a young man on phenytoin who developed acute neurologic symptoms after isradipine was introduced to his treatment regimen and discuss the possible causes of this drug interaction .", "tokens": ["To", "report", "a", "young", "man", "on", "phenytoin", "who", "developed", "acute", "neurologic", "symptoms", "after", "isradipine", "was", "introduced", "to", "his", "treatment", "regimen", "and", "discuss", "the", "possible", "causes", "of", "this", "drug", "interaction", "."], "event_mentions": [{"id": "12196060_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "12196060_2_Ent0", "role": "Subject", "text": "a young man", "start": 2, "end": 5}, {"entity_id": "12196060_2_Ent1", "role": "Subject_Age", "text": "young", "start": 3, "end": 4}, {"entity_id": "12196060_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 4, "end": 5}, {"entity_id": "12196060_2_Ent4", "role": "Treatment", "text": "phenytoin", "start": 6, "end": 7}, {"entity_id": "12196060_2_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 6, "end": 7}, {"entity_id": "12196060_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 6, "end": 7}, {"entity_id": "12196060_2_Ent3", "role": "Effect", "text": "acute neurologic symptoms", "start": 9, "end": 12}, {"entity_id": "12196060_2_Ent5", "role": "Treatment", "text": "isradipine", "start": 13, "end": 14}, {"entity_id": "12196060_2_Ent6", "role": "Treatment_Drug", "text": "isradipine", "start": 13, "end": 14}, {"entity_id": "12196060_2_Ent9", "role": "Combination_Drug", "text": "isradipine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12196060_2_Ent0", "text": "a young man", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12196060_2_Ent1", "text": "young", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12196060_2_Ent2", "text": "man", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12196060_2_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12196060_2_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12196060_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12196060_2_Ent3", "text": "acute neurologic symptoms", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12196060_2_Ent5", "text": "isradipine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12196060_2_Ent6", "text": "isradipine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12196060_2_Ent9", "text": "isradipine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12218252_1", "wnd_id": "12218252_1_1", "text": "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept .", "tokens": ["Generalised", "pustular", "psoriasis", "induced", "by", "cyclosporin", "a", "withdrawal", "responding", "to", "the", "tumour", "necrosis", "factor", "alpha", "inhibitor", "etanercept", "."], "event_mentions": [{"id": "12218252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "12218252_1_Ent0", "role": "Effect", "text": "Generalised pustular psoriasis", "start": 0, "end": 3}, {"entity_id": "12218252_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporin", "start": 5, "end": 6}, {"entity_id": "12218252_1_Ent1", "role": "Treatment", "text": "cyclosporin a withdrawal", "start": 5, "end": 8}]}, {"id": "12218252_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responding", "start": 8, "end": 9}, "arguments": [{"entity_id": "12218252_1_Ent4", "role": "Treatment_Disorder", "text": "Generalised pustular psoriasis induced by cyclosporin a withdrawal", "start": 0, "end": 8}, {"entity_id": "12218252_1_Ent3", "role": "Treatment", "text": "the tumour necrosis factor alpha inhibitor etanercept", "start": 10, "end": 17}, {"entity_id": "12218252_1_Ent5", "role": "Treatment_Drug", "text": "etanercept", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12218252_1_Ent0", "text": "Generalised pustular psoriasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12218252_1_Ent4", "text": "Generalised pustular psoriasis induced by cyclosporin a withdrawal", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12218252_1_Ent2", "text": "cyclosporin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12218252_1_Ent1", "text": "cyclosporin a withdrawal", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12218252_1_Ent3", "text": "the tumour necrosis factor alpha inhibitor etanercept", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "12218252_1_Ent5", "text": "etanercept", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12234159_2", "wnd_id": "12234159_2_1", "text": "Rofecoxib , used for dysmenorrhea , caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand .", "tokens": ["Rofecoxib", ",", "used", "for", "dysmenorrhea", ",", "caused", "a", "herpetiform", "fixed", "drug", "eruption", "predominantly", "involving", "the", "lips", "with", "classic", "clinical", "and", "histological", "findings", "in", "a", "red", "-", "brown", "lesion", "on", "the", "dorsal", "hand", "."], "event_mentions": [{"id": "12234159_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 6, "end": 7}, "arguments": [{"entity_id": "12234159_2_Ent1", "role": "Treatment", "text": "Rofecoxib", "start": 0, "end": 1}, {"entity_id": "12234159_2_Ent3", "role": "Treatment_Drug", "text": "Rofecoxib", "start": 0, "end": 1}, {"entity_id": "12234159_2_Ent2", "role": "Treatment_Disorder", "text": "dysmenorrhea", "start": 4, "end": 5}, {"entity_id": "12234159_2_Ent0", "role": "Effect", "text": "herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand", "start": 8, "end": 32}]}], "entity_mentions": [{"id": "12234159_2_Ent1", "text": "Rofecoxib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12234159_2_Ent3", "text": "Rofecoxib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12234159_2_Ent2", "text": "dysmenorrhea", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12234159_2_Ent0", "text": "herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red - brown lesion on the dorsal hand", "entity_type": "Entity", "start": 8, "end": 32}], "lang": "en"}
{"doc_id": "12243603_1", "wnd_id": "12243603_1_1", "text": "Rhabdomyolysis with concurrent atorvastatin and diltiazem .", "tokens": ["Rhabdomyolysis", "with", "concurrent", "atorvastatin", "and", "diltiazem", "."], "event_mentions": [{"id": "12243603_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 1, "end": 2}, "arguments": [{"entity_id": "12243603_1_Ent0", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_1_Ent2", "role": "Treatment", "text": "atorvastatin", "start": 3, "end": 4}, {"entity_id": "12243603_1_Ent3", "role": "Treatment_Drug", "text": "atorvastatin", "start": 3, "end": 4}, {"entity_id": "12243603_1_Ent5", "role": "Combination_Drug", "text": "atorvastatin", "start": 3, "end": 4}, {"entity_id": "12243603_1_Ent1", "role": "Treatment", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "12243603_1_Ent4", "role": "Treatment_Drug", "text": "diltiazem", "start": 5, "end": 6}, {"entity_id": "12243603_1_Ent6", "role": "Combination_Drug", "text": "diltiazem", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12243603_1_Ent0", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_1_Ent2", "text": "atorvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12243603_1_Ent3", "text": "atorvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12243603_1_Ent5", "text": "atorvastatin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12243603_1_Ent1", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_1_Ent4", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_1_Ent6", "text": "diltiazem", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12243603_12", "wnd_id": "12243603_12_1", "text": "All patients beginning HMG - CoA reductase inhibitor therapy should be counseled regarding the signs and symptoms of muscle injury ; particular attention should be paid to those patients who are taking medications that may interact .", "tokens": ["All", "patients", "beginning", "HMG", "-", "CoA", "reductase", "inhibitor", "therapy", "should", "be", "counseled", "regarding", "the", "signs", "and", "symptoms", "of", "muscle", "injury", ";", "particular", "attention", "should", "be", "paid", "to", "those", "patients", "who", "are", "taking", "medications", "that", "may", "interact", "."], "event_mentions": [{"id": "12243603_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "regarding", "start": 12, "end": 13}, "arguments": [{"entity_id": "12243603_12_Ent0", "role": "Subject", "text": "All patients", "start": 0, "end": 2}, {"entity_id": "12243603_12_Ent2", "role": "Treatment", "text": "HMG - CoA reductase inhibitor", "start": 3, "end": 8}, {"entity_id": "12243603_12_Ent3", "role": "Treatment_Drug", "text": "HMG - CoA reductase inhibitor", "start": 3, "end": 8}, {"entity_id": "12243603_12_Ent1", "role": "Effect", "text": "the signs and symptoms of muscle injury", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "12243603_12_Ent0", "text": "All patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12243603_12_Ent2", "text": "HMG - CoA reductase inhibitor", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12243603_12_Ent3", "text": "HMG - CoA reductase inhibitor", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12243603_12_Ent1", "text": "the signs and symptoms of muscle injury", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "12243603_6", "wnd_id": "12243603_6_1", "text": "Rhabdomyolysis has been reported in patients receiving hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism .", "tokens": ["Rhabdomyolysis", "has", "been", "reported", "in", "patients", "receiving", "hydroxymethylglutaryl", "coenzyme", "A", "(", "HMG", "-", "CoA", ")", "reductase", "inhibitors", "when", "coadministered", "with", "agents", "that", "may", "inhibit", "their", "metabolism", "."], "event_mentions": [{"id": "12243603_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12243603_6_Ent1", "role": "Effect", "text": "Rhabdomyolysis", "start": 0, "end": 1}, {"entity_id": "12243603_6_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "12243603_6_Ent3", "role": "Treatment_Drug", "text": "hydroxymethylglutaryl coenzyme A", "start": 7, "end": 10}, {"entity_id": "12243603_6_Ent5", "role": "Combination_Drug", "text": "hydroxymethylglutaryl coenzyme A", "start": 7, "end": 10}, {"entity_id": "12243603_6_Ent2", "role": "Treatment", "text": "hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism", "start": 7, "end": 26}, {"entity_id": "12243603_6_Ent4", "role": "Treatment_Drug", "text": "agents that may inhibit their metabolism", "start": 20, "end": 26}, {"entity_id": "12243603_6_Ent6", "role": "Combination_Drug", "text": "agents that may inhibit their metabolism", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "12243603_6_Ent1", "text": "Rhabdomyolysis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_6_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12243603_6_Ent3", "text": "hydroxymethylglutaryl coenzyme A", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12243603_6_Ent5", "text": "hydroxymethylglutaryl coenzyme A", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "12243603_6_Ent2", "text": "hydroxymethylglutaryl coenzyme A ( HMG - CoA ) reductase inhibitors when coadministered with agents that may inhibit their metabolism", "entity_type": "Entity", "start": 7, "end": 26}, {"id": "12243603_6_Ent4", "text": "agents that may inhibit their metabolism", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "12243603_6_Ent6", "text": "agents that may inhibit their metabolism", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "12243603_7", "wnd_id": "12243603_7_1", "text": "Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia .", "tokens": ["Atorvastatin", "is", "the", "most", "potent", "of", "this", "class", "of", "agents", "currently", "available", "and", "is", "commonly", "used", "in", "the", "treatment", "of", "hyperlipidemia", "."], "event_mentions": [{"id": "12243603_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 18, "end": 19}, "arguments": [{"entity_id": "12243603_7_Ent1", "role": "Treatment", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "12243603_7_Ent3", "role": "Treatment_Drug", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "12243603_7_Ent0", "role": "Effect", "text": "most potent", "start": 3, "end": 5}, {"entity_id": "12243603_7_Ent2", "role": "Treatment_Disorder", "text": "hyperlipidemia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "12243603_7_Ent1", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_7_Ent3", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12243603_7_Ent0", "text": "most potent", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "12243603_7_Ent2", "text": "hyperlipidemia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "12324937_2", "wnd_id": "12324937_2_1", "text": "CONCLUSION : There are only a few confirmed cases of gemcitabine - associated HUS despite the widespread use of the drug .", "tokens": ["CONCLUSION", ":", "There", "are", "only", "a", "few", "confirmed", "cases", "of", "gemcitabine", "-", "associated", "HUS", "despite", "the", "widespread", "use", "of", "the", "drug", "."], "event_mentions": [{"id": "12324937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "12324937_2_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "12324937_2_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "12324937_2_Ent0", "role": "Effect", "text": "HUS", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12324937_2_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12324937_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12324937_2_Ent0", "text": "HUS", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12365708_3", "wnd_id": "12365708_3_1", "text": "CASE REPORT : Soon after initiation of amiodarone HCl ( 200 mg / day ) , a 76 - year - old man came to us with symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision .", "tokens": ["CASE", "REPORT", ":", "Soon", "after", "initiation", "of", "amiodarone", "HCl", "(", "200", "mg", "/", "day", ")", ",", "a", "76", "-", "year", "-", "old", "man", "came", "to", "us", "with", "symptoms", "of", "visual", "\"", "shining", ",", "\"", "glare", ",", "color", "vision", "anomalies", ",", "and", "gradually", "decreased", "vision", "."], "event_mentions": [{"id": "12365708_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after initiation", "start": 4, "end": 6}, "arguments": [{"entity_id": "12365708_3_Ent4", "role": "Treatment", "text": "amiodarone HCl", "start": 7, "end": 9}, {"entity_id": "12365708_3_Ent5", "role": "Treatment_Drug", "text": "amiodarone HCl", "start": 7, "end": 9}, {"entity_id": "12365708_3_Ent6", "role": "Treatment_Dosage", "text": "( 200 mg", "start": 9, "end": 12}, {"entity_id": "12365708_3_Ent7", "role": "Treatment_Freq", "text": "day", "start": 13, "end": 14}, {"entity_id": "12365708_3_Ent0", "role": "Subject", "text": "a 76 - year - old man", "start": 16, "end": 23}, {"entity_id": "12365708_3_Ent1", "role": "Subject_Age", "text": "76 - year - old", "start": 17, "end": 22}, {"entity_id": "12365708_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 22, "end": 23}, {"entity_id": "12365708_3_Ent3", "role": "Effect", "text": "symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision", "start": 27, "end": 44}]}], "entity_mentions": [{"id": "12365708_3_Ent4", "text": "amiodarone HCl", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12365708_3_Ent5", "text": "amiodarone HCl", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12365708_3_Ent6", "text": "( 200 mg", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12365708_3_Ent7", "text": "day", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12365708_3_Ent0", "text": "a 76 - year - old man", "entity_type": "Entity", "start": 16, "end": 23}, {"id": "12365708_3_Ent1", "text": "76 - year - old", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "12365708_3_Ent2", "text": "man", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "12365708_3_Ent3", "text": "symptoms of visual \" shining , \" glare , color vision anomalies , and gradually decreased vision", "entity_type": "Entity", "start": 27, "end": 44}], "lang": "en"}
{"doc_id": "12399645_4", "wnd_id": "12399645_4_1", "text": "We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) 1.5 months after commencement of mizoribin prescription when his arthritis was improved .", "tokens": ["We", "describe", "a", "74", "-", "year", "-", "old", "man", "with", "rheumatoid", "arthritis", "(", "RA", ")", "who", "developed", "syndrome", "of", "inappropriate", "secretion", "of", "antidiuretic", "hormone", "(", "SIADH", ")", "1.5", "months", "after", "commencement", "of", "mizoribin", "prescription", "when", "his", "arthritis", "was", "improved", "."], "event_mentions": [{"id": "12399645_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "12399645_4_Ent0", "role": "Subject", "text": "a 74 - year - old man with rheumatoid arthritis ( RA )", "start": 2, "end": 15}, {"entity_id": "12399645_4_Ent1", "role": "Subject_Age", "text": "74 - year - old", "start": 3, "end": 8}, {"entity_id": "12399645_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "12399645_4_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}, {"entity_id": "12399645_4_Ent3", "role": "Effect", "text": "syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "start": 17, "end": 27}, {"entity_id": "12399645_4_Ent5", "role": "Treatment_Time_elapsed", "text": "1.5 months after", "start": 27, "end": 30}, {"entity_id": "12399645_4_Ent4", "role": "Treatment", "text": "1.5 months after commencement of mizoribin prescription", "start": 27, "end": 34}, {"entity_id": "12399645_4_Ent6", "role": "Treatment_Drug", "text": "mizoribin", "start": 32, "end": 33}]}], "entity_mentions": [{"id": "12399645_4_Ent0", "text": "a 74 - year - old man with rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 2, "end": 15}, {"id": "12399645_4_Ent1", "text": "74 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "12399645_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "12399645_4_Ent7", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12399645_4_Ent3", "text": "syndrome of inappropriate secretion of antidiuretic hormone ( SIADH )", "entity_type": "Entity", "start": 17, "end": 27}, {"id": "12399645_4_Ent5", "text": "1.5 months after", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "12399645_4_Ent4", "text": "1.5 months after commencement of mizoribin prescription", "entity_type": "Entity", "start": 27, "end": 34}, {"id": "12399645_4_Ent6", "text": "mizoribin", "entity_type": "Entity", "start": 32, "end": 33}], "lang": "en"}
{"doc_id": "12424571_2", "wnd_id": "12424571_2_1", "text": "We herein report this rare case of acute onset of nephrotic syndrome during interferon - alpha retreatment .", "tokens": ["We", "herein", "report", "this", "rare", "case", "of", "acute", "onset", "of", "nephrotic", "syndrome", "during", "interferon", "-", "alpha", "retreatment", "."], "event_mentions": [{"id": "12424571_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 12, "end": 13}, "arguments": [{"entity_id": "12424571_2_Ent0", "role": "Effect", "text": "acute onset of nephrotic syndrome", "start": 7, "end": 12}, {"entity_id": "12424571_2_Ent1", "role": "Treatment", "text": "interferon - alpha", "start": 13, "end": 16}, {"entity_id": "12424571_2_Ent2", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "12424571_2_Ent0", "text": "acute onset of nephrotic syndrome", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12424571_2_Ent1", "text": "interferon - alpha", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "12424571_2_Ent2", "text": "interferon - alpha", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "12452753_1", "wnd_id": "12452753_1_1", "text": "Capecitabine was discontinued and the allergic reactions resolved after the woman took diphenhydramine for 1 week .", "tokens": ["Capecitabine", "was", "discontinued", "and", "the", "allergic", "reactions", "resolved", "after", "the", "woman", "took", "diphenhydramine", "for", "1", "week", "."], "event_mentions": [{"id": "12452753_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "took", "start": 11, "end": 12}, "arguments": [{"entity_id": "12452753_1_Ent2", "role": "Effect", "text": "Capecitabine was discontinued and the allergic reactions resolved", "start": 0, "end": 8}, {"entity_id": "12452753_1_Ent0", "role": "Subject", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12452753_1_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "12452753_1_Ent4", "role": "Treatment_Drug", "text": "diphenhydramine", "start": 12, "end": 13}, {"entity_id": "12452753_1_Ent3", "role": "Treatment", "text": "diphenhydramine for 1 week", "start": 12, "end": 16}, {"entity_id": "12452753_1_Ent5", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12452753_1_Ent2", "text": "Capecitabine was discontinued and the allergic reactions resolved", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12452753_1_Ent0", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12452753_1_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12452753_1_Ent4", "text": "diphenhydramine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12452753_1_Ent3", "text": "diphenhydramine for 1 week", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "12452753_1_Ent5", "text": "1 week", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12452753_6", "wnd_id": "12452753_6_1", "text": "She developed a generalized rash and itching , sore throat , and dizziness approximately 4 hours after the first dose of capecitabine .", "tokens": ["She", "developed", "a", "generalized", "rash", "and", "itching", ",", "sore", "throat", ",", "and", "dizziness", "approximately", "4", "hours", "after", "the", "first", "dose", "of", "capecitabine", "."], "event_mentions": [{"id": "12452753_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "12452753_6_Ent0", "role": "Effect", "text": "a generalized rash and itching , sore throat , and dizziness", "start": 2, "end": 13}, {"entity_id": "12452753_6_Ent1", "role": "Treatment", "text": "approximately 4 hours after the first dose of capecitabine", "start": 13, "end": 22}, {"entity_id": "12452753_6_Ent2", "role": "Treatment_Time_elapsed", "text": "4 hours", "start": 14, "end": 16}, {"entity_id": "12452753_6_Ent3", "role": "Treatment_Drug", "text": "capecitabine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12452753_6_Ent0", "text": "a generalized rash and itching , sore throat , and dizziness", "entity_type": "Entity", "start": 2, "end": 13}, {"id": "12452753_6_Ent1", "text": "approximately 4 hours after the first dose of capecitabine", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "12452753_6_Ent2", "text": "4 hours", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "12452753_6_Ent3", "text": "capecitabine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12455453_1", "wnd_id": "12455453_1_1", "text": "After five and six weeks of continuous oral administration of methylprednisolone , the boys developed steroid diabetes .", "tokens": ["After", "five", "and", "six", "weeks", "of", "continuous", "oral", "administration", "of", "methylprednisolone", ",", "the", "boys", "developed", "steroid", "diabetes", "."], "event_mentions": [{"id": "12455453_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "12455453_1_Ent4", "role": "Treatment_Duration", "text": "After five and six weeks", "start": 0, "end": 5}, {"entity_id": "12455453_1_Ent3", "role": "Treatment", "text": "After five and six weeks of continuous oral administration of methylprednisolone", "start": 0, "end": 11}, {"entity_id": "12455453_1_Ent5", "role": "Treatment_Route", "text": "oral", "start": 7, "end": 8}, {"entity_id": "12455453_1_Ent6", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 10, "end": 11}, {"entity_id": "12455453_1_Ent0", "role": "Subject", "text": "boys", "start": 13, "end": 14}, {"entity_id": "12455453_1_Ent1", "role": "Subject_Gender", "text": "boys", "start": 13, "end": 14}, {"entity_id": "12455453_1_Ent2", "role": "Effect", "text": "steroid diabetes", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "12455453_1_Ent4", "text": "After five and six weeks", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "12455453_1_Ent3", "text": "After five and six weeks of continuous oral administration of methylprednisolone", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "12455453_1_Ent5", "text": "oral", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12455453_1_Ent6", "text": "methylprednisolone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12455453_1_Ent0", "text": "boys", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12455453_1_Ent1", "text": "boys", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12455453_1_Ent2", "text": "steroid diabetes", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "12455453_2", "wnd_id": "12455453_2_1", "text": "Reduction of methylprednisolone dosage rather than insulin therapy resulted in better control of glycemia .", "tokens": ["Reduction", "of", "methylprednisolone", "dosage", "rather", "than", "insulin", "therapy", "resulted", "in", "better", "control", "of", "glycemia", "."], "event_mentions": [{"id": "12455453_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 8, "end": 9}, "arguments": [{"entity_id": "12455453_2_Ent2", "role": "Treatment_Dosage", "text": "Reduction", "start": 0, "end": 1}, {"entity_id": "12455453_2_Ent0", "role": "Treatment", "text": "Reduction of methylprednisolone dosage rather than insulin therapy", "start": 0, "end": 8}, {"entity_id": "12455453_2_Ent1", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 2, "end": 3}, {"entity_id": "12455453_2_Ent3", "role": "Treatment_Disorder", "text": "glycemia", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "12455453_2_Ent2", "text": "Reduction", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12455453_2_Ent0", "text": "Reduction of methylprednisolone dosage rather than insulin therapy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "12455453_2_Ent1", "text": "methylprednisolone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12455453_2_Ent3", "text": "glycemia", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "12460237_1", "wnd_id": "12460237_1_1", "text": "Recurrent palmar - plantar erythrodysaesthesia following high - dose cytarabine treatment for acute lymphoblastic leukemia .", "tokens": ["Recurrent", "palmar", "-", "plantar", "erythrodysaesthesia", "following", "high", "-", "dose", "cytarabine", "treatment", "for", "acute", "lymphoblastic", "leukemia", "."], "event_mentions": [{"id": "12460237_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 10, "end": 11}, "arguments": [{"entity_id": "12460237_1_Ent0", "role": "Effect", "text": "palmar - plantar erythrodysaesthesia", "start": 1, "end": 5}, {"entity_id": "12460237_1_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 6, "end": 9}, {"entity_id": "12460237_1_Ent1", "role": "Treatment", "text": "high - dose cytarabine", "start": 6, "end": 10}, {"entity_id": "12460237_1_Ent2", "role": "Treatment_Drug", "text": "cytarabine", "start": 9, "end": 10}, {"entity_id": "12460237_1_Ent4", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "12460237_1_Ent0", "text": "palmar - plantar erythrodysaesthesia", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "12460237_1_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12460237_1_Ent1", "text": "high - dose cytarabine", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "12460237_1_Ent2", "text": "cytarabine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12460237_1_Ent4", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "12460237_2", "wnd_id": "12460237_2_1", "text": "Palmar - plantar erythrodysaesthesia ( PPE ) is an uncommon cutaneous complication of cytotoxic chemotherapy which generally presents as a painful erythema involving the palms and soles .", "tokens": ["Palmar", "-", "plantar", "erythrodysaesthesia", "(", "PPE", ")", "is", "an", "uncommon", "cutaneous", "complication", "of", "cytotoxic", "chemotherapy", "which", "generally", "presents", "as", "a", "painful", "erythema", "involving", "the", "palms", "and", "soles", "."], "event_mentions": [{"id": "12460237_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 11, "end": 12}, "arguments": [{"entity_id": "12460237_2_Ent0", "role": "Effect", "text": "Palmar - plantar erythrodysaesthesia ( PPE )", "start": 0, "end": 7}, {"entity_id": "12460237_2_Ent1", "role": "Effect", "text": "an uncommon cutaneous complication", "start": 8, "end": 12}, {"entity_id": "12460237_2_Ent4", "role": "Treatment_Drug", "text": "cytotoxic", "start": 13, "end": 14}, {"entity_id": "12460237_2_Ent3", "role": "Treatment", "text": "cytotoxic chemotherapy", "start": 13, "end": 15}, {"entity_id": "12460237_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 14, "end": 15}, {"entity_id": "12460237_2_Ent2", "role": "Effect", "text": "a painful erythema involving the palms and soles", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "12460237_2_Ent0", "text": "Palmar - plantar erythrodysaesthesia ( PPE )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "12460237_2_Ent1", "text": "an uncommon cutaneous complication", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "12460237_2_Ent4", "text": "cytotoxic", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12460237_2_Ent3", "text": "cytotoxic chemotherapy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "12460237_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12460237_2_Ent2", "text": "a painful erythema involving the palms and soles", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "12488741_2", "wnd_id": "12488741_2_1", "text": "Proton MRS examination demonstrated a persistent lactate elevation during metronidazole treatment .", "tokens": ["Proton", "MRS", "examination", "demonstrated", "a", "persistent", "lactate", "elevation", "during", "metronidazole", "treatment", "."], "event_mentions": [{"id": "12488741_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "12488741_2_Ent0", "role": "Effect", "text": "persistent lactate elevation", "start": 5, "end": 8}, {"entity_id": "12488741_2_Ent1", "role": "Treatment", "text": "metronidazole", "start": 9, "end": 10}, {"entity_id": "12488741_2_Ent2", "role": "Treatment_Drug", "text": "metronidazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "12488741_2_Ent0", "text": "persistent lactate elevation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12488741_2_Ent1", "text": "metronidazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12488741_2_Ent2", "text": "metronidazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "12494253_3", "wnd_id": "12494253_3_1", "text": "Anaphylaxis to cisplatin is an infrequent life - threatening complication which may occur even in patients who have received prior treatment with cisplatin .", "tokens": ["Anaphylaxis", "to", "cisplatin", "is", "an", "infrequent", "life", "-", "threatening", "complication", "which", "may", "occur", "even", "in", "patients", "who", "have", "received", "prior", "treatment", "with", "cisplatin", "."], "event_mentions": [{"id": "12494253_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 12, "end": 13}, "arguments": [{"entity_id": "12494253_3_Ent1", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "12494253_3_Ent2", "role": "Treatment", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "12494253_3_Ent3", "role": "Treatment_Drug", "text": "cisplatin", "start": 2, "end": 3}, {"entity_id": "12494253_3_Ent0", "role": "Subject", "text": "patients", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "12494253_3_Ent1", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12494253_3_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12494253_3_Ent3", "text": "cisplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12494253_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "12503933_2", "wnd_id": "12503933_2_1", "text": "A second possibility is an interaction between clarithromycin and isradipine , potentially increasing the hepatic toxicity of isradipine .", "tokens": ["A", "second", "possibility", "is", "an", "interaction", "between", "clarithromycin", "and", "isradipine", ",", "potentially", "increasing", "the", "hepatic", "toxicity", "of", "isradipine", "."], "event_mentions": [{"id": "12503933_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increasing", "start": 12, "end": 13}, "arguments": [{"entity_id": "12503933_2_Ent1", "role": "Treatment", "text": "interaction between clarithromycin and isradipine", "start": 5, "end": 10}, {"entity_id": "12503933_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 7, "end": 8}, {"entity_id": "12503933_2_Ent4", "role": "Combination_Drug", "text": "clarithromycin", "start": 7, "end": 8}, {"entity_id": "12503933_2_Ent3", "role": "Treatment_Drug", "text": "isradipine", "start": 9, "end": 10}, {"entity_id": "12503933_2_Ent5", "role": "Combination_Drug", "text": "isradipine", "start": 9, "end": 10}, {"entity_id": "12503933_2_Ent0", "role": "Effect", "text": "hepatic toxicity", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "12503933_2_Ent1", "text": "interaction between clarithromycin and isradipine", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "12503933_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12503933_2_Ent4", "text": "clarithromycin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12503933_2_Ent3", "text": "isradipine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_2_Ent5", "text": "isradipine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12503933_2_Ent0", "text": "hepatic toxicity", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "12504711_1", "wnd_id": "12504711_1_1", "text": "A paradoxical ocular effect of brimonidine .", "tokens": ["A", "paradoxical", "ocular", "effect", "of", "brimonidine", "."], "event_mentions": [{"id": "12504711_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 4, "end": 5}, "arguments": [{"entity_id": "12504711_1_Ent0", "role": "Effect", "text": "paradoxical ocular effect", "start": 1, "end": 4}, {"entity_id": "12504711_1_Ent1", "role": "Treatment", "text": "brimonidine", "start": 5, "end": 6}, {"entity_id": "12504711_1_Ent2", "role": "Treatment_Drug", "text": "brimonidine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12504711_1_Ent0", "text": "paradoxical ocular effect", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12504711_1_Ent1", "text": "brimonidine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12504711_1_Ent2", "text": "brimonidine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12504711_2", "wnd_id": "12504711_2_1", "text": "CONCLUSION : Under certain circumstances topical brimonidine can cause paradoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine .", "tokens": ["CONCLUSION", ":", "Under", "certain", "circumstances", "topical", "brimonidine", "can", "cause", "paradoxical", "raised", "IOP", "necessitating", "vigilance", "in", "follow", "-", "up", "of", "patients", "on", "topical", "brimonidine", "."], "event_mentions": [{"id": "12504711_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "12504711_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 5, "end": 6}, {"entity_id": "12504711_2_Ent2", "role": "Treatment", "text": "topical brimonidine", "start": 5, "end": 7}, {"entity_id": "12504711_2_Ent4", "role": "Treatment_Drug", "text": "brimonidine", "start": 6, "end": 7}, {"entity_id": "12504711_2_Ent1", "role": "Effect", "text": "raised IOP", "start": 10, "end": 12}, {"entity_id": "12504711_2_Ent0", "role": "Subject", "text": "patients on topical brimonidine", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "12504711_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12504711_2_Ent2", "text": "topical brimonidine", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "12504711_2_Ent4", "text": "brimonidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12504711_2_Ent1", "text": "raised IOP", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "12504711_2_Ent0", "text": "patients on topical brimonidine", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "12504711_4", "wnd_id": "12504711_4_1", "text": "RESULTS : Brimonidine was observed to cause IOP elevation , confirmed on rechallenge , scoring 8 ( strong probability ) on an adverse drug reaction probability score .", "tokens": ["RESULTS", ":", "Brimonidine", "was", "observed", "to", "cause", "IOP", "elevation", ",", "confirmed", "on", "rechallenge", ",", "scoring", "8", "(", "strong", "probability", ")", "on", "an", "adverse", "drug", "reaction", "probability", "score", "."], "event_mentions": [{"id": "12504711_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "12504711_4_Ent1", "role": "Treatment", "text": "Brimonidine", "start": 2, "end": 3}, {"entity_id": "12504711_4_Ent2", "role": "Treatment_Drug", "text": "Brimonidine", "start": 2, "end": 3}, {"entity_id": "12504711_4_Ent0", "role": "Effect", "text": "IOP elevation", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "12504711_4_Ent1", "text": "Brimonidine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12504711_4_Ent2", "text": "Brimonidine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "12504711_4_Ent0", "text": "IOP elevation", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "12507063_1", "wnd_id": "12507063_1_1", "text": "Although gabapentin withdrawal has been previously reported and usually consists of anxiety , diaphoresis , and palpitations , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal .", "tokens": ["Although", "gabapentin", "withdrawal", "has", "been", "previously", "reported", "and", "usually", "consists", "of", "anxiety", ",", "diaphoresis", ",", "and", "palpitations", ",", "this", "is", "the", "first", "reported", "patient", "with", "generalized", "seizures", "and", "status", "epilepticus", "secondary", "to", "gabapentin", "withdrawal", "."], "event_mentions": [{"id": "12507063_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 24, "end": 25}, "arguments": [{"entity_id": "12507063_1_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}, {"entity_id": "12507063_1_Ent1", "role": "Effect", "text": "generalized seizures and status epilepticus", "start": 25, "end": 30}, {"entity_id": "12507063_1_Ent2", "role": "Treatment", "text": "secondary to gabapentin withdrawal", "start": 30, "end": 34}, {"entity_id": "12507063_1_Ent3", "role": "Treatment_Drug", "text": "gabapentin", "start": 32, "end": 33}, {"entity_id": "12507063_1_Ent4", "role": "Treatment_Dosage", "text": "withdrawal", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "12507063_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12507063_1_Ent1", "text": "generalized seizures and status epilepticus", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "12507063_1_Ent2", "text": "secondary to gabapentin withdrawal", "entity_type": "Entity", "start": 30, "end": 34}, {"id": "12507063_1_Ent3", "text": "gabapentin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "12507063_1_Ent4", "text": "withdrawal", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "12507063_2", "wnd_id": "12507063_2_1", "text": "Gabapentin withdrawal presenting as status epilepticus .", "tokens": ["Gabapentin", "withdrawal", "presenting", "as", "status", "epilepticus", "."], "event_mentions": [{"id": "12507063_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 2, "end": 3}, "arguments": [{"entity_id": "12507063_2_Ent2", "role": "Treatment_Drug", "text": "Gabapentin", "start": 0, "end": 1}, {"entity_id": "12507063_2_Ent1", "role": "Treatment", "text": "Gabapentin withdrawal", "start": 0, "end": 2}, {"entity_id": "12507063_2_Ent0", "role": "Effect", "text": "status epilepticus", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "12507063_2_Ent2", "text": "Gabapentin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12507063_2_Ent1", "text": "Gabapentin withdrawal", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12507063_2_Ent0", "text": "status epilepticus", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "12540009_4", "wnd_id": "12540009_4_1", "text": "We report the first case of doxycycline - induced hypoglycemia in a young nondiabetic man .", "tokens": ["We", "report", "the", "first", "case", "of", "doxycycline", "-", "induced", "hypoglycemia", "in", "a", "young", "nondiabetic", "man", "."], "event_mentions": [{"id": "12540009_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "12540009_4_Ent5", "role": "Treatment", "text": "doxycycline", "start": 6, "end": 7}, {"entity_id": "12540009_4_Ent6", "role": "Treatment_Drug", "text": "doxycycline", "start": 6, "end": 7}, {"entity_id": "12540009_4_Ent4", "role": "Effect", "text": "hypoglycemia", "start": 9, "end": 10}, {"entity_id": "12540009_4_Ent0", "role": "Subject", "text": "a young nondiabetic man", "start": 11, "end": 15}, {"entity_id": "12540009_4_Ent1", "role": "Subject_Age", "text": "young", "start": 12, "end": 13}, {"entity_id": "12540009_4_Ent2", "role": "Subject_Disorder", "text": "nondiabetic", "start": 13, "end": 14}, {"entity_id": "12540009_4_Ent3", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "12540009_4_Ent5", "text": "doxycycline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12540009_4_Ent6", "text": "doxycycline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12540009_4_Ent4", "text": "hypoglycemia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12540009_4_Ent0", "text": "a young nondiabetic man", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "12540009_4_Ent1", "text": "young", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12540009_4_Ent2", "text": "nondiabetic", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "12540009_4_Ent3", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "12590235_1", "wnd_id": "12590235_1_1", "text": "Both 6 - MP and AZA are widely used and are known to cause hepatotoxicity in a proportion of patients .", "tokens": ["Both", "6", "-", "MP", "and", "AZA", "are", "widely", "used", "and", "are", "known", "to", "cause", "hepatotoxicity", "in", "a", "proportion", "of", "patients", "."], "event_mentions": [{"id": "12590235_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used", "start": 8, "end": 9}, "arguments": [{"entity_id": "12590235_1_Ent4", "role": "Treatment_Drug", "text": "6 - MP", "start": 1, "end": 4}, {"entity_id": "12590235_1_Ent5", "role": "Combination_Drug", "text": "6 - MP", "start": 1, "end": 4}, {"entity_id": "12590235_1_Ent2", "role": "Treatment", "text": "6 - MP and AZA", "start": 1, "end": 6}, {"entity_id": "12590235_1_Ent3", "role": "Treatment_Drug", "text": "AZA", "start": 5, "end": 6}, {"entity_id": "12590235_1_Ent6", "role": "Combination_Drug", "text": "AZA", "start": 5, "end": 6}, {"entity_id": "12590235_1_Ent1", "role": "Effect", "text": "hepatotoxicity", "start": 14, "end": 15}, {"entity_id": "12590235_1_Ent0", "role": "Subject", "text": "a proportion of patients", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "12590235_1_Ent4", "text": "6 - MP", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12590235_1_Ent5", "text": "6 - MP", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "12590235_1_Ent2", "text": "6 - MP and AZA", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12590235_1_Ent3", "text": "AZA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12590235_1_Ent6", "text": "AZA", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12590235_1_Ent1", "text": "hepatotoxicity", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "12590235_1_Ent0", "text": "a proportion of patients", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "1261772_3", "wnd_id": "1261772_3_1", "text": "These observations indicate that submassive hepatic necrosis may result from treatment with propylthiouracil and are consistent with the notion that sensitization mechanisms may be responsible for the hepatic injury induced by this drug .", "tokens": ["These", "observations", "indicate", "that", "submassive", "hepatic", "necrosis", "may", "result", "from", "treatment", "with", "propylthiouracil", "and", "are", "consistent", "with", "the", "notion", "that", "sensitization", "mechanisms", "may", "be", "responsible", "for", "the", "hepatic", "injury", "induced", "by", "this", "drug", "."], "event_mentions": [{"id": "1261772_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 8, "end": 9}, "arguments": [{"entity_id": "1261772_3_Ent0", "role": "Effect", "text": "submassive hepatic necrosis", "start": 4, "end": 7}, {"entity_id": "1261772_3_Ent1", "role": "Treatment", "text": "propylthiouracil", "start": 12, "end": 13}, {"entity_id": "1261772_3_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1261772_3_Ent0", "text": "submassive hepatic necrosis", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1261772_3_Ent1", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "1261772_3_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12625995_1", "wnd_id": "12625995_1_1", "text": "Akathisia is a relatively rare side effect with the newer atypical antipsychotic agents , particularly clozapine , and is easily misdiagnosed in children .", "tokens": ["Akathisia", "is", "a", "relatively", "rare", "side", "effect", "with", "the", "newer", "atypical", "antipsychotic", "agents", ",", "particularly", "clozapine", ",", "and", "is", "easily", "misdiagnosed", "in", "children", "."], "event_mentions": [{"id": "12625995_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 7, "end": 8}, "arguments": [{"entity_id": "12625995_1_Ent1", "role": "Effect", "text": "Akathisia", "start": 0, "end": 1}, {"entity_id": "12625995_1_Ent2", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "12625995_1_Ent0", "role": "Subject", "text": "children", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12625995_1_Ent1", "text": "Akathisia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "12625995_1_Ent0", "text": "children", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12625995_2", "wnd_id": "12625995_2_1", "text": "Clozapine - induced akathisia in children with schizophrenia .", "tokens": ["Clozapine", "-", "induced", "akathisia", "in", "children", "with", "schizophrenia", "."], "event_mentions": [{"id": "12625995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12625995_2_Ent3", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "12625995_2_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "12625995_2_Ent2", "role": "Effect", "text": "akathisia", "start": 3, "end": 4}, {"entity_id": "12625995_2_Ent1", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "12625995_2_Ent0", "role": "Subject", "text": "children with schizophrenia", "start": 5, "end": 8}, {"entity_id": "12625995_2_Ent5", "role": "Treatment_Disorder", "text": "schizophrenia", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12625995_2_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_2_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12625995_2_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12625995_2_Ent1", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12625995_2_Ent0", "text": "children with schizophrenia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "12625995_2_Ent5", "text": "schizophrenia", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12630660_6", "wnd_id": "12630660_6_1", "text": "After reviewing the literature we suggest the CPM was a complication of lithium toxicity which affected the lateral geniculate nucleus which produced blindness .", "tokens": ["After", "reviewing", "the", "literature", "we", "suggest", "the", "CPM", "was", "a", "complication", "of", "lithium", "toxicity", "which", "affected", "the", "lateral", "geniculate", "nucleus", "which", "produced", "blindness", "."], "event_mentions": [{"id": "12630660_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 10, "end": 11}, "arguments": [{"entity_id": "12630660_6_Ent0", "role": "Effect", "text": "CPM", "start": 7, "end": 8}, {"entity_id": "12630660_6_Ent3", "role": "Treatment", "text": "lithium", "start": 12, "end": 13}, {"entity_id": "12630660_6_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 12, "end": 13}, {"entity_id": "12630660_6_Ent1", "role": "Effect", "text": "lithium toxicity", "start": 12, "end": 14}, {"entity_id": "12630660_6_Ent2", "role": "Effect", "text": "blindness", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "12630660_6_Ent0", "text": "CPM", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "12630660_6_Ent3", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12630660_6_Ent4", "text": "lithium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12630660_6_Ent1", "text": "lithium toxicity", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "12630660_6_Ent2", "text": "blindness", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "12635752_1", "wnd_id": "12635752_1_1", "text": "Antithyroid treatment with propylthiouracil ( PTU ) resulted in elevated hepatic enzymes and after the 12th week of pregnancy treatment was changed to carbimazole ( CBZ ) .", "tokens": ["Antithyroid", "treatment", "with", "propylthiouracil", "(", "PTU", ")", "resulted", "in", "elevated", "hepatic", "enzymes", "and", "after", "the", "12th", "week", "of", "pregnancy", "treatment", "was", "changed", "to", "carbimazole", "(", "CBZ", ")", "."], "event_mentions": [{"id": "12635752_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulted", "start": 7, "end": 8}, "arguments": [{"entity_id": "12635752_1_Ent4", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 3, "end": 4}, {"entity_id": "12635752_1_Ent3", "role": "Treatment", "text": "propylthiouracil ( PTU )", "start": 3, "end": 7}, {"entity_id": "12635752_1_Ent2", "role": "Effect", "text": "elevated hepatic enzymes", "start": 9, "end": 12}, {"entity_id": "12635752_1_Ent0", "role": "Subject", "text": "12th week of pregnancy", "start": 15, "end": 19}, {"entity_id": "12635752_1_Ent1", "role": "Subject_Disorder", "text": "pregnancy", "start": 18, "end": 19}]}, {"id": "12635752_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "changed", "start": 21, "end": 22}, "arguments": [{"entity_id": "12635752_1_Ent8", "role": "Treatment_Disorder", "text": "Antithyroid", "start": 0, "end": 1}, {"entity_id": "12635752_1_Ent5", "role": "Subject", "text": "12th week of pregnancy", "start": 15, "end": 19}, {"entity_id": "12635752_1_Ent6", "role": "Subject_Disorder", "text": "pregnancy", "start": 18, "end": 19}, {"entity_id": "12635752_1_Ent9", "role": "Treatment_Drug", "text": "carbimazole", "start": 23, "end": 24}, {"entity_id": "12635752_1_Ent7", "role": "Treatment", "text": "carbimazole ( CBZ )", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "12635752_1_Ent8", "text": "Antithyroid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12635752_1_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12635752_1_Ent3", "text": "propylthiouracil ( PTU )", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "12635752_1_Ent2", "text": "elevated hepatic enzymes", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "12635752_1_Ent0", "text": "12th week of pregnancy", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12635752_1_Ent5", "text": "12th week of pregnancy", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12635752_1_Ent1", "text": "pregnancy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12635752_1_Ent6", "text": "pregnancy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "12635752_1_Ent9", "text": "carbimazole", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "12635752_1_Ent7", "text": "carbimazole ( CBZ )", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "12656748_1", "wnd_id": "12656748_1_1", "text": "A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed chronic myeloid leukaemia ( CML ) after continuous uneventful treatment with hydroxyurea for 18 yr .", "tokens": ["A", "58", "-", "yr", "-", "old", "male", "patient", "with", "essential", "thrombocythaemia", "(", "ET", ")", "developed", "chronic", "myeloid", "leukaemia", "(", "CML", ")", "after", "continuous", "uneventful", "treatment", "with", "hydroxyurea", "for", "18", "yr", "."], "event_mentions": [{"id": "12656748_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "12656748_1_Ent0", "role": "Subject", "text": "A 58 - yr - old male patient with essential thrombocythaemia ( ET )", "start": 0, "end": 14}, {"entity_id": "12656748_1_Ent1", "role": "Subject_Age", "text": "58 - yr - old", "start": 1, "end": 6}, {"entity_id": "12656748_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "12656748_1_Ent5", "role": "Treatment_Disorder", "text": "essential thrombocythaemia ( ET )", "start": 9, "end": 14}, {"entity_id": "12656748_1_Ent3", "role": "Effect", "text": "chronic myeloid leukaemia ( CML )", "start": 15, "end": 21}, {"entity_id": "12656748_1_Ent4", "role": "Treatment", "text": "continuous uneventful treatment with hydroxyurea for 18 yr", "start": 22, "end": 30}, {"entity_id": "12656748_1_Ent6", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 26, "end": 27}, {"entity_id": "12656748_1_Ent7", "role": "Treatment_Duration", "text": "18 yr", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "12656748_1_Ent0", "text": "A 58 - yr - old male patient with essential thrombocythaemia ( ET )", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "12656748_1_Ent1", "text": "58 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "12656748_1_Ent2", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12656748_1_Ent5", "text": "essential thrombocythaemia ( ET )", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12656748_1_Ent3", "text": "chronic myeloid leukaemia ( CML )", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "12656748_1_Ent4", "text": "continuous uneventful treatment with hydroxyurea for 18 yr", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "12656748_1_Ent6", "text": "hydroxyurea", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "12656748_1_Ent7", "text": "18 yr", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "12659609_1", "wnd_id": "12659609_1_1", "text": "Toxicity related to chloroquine treatment of resistant vivax malaria .", "tokens": ["Toxicity", "related", "to", "chloroquine", "treatment", "of", "resistant", "vivax", "malaria", "."], "event_mentions": [{"id": "12659609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 1, "end": 2}, "arguments": [{"entity_id": "12659609_1_Ent0", "role": "Effect", "text": "Toxicity", "start": 0, "end": 1}, {"entity_id": "12659609_1_Ent1", "role": "Treatment", "text": "chloroquine", "start": 3, "end": 4}, {"entity_id": "12659609_1_Ent2", "role": "Treatment_Drug", "text": "chloroquine", "start": 3, "end": 4}, {"entity_id": "12659609_1_Ent3", "role": "Treatment_Disorder", "text": "resistant vivax malaria", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "12659609_1_Ent0", "text": "Toxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12659609_1_Ent1", "text": "chloroquine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12659609_1_Ent2", "text": "chloroquine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12659609_1_Ent3", "text": "resistant vivax malaria", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "12699871_4", "wnd_id": "12699871_4_1", "text": "Tacrolimus ( FK506) - induced mutism after liver transplant .", "tokens": ["Tacrolimus", "(", "FK506)", "-", "induced", "mutism", "after", "liver", "transplant", "."], "event_mentions": [{"id": "12699871_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "12699871_4_Ent2", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "12699871_4_Ent1", "role": "Treatment", "text": "Tacrolimus ( FK506)", "start": 0, "end": 3}, {"entity_id": "12699871_4_Ent0", "role": "Effect", "text": "mutism", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "12699871_4_Ent2", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12699871_4_Ent1", "text": "Tacrolimus ( FK506)", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "12699871_4_Ent0", "text": "mutism", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "12707728_1", "wnd_id": "12707728_1_1", "text": "Intrathecal methotrexate - induced acute cerebellar syndrome .", "tokens": ["Intrathecal", "methotrexate", "-", "induced", "acute", "cerebellar", "syndrome", "."], "event_mentions": [{"id": "12707728_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "12707728_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "12707728_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 1, "end": 2}, {"entity_id": "12707728_1_Ent0", "role": "Effect", "text": "acute cerebellar syndrome", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "12707728_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12707728_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "12707728_1_Ent0", "text": "acute cerebellar syndrome", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "12707728_2", "wnd_id": "12707728_2_1", "text": "We describe a patient who developed acute cerebellar syndrome after prophylactic intrathecal methotrexate administration and recovered spontaneously .", "tokens": ["We", "describe", "a", "patient", "who", "developed", "acute", "cerebellar", "syndrome", "after", "prophylactic", "intrathecal", "methotrexate", "administration", "and", "recovered", "spontaneously", "."], "event_mentions": [{"id": "12707728_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "12707728_2_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "12707728_2_Ent1", "role": "Effect", "text": "acute cerebellar syndrome", "start": 6, "end": 9}, {"entity_id": "12707728_2_Ent2", "role": "Treatment", "text": "prophylactic intrathecal methotrexate administration", "start": 10, "end": 14}, {"entity_id": "12707728_2_Ent4", "role": "Treatment_Route", "text": "intrathecal", "start": 11, "end": 12}, {"entity_id": "12707728_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "12707728_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "12707728_2_Ent1", "text": "acute cerebellar syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12707728_2_Ent2", "text": "prophylactic intrathecal methotrexate administration", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "12707728_2_Ent4", "text": "intrathecal", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12707728_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "12751276_1", "wnd_id": "12751276_1_1", "text": "Isoniazid - induced anaphylaxis .", "tokens": ["Isoniazid", "-", "induced", "anaphylaxis", "."], "event_mentions": [{"id": "12751276_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "12751276_1_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12751276_1_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "12751276_1_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "12751276_1_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12751276_1_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12751276_1_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "12776809_1", "wnd_id": "12776809_1_1", "text": "Safety aspects of a coumarin - troxerutin combination regarding liver function in a double - blind placebo - controlled study .", "tokens": ["Safety", "aspects", "of", "a", "coumarin", "-", "troxerutin", "combination", "regarding", "liver", "function", "in", "a", "double", "-", "blind", "placebo", "-", "controlled", "study", "."], "event_mentions": [{"id": "12776809_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Safety aspects", "start": 0, "end": 2}, "arguments": [{"entity_id": "12776809_1_Ent2", "role": "Treatment_Drug", "text": "coumarin", "start": 4, "end": 5}, {"entity_id": "12776809_1_Ent5", "role": "Combination_Drug", "text": "coumarin", "start": 4, "end": 5}, {"entity_id": "12776809_1_Ent1", "role": "Treatment", "text": "coumarin - troxerutin combination", "start": 4, "end": 8}, {"entity_id": "12776809_1_Ent3", "role": "Treatment_Drug", "text": "troxerutin", "start": 6, "end": 7}, {"entity_id": "12776809_1_Ent4", "role": "Combination_Drug", "text": "troxerutin", "start": 6, "end": 7}, {"entity_id": "12776809_1_Ent0", "role": "Effect", "text": "liver function", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "12776809_1_Ent2", "text": "coumarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12776809_1_Ent5", "text": "coumarin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12776809_1_Ent1", "text": "coumarin - troxerutin combination", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "12776809_1_Ent3", "text": "troxerutin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12776809_1_Ent4", "text": "troxerutin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "12776809_1_Ent0", "text": "liver function", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "12786839_2", "wnd_id": "12786839_2_1", "text": "Slow acetylator genotypes as a possible risk factor for infectious mononucleosis - like syndrome induced by salazosulfapyridine .", "tokens": ["Slow", "acetylator", "genotypes", "as", "a", "possible", "risk", "factor", "for", "infectious", "mononucleosis", "-", "like", "syndrome", "induced", "by", "salazosulfapyridine", "."], "event_mentions": [{"id": "12786839_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 14, "end": 16}, "arguments": [{"entity_id": "12786839_2_Ent0", "role": "Effect", "text": "infectious mononucleosis - like syndrome", "start": 9, "end": 14}, {"entity_id": "12786839_2_Ent1", "role": "Treatment", "text": "salazosulfapyridine", "start": 16, "end": 17}, {"entity_id": "12786839_2_Ent2", "role": "Treatment_Drug", "text": "salazosulfapyridine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "12786839_2_Ent0", "text": "infectious mononucleosis - like syndrome", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "12786839_2_Ent1", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12786839_2_Ent2", "text": "salazosulfapyridine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "12792223_4", "wnd_id": "12792223_4_1", "text": "We report in detail an unusual adverse reaction to infliximab therapy , a drug - induced lupus - like clinical syndrome .", "tokens": ["We", "report", "in", "detail", "an", "unusual", "adverse", "reaction", "to", "infliximab", "therapy", ",", "a", "drug", "-", "induced", "lupus", "-", "like", "clinical", "syndrome", "."], "event_mentions": [{"id": "12792223_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "12792223_4_Ent1", "role": "Treatment", "text": "infliximab", "start": 9, "end": 10}, {"entity_id": "12792223_4_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 9, "end": 10}, {"entity_id": "12792223_4_Ent0", "role": "Effect", "text": "lupus - like clinical syndrome", "start": 16, "end": 21}]}], "entity_mentions": [{"id": "12792223_4_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12792223_4_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12792223_4_Ent0", "text": "lupus - like clinical syndrome", "entity_type": "Entity", "start": 16, "end": 21}], "lang": "en"}
{"doc_id": "12796597_1", "wnd_id": "12796597_1_1", "text": "Chronic myelogenous leukemia ( CML ) , hepatitis C , and interferon alpha ( IFNalpha ) have all been associated with renal dysfunction .", "tokens": ["Chronic", "myelogenous", "leukemia", "(", "CML", ")", ",", "hepatitis", "C", ",", "and", "interferon", "alpha", "(", "IFNalpha", ")", "have", "all", "been", "associated", "with", "renal", "dysfunction", "."], "event_mentions": [{"id": "12796597_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 19, "end": 20}, "arguments": [{"entity_id": "12796597_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 11, "end": 13}, {"entity_id": "12796597_1_Ent1", "role": "Treatment", "text": "interferon alpha ( IFNalpha )", "start": 11, "end": 16}, {"entity_id": "12796597_1_Ent0", "role": "Effect", "text": "renal dysfunction", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "12796597_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "12796597_1_Ent1", "text": "interferon alpha ( IFNalpha )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "12796597_1_Ent0", "text": "renal dysfunction", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "12802933_3", "wnd_id": "12802933_3_1", "text": "We report the first case , to our knowledge , of rituximab - related autoimmune hemolytic anemia .", "tokens": ["We", "report", "the", "first", "case", ",", "to", "our", "knowledge", ",", "of", "rituximab", "-", "related", "autoimmune", "hemolytic", "anemia", "."], "event_mentions": [{"id": "12802933_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 13, "end": 14}, "arguments": [{"entity_id": "12802933_3_Ent1", "role": "Treatment", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "12802933_3_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 11, "end": 12}, {"entity_id": "12802933_3_Ent0", "role": "Effect", "text": "autoimmune hemolytic anemia", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "12802933_3_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12802933_3_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12802933_3_Ent0", "text": "autoimmune hemolytic anemia", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "12811715_2", "wnd_id": "12811715_2_1", "text": "Diphenhydramine - induced wide complex dysrhythmia responds to treatment with sodium bicarbonate .", "tokens": ["Diphenhydramine", "-", "induced", "wide", "complex", "dysrhythmia", "responds", "to", "treatment", "with", "sodium", "bicarbonate", "."], "event_mentions": [{"id": "12811715_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "to", "start": 7, "end": 8}, "arguments": [{"entity_id": "12811715_2_Ent2", "role": "Treatment_Drug", "text": "Diphenhydramine", "start": 0, "end": 1}, {"entity_id": "12811715_2_Ent1", "role": "Treatment_Disorder", "text": "Diphenhydramine - induced wide complex dysrhythmia", "start": 0, "end": 6}, {"entity_id": "12811715_2_Ent0", "role": "Treatment", "text": "treatment with sodium bicarbonate", "start": 8, "end": 12}, {"entity_id": "12811715_2_Ent3", "role": "Treatment_Drug", "text": "sodium bicarbonate", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "12811715_2_Ent2", "text": "Diphenhydramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12811715_2_Ent1", "text": "Diphenhydramine - induced wide complex dysrhythmia", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "12811715_2_Ent0", "text": "treatment with sodium bicarbonate", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "12811715_2_Ent3", "text": "sodium bicarbonate", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "12851279_13", "wnd_id": "12851279_13_1", "text": "There was an increase in serious adverse events with bleeding in the tifacogin group in both cohorts ( 6.5 % tifacogin and 4.8 % placebo for high INR ; 6.0 % tifacogin and 3.3 % placebo for low INR ) .", "tokens": ["There", "was", "an", "increase", "in", "serious", "adverse", "events", "with", "bleeding", "in", "the", "tifacogin", "group", "in", "both", "cohorts", "(", "6.5", "%", "tifacogin", "and", "4.8", "%", "placebo", "for", "high", "INR", ";", "6.0", "%", "tifacogin", "and", "3.3", "%", "placebo", "for", "low", "INR", ")", "."], "event_mentions": [{"id": "12851279_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse events", "start": 6, "end": 8}, "arguments": [{"entity_id": "12851279_13_Ent0", "role": "Effect", "text": "bleeding", "start": 9, "end": 10}, {"entity_id": "12851279_13_Ent1", "role": "Treatment", "text": "tifacogin", "start": 12, "end": 13}, {"entity_id": "12851279_13_Ent2", "role": "Treatment_Drug", "text": "tifacogin", "start": 12, "end": 13}, {"entity_id": "12851279_13_Ent3", "role": "Treatment_Disorder", "text": "high INR", "start": 26, "end": 28}, {"entity_id": "12851279_13_Ent4", "role": "Treatment_Disorder", "text": "low INR", "start": 37, "end": 39}]}], "entity_mentions": [{"id": "12851279_13_Ent0", "text": "bleeding", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12851279_13_Ent1", "text": "tifacogin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12851279_13_Ent2", "text": "tifacogin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12851279_13_Ent3", "text": "high INR", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "12851279_13_Ent4", "text": "low INR", "entity_type": "Entity", "start": 37, "end": 39}], "lang": "en"}
{"doc_id": "12851279_15", "wnd_id": "12851279_15_1", "text": "Tifacogin administration was associated with an increase in risk of bleeding , irrespective of baseline INR .", "tokens": ["Tifacogin", "administration", "was", "associated", "with", "an", "increase", "in", "risk", "of", "bleeding", ",", "irrespective", "of", "baseline", "INR", "."], "event_mentions": [{"id": "12851279_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "12851279_15_Ent1", "role": "Treatment", "text": "Tifacogin", "start": 0, "end": 1}, {"entity_id": "12851279_15_Ent2", "role": "Treatment_Drug", "text": "Tifacogin", "start": 0, "end": 1}, {"entity_id": "12851279_15_Ent0", "role": "Effect", "text": "an increase in risk of bleeding", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "12851279_15_Ent1", "text": "Tifacogin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12851279_15_Ent2", "text": "Tifacogin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "12851279_15_Ent0", "text": "an increase in risk of bleeding", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "12852380_1", "wnd_id": "12852380_1_1", "text": "However , in order to avoid neuropathic side effects , patients under thalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug .", "tokens": ["However", ",", "in", "order", "to", "avoid", "neuropathic", "side", "effects", ",", "patients", "under", "thalidomide", "therapy", "should", "be", "monitored", "every", "6", "months", "with", "nerve", "conduction", "studies", "while", "taking", "the", "drug", "."], "event_mentions": [{"id": "12852380_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "under", "start": 11, "end": 12}, "arguments": [{"entity_id": "12852380_1_Ent1", "role": "Effect", "text": "neuropathic side effects", "start": 6, "end": 9}, {"entity_id": "12852380_1_Ent0", "role": "Subject", "text": "patients", "start": 10, "end": 11}, {"entity_id": "12852380_1_Ent3", "role": "Treatment_Drug", "text": "thalidomide", "start": 12, "end": 13}, {"entity_id": "12852380_1_Ent2", "role": "Treatment", "text": "thalidomide therapy", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "12852380_1_Ent1", "text": "neuropathic side effects", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12852380_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12852380_1_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "12852380_1_Ent2", "text": "thalidomide therapy", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "12860350_2", "wnd_id": "12860350_2_1", "text": "We describe a premenopausal woman who , while having tamoxifen due to a diagnosis of in situ ductal carcinoma , developed endometriosis requiring surgery .", "tokens": ["We", "describe", "a", "premenopausal", "woman", "who", ",", "while", "having", "tamoxifen", "due", "to", "a", "diagnosis", "of", "in", "situ", "ductal", "carcinoma", ",", "developed", "endometriosis", "requiring", "surgery", "."], "event_mentions": [{"id": "12860350_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "12860350_2_Ent0", "role": "Subject", "text": "a premenopausal woman", "start": 2, "end": 5}, {"entity_id": "12860350_2_Ent2", "role": "Subject_Age", "text": "premenopausal", "start": 3, "end": 4}, {"entity_id": "12860350_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "12860350_2_Ent4", "role": "Treatment", "text": "tamoxifen", "start": 9, "end": 10}, {"entity_id": "12860350_2_Ent5", "role": "Treatment_Drug", "text": "tamoxifen", "start": 9, "end": 10}, {"entity_id": "12860350_2_Ent6", "role": "Treatment_Disorder", "text": "in situ ductal carcinoma", "start": 15, "end": 19}, {"entity_id": "12860350_2_Ent3", "role": "Effect", "text": "endometriosis", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "12860350_2_Ent0", "text": "a premenopausal woman", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "12860350_2_Ent2", "text": "premenopausal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "12860350_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12860350_2_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12860350_2_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12860350_2_Ent6", "text": "in situ ductal carcinoma", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "12860350_2_Ent3", "text": "endometriosis", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "12862258_2", "wnd_id": "12862258_2_1", "text": "Fatal agranulocytosis in an Indian male receiving 100 mg of dapsone daily , hospitalized for mid - borderline leprosy in type I reaction with triple nerve paralysis is reported .", "tokens": ["Fatal", "agranulocytosis", "in", "an", "Indian", "male", "receiving", "100", "mg", "of", "dapsone", "daily", ",", "hospitalized", "for", "mid", "-", "borderline", "leprosy", "in", "type", "I", "reaction", "with", "triple", "nerve", "paralysis", "is", "reported", "."], "event_mentions": [{"id": "12862258_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 6, "end": 7}, "arguments": [{"entity_id": "12862258_2_Ent3", "role": "Effect", "text": "Fatal agranulocytosis", "start": 0, "end": 2}, {"entity_id": "12862258_2_Ent1", "role": "Subject_Race", "text": "Indian", "start": 4, "end": 5}, {"entity_id": "12862258_2_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "12862258_2_Ent5", "role": "Treatment_Dosage", "text": "100 mg", "start": 7, "end": 9}, {"entity_id": "12862258_2_Ent4", "role": "Treatment", "text": "100 mg of dapsone daily", "start": 7, "end": 12}, {"entity_id": "12862258_2_Ent6", "role": "Treatment_Drug", "text": "dapsone", "start": 10, "end": 11}, {"entity_id": "12862258_2_Ent7", "role": "Treatment_Freq", "text": "daily", "start": 11, "end": 12}, {"entity_id": "12862258_2_Ent0", "role": "Subject", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "start": 15, "end": 27}, {"entity_id": "12862258_2_Ent8", "role": "Treatment_Disorder", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "start": 15, "end": 27}]}], "entity_mentions": [{"id": "12862258_2_Ent3", "text": "Fatal agranulocytosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "12862258_2_Ent1", "text": "Indian", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_2_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "12862258_2_Ent5", "text": "100 mg", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "12862258_2_Ent4", "text": "100 mg of dapsone daily", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12862258_2_Ent6", "text": "dapsone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "12862258_2_Ent7", "text": "daily", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "12862258_2_Ent0", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "12862258_2_Ent8", "text": "mid - borderline leprosy in type I reaction with triple nerve paralysis", "entity_type": "Entity", "start": 15, "end": 27}], "lang": "en"}
{"doc_id": "12862258_3", "wnd_id": "12862258_3_1", "text": "Various case reports concerning dapsone - induced agranulocytosis are reviewed .", "tokens": ["Various", "case", "reports", "concerning", "dapsone", "-", "induced", "agranulocytosis", "are", "reviewed", "."], "event_mentions": [{"id": "12862258_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "12862258_3_Ent1", "role": "Treatment", "text": "dapsone", "start": 4, "end": 5}, {"entity_id": "12862258_3_Ent2", "role": "Treatment_Drug", "text": "dapsone", "start": 4, "end": 5}, {"entity_id": "12862258_3_Ent0", "role": "Effect", "text": "agranulocytosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "12862258_3_Ent1", "text": "dapsone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_3_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "12862258_3_Ent0", "text": "agranulocytosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "12869178_2", "wnd_id": "12869178_2_1", "text": "Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced thrombocytopenia ( HIT ) postoperatively .", "tokens": ["Most", "cardiac", "surgical", "patients", "have", "had", "previous", "exposure", "to", "heparin", "for", "diagnostic", "or", "therapeutic", "interventions", "and", "hence", "have", "an", "increased", "susceptibility", "to", "developing", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "postoperatively", "."], "event_mentions": [{"id": "12869178_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 22, "end": 23}, "arguments": [{"entity_id": "12869178_2_Ent0", "role": "Subject", "text": "Most cardiac surgical patients", "start": 0, "end": 4}, {"entity_id": "12869178_2_Ent1", "role": "Subject_Disorder", "text": "cardiac surgical", "start": 1, "end": 3}, {"entity_id": "12869178_2_Ent3", "role": "Treatment", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "12869178_2_Ent4", "role": "Treatment_Drug", "text": "heparin", "start": 9, "end": 10}, {"entity_id": "12869178_2_Ent2", "role": "Effect", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "12869178_2_Ent0", "text": "Most cardiac surgical patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "12869178_2_Ent1", "text": "cardiac surgical", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "12869178_2_Ent3", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12869178_2_Ent4", "text": "heparin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "12869178_2_Ent2", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "1288290_1", "wnd_id": "1288290_1_1", "text": "Proliferation of abnormal bone marrow histiocytes , an undesired effect of granulocyte macrophage - colony - stimulating factor therapy in a patient with Hurler 's syndrome undergoing bone marrow transplantation .", "tokens": ["Proliferation", "of", "abnormal", "bone", "marrow", "histiocytes", ",", "an", "undesired", "effect", "of", "granulocyte", "macrophage", "-", "colony", "-", "stimulating", "factor", "therapy", "in", "a", "patient", "with", "Hurler", "'s", "syndrome", "undergoing", "bone", "marrow", "transplantation", "."], "event_mentions": [{"id": "1288290_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "undesired effect", "start": 8, "end": 10}, "arguments": [{"entity_id": "1288290_1_Ent1", "role": "Effect", "text": "Proliferation of abnormal bone marrow histiocytes", "start": 0, "end": 6}, {"entity_id": "1288290_1_Ent2", "role": "Treatment", "text": "granulocyte macrophage - colony - stimulating factor", "start": 11, "end": 18}, {"entity_id": "1288290_1_Ent3", "role": "Treatment_Drug", "text": "granulocyte macrophage - colony - stimulating factor", "start": 11, "end": 18}, {"entity_id": "1288290_1_Ent0", "role": "Subject", "text": "a patient with Hurler 's syndrome", "start": 20, "end": 26}, {"entity_id": "1288290_1_Ent4", "role": "Treatment_Disorder", "text": "Hurler 's syndrome", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "1288290_1_Ent1", "text": "Proliferation of abnormal bone marrow histiocytes", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1288290_1_Ent2", "text": "granulocyte macrophage - colony - stimulating factor", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "1288290_1_Ent3", "text": "granulocyte macrophage - colony - stimulating factor", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "1288290_1_Ent0", "text": "a patient with Hurler 's syndrome", "entity_type": "Entity", "start": 20, "end": 26}, {"id": "1288290_1_Ent4", "text": "Hurler 's syndrome", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "12889716_3", "wnd_id": "12889716_3_1", "text": "To our knowledge , this is the first case reported in the English literature of a generalized exanthem due to subcutaneous injection of enoxaparin .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "case", "reported", "in", "the", "English", "literature", "of", "a", "generalized", "exanthem", "due", "to", "subcutaneous", "injection", "of", "enoxaparin", "."], "event_mentions": [{"id": "12889716_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 18, "end": 19}, "arguments": [{"entity_id": "12889716_3_Ent0", "role": "Subject", "text": "the first case", "start": 6, "end": 9}, {"entity_id": "12889716_3_Ent1", "role": "Effect", "text": "generalized exanthem", "start": 16, "end": 18}, {"entity_id": "12889716_3_Ent3", "role": "Treatment_Route", "text": "subcutaneous injection", "start": 20, "end": 22}, {"entity_id": "12889716_3_Ent2", "role": "Treatment", "text": "subcutaneous injection of enoxaparin", "start": 20, "end": 24}, {"entity_id": "12889716_3_Ent4", "role": "Treatment_Drug", "text": "enoxaparin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "12889716_3_Ent0", "text": "the first case", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "12889716_3_Ent1", "text": "generalized exanthem", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "12889716_3_Ent3", "text": "subcutaneous injection", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "12889716_3_Ent2", "text": "subcutaneous injection of enoxaparin", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "12889716_3_Ent4", "text": "enoxaparin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "12921505_4", "wnd_id": "12921505_4_1", "text": "OBJECTIVE : To report a case of significant hepatic and renal failure with the use of argatroban in a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD ) .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "significant", "hepatic", "and", "renal", "failure", "with", "the", "use", "of", "argatroban", "in", "a", "patient", "with", "heparin", "-", "induced", "thrombocytopenia", "(", "HIT", ")", "requiring", "continuous", "veno", "-", "veno", "hemodialysis", "(", "CVVHD", ")", "."], "event_mentions": [{"id": "12921505_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "12921505_4_Ent2", "role": "Effect", "text": "significant hepatic and renal failure", "start": 7, "end": 12}, {"entity_id": "12921505_4_Ent3", "role": "Treatment", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent4", "role": "Treatment_Drug", "text": "argatroban", "start": 16, "end": 17}, {"entity_id": "12921505_4_Ent0", "role": "Subject", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "start": 18, "end": 37}, {"entity_id": "12921505_4_Ent1", "role": "Subject_Disorder", "text": "heparin - induced thrombocytopenia ( HIT )", "start": 21, "end": 28}]}, {"id": "12921505_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "12921505_4_Ent6", "role": "Treatment", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent7", "role": "Treatment_Drug", "text": "heparin", "start": 21, "end": 22}, {"entity_id": "12921505_4_Ent5", "role": "Effect", "text": "thrombocytopenia", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "12921505_4_Ent2", "text": "significant hepatic and renal failure", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "12921505_4_Ent3", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent4", "text": "argatroban", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "12921505_4_Ent0", "text": "a patient with heparin - induced thrombocytopenia ( HIT ) requiring continuous veno - veno hemodialysis ( CVVHD )", "entity_type": "Entity", "start": 18, "end": 37}, {"id": "12921505_4_Ent6", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent7", "text": "heparin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "12921505_4_Ent1", "text": "heparin - induced thrombocytopenia ( HIT )", "entity_type": "Entity", "start": 21, "end": 28}, {"id": "12921505_4_Ent5", "text": "thrombocytopenia", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "1295628_4", "wnd_id": "1295628_4_1", "text": "The cases of CBZ - induced SLE reported in the literature were reviewed .", "tokens": ["The", "cases", "of", "CBZ", "-", "induced", "SLE", "reported", "in", "the", "literature", "were", "reviewed", "."], "event_mentions": [{"id": "1295628_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "1295628_4_Ent1", "role": "Treatment", "text": "CBZ", "start": 3, "end": 4}, {"entity_id": "1295628_4_Ent2", "role": "Treatment_Drug", "text": "CBZ", "start": 3, "end": 4}, {"entity_id": "1295628_4_Ent0", "role": "Effect", "text": "SLE", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "1295628_4_Ent1", "text": "CBZ", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1295628_4_Ent2", "text": "CBZ", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1295628_4_Ent0", "text": "SLE", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "1359782_3", "wnd_id": "1359782_3_1", "text": "Sulfasalazine - induced lung disorder is an extremely rare entity which must be considered in all ulcerative colitis patients while on sulfasalazine therapy , despite the absence of pulmonary symptomatology .", "tokens": ["Sulfasalazine", "-", "induced", "lung", "disorder", "is", "an", "extremely", "rare", "entity", "which", "must", "be", "considered", "in", "all", "ulcerative", "colitis", "patients", "while", "on", "sulfasalazine", "therapy", ",", "despite", "the", "absence", "of", "pulmonary", "symptomatology", "."], "event_mentions": [{"id": "1359782_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1359782_3_Ent1", "role": "Treatment", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent2", "role": "Treatment_Disorder", "text": "Sulfasalazine", "start": 0, "end": 1}, {"entity_id": "1359782_3_Ent0", "role": "Effect", "text": "lung disorder", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "1359782_3_Ent1", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent2", "text": "Sulfasalazine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1359782_3_Ent0", "text": "lung disorder", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1401493_1", "wnd_id": "1401493_1_1", "text": "We report a case of acne fulminans occurring during treatment with 13 - cis - retinoic acid for cystic acne .", "tokens": ["We", "report", "a", "case", "of", "acne", "fulminans", "occurring", "during", "treatment", "with", "13", "-", "cis", "-", "retinoic", "acid", "for", "cystic", "acne", "."], "event_mentions": [{"id": "1401493_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "1401493_1_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1401493_1_Ent1", "role": "Effect", "text": "acne fulminans", "start": 5, "end": 7}, {"entity_id": "1401493_1_Ent2", "role": "Treatment", "text": "13 - cis - retinoic acid", "start": 11, "end": 17}, {"entity_id": "1401493_1_Ent3", "role": "Treatment_Drug", "text": "13 - cis - retinoic acid", "start": 11, "end": 17}, {"entity_id": "1401493_1_Ent4", "role": "Treatment_Disorder", "text": "cystic acne", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "1401493_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1401493_1_Ent1", "text": "acne fulminans", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1401493_1_Ent2", "text": "13 - cis - retinoic acid", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "1401493_1_Ent3", "text": "13 - cis - retinoic acid", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "1401493_1_Ent4", "text": "cystic acne", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "1414247_1", "wnd_id": "1414247_1_1", "text": "Carbamyl phosphate synthetase - 1 deficiency discovered after valproic acid - induced coma .", "tokens": ["Carbamyl", "phosphate", "synthetase", "-", "1", "deficiency", "discovered", "after", "valproic", "acid", "-", "induced", "coma", "."], "event_mentions": [{"id": "1414247_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "1414247_1_Ent1", "role": "Effect", "text": "Carbamyl phosphate synthetase - 1 deficiency", "start": 0, "end": 6}, {"entity_id": "1414247_1_Ent2", "role": "Treatment", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "1414247_1_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "1414247_1_Ent0", "role": "Effect", "text": "coma", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "1414247_1_Ent1", "text": "Carbamyl phosphate synthetase - 1 deficiency", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1414247_1_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1414247_1_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1414247_1_Ent0", "text": "coma", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "1414247_2", "wnd_id": "1414247_2_1", "text": "Valproic acid induced coma is presented in an adult patient without a history of metabolic disease .", "tokens": ["Valproic", "acid", "induced", "coma", "is", "presented", "in", "an", "adult", "patient", "without", "a", "history", "of", "metabolic", "disease", "."], "event_mentions": [{"id": "1414247_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1414247_2_Ent3", "role": "Treatment", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "1414247_2_Ent4", "role": "Treatment_Drug", "text": "Valproic acid", "start": 0, "end": 2}, {"entity_id": "1414247_2_Ent2", "role": "Effect", "text": "coma", "start": 3, "end": 4}, {"entity_id": "1414247_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 8, "end": 9}, {"entity_id": "1414247_2_Ent0", "role": "Subject", "text": "adult patient without a history of metabolic disease", "start": 8, "end": 16}]}], "entity_mentions": [{"id": "1414247_2_Ent3", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1414247_2_Ent4", "text": "Valproic acid", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1414247_2_Ent2", "text": "coma", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "1414247_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1414247_2_Ent0", "text": "adult patient without a history of metabolic disease", "entity_type": "Entity", "start": 8, "end": 16}], "lang": "en"}
{"doc_id": "1422497_1", "wnd_id": "1422497_1_1", "text": "Encephalopathy and seizures induced by intravesical alum irrigations .", "tokens": ["Encephalopathy", "and", "seizures", "induced", "by", "intravesical", "alum", "irrigations", "."], "event_mentions": [{"id": "1422497_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1422497_1_Ent0", "role": "Effect", "text": "Encephalopathy and seizures", "start": 0, "end": 3}, {"entity_id": "1422497_1_Ent3", "role": "Treatment_Route", "text": "intravesical", "start": 5, "end": 6}, {"entity_id": "1422497_1_Ent1", "role": "Treatment", "text": "intravesical alum irrigations", "start": 5, "end": 8}, {"entity_id": "1422497_1_Ent2", "role": "Treatment_Drug", "text": "alum", "start": 6, "end": 7}, {"entity_id": "1422497_1_Ent4", "role": "Treatment_Route", "text": "irrigations", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1422497_1_Ent0", "text": "Encephalopathy and seizures", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1422497_1_Ent3", "text": "intravesical", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1422497_1_Ent1", "text": "intravesical alum irrigations", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1422497_1_Ent2", "text": "alum", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1422497_1_Ent4", "text": "irrigations", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "1445134_1", "wnd_id": "1445134_1_1", "text": "Gestational diabetes was no less severe ( degree of hyperglycaemia , need for insulin therapy ) when associated with norethisterone .", "tokens": ["Gestational", "diabetes", "was", "no", "less", "severe", "(", "degree", "of", "hyperglycaemia", ",", "need", "for", "insulin", "therapy", ")", "when", "associated", "with", "norethisterone", "."], "event_mentions": [{"id": "1445134_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "1445134_1_Ent0", "role": "Effect", "text": "Gestational diabetes", "start": 0, "end": 2}, {"entity_id": "1445134_1_Ent1", "role": "Treatment", "text": "norethisterone", "start": 19, "end": 20}, {"entity_id": "1445134_1_Ent2", "role": "Treatment_Drug", "text": "norethisterone", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "1445134_1_Ent0", "text": "Gestational diabetes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1445134_1_Ent1", "text": "norethisterone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "1445134_1_Ent2", "text": "norethisterone", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "14514135_1", "wnd_id": "14514135_1_1", "text": "Neutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient : a complication of cyclophosphamide .", "tokens": ["Neutrophilic", "eccrine", "hidradenitis", "mimicking", "cutaneous", "vasculitis", "in", "a", "lupus", "patient", ":", "a", "complication", "of", "cyclophosphamide", "."], "event_mentions": [{"id": "14514135_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 12, "end": 13}, "arguments": [{"entity_id": "14514135_1_Ent1", "role": "Effect", "text": "Neutrophilic eccrine hidradenitis", "start": 0, "end": 3}, {"entity_id": "14514135_1_Ent0", "role": "Subject", "text": "a lupus patient", "start": 7, "end": 10}, {"entity_id": "14514135_1_Ent3", "role": "Treatment_Disorder", "text": "lupus", "start": 8, "end": 9}, {"entity_id": "14514135_1_Ent2", "role": "Treatment", "text": "cyclophosphamide", "start": 14, "end": 15}, {"entity_id": "14514135_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "14514135_1_Ent1", "text": "Neutrophilic eccrine hidradenitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14514135_1_Ent0", "text": "a lupus patient", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "14514135_1_Ent3", "text": "lupus", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14514135_1_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "14514135_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "14522628_2", "wnd_id": "14522628_2_1", "text": "Skin rash and splinter hemorrhages from ganciclovir .", "tokens": ["Skin", "rash", "and", "splinter", "hemorrhages", "from", "ganciclovir", "."], "event_mentions": [{"id": "14522628_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 5, "end": 6}, "arguments": [{"entity_id": "14522628_2_Ent0", "role": "Effect", "text": "Skin rash and splinter hemorrhages", "start": 0, "end": 5}, {"entity_id": "14522628_2_Ent1", "role": "Treatment", "text": "ganciclovir", "start": 6, "end": 7}, {"entity_id": "14522628_2_Ent2", "role": "Treatment_Drug", "text": "ganciclovir", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14522628_2_Ent0", "text": "Skin rash and splinter hemorrhages", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14522628_2_Ent1", "text": "ganciclovir", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14522628_2_Ent2", "text": "ganciclovir", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14526130_2", "wnd_id": "14526130_2_1", "text": "CASE REPORT : We report the case of a 58 year old patient who , after 2 days of treatment with roxithromycin and betamethasone , manifested acute pancreatitis .", "tokens": ["CASE", "REPORT", ":", "We", "report", "the", "case", "of", "a", "58", "year", "old", "patient", "who", ",", "after", "2", "days", "of", "treatment", "with", "roxithromycin", "and", "betamethasone", ",", "manifested", "acute", "pancreatitis", "."], "event_mentions": [{"id": "14526130_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 25, "end": 26}, "arguments": [{"entity_id": "14526130_2_Ent0", "role": "Subject", "text": "a 58 year old patient", "start": 8, "end": 13}, {"entity_id": "14526130_2_Ent1", "role": "Subject_Age", "text": "58 year old", "start": 9, "end": 12}, {"entity_id": "14526130_2_Ent3", "role": "Treatment", "text": "after 2 days of treatment with roxithromycin", "start": 15, "end": 22}, {"entity_id": "14526130_2_Ent7", "role": "Treatment_Time_elapsed", "text": "2 days", "start": 16, "end": 18}, {"entity_id": "14526130_2_Ent5", "role": "Treatment_Drug", "text": "roxithromycin", "start": 21, "end": 22}, {"entity_id": "14526130_2_Ent8", "role": "Combination_Drug", "text": "roxithromycin", "start": 21, "end": 22}, {"entity_id": "14526130_2_Ent4", "role": "Treatment", "text": "betamethasone", "start": 23, "end": 24}, {"entity_id": "14526130_2_Ent6", "role": "Treatment_Drug", "text": "betamethasone", "start": 23, "end": 24}, {"entity_id": "14526130_2_Ent9", "role": "Combination_Drug", "text": "betamethasone", "start": 23, "end": 24}, {"entity_id": "14526130_2_Ent2", "role": "Effect", "text": "acute pancreatitis", "start": 26, "end": 28}]}], "entity_mentions": [{"id": "14526130_2_Ent0", "text": "a 58 year old patient", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "14526130_2_Ent1", "text": "58 year old", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "14526130_2_Ent3", "text": "after 2 days of treatment with roxithromycin", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "14526130_2_Ent7", "text": "2 days", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "14526130_2_Ent5", "text": "roxithromycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14526130_2_Ent8", "text": "roxithromycin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14526130_2_Ent4", "text": "betamethasone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "14526130_2_Ent6", "text": "betamethasone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "14526130_2_Ent9", "text": "betamethasone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "14526130_2_Ent2", "text": "acute pancreatitis", "entity_type": "Entity", "start": 26, "end": 28}], "lang": "en"}
{"doc_id": "14530108_4", "wnd_id": "14530108_4_1", "text": "The mechanism of RTA induced by FK506 has not yet been clearly elucidated .", "tokens": ["The", "mechanism", "of", "RTA", "induced", "by", "FK506", "has", "not", "yet", "been", "clearly", "elucidated", "."], "event_mentions": [{"id": "14530108_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "14530108_4_Ent0", "role": "Effect", "text": "RTA", "start": 3, "end": 4}, {"entity_id": "14530108_4_Ent1", "role": "Treatment", "text": "FK506", "start": 6, "end": 7}, {"entity_id": "14530108_4_Ent2", "role": "Treatment_Drug", "text": "FK506", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14530108_4_Ent0", "text": "RTA", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14530108_4_Ent1", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14530108_4_Ent2", "text": "FK506", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14561622_1", "wnd_id": "14561622_1_1", "text": "Neurotoxicity of intrathecal methotrexate : MR imaging findings .", "tokens": ["Neurotoxicity", "of", "intrathecal", "methotrexate", ":", "MR", "imaging", "findings", "."], "event_mentions": [{"id": "14561622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 1, "end": 2}, "arguments": [{"entity_id": "14561622_1_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "14561622_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "14561622_1_Ent1", "role": "Treatment", "text": "intrathecal methotrexate", "start": 2, "end": 4}, {"entity_id": "14561622_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14561622_1_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14561622_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14561622_1_Ent1", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "14561622_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14566215_1", "wnd_id": "14566215_1_1", "text": "In this article lithium is not discussed , although there are a number of concerns about lithium 's potential teratogenicity , and it has been implicated in Epstein 's anomaly , a congenital heart defect among infants born to women taking lithium ; as with other medications , however , the data have specific limitations .", "tokens": ["In", "this", "article", "lithium", "is", "not", "discussed", ",", "although", "there", "are", "a", "number", "of", "concerns", "about", "lithium", "'s", "potential", "teratogenicity", ",", "and", "it", "has", "been", "implicated", "in", "Epstein", "'s", "anomaly", ",", "a", "congenital", "heart", "defect", "among", "infants", "born", "to", "women", "taking", "lithium", ";", "as", "with", "other", "medications", ",", "however", ",", "the", "data", "have", "specific", "limitations", "."], "event_mentions": [{"id": "14566215_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicated", "start": 25, "end": 26}, "arguments": [{"entity_id": "14566215_1_Ent0", "role": "Effect", "text": "Epstein 's anomaly", "start": 27, "end": 30}, {"entity_id": "14566215_1_Ent1", "role": "Treatment", "text": "lithium", "start": 41, "end": 42}, {"entity_id": "14566215_1_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "14566215_1_Ent0", "text": "Epstein 's anomaly", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "14566215_1_Ent1", "text": "lithium", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "14566215_1_Ent2", "text": "lithium", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "14585456_1", "wnd_id": "14585456_1_1", "text": "We present a case of a 20 - year - old woman who ingested 900 mg of glyburide causing refractory hypoglycemia resistant to treatment with intravenous dextrose , glucagon , and diazoxide .", "tokens": ["We", "present", "a", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "who", "ingested", "900", "mg", "of", "glyburide", "causing", "refractory", "hypoglycemia", "resistant", "to", "treatment", "with", "intravenous", "dextrose", ",", "glucagon", ",", "and", "diazoxide", "."], "event_mentions": [{"id": "14585456_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "ingested", "start": 13, "end": 14}, "arguments": [{"entity_id": "14585456_1_Ent0", "role": "Subject", "text": "a 20 - year - old woman", "start": 5, "end": 12}, {"entity_id": "14585456_1_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "14585456_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "14585456_1_Ent5", "role": "Treatment_Dosage", "text": "900 mg", "start": 14, "end": 16}, {"entity_id": "14585456_1_Ent4", "role": "Treatment", "text": "900 mg of glyburide", "start": 14, "end": 18}, {"entity_id": "14585456_1_Ent6", "role": "Treatment_Drug", "text": "glyburide", "start": 17, "end": 18}, {"entity_id": "14585456_1_Ent3", "role": "Effect", "text": "refractory hypoglycemia", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "14585456_1_Ent0", "text": "a 20 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "14585456_1_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "14585456_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "14585456_1_Ent5", "text": "900 mg", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "14585456_1_Ent4", "text": "900 mg of glyburide", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "14585456_1_Ent6", "text": "glyburide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "14585456_1_Ent3", "text": "refractory hypoglycemia", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "14601701_1", "wnd_id": "14601701_1_1", "text": "Ocular ethambutol toxicity .", "tokens": ["Ocular", "ethambutol", "toxicity", "."], "event_mentions": [{"id": "14601701_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 2, "end": 3}, "arguments": [{"entity_id": "14601701_1_Ent2", "role": "Treatment_Route", "text": "Ocular", "start": 0, "end": 1}, {"entity_id": "14601701_1_Ent1", "role": "Treatment", "text": "Ocular ethambutol", "start": 0, "end": 2}, {"entity_id": "14601701_1_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 1, "end": 2}, {"entity_id": "14601701_1_Ent0", "role": "Effect", "text": "toxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "14601701_1_Ent2", "text": "Ocular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14601701_1_Ent1", "text": "Ocular ethambutol", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14601701_1_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "14601701_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "14607011_1", "wnd_id": "14607011_1_1", "text": "Fatal cold medication intoxication in an infant .", "tokens": ["Fatal", "cold", "medication", "intoxication", "in", "an", "infant", "."], "event_mentions": [{"id": "14607011_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "14607011_1_Ent2", "role": "Effect", "text": "Fatal cold medication intoxication", "start": 0, "end": 4}, {"entity_id": "14607011_1_Ent3", "role": "Treatment", "text": "cold medication", "start": 1, "end": 3}, {"entity_id": "14607011_1_Ent4", "role": "Treatment_Drug", "text": "cold medication", "start": 1, "end": 3}, {"entity_id": "14607011_1_Ent0", "role": "Subject", "text": "infant", "start": 6, "end": 7}, {"entity_id": "14607011_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "14607011_1_Ent2", "text": "Fatal cold medication intoxication", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "14607011_1_Ent3", "text": "cold medication", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14607011_1_Ent4", "text": "cold medication", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14607011_1_Ent0", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14607011_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "14614357_1", "wnd_id": "14614357_1_1", "text": "Early overanticoagulation with acenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9 .", "tokens": ["Early", "overanticoagulation", "with", "acenocoumarol", "due", "to", "a", "genetic", "polymorphism", "of", "cytochrome", "P450", "CYP2C9", "."], "event_mentions": [{"id": "14614357_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 2, "end": 3}, "arguments": [{"entity_id": "14614357_1_Ent0", "role": "Effect", "text": "Early overanticoagulation", "start": 0, "end": 2}, {"entity_id": "14614357_1_Ent1", "role": "Treatment", "text": "acenocoumarol", "start": 3, "end": 4}, {"entity_id": "14614357_1_Ent2", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14614357_1_Ent0", "text": "Early overanticoagulation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14614357_1_Ent1", "text": "acenocoumarol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14614357_1_Ent2", "text": "acenocoumarol", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14660304_1", "wnd_id": "14660304_1_1", "text": "Infectious toxicity of dexamethasone during all remission - induction chemotherapy : report of two cases and literature review .", "tokens": ["Infectious", "toxicity", "of", "dexamethasone", "during", "all", "remission", "-", "induction", "chemotherapy", ":", "report", "of", "two", "cases", "and", "literature", "review", "."], "event_mentions": [{"id": "14660304_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "14660304_1_Ent2", "role": "Effect", "text": "Infectious toxicity", "start": 0, "end": 2}, {"entity_id": "14660304_1_Ent3", "role": "Treatment", "text": "dexamethasone", "start": 3, "end": 4}, {"entity_id": "14660304_1_Ent5", "role": "Treatment_Drug", "text": "dexamethasone", "start": 3, "end": 4}, {"entity_id": "14660304_1_Ent4", "role": "Treatment", "text": "all remission - induction chemotherapy", "start": 5, "end": 10}, {"entity_id": "14660304_1_Ent6", "role": "Treatment_Route", "text": "chemotherapy", "start": 9, "end": 10}, {"entity_id": "14660304_1_Ent1", "role": "Subject_Population", "text": "two", "start": 13, "end": 14}, {"entity_id": "14660304_1_Ent0", "role": "Subject", "text": "two cases", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "14660304_1_Ent2", "text": "Infectious toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14660304_1_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14660304_1_Ent5", "text": "dexamethasone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14660304_1_Ent4", "text": "all remission - induction chemotherapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "14660304_1_Ent6", "text": "chemotherapy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14660304_1_Ent1", "text": "two", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14660304_1_Ent0", "text": "two cases", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "14660304_2", "wnd_id": "14660304_2_1", "text": "Traditionally , children with acute lymphoblastic leukemia receive prednisone , as part of multiagent remission - induction chemotherapy .", "tokens": ["Traditionally", ",", "children", "with", "acute", "lymphoblastic", "leukemia", "receive", "prednisone", ",", "as", "part", "of", "multiagent", "remission", "-", "induction", "chemotherapy", "."], "event_mentions": [{"id": "14660304_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receive", "start": 7, "end": 8}, "arguments": [{"entity_id": "14660304_2_Ent1", "role": "Subject_Age", "text": "children", "start": 2, "end": 3}, {"entity_id": "14660304_2_Ent0", "role": "Subject", "text": "children with acute lymphoblastic leukemia", "start": 2, "end": 7}, {"entity_id": "14660304_2_Ent3", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 4, "end": 7}, {"entity_id": "14660304_2_Ent2", "role": "Treatment", "text": "prednisone", "start": 8, "end": 9}, {"entity_id": "14660304_2_Ent4", "role": "Treatment_Drug", "text": "prednisone", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "14660304_2_Ent1", "text": "children", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14660304_2_Ent0", "text": "children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "14660304_2_Ent3", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "14660304_2_Ent2", "text": "prednisone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14660304_2_Ent4", "text": "prednisone", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "14679124_1", "wnd_id": "14679124_1_1", "text": "Epirubicin - cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially : randomized phase III trial in postmenopausal node - positive breast cancer patients .", "tokens": ["Epirubicin", "-", "cyclophosphamide", "adjuvant", "chemotherapy", "plus", "tamoxifen", "administered", "concurrently", "versus", "sequentially", ":", "randomized", "phase", "III", "trial", "in", "postmenopausal", "node", "-", "positive", "breast", "cancer", "patients", "."], "event_mentions": [{"id": "14679124_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "administered", "start": 7, "end": 8}, "arguments": [{"entity_id": "14679124_1_Ent3", "role": "Treatment_Drug", "text": "Epirubicin - cyclophosphamide", "start": 0, "end": 3}, {"entity_id": "14679124_1_Ent6", "role": "Combination_Drug", "text": "Epirubicin - cyclophosphamide", "start": 0, "end": 3}, {"entity_id": "14679124_1_Ent1", "role": "Treatment", "text": "Epirubicin - cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently", "start": 0, "end": 9}, {"entity_id": "14679124_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "14679124_1_Ent5", "role": "Combination_Drug", "text": "tamoxifen", "start": 6, "end": 7}, {"entity_id": "14679124_1_Ent0", "role": "Subject", "text": "postmenopausal node - positive breast cancer patients", "start": 17, "end": 24}, {"entity_id": "14679124_1_Ent4", "role": "Treatment_Disorder", "text": "node - positive breast cancer", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "14679124_1_Ent3", "text": "Epirubicin - cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14679124_1_Ent6", "text": "Epirubicin - cyclophosphamide", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "14679124_1_Ent1", "text": "Epirubicin - cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "14679124_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14679124_1_Ent5", "text": "tamoxifen", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14679124_1_Ent0", "text": "postmenopausal node - positive breast cancer patients", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "14679124_1_Ent4", "text": "node - positive breast cancer", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "14684937_2", "wnd_id": "14684937_2_1", "text": "Iatrogenic hypercalcemia due to vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics in a case of psoriasis .", "tokens": ["Iatrogenic", "hypercalcemia", "due", "to", "vitamin", "D3", "ointment", "(", "1,24(OH)2D3", ")", "combined", "with", "thiazide", "diuretics", "in", "a", "case", "of", "psoriasis", "."], "event_mentions": [{"id": "14684937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "14684937_2_Ent0", "role": "Effect", "text": "Iatrogenic hypercalcemia", "start": 0, "end": 2}, {"entity_id": "14684937_2_Ent3", "role": "Treatment_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent6", "role": "Combination_Drug", "text": "vitamin D3", "start": 4, "end": 6}, {"entity_id": "14684937_2_Ent1", "role": "Treatment", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "start": 4, "end": 14}, {"entity_id": "14684937_2_Ent5", "role": "Treatment_Route", "text": "ointment", "start": 6, "end": 7}, {"entity_id": "14684937_2_Ent4", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent7", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 12, "end": 14}, {"entity_id": "14684937_2_Ent2", "role": "Treatment_Disorder", "text": "psoriasis", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "14684937_2_Ent0", "text": "Iatrogenic hypercalcemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "14684937_2_Ent3", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent6", "text": "vitamin D3", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "14684937_2_Ent1", "text": "vitamin D3 ointment ( 1,24(OH)2D3 ) combined with thiazide diuretics", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "14684937_2_Ent5", "text": "ointment", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14684937_2_Ent4", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent7", "text": "thiazide diuretics", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "14684937_2_Ent2", "text": "psoriasis", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "14690166_1", "wnd_id": "14690166_1_1", "text": "2 - Chloro - deoxyadenosine induces durable complete remission in Castleman 's disease but may accelerate its transformation to non - Hodgkin 's lymphoma .", "tokens": ["2", "-", "Chloro", "-", "deoxyadenosine", "induces", "durable", "complete", "remission", "in", "Castleman", "'s", "disease", "but", "may", "accelerate", "its", "transformation", "to", "non", "-", "Hodgkin", "'s", "lymphoma", "."], "event_mentions": [{"id": "14690166_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 15, "end": 16}, "arguments": [{"entity_id": "14690166_1_Ent1", "role": "Treatment", "text": "2 - Chloro - deoxyadenosine", "start": 0, "end": 5}, {"entity_id": "14690166_1_Ent2", "role": "Treatment_Drug", "text": "2 - Chloro - deoxyadenosine", "start": 0, "end": 5}, {"entity_id": "14690166_1_Ent3", "role": "Treatment_Disorder", "text": "Castleman 's disease", "start": 10, "end": 13}, {"entity_id": "14690166_1_Ent0", "role": "Effect", "text": "non - Hodgkin 's lymphoma", "start": 19, "end": 24}]}], "entity_mentions": [{"id": "14690166_1_Ent1", "text": "2 - Chloro - deoxyadenosine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14690166_1_Ent2", "text": "2 - Chloro - deoxyadenosine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14690166_1_Ent3", "text": "Castleman 's disease", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "14690166_1_Ent0", "text": "non - Hodgkin 's lymphoma", "entity_type": "Entity", "start": 19, "end": 24}], "lang": "en"}
{"doc_id": "14690166_6", "wnd_id": "14690166_6_1", "text": "Therefore , it is reasonable to conclude that : 1 ) 2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that 2 - CdA may accelerate the transformation of MCD to NHL can not be ruled out .", "tokens": ["Therefore", ",", "it", "is", "reasonable", "to", "conclude", "that", ":", "1", ")", "2", "-", "CdA", "can", "induce", "durable", "complete", "remission", "in", "MCD", "patients", "but", "unfortunately", "it", "can", "not", "cure", "the", "disease", ";", "2", ")", "the", "possibility", "that", "2", "-", "CdA", "may", "accelerate", "the", "transformation", "of", "MCD", "to", "NHL", "can", "not", "be", "ruled", "out", "."], "event_mentions": [{"id": "14690166_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "induce", "start": 15, "end": 16}, "arguments": [{"entity_id": "14690166_6_Ent1", "role": "Treatment", "text": "2 - CdA", "start": 11, "end": 14}, {"entity_id": "14690166_6_Ent3", "role": "Treatment_Drug", "text": "2 - CdA", "start": 11, "end": 14}, {"entity_id": "14690166_6_Ent0", "role": "Effect", "text": "durable complete remission", "start": 16, "end": 19}, {"entity_id": "14690166_6_Ent2", "role": "Treatment_Disorder", "text": "MCD", "start": 20, "end": 21}]}, {"id": "14690166_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "accelerate", "start": 40, "end": 41}, "arguments": [{"entity_id": "14690166_6_Ent5", "role": "Treatment", "text": "2 - CdA", "start": 36, "end": 39}, {"entity_id": "14690166_6_Ent6", "role": "Treatment_Drug", "text": "2 - CdA", "start": 36, "end": 39}, {"entity_id": "14690166_6_Ent4", "role": "Effect", "text": "the transformation of MCD to NHL", "start": 41, "end": 47}]}], "entity_mentions": [{"id": "14690166_6_Ent1", "text": "2 - CdA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "14690166_6_Ent3", "text": "2 - CdA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "14690166_6_Ent0", "text": "durable complete remission", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "14690166_6_Ent2", "text": "MCD", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "14690166_6_Ent5", "text": "2 - CdA", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "14690166_6_Ent6", "text": "2 - CdA", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "14690166_6_Ent4", "text": "the transformation of MCD to NHL", "entity_type": "Entity", "start": 41, "end": 47}], "lang": "en"}
{"doc_id": "1469187_1", "wnd_id": "1469187_1_1", "text": "Treatment of a patient with severe digitoxin intoxication by Fab fragments of anti - digitalis antibodies .", "tokens": ["Treatment", "of", "a", "patient", "with", "severe", "digitoxin", "intoxication", "by", "Fab", "fragments", "of", "anti", "-", "digitalis", "antibodies", "."], "event_mentions": [{"id": "1469187_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Treatment", "start": 0, "end": 1}, "arguments": [{"entity_id": "1469187_1_Ent0", "role": "Subject", "text": "a patient with severe digitoxin intoxication", "start": 2, "end": 8}, {"entity_id": "1469187_1_Ent2", "role": "Treatment_Disorder", "text": "digitoxin intoxication", "start": 6, "end": 8}, {"entity_id": "1469187_1_Ent1", "role": "Treatment", "text": "Fab fragments of anti - digitalis antibodies", "start": 9, "end": 16}, {"entity_id": "1469187_1_Ent3", "role": "Treatment_Drug", "text": "Fab fragments of anti - digitalis antibodies", "start": 9, "end": 16}]}], "entity_mentions": [{"id": "1469187_1_Ent0", "text": "a patient with severe digitoxin intoxication", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "1469187_1_Ent2", "text": "digitoxin intoxication", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "1469187_1_Ent1", "text": "Fab fragments of anti - digitalis antibodies", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "1469187_1_Ent3", "text": "Fab fragments of anti - digitalis antibodies", "entity_type": "Entity", "start": 9, "end": 16}], "lang": "en"}
{"doc_id": "1469187_2", "wnd_id": "1469187_2_1", "text": "A massive digitoxin ( DGTX ) intoxication in a 36 - year - old man ( 35 mg DGTX ) was treated by prolonged and repeated i.v .- infusions of Fab fragments of anti - digitalis antibodies ( FAB ) .", "tokens": ["A", "massive", "digitoxin", "(", "DGTX", ")", "intoxication", "in", "a", "36", "-", "year", "-", "old", "man", "(", "35", "mg", "DGTX", ")", "was", "treated", "by", "prolonged", "and", "repeated", "i.v", ".-", "infusions", "of", "Fab", "fragments", "of", "anti", "-", "digitalis", "antibodies", "(", "FAB", ")", "."], "event_mentions": [{"id": "1469187_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 21, "end": 22}, "arguments": [{"entity_id": "1469187_2_Ent0", "role": "Subject", "text": "A massive digitoxin ( DGTX ) intoxication in a 36 - year - old man ( 35 mg DGTX )", "start": 0, "end": 20}, {"entity_id": "1469187_2_Ent4", "role": "Treatment_Disorder", "text": "massive digitoxin ( DGTX ) intoxication", "start": 1, "end": 7}, {"entity_id": "1469187_2_Ent1", "role": "Subject_Age", "text": "36 - year - old", "start": 9, "end": 14}, {"entity_id": "1469187_2_Ent2", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "1469187_2_Ent3", "role": "Treatment", "text": "prolonged and repeated i.v .- infusions of Fab fragments of anti - digitalis antibodies ( FAB )", "start": 23, "end": 40}, {"entity_id": "1469187_2_Ent5", "role": "Treatment_Route", "text": "i.v .- infusions", "start": 26, "end": 29}, {"entity_id": "1469187_2_Ent6", "role": "Treatment_Drug", "text": "anti - digitalis antibodies", "start": 33, "end": 37}]}], "entity_mentions": [{"id": "1469187_2_Ent0", "text": "A massive digitoxin ( DGTX ) intoxication in a 36 - year - old man ( 35 mg DGTX )", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "1469187_2_Ent4", "text": "massive digitoxin ( DGTX ) intoxication", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "1469187_2_Ent1", "text": "36 - year - old", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "1469187_2_Ent2", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1469187_2_Ent3", "text": "prolonged and repeated i.v .- infusions of Fab fragments of anti - digitalis antibodies ( FAB )", "entity_type": "Entity", "start": 23, "end": 40}, {"id": "1469187_2_Ent5", "text": "i.v .- infusions", "entity_type": "Entity", "start": 26, "end": 29}, {"id": "1469187_2_Ent6", "text": "anti - digitalis antibodies", "entity_type": "Entity", "start": 33, "end": 37}], "lang": "en"}
{"doc_id": "14697943_3", "wnd_id": "14697943_3_1", "text": "We now present four cases of RSDS in kidney transplant recipients treated with tacrolimus .", "tokens": ["We", "now", "present", "four", "cases", "of", "RSDS", "in", "kidney", "transplant", "recipients", "treated", "with", "tacrolimus", "."], "event_mentions": [{"id": "14697943_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "14697943_3_Ent3", "role": "Subject_Population", "text": "four", "start": 3, "end": 4}, {"entity_id": "14697943_3_Ent0", "role": "Subject", "text": "four cases", "start": 3, "end": 5}, {"entity_id": "14697943_3_Ent4", "role": "Effect", "text": "RSDS", "start": 6, "end": 7}, {"entity_id": "14697943_3_Ent2", "role": "Subject_Disorder", "text": "kidney transplant", "start": 8, "end": 10}, {"entity_id": "14697943_3_Ent1", "role": "Subject", "text": "kidney transplant recipients", "start": 8, "end": 11}, {"entity_id": "14697943_3_Ent5", "role": "Treatment", "text": "tacrolimus", "start": 13, "end": 14}, {"entity_id": "14697943_3_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "14697943_3_Ent3", "text": "four", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "14697943_3_Ent0", "text": "four cases", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "14697943_3_Ent4", "text": "RSDS", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "14697943_3_Ent2", "text": "kidney transplant", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14697943_3_Ent1", "text": "kidney transplant recipients", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "14697943_3_Ent5", "text": "tacrolimus", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "14697943_3_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "14700673_1", "wnd_id": "14700673_1_1", "text": "CONCLUSIONS : Topiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing , resulting in acute myopia and angle - closure glaucoma .", "tokens": ["CONCLUSIONS", ":", "Topiramate", "may", "be", "associated", "with", "ciliochoroidal", "effusion", "with", "forward", "displacement", "of", "the", "lens", "-", "iris", "diaphragm", "and", "anterior", "chamber", "shallowing", ",", "resulting", "in", "acute", "myopia", "and", "angle", "-", "closure", "glaucoma", "."], "event_mentions": [{"id": "14700673_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 23, "end": 24}, "arguments": [{"entity_id": "14700673_1_Ent1", "role": "Treatment", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "14700673_1_Ent2", "role": "Treatment_Drug", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "14700673_1_Ent0", "role": "Effect", "text": "acute myopia and angle - closure glaucoma", "start": 25, "end": 32}]}], "entity_mentions": [{"id": "14700673_1_Ent1", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14700673_1_Ent2", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "14700673_1_Ent0", "text": "acute myopia and angle - closure glaucoma", "entity_type": "Entity", "start": 25, "end": 32}], "lang": "en"}
{"doc_id": "14700673_3", "wnd_id": "14700673_3_1", "text": "METHODS : In an institutional practice setting , two women , aged 25 and 45 , developed acute myopia after starting topiramate for epilepsy .", "tokens": ["METHODS", ":", "In", "an", "institutional", "practice", "setting", ",", "two", "women", ",", "aged", "25", "and", "45", ",", "developed", "acute", "myopia", "after", "starting", "topiramate", "for", "epilepsy", "."], "event_mentions": [{"id": "14700673_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "14700673_3_Ent1", "role": "Subject_Population", "text": "two", "start": 8, "end": 9}, {"entity_id": "14700673_3_Ent0", "role": "Subject", "text": "two women , aged 25 and 45", "start": 8, "end": 15}, {"entity_id": "14700673_3_Ent2", "role": "Subject_Gender", "text": "women", "start": 9, "end": 10}, {"entity_id": "14700673_3_Ent3", "role": "Subject_Age", "text": "aged 25 and 45", "start": 11, "end": 15}, {"entity_id": "14700673_3_Ent4", "role": "Effect", "text": "acute myopia", "start": 17, "end": 19}, {"entity_id": "14700673_3_Ent5", "role": "Treatment", "text": "topiramate", "start": 21, "end": 22}, {"entity_id": "14700673_3_Ent6", "role": "Treatment_Drug", "text": "topiramate", "start": 21, "end": 22}, {"entity_id": "14700673_3_Ent7", "role": "Treatment_Disorder", "text": "epilepsy", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "14700673_3_Ent1", "text": "two", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "14700673_3_Ent0", "text": "two women , aged 25 and 45", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "14700673_3_Ent2", "text": "women", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14700673_3_Ent3", "text": "aged 25 and 45", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "14700673_3_Ent4", "text": "acute myopia", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "14700673_3_Ent5", "text": "topiramate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14700673_3_Ent6", "text": "topiramate", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "14700673_3_Ent7", "text": "epilepsy", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "14740795_2", "wnd_id": "14740795_2_1", "text": "Amifostine - induced fever : case report and review of the literature .", "tokens": ["Amifostine", "-", "induced", "fever", ":", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "14740795_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "14740795_2_Ent1", "role": "Treatment", "text": "Amifostine", "start": 0, "end": 1}, {"entity_id": "14740795_2_Ent2", "role": "Treatment_Drug", "text": "Amifostine", "start": 0, "end": 1}, {"entity_id": "14740795_2_Ent0", "role": "Effect", "text": "fever", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "14740795_2_Ent1", "text": "Amifostine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14740795_2_Ent2", "text": "Amifostine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "14740795_2_Ent0", "text": "fever", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "14742791_2", "wnd_id": "14742791_2_1", "text": "After 5 weeks of therapy , she stopped taking pantoprazole due to general malaise .", "tokens": ["After", "5", "weeks", "of", "therapy", ",", "she", "stopped", "taking", "pantoprazole", "due", "to", "general", "malaise", "."], "event_mentions": [{"id": "14742791_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 10, "end": 12}, "arguments": [{"entity_id": "14742791_2_Ent2", "role": "Treatment", "text": "After 5 weeks of therapy", "start": 0, "end": 5}, {"entity_id": "14742791_2_Ent3", "role": "Treatment_Time_elapsed", "text": "5 weeks", "start": 1, "end": 3}, {"entity_id": "14742791_2_Ent1", "role": "Treatment", "text": "taking pantoprazole", "start": 8, "end": 10}, {"entity_id": "14742791_2_Ent4", "role": "Treatment_Drug", "text": "pantoprazole", "start": 9, "end": 10}, {"entity_id": "14742791_2_Ent0", "role": "Effect", "text": "general malaise", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "14742791_2_Ent2", "text": "After 5 weeks of therapy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "14742791_2_Ent3", "text": "5 weeks", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14742791_2_Ent1", "text": "taking pantoprazole", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "14742791_2_Ent4", "text": "pantoprazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "14742791_2_Ent0", "text": "general malaise", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "1477441_3", "wnd_id": "1477441_3_1", "text": "Fixed drug eruption of the scrotum due to methylphenidate .", "tokens": ["Fixed", "drug", "eruption", "of", "the", "scrotum", "due", "to", "methylphenidate", "."], "event_mentions": [{"id": "1477441_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "1477441_3_Ent0", "role": "Effect", "text": "Fixed drug eruption of the scrotum", "start": 0, "end": 6}, {"entity_id": "1477441_3_Ent1", "role": "Treatment", "text": "methylphenidate", "start": 8, "end": 9}, {"entity_id": "1477441_3_Ent2", "role": "Treatment_Drug", "text": "methylphenidate", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1477441_3_Ent0", "text": "Fixed drug eruption of the scrotum", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "1477441_3_Ent1", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1477441_3_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "14964753_6", "wnd_id": "14964753_6_1", "text": "The ACE inhibitors can cause various skin side effects ; however , it rarely causes cutaneous vasculitis .", "tokens": ["The", "ACE", "inhibitors", "can", "cause", "various", "skin", "side", "effects", ";", "however", ",", "it", "rarely", "causes", "cutaneous", "vasculitis", "."], "event_mentions": [{"id": "14964753_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "14964753_6_Ent1", "role": "Treatment", "text": "ACE inhibitors", "start": 1, "end": 3}, {"entity_id": "14964753_6_Ent2", "role": "Treatment_Drug", "text": "ACE inhibitors", "start": 1, "end": 3}, {"entity_id": "14964753_6_Ent0", "role": "Effect", "text": "skin side effects", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "14964753_6_Ent1", "text": "ACE inhibitors", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14964753_6_Ent2", "text": "ACE inhibitors", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "14964753_6_Ent0", "text": "skin side effects", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "14964753_8", "wnd_id": "14964753_8_1", "text": "Previous successful treatment with one ACE inhibitor does not rule out the vasculitis caused by the drug from the same group .", "tokens": ["Previous", "successful", "treatment", "with", "one", "ACE", "inhibitor", "does", "not", "rule", "out", "the", "vasculitis", "caused", "by", "the", "drug", "from", "the", "same", "group", "."], "event_mentions": [{"id": "14964753_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "14964753_8_Ent1", "role": "Treatment", "text": "ACE inhibitor", "start": 5, "end": 7}, {"entity_id": "14964753_8_Ent2", "role": "Treatment_Drug", "text": "ACE inhibitor", "start": 5, "end": 7}, {"entity_id": "14964753_8_Ent0", "role": "Effect", "text": "vasculitis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "14964753_8_Ent1", "text": "ACE inhibitor", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14964753_8_Ent2", "text": "ACE inhibitor", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "14964753_8_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "14968106_2", "wnd_id": "14968106_2_1", "text": "Neurological improvement and rehabilitation potential following toxic myelopathy due to intrathecal injection of doxorubicin .", "tokens": ["Neurological", "improvement", "and", "rehabilitation", "potential", "following", "toxic", "myelopathy", "due", "to", "intrathecal", "injection", "of", "doxorubicin", "."], "event_mentions": [{"id": "14968106_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 8, "end": 10}, "arguments": [{"entity_id": "14968106_2_Ent0", "role": "Effect", "text": "toxic myelopathy", "start": 6, "end": 8}, {"entity_id": "14968106_2_Ent2", "role": "Treatment_Route", "text": "intrathecal injection", "start": 10, "end": 12}, {"entity_id": "14968106_2_Ent1", "role": "Treatment", "text": "intrathecal injection of doxorubicin", "start": 10, "end": 14}, {"entity_id": "14968106_2_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "14968106_2_Ent0", "text": "toxic myelopathy", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "14968106_2_Ent2", "text": "intrathecal injection", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "14968106_2_Ent1", "text": "intrathecal injection of doxorubicin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "14968106_2_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "15013892_1", "wnd_id": "15013892_1_1", "text": "Bull's - eye maculopathy associated with quinacrine therapy for malaria .", "tokens": ["Bull's", "-", "eye", "maculopathy", "associated", "with", "quinacrine", "therapy", "for", "malaria", "."], "event_mentions": [{"id": "15013892_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15013892_1_Ent0", "role": "Effect", "text": "Bull's - eye maculopathy", "start": 0, "end": 4}, {"entity_id": "15013892_1_Ent1", "role": "Treatment", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent2", "role": "Treatment_Drug", "text": "quinacrine", "start": 6, "end": 7}, {"entity_id": "15013892_1_Ent3", "role": "Treatment_Disorder", "text": "malaria", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15013892_1_Ent0", "text": "Bull's - eye maculopathy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15013892_1_Ent1", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent2", "text": "quinacrine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15013892_1_Ent3", "text": "malaria", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15028964_3", "wnd_id": "15028964_3_1", "text": "Beyond the predictable pharmacokinetic drug - drug interaction requiring a significant warfarin dose reduction , the iodine - rich amiodarone affects the thyroid gland , causing overt hypothyroidism or thyrotoxicosis in 14% - 18 % of cases .", "tokens": ["Beyond", "the", "predictable", "pharmacokinetic", "drug", "-", "drug", "interaction", "requiring", "a", "significant", "warfarin", "dose", "reduction", ",", "the", "iodine", "-", "rich", "amiodarone", "affects", "the", "thyroid", "gland", ",", "causing", "overt", "hypothyroidism", "or", "thyrotoxicosis", "in", "14%", "-", "18", "%", "of", "cases", "."], "event_mentions": [{"id": "15028964_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 25, "end": 26}, "arguments": [{"entity_id": "15028964_3_Ent1", "role": "Treatment", "text": "iodine - rich amiodarone", "start": 16, "end": 20}, {"entity_id": "15028964_3_Ent2", "role": "Treatment_Drug", "text": "iodine - rich amiodarone", "start": 16, "end": 20}, {"entity_id": "15028964_3_Ent0", "role": "Effect", "text": "overt hypothyroidism or thyrotoxicosis", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "15028964_3_Ent1", "text": "iodine - rich amiodarone", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "15028964_3_Ent2", "text": "iodine - rich amiodarone", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "15028964_3_Ent0", "text": "overt hypothyroidism or thyrotoxicosis", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "15028964_7", "wnd_id": "15028964_7_1", "text": "Given that significant thyroid disorders may be only mildly symptomatic and thus may escape clinical detection , we suggest that thyroid function should be tested in any patient with otherwise unexplained changes in warfarin dose requirements , particularly if concomitantly treated with amiodarone .", "tokens": ["Given", "that", "significant", "thyroid", "disorders", "may", "be", "only", "mildly", "symptomatic", "and", "thus", "may", "escape", "clinical", "detection", ",", "we", "suggest", "that", "thyroid", "function", "should", "be", "tested", "in", "any", "patient", "with", "otherwise", "unexplained", "changes", "in", "warfarin", "dose", "requirements", ",", "particularly", "if", "concomitantly", "treated", "with", "amiodarone", "."], "event_mentions": [{"id": "15028964_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "changes", "start": 31, "end": 32}, "arguments": [{"entity_id": "15028964_7_Ent0", "role": "Effect", "text": "significant thyroid disorders", "start": 2, "end": 5}, {"entity_id": "15028964_7_Ent1", "role": "Treatment", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "15028964_7_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "15028964_7_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "15028964_7_Ent2", "role": "Treatment", "text": "with amiodarone", "start": 41, "end": 43}, {"entity_id": "15028964_7_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 42, "end": 43}, {"entity_id": "15028964_7_Ent5", "role": "Combination_Drug", "text": "amiodarone", "start": 42, "end": 43}]}], "entity_mentions": [{"id": "15028964_7_Ent0", "text": "significant thyroid disorders", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15028964_7_Ent1", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15028964_7_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15028964_7_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15028964_7_Ent2", "text": "with amiodarone", "entity_type": "Entity", "start": 41, "end": 43}, {"id": "15028964_7_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "15028964_7_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 42, "end": 43}], "lang": "en"}
{"doc_id": "150825_2", "wnd_id": "150825_2_1", "text": "A second episode of jaundice followed the intravaginal administration of a mixture of furazolidone and nifuroxime .", "tokens": ["A", "second", "episode", "of", "jaundice", "followed", "the", "intravaginal", "administration", "of", "a", "mixture", "of", "furazolidone", "and", "nifuroxime", "."], "event_mentions": [{"id": "150825_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 5, "end": 6}, "arguments": [{"entity_id": "150825_2_Ent0", "role": "Effect", "text": "jaundice", "start": 4, "end": 5}, {"entity_id": "150825_2_Ent4", "role": "Treatment_Route", "text": "intravaginal", "start": 7, "end": 8}, {"entity_id": "150825_2_Ent1", "role": "Treatment", "text": "intravaginal administration of a mixture of furazolidone and nifuroxime", "start": 7, "end": 16}, {"entity_id": "150825_2_Ent2", "role": "Treatment_Drug", "text": "furazolidone", "start": 13, "end": 14}, {"entity_id": "150825_2_Ent5", "role": "Combination_Drug", "text": "furazolidone", "start": 13, "end": 14}, {"entity_id": "150825_2_Ent3", "role": "Treatment_Drug", "text": "nifuroxime", "start": 15, "end": 16}, {"entity_id": "150825_2_Ent6", "role": "Combination_Drug", "text": "nifuroxime", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "150825_2_Ent0", "text": "jaundice", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "150825_2_Ent4", "text": "intravaginal", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "150825_2_Ent1", "text": "intravaginal administration of a mixture of furazolidone and nifuroxime", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "150825_2_Ent2", "text": "furazolidone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "150825_2_Ent5", "text": "furazolidone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "150825_2_Ent3", "text": "nifuroxime", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "150825_2_Ent6", "text": "nifuroxime", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "1509179_3", "wnd_id": "1509179_3_1", "text": "This profile should trigger a \" red flag \" as to the possibility of phenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors .", "tokens": ["This", "profile", "should", "trigger", "a", "\"", "red", "flag", "\"", "as", "to", "the", "possibility", "of", "phenobarbital", "behavioral", "side", "effects", "or", "exacerbation", "of", "preexisting", "maladaptive", "behaviors", "."], "event_mentions": [{"id": "1509179_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "trigger", "start": 3, "end": 4}, "arguments": [{"entity_id": "1509179_3_Ent1", "role": "Treatment", "text": "phenobarbital", "start": 14, "end": 15}, {"entity_id": "1509179_3_Ent2", "role": "Treatment_Drug", "text": "phenobarbital", "start": 14, "end": 15}, {"entity_id": "1509179_3_Ent0", "role": "Effect", "text": "behavioral side effects or exacerbation of preexisting maladaptive behaviors", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "1509179_3_Ent1", "text": "phenobarbital", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1509179_3_Ent2", "text": "phenobarbital", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "1509179_3_Ent0", "text": "behavioral side effects or exacerbation of preexisting maladaptive behaviors", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "15097937_2", "wnd_id": "15097937_2_1", "text": "Anticonvulsant hypersensitivity syndrome associated with Bellamine S , a therapy for menopausal symptoms .", "tokens": ["Anticonvulsant", "hypersensitivity", "syndrome", "associated", "with", "Bellamine", "S", ",", "a", "therapy", "for", "menopausal", "symptoms", "."], "event_mentions": [{"id": "15097937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15097937_2_Ent0", "role": "Effect", "text": "Anticonvulsant hypersensitivity syndrome", "start": 0, "end": 3}, {"entity_id": "15097937_2_Ent3", "role": "Treatment_Drug", "text": "Bellamine S", "start": 5, "end": 7}, {"entity_id": "15097937_2_Ent1", "role": "Treatment", "text": "Bellamine S , a therapy for menopausal symptoms", "start": 5, "end": 13}, {"entity_id": "15097937_2_Ent2", "role": "Treatment_Disorder", "text": "menopausal symptoms .", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "15097937_2_Ent0", "text": "Anticonvulsant hypersensitivity syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15097937_2_Ent3", "text": "Bellamine S", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15097937_2_Ent1", "text": "Bellamine S , a therapy for menopausal symptoms", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "15097937_2_Ent2", "text": "menopausal symptoms .", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "15157248_1", "wnd_id": "15157248_1_1", "text": "An immediate hemolytic reaction induced by repeated administration of oxaliplatin .", "tokens": ["An", "immediate", "hemolytic", "reaction", "induced", "by", "repeated", "administration", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15157248_1_Ent0", "role": "Effect", "text": "immediate hemolytic reaction", "start": 1, "end": 4}, {"entity_id": "15157248_1_Ent2", "role": "Treatment_Freq", "text": "repeated", "start": 6, "end": 7}, {"entity_id": "15157248_1_Ent1", "role": "Treatment", "text": "repeated administration of oxaliplatin", "start": 6, "end": 10}, {"entity_id": "15157248_1_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15157248_1_Ent0", "text": "immediate hemolytic reaction", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "15157248_1_Ent2", "text": "repeated", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15157248_1_Ent1", "text": "repeated administration of oxaliplatin", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "15157248_1_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15157248_2", "wnd_id": "15157248_2_1", "text": "CASE REPORT : We report a patient who developed a DAT - positive hemolytic episode after a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin .", "tokens": ["CASE", "REPORT", ":", "We", "report", "a", "patient", "who", "developed", "a", "DAT", "-", "positive", "hemolytic", "episode", "after", "a", "red", "cell", "(", "RBC", ")", "transfusion", "was", "delivered", "during", "the", "infusion", "of", "her", "17th", "cycle", "of", "oxaliplatin", "."], "event_mentions": [{"id": "15157248_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "15157248_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "15157248_2_Ent1", "role": "Effect", "text": "developed a DAT - positive hemolytic episode", "start": 8, "end": 15}, {"entity_id": "15157248_2_Ent4", "role": "Treatment_Drug", "text": "a red cell", "start": 16, "end": 19}, {"entity_id": "15157248_2_Ent9", "role": "Combination_Drug", "text": "a red cell", "start": 16, "end": 19}, {"entity_id": "15157248_2_Ent2", "role": "Treatment", "text": "a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin", "start": 16, "end": 34}, {"entity_id": "15157248_2_Ent6", "role": "Treatment_Route", "text": "transfusion", "start": 22, "end": 23}, {"entity_id": "15157248_2_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 27, "end": 28}, {"entity_id": "15157248_2_Ent7", "role": "Treatment_Duration", "text": "17th cycle", "start": 30, "end": 32}, {"entity_id": "15157248_2_Ent3", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 33, "end": 34}, {"entity_id": "15157248_2_Ent8", "role": "Combination_Drug", "text": "oxaliplatin", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "15157248_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15157248_2_Ent1", "text": "developed a DAT - positive hemolytic episode", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "15157248_2_Ent4", "text": "a red cell", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15157248_2_Ent9", "text": "a red cell", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15157248_2_Ent2", "text": "a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of oxaliplatin", "entity_type": "Entity", "start": 16, "end": 34}, {"id": "15157248_2_Ent6", "text": "transfusion", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15157248_2_Ent5", "text": "infusion", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "15157248_2_Ent7", "text": "17th cycle", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "15157248_2_Ent3", "text": "oxaliplatin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "15157248_2_Ent8", "text": "oxaliplatin", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "15162903_2", "wnd_id": "15162903_2_1", "text": "Clinicians should be aware of the signs and symptoms of neurotoxicity during treatment , as well as predisposing factors that put patients receiving methotrexate at risk for neurotoxic effects .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "signs", "and", "symptoms", "of", "neurotoxicity", "during", "treatment", ",", "as", "well", "as", "predisposing", "factors", "that", "put", "patients", "receiving", "methotrexate", "at", "risk", "for", "neurotoxic", "effects", "."], "event_mentions": [{"id": "15162903_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 25, "end": 26}, "arguments": [{"entity_id": "15162903_2_Ent0", "role": "Subject", "text": "patients", "start": 21, "end": 22}, {"entity_id": "15162903_2_Ent2", "role": "Treatment", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "15162903_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 23, "end": 24}, {"entity_id": "15162903_2_Ent1", "role": "Effect", "text": "neurotoxic effects", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "15162903_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "15162903_2_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15162903_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15162903_2_Ent1", "text": "neurotoxic effects", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "15224368_1", "wnd_id": "15224368_1_1", "text": "Sweet 's syndrome associated with sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment .", "tokens": ["Sweet", "'s", "syndrome", "associated", "with", "sargramostim", "(", "granulocyte", "-", "macrophage", "colony", "stimulating", "factor", ")", "treatment", "."], "event_mentions": [{"id": "15224368_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "15224368_1_Ent0", "role": "Effect", "text": "Sweet 's syndrome", "start": 0, "end": 3}, {"entity_id": "15224368_1_Ent2", "role": "Treatment_Drug", "text": "sargramostim", "start": 5, "end": 6}, {"entity_id": "15224368_1_Ent1", "role": "Treatment", "text": "sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment", "start": 5, "end": 15}]}], "entity_mentions": [{"id": "15224368_1_Ent0", "text": "Sweet 's syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15224368_1_Ent2", "text": "sargramostim", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15224368_1_Ent1", "text": "sargramostim ( granulocyte - macrophage colony stimulating factor ) treatment", "entity_type": "Entity", "start": 5, "end": 15}], "lang": "en"}
{"doc_id": "15235919_1", "wnd_id": "15235919_1_1", "text": "Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment .", "tokens": ["Sudden", "cardiac", "death", "due", "to", "hypersensitivity", "myocarditis", "during", "clozapine", "treatment", "."], "event_mentions": [{"id": "15235919_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 7, "end": 8}, "arguments": [{"entity_id": "15235919_1_Ent0", "role": "Effect", "text": "Sudden cardiac death due to hypersensitivity myocarditis", "start": 0, "end": 7}, {"entity_id": "15235919_1_Ent1", "role": "Treatment", "text": "clozapine", "start": 8, "end": 9}, {"entity_id": "15235919_1_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "15235919_1_Ent0", "text": "Sudden cardiac death due to hypersensitivity myocarditis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "15235919_1_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15235919_1_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "15235919_2", "wnd_id": "15235919_2_1", "text": "The autopsy findings and a detailed medical history supported the conclusion that clozapine - induced hypersensitivity myocarditis was the most likely cause of death .", "tokens": ["The", "autopsy", "findings", "and", "a", "detailed", "medical", "history", "supported", "the", "conclusion", "that", "clozapine", "-", "induced", "hypersensitivity", "myocarditis", "was", "the", "most", "likely", "cause", "of", "death", "."], "event_mentions": [{"id": "15235919_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "15235919_2_Ent2", "role": "Treatment", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "15235919_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 12, "end": 13}, {"entity_id": "15235919_2_Ent0", "role": "Effect", "text": "hypersensitivity myocarditis", "start": 15, "end": 17}, {"entity_id": "15235919_2_Ent1", "role": "Effect", "text": "death", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15235919_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15235919_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15235919_2_Ent0", "text": "hypersensitivity myocarditis", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15235919_2_Ent1", "text": "death", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15235919_3", "wnd_id": "15235919_3_1", "text": "The case concerns the sudden death of a 29 - year - old male during clozapine therapy started 2 weeks before .", "tokens": ["The", "case", "concerns", "the", "sudden", "death", "of", "a", "29", "-", "year", "-", "old", "male", "during", "clozapine", "therapy", "started", "2", "weeks", "before", "."], "event_mentions": [{"id": "15235919_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 14, "end": 15}, "arguments": [{"entity_id": "15235919_3_Ent3", "role": "Effect", "text": "sudden death", "start": 4, "end": 6}, {"entity_id": "15235919_3_Ent0", "role": "Subject", "text": "a 29 - year - old male", "start": 7, "end": 14}, {"entity_id": "15235919_3_Ent1", "role": "Subject_Age", "text": "29 - year - old", "start": 8, "end": 13}, {"entity_id": "15235919_3_Ent2", "role": "Subject_Population", "text": "male", "start": 13, "end": 14}, {"entity_id": "15235919_3_Ent4", "role": "Treatment", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent5", "role": "Treatment_Drug", "text": "clozapine", "start": 15, "end": 16}, {"entity_id": "15235919_3_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks before", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "15235919_3_Ent3", "text": "sudden death", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15235919_3_Ent0", "text": "a 29 - year - old male", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "15235919_3_Ent1", "text": "29 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "15235919_3_Ent2", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15235919_3_Ent4", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent5", "text": "clozapine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15235919_3_Ent6", "text": "2 weeks before", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "15239684_2", "wnd_id": "15239684_2_1", "text": "The findings were judged to be consistent with soft - tissue injury associated with intravenous administration of phenytoin , also termed purple glove syndrome .", "tokens": ["The", "findings", "were", "judged", "to", "be", "consistent", "with", "soft", "-", "tissue", "injury", "associated", "with", "intravenous", "administration", "of", "phenytoin", ",", "also", "termed", "purple", "glove", "syndrome", "."], "event_mentions": [{"id": "15239684_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "15239684_2_Ent0", "role": "Effect", "text": "soft - tissue injury", "start": 8, "end": 12}, {"entity_id": "15239684_2_Ent2", "role": "Treatment_Route", "text": "intravenous administration", "start": 14, "end": 16}, {"entity_id": "15239684_2_Ent1", "role": "Treatment", "text": "intravenous administration of phenytoin", "start": 14, "end": 18}, {"entity_id": "15239684_2_Ent3", "role": "Treatment_Drug", "text": "phenytoin", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15239684_2_Ent0", "text": "soft - tissue injury", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15239684_2_Ent2", "text": "intravenous administration", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15239684_2_Ent1", "text": "intravenous administration of phenytoin", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "15239684_2_Ent3", "text": "phenytoin", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15279668_2", "wnd_id": "15279668_2_1", "text": "We discuss a case with significant progressive peripheral neurological deterioration following administration of both fludarabine and cytarabine as part of the FLA ( fludarabine and cytarabine ) regime .", "tokens": ["We", "discuss", "a", "case", "with", "significant", "progressive", "peripheral", "neurological", "deterioration", "following", "administration", "of", "both", "fludarabine", "and", "cytarabine", "as", "part", "of", "the", "FLA", "(", "fludarabine", "and", "cytarabine", ")", "regime", "."], "event_mentions": [{"id": "15279668_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "15279668_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15279668_2_Ent1", "role": "Effect", "text": "significant progressive peripheral neurological deterioration", "start": 5, "end": 10}, {"entity_id": "15279668_2_Ent4", "role": "Treatment_Drug", "text": "fludarabine", "start": 14, "end": 15}, {"entity_id": "15279668_2_Ent7", "role": "Combination_Drug", "text": "fludarabine", "start": 14, "end": 15}, {"entity_id": "15279668_2_Ent2", "role": "Treatment", "text": "fludarabine and cytarabine", "start": 14, "end": 17}, {"entity_id": "15279668_2_Ent5", "role": "Treatment_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "15279668_2_Ent8", "role": "Combination_Drug", "text": "cytarabine", "start": 16, "end": 17}, {"entity_id": "15279668_2_Ent6", "role": "Treatment_Drug", "text": "FLA ( fludarabine and cytarabine )", "start": 21, "end": 27}, {"entity_id": "15279668_2_Ent3", "role": "Treatment", "text": "FLA ( fludarabine and cytarabine ) regime", "start": 21, "end": 28}]}], "entity_mentions": [{"id": "15279668_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15279668_2_Ent1", "text": "significant progressive peripheral neurological deterioration", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "15279668_2_Ent4", "text": "fludarabine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15279668_2_Ent7", "text": "fludarabine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15279668_2_Ent2", "text": "fludarabine and cytarabine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "15279668_2_Ent5", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15279668_2_Ent8", "text": "cytarabine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15279668_2_Ent6", "text": "FLA ( fludarabine and cytarabine )", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "15279668_2_Ent3", "text": "FLA ( fludarabine and cytarabine ) regime", "entity_type": "Entity", "start": 21, "end": 28}], "lang": "en"}
{"doc_id": "15286697_2", "wnd_id": "15286697_2_1", "text": "Pulmonary fibrosis is a severe complication associated with bis - chloronitrosourea ( BCNU ) therapy .", "tokens": ["Pulmonary", "fibrosis", "is", "a", "severe", "complication", "associated", "with", "bis", "-", "chloronitrosourea", "(", "BCNU", ")", "therapy", "."], "event_mentions": [{"id": "15286697_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "15286697_2_Ent0", "role": "Effect", "text": "Pulmonary fibrosis is a severe complication", "start": 0, "end": 6}, {"entity_id": "15286697_2_Ent2", "role": "Treatment_Drug", "text": "bis - chloronitrosourea", "start": 8, "end": 11}, {"entity_id": "15286697_2_Ent1", "role": "Treatment", "text": "bis - chloronitrosourea ( BCNU ) therapy", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "15286697_2_Ent0", "text": "Pulmonary fibrosis is a severe complication", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15286697_2_Ent2", "text": "bis - chloronitrosourea", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15286697_2_Ent1", "text": "bis - chloronitrosourea ( BCNU ) therapy", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "15316423_1", "wnd_id": "15316423_1_1", "text": "Extensive forearm deep venous thrombosis following a severe infliximab infusion reaction .", "tokens": ["Extensive", "forearm", "deep", "venous", "thrombosis", "following", "a", "severe", "infliximab", "infusion", "reaction", "."], "event_mentions": [{"id": "15316423_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "15316423_1_Ent0", "role": "Effect", "text": "Extensive forearm deep venous thrombosis", "start": 0, "end": 5}, {"entity_id": "15316423_1_Ent2", "role": "Treatment", "text": "infliximab", "start": 8, "end": 9}, {"entity_id": "15316423_1_Ent3", "role": "Treatment_Drug", "text": "infliximab", "start": 8, "end": 9}, {"entity_id": "15316423_1_Ent1", "role": "Effect", "text": "infusion reaction", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15316423_1_Ent0", "text": "Extensive forearm deep venous thrombosis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15316423_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15316423_1_Ent3", "text": "infliximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15316423_1_Ent1", "text": "infusion reaction", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15331204_7", "wnd_id": "15331204_7_1", "text": "After 3 - to 13 - month period of therapy without indapamide , glucose levels of all patients decreased and diabetes disappeared .", "tokens": ["After", "3", "-", "to", "13", "-", "month", "period", "of", "therapy", "without", "indapamide", ",", "glucose", "levels", "of", "all", "patients", "decreased", "and", "diabetes", "disappeared", "."], "event_mentions": [{"id": "15331204_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "15331204_7_Ent3", "role": "Treatment_Time_elapsed", "text": "3 - to 13 - month", "start": 1, "end": 7}, {"entity_id": "15331204_7_Ent1", "role": "Treatment", "text": "3 - to 13 - month period of therapy without indapamide", "start": 1, "end": 12}, {"entity_id": "15331204_7_Ent2", "role": "Treatment_Drug", "text": "indapamide", "start": 11, "end": 12}, {"entity_id": "15331204_7_Ent0", "role": "Effect", "text": "glucose levels of all patients decreased and diabetes disappeared", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "15331204_7_Ent3", "text": "3 - to 13 - month", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "15331204_7_Ent1", "text": "3 - to 13 - month period of therapy without indapamide", "entity_type": "Entity", "start": 1, "end": 12}, {"id": "15331204_7_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15331204_7_Ent0", "text": "glucose levels of all patients decreased and diabetes disappeared", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "15331204_8", "wnd_id": "15331204_8_1", "text": "After stopping indapamide , glucose tolerance impairing may be reversed .", "tokens": ["After", "stopping", "indapamide", ",", "glucose", "tolerance", "impairing", "may", "be", "reversed", "."], "event_mentions": [{"id": "15331204_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "stopping", "start": 1, "end": 2}, "arguments": [{"entity_id": "15331204_8_Ent2", "role": "Treatment_Drug", "text": "indapamide", "start": 2, "end": 3}, {"entity_id": "15331204_8_Ent0", "role": "Treatment", "text": "indapamide , glucose tolerance impairing", "start": 2, "end": 7}, {"entity_id": "15331204_8_Ent1", "role": "Treatment_Disorder", "text": "glucose tolerance impairing", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "15331204_8_Ent2", "text": "indapamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15331204_8_Ent0", "text": "indapamide , glucose tolerance impairing", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "15331204_8_Ent1", "text": "glucose tolerance impairing", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "15338554_3", "wnd_id": "15338554_3_1", "text": "In addition to disease refractoriness , rare instances of disease progression from chronic phase to blast crisis during imatinib therapy have recently been anecdotally reported .", "tokens": ["In", "addition", "to", "disease", "refractoriness", ",", "rare", "instances", "of", "disease", "progression", "from", "chronic", "phase", "to", "blast", "crisis", "during", "imatinib", "therapy", "have", "recently", "been", "anecdotally", "reported", "."], "event_mentions": [{"id": "15338554_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 17, "end": 18}, "arguments": [{"entity_id": "15338554_3_Ent0", "role": "Effect", "text": "disease progression from chronic phase to blast crisis", "start": 9, "end": 17}, {"entity_id": "15338554_3_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "15338554_3_Ent1", "role": "Treatment", "text": "imatinib therapy", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "15338554_3_Ent0", "text": "disease progression from chronic phase to blast crisis", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "15338554_3_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15338554_3_Ent1", "text": "imatinib therapy", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "15338554_4", "wnd_id": "15338554_4_1", "text": "OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to blast crisis while taking imatinib and to perform a review of the literature .", "tokens": ["OBJECTIVES", ":", "To", "describe", "the", "clinicopathologic", "features", "of", "3", "patients", "with", "CML", "who", "rapidly", "progressed", "from", "chronic", "phase", "to", "blast", "crisis", "while", "taking", "imatinib", "and", "to", "perform", "a", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "15338554_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "progressed", "start": 14, "end": 15}, "arguments": [{"entity_id": "15338554_4_Ent1", "role": "Subject_Population", "text": "3", "start": 8, "end": 9}, {"entity_id": "15338554_4_Ent0", "role": "Subject", "text": "3 patients with CML", "start": 8, "end": 12}, {"entity_id": "15338554_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 11, "end": 12}, {"entity_id": "15338554_4_Ent2", "role": "Effect", "text": "from chronic phase to blast crisis", "start": 15, "end": 21}, {"entity_id": "15338554_4_Ent3", "role": "Treatment", "text": "imatinib", "start": 23, "end": 24}, {"entity_id": "15338554_4_Ent5", "role": "Treatment_Drug", "text": "imatinib", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15338554_4_Ent1", "text": "3", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15338554_4_Ent0", "text": "3 patients with CML", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15338554_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15338554_4_Ent2", "text": "from chronic phase to blast crisis", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "15338554_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15338554_4_Ent5", "text": "imatinib", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15359206_1", "wnd_id": "15359206_1_1", "text": "Easily reversible hypoxemia and hypotension induced by nimodipine .", "tokens": ["Easily", "reversible", "hypoxemia", "and", "hypotension", "induced", "by", "nimodipine", "."], "event_mentions": [{"id": "15359206_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "15359206_1_Ent0", "role": "Effect", "text": "hypoxemia and hypotension", "start": 2, "end": 5}, {"entity_id": "15359206_1_Ent1", "role": "Treatment", "text": "nimodipine", "start": 7, "end": 8}, {"entity_id": "15359206_1_Ent2", "role": "Treatment_Drug", "text": "nimodipine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "15359206_1_Ent0", "text": "hypoxemia and hypotension", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "15359206_1_Ent1", "text": "nimodipine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15359206_1_Ent2", "text": "nimodipine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "15368548_1", "wnd_id": "15368548_1_1", "text": "L - asparaginase - induced pancreatitis is an uncommon but potential lethal complication of the treatment of leukemia .", "tokens": ["L", "-", "asparaginase", "-", "induced", "pancreatitis", "is", "an", "uncommon", "but", "potential", "lethal", "complication", "of", "the", "treatment", "of", "leukemia", "."], "event_mentions": [{"id": "15368548_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15368548_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "15368548_1_Ent0", "role": "Effect", "text": "pancreatitis", "start": 5, "end": 6}, {"entity_id": "15368548_1_Ent3", "role": "Treatment_Disorder", "text": "leukemia", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15368548_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15368548_1_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15368548_1_Ent3", "text": "leukemia", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15368548_3", "wnd_id": "15368548_3_1", "text": "Most cases of pancreatitis associated with L - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation .", "tokens": ["Most", "cases", "of", "pancreatitis", "associated", "with", "L", "-", "asparaginase", "toxicity", "are", "self", "-", "limiting", "and", "respond", "favorably", "to", "nasogastric", "decompression", "and", "intravenous", "hyperalimentation", "."], "event_mentions": [{"id": "15368548_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15368548_3_Ent0", "role": "Subject", "text": "Most cases", "start": 0, "end": 2}, {"entity_id": "15368548_3_Ent1", "role": "Effect", "text": "pancreatitis", "start": 3, "end": 4}, {"entity_id": "15368548_3_Ent2", "role": "Treatment", "text": "L - asparaginase", "start": 6, "end": 9}, {"entity_id": "15368548_3_Ent3", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "15368548_3_Ent0", "text": "Most cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15368548_3_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15368548_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15368548_3_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "15368548_5", "wnd_id": "15368548_5_1", "text": "We present a pediatric patient with leukemia and a severe , L - asparaginase - induced necrotizing pancreatitis , treated successfully with percutaneous drainage used to flush the infected necrotic parts .", "tokens": ["We", "present", "a", "pediatric", "patient", "with", "leukemia", "and", "a", "severe", ",", "L", "-", "asparaginase", "-", "induced", "necrotizing", "pancreatitis", ",", "treated", "successfully", "with", "percutaneous", "drainage", "used", "to", "flush", "the", "infected", "necrotic", "parts", "."], "event_mentions": [{"id": "15368548_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "15368548_5_Ent7", "role": "Treatment", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "15368548_5_Ent8", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 11, "end": 14}, {"entity_id": "15368548_5_Ent6", "role": "Effect", "text": "necrotizing pancreatitis", "start": 16, "end": 18}]}, {"id": "15368548_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "used to", "start": 24, "end": 26}, "arguments": [{"entity_id": "15368548_5_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 3, "end": 4}, {"entity_id": "15368548_5_Ent0", "role": "Subject", "text": "pediatric patient with leukemia and a severe , L - asparaginase - induced necrotizing pancreatitis", "start": 3, "end": 18}, {"entity_id": "15368548_5_Ent2", "role": "Subject_Disorder", "text": "leukemia", "start": 6, "end": 7}, {"entity_id": "15368548_5_Ent5", "role": "Treatment_Disorder", "text": "L - asparaginase - induced necrotizing pancreatitis", "start": 11, "end": 18}, {"entity_id": "15368548_5_Ent4", "role": "Treatment", "text": "percutaneous drainage", "start": 22, "end": 24}, {"entity_id": "15368548_5_Ent3", "role": "Effect", "text": "flush the infected necrotic parts .", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "15368548_5_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15368548_5_Ent0", "text": "pediatric patient with leukemia and a severe , L - asparaginase - induced necrotizing pancreatitis", "entity_type": "Entity", "start": 3, "end": 18}, {"id": "15368548_5_Ent2", "text": "leukemia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15368548_5_Ent7", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15368548_5_Ent8", "text": "L - asparaginase", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "15368548_5_Ent5", "text": "L - asparaginase - induced necrotizing pancreatitis", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "15368548_5_Ent6", "text": "necrotizing pancreatitis", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15368548_5_Ent4", "text": "percutaneous drainage", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "15368548_5_Ent3", "text": "flush the infected necrotic parts .", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "15379082_1", "wnd_id": "15379082_1_1", "text": "Disulfiram - induced fulminant hepatic failure in an active duty soldier .", "tokens": ["Disulfiram", "-", "induced", "fulminant", "hepatic", "failure", "in", "an", "active", "duty", "soldier", "."], "event_mentions": [{"id": "15379082_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15379082_1_Ent2", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "15379082_1_Ent3", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "15379082_1_Ent1", "role": "Effect", "text": "fulminant hepatic failure", "start": 3, "end": 6}, {"entity_id": "15379082_1_Ent0", "role": "Subject", "text": "an active duty soldier", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "15379082_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15379082_1_Ent3", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15379082_1_Ent1", "text": "fulminant hepatic failure", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15379082_1_Ent0", "text": "an active duty soldier", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "15383642_15", "wnd_id": "15383642_15_1", "text": "Based upon the literature review , the hypotension in this patient was possibly due to the interaction between tizanidine and lisinopril .", "tokens": ["Based", "upon", "the", "literature", "review", ",", "the", "hypotension", "in", "this", "patient", "was", "possibly", "due", "to", "the", "interaction", "between", "tizanidine", "and", "lisinopril", "."], "event_mentions": [{"id": "15383642_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 13, "end": 14}, "arguments": [{"entity_id": "15383642_15_Ent1", "role": "Effect", "text": "the hypotension", "start": 6, "end": 8}, {"entity_id": "15383642_15_Ent0", "role": "Subject", "text": "this patient", "start": 9, "end": 11}, {"entity_id": "15383642_15_Ent2", "role": "Treatment", "text": "the interaction between tizanidine and lisinopril", "start": 15, "end": 21}, {"entity_id": "15383642_15_Ent3", "role": "Treatment_Drug", "text": "tizanidine", "start": 18, "end": 19}, {"entity_id": "15383642_15_Ent5", "role": "Combination_Drug", "text": "tizanidine", "start": 18, "end": 19}, {"entity_id": "15383642_15_Ent4", "role": "Treatment_Drug", "text": "lisinopril", "start": 20, "end": 21}, {"entity_id": "15383642_15_Ent6", "role": "Combination_Drug", "text": "lisinopril", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "15383642_15_Ent1", "text": "the hypotension", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15383642_15_Ent0", "text": "this patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15383642_15_Ent2", "text": "the interaction between tizanidine and lisinopril", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "15383642_15_Ent3", "text": "tizanidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15383642_15_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "15383642_15_Ent4", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15383642_15_Ent6", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "15383642_2", "wnd_id": "15383642_2_1", "text": "To report a case in which significant hypotension occurred after initiation of tizanidine in a patient using the antihypertensive agent lisinopril .", "tokens": ["To", "report", "a", "case", "in", "which", "significant", "hypotension", "occurred", "after", "initiation", "of", "tizanidine", "in", "a", "patient", "using", "the", "antihypertensive", "agent", "lisinopril", "."], "event_mentions": [{"id": "15383642_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "15383642_2_Ent1", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "15383642_2_Ent2", "role": "Effect", "text": "hypotension", "start": 7, "end": 8}, {"entity_id": "15383642_2_Ent3", "role": "Treatment", "text": "initiation of tizanidine", "start": 10, "end": 13}, {"entity_id": "15383642_2_Ent6", "role": "Treatment_Drug", "text": "tizanidine", "start": 12, "end": 13}, {"entity_id": "15383642_2_Ent0", "role": "Subject", "text": "a patient", "start": 14, "end": 16}, {"entity_id": "15383642_2_Ent4", "role": "Treatment", "text": "lisinopril", "start": 20, "end": 21}, {"entity_id": "15383642_2_Ent5", "role": "Treatment_Drug", "text": "lisinopril", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "15383642_2_Ent1", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "15383642_2_Ent2", "text": "hypotension", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15383642_2_Ent3", "text": "initiation of tizanidine", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15383642_2_Ent6", "text": "tizanidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15383642_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15383642_2_Ent4", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "15383642_2_Ent5", "text": "lisinopril", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "15479299_1", "wnd_id": "15479299_1_1", "text": "Progressive anemia following combination therapy with interferon - alpha and interleukin - 2 in a patient with metastatic renal cell carcinoma .", "tokens": ["Progressive", "anemia", "following", "combination", "therapy", "with", "interferon", "-", "alpha", "and", "interleukin", "-", "2", "in", "a", "patient", "with", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "15479299_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "15479299_1_Ent1", "role": "Effect", "text": "Progressive anemia", "start": 0, "end": 2}, {"entity_id": "15479299_1_Ent2", "role": "Treatment", "text": "combination therapy with interferon - alpha and interleukin - 2", "start": 3, "end": 13}, {"entity_id": "15479299_1_Ent4", "role": "Treatment_Drug", "text": "interferon - alpha", "start": 6, "end": 9}, {"entity_id": "15479299_1_Ent6", "role": "Combination_Drug", "text": "interferon - alpha", "start": 6, "end": 9}, {"entity_id": "15479299_1_Ent5", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 10, "end": 13}, {"entity_id": "15479299_1_Ent7", "role": "Combination_Drug", "text": "interleukin - 2", "start": 10, "end": 13}, {"entity_id": "15479299_1_Ent0", "role": "Subject", "text": "a patient with metastatic renal cell carcinoma", "start": 14, "end": 21}, {"entity_id": "15479299_1_Ent3", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "15479299_1_Ent1", "text": "Progressive anemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15479299_1_Ent2", "text": "combination therapy with interferon - alpha and interleukin - 2", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "15479299_1_Ent4", "text": "interferon - alpha", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15479299_1_Ent6", "text": "interferon - alpha", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "15479299_1_Ent5", "text": "interleukin - 2", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15479299_1_Ent7", "text": "interleukin - 2", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "15479299_1_Ent0", "text": "a patient with metastatic renal cell carcinoma", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "15479299_1_Ent3", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "15479299_2", "wnd_id": "15479299_2_1", "text": "We report a case of severe anemia , which responded well to steroid therapy , in a patient receiving IL - 2 plus IFN - alpha for metastatic renal cell carcinoma .", "tokens": ["We", "report", "a", "case", "of", "severe", "anemia", ",", "which", "responded", "well", "to", "steroid", "therapy", ",", "in", "a", "patient", "receiving", "IL", "-", "2", "plus", "IFN", "-", "alpha", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "15479299_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 9, "end": 10}, "arguments": [{"entity_id": "15479299_2_Ent9", "role": "Treatment_Disorder", "text": "severe anemia", "start": 5, "end": 7}, {"entity_id": "15479299_2_Ent8", "role": "Treatment", "text": "steroid", "start": 12, "end": 13}, {"entity_id": "15479299_2_Ent10", "role": "Treatment_Drug", "text": "steroid", "start": 12, "end": 13}]}, {"id": "15479299_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 18, "end": 19}, "arguments": [{"entity_id": "15479299_2_Ent1", "role": "Effect", "text": "severe anemia", "start": 5, "end": 7}, {"entity_id": "15479299_2_Ent0", "role": "Subject", "text": "a patient", "start": 16, "end": 18}, {"entity_id": "15479299_2_Ent4", "role": "Treatment_Drug", "text": "IL - 2", "start": 19, "end": 22}, {"entity_id": "15479299_2_Ent7", "role": "Combination_Drug", "text": "IL - 2", "start": 19, "end": 22}, {"entity_id": "15479299_2_Ent2", "role": "Treatment", "text": "IL - 2 plus IFN - alpha", "start": 19, "end": 26}, {"entity_id": "15479299_2_Ent5", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "15479299_2_Ent6", "role": "Combination_Drug", "text": "IFN - alpha", "start": 23, "end": 26}, {"entity_id": "15479299_2_Ent3", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "15479299_2_Ent1", "text": "severe anemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15479299_2_Ent9", "text": "severe anemia", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15479299_2_Ent8", "text": "steroid", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15479299_2_Ent10", "text": "steroid", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15479299_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "15479299_2_Ent4", "text": "IL - 2", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "15479299_2_Ent7", "text": "IL - 2", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "15479299_2_Ent2", "text": "IL - 2 plus IFN - alpha", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15479299_2_Ent5", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15479299_2_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "15479299_2_Ent3", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "15482394_4", "wnd_id": "15482394_4_1", "text": "In view of our experience in the present case , it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid fatal haemorrhage after initiating warfarin therapy regardless of the dosage .", "tokens": ["In", "view", "of", "our", "experience", "in", "the", "present", "case", ",", "it", "should", "be", "stressed", "that", "close", "monitoring", "of", "coagulation", "capacity", "is", "necessary", "in", "critically", "ill", "patients", "in", "order", "to", "avoid", "fatal", "haemorrhage", "after", "initiating", "warfarin", "therapy", "regardless", "of", "the", "dosage", "."], "event_mentions": [{"id": "15482394_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 32, "end": 33}, "arguments": [{"entity_id": "15482394_4_Ent0", "role": "Effect", "text": "haemorrhage", "start": 31, "end": 32}, {"entity_id": "15482394_4_Ent1", "role": "Treatment", "text": "initiating warfarin therapy regardless of the dosage", "start": 33, "end": 40}, {"entity_id": "15482394_4_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "15482394_4_Ent0", "text": "haemorrhage", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "15482394_4_Ent1", "text": "initiating warfarin therapy regardless of the dosage", "entity_type": "Entity", "start": 33, "end": 40}, {"id": "15482394_4_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "15494638_1", "wnd_id": "15494638_1_1", "text": "Peripheral neuropathy associated with capecitabine .", "tokens": ["Peripheral", "neuropathy", "associated", "with", "capecitabine", "."], "event_mentions": [{"id": "15494638_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15494638_1_Ent0", "role": "Effect", "text": "Peripheral neuropathy", "start": 0, "end": 2}, {"entity_id": "15494638_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 4, "end": 5}, {"entity_id": "15494638_1_Ent1", "role": "Treatment", "text": "capecitabine .", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "15494638_1_Ent0", "text": "Peripheral neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15494638_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15494638_1_Ent1", "text": "capecitabine .", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "15494638_17", "wnd_id": "15494638_17_1", "text": "Neurotoxicity occurs most often with intermittent high dose 5 - FU as bolus injection or 24 - to 48 - h infusions .", "tokens": ["Neurotoxicity", "occurs", "most", "often", "with", "intermittent", "high", "dose", "5", "-", "FU", "as", "bolus", "injection", "or", "24", "-", "to", "48", "-", "h", "infusions", "."], "event_mentions": [{"id": "15494638_17_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 1, "end": 2}, "arguments": [{"entity_id": "15494638_17_Ent0", "role": "Effect", "text": "Neurotoxicity", "start": 0, "end": 1}, {"entity_id": "15494638_17_Ent1", "role": "Treatment", "text": "intermittent high dose 5 - FU as bolus injection or 24 - to 48 - h infusions", "start": 5, "end": 22}, {"entity_id": "15494638_17_Ent2", "role": "Treatment_Dosage", "text": "high dose", "start": 6, "end": 8}, {"entity_id": "15494638_17_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 8, "end": 11}, {"entity_id": "15494638_17_Ent4", "role": "Treatment_Route", "text": "injection", "start": 13, "end": 14}, {"entity_id": "15494638_17_Ent5", "role": "Treatment_Route", "text": "infusions", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "15494638_17_Ent0", "text": "Neurotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15494638_17_Ent1", "text": "intermittent high dose 5 - FU as bolus injection or 24 - to 48 - h infusions", "entity_type": "Entity", "start": 5, "end": 22}, {"id": "15494638_17_Ent2", "text": "high dose", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15494638_17_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "15494638_17_Ent4", "text": "injection", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15494638_17_Ent5", "text": "infusions", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "15494638_2", "wnd_id": "15494638_2_1", "text": "5 - fluorouracil ( 5 - FU) - associated peripheral neuropathy is an uncommon event .", "tokens": ["5", "-", "fluorouracil", "(", "5", "-", "FU)", "-", "associated", "peripheral", "neuropathy", "is", "an", "uncommon", "event", "."], "event_mentions": [{"id": "15494638_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "15494638_2_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 0, "end": 3}, {"entity_id": "15494638_2_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 0, "end": 3}, {"entity_id": "15494638_2_Ent0", "role": "Effect", "text": "peripheral neuropathy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "15494638_2_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_2_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15494638_2_Ent0", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "15494638_3", "wnd_id": "15494638_3_1", "text": "Capecitabine ( CAP ) is a pro - drug of 5 - FU and peripheral neuropathy associated with CAP has not been reported .", "tokens": ["Capecitabine", "(", "CAP", ")", "is", "a", "pro", "-", "drug", "of", "5", "-", "FU", "and", "peripheral", "neuropathy", "associated", "with", "CAP", "has", "not", "been", "reported", "."], "event_mentions": [{"id": "15494638_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "15494638_3_Ent0", "role": "Effect", "text": "peripheral neuropathy", "start": 14, "end": 16}, {"entity_id": "15494638_3_Ent1", "role": "Treatment", "text": "CAP", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "15494638_3_Ent0", "text": "peripheral neuropathy", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "15494638_3_Ent1", "text": "CAP", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "15516308_1", "wnd_id": "15516308_1_1", "text": "Fatal overdoses associated with quetiapine .", "tokens": ["Fatal", "overdoses", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "15516308_1_Ent0", "role": "Effect", "text": "Fatal overdoses", "start": 0, "end": 2}, {"entity_id": "15516308_1_Ent1", "role": "Treatment", "text": "quetiapine", "start": 4, "end": 5}, {"entity_id": "15516308_1_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "15516308_1_Ent0", "text": "Fatal overdoses", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15516308_1_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15516308_1_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "15516308_3", "wnd_id": "15516308_3_1", "text": "We present three cases from the Provincial Toxicology Center of British Columbia , Canada in which suicidal overdose deaths were associated with quetiapine .", "tokens": ["We", "present", "three", "cases", "from", "the", "Provincial", "Toxicology", "Center", "of", "British", "Columbia", ",", "Canada", "in", "which", "suicidal", "overdose", "deaths", "were", "associated", "with", "quetiapine", "."], "event_mentions": [{"id": "15516308_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 20, "end": 21}, "arguments": [{"entity_id": "15516308_3_Ent0", "role": "Effect", "text": "suicidal overdose deaths", "start": 16, "end": 19}, {"entity_id": "15516308_3_Ent1", "role": "Treatment", "text": "quetiapine", "start": 22, "end": 23}, {"entity_id": "15516308_3_Ent2", "role": "Treatment_Drug", "text": "quetiapine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "15516308_3_Ent0", "text": "suicidal overdose deaths", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "15516308_3_Ent1", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15516308_3_Ent2", "text": "quetiapine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "15522120_1", "wnd_id": "15522120_1_1", "text": "Itch and skin rash from chocolate during fluoxetine and sertraline treatment : case report .", "tokens": ["Itch", "and", "skin", "rash", "from", "chocolate", "during", "fluoxetine", "and", "sertraline", "treatment", ":", "case", "report", "."], "event_mentions": [{"id": "15522120_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 4, "end": 5}, "arguments": [{"entity_id": "15522120_1_Ent0", "role": "Effect", "text": "Itch and skin rash", "start": 0, "end": 4}, {"entity_id": "15522120_1_Ent2", "role": "Treatment_Drug", "text": "chocolate", "start": 5, "end": 6}, {"entity_id": "15522120_1_Ent6", "role": "Combination_Drug", "text": "chocolate", "start": 5, "end": 6}, {"entity_id": "15522120_1_Ent1", "role": "Treatment", "text": "chocolate during fluoxetine and sertraline treatment", "start": 5, "end": 11}, {"entity_id": "15522120_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "15522120_1_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "15522120_1_Ent4", "role": "Treatment_Drug", "text": "sertraline", "start": 9, "end": 10}, {"entity_id": "15522120_1_Ent7", "role": "Combination_Drug", "text": "sertraline", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "15522120_1_Ent0", "text": "Itch and skin rash", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "15522120_1_Ent2", "text": "chocolate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_1_Ent6", "text": "chocolate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15522120_1_Ent1", "text": "chocolate during fluoxetine and sertraline treatment", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "15522120_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15522120_1_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15522120_1_Ent4", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15522120_1_Ent7", "text": "sertraline", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "15543388_2", "wnd_id": "15543388_2_1", "text": "Celiac disease onset after pegylated interferon and ribavirin treatment of chronic hepatitis C.", "tokens": ["Celiac", "disease", "onset", "after", "pegylated", "interferon", "and", "ribavirin", "treatment", "of", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15543388_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "onset", "start": 2, "end": 3}, "arguments": [{"entity_id": "15543388_2_Ent0", "role": "Effect", "text": "Celiac disease", "start": 0, "end": 2}, {"entity_id": "15543388_2_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent5", "role": "Combination_Drug", "text": "pegylated interferon", "start": 4, "end": 6}, {"entity_id": "15543388_2_Ent1", "role": "Treatment", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "start": 4, "end": 13}, {"entity_id": "15543388_2_Ent3", "role": "Treatment_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent6", "role": "Combination_Drug", "text": "ribavirin treatment", "start": 7, "end": 9}, {"entity_id": "15543388_2_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "15543388_2_Ent0", "text": "Celiac disease", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15543388_2_Ent2", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent5", "text": "pegylated interferon", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15543388_2_Ent1", "text": "pegylated interferon and ribavirin treatment of chronic hepatitis C.", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "15543388_2_Ent3", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent6", "text": "ribavirin treatment", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15543388_2_Ent4", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "15549981_1", "wnd_id": "15549981_1_1", "text": "We present two cases of anaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine , but occurred following the administration of the alpha - agonist metaraminol .", "tokens": ["We", "present", "two", "cases", "of", "anaphylaxis", "under", "anaesthesia", "where", "return", "of", "spontaneous", "circulation", "was", "refractory", "to", "epinephrine", ",", "but", "occurred", "following", "the", "administration", "of", "the", "alpha", "-", "agonist", "metaraminol", "."], "event_mentions": [{"id": "15549981_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "occurred", "start": 19, "end": 20}, "arguments": [{"entity_id": "15549981_1_Ent3", "role": "Treatment_Disorder", "text": "anaphylaxis under anaesthesia", "start": 5, "end": 8}, {"entity_id": "15549981_1_Ent0", "role": "Effect", "text": "return of spontaneous circulation", "start": 9, "end": 13}, {"entity_id": "15549981_1_Ent1", "role": "Treatment", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent5", "role": "Treatment_Drug", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent6", "role": "Combination_Drug", "text": "epinephrine", "start": 16, "end": 17}, {"entity_id": "15549981_1_Ent2", "role": "Treatment", "text": "administration of the alpha - agonist metaraminol", "start": 22, "end": 29}, {"entity_id": "15549981_1_Ent4", "role": "Treatment_Drug", "text": "metaraminol", "start": 28, "end": 29}, {"entity_id": "15549981_1_Ent7", "role": "Combination_Drug", "text": "metaraminol", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "15549981_1_Ent3", "text": "anaphylaxis under anaesthesia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "15549981_1_Ent0", "text": "return of spontaneous circulation", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "15549981_1_Ent1", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent5", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent6", "text": "epinephrine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15549981_1_Ent2", "text": "administration of the alpha - agonist metaraminol", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "15549981_1_Ent4", "text": "metaraminol", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "15549981_1_Ent7", "text": "metaraminol", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "15554737_1", "wnd_id": "15554737_1_1", "text": "In this article , we describe another case of subcutaneous changes following repeated glatiramer acetate injection , presented as localized panniculitis in the area around the injection sites , in a 46 - year - old female patient who was treated with glatiramer acetate for 18 months .", "tokens": ["In", "this", "article", ",", "we", "describe", "another", "case", "of", "subcutaneous", "changes", "following", "repeated", "glatiramer", "acetate", "injection", ",", "presented", "as", "localized", "panniculitis", "in", "the", "area", "around", "the", "injection", "sites", ",", "in", "a", "46", "-", "year", "-", "old", "female", "patient", "who", "was", "treated", "with", "glatiramer", "acetate", "for", "18", "months", "."], "event_mentions": [{"id": "15554737_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 11, "end": 12}, "arguments": [{"entity_id": "15554737_1_Ent3", "role": "Effect", "text": "subcutaneous changes", "start": 9, "end": 11}, {"entity_id": "15554737_1_Ent5", "role": "Treatment", "text": "repeated glatiramer acetate injection", "start": 12, "end": 16}, {"entity_id": "15554737_1_Ent6", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 13, "end": 15}, {"entity_id": "15554737_1_Ent7", "role": "Treatment_Route", "text": "injection", "start": 15, "end": 16}, {"entity_id": "15554737_1_Ent4", "role": "Effect", "text": "presented as localized panniculitis in the area around the injection sites", "start": 17, "end": 28}, {"entity_id": "15554737_1_Ent0", "role": "Subject", "text": "a 46 - year - old female patient", "start": 30, "end": 38}, {"entity_id": "15554737_1_Ent1", "role": "Subject_Age", "text": "46 - year - old", "start": 31, "end": 36}, {"entity_id": "15554737_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 36, "end": 37}]}, {"id": "15554737_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 40, "end": 41}, "arguments": [{"entity_id": "15554737_1_Ent8", "role": "Subject", "text": "a 46 - year - old female patient", "start": 30, "end": 38}, {"entity_id": "15554737_1_Ent9", "role": "Subject_Age", "text": "46 - year - old", "start": 31, "end": 36}, {"entity_id": "15554737_1_Ent10", "role": "Subject_Gender", "text": "female", "start": 36, "end": 37}, {"entity_id": "15554737_1_Ent12", "role": "Treatment_Drug", "text": "glatiramer acetate", "start": 42, "end": 44}, {"entity_id": "15554737_1_Ent11", "role": "Treatment", "text": "glatiramer acetate for 18 months", "start": 42, "end": 47}, {"entity_id": "15554737_1_Ent13", "role": "Treatment_Time_elapsed", "text": "18 months .", "start": 45, "end": 48}]}], "entity_mentions": [{"id": "15554737_1_Ent3", "text": "subcutaneous changes", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15554737_1_Ent5", "text": "repeated glatiramer acetate injection", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "15554737_1_Ent6", "text": "glatiramer acetate", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "15554737_1_Ent7", "text": "injection", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15554737_1_Ent4", "text": "presented as localized panniculitis in the area around the injection sites", "entity_type": "Entity", "start": 17, "end": 28}, {"id": "15554737_1_Ent0", "text": "a 46 - year - old female patient", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "15554737_1_Ent8", "text": "a 46 - year - old female patient", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "15554737_1_Ent1", "text": "46 - year - old", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "15554737_1_Ent9", "text": "46 - year - old", "entity_type": "Entity", "start": 31, "end": 36}, {"id": "15554737_1_Ent2", "text": "female", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15554737_1_Ent10", "text": "female", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "15554737_1_Ent12", "text": "glatiramer acetate", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "15554737_1_Ent11", "text": "glatiramer acetate for 18 months", "entity_type": "Entity", "start": 42, "end": 47}, {"id": "15554737_1_Ent13", "text": "18 months .", "entity_type": "Entity", "start": 45, "end": 48}], "lang": "en"}
{"doc_id": "15554737_2", "wnd_id": "15554737_2_1", "text": "Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis .", "tokens": ["Localized", "panniculitis", "and", "subsequent", "lipoatrophy", "with", "subcutaneous", "glatiramer", "acetate", "(", "Copaxone", ")", "injection", "for", "the", "treatment", "of", "multiple", "sclerosis", "."], "event_mentions": [{"id": "15554737_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 5, "end": 6}, "arguments": [{"entity_id": "15554737_2_Ent0", "role": "Effect", "text": "Localized panniculitis and subsequent lipoatrophy", "start": 0, "end": 5}, {"entity_id": "15554737_2_Ent1", "role": "Treatment", "text": "subcutaneous glatiramer acetate ( Copaxone ) injection", "start": 6, "end": 13}, {"entity_id": "15554737_2_Ent2", "role": "Treatment_Drug", "text": "glatiramer acetate ( Copaxone )", "start": 7, "end": 12}, {"entity_id": "15554737_2_Ent3", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}, {"entity_id": "15554737_2_Ent4", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15554737_2_Ent0", "text": "Localized panniculitis and subsequent lipoatrophy", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "15554737_2_Ent1", "text": "subcutaneous glatiramer acetate ( Copaxone ) injection", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "15554737_2_Ent2", "text": "glatiramer acetate ( Copaxone )", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "15554737_2_Ent3", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15554737_2_Ent4", "text": "multiple sclerosis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15571949_1", "wnd_id": "15571949_1_1", "text": "In four patients , thrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing busulfan .", "tokens": ["In", "four", "patients", ",", "thrombosis", "occurred", "2", "-", "45", "days", "after", "severe", "hepatic", "veno", "-", "occlusive", "disease", "(", "HVOD", ")", "secondary", "to", "intensive", "chemotherapy", "containing", "busulfan", "."], "event_mentions": [{"id": "15571949_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 20, "end": 21}, "arguments": [{"entity_id": "15571949_1_Ent1", "role": "Subject_Population", "text": "four", "start": 1, "end": 2}, {"entity_id": "15571949_1_Ent0", "role": "Subject", "text": "four patients", "start": 1, "end": 3}, {"entity_id": "15571949_1_Ent2", "role": "Effect", "text": "thrombosis occurred", "start": 4, "end": 6}, {"entity_id": "15571949_1_Ent5", "role": "Treatment_Time_elapsed", "text": "2 - 45 days after", "start": 6, "end": 11}, {"entity_id": "15571949_1_Ent3", "role": "Effect", "text": "severe hepatic veno - occlusive disease ( HVOD )", "start": 11, "end": 20}, {"entity_id": "15571949_1_Ent4", "role": "Treatment", "text": "intensive chemotherapy containing busulfan", "start": 22, "end": 26}, {"entity_id": "15571949_1_Ent6", "role": "Treatment_Drug", "text": "busulfan", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15571949_1_Ent1", "text": "four", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15571949_1_Ent0", "text": "four patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "15571949_1_Ent2", "text": "thrombosis occurred", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15571949_1_Ent5", "text": "2 - 45 days after", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15571949_1_Ent3", "text": "severe hepatic veno - occlusive disease ( HVOD )", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "15571949_1_Ent4", "text": "intensive chemotherapy containing busulfan", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "15571949_1_Ent6", "text": "busulfan", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15580406_3", "wnd_id": "15580406_3_1", "text": "Vogt - Koyanagi - Harada disease occurring during interferon alpha therapy for chronic hepatitis C.", "tokens": ["Vogt", "-", "Koyanagi", "-", "Harada", "disease", "occurring", "during", "interferon", "alpha", "therapy", "for", "chronic", "hepatitis", "C."], "event_mentions": [{"id": "15580406_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 6, "end": 7}, "arguments": [{"entity_id": "15580406_3_Ent0", "role": "Effect", "text": "Vogt - Koyanagi - Harada disease", "start": 0, "end": 6}, {"entity_id": "15580406_3_Ent1", "role": "Treatment", "text": "interferon alpha", "start": 8, "end": 10}, {"entity_id": "15580406_3_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 8, "end": 10}, {"entity_id": "15580406_3_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C.", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "15580406_3_Ent0", "text": "Vogt - Koyanagi - Harada disease", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15580406_3_Ent1", "text": "interferon alpha", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15580406_3_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "15580406_3_Ent3", "text": "chronic hepatitis C.", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "15588385_3", "wnd_id": "15588385_3_1", "text": "Successful treatment of hyperthyroidism with amiodarone in a patient with propylthiouracil - induced acute hepatic failure .", "tokens": ["Successful", "treatment", "of", "hyperthyroidism", "with", "amiodarone", "in", "a", "patient", "with", "propylthiouracil", "-", "induced", "acute", "hepatic", "failure", "."], "event_mentions": [{"id": "15588385_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 1, "end": 2}, "arguments": [{"entity_id": "15588385_3_Ent3", "role": "Treatment_Disorder", "text": "hyperthyroidism", "start": 3, "end": 4}, {"entity_id": "15588385_3_Ent2", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "15588385_3_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "15588385_3_Ent0", "role": "Subject", "text": "a patient with propylthiouracil - induced acute hepatic failure", "start": 7, "end": 16}, {"entity_id": "15588385_3_Ent1", "role": "Subject_Disorder", "text": "propylthiouracil - induced acute hepatic failure", "start": 10, "end": 16}]}, {"id": "15588385_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "15588385_3_Ent6", "role": "Treatment", "text": "propylthiouracil", "start": 10, "end": 11}, {"entity_id": "15588385_3_Ent7", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 10, "end": 11}, {"entity_id": "15588385_3_Ent5", "role": "Effect", "text": "acute hepatic failure", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "15588385_3_Ent3", "text": "hyperthyroidism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15588385_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15588385_3_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15588385_3_Ent0", "text": "a patient with propylthiouracil - induced acute hepatic failure", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "15588385_3_Ent6", "text": "propylthiouracil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15588385_3_Ent7", "text": "propylthiouracil", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15588385_3_Ent1", "text": "propylthiouracil - induced acute hepatic failure", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "15588385_3_Ent5", "text": "acute hepatic failure", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "15595320_1", "wnd_id": "15595320_1_1", "text": "Epstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and rofecoxib : idiosyncratic reaction or pharmacogenetics ?", "tokens": ["Epstein", "-", "Barr", "virus", "-", "associated", "lymphoproliferative", "disorder", "in", "a", "patient", "with", "rheumatoid", "arthritis", "on", "methotrexate", "and", "rofecoxib", ":", "idiosyncratic", "reaction", "or", "pharmacogenetics", "?"], "event_mentions": [{"id": "15595320_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "15595320_1_Ent1", "role": "Effect", "text": "Epstein - Barr virus - associated lymphoproliferative disorder", "start": 0, "end": 8}, {"entity_id": "15595320_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 9, "end": 14}, {"entity_id": "15595320_1_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "15595320_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "15595320_1_Ent2", "role": "Treatment", "text": "methotrexate and rofecoxib", "start": 15, "end": 18}, {"entity_id": "15595320_1_Ent5", "role": "Treatment_Drug", "text": "rofecoxib", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15595320_1_Ent1", "text": "Epstein - Barr virus - associated lymphoproliferative disorder", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15595320_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "15595320_1_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "15595320_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "15595320_1_Ent2", "text": "methotrexate and rofecoxib", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "15595320_1_Ent5", "text": "rofecoxib", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "15611427_2", "wnd_id": "15611427_2_1", "text": "Psoriasis triggered by toll - like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors .", "tokens": ["Psoriasis", "triggered", "by", "toll", "-", "like", "receptor", "7", "agonist", "imiquimod", "in", "the", "presence", "of", "dermal", "plasmacytoid", "dendritic", "cell", "precursors", "."], "event_mentions": [{"id": "15611427_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "triggered", "start": 1, "end": 2}, "arguments": [{"entity_id": "15611427_2_Ent0", "role": "Effect", "text": "Psoriasis", "start": 0, "end": 1}, {"entity_id": "15611427_2_Ent1", "role": "Treatment", "text": "imiquimod", "start": 9, "end": 10}, {"entity_id": "15611427_2_Ent3", "role": "Treatment_Drug", "text": "imiquimod", "start": 9, "end": 10}, {"entity_id": "15611427_2_Ent2", "role": "Treatment_Disorder", "text": "dermal plasmacytoid dendritic cell precursors", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "15611427_2_Ent0", "text": "Psoriasis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15611427_2_Ent1", "text": "imiquimod", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15611427_2_Ent3", "text": "imiquimod", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15611427_2_Ent2", "text": "dermal plasmacytoid dendritic cell precursors", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "15623719_1", "wnd_id": "15623719_1_1", "text": "Vision declined after treatment with methylprednisolone , after which fundus examination became consistent with progressive outer retinal necrosis .", "tokens": ["Vision", "declined", "after", "treatment", "with", "methylprednisolone", ",", "after", "which", "fundus", "examination", "became", "consistent", "with", "progressive", "outer", "retinal", "necrosis", "."], "event_mentions": [{"id": "15623719_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "15623719_1_Ent0", "role": "Effect", "text": "Vision declined", "start": 0, "end": 2}, {"entity_id": "15623719_1_Ent1", "role": "Treatment", "text": "methylprednisolone", "start": 5, "end": 6}, {"entity_id": "15623719_1_Ent2", "role": "Treatment_Drug", "text": "methylprednisolone", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15623719_1_Ent0", "text": "Vision declined", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15623719_1_Ent1", "text": "methylprednisolone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15623719_1_Ent2", "text": "methylprednisolone", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15628319_4", "wnd_id": "15628319_4_1", "text": "We report AZA - induced drug eruption that developed in two cases of systemic scleroderma with polymyositis .", "tokens": ["We", "report", "AZA", "-", "induced", "drug", "eruption", "that", "developed", "in", "two", "cases", "of", "systemic", "scleroderma", "with", "polymyositis", "."], "event_mentions": [{"id": "15628319_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "15628319_4_Ent3", "role": "Treatment", "text": "AZA", "start": 2, "end": 3}, {"entity_id": "15628319_4_Ent4", "role": "Treatment_Drug", "text": "AZA", "start": 2, "end": 3}, {"entity_id": "15628319_4_Ent2", "role": "Effect", "text": "drug eruption", "start": 5, "end": 7}, {"entity_id": "15628319_4_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "15628319_4_Ent0", "role": "Subject", "text": "two cases of systemic scleroderma with polymyositis", "start": 10, "end": 17}, {"entity_id": "15628319_4_Ent5", "role": "Treatment_Disorder", "text": "systemic scleroderma with polymyositis", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "15628319_4_Ent3", "text": "AZA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15628319_4_Ent4", "text": "AZA", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "15628319_4_Ent2", "text": "drug eruption", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "15628319_4_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "15628319_4_Ent0", "text": "two cases of systemic scleroderma with polymyositis", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "15628319_4_Ent5", "text": "systemic scleroderma with polymyositis", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "15671134_3", "wnd_id": "15671134_3_1", "text": "These findings suggest that clozapine - induced seizures can be successfully treated , that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer / anti - epileptic medication can improve the outcome of treatment - resistant schizophrenia .", "tokens": ["These", "findings", "suggest", "that", "clozapine", "-", "induced", "seizures", "can", "be", "successfully", "treated", ",", "that", "gradual", "dose", "titration", "can", "reduce", "the", "likelihood", "of", "further", "episodes", "of", "seizures", "and", "that", "concomitant", "use", "of", "a", "suitable", "mood", "stabilizer", "/", "anti", "-", "epileptic", "medication", "can", "improve", "the", "outcome", "of", "treatment", "-", "resistant", "schizophrenia", "."], "event_mentions": [{"id": "15671134_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "15671134_3_Ent1", "role": "Treatment", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "15671134_3_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 4, "end": 5}, {"entity_id": "15671134_3_Ent0", "role": "Effect", "text": "seizures", "start": 7, "end": 8}]}, {"id": "15671134_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15671134_3_Ent7", "role": "Treatment_Disorder", "text": "clozapine - induced seizures", "start": 4, "end": 8}, {"entity_id": "15671134_3_Ent5", "role": "Treatment", "text": "gradual dose titration", "start": 14, "end": 17}, {"entity_id": "15671134_3_Ent3", "role": "Effect", "text": "the likelihood of further episodes of seizures", "start": 19, "end": 26}, {"entity_id": "15671134_3_Ent6", "role": "Treatment", "text": "concomitant use of a suitable mood stabilizer / anti - epileptic medication", "start": 28, "end": 40}, {"entity_id": "15671134_3_Ent4", "role": "Effect", "text": "improve the outcome of treatment - resistant schizophrenia", "start": 41, "end": 49}]}], "entity_mentions": [{"id": "15671134_3_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15671134_3_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15671134_3_Ent7", "text": "clozapine - induced seizures", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "15671134_3_Ent0", "text": "seizures", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15671134_3_Ent5", "text": "gradual dose titration", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "15671134_3_Ent3", "text": "the likelihood of further episodes of seizures", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "15671134_3_Ent6", "text": "concomitant use of a suitable mood stabilizer / anti - epileptic medication", "entity_type": "Entity", "start": 28, "end": 40}, {"id": "15671134_3_Ent4", "text": "improve the outcome of treatment - resistant schizophrenia", "entity_type": "Entity", "start": 41, "end": 49}], "lang": "en"}
{"doc_id": "15685264_1", "wnd_id": "15685264_1_1", "text": "Carbamazepine toxicity following Oxybutynin and Dantrolene administration : a case report .", "tokens": ["Carbamazepine", "toxicity", "following", "Oxybutynin", "and", "Dantrolene", "administration", ":", "a", "case", "report", "."], "event_mentions": [{"id": "15685264_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "15685264_1_Ent0", "role": "Effect", "text": "Carbamazepine toxicity", "start": 0, "end": 2}, {"entity_id": "15685264_1_Ent2", "role": "Treatment_Drug", "text": "Oxybutynin", "start": 3, "end": 4}, {"entity_id": "15685264_1_Ent5", "role": "Combination_Drug", "text": "Oxybutynin", "start": 3, "end": 4}, {"entity_id": "15685264_1_Ent1", "role": "Treatment", "text": "Oxybutynin and Dantrolene", "start": 3, "end": 6}, {"entity_id": "15685264_1_Ent3", "role": "Treatment_Drug", "text": "Dantrolene", "start": 5, "end": 6}, {"entity_id": "15685264_1_Ent4", "role": "Combination_Drug", "text": "Dantrolene", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "15685264_1_Ent0", "text": "Carbamazepine toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15685264_1_Ent2", "text": "Oxybutynin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15685264_1_Ent5", "text": "Oxybutynin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15685264_1_Ent1", "text": "Oxybutynin and Dantrolene", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "15685264_1_Ent3", "text": "Dantrolene", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "15685264_1_Ent4", "text": "Dantrolene", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "15685264_7", "wnd_id": "15685264_7_1", "text": "After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene , she presented the clinical symptoms and laboratory finding of Carbamazepine intoxication .", "tokens": ["After", "administration", "of", "Oxybutynin", "concomitantly", "with", "an", "increase", "in", "the", "dose", "of", "Dantrolene", ",", "she", "presented", "the", "clinical", "symptoms", "and", "laboratory", "finding", "of", "Carbamazepine", "intoxication", "."], "event_mentions": [{"id": "15685264_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "15685264_7_Ent6", "role": "Treatment_Drug", "text": "Oxybutynin", "start": 3, "end": 4}, {"entity_id": "15685264_7_Ent8", "role": "Combination_Drug", "text": "Oxybutynin", "start": 3, "end": 4}, {"entity_id": "15685264_7_Ent3", "role": "Treatment", "text": "Oxybutynin concomitantly with an increase in the dose of Dantrolene", "start": 3, "end": 13}, {"entity_id": "15685264_7_Ent7", "role": "Treatment_Drug", "text": "Dantrolene", "start": 12, "end": 13}, {"entity_id": "15685264_7_Ent9", "role": "Combination_Drug", "text": "Dantrolene", "start": 12, "end": 13}, {"entity_id": "15685264_7_Ent0", "role": "Subject", "text": "she", "start": 14, "end": 15}, {"entity_id": "15685264_7_Ent1", "role": "Subject_Gender", "text": "she", "start": 14, "end": 15}, {"entity_id": "15685264_7_Ent2", "role": "Effect", "text": "clinical symptoms and laboratory finding of Carbamazepine intoxication", "start": 17, "end": 25}, {"entity_id": "15685264_7_Ent4", "role": "Treatment", "text": "Carbamazepine", "start": 23, "end": 24}, {"entity_id": "15685264_7_Ent5", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "15685264_7_Ent6", "text": "Oxybutynin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15685264_7_Ent8", "text": "Oxybutynin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15685264_7_Ent3", "text": "Oxybutynin concomitantly with an increase in the dose of Dantrolene", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "15685264_7_Ent7", "text": "Dantrolene", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15685264_7_Ent9", "text": "Dantrolene", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15685264_7_Ent0", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15685264_7_Ent1", "text": "she", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15685264_7_Ent2", "text": "clinical symptoms and laboratory finding of Carbamazepine intoxication", "entity_type": "Entity", "start": 17, "end": 25}, {"id": "15685264_7_Ent4", "text": "Carbamazepine", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15685264_7_Ent5", "text": "Carbamazepine", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "15694139_2", "wnd_id": "15694139_2_1", "text": "Thalidomide was withdrawn from world markets in 1961 following recognition of its teratogenic effects .", "tokens": ["Thalidomide", "was", "withdrawn", "from", "world", "markets", "in", "1961", "following", "recognition", "of", "its", "teratogenic", "effects", "."], "event_mentions": [{"id": "15694139_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "15694139_2_Ent1", "role": "Treatment", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent2", "role": "Treatment_Drug", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_2_Ent0", "role": "Effect", "text": "teratogenic effects", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "15694139_2_Ent1", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent2", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_2_Ent0", "text": "teratogenic effects", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "15694139_6", "wnd_id": "15694139_6_1", "text": "Thalidomide neuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment , in the phenomenon of ' coasting ' .", "tokens": ["Thalidomide", "neuropathy", "is", "often", "associated", "with", "proximal", "weakness", "and", "may", "progress", "even", "after", "discontinuation", "of", "treatment", ",", "in", "the", "phenomenon", "of", "'", "coasting", "'", "."], "event_mentions": [{"id": "15694139_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "15694139_6_Ent2", "role": "Treatment", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_6_Ent3", "role": "Treatment_Drug", "text": "Thalidomide", "start": 0, "end": 1}, {"entity_id": "15694139_6_Ent0", "role": "Effect", "text": "neuropathy", "start": 1, "end": 2}, {"entity_id": "15694139_6_Ent1", "role": "Effect", "text": "proximal weakness", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15694139_6_Ent2", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_6_Ent3", "text": "Thalidomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_6_Ent0", "text": "neuropathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "15694139_6_Ent1", "text": "proximal weakness", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "15694139_7", "wnd_id": "15694139_7_1", "text": "Children treated with thalidomide should undergo regular neurophysiologic studies in order to detect presymptomatic or progressive peripheral neuropathy .", "tokens": ["Children", "treated", "with", "thalidomide", "should", "undergo", "regular", "neurophysiologic", "studies", "in", "order", "to", "detect", "presymptomatic", "or", "progressive", "peripheral", "neuropathy", "."], "event_mentions": [{"id": "15694139_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "detect", "start": 12, "end": 13}, "arguments": [{"entity_id": "15694139_7_Ent0", "role": "Subject", "text": "Children", "start": 0, "end": 1}, {"entity_id": "15694139_7_Ent1", "role": "Subject_Age", "text": "Children", "start": 0, "end": 1}, {"entity_id": "15694139_7_Ent3", "role": "Treatment", "text": "thalidomide", "start": 3, "end": 4}, {"entity_id": "15694139_7_Ent4", "role": "Treatment_Drug", "text": "thalidomide", "start": 3, "end": 4}, {"entity_id": "15694139_7_Ent2", "role": "Effect", "text": "presymptomatic or progressive peripheral neuropathy", "start": 13, "end": 18}]}], "entity_mentions": [{"id": "15694139_7_Ent0", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_7_Ent1", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "15694139_7_Ent3", "text": "thalidomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15694139_7_Ent4", "text": "thalidomide", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15694139_7_Ent2", "text": "presymptomatic or progressive peripheral neuropathy", "entity_type": "Entity", "start": 13, "end": 18}], "lang": "en"}
{"doc_id": "15719254_2", "wnd_id": "15719254_2_1", "text": "It is likely that RA contributed to the deterioration in renal function in these patients .", "tokens": ["It", "is", "likely", "that", "RA", "contributed", "to", "the", "deterioration", "in", "renal", "function", "in", "these", "patients", "."], "event_mentions": [{"id": "15719254_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 5, "end": 6}, "arguments": [{"entity_id": "15719254_2_Ent1", "role": "Treatment", "text": "RA", "start": 4, "end": 5}, {"entity_id": "15719254_2_Ent2", "role": "Treatment_Drug", "text": "RA", "start": 4, "end": 5}, {"entity_id": "15719254_2_Ent0", "role": "Effect", "text": "deterioration in renal function", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "15719254_2_Ent1", "text": "RA", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15719254_2_Ent2", "text": "RA", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "15719254_2_Ent0", "text": "deterioration in renal function", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "15752306_6", "wnd_id": "15752306_6_1", "text": "These cases highlight the occurrence of livedo reticularis as an uncommon side - effect of interferon alpha treatment .", "tokens": ["These", "cases", "highlight", "the", "occurrence", "of", "livedo", "reticularis", "as", "an", "uncommon", "side", "-", "effect", "of", "interferon", "alpha", "treatment", "."], "event_mentions": [{"id": "15752306_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side - effect", "start": 11, "end": 14}, "arguments": [{"entity_id": "15752306_6_Ent0", "role": "Subject", "text": "These cases", "start": 0, "end": 2}, {"entity_id": "15752306_6_Ent1", "role": "Effect", "text": "livedo reticularis", "start": 6, "end": 8}, {"entity_id": "15752306_6_Ent2", "role": "Treatment", "text": "interferon alpha", "start": 15, "end": 17}, {"entity_id": "15752306_6_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "15752306_6_Ent0", "text": "These cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15752306_6_Ent1", "text": "livedo reticularis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15752306_6_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "15752306_6_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "15770343_2", "wnd_id": "15770343_2_1", "text": "During the anti - tuberculous therapy , visual loss can be related to ethambutol toxicity or the tuberculosis infection itself .", "tokens": ["During", "the", "anti", "-", "tuberculous", "therapy", ",", "visual", "loss", "can", "be", "related", "to", "ethambutol", "toxicity", "or", "the", "tuberculosis", "infection", "itself", "."], "event_mentions": [{"id": "15770343_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "15770343_2_Ent0", "role": "Effect", "text": "visual loss", "start": 7, "end": 9}, {"entity_id": "15770343_2_Ent1", "role": "Treatment", "text": "ethambutol", "start": 13, "end": 14}, {"entity_id": "15770343_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 13, "end": 14}, {"entity_id": "15770343_2_Ent3", "role": "Treatment_Disorder", "text": "tuberculosis infection", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "15770343_2_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "15770343_2_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15770343_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15770343_2_Ent3", "text": "tuberculosis infection", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "15770343_3", "wnd_id": "15770343_3_1", "text": "In addition , ethambutol rarely causes visual loss during the early period or when given at lower doses .", "tokens": ["In", "addition", ",", "ethambutol", "rarely", "causes", "visual", "loss", "during", "the", "early", "period", "or", "when", "given", "at", "lower", "doses", "."], "event_mentions": [{"id": "15770343_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 5, "end": 6}, "arguments": [{"entity_id": "15770343_3_Ent1", "role": "Treatment", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "15770343_3_Ent3", "role": "Treatment_Drug", "text": "ethambutol", "start": 3, "end": 4}, {"entity_id": "15770343_3_Ent0", "role": "Effect", "text": "visual loss", "start": 6, "end": 8}, {"entity_id": "15770343_3_Ent2", "role": "Treatment", "text": "during the early period or when given at lower doses", "start": 8, "end": 18}, {"entity_id": "15770343_3_Ent4", "role": "Treatment_Time_elapsed", "text": "early period", "start": 10, "end": 12}, {"entity_id": "15770343_3_Ent5", "role": "Treatment_Dosage", "text": "lower doses", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "15770343_3_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15770343_3_Ent3", "text": "ethambutol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15770343_3_Ent0", "text": "visual loss", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15770343_3_Ent2", "text": "during the early period or when given at lower doses", "entity_type": "Entity", "start": 8, "end": 18}, {"id": "15770343_3_Ent4", "text": "early period", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "15770343_3_Ent5", "text": "lower doses", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "15773973_3", "wnd_id": "15773973_3_1", "text": "We report the case of a 40 - year - old woman who developed fulminant hepatic failure and aplastic anaemia following a course of oral flucloxacillin .", "tokens": ["We", "report", "the", "case", "of", "a", "40", "-", "year", "-", "old", "woman", "who", "developed", "fulminant", "hepatic", "failure", "and", "aplastic", "anaemia", "following", "a", "course", "of", "oral", "flucloxacillin", "."], "event_mentions": [{"id": "15773973_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "15773973_3_Ent0", "role": "Subject", "text": "a 40 - year - old woman", "start": 5, "end": 12}, {"entity_id": "15773973_3_Ent1", "role": "Subject_Age", "text": "40 - year - old", "start": 6, "end": 11}, {"entity_id": "15773973_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "15773973_3_Ent3", "role": "Effect", "text": "fulminant hepatic failure and aplastic anaemia", "start": 14, "end": 20}, {"entity_id": "15773973_3_Ent7", "role": "Treatment_Duration", "text": "a course", "start": 21, "end": 23}, {"entity_id": "15773973_3_Ent4", "role": "Treatment", "text": "a course of oral flucloxacillin", "start": 21, "end": 26}, {"entity_id": "15773973_3_Ent5", "role": "Treatment_Route", "text": "oral", "start": 24, "end": 25}, {"entity_id": "15773973_3_Ent6", "role": "Treatment_Drug", "text": "flucloxacillin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15773973_3_Ent0", "text": "a 40 - year - old woman", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "15773973_3_Ent1", "text": "40 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "15773973_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "15773973_3_Ent3", "text": "fulminant hepatic failure and aplastic anaemia", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "15773973_3_Ent7", "text": "a course", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "15773973_3_Ent4", "text": "a course of oral flucloxacillin", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "15773973_3_Ent5", "text": "oral", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "15773973_3_Ent6", "text": "flucloxacillin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15779196_1", "wnd_id": "15779196_1_1", "text": "Four days after intravenous Zoledronic acid , the patient presented to emergency room with complaints of carpopedal spasm and bronchospasm .", "tokens": ["Four", "days", "after", "intravenous", "Zoledronic", "acid", ",", "the", "patient", "presented", "to", "emergency", "room", "with", "complaints", "of", "carpopedal", "spasm", "and", "bronchospasm", "."], "event_mentions": [{"id": "15779196_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complaints", "start": 14, "end": 15}, "arguments": [{"entity_id": "15779196_1_Ent3", "role": "Treatment_Time_elapsed", "text": "Four days after", "start": 0, "end": 3}, {"entity_id": "15779196_1_Ent2", "role": "Treatment", "text": "Four days after intravenous Zoledronic acid", "start": 0, "end": 6}, {"entity_id": "15779196_1_Ent4", "role": "Treatment_Route", "text": "intravenous", "start": 3, "end": 4}, {"entity_id": "15779196_1_Ent5", "role": "Treatment_Drug", "text": "Zoledronic acid", "start": 4, "end": 6}, {"entity_id": "15779196_1_Ent0", "role": "Subject", "text": "patient", "start": 8, "end": 9}, {"entity_id": "15779196_1_Ent1", "role": "Effect", "text": "carpopedal spasm and bronchospasm", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "15779196_1_Ent3", "text": "Four days after", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15779196_1_Ent2", "text": "Four days after intravenous Zoledronic acid", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "15779196_1_Ent4", "text": "intravenous", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "15779196_1_Ent5", "text": "Zoledronic acid", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "15779196_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15779196_1_Ent1", "text": "carpopedal spasm and bronchospasm", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "15811174_2", "wnd_id": "15811174_2_1", "text": "Clearance rates of cerivastatin metabolites in a patient with cerivastatin - induced rhabdomyolysis .", "tokens": ["Clearance", "rates", "of", "cerivastatin", "metabolites", "in", "a", "patient", "with", "cerivastatin", "-", "induced", "rhabdomyolysis", "."], "event_mentions": [{"id": "15811174_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "15811174_2_Ent1", "role": "Treatment", "text": "cerivastatin", "start": 9, "end": 10}, {"entity_id": "15811174_2_Ent2", "role": "Treatment_Drug", "text": "cerivastatin", "start": 9, "end": 10}, {"entity_id": "15811174_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "15811174_2_Ent1", "text": "cerivastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15811174_2_Ent2", "text": "cerivastatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15811174_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "15823103_1", "wnd_id": "15823103_1_1", "text": "Carboplatin hypersensitivity induced by low - dose paclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer .", "tokens": ["Carboplatin", "hypersensitivity", "induced", "by", "low", "-", "dose", "paclitaxel", "/", "carboplatin", "in", "multiple", "platinum", "-", "treated", "patients", "with", "recurrent", "ovarian", "cancer", "."], "event_mentions": [{"id": "15823103_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "15823103_1_Ent1", "role": "Effect", "text": "Carboplatin hypersensitivity", "start": 0, "end": 2}, {"entity_id": "15823103_1_Ent6", "role": "Treatment_Dosage", "text": "low - dose", "start": 4, "end": 7}, {"entity_id": "15823103_1_Ent2", "role": "Treatment", "text": "low - dose paclitaxel / carboplatin", "start": 4, "end": 10}, {"entity_id": "15823103_1_Ent3", "role": "Treatment_Drug", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "15823103_1_Ent8", "role": "Combination_Drug", "text": "paclitaxel", "start": 7, "end": 8}, {"entity_id": "15823103_1_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 9, "end": 10}, {"entity_id": "15823103_1_Ent9", "role": "Combination_Drug", "text": "carboplatin", "start": 9, "end": 10}, {"entity_id": "15823103_1_Ent0", "role": "Subject", "text": "multiple platinum - treated patients with recurrent ovarian cancer", "start": 11, "end": 20}, {"entity_id": "15823103_1_Ent5", "role": "Treatment_Drug", "text": "platinum", "start": 12, "end": 13}, {"entity_id": "15823103_1_Ent7", "role": "Treatment_Disorder", "text": "recurrent ovarian cancer", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "15823103_1_Ent1", "text": "Carboplatin hypersensitivity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15823103_1_Ent6", "text": "low - dose", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "15823103_1_Ent2", "text": "low - dose paclitaxel / carboplatin", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "15823103_1_Ent3", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15823103_1_Ent8", "text": "paclitaxel", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15823103_1_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15823103_1_Ent9", "text": "carboplatin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "15823103_1_Ent0", "text": "multiple platinum - treated patients with recurrent ovarian cancer", "entity_type": "Entity", "start": 11, "end": 20}, {"id": "15823103_1_Ent5", "text": "platinum", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "15823103_1_Ent7", "text": "recurrent ovarian cancer", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "15827071_4", "wnd_id": "15827071_4_1", "text": "A 38 - year - old white female with cystic fibrosis treated with venlafaxine 300 mg / day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection .", "tokens": ["A", "38", "-", "year", "-", "old", "white", "female", "with", "cystic", "fibrosis", "treated", "with", "venlafaxine", "300", "mg", "/", "day", "for", "one", "year", "was", "prescribed", "linezolid", "600", "mg", "intravenously", "every", "12", "hours", "for", "treatment", "of", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "(", "MRSA", ")", "pulmonary", "infection", "."], "event_mentions": [{"id": "15827071_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "15827071_4_Ent0", "role": "Subject", "text": "A 38 - year - old white female", "start": 0, "end": 8}, {"entity_id": "15827071_4_Ent1", "role": "Subject_Age", "text": "38 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_4_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "15827071_4_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "15827071_4_Ent5", "role": "Treatment_Disorder", "text": "cystic fibrosis", "start": 9, "end": 11}, {"entity_id": "15827071_4_Ent7", "role": "Treatment_Drug", "text": "venlafaxine", "start": 13, "end": 14}, {"entity_id": "15827071_4_Ent4", "role": "Treatment", "text": "venlafaxine 300 mg / day for one year", "start": 13, "end": 21}, {"entity_id": "15827071_4_Ent6", "role": "Treatment_Dosage", "text": "300 mg / day", "start": 14, "end": 18}, {"entity_id": "15827071_4_Ent8", "role": "Treatment_Duration", "text": "one year", "start": 19, "end": 21}]}, {"id": "15827071_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 31, "end": 32}, "arguments": [{"entity_id": "15827071_4_Ent9", "role": "Subject", "text": "A 38 - year - old white female", "start": 0, "end": 8}, {"entity_id": "15827071_4_Ent10", "role": "Subject_Age", "text": "38 - year - old", "start": 1, "end": 6}, {"entity_id": "15827071_4_Ent11", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "15827071_4_Ent12", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "15827071_4_Ent15", "role": "Treatment_Drug", "text": "linezolid", "start": 23, "end": 24}, {"entity_id": "15827071_4_Ent13", "role": "Treatment", "text": "linezolid 600 mg intravenously every 12 hours", "start": 23, "end": 30}, {"entity_id": "15827071_4_Ent16", "role": "Treatment_Dosage", "text": "600 mg", "start": 24, "end": 26}, {"entity_id": "15827071_4_Ent18", "role": "Treatment_Route", "text": "intravenously", "start": 26, "end": 27}, {"entity_id": "15827071_4_Ent17", "role": "Treatment_Freq", "text": "every 12 hours", "start": 27, "end": 30}, {"entity_id": "15827071_4_Ent14", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection", "start": 33, "end": 43}]}], "entity_mentions": [{"id": "15827071_4_Ent0", "text": "A 38 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15827071_4_Ent9", "text": "A 38 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "15827071_4_Ent1", "text": "38 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_4_Ent10", "text": "38 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "15827071_4_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_4_Ent11", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "15827071_4_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15827071_4_Ent12", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "15827071_4_Ent5", "text": "cystic fibrosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "15827071_4_Ent7", "text": "venlafaxine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "15827071_4_Ent4", "text": "venlafaxine 300 mg / day for one year", "entity_type": "Entity", "start": 13, "end": 21}, {"id": "15827071_4_Ent6", "text": "300 mg / day", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "15827071_4_Ent8", "text": "one year", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "15827071_4_Ent15", "text": "linezolid", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "15827071_4_Ent13", "text": "linezolid 600 mg intravenously every 12 hours", "entity_type": "Entity", "start": 23, "end": 30}, {"id": "15827071_4_Ent16", "text": "600 mg", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "15827071_4_Ent18", "text": "intravenously", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15827071_4_Ent17", "text": "every 12 hours", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "15827071_4_Ent14", "text": "methicillin - resistant Staphylococcus aureus ( MRSA ) pulmonary infection", "entity_type": "Entity", "start": 33, "end": 43}], "lang": "en"}
{"doc_id": "15840734_11", "wnd_id": "15840734_11_1", "text": "CONCLUSIONS : An objective causality assessment revealed that fluphenazine was the probable cause of NMS in this patient .", "tokens": ["CONCLUSIONS", ":", "An", "objective", "causality", "assessment", "revealed", "that", "fluphenazine", "was", "the", "probable", "cause", "of", "NMS", "in", "this", "patient", "."], "event_mentions": [{"id": "15840734_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 12, "end": 13}, "arguments": [{"entity_id": "15840734_11_Ent2", "role": "Treatment", "text": "fluphenazine", "start": 8, "end": 9}, {"entity_id": "15840734_11_Ent3", "role": "Treatment_Drug", "text": "fluphenazine", "start": 8, "end": 9}, {"entity_id": "15840734_11_Ent1", "role": "Effect", "text": "NMS", "start": 14, "end": 15}, {"entity_id": "15840734_11_Ent0", "role": "Subject", "text": "patient", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "15840734_11_Ent2", "text": "fluphenazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15840734_11_Ent3", "text": "fluphenazine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "15840734_11_Ent1", "text": "NMS", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "15840734_11_Ent0", "text": "patient", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "1584367_1", "wnd_id": "1584367_1_1", "text": "Intraventricular vancomycin - induced cerebrospinal fluid eosinophilia : report of two patients .", "tokens": ["Intraventricular", "vancomycin", "-", "induced", "cerebrospinal", "fluid", "eosinophilia", ":", "report", "of", "two", "patients", "."], "event_mentions": [{"id": "1584367_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "1584367_1_Ent4", "role": "Treatment_Route", "text": "Intraventricular", "start": 0, "end": 1}, {"entity_id": "1584367_1_Ent3", "role": "Treatment", "text": "Intraventricular vancomycin", "start": 0, "end": 2}, {"entity_id": "1584367_1_Ent5", "role": "Treatment_Drug", "text": "vancomycin", "start": 1, "end": 2}, {"entity_id": "1584367_1_Ent2", "role": "Effect", "text": "cerebrospinal fluid eosinophilia", "start": 4, "end": 7}, {"entity_id": "1584367_1_Ent1", "role": "Subject_Population", "text": "two", "start": 10, "end": 11}, {"entity_id": "1584367_1_Ent0", "role": "Subject", "text": "two patients .", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "1584367_1_Ent4", "text": "Intraventricular", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1584367_1_Ent3", "text": "Intraventricular vancomycin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1584367_1_Ent5", "text": "vancomycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "1584367_1_Ent2", "text": "cerebrospinal fluid eosinophilia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "1584367_1_Ent1", "text": "two", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1584367_1_Ent0", "text": "two patients .", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "1584367_2", "wnd_id": "1584367_2_1", "text": "We propose a mechanism of vancomycin - induced mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE .", "tokens": ["We", "propose", "a", "mechanism", "of", "vancomycin", "-", "induced", "mast", "cell", "degranulation", "and", "subsequent", "release", "of", "eosinophil", "chemotactic", "factor", "as", "a", "cause", "of", "CSFE", "."], "event_mentions": [{"id": "1584367_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "1584367_2_Ent1", "role": "Treatment", "text": "vancomycin", "start": 5, "end": 6}, {"entity_id": "1584367_2_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 5, "end": 6}, {"entity_id": "1584367_2_Ent0", "role": "Effect", "text": "mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE", "start": 8, "end": 23}]}], "entity_mentions": [{"id": "1584367_2_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1584367_2_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "1584367_2_Ent0", "text": "mast cell degranulation and subsequent release of eosinophil chemotactic factor as a cause of CSFE", "entity_type": "Entity", "start": 8, "end": 23}], "lang": "en"}
{"doc_id": "15857283_1", "wnd_id": "15857283_1_1", "text": "CONCLUSIONS : In these 3 cases , the unique positive ocular finding was corneal endothelial deposits , which may be related to the use of rifabutin .", "tokens": ["CONCLUSIONS", ":", "In", "these", "3", "cases", ",", "the", "unique", "positive", "ocular", "finding", "was", "corneal", "endothelial", "deposits", ",", "which", "may", "be", "related", "to", "the", "use", "of", "rifabutin", "."], "event_mentions": [{"id": "15857283_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 20, "end": 21}, "arguments": [{"entity_id": "15857283_1_Ent0", "role": "Effect", "text": "corneal endothelial deposits", "start": 13, "end": 16}, {"entity_id": "15857283_1_Ent1", "role": "Treatment", "text": "rifabutin", "start": 25, "end": 26}, {"entity_id": "15857283_1_Ent2", "role": "Treatment_Drug", "text": "rifabutin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "15857283_1_Ent0", "text": "corneal endothelial deposits", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "15857283_1_Ent1", "text": "rifabutin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "15857283_1_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "15878975_4", "wnd_id": "15878975_4_1", "text": "The purpose of this review is to increase awareness among physicians and other health care professionals that DIC may be a rare but potentially severe complication of anti - D IGIV treatment .", "tokens": ["The", "purpose", "of", "this", "review", "is", "to", "increase", "awareness", "among", "physicians", "and", "other", "health", "care", "professionals", "that", "DIC", "may", "be", "a", "rare", "but", "potentially", "severe", "complication", "of", "anti", "-", "D", "IGIV", "treatment", "."], "event_mentions": [{"id": "15878975_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 25, "end": 26}, "arguments": [{"entity_id": "15878975_4_Ent0", "role": "Effect", "text": "DIC", "start": 17, "end": 18}, {"entity_id": "15878975_4_Ent1", "role": "Treatment", "text": "anti - D IGIV", "start": 27, "end": 31}, {"entity_id": "15878975_4_Ent2", "role": "Treatment_Drug", "text": "anti - D IGIV", "start": 27, "end": 31}]}], "entity_mentions": [{"id": "15878975_4_Ent0", "text": "DIC", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "15878975_4_Ent1", "text": "anti - D IGIV", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "15878975_4_Ent2", "text": "anti - D IGIV", "entity_type": "Entity", "start": 27, "end": 31}], "lang": "en"}
{"doc_id": "15944830_5", "wnd_id": "15944830_5_1", "text": "The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy , and the latter patient complained twice during IFN therapy that his visual acuity had decreased .", "tokens": ["The", "former", "patient", "had", "complained", "once", "that", "his", "visual", "acuity", "had", "decreased", "after", "the", "termination", "of", "IFN", "therapy", ",", "and", "the", "latter", "patient", "complained", "twice", "during", "IFN", "therapy", "that", "his", "visual", "acuity", "had", "decreased", "."], "event_mentions": [{"id": "15944830_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "15944830_5_Ent0", "role": "Subject", "text": "The former patient", "start": 0, "end": 3}, {"entity_id": "15944830_5_Ent1", "role": "Effect", "text": "visual acuity had decreased", "start": 8, "end": 12}, {"entity_id": "15944830_5_Ent2", "role": "Treatment", "text": "IFN", "start": 16, "end": 17}, {"entity_id": "15944830_5_Ent3", "role": "Treatment_Drug", "text": "IFN", "start": 16, "end": 17}]}, {"id": "15944830_5_Evt1", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 25, "end": 26}, "arguments": [{"entity_id": "15944830_5_Ent4", "role": "Subject", "text": "patient", "start": 22, "end": 23}, {"entity_id": "15944830_5_Ent7", "role": "Treatment_Drug", "text": "IFN", "start": 26, "end": 27}, {"entity_id": "15944830_5_Ent6", "role": "Treatment", "text": "IFN therapy", "start": 26, "end": 28}, {"entity_id": "15944830_5_Ent5", "role": "Effect", "text": "visual acuity had decreased", "start": 30, "end": 34}]}], "entity_mentions": [{"id": "15944830_5_Ent0", "text": "The former patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "15944830_5_Ent1", "text": "visual acuity had decreased", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "15944830_5_Ent2", "text": "IFN", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15944830_5_Ent3", "text": "IFN", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "15944830_5_Ent4", "text": "patient", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "15944830_5_Ent7", "text": "IFN", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "15944830_5_Ent6", "text": "IFN therapy", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "15944830_5_Ent5", "text": "visual acuity had decreased", "entity_type": "Entity", "start": 30, "end": 34}], "lang": "en"}
{"doc_id": "15965422_2", "wnd_id": "15965422_2_1", "text": "Cutaneous necrosis as a result of interferon alfa is an infrequent complication with unknown pathogenesis , in which a cutaneous local immune - mediated inflammatory process might be involved .", "tokens": ["Cutaneous", "necrosis", "as", "a", "result", "of", "interferon", "alfa", "is", "an", "infrequent", "complication", "with", "unknown", "pathogenesis", ",", "in", "which", "a", "cutaneous", "local", "immune", "-", "mediated", "inflammatory", "process", "might", "be", "involved", "."], "event_mentions": [{"id": "15965422_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 4, "end": 5}, "arguments": [{"entity_id": "15965422_2_Ent0", "role": "Effect", "text": "Cutaneous necrosis", "start": 0, "end": 2}, {"entity_id": "15965422_2_Ent1", "role": "Treatment", "text": "interferon alfa", "start": 6, "end": 8}, {"entity_id": "15965422_2_Ent2", "role": "Treatment_Drug", "text": "interferon alfa", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "15965422_2_Ent0", "text": "Cutaneous necrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "15965422_2_Ent1", "text": "interferon alfa", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "15965422_2_Ent2", "text": "interferon alfa", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16005413_5", "wnd_id": "16005413_5_1", "text": "Four elderly LTCF residents treated with serotonergic antidepressants including selective serotonin reuptake inhibitor ( SSRI ) or mirtazapine and opioids .", "tokens": ["Four", "elderly", "LTCF", "residents", "treated", "with", "serotonergic", "antidepressants", "including", "selective", "serotonin", "reuptake", "inhibitor", "(", "SSRI", ")", "or", "mirtazapine", "and", "opioids", "."], "event_mentions": [{"id": "16005413_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 4, "end": 5}, "arguments": [{"entity_id": "16005413_5_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "16005413_5_Ent0", "role": "Subject", "text": "Four elderly LTCF residents", "start": 0, "end": 4}, {"entity_id": "16005413_5_Ent2", "role": "Subject_Age", "text": "elderly", "start": 1, "end": 2}, {"entity_id": "16005413_5_Ent4", "role": "Treatment_Disorder", "text": "LTCF", "start": 2, "end": 3}, {"entity_id": "16005413_5_Ent3", "role": "Treatment", "text": "serotonergic antidepressants including selective serotonin reuptake inhibitor ( SSRI ) or mirtazapine and opioids", "start": 6, "end": 20}, {"entity_id": "16005413_5_Ent5", "role": "Treatment_Drug", "text": "selective serotonin reuptake inhibitor", "start": 9, "end": 13}, {"entity_id": "16005413_5_Ent6", "role": "Treatment_Drug", "text": "mirtazapine", "start": 17, "end": 18}, {"entity_id": "16005413_5_Ent9", "role": "Combination_Drug", "text": "mirtazapine", "start": 17, "end": 18}, {"entity_id": "16005413_5_Ent7", "role": "Treatment_Drug", "text": "opioids", "start": 19, "end": 20}, {"entity_id": "16005413_5_Ent8", "role": "Combination_Drug", "text": "opioids", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16005413_5_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16005413_5_Ent0", "text": "Four elderly LTCF residents", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16005413_5_Ent2", "text": "elderly", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16005413_5_Ent4", "text": "LTCF", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16005413_5_Ent3", "text": "serotonergic antidepressants including selective serotonin reuptake inhibitor ( SSRI ) or mirtazapine and opioids", "entity_type": "Entity", "start": 6, "end": 20}, {"id": "16005413_5_Ent5", "text": "selective serotonin reuptake inhibitor", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16005413_5_Ent6", "text": "mirtazapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16005413_5_Ent9", "text": "mirtazapine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16005413_5_Ent7", "text": "opioids", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16005413_5_Ent8", "text": "opioids", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16029707_3", "wnd_id": "16029707_3_1", "text": "The multiple comedones and ruptured epidermoid cysts are newly reported adverse effects of imiquimod therapy .", "tokens": ["The", "multiple", "comedones", "and", "ruptured", "epidermoid", "cysts", "are", "newly", "reported", "adverse", "effects", "of", "imiquimod", "therapy", "."], "event_mentions": [{"id": "16029707_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "16029707_3_Ent0", "role": "Effect", "text": "multiple comedones and ruptured epidermoid cysts", "start": 1, "end": 7}, {"entity_id": "16029707_3_Ent2", "role": "Treatment_Drug", "text": "imiquimod", "start": 13, "end": 14}, {"entity_id": "16029707_3_Ent1", "role": "Treatment", "text": "imiquimod therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16029707_3_Ent0", "text": "multiple comedones and ruptured epidermoid cysts", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16029707_3_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16029707_3_Ent1", "text": "imiquimod therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16035204_1", "wnd_id": "16035204_1_1", "text": "We report an unusual case of massive fluoxetine ingestion resulting in neurological and cardiovascular toxicity resulting in death .", "tokens": ["We", "report", "an", "unusual", "case", "of", "massive", "fluoxetine", "ingestion", "resulting", "in", "neurological", "and", "cardiovascular", "toxicity", "resulting", "in", "death", "."], "event_mentions": [{"id": "16035204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting in", "start": 9, "end": 11}, "arguments": [{"entity_id": "16035204_1_Ent0", "role": "Subject", "text": "an unusual case", "start": 2, "end": 5}, {"entity_id": "16035204_1_Ent4", "role": "Treatment_Dosage", "text": "massive", "start": 6, "end": 7}, {"entity_id": "16035204_1_Ent2", "role": "Treatment", "text": "massive fluoxetine ingestion", "start": 6, "end": 9}, {"entity_id": "16035204_1_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 7, "end": 8}, {"entity_id": "16035204_1_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 8, "end": 9}, {"entity_id": "16035204_1_Ent1", "role": "Effect", "text": "neurological and cardiovascular toxicity resulting in death", "start": 11, "end": 18}]}], "entity_mentions": [{"id": "16035204_1_Ent0", "text": "an unusual case", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "16035204_1_Ent4", "text": "massive", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16035204_1_Ent2", "text": "massive fluoxetine ingestion", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16035204_1_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16035204_1_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16035204_1_Ent1", "text": "neurological and cardiovascular toxicity resulting in death", "entity_type": "Entity", "start": 11, "end": 18}], "lang": "en"}
{"doc_id": "16099004_1", "wnd_id": "16099004_1_1", "text": "Recrudescence of imported falciparum malaria after quinine therapy : potential drug interaction with phenytoin .", "tokens": ["Recrudescence", "of", "imported", "falciparum", "malaria", "after", "quinine", "therapy", ":", "potential", "drug", "interaction", "with", "phenytoin", "."], "event_mentions": [{"id": "16099004_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "16099004_1_Ent0", "role": "Effect", "text": "Recrudescence of imported falciparum malaria", "start": 0, "end": 5}, {"entity_id": "16099004_1_Ent1", "role": "Treatment", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "16099004_1_Ent3", "role": "Treatment_Drug", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "16099004_1_Ent6", "role": "Combination_Drug", "text": "quinine", "start": 6, "end": 7}, {"entity_id": "16099004_1_Ent2", "role": "Treatment", "text": "phenytoin", "start": 13, "end": 14}, {"entity_id": "16099004_1_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 13, "end": 14}, {"entity_id": "16099004_1_Ent5", "role": "Combination_Drug", "text": "phenytoin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16099004_1_Ent0", "text": "Recrudescence of imported falciparum malaria", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16099004_1_Ent1", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16099004_1_Ent3", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16099004_1_Ent6", "text": "quinine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16099004_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16099004_1_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16099004_1_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16132305_1", "wnd_id": "16132305_1_1", "text": "Captopril - induced pulmonary infiltrates with eosinophilia in an infant with congenital heart disease .", "tokens": ["Captopril", "-", "induced", "pulmonary", "infiltrates", "with", "eosinophilia", "in", "an", "infant", "with", "congenital", "heart", "disease", "."], "event_mentions": [{"id": "16132305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16132305_1_Ent4", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "16132305_1_Ent5", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "16132305_1_Ent3", "role": "Effect", "text": "pulmonary infiltrates with eosinophilia", "start": 3, "end": 7}, {"entity_id": "16132305_1_Ent0", "role": "Subject", "text": "an infant with congenital heart disease", "start": 8, "end": 14}, {"entity_id": "16132305_1_Ent1", "role": "Subject_Age", "text": "infant", "start": 9, "end": 10}, {"entity_id": "16132305_1_Ent2", "role": "Subject_Disorder", "text": "congenital heart disease", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "16132305_1_Ent4", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16132305_1_Ent5", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16132305_1_Ent3", "text": "pulmonary infiltrates with eosinophilia", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16132305_1_Ent0", "text": "an infant with congenital heart disease", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "16132305_1_Ent1", "text": "infant", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16132305_1_Ent2", "text": "congenital heart disease", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "16132305_2", "wnd_id": "16132305_2_1", "text": "We report a case of an infant with complex congenital heart disease who was placed on captopril for afterload reduction following cardiac surgery and subsequently developed pulmonary infiltrates with eosinophilia .", "tokens": ["We", "report", "a", "case", "of", "an", "infant", "with", "complex", "congenital", "heart", "disease", "who", "was", "placed", "on", "captopril", "for", "afterload", "reduction", "following", "cardiac", "surgery", "and", "subsequently", "developed", "pulmonary", "infiltrates", "with", "eosinophilia", "."], "event_mentions": [{"id": "16132305_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "16132305_2_Ent0", "role": "Subject", "text": "an infant with complex congenital heart disease", "start": 5, "end": 12}, {"entity_id": "16132305_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 6, "end": 7}, {"entity_id": "16132305_2_Ent5", "role": "Treatment_Disorder", "text": "congenital heart disease", "start": 9, "end": 12}, {"entity_id": "16132305_2_Ent3", "role": "Treatment", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "16132305_2_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 16, "end": 17}, {"entity_id": "16132305_2_Ent2", "role": "Effect", "text": "pulmonary infiltrates with eosinophilia", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "16132305_2_Ent0", "text": "an infant with complex congenital heart disease", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "16132305_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16132305_2_Ent5", "text": "congenital heart disease", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16132305_2_Ent3", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16132305_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16132305_2_Ent2", "text": "pulmonary infiltrates with eosinophilia", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "16132305_5", "wnd_id": "16132305_5_1", "text": "After discontinuing captopril and starting systemic steroids , her symptomatology rapidly improved , and her eosinophilia and radiographic abnormalities both resolved .", "tokens": ["After", "discontinuing", "captopril", "and", "starting", "systemic", "steroids", ",", "her", "symptomatology", "rapidly", "improved", ",", "and", "her", "eosinophilia", "and", "radiographic", "abnormalities", "both", "resolved", "."], "event_mentions": [{"id": "16132305_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 20, "end": 21}, "arguments": [{"entity_id": "16132305_5_Ent1", "role": "Treatment", "text": "discontinuing captopril and starting systemic steroids", "start": 1, "end": 7}, {"entity_id": "16132305_5_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 2, "end": 3}, {"entity_id": "16132305_5_Ent3", "role": "Treatment_Drug", "text": "steroids", "start": 6, "end": 7}, {"entity_id": "16132305_5_Ent0", "role": "Effect", "text": "her eosinophilia and radiographic abnormalities both resolved", "start": 14, "end": 21}, {"entity_id": "16132305_5_Ent4", "role": "Treatment_Disorder", "text": "eosinophilia", "start": 15, "end": 16}, {"entity_id": "16132305_5_Ent5", "role": "Treatment_Disorder", "text": "radiographic abnormalities", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "16132305_5_Ent1", "text": "discontinuing captopril and starting systemic steroids", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "16132305_5_Ent2", "text": "captopril", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16132305_5_Ent3", "text": "steroids", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16132305_5_Ent0", "text": "her eosinophilia and radiographic abnormalities both resolved", "entity_type": "Entity", "start": 14, "end": 21}, {"id": "16132305_5_Ent4", "text": "eosinophilia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16132305_5_Ent5", "text": "radiographic abnormalities", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "16146480_1", "wnd_id": "16146480_1_1", "text": "Can propofol precipitate pancreatitis in patients with Cushing 's syndrome ?", "tokens": ["Can", "propofol", "precipitate", "pancreatitis", "in", "patients", "with", "Cushing", "'s", "syndrome", "?"], "event_mentions": [{"id": "16146480_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 2, "end": 3}, "arguments": [{"entity_id": "16146480_1_Ent2", "role": "Treatment", "text": "propofol", "start": 1, "end": 2}, {"entity_id": "16146480_1_Ent3", "role": "Treatment_Drug", "text": "propofol", "start": 1, "end": 2}, {"entity_id": "16146480_1_Ent1", "role": "Effect", "text": "pancreatitis", "start": 3, "end": 4}, {"entity_id": "16146480_1_Ent0", "role": "Subject", "text": "patients with Cushing 's syndrome ?", "start": 5, "end": 11}, {"entity_id": "16146480_1_Ent4", "role": "Treatment_Disorder", "text": "Cushing 's syndrome", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "16146480_1_Ent2", "text": "propofol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16146480_1_Ent3", "text": "propofol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16146480_1_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16146480_1_Ent0", "text": "patients with Cushing 's syndrome ?", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16146480_1_Ent4", "text": "Cushing 's syndrome", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "16160485_1", "wnd_id": "16160485_1_1", "text": "CD20 - negative T - cell - rich B - cell lymphoma as a progression of a nodular lymphocyte - predominant Hodgkin 's lymphoma treated with rituximab : a molecular analysis using laser capture microdissection .", "tokens": ["CD20", "-", "negative", "T", "-", "cell", "-", "rich", "B", "-", "cell", "lymphoma", "as", "a", "progression", "of", "a", "nodular", "lymphocyte", "-", "predominant", "Hodgkin", "'s", "lymphoma", "treated", "with", "rituximab", ":", "a", "molecular", "analysis", "using", "laser", "capture", "microdissection", "."], "event_mentions": [{"id": "16160485_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 24, "end": 25}, "arguments": [{"entity_id": "16160485_1_Ent0", "role": "Effect", "text": "CD20 - negative T - cell - rich B - cell lymphoma", "start": 0, "end": 12}, {"entity_id": "16160485_1_Ent3", "role": "Treatment_Disorder", "text": "nodular lymphocyte - predominant Hodgkin 's lymphoma", "start": 17, "end": 24}, {"entity_id": "16160485_1_Ent1", "role": "Treatment", "text": "rituximab", "start": 26, "end": 27}, {"entity_id": "16160485_1_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16160485_1_Ent0", "text": "CD20 - negative T - cell - rich B - cell lymphoma", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "16160485_1_Ent3", "text": "nodular lymphocyte - predominant Hodgkin 's lymphoma", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "16160485_1_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16160485_1_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16192734_3", "wnd_id": "16192734_3_1", "text": "We report here a rare case of ritodrine - hydrochloride - induced rhabdomyolysis in a pregnant patient with myotonic dystrophy .", "tokens": ["We", "report", "here", "a", "rare", "case", "of", "ritodrine", "-", "hydrochloride", "-", "induced", "rhabdomyolysis", "in", "a", "pregnant", "patient", "with", "myotonic", "dystrophy", "."], "event_mentions": [{"id": "16192734_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 11, "end": 12}, "arguments": [{"entity_id": "16192734_3_Ent3", "role": "Treatment", "text": "ritodrine - hydrochloride", "start": 7, "end": 10}, {"entity_id": "16192734_3_Ent4", "role": "Treatment_Drug", "text": "ritodrine - hydrochloride", "start": 7, "end": 10}, {"entity_id": "16192734_3_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 12, "end": 13}, {"entity_id": "16192734_3_Ent1", "role": "Subject_Gender", "text": "pregnant", "start": 15, "end": 16}, {"entity_id": "16192734_3_Ent0", "role": "Subject", "text": "pregnant patient with myotonic dystrophy .", "start": 15, "end": 21}, {"entity_id": "16192734_3_Ent5", "role": "Treatment_Disorder", "text": "myotonic dystrophy", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16192734_3_Ent3", "text": "ritodrine - hydrochloride", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16192734_3_Ent4", "text": "ritodrine - hydrochloride", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16192734_3_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "16192734_3_Ent1", "text": "pregnant", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16192734_3_Ent0", "text": "pregnant patient with myotonic dystrophy .", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "16192734_3_Ent5", "text": "myotonic dystrophy", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16204273_2", "wnd_id": "16204273_2_1", "text": "This report describes a probable case of infliximab - induced membranous nephropathy .", "tokens": ["This", "report", "describes", "a", "probable", "case", "of", "infliximab", "-", "induced", "membranous", "nephropathy", "."], "event_mentions": [{"id": "16204273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "16204273_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16204273_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 7, "end": 8}, {"entity_id": "16204273_2_Ent0", "role": "Effect", "text": "membranous nephropathy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "16204273_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16204273_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16204273_2_Ent0", "text": "membranous nephropathy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "16225183_1", "wnd_id": "16225183_1_1", "text": "Nephrotic syndrome in a multiple sclerosis patient treated with interferon beta 1a .", "tokens": ["Nephrotic", "syndrome", "in", "a", "multiple", "sclerosis", "patient", "treated", "with", "interferon", "beta", "1a", "."], "event_mentions": [{"id": "16225183_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16225183_1_Ent1", "role": "Effect", "text": "Nephrotic syndrome", "start": 0, "end": 2}, {"entity_id": "16225183_1_Ent0", "role": "Subject", "text": "a multiple sclerosis patient", "start": 3, "end": 7}, {"entity_id": "16225183_1_Ent4", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 4, "end": 6}, {"entity_id": "16225183_1_Ent2", "role": "Treatment", "text": "interferon beta 1a", "start": 9, "end": 12}, {"entity_id": "16225183_1_Ent3", "role": "Treatment_Drug", "text": "interferon beta 1a", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "16225183_1_Ent1", "text": "Nephrotic syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16225183_1_Ent0", "text": "a multiple sclerosis patient", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16225183_1_Ent4", "text": "multiple sclerosis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16225183_1_Ent2", "text": "interferon beta 1a", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "16225183_1_Ent3", "text": "interferon beta 1a", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "16225183_6", "wnd_id": "16225183_6_1", "text": "CASE REPORT : We present a case of a 28 - yr - old male who developed a severe case of nephrotic syndrome while being treated for relapsing / remitting Multiple Sclerosis ( RRMS ) with weekly injections of interferon beta 1a .", "tokens": ["CASE", "REPORT", ":", "We", "present", "a", "case", "of", "a", "28", "-", "yr", "-", "old", "male", "who", "developed", "a", "severe", "case", "of", "nephrotic", "syndrome", "while", "being", "treated", "for", "relapsing", "/", "remitting", "Multiple", "Sclerosis", "(", "RRMS", ")", "with", "weekly", "injections", "of", "interferon", "beta", "1a", "."], "event_mentions": [{"id": "16225183_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "16225183_6_Ent2", "role": "Subject_Age", "text": "28 - yr - old", "start": 9, "end": 14}, {"entity_id": "16225183_6_Ent0", "role": "Subject", "text": "28 - yr - old male", "start": 9, "end": 15}, {"entity_id": "16225183_6_Ent3", "role": "Subject_Gender", "text": "male", "start": 14, "end": 15}, {"entity_id": "16225183_6_Ent4", "role": "Effect", "text": "nephrotic syndrome", "start": 21, "end": 23}, {"entity_id": "16225183_6_Ent9", "role": "Treatment_Disorder", "text": "relapsing / remitting Multiple Sclerosis", "start": 27, "end": 32}, {"entity_id": "16225183_6_Ent1", "role": "Subject", "text": "relapsing / remitting Multiple Sclerosis ( RRMS )", "start": 27, "end": 35}, {"entity_id": "16225183_6_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 36, "end": 37}, {"entity_id": "16225183_6_Ent5", "role": "Treatment", "text": "weekly injections of interferon beta 1a", "start": 36, "end": 42}, {"entity_id": "16225183_6_Ent7", "role": "Treatment_Route", "text": "injections", "start": 37, "end": 38}, {"entity_id": "16225183_6_Ent8", "role": "Treatment_Drug", "text": "interferon beta 1a", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "16225183_6_Ent2", "text": "28 - yr - old", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "16225183_6_Ent0", "text": "28 - yr - old male", "entity_type": "Entity", "start": 9, "end": 15}, {"id": "16225183_6_Ent3", "text": "male", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16225183_6_Ent4", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "16225183_6_Ent9", "text": "relapsing / remitting Multiple Sclerosis", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "16225183_6_Ent1", "text": "relapsing / remitting Multiple Sclerosis ( RRMS )", "entity_type": "Entity", "start": 27, "end": 35}, {"id": "16225183_6_Ent6", "text": "weekly", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "16225183_6_Ent5", "text": "weekly injections of interferon beta 1a", "entity_type": "Entity", "start": 36, "end": 42}, {"id": "16225183_6_Ent7", "text": "injections", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16225183_6_Ent8", "text": "interferon beta 1a", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "16237130_1", "wnd_id": "16237130_1_1", "text": "Capecitabine - induced multifocal leukoencephalopathy : a report of five cases .", "tokens": ["Capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", ":", "a", "report", "of", "five", "cases", "."], "event_mentions": [{"id": "16237130_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16237130_1_Ent3", "role": "Treatment", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent4", "role": "Treatment_Drug", "text": "Capecitabine", "start": 0, "end": 1}, {"entity_id": "16237130_1_Ent2", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 3, "end": 5}, {"entity_id": "16237130_1_Ent1", "role": "Subject_Population", "text": "five", "start": 9, "end": 10}, {"entity_id": "16237130_1_Ent0", "role": "Subject", "text": "five cases", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16237130_1_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent4", "text": "Capecitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16237130_1_Ent2", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16237130_1_Ent1", "text": "five", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16237130_1_Ent0", "text": "five cases", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16237130_2", "wnd_id": "16237130_2_1", "text": "The authors report five additional cases of capecitabine - induced multifocal leukoencephalopathy .", "tokens": ["The", "authors", "report", "five", "additional", "cases", "of", "capecitabine", "-", "induced", "multifocal", "leukoencephalopathy", "."], "event_mentions": [{"id": "16237130_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "16237130_2_Ent1", "role": "Treatment", "text": "capecitabine", "start": 7, "end": 8}, {"entity_id": "16237130_2_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 7, "end": 8}, {"entity_id": "16237130_2_Ent0", "role": "Effect", "text": "multifocal leukoencephalopathy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "16237130_2_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16237130_2_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16237130_2_Ent0", "text": "multifocal leukoencephalopathy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "1624172_3", "wnd_id": "1624172_3_1", "text": "Thyroid dysfunction has been reported in patients with malignant disease treated with recombinant alpha interferon .", "tokens": ["Thyroid", "dysfunction", "has", "been", "reported", "in", "patients", "with", "malignant", "disease", "treated", "with", "recombinant", "alpha", "interferon", "."], "event_mentions": [{"id": "1624172_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 4, "end": 5}, "arguments": [{"entity_id": "1624172_3_Ent1", "role": "Effect", "text": "Thyroid dysfunction", "start": 0, "end": 2}, {"entity_id": "1624172_3_Ent0", "role": "Subject", "text": "patients with malignant disease", "start": 6, "end": 10}, {"entity_id": "1624172_3_Ent3", "role": "Treatment_Disorder", "text": "malignant disease", "start": 8, "end": 10}, {"entity_id": "1624172_3_Ent2", "role": "Treatment", "text": "recombinant alpha interferon", "start": 12, "end": 15}, {"entity_id": "1624172_3_Ent4", "role": "Treatment_Drug", "text": "recombinant alpha interferon", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "1624172_3_Ent1", "text": "Thyroid dysfunction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1624172_3_Ent0", "text": "patients with malignant disease", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "1624172_3_Ent3", "text": "malignant disease", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "1624172_3_Ent2", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "1624172_3_Ent4", "text": "recombinant alpha interferon", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "16244351_2", "wnd_id": "16244351_2_1", "text": "Vardenafil is a new oral phosphodiesterase inhibitor used for erectile dysfunction .", "tokens": ["Vardenafil", "is", "a", "new", "oral", "phosphodiesterase", "inhibitor", "used", "for", "erectile", "dysfunction", "."], "event_mentions": [{"id": "16244351_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used for", "start": 7, "end": 9}, "arguments": [{"entity_id": "16244351_2_Ent2", "role": "Treatment_Drug", "text": "Vardenafil", "start": 0, "end": 1}, {"entity_id": "16244351_2_Ent0", "role": "Treatment", "text": "Vardenafil is a new oral phosphodiesterase inhibitor", "start": 0, "end": 7}, {"entity_id": "16244351_2_Ent3", "role": "Treatment_Route", "text": "oral", "start": 4, "end": 5}, {"entity_id": "16244351_2_Ent1", "role": "Treatment_Disorder", "text": "erectile dysfunction", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16244351_2_Ent2", "text": "Vardenafil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16244351_2_Ent0", "text": "Vardenafil is a new oral phosphodiesterase inhibitor", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "16244351_2_Ent3", "text": "oral", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16244351_2_Ent1", "text": "erectile dysfunction", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16244351_3", "wnd_id": "16244351_3_1", "text": "We report a case admitted with a first - detected , symptomatic paroxysmal atrial fibrillation in a healthy patient after self - medication with vardenafil .", "tokens": ["We", "report", "a", "case", "admitted", "with", "a", "first", "-", "detected", ",", "symptomatic", "paroxysmal", "atrial", "fibrillation", "in", "a", "healthy", "patient", "after", "self", "-", "medication", "with", "vardenafil", "."], "event_mentions": [{"id": "16244351_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 19, "end": 20}, "arguments": [{"entity_id": "16244351_3_Ent1", "role": "Effect", "text": "symptomatic paroxysmal atrial fibrillation", "start": 11, "end": 15}, {"entity_id": "16244351_3_Ent0", "role": "Subject", "text": "a healthy patient", "start": 16, "end": 19}, {"entity_id": "16244351_3_Ent2", "role": "Treatment", "text": "vardenafil", "start": 24, "end": 25}, {"entity_id": "16244351_3_Ent3", "role": "Treatment_Drug", "text": "vardenafil", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16244351_3_Ent1", "text": "symptomatic paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16244351_3_Ent0", "text": "a healthy patient", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16244351_3_Ent2", "text": "vardenafil", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16244351_3_Ent3", "text": "vardenafil", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16249064_1", "wnd_id": "16249064_1_1", "text": "We describe a case of infection with Mycobacterium abscessus in a 67 - year - old woman receiving infliximab as a component of her therapy for RA .", "tokens": ["We", "describe", "a", "case", "of", "infection", "with", "Mycobacterium", "abscessus", "in", "a", "67", "-", "year", "-", "old", "woman", "receiving", "infliximab", "as", "a", "component", "of", "her", "therapy", "for", "RA", "."], "event_mentions": [{"id": "16249064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 17, "end": 18}, "arguments": [{"entity_id": "16249064_1_Ent4", "role": "Effect", "text": "infection with Mycobacterium abscessus", "start": 5, "end": 9}, {"entity_id": "16249064_1_Ent0", "role": "Subject", "text": "a 67 - year - old woman", "start": 10, "end": 17}, {"entity_id": "16249064_1_Ent2", "role": "Subject_Age", "text": "67 - year - old", "start": 11, "end": 16}, {"entity_id": "16249064_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 16, "end": 17}, {"entity_id": "16249064_1_Ent6", "role": "Treatment_Drug", "text": "infliximab", "start": 18, "end": 19}, {"entity_id": "16249064_1_Ent5", "role": "Treatment", "text": "infliximab as a component of her therapy", "start": 18, "end": 25}, {"entity_id": "16249064_1_Ent1", "role": "Subject", "text": "RA", "start": 26, "end": 27}, {"entity_id": "16249064_1_Ent7", "role": "Treatment_Disorder", "text": "RA", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "16249064_1_Ent4", "text": "infection with Mycobacterium abscessus", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16249064_1_Ent0", "text": "a 67 - year - old woman", "entity_type": "Entity", "start": 10, "end": 17}, {"id": "16249064_1_Ent2", "text": "67 - year - old", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "16249064_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16249064_1_Ent6", "text": "infliximab", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "16249064_1_Ent5", "text": "infliximab as a component of her therapy", "entity_type": "Entity", "start": 18, "end": 25}, {"id": "16249064_1_Ent1", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16249064_1_Ent7", "text": "RA", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "16268429_1", "wnd_id": "16268429_1_1", "text": "In this case senna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury .", "tokens": ["In", "this", "case", "senna", "was", "likely", "the", "cause", "of", "a", "subacute", "cholestatic", "hepatitis", "exemplifying", "again", "the", "potential", "role", "of", "herbal", "related", "liver", "injury", "."], "event_mentions": [{"id": "16268429_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "16268429_1_Ent2", "role": "Treatment", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent3", "role": "Treatment_Drug", "text": "senna", "start": 3, "end": 4}, {"entity_id": "16268429_1_Ent0", "role": "Effect", "text": "a subacute cholestatic hepatitis", "start": 9, "end": 13}, {"entity_id": "16268429_1_Ent1", "role": "Effect", "text": "herbal related liver injury", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "16268429_1_Ent2", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent3", "text": "senna", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16268429_1_Ent0", "text": "a subacute cholestatic hepatitis", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16268429_1_Ent1", "text": "herbal related liver injury", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "16284443_4", "wnd_id": "16284443_4_1", "text": "To our knowledge , this is the first report of insulin - induced lipohypertrophy with detailed histological examinations .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "report", "of", "insulin", "-", "induced", "lipohypertrophy", "with", "detailed", "histological", "examinations", "."], "event_mentions": [{"id": "16284443_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16284443_4_Ent1", "role": "Treatment", "text": "insulin", "start": 10, "end": 11}, {"entity_id": "16284443_4_Ent2", "role": "Treatment_Drug", "text": "insulin", "start": 10, "end": 11}, {"entity_id": "16284443_4_Ent0", "role": "Effect", "text": "lipohypertrophy", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16284443_4_Ent1", "text": "insulin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16284443_4_Ent2", "text": "insulin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16284443_4_Ent0", "text": "lipohypertrophy", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "1628669_1", "wnd_id": "1628669_1_1", "text": "A 7 - year - old girl developed diabetes mellitus and exocrine pancreatic insufficiency after 3.5 years of almost continuous treatment with azathioprine and/or prednisone for idiopathic auto - immune haemolytic anaemia .", "tokens": ["A", "7", "-", "year", "-", "old", "girl", "developed", "diabetes", "mellitus", "and", "exocrine", "pancreatic", "insufficiency", "after", "3.5", "years", "of", "almost", "continuous", "treatment", "with", "azathioprine", "and/or", "prednisone", "for", "idiopathic", "auto", "-", "immune", "haemolytic", "anaemia", "."], "event_mentions": [{"id": "1628669_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "1628669_1_Ent0", "role": "Subject", "text": "A 7 - year - old girl", "start": 0, "end": 7}, {"entity_id": "1628669_1_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 1, "end": 6}, {"entity_id": "1628669_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "1628669_1_Ent3", "role": "Effect", "text": "diabetes mellitus and exocrine pancreatic insufficiency", "start": 8, "end": 14}, {"entity_id": "1628669_1_Ent10", "role": "Treatment_Duration", "text": "3.5 years", "start": 15, "end": 17}, {"entity_id": "1628669_1_Ent4", "role": "Treatment", "text": "3.5 years of almost continuous treatment with azathioprine and/or prednisone", "start": 15, "end": 25}, {"entity_id": "1628669_1_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}, {"entity_id": "1628669_1_Ent7", "role": "Treatment_Drug", "text": "azathioprine", "start": 22, "end": 23}, {"entity_id": "1628669_1_Ent11", "role": "Combination_Drug", "text": "azathioprine", "start": 22, "end": 23}, {"entity_id": "1628669_1_Ent6", "role": "Treatment_Drug", "text": "prednisone", "start": 24, "end": 25}, {"entity_id": "1628669_1_Ent8", "role": "Treatment_Drug", "text": "prednisone", "start": 24, "end": 25}, {"entity_id": "1628669_1_Ent12", "role": "Combination_Drug", "text": "prednisone", "start": 24, "end": 25}, {"entity_id": "1628669_1_Ent9", "role": "Treatment_Disorder", "text": "idiopathic auto - immune haemolytic anaemia", "start": 26, "end": 32}]}], "entity_mentions": [{"id": "1628669_1_Ent0", "text": "A 7 - year - old girl", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "1628669_1_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "1628669_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1628669_1_Ent3", "text": "diabetes mellitus and exocrine pancreatic insufficiency", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "1628669_1_Ent10", "text": "3.5 years", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "1628669_1_Ent4", "text": "3.5 years of almost continuous treatment with azathioprine and/or prednisone", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "1628669_1_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1628669_1_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1628669_1_Ent11", "text": "azathioprine", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "1628669_1_Ent6", "text": "prednisone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1628669_1_Ent8", "text": "prednisone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1628669_1_Ent12", "text": "prednisone", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "1628669_1_Ent9", "text": "idiopathic auto - immune haemolytic anaemia", "entity_type": "Entity", "start": 26, "end": 32}], "lang": "en"}
{"doc_id": "16298824_2", "wnd_id": "16298824_2_1", "text": "ARDS has been associated with the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines .", "tokens": ["ARDS", "has", "been", "associated", "with", "the", "administration", "of", "other", "monoclonal", "antibodies", ",", "such", "as", "infliximab", ",", "gemtuzumab", "ozogamicin", ",", "and", "OKT3", "and", "is", "believed", "to", "be", "directly", "mediated", "by", "release", "of", "proinflammatory", "cytokines", "."], "event_mentions": [{"id": "16298824_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16298824_2_Ent0", "role": "Effect", "text": "ARDS", "start": 0, "end": 1}, {"entity_id": "16298824_2_Ent1", "role": "Treatment", "text": "the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3", "start": 5, "end": 21}, {"entity_id": "16298824_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 14, "end": 15}, {"entity_id": "16298824_2_Ent3", "role": "Treatment_Drug", "text": "gemtuzumab", "start": 16, "end": 17}, {"entity_id": "16298824_2_Ent4", "role": "Treatment_Drug", "text": "ozogamicin", "start": 17, "end": 18}, {"entity_id": "16298824_2_Ent5", "role": "Treatment_Drug", "text": "OKT3", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "16298824_2_Ent0", "text": "ARDS", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16298824_2_Ent1", "text": "the administration of other monoclonal antibodies , such as infliximab , gemtuzumab ozogamicin , and OKT3", "entity_type": "Entity", "start": 5, "end": 21}, {"id": "16298824_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16298824_2_Ent3", "text": "gemtuzumab", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16298824_2_Ent4", "text": "ozogamicin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16298824_2_Ent5", "text": "OKT3", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "16317298_2", "wnd_id": "16317298_2_1", "text": "Gemcitabine should be added to the list of drugs known to cause radiation recall .", "tokens": ["Gemcitabine", "should", "be", "added", "to", "the", "list", "of", "drugs", "known", "to", "cause", "radiation", "recall", "."], "event_mentions": [{"id": "16317298_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "16317298_2_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_2_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "16317298_2_Ent0", "role": "Effect", "text": "radiation recall", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16317298_2_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_2_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16317298_2_Ent0", "text": "radiation recall", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16326413_1", "wnd_id": "16326413_1_1", "text": "A 17 - year - old boy with acute lymphoblastic leukemia developed acute renal failure within 48 h of an intravenous high - dose methotrexate ( 5 g / m2 ) infusion .", "tokens": ["A", "17", "-", "year", "-", "old", "boy", "with", "acute", "lymphoblastic", "leukemia", "developed", "acute", "renal", "failure", "within", "48", "h", "of", "an", "intravenous", "high", "-", "dose", "methotrexate", "(", "5", "g", "/", "m2", ")", "infusion", "."], "event_mentions": [{"id": "16326413_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "16326413_1_Ent1", "role": "Subject_Age", "text": "17 - year - old", "start": 1, "end": 6}, {"entity_id": "16326413_1_Ent0", "role": "Subject", "text": "17 - year - old boy with acute lymphoblastic leukemia", "start": 1, "end": 11}, {"entity_id": "16326413_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "16326413_1_Ent9", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 8, "end": 11}, {"entity_id": "16326413_1_Ent3", "role": "Effect", "text": "acute renal failure", "start": 12, "end": 15}, {"entity_id": "16326413_1_Ent8", "role": "Treatment_Time_elapsed", "text": "within 48 h", "start": 15, "end": 18}, {"entity_id": "16326413_1_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 20, "end": 21}, {"entity_id": "16326413_1_Ent4", "role": "Treatment", "text": "intravenous high - dose methotrexate ( 5 g / m2 ) infusion", "start": 20, "end": 32}, {"entity_id": "16326413_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 24, "end": 25}, {"entity_id": "16326413_1_Ent7", "role": "Treatment_Dosage", "text": "5 g / m2", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "16326413_1_Ent1", "text": "17 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16326413_1_Ent0", "text": "17 - year - old boy with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "16326413_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16326413_1_Ent9", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "16326413_1_Ent3", "text": "acute renal failure", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16326413_1_Ent8", "text": "within 48 h", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "16326413_1_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "16326413_1_Ent4", "text": "intravenous high - dose methotrexate ( 5 g / m2 ) infusion", "entity_type": "Entity", "start": 20, "end": 32}, {"id": "16326413_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16326413_1_Ent7", "text": "5 g / m2", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "16326413_3", "wnd_id": "16326413_3_1", "text": "Methotrexate - associated nephropathy is a rare complication in pediatric oncology , and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development .", "tokens": ["Methotrexate", "-", "associated", "nephropathy", "is", "a", "rare", "complication", "in", "pediatric", "oncology", ",", "and", "a", "review", "of", "the", "literature", "suggests", "that", "exposure", "to", "nephrotoxic", "agents", "may", "be", "a", "significant", "but", "perhaps", "underrecognized", "risk", "factor", "for", "its", "development", "."], "event_mentions": [{"id": "16326413_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "16326413_3_Ent1", "role": "Treatment", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "16326413_3_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 0, "end": 1}, {"entity_id": "16326413_3_Ent0", "role": "Effect", "text": "nephropathy", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16326413_3_Ent1", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16326413_3_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16326413_3_Ent0", "text": "nephropathy", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16341621_3", "wnd_id": "16341621_3_1", "text": "To our knowledge , this is the first granulomatous reaction described after calcium hydroxylapatite injection .", "tokens": ["To", "our", "knowledge", ",", "this", "is", "the", "first", "granulomatous", "reaction", "described", "after", "calcium", "hydroxylapatite", "injection", "."], "event_mentions": [{"id": "16341621_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "16341621_3_Ent0", "role": "Effect", "text": "granulomatous reaction", "start": 8, "end": 10}, {"entity_id": "16341621_3_Ent2", "role": "Treatment_Drug", "text": "calcium hydroxylapatite", "start": 12, "end": 14}, {"entity_id": "16341621_3_Ent1", "role": "Treatment", "text": "calcium hydroxylapatite injection", "start": 12, "end": 15}, {"entity_id": "16341621_3_Ent3", "role": "Treatment_Route", "text": "injection", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "16341621_3_Ent0", "text": "granulomatous reaction", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16341621_3_Ent2", "text": "calcium hydroxylapatite", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16341621_3_Ent1", "text": "calcium hydroxylapatite injection", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16341621_3_Ent3", "text": "injection", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "16352777_1", "wnd_id": "16352777_1_1", "text": "CASE SUMMARY : A 57 - year - old female with cardiomyopathy and \" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy documented as pancreatitis presented with symptoms consistent with pancreatitis after use of furosemide .", "tokens": ["CASE", "SUMMARY", ":", "A", "57", "-", "year", "-", "old", "female", "with", "cardiomyopathy", "and", "\"", "sulfa", "\"", "(", "trimethoprim", "/", "sulfamethoxazole", ")", "allergy", "documented", "as", "pancreatitis", "presented", "with", "symptoms", "consistent", "with", "pancreatitis", "after", "use", "of", "furosemide", "."], "event_mentions": [{"id": "16352777_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after use", "start": 31, "end": 33}, "arguments": [{"entity_id": "16352777_1_Ent0", "role": "Subject", "text": "A 57 - year - old female with cardiomyopathy and \" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "start": 3, "end": 22}, {"entity_id": "16352777_1_Ent1", "role": "Subject_Age", "text": "57 - year - old", "start": 4, "end": 9}, {"entity_id": "16352777_1_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "16352777_1_Ent3", "role": "Subject_Disorder", "text": "cardiomyopathy", "start": 11, "end": 12}, {"entity_id": "16352777_1_Ent4", "role": "Subject_Disorder", "text": "\" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "start": 13, "end": 22}, {"entity_id": "16352777_1_Ent5", "role": "Effect", "text": "pancreatitis", "start": 24, "end": 25}, {"entity_id": "16352777_1_Ent6", "role": "Treatment", "text": "furosemide", "start": 34, "end": 35}, {"entity_id": "16352777_1_Ent7", "role": "Treatment_Drug", "text": "furosemide", "start": 34, "end": 35}]}], "entity_mentions": [{"id": "16352777_1_Ent0", "text": "A 57 - year - old female with cardiomyopathy and \" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "entity_type": "Entity", "start": 3, "end": 22}, {"id": "16352777_1_Ent1", "text": "57 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16352777_1_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16352777_1_Ent3", "text": "cardiomyopathy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16352777_1_Ent4", "text": "\" sulfa \" ( trimethoprim / sulfamethoxazole ) allergy", "entity_type": "Entity", "start": 13, "end": 22}, {"id": "16352777_1_Ent5", "text": "pancreatitis", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16352777_1_Ent6", "text": "furosemide", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16352777_1_Ent7", "text": "furosemide", "entity_type": "Entity", "start": 34, "end": 35}], "lang": "en"}
{"doc_id": "1635565_2", "wnd_id": "1635565_2_1", "text": "CONCLUSIONS : The administration of prostaglandin E1 to neonates can cause gastric - outlet obstruction due to antral hyperplasia .", "tokens": ["CONCLUSIONS", ":", "The", "administration", "of", "prostaglandin", "E1", "to", "neonates", "can", "cause", "gastric", "-", "outlet", "obstruction", "due", "to", "antral", "hyperplasia", "."], "event_mentions": [{"id": "1635565_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 10, "end": 11}, "arguments": [{"entity_id": "1635565_2_Ent3", "role": "Treatment", "text": "prostaglandin E1", "start": 5, "end": 7}, {"entity_id": "1635565_2_Ent4", "role": "Treatment_Drug", "text": "prostaglandin E1", "start": 5, "end": 7}, {"entity_id": "1635565_2_Ent0", "role": "Subject", "text": "neonates", "start": 8, "end": 9}, {"entity_id": "1635565_2_Ent1", "role": "Subject_Age", "text": "neonates", "start": 8, "end": 9}, {"entity_id": "1635565_2_Ent2", "role": "Effect", "text": "gastric - outlet obstruction due to antral hyperplasia", "start": 11, "end": 19}]}], "entity_mentions": [{"id": "1635565_2_Ent3", "text": "prostaglandin E1", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1635565_2_Ent4", "text": "prostaglandin E1", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1635565_2_Ent0", "text": "neonates", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1635565_2_Ent1", "text": "neonates", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1635565_2_Ent2", "text": "gastric - outlet obstruction due to antral hyperplasia", "entity_type": "Entity", "start": 11, "end": 19}], "lang": "en"}
{"doc_id": "16357738_3", "wnd_id": "16357738_3_1", "text": "We report a case of a young woman with SLE and thrombocytopenia , who developed severe perspiration , headache , and seizure after receiving cyclosporine .", "tokens": ["We", "report", "a", "case", "of", "a", "young", "woman", "with", "SLE", "and", "thrombocytopenia", ",", "who", "developed", "severe", "perspiration", ",", "headache", ",", "and", "seizure", "after", "receiving", "cyclosporine", "."], "event_mentions": [{"id": "16357738_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "16357738_3_Ent2", "role": "Subject_Age", "text": "young", "start": 6, "end": 7}, {"entity_id": "16357738_3_Ent0", "role": "Subject", "text": "young woman with SLE and thrombocytopenia", "start": 6, "end": 12}, {"entity_id": "16357738_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "16357738_3_Ent7", "role": "Treatment_Disorder", "text": "SLE", "start": 9, "end": 10}, {"entity_id": "16357738_3_Ent1", "role": "Subject_Disorder", "text": "thrombocytopenia", "start": 11, "end": 12}, {"entity_id": "16357738_3_Ent4", "role": "Effect", "text": "severe perspiration , headache , and seizure", "start": 15, "end": 22}, {"entity_id": "16357738_3_Ent5", "role": "Treatment", "text": "cyclosporine", "start": 24, "end": 25}, {"entity_id": "16357738_3_Ent6", "role": "Treatment_Drug", "text": "cyclosporine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "16357738_3_Ent2", "text": "young", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16357738_3_Ent0", "text": "young woman with SLE and thrombocytopenia", "entity_type": "Entity", "start": 6, "end": 12}, {"id": "16357738_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16357738_3_Ent7", "text": "SLE", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16357738_3_Ent1", "text": "thrombocytopenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16357738_3_Ent4", "text": "severe perspiration , headache , and seizure", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "16357738_3_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16357738_3_Ent6", "text": "cyclosporine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "16371793_2", "wnd_id": "16371793_2_1", "text": "PURPOSE : The intravitreal application of triamcinolone acetonide as treatment of long - standing , therapy - resistant cystoid macular edema after penetrating keratoplasty is reported .", "tokens": ["PURPOSE", ":", "The", "intravitreal", "application", "of", "triamcinolone", "acetonide", "as", "treatment", "of", "long", "-", "standing", ",", "therapy", "-", "resistant", "cystoid", "macular", "edema", "after", "penetrating", "keratoplasty", "is", "reported", "."], "event_mentions": [{"id": "16371793_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 9, "end": 10}, "arguments": [{"entity_id": "16371793_2_Ent0", "role": "Treatment", "text": "The intravitreal application of triamcinolone acetonide", "start": 2, "end": 8}, {"entity_id": "16371793_2_Ent1", "role": "Treatment_Route", "text": "intravitreal", "start": 3, "end": 4}, {"entity_id": "16371793_2_Ent2", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 6, "end": 8}, {"entity_id": "16371793_2_Ent3", "role": "Treatment_Disorder", "text": "cystoid macular edema", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "16371793_2_Ent0", "text": "The intravitreal application of triamcinolone acetonide", "entity_type": "Entity", "start": 2, "end": 8}, {"id": "16371793_2_Ent1", "text": "intravitreal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16371793_2_Ent2", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16371793_2_Ent3", "text": "cystoid macular edema", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "16393774_3", "wnd_id": "16393774_3_1", "text": "Therapy with IFN - beta has rarely been associated with the development of autoimmune disorders .", "tokens": ["Therapy", "with", "IFN", "-", "beta", "has", "rarely", "been", "associated", "with", "the", "development", "of", "autoimmune", "disorders", "."], "event_mentions": [{"id": "16393774_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 11, "end": 12}, "arguments": [{"entity_id": "16393774_3_Ent1", "role": "Treatment", "text": "IFN - beta", "start": 2, "end": 5}, {"entity_id": "16393774_3_Ent2", "role": "Treatment_Drug", "text": "IFN - beta", "start": 2, "end": 5}, {"entity_id": "16393774_3_Ent0", "role": "Effect", "text": "autoimmune disorders", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "16393774_3_Ent1", "text": "IFN - beta", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "16393774_3_Ent2", "text": "IFN - beta", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "16393774_3_Ent0", "text": "autoimmune disorders", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "16396068_1", "wnd_id": "16396068_1_1", "text": "Trimethoprim - sulfamethoxazole - induced aseptic meningitis .", "tokens": ["Trimethoprim", "-", "sulfamethoxazole", "-", "induced", "aseptic", "meningitis", "."], "event_mentions": [{"id": "16396068_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16396068_1_Ent1", "role": "Treatment", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "16396068_1_Ent2", "role": "Treatment_Drug", "text": "Trimethoprim - sulfamethoxazole", "start": 0, "end": 3}, {"entity_id": "16396068_1_Ent0", "role": "Effect", "text": "aseptic meningitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16396068_1_Ent1", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16396068_1_Ent2", "text": "Trimethoprim - sulfamethoxazole", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16396068_1_Ent0", "text": "aseptic meningitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16404563_6", "wnd_id": "16404563_6_1", "text": "In this paper , we report a patient with primary anti - phospholipid syndrome treated by corticosteroid , who developed disseminated nocardiosis .", "tokens": ["In", "this", "paper", ",", "we", "report", "a", "patient", "with", "primary", "anti", "-", "phospholipid", "syndrome", "treated", "by", "corticosteroid", ",", "who", "developed", "disseminated", "nocardiosis", "."], "event_mentions": [{"id": "16404563_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16404563_6_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "16404563_6_Ent4", "role": "Treatment_Disorder", "text": "anti - phospholipid syndrome", "start": 10, "end": 14}, {"entity_id": "16404563_6_Ent2", "role": "Treatment", "text": "corticosteroid", "start": 16, "end": 17}, {"entity_id": "16404563_6_Ent3", "role": "Treatment_Drug", "text": "corticosteroid", "start": 16, "end": 17}, {"entity_id": "16404563_6_Ent1", "role": "Effect", "text": "disseminated nocardiosis", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "16404563_6_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16404563_6_Ent4", "text": "anti - phospholipid syndrome", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "16404563_6_Ent2", "text": "corticosteroid", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16404563_6_Ent3", "text": "corticosteroid", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16404563_6_Ent1", "text": "disseminated nocardiosis", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "1642627_1", "wnd_id": "1642627_1_1", "text": "A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent triazolam - induced eating disorder .", "tokens": ["A", "combination", "of", "behavioural", "and", "cognitive", "adverse", "effects", "is", "illustrated", "in", "this", "case", "report", "of", "a", "recurrent", "triazolam", "-", "induced", "eating", "disorder", "."], "event_mentions": [{"id": "1642627_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "1642627_1_Ent1", "role": "Treatment", "text": "triazolam", "start": 17, "end": 18}, {"entity_id": "1642627_1_Ent2", "role": "Treatment_Drug", "text": "triazolam", "start": 17, "end": 18}, {"entity_id": "1642627_1_Ent0", "role": "Effect", "text": "eating disorder", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "1642627_1_Ent1", "text": "triazolam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1642627_1_Ent2", "text": "triazolam", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "1642627_1_Ent0", "text": "eating disorder", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "16432996_1", "wnd_id": "16432996_1_1", "text": "Development of sarcoidosis during interferon alpha 2b and ribavirin combination therapy for chronic hepatitis C -- a case report and review of the literature .", "tokens": ["Development", "of", "sarcoidosis", "during", "interferon", "alpha", "2b", "and", "ribavirin", "combination", "therapy", "for", "chronic", "hepatitis", "C", "--", "a", "case", "report", "and", "review", "of", "the", "literature", "."], "event_mentions": [{"id": "16432996_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "16432996_1_Ent0", "role": "Effect", "text": "sarcoidosis", "start": 2, "end": 3}, {"entity_id": "16432996_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha 2b", "start": 4, "end": 7}, {"entity_id": "16432996_1_Ent6", "role": "Combination_Drug", "text": "interferon alpha 2b", "start": 4, "end": 7}, {"entity_id": "16432996_1_Ent1", "role": "Treatment", "text": "interferon alpha 2b and ribavirin", "start": 4, "end": 9}, {"entity_id": "16432996_1_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 8, "end": 9}, {"entity_id": "16432996_1_Ent5", "role": "Combination_Drug", "text": "ribavirin", "start": 8, "end": 9}, {"entity_id": "16432996_1_Ent4", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "16432996_1_Ent0", "text": "sarcoidosis", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16432996_1_Ent2", "text": "interferon alpha 2b", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16432996_1_Ent6", "text": "interferon alpha 2b", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "16432996_1_Ent1", "text": "interferon alpha 2b and ribavirin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16432996_1_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16432996_1_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16432996_1_Ent4", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "16432996_14", "wnd_id": "16432996_14_1", "text": "We suggest that sarcoidosis may develop in chronic hepatitis C patients during interferon alpha and/or ribavirin treatment , and diagnostic tests for this adverse effect should be performed during the follow - ups .", "tokens": ["We", "suggest", "that", "sarcoidosis", "may", "develop", "in", "chronic", "hepatitis", "C", "patients", "during", "interferon", "alpha", "and/or", "ribavirin", "treatment", ",", "and", "diagnostic", "tests", "for", "this", "adverse", "effect", "should", "be", "performed", "during", "the", "follow", "-", "ups", "."], "event_mentions": [{"id": "16432996_14_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 5, "end": 6}, "arguments": [{"entity_id": "16432996_14_Ent1", "role": "Effect", "text": "sarcoidosis", "start": 3, "end": 4}, {"entity_id": "16432996_14_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis C", "start": 7, "end": 10}, {"entity_id": "16432996_14_Ent0", "role": "Subject", "text": "chronic hepatitis C patients", "start": 7, "end": 11}, {"entity_id": "16432996_14_Ent4", "role": "Treatment_Drug", "text": "interferon alpha", "start": 12, "end": 14}, {"entity_id": "16432996_14_Ent2", "role": "Treatment", "text": "interferon alpha and/or ribavirin", "start": 12, "end": 16}, {"entity_id": "16432996_14_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16432996_14_Ent1", "text": "sarcoidosis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16432996_14_Ent3", "text": "chronic hepatitis C", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16432996_14_Ent0", "text": "chronic hepatitis C patients", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "16432996_14_Ent4", "text": "interferon alpha", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "16432996_14_Ent2", "text": "interferon alpha and/or ribavirin", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "16432996_14_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16432996_4", "wnd_id": "16432996_4_1", "text": "We report a case with chronic hepatitis C ( CHC ) who developed sarcoidosis after the treatment by interferon alpha and ribavirin .", "tokens": ["We", "report", "a", "case", "with", "chronic", "hepatitis", "C", "(", "CHC", ")", "who", "developed", "sarcoidosis", "after", "the", "treatment", "by", "interferon", "alpha", "and", "ribavirin", "."], "event_mentions": [{"id": "16432996_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "16432996_4_Ent2", "role": "Treatment_Disorder", "text": "chronic hepatitis C ( CHC )", "start": 5, "end": 11}, {"entity_id": "16432996_4_Ent0", "role": "Effect", "text": "sarcoidosis", "start": 13, "end": 14}, {"entity_id": "16432996_4_Ent1", "role": "Treatment", "text": "treatment by interferon alpha and ribavirin", "start": 16, "end": 22}, {"entity_id": "16432996_4_Ent3", "role": "Treatment_Drug", "text": "interferon alpha", "start": 18, "end": 20}, {"entity_id": "16432996_4_Ent5", "role": "Combination_Drug", "text": "interferon alpha", "start": 18, "end": 20}, {"entity_id": "16432996_4_Ent4", "role": "Treatment_Drug", "text": "ribavirin", "start": 21, "end": 22}, {"entity_id": "16432996_4_Ent6", "role": "Combination_Drug", "text": "ribavirin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16432996_4_Ent2", "text": "chronic hepatitis C ( CHC )", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "16432996_4_Ent0", "text": "sarcoidosis", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16432996_4_Ent1", "text": "treatment by interferon alpha and ribavirin", "entity_type": "Entity", "start": 16, "end": 22}, {"id": "16432996_4_Ent3", "text": "interferon alpha", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "16432996_4_Ent5", "text": "interferon alpha", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "16432996_4_Ent4", "text": "ribavirin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16432996_4_Ent6", "text": "ribavirin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "16436462_1", "wnd_id": "16436462_1_1", "text": "Neutropenic colitis during standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer .", "tokens": ["Neutropenic", "colitis", "during", "standard", "dose", "combination", "chemotherapy", "with", "nedaplatin", "and", "irinotecan", "for", "testicular", "cancer", "."], "event_mentions": [{"id": "16436462_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "16436462_1_Ent0", "role": "Effect", "text": "Neutropenic colitis", "start": 0, "end": 2}, {"entity_id": "16436462_1_Ent3", "role": "Treatment_Dosage", "text": "standard dose", "start": 3, "end": 5}, {"entity_id": "16436462_1_Ent1", "role": "Treatment", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "start": 3, "end": 14}, {"entity_id": "16436462_1_Ent4", "role": "Treatment_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent6", "role": "Combination_Drug", "text": "nedaplatin", "start": 8, "end": 9}, {"entity_id": "16436462_1_Ent5", "role": "Treatment_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent7", "role": "Combination_Drug", "text": "irinotecan", "start": 10, "end": 11}, {"entity_id": "16436462_1_Ent2", "role": "Treatment_Disorder", "text": "testicular cancer", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16436462_1_Ent0", "text": "Neutropenic colitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16436462_1_Ent3", "text": "standard dose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16436462_1_Ent1", "text": "standard dose combination chemotherapy with nedaplatin and irinotecan for testicular cancer", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "16436462_1_Ent4", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent6", "text": "nedaplatin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16436462_1_Ent5", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent7", "text": "irinotecan", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16436462_1_Ent2", "text": "testicular cancer", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16449538_4", "wnd_id": "16449538_4_1", "text": "NCSE , an epileptic disorder in which typical convulsive activity is absent , has previously been reported in only 4 patients receiving ifosfamide .", "tokens": ["NCSE", ",", "an", "epileptic", "disorder", "in", "which", "typical", "convulsive", "activity", "is", "absent", ",", "has", "previously", "been", "reported", "in", "only", "4", "patients", "receiving", "ifosfamide", "."], "event_mentions": [{"id": "16449538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 21, "end": 22}, "arguments": [{"entity_id": "16449538_4_Ent2", "role": "Effect", "text": "NCSE", "start": 0, "end": 1}, {"entity_id": "16449538_4_Ent1", "role": "Subject_Population", "text": "4", "start": 19, "end": 20}, {"entity_id": "16449538_4_Ent0", "role": "Subject", "text": "4 patients", "start": 19, "end": 21}, {"entity_id": "16449538_4_Ent3", "role": "Treatment", "text": "ifosfamide", "start": 22, "end": 23}, {"entity_id": "16449538_4_Ent4", "role": "Treatment_Drug", "text": "ifosfamide", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "16449538_4_Ent2", "text": "NCSE", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16449538_4_Ent1", "text": "4", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16449538_4_Ent0", "text": "4 patients", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "16449538_4_Ent3", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16449538_4_Ent4", "text": "ifosfamide", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "16490518_3", "wnd_id": "16490518_3_1", "text": "Severe steroid - induced glaucoma following intravitreal injection of triamcinolone acetonide .", "tokens": ["Severe", "steroid", "-", "induced", "glaucoma", "following", "intravitreal", "injection", "of", "triamcinolone", "acetonide", "."], "event_mentions": [{"id": "16490518_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "16490518_3_Ent2", "role": "Treatment_Drug", "text": "steroid", "start": 1, "end": 2}, {"entity_id": "16490518_3_Ent0", "role": "Effect", "text": "glaucoma", "start": 4, "end": 5}, {"entity_id": "16490518_3_Ent4", "role": "Treatment_Route", "text": "intravitreal injection", "start": 6, "end": 8}, {"entity_id": "16490518_3_Ent1", "role": "Treatment", "text": "intravitreal injection of triamcinolone acetonide", "start": 6, "end": 11}, {"entity_id": "16490518_3_Ent3", "role": "Treatment_Drug", "text": "triamcinolone acetonide", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "16490518_3_Ent2", "text": "steroid", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16490518_3_Ent0", "text": "glaucoma", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "16490518_3_Ent4", "text": "intravitreal injection", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16490518_3_Ent1", "text": "intravitreal injection of triamcinolone acetonide", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16490518_3_Ent3", "text": "triamcinolone acetonide", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "16498048_5", "wnd_id": "16498048_5_1", "text": "We have described three patients with hepatitis C for whom IFN - alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease .", "tokens": ["We", "have", "described", "three", "patients", "with", "hepatitis", "C", "for", "whom", "IFN", "-", "alpha", "and", "ribavirin", "were", "prescribed", "and", "who", "developed", "two", "successive", "phases", "of", "silent", "thyroiditis", "followed", "by", "hyperthryroidism", "relapse", "due", "to", "Graves", "'", "disease", "."], "event_mentions": [{"id": "16498048_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "16498048_5_Ent1", "role": "Subject_Population", "text": "three", "start": 3, "end": 4}, {"entity_id": "16498048_5_Ent0", "role": "Subject", "text": "three patients with hepatitis C", "start": 3, "end": 8}, {"entity_id": "16498048_5_Ent5", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 6, "end": 8}, {"entity_id": "16498048_5_Ent6", "role": "Treatment_Drug", "text": "IFN - alpha", "start": 10, "end": 13}, {"entity_id": "16498048_5_Ent4", "role": "Treatment", "text": "IFN - alpha and ribavirin", "start": 10, "end": 15}, {"entity_id": "16498048_5_Ent7", "role": "Treatment_Drug", "text": "ribavirin", "start": 14, "end": 15}, {"entity_id": "16498048_5_Ent3", "role": "Effect", "text": "two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease", "start": 20, "end": 35}, {"entity_id": "16498048_5_Ent2", "role": "Subject_Disorder", "text": "Graves ' disease", "start": 32, "end": 35}]}], "entity_mentions": [{"id": "16498048_5_Ent1", "text": "three", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16498048_5_Ent0", "text": "three patients with hepatitis C", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "16498048_5_Ent5", "text": "hepatitis C", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "16498048_5_Ent6", "text": "IFN - alpha", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16498048_5_Ent4", "text": "IFN - alpha and ribavirin", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "16498048_5_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16498048_5_Ent3", "text": "two successive phases of silent thyroiditis followed by hyperthryroidism relapse due to Graves ' disease", "entity_type": "Entity", "start": 20, "end": 35}, {"id": "16498048_5_Ent2", "text": "Graves ' disease", "entity_type": "Entity", "start": 32, "end": 35}], "lang": "en"}
{"doc_id": "16503727_2", "wnd_id": "16503727_2_1", "text": "Dipyrone - induced granulocytopenia : a case for awareness .", "tokens": ["Dipyrone", "-", "induced", "granulocytopenia", ":", "a", "case", "for", "awareness", "."], "event_mentions": [{"id": "16503727_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "16503727_2_Ent2", "role": "Treatment", "text": "Dipyrone", "start": 0, "end": 1}, {"entity_id": "16503727_2_Ent3", "role": "Treatment_Drug", "text": "Dipyrone", "start": 0, "end": 1}, {"entity_id": "16503727_2_Ent1", "role": "Effect", "text": "granulocytopenia", "start": 3, "end": 4}, {"entity_id": "16503727_2_Ent0", "role": "Subject", "text": "a case", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "16503727_2_Ent2", "text": "Dipyrone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16503727_2_Ent3", "text": "Dipyrone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16503727_2_Ent1", "text": "granulocytopenia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "16503727_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "16515630_1", "wnd_id": "16515630_1_1", "text": "Fatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report , we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer .", "tokens": ["Fatal", "lung", "fibrosis", "caused", "by", "paclitaxel", "toxicity", "has", "not", "been", "reported", "In", "this", "report", ",", "we", "describe", "the", "case", "of", "a", "62", "-", "year", "-", "old", "woman", "who", "received", "six", "cycles", "of", "paclitaxel", "and", "carboplatin", "as", "combination", "chemotherapy", "for", "advanced", "ovarian", "cancer", "."], "event_mentions": [{"id": "16515630_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "received", "start": 28, "end": 29}, "arguments": [{"entity_id": "16515630_1_Ent4", "role": "Effect", "text": "Fatal lung fibrosis", "start": 0, "end": 3}, {"entity_id": "16515630_1_Ent2", "role": "Subject_Age", "text": "62 - year - old", "start": 21, "end": 26}, {"entity_id": "16515630_1_Ent0", "role": "Subject", "text": "62 - year - old woman", "start": 21, "end": 27}, {"entity_id": "16515630_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 26, "end": 27}, {"entity_id": "16515630_1_Ent6", "role": "Treatment_Dosage", "text": "six cycles", "start": 29, "end": 31}, {"entity_id": "16515630_1_Ent5", "role": "Treatment", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "start": 29, "end": 38}, {"entity_id": "16515630_1_Ent7", "role": "Treatment_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent11", "role": "Combination_Drug", "text": "paclitaxel", "start": 32, "end": 33}, {"entity_id": "16515630_1_Ent8", "role": "Treatment_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent12", "role": "Combination_Drug", "text": "carboplatin", "start": 34, "end": 35}, {"entity_id": "16515630_1_Ent10", "role": "Treatment_Route", "text": "chemotherapy", "start": 37, "end": 38}, {"entity_id": "16515630_1_Ent1", "role": "Subject", "text": "advanced ovarian cancer", "start": 39, "end": 42}, {"entity_id": "16515630_1_Ent9", "role": "Treatment_Disorder", "text": "advanced ovarian cancer", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "16515630_1_Ent4", "text": "Fatal lung fibrosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16515630_1_Ent2", "text": "62 - year - old", "entity_type": "Entity", "start": 21, "end": 26}, {"id": "16515630_1_Ent0", "text": "62 - year - old woman", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "16515630_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "16515630_1_Ent6", "text": "six cycles", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16515630_1_Ent5", "text": "six cycles of paclitaxel and carboplatin as combination chemotherapy", "entity_type": "Entity", "start": 29, "end": 38}, {"id": "16515630_1_Ent7", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent11", "text": "paclitaxel", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "16515630_1_Ent8", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent12", "text": "carboplatin", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "16515630_1_Ent10", "text": "chemotherapy", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16515630_1_Ent1", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}, {"id": "16515630_1_Ent9", "text": "advanced ovarian cancer", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "16515630_3", "wnd_id": "16515630_3_1", "text": "Physicians should keep in mind that taxanes such as paclitaxel have the potential to cause pneumonitis and lung fibrosis .", "tokens": ["Physicians", "should", "keep", "in", "mind", "that", "taxanes", "such", "as", "paclitaxel", "have", "the", "potential", "to", "cause", "pneumonitis", "and", "lung", "fibrosis", "."], "event_mentions": [{"id": "16515630_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 14, "end": 15}, "arguments": [{"entity_id": "16515630_3_Ent2", "role": "Treatment_Drug", "text": "taxanes", "start": 6, "end": 7}, {"entity_id": "16515630_3_Ent1", "role": "Treatment", "text": "taxanes such as paclitaxel", "start": 6, "end": 10}, {"entity_id": "16515630_3_Ent0", "role": "Effect", "text": "pneumonitis and lung fibrosis", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "16515630_3_Ent2", "text": "taxanes", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16515630_3_Ent1", "text": "taxanes such as paclitaxel", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "16515630_3_Ent0", "text": "pneumonitis and lung fibrosis", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "16515630_4", "wnd_id": "16515630_4_1", "text": "Pulmonary fibrosis is a complication of paclitaxel therapy that may occur despite treatments with corticosteroids .", "tokens": ["Pulmonary", "fibrosis", "is", "a", "complication", "of", "paclitaxel", "therapy", "that", "may", "occur", "despite", "treatments", "with", "corticosteroids", "."], "event_mentions": [{"id": "16515630_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "16515630_4_Ent0", "role": "Effect", "text": "Pulmonary fibrosis", "start": 0, "end": 2}, {"entity_id": "16515630_4_Ent2", "role": "Treatment_Drug", "text": "paclitaxel", "start": 6, "end": 7}, {"entity_id": "16515630_4_Ent1", "role": "Treatment", "text": "paclitaxel therapy", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "16515630_4_Ent0", "text": "Pulmonary fibrosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16515630_4_Ent2", "text": "paclitaxel", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16515630_4_Ent1", "text": "paclitaxel therapy", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "16527771_2", "wnd_id": "16527771_2_1", "text": "The visual loss in this patient seems to result from phenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve .", "tokens": ["The", "visual", "loss", "in", "this", "patient", "seems", "to", "result", "from", "phenol", "neurotoxicity", "rather", "than", "mechanical", "compression", "of", "the", "intraorbital", "optic", "nerve", "."], "event_mentions": [{"id": "16527771_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 8, "end": 9}, "arguments": [{"entity_id": "16527771_2_Ent1", "role": "Effect", "text": "visual loss", "start": 1, "end": 3}, {"entity_id": "16527771_2_Ent0", "role": "Subject", "text": "patient", "start": 5, "end": 6}, {"entity_id": "16527771_2_Ent3", "role": "Treatment", "text": "phenol", "start": 10, "end": 11}, {"entity_id": "16527771_2_Ent4", "role": "Treatment_Drug", "text": "phenol", "start": 10, "end": 11}, {"entity_id": "16527771_2_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16527771_2_Ent1", "text": "visual loss", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "16527771_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16527771_2_Ent3", "text": "phenol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16527771_2_Ent4", "text": "phenol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16527771_2_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16531969_1", "wnd_id": "16531969_1_1", "text": "Drug induced liver injury secondary to interferon - beta ( IFN - beta ) in multiple sclerosis .", "tokens": ["Drug", "induced", "liver", "injury", "secondary", "to", "interferon", "-", "beta", "(", "IFN", "-", "beta", ")", "in", "multiple", "sclerosis", "."], "event_mentions": [{"id": "16531969_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 4, "end": 5}, "arguments": [{"entity_id": "16531969_1_Ent0", "role": "Effect", "text": "liver injury", "start": 2, "end": 4}, {"entity_id": "16531969_1_Ent2", "role": "Treatment_Drug", "text": "interferon - beta", "start": 6, "end": 9}, {"entity_id": "16531969_1_Ent1", "role": "Treatment", "text": "interferon - beta ( IFN - beta )", "start": 6, "end": 14}, {"entity_id": "16531969_1_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "16531969_1_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16531969_1_Ent2", "text": "interferon - beta", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16531969_1_Ent1", "text": "interferon - beta ( IFN - beta )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16531969_1_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "16537817_1", "wnd_id": "16537817_1_1", "text": "Simvastatin - amiodarone interaction resulting in rhabdomyolysis , azotemia , and possible hepatotoxicity .", "tokens": ["Simvastatin", "-", "amiodarone", "interaction", "resulting", "in", "rhabdomyolysis", ",", "azotemia", ",", "and", "possible", "hepatotoxicity", "."], "event_mentions": [{"id": "16537817_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 4, "end": 5}, "arguments": [{"entity_id": "16537817_1_Ent3", "role": "Treatment_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "16537817_1_Ent5", "role": "Combination_Drug", "text": "Simvastatin", "start": 0, "end": 1}, {"entity_id": "16537817_1_Ent1", "role": "Treatment", "text": "Simvastatin - amiodarone interaction", "start": 0, "end": 4}, {"entity_id": "16537817_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "16537817_1_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 2, "end": 3}, {"entity_id": "16537817_1_Ent0", "role": "Effect", "text": "rhabdomyolysis , azotemia , and possible hepatotoxicity", "start": 6, "end": 13}]}], "entity_mentions": [{"id": "16537817_1_Ent3", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16537817_1_Ent5", "text": "Simvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16537817_1_Ent1", "text": "Simvastatin - amiodarone interaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16537817_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16537817_1_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16537817_1_Ent0", "text": "rhabdomyolysis , azotemia , and possible hepatotoxicity", "entity_type": "Entity", "start": 6, "end": 13}], "lang": "en"}
{"doc_id": "16537817_10", "wnd_id": "16537817_10_1", "text": "An objective causal assessment suggests that rhabdomyolysis , renal failure , and possibly hepatotoxicity were probably related to an amiodarone - simvastatin interaction .", "tokens": ["An", "objective", "causal", "assessment", "suggests", "that", "rhabdomyolysis", ",", "renal", "failure", ",", "and", "possibly", "hepatotoxicity", "were", "probably", "related", "to", "an", "amiodarone", "-", "simvastatin", "interaction", "."], "event_mentions": [{"id": "16537817_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 16, "end": 17}, "arguments": [{"entity_id": "16537817_10_Ent0", "role": "Effect", "text": "rhabdomyolysis , renal failure , and possibly hepatotoxicity", "start": 6, "end": 14}, {"entity_id": "16537817_10_Ent1", "role": "Treatment", "text": "an amiodarone - simvastatin interaction", "start": 18, "end": 23}, {"entity_id": "16537817_10_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "16537817_10_Ent4", "role": "Combination_Drug", "text": "amiodarone", "start": 19, "end": 20}, {"entity_id": "16537817_10_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 21, "end": 22}, {"entity_id": "16537817_10_Ent5", "role": "Combination_Drug", "text": "simvastatin", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "16537817_10_Ent0", "text": "rhabdomyolysis , renal failure , and possibly hepatotoxicity", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "16537817_10_Ent1", "text": "an amiodarone - simvastatin interaction", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "16537817_10_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16537817_10_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16537817_10_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16537817_10_Ent5", "text": "simvastatin", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "1655228_1", "wnd_id": "1655228_1_1", "text": "Cardiac toxicity related to BCNU has not been described well .", "tokens": ["Cardiac", "toxicity", "related", "to", "BCNU", "has", "not", "been", "described", "well", "."], "event_mentions": [{"id": "1655228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "1655228_1_Ent0", "role": "Effect", "text": "Cardiac toxicity", "start": 0, "end": 2}, {"entity_id": "1655228_1_Ent1", "role": "Treatment", "text": "BCNU", "start": 4, "end": 5}, {"entity_id": "1655228_1_Ent2", "role": "Treatment_Drug", "text": "BCNU", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1655228_1_Ent0", "text": "Cardiac toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1655228_1_Ent1", "text": "BCNU", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1655228_1_Ent2", "text": "BCNU", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "16580907_1", "wnd_id": "16580907_1_1", "text": "Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency : first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2 .", "tokens": ["Severe", "arrhythmia", "as", "a", "result", "of", "the", "interaction", "of", "cetirizine", "and", "pilsicainide", "in", "a", "patient", "with", "renal", "insufficiency", ":", "first", "case", "presentation", "showing", "competition", "for", "excretion", "via", "renal", "multidrug", "resistance", "protein", "1", "and", "organic", "cation", "transporter", "2", "."], "event_mentions": [{"id": "16580907_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "result", "start": 4, "end": 5}, "arguments": [{"entity_id": "16580907_1_Ent2", "role": "Effect", "text": "Severe arrhythmia", "start": 0, "end": 2}, {"entity_id": "16580907_1_Ent3", "role": "Treatment", "text": "interaction of cetirizine and pilsicainide", "start": 7, "end": 12}, {"entity_id": "16580907_1_Ent4", "role": "Treatment_Drug", "text": "cetirizine", "start": 9, "end": 10}, {"entity_id": "16580907_1_Ent6", "role": "Combination_Drug", "text": "cetirizine", "start": 9, "end": 10}, {"entity_id": "16580907_1_Ent5", "role": "Treatment_Drug", "text": "pilsicainide", "start": 11, "end": 12}, {"entity_id": "16580907_1_Ent7", "role": "Combination_Drug", "text": "pilsicainide", "start": 11, "end": 12}, {"entity_id": "16580907_1_Ent0", "role": "Subject", "text": "a patient with renal insufficiency", "start": 13, "end": 18}, {"entity_id": "16580907_1_Ent1", "role": "Subject_Disorder", "text": "renal insufficiency", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "16580907_1_Ent2", "text": "Severe arrhythmia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16580907_1_Ent3", "text": "interaction of cetirizine and pilsicainide", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "16580907_1_Ent4", "text": "cetirizine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16580907_1_Ent6", "text": "cetirizine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16580907_1_Ent5", "text": "pilsicainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16580907_1_Ent7", "text": "pilsicainide", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16580907_1_Ent0", "text": "a patient with renal insufficiency", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "16580907_1_Ent1", "text": "renal insufficiency", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "16603845_1", "wnd_id": "16603845_1_1", "text": "Shortly after chemotherapy and an injection of pegfilgrastim , the patient developed poorly defined , rapidly progressive erythema , edema , and pain in his right forearm .", "tokens": ["Shortly", "after", "chemotherapy", "and", "an", "injection", "of", "pegfilgrastim", ",", "the", "patient", "developed", "poorly", "defined", ",", "rapidly", "progressive", "erythema", ",", "edema", ",", "and", "pain", "in", "his", "right", "forearm", "."], "event_mentions": [{"id": "16603845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "16603845_1_Ent2", "role": "Treatment", "text": "pegfilgrastim", "start": 7, "end": 8}, {"entity_id": "16603845_1_Ent3", "role": "Treatment_Drug", "text": "pegfilgrastim", "start": 7, "end": 8}, {"entity_id": "16603845_1_Ent0", "role": "Subject", "text": "the patient", "start": 9, "end": 11}, {"entity_id": "16603845_1_Ent1", "role": "Effect", "text": "poorly defined , rapidly progressive erythema , edema , and pain in his right forearm", "start": 12, "end": 27}]}], "entity_mentions": [{"id": "16603845_1_Ent2", "text": "pegfilgrastim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16603845_1_Ent3", "text": "pegfilgrastim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16603845_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16603845_1_Ent1", "text": "poorly defined , rapidly progressive erythema , edema , and pain in his right forearm", "entity_type": "Entity", "start": 12, "end": 27}], "lang": "en"}
{"doc_id": "16615675_1", "wnd_id": "16615675_1_1", "text": "After excluding other causes of long QT syndrome , the HCQ was suspected as the cause of her ventricular tachycardia .", "tokens": ["After", "excluding", "other", "causes", "of", "long", "QT", "syndrome", ",", "the", "HCQ", "was", "suspected", "as", "the", "cause", "of", "her", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "16615675_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspected", "start": 12, "end": 13}, "arguments": [{"entity_id": "16615675_1_Ent3", "role": "Treatment", "text": "HCQ", "start": 10, "end": 11}, {"entity_id": "16615675_1_Ent4", "role": "Treatment_Drug", "text": "HCQ", "start": 10, "end": 11}, {"entity_id": "16615675_1_Ent0", "role": "Subject", "text": "her", "start": 17, "end": 18}, {"entity_id": "16615675_1_Ent1", "role": "Subject_Gender", "text": "her", "start": 17, "end": 18}, {"entity_id": "16615675_1_Ent2", "role": "Effect", "text": "ventricular tachycardia", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16615675_1_Ent3", "text": "HCQ", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16615675_1_Ent4", "text": "HCQ", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16615675_1_Ent0", "text": "her", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16615675_1_Ent1", "text": "her", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16615675_1_Ent2", "text": "ventricular tachycardia", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16615675_2", "wnd_id": "16615675_2_1", "text": "Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia .", "tokens": ["Chronic", "hydroxychloroquine", "use", "associated", "with", "QT", "prolongation", "and", "refractory", "ventricular", "arrhythmia", "."], "event_mentions": [{"id": "16615675_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "16615675_2_Ent1", "role": "Treatment", "text": "Chronic hydroxychloroquine", "start": 0, "end": 2}, {"entity_id": "16615675_2_Ent2", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 1, "end": 2}, {"entity_id": "16615675_2_Ent0", "role": "Effect", "text": "QT prolongation and refractory ventricular arrhythmia", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "16615675_2_Ent1", "text": "Chronic hydroxychloroquine", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16615675_2_Ent2", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16615675_2_Ent0", "text": "QT prolongation and refractory ventricular arrhythmia", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "16629074_1", "wnd_id": "16629074_1_1", "text": "PURPOSE : To report a case of traumatic flap dehiscence and Enterobacter keratitis 34 months after LASIK .", "tokens": ["PURPOSE", ":", "To", "report", "a", "case", "of", "traumatic", "flap", "dehiscence", "and", "Enterobacter", "keratitis", "34", "months", "after", "LASIK", "."], "event_mentions": [{"id": "16629074_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "16629074_1_Ent0", "role": "Effect", "text": "traumatic flap dehiscence and Enterobacter keratitis", "start": 7, "end": 13}, {"entity_id": "16629074_1_Ent2", "role": "Treatment_Time_elapsed", "text": "34 months after", "start": 13, "end": 16}, {"entity_id": "16629074_1_Ent1", "role": "Treatment", "text": "34 months after LASIK", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "16629074_1_Ent0", "text": "traumatic flap dehiscence and Enterobacter keratitis", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "16629074_1_Ent2", "text": "34 months after", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "16629074_1_Ent1", "text": "34 months after LASIK", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "16637972_2", "wnd_id": "16637972_2_1", "text": "An unusual presentation of spontaneous sub - conjunctival haematoma in a patient receiving warfarin .", "tokens": ["An", "unusual", "presentation", "of", "spontaneous", "sub", "-", "conjunctival", "haematoma", "in", "a", "patient", "receiving", "warfarin", "."], "event_mentions": [{"id": "16637972_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 9, "end": 10}, "arguments": [{"entity_id": "16637972_2_Ent1", "role": "Effect", "text": "spontaneous sub - conjunctival haematoma", "start": 4, "end": 9}, {"entity_id": "16637972_2_Ent0", "role": "Subject", "text": "a patient", "start": 10, "end": 12}, {"entity_id": "16637972_2_Ent2", "role": "Treatment", "text": "warfarin", "start": 13, "end": 14}, {"entity_id": "16637972_2_Ent3", "role": "Treatment_Drug", "text": "warfarin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "16637972_2_Ent1", "text": "spontaneous sub - conjunctival haematoma", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16637972_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "16637972_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16637972_2_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "16649344_3", "wnd_id": "16649344_3_1", "text": "Sirolimus works differently from the immunosuppressants currently available , and except for increased lipid levels , the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus .", "tokens": ["Sirolimus", "works", "differently", "from", "the", "immunosuppressants", "currently", "available", ",", "and", "except", "for", "increased", "lipid", "levels", ",", "the", "adverse", "reaction", "profile", "of", "sirolimus", "does", "not", "appear", "to", "overlap", "to", "any", "great", "extent", "with", "that", "associated", "with", "cyclosporine", "or", "tacrolimus", "."], "event_mentions": [{"id": "16649344_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "for", "start": 11, "end": 12}, "arguments": [{"entity_id": "16649344_3_Ent2", "role": "Treatment_Drug", "text": "Sirolimus", "start": 0, "end": 1}, {"entity_id": "16649344_3_Ent1", "role": "Treatment", "text": "Sirolimus works differently from the immunosuppressants currently available", "start": 0, "end": 8}, {"entity_id": "16649344_3_Ent3", "role": "Treatment_Drug", "text": "immunosuppressants", "start": 5, "end": 6}, {"entity_id": "16649344_3_Ent0", "role": "Effect", "text": "increased lipid levels", "start": 12, "end": 15}, {"entity_id": "16649344_3_Ent4", "role": "Treatment_Drug", "text": "sirolimus", "start": 21, "end": 22}, {"entity_id": "16649344_3_Ent5", "role": "Treatment_Drug", "text": "cyclosporine", "start": 35, "end": 36}, {"entity_id": "16649344_3_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "16649344_3_Ent2", "text": "Sirolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16649344_3_Ent1", "text": "Sirolimus works differently from the immunosuppressants currently available", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16649344_3_Ent3", "text": "immunosuppressants", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "16649344_3_Ent0", "text": "increased lipid levels", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "16649344_3_Ent4", "text": "sirolimus", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16649344_3_Ent5", "text": "cyclosporine", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "16649344_3_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "16680561_10", "wnd_id": "16680561_10_1", "text": "Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .", "tokens": ["Fewer", "subjects", "reported", "adverse", "events", "following", "treatment", "with", "desipramine", "alone", "than", "when", "receiving", "desipramine", "with", "cinacalcet", "(", "33", "versus", "86", "%", ")", ",", "the", "most", "frequent", "of", "which", "(", "nausea", "and", "headache", ")", "have", "been", "reported", "for", "patients", "treated", "with", "either", "desipramine", "or", "cinacalcet", "."], "event_mentions": [{"id": "16680561_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 35, "end": 36}, "arguments": [{"entity_id": "16680561_10_Ent5", "role": "Treatment_Drug", "text": "desipramine", "start": 8, "end": 9}, {"entity_id": "16680561_10_Ent6", "role": "Treatment_Drug", "text": "desipramine", "start": 13, "end": 14}, {"entity_id": "16680561_10_Ent8", "role": "Combination_Drug", "text": "desipramine", "start": 13, "end": 14}, {"entity_id": "16680561_10_Ent7", "role": "Treatment_Drug", "text": "cinacalcet", "start": 15, "end": 16}, {"entity_id": "16680561_10_Ent9", "role": "Combination_Drug", "text": "cinacalcet", "start": 15, "end": 16}, {"entity_id": "16680561_10_Ent1", "role": "Effect", "text": "nausea and headache", "start": 29, "end": 32}, {"entity_id": "16680561_10_Ent0", "role": "Subject", "text": "patients", "start": 37, "end": 38}, {"entity_id": "16680561_10_Ent3", "role": "Treatment_Drug", "text": "desipramine", "start": 41, "end": 42}, {"entity_id": "16680561_10_Ent2", "role": "Treatment", "text": "desipramine or cinacalcet", "start": 41, "end": 44}, {"entity_id": "16680561_10_Ent4", "role": "Treatment_Drug", "text": "cinacalcet", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "16680561_10_Ent5", "text": "desipramine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16680561_10_Ent6", "text": "desipramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16680561_10_Ent8", "text": "desipramine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16680561_10_Ent7", "text": "cinacalcet", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16680561_10_Ent9", "text": "cinacalcet", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16680561_10_Ent1", "text": "nausea and headache", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "16680561_10_Ent0", "text": "patients", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "16680561_10_Ent3", "text": "desipramine", "entity_type": "Entity", "start": 41, "end": 42}, {"id": "16680561_10_Ent2", "text": "desipramine or cinacalcet", "entity_type": "Entity", "start": 41, "end": 44}, {"id": "16680561_10_Ent4", "text": "cinacalcet", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "16682062_3", "wnd_id": "16682062_3_1", "text": "We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed severe hepatitis , identified 1 month after a single dose of ivermectin .", "tokens": ["We", "report", "the", "case", "of", "a", "20", "-", "year", "-", "old", "woman", "originally", "from", "Cameroon", "who", "was", "infected", "by", "the", "L.", "loa", "parasite", "and", "developed", "severe", "hepatitis", ",", "identified", "1", "month", "after", "a", "single", "dose", "of", "ivermectin", "."], "event_mentions": [{"id": "16682062_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 24, "end": 25}, "arguments": [{"entity_id": "16682062_3_Ent1", "role": "Subject_Age", "text": "20 - year - old", "start": 6, "end": 11}, {"entity_id": "16682062_3_Ent0", "role": "Subject", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "start": 6, "end": 23}, {"entity_id": "16682062_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "16682062_3_Ent3", "role": "Subject_Race", "text": "Cameroon", "start": 14, "end": 15}, {"entity_id": "16682062_3_Ent6", "role": "Treatment_Disorder", "text": "infected by the L. loa parasite", "start": 17, "end": 23}, {"entity_id": "16682062_3_Ent4", "role": "Effect", "text": "severe hepatitis", "start": 25, "end": 27}, {"entity_id": "16682062_3_Ent7", "role": "Treatment_Time_elapsed", "text": "1 month", "start": 29, "end": 31}, {"entity_id": "16682062_3_Ent5", "role": "Treatment", "text": "1 month after a single dose of ivermectin", "start": 29, "end": 37}, {"entity_id": "16682062_3_Ent8", "role": "Treatment_Dosage", "text": "single dose", "start": 33, "end": 35}, {"entity_id": "16682062_3_Ent9", "role": "Treatment_Drug", "text": "ivermectin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "16682062_3_Ent1", "text": "20 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "16682062_3_Ent0", "text": "20 - year - old woman originally from Cameroon who was infected by the L. loa parasite", "entity_type": "Entity", "start": 6, "end": 23}, {"id": "16682062_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "16682062_3_Ent3", "text": "Cameroon", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16682062_3_Ent6", "text": "infected by the L. loa parasite", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "16682062_3_Ent4", "text": "severe hepatitis", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "16682062_3_Ent7", "text": "1 month", "entity_type": "Entity", "start": 29, "end": 31}, {"id": "16682062_3_Ent5", "text": "1 month after a single dose of ivermectin", "entity_type": "Entity", "start": 29, "end": 37}, {"id": "16682062_3_Ent8", "text": "single dose", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "16682062_3_Ent9", "text": "ivermectin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "16685007_2", "wnd_id": "16685007_2_1", "text": "Oral corticosteroids ( OCS ) may be associated with systemic adverse events ( AEs ) , which can be reduced by replacing OCS with inhaled corticosteroids ( ICS ) .", "tokens": ["Oral", "corticosteroids", "(", "OCS", ")", "may", "be", "associated", "with", "systemic", "adverse", "events", "(", "AEs", ")", ",", "which", "can", "be", "reduced", "by", "replacing", "OCS", "with", "inhaled", "corticosteroids", "(", "ICS", ")", "."], "event_mentions": [{"id": "16685007_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "16685007_2_Ent3", "role": "Treatment_Route", "text": "Oral", "start": 0, "end": 1}, {"entity_id": "16685007_2_Ent1", "role": "Treatment", "text": "Oral corticosteroids ( OCS )", "start": 0, "end": 5}, {"entity_id": "16685007_2_Ent2", "role": "Treatment_Drug", "text": "corticosteroids", "start": 1, "end": 2}, {"entity_id": "16685007_2_Ent0", "role": "Effect", "text": "systemic adverse events ( AEs )", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "16685007_2_Ent3", "text": "Oral", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16685007_2_Ent1", "text": "Oral corticosteroids ( OCS )", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "16685007_2_Ent2", "text": "corticosteroids", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "16685007_2_Ent0", "text": "systemic adverse events ( AEs )", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "16685007_5", "wnd_id": "16685007_5_1", "text": "Adult and adolescent patients ( > or = 12 years old ; n = 141 ) with severe , persistent , oral steroid ( prednisone) - dependent asthma .", "tokens": ["Adult", "and", "adolescent", "patients", "(", ">", "or", "=", "12", "years", "old", ";", "n", "=", "141", ")", "with", "severe", ",", "persistent", ",", "oral", "steroid", "(", "prednisone)", "-", "dependent", "asthma", "."], "event_mentions": [{"id": "16685007_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "dependent", "start": 26, "end": 27}, "arguments": [{"entity_id": "16685007_5_Ent1", "role": "Subject_Age", "text": "Adult and adolescent", "start": 0, "end": 3}, {"entity_id": "16685007_5_Ent0", "role": "Subject", "text": "Adult and adolescent patients", "start": 0, "end": 4}, {"entity_id": "16685007_5_Ent4", "role": "Treatment_Route", "text": "oral", "start": 21, "end": 22}, {"entity_id": "16685007_5_Ent3", "role": "Treatment", "text": "oral steroid ( prednisone)", "start": 21, "end": 25}, {"entity_id": "16685007_5_Ent5", "role": "Treatment_Drug", "text": "steroid", "start": 22, "end": 23}, {"entity_id": "16685007_5_Ent6", "role": "Treatment_Drug", "text": "prednisone)", "start": 24, "end": 25}, {"entity_id": "16685007_5_Ent2", "role": "Effect", "text": "asthma", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "16685007_5_Ent1", "text": "Adult and adolescent", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16685007_5_Ent0", "text": "Adult and adolescent patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "16685007_5_Ent4", "text": "oral", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "16685007_5_Ent3", "text": "oral steroid ( prednisone)", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "16685007_5_Ent5", "text": "steroid", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "16685007_5_Ent6", "text": "prednisone)", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "16685007_5_Ent2", "text": "asthma", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "16685112_2", "wnd_id": "16685112_2_1", "text": "CONCLUSIONS : This is the second case report that describes gemcitabine - induced radiation recall in rectus abdominus muscles after gemcitabine - based radiation therapy .", "tokens": ["CONCLUSIONS", ":", "This", "is", "the", "second", "case", "report", "that", "describes", "gemcitabine", "-", "induced", "radiation", "recall", "in", "rectus", "abdominus", "muscles", "after", "gemcitabine", "-", "based", "radiation", "therapy", "."], "event_mentions": [{"id": "16685112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "16685112_2_Ent1", "role": "Treatment", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16685112_2_Ent2", "role": "Treatment_Drug", "text": "gemcitabine", "start": 10, "end": 11}, {"entity_id": "16685112_2_Ent0", "role": "Effect", "text": "radiation recall in rectus abdominus muscles", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "16685112_2_Ent1", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16685112_2_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "16685112_2_Ent0", "text": "radiation recall in rectus abdominus muscles", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "16697705_2", "wnd_id": "16697705_2_1", "text": "This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy .", "tokens": ["This", "case", "highlights", "the", "possible", "development", "of", "acute", "coronary", "syndrome", "as", "a", "side", "effect", "of", "Capecitabine", "therapy", "."], "event_mentions": [{"id": "16697705_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 5, "end": 6}, "arguments": [{"entity_id": "16697705_2_Ent0", "role": "Subject", "text": "This case", "start": 0, "end": 2}, {"entity_id": "16697705_2_Ent1", "role": "Effect", "text": "acute coronary syndrome", "start": 7, "end": 10}, {"entity_id": "16697705_2_Ent2", "role": "Treatment", "text": "Capecitabine", "start": 15, "end": 16}, {"entity_id": "16697705_2_Ent3", "role": "Treatment_Drug", "text": "Capecitabine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "16697705_2_Ent0", "text": "This case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16697705_2_Ent1", "text": "acute coronary syndrome", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "16697705_2_Ent2", "text": "Capecitabine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "16697705_2_Ent3", "text": "Capecitabine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "16728538_4", "wnd_id": "16728538_4_1", "text": "We report on a patient with acromegaly who developed severe drug - induced hepatitis during combined treatment with the long - acting somatostatin - analog octreotide and the GH receptor antagonist pegvisomant .", "tokens": ["We", "report", "on", "a", "patient", "with", "acromegaly", "who", "developed", "severe", "drug", "-", "induced", "hepatitis", "during", "combined", "treatment", "with", "the", "long", "-", "acting", "somatostatin", "-", "analog", "octreotide", "and", "the", "GH", "receptor", "antagonist", "pegvisomant", "."], "event_mentions": [{"id": "16728538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "16728538_4_Ent0", "role": "Subject", "text": "a patient with acromegaly", "start": 3, "end": 7}, {"entity_id": "16728538_4_Ent4", "role": "Treatment_Disorder", "text": "acromegaly", "start": 6, "end": 7}, {"entity_id": "16728538_4_Ent1", "role": "Effect", "text": "hepatitis", "start": 13, "end": 14}, {"entity_id": "16728538_4_Ent2", "role": "Treatment", "text": "long - acting somatostatin - analog octreotide", "start": 19, "end": 26}, {"entity_id": "16728538_4_Ent6", "role": "Treatment_Drug", "text": "octreotide", "start": 25, "end": 26}, {"entity_id": "16728538_4_Ent8", "role": "Combination_Drug", "text": "octreotide", "start": 25, "end": 26}, {"entity_id": "16728538_4_Ent3", "role": "Treatment", "text": "GH receptor antagonist pegvisomant", "start": 28, "end": 32}, {"entity_id": "16728538_4_Ent5", "role": "Treatment_Drug", "text": "pegvisomant", "start": 31, "end": 32}, {"entity_id": "16728538_4_Ent7", "role": "Combination_Drug", "text": "pegvisomant", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "16728538_4_Ent0", "text": "a patient with acromegaly", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "16728538_4_Ent4", "text": "acromegaly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16728538_4_Ent1", "text": "hepatitis", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16728538_4_Ent2", "text": "long - acting somatostatin - analog octreotide", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "16728538_4_Ent6", "text": "octreotide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16728538_4_Ent8", "text": "octreotide", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "16728538_4_Ent3", "text": "GH receptor antagonist pegvisomant", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "16728538_4_Ent5", "text": "pegvisomant", "entity_type": "Entity", "start": 31, "end": 32}, {"id": "16728538_4_Ent7", "text": "pegvisomant", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "16765687_1", "wnd_id": "16765687_1_1", "text": "PURPOSE : Topiramate - induced angle - closure glaucoma ( TiACG ) is believed to be related to its sulfonamide moiety .", "tokens": ["PURPOSE", ":", "Topiramate", "-", "induced", "angle", "-", "closure", "glaucoma", "(", "TiACG", ")", "is", "believed", "to", "be", "related", "to", "its", "sulfonamide", "moiety", "."], "event_mentions": [{"id": "16765687_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "16765687_1_Ent1", "role": "Treatment", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "16765687_1_Ent2", "role": "Treatment_Drug", "text": "Topiramate", "start": 2, "end": 3}, {"entity_id": "16765687_1_Ent0", "role": "Effect", "text": "angle - closure glaucoma ( TiACG )", "start": 5, "end": 12}]}], "entity_mentions": [{"id": "16765687_1_Ent1", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16765687_1_Ent2", "text": "Topiramate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16765687_1_Ent0", "text": "angle - closure glaucoma ( TiACG )", "entity_type": "Entity", "start": 5, "end": 12}], "lang": "en"}
{"doc_id": "16767537_3", "wnd_id": "16767537_3_1", "text": "We report a patient who developed spontaneous splenic infarction after the use of sumatriptan for the treatment of migraine headache .", "tokens": ["We", "report", "a", "patient", "who", "developed", "spontaneous", "splenic", "infarction", "after", "the", "use", "of", "sumatriptan", "for", "the", "treatment", "of", "migraine", "headache", "."], "event_mentions": [{"id": "16767537_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "16767537_3_Ent0", "role": "Subject", "text": "a patient", "start": 2, "end": 4}, {"entity_id": "16767537_3_Ent1", "role": "Effect", "text": "spontaneous splenic infarction", "start": 6, "end": 9}, {"entity_id": "16767537_3_Ent2", "role": "Treatment", "text": "sumatriptan", "start": 13, "end": 14}, {"entity_id": "16767537_3_Ent4", "role": "Treatment_Drug", "text": "sumatriptan", "start": 13, "end": 14}, {"entity_id": "16767537_3_Ent3", "role": "Treatment_Disorder", "text": "migraine headache", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "16767537_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16767537_3_Ent1", "text": "spontaneous splenic infarction", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "16767537_3_Ent2", "text": "sumatriptan", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16767537_3_Ent4", "text": "sumatriptan", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "16767537_3_Ent3", "text": "migraine headache", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "16791713_4", "wnd_id": "16791713_4_1", "text": "We conclude that myocardial infarction may develop in patients treated with high - dose glucocorticoids for Graves ' ophthalmopathy , and increased blood pressure may herald this complication .", "tokens": ["We", "conclude", "that", "myocardial", "infarction", "may", "develop", "in", "patients", "treated", "with", "high", "-", "dose", "glucocorticoids", "for", "Graves", "'", "ophthalmopathy", ",", "and", "increased", "blood", "pressure", "may", "herald", "this", "complication", "."], "event_mentions": [{"id": "16791713_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 6, "end": 7}, "arguments": [{"entity_id": "16791713_4_Ent1", "role": "Effect", "text": "myocardial infarction", "start": 3, "end": 5}, {"entity_id": "16791713_4_Ent0", "role": "Subject", "text": "patients", "start": 8, "end": 9}, {"entity_id": "16791713_4_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "16791713_4_Ent3", "role": "Treatment", "text": "high - dose glucocorticoids", "start": 11, "end": 15}, {"entity_id": "16791713_4_Ent4", "role": "Treatment_Drug", "text": "glucocorticoids", "start": 14, "end": 15}, {"entity_id": "16791713_4_Ent6", "role": "Treatment_Disorder", "text": "Graves ' ophthalmopathy", "start": 16, "end": 19}, {"entity_id": "16791713_4_Ent2", "role": "Effect", "text": "increased blood pressure", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "16791713_4_Ent1", "text": "myocardial infarction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "16791713_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16791713_4_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "16791713_4_Ent3", "text": "high - dose glucocorticoids", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "16791713_4_Ent4", "text": "glucocorticoids", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "16791713_4_Ent6", "text": "Graves ' ophthalmopathy", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "16791713_4_Ent2", "text": "increased blood pressure", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "16816519_5", "wnd_id": "16816519_5_1", "text": "Five days after the fourth dose of vincristine , she presented with bilateral ptosis .", "tokens": ["Five", "days", "after", "the", "fourth", "dose", "of", "vincristine", ",", "she", "presented", "with", "bilateral", "ptosis", "."], "event_mentions": [{"id": "16816519_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 10, "end": 11}, "arguments": [{"entity_id": "16816519_5_Ent4", "role": "Treatment_Time_elapsed", "text": "Five days", "start": 0, "end": 2}, {"entity_id": "16816519_5_Ent3", "role": "Treatment", "text": "Five days after the fourth dose of vincristine", "start": 0, "end": 8}, {"entity_id": "16816519_5_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 7, "end": 8}, {"entity_id": "16816519_5_Ent0", "role": "Subject", "text": "she", "start": 9, "end": 10}, {"entity_id": "16816519_5_Ent1", "role": "Subject_Gender", "text": "she", "start": 9, "end": 10}, {"entity_id": "16816519_5_Ent2", "role": "Effect", "text": "bilateral ptosis", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "16816519_5_Ent4", "text": "Five days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "16816519_5_Ent3", "text": "Five days after the fourth dose of vincristine", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "16816519_5_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16816519_5_Ent0", "text": "she", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16816519_5_Ent1", "text": "she", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16816519_5_Ent2", "text": "bilateral ptosis", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "16854757_1", "wnd_id": "16854757_1_1", "text": "We describe a case of a man treated with an EGFR - inhibitor ( erlotinib ) for a cell lung cancer who developed skin manifestations localized in an uncommon area and with an atypical evolution .", "tokens": ["We", "describe", "a", "case", "of", "a", "man", "treated", "with", "an", "EGFR", "-", "inhibitor", "(", "erlotinib", ")", "for", "a", "cell", "lung", "cancer", "who", "developed", "skin", "manifestations", "localized", "in", "an", "uncommon", "area", "and", "with", "an", "atypical", "evolution", "."], "event_mentions": [{"id": "16854757_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "16854757_1_Ent0", "role": "Subject", "text": "a man", "start": 5, "end": 7}, {"entity_id": "16854757_1_Ent1", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "16854757_1_Ent5", "role": "Treatment_Drug", "text": "EGFR - inhibitor", "start": 10, "end": 13}, {"entity_id": "16854757_1_Ent3", "role": "Treatment", "text": "EGFR - inhibitor ( erlotinib )", "start": 10, "end": 16}, {"entity_id": "16854757_1_Ent4", "role": "Treatment_Disorder", "text": "cell lung cancer", "start": 18, "end": 21}, {"entity_id": "16854757_1_Ent2", "role": "Effect", "text": "skin manifestations localized in an uncommon area and with an atypical evolution", "start": 23, "end": 35}]}], "entity_mentions": [{"id": "16854757_1_Ent0", "text": "a man", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "16854757_1_Ent1", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16854757_1_Ent5", "text": "EGFR - inhibitor", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "16854757_1_Ent3", "text": "EGFR - inhibitor ( erlotinib )", "entity_type": "Entity", "start": 10, "end": 16}, {"id": "16854757_1_Ent4", "text": "cell lung cancer", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "16854757_1_Ent2", "text": "skin manifestations localized in an uncommon area and with an atypical evolution", "entity_type": "Entity", "start": 23, "end": 35}], "lang": "en"}
{"doc_id": "16882112_2", "wnd_id": "16882112_2_1", "text": "Serotonin syndrome , which occurs as a result of enhanced serotonin concentration in the central nervous system , is a well - known adverse effect of serotonin - active medications .", "tokens": ["Serotonin", "syndrome", ",", "which", "occurs", "as", "a", "result", "of", "enhanced", "serotonin", "concentration", "in", "the", "central", "nervous", "system", ",", "is", "a", "well", "-", "known", "adverse", "effect", "of", "serotonin", "-", "active", "medications", "."], "event_mentions": [{"id": "16882112_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurs", "start": 4, "end": 5}, "arguments": [{"entity_id": "16882112_2_Ent0", "role": "Effect", "text": "Serotonin syndrome ,", "start": 0, "end": 3}, {"entity_id": "16882112_2_Ent1", "role": "Treatment", "text": "serotonin - active medications", "start": 26, "end": 30}]}], "entity_mentions": [{"id": "16882112_2_Ent0", "text": "Serotonin syndrome ,", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16882112_2_Ent1", "text": "serotonin - active medications", "entity_type": "Entity", "start": 26, "end": 30}], "lang": "en"}
{"doc_id": "16882112_3", "wnd_id": "16882112_3_1", "text": "The concomitant use of antidepressant drugs associated with lithium as a co - adjuvant seems to increase the risk of this adverse reaction .", "tokens": ["The", "concomitant", "use", "of", "antidepressant", "drugs", "associated", "with", "lithium", "as", "a", "co", "-", "adjuvant", "seems", "to", "increase", "the", "risk", "of", "this", "adverse", "reaction", "."], "event_mentions": [{"id": "16882112_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 16, "end": 17}, "arguments": [{"entity_id": "16882112_3_Ent1", "role": "Treatment", "text": "concomitant use of antidepressant drugs associated with lithium as a co - adjuvant", "start": 1, "end": 14}, {"entity_id": "16882112_3_Ent2", "role": "Treatment_Drug", "text": "antidepressant drugs", "start": 4, "end": 6}, {"entity_id": "16882112_3_Ent4", "role": "Combination_Drug", "text": "antidepressant drugs", "start": 4, "end": 6}, {"entity_id": "16882112_3_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "16882112_3_Ent5", "role": "Combination_Drug", "text": "lithium", "start": 8, "end": 9}, {"entity_id": "16882112_3_Ent0", "role": "Effect", "text": "adverse reaction", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "16882112_3_Ent1", "text": "concomitant use of antidepressant drugs associated with lithium as a co - adjuvant", "entity_type": "Entity", "start": 1, "end": 14}, {"id": "16882112_3_Ent2", "text": "antidepressant drugs", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16882112_3_Ent4", "text": "antidepressant drugs", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "16882112_3_Ent3", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16882112_3_Ent5", "text": "lithium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16882112_3_Ent0", "text": "adverse reaction", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "16882112_5", "wnd_id": "16882112_5_1", "text": "A 71 - year - old woman developed serotonin syndrome while receiving treatment with moderate doses of lithium and venlafaxine for refractory depression .", "tokens": ["A", "71", "-", "year", "-", "old", "woman", "developed", "serotonin", "syndrome", "while", "receiving", "treatment", "with", "moderate", "doses", "of", "lithium", "and", "venlafaxine", "for", "refractory", "depression", "."], "event_mentions": [{"id": "16882112_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "16882112_5_Ent0", "role": "Subject", "text": "A 71 - year - old woman", "start": 0, "end": 7}, {"entity_id": "16882112_5_Ent1", "role": "Subject_Age", "text": "71 - year - old", "start": 1, "end": 6}, {"entity_id": "16882112_5_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "16882112_5_Ent3", "role": "Effect", "text": "serotonin syndrome", "start": 8, "end": 10}, {"entity_id": "16882112_5_Ent6", "role": "Treatment_Dosage", "text": "moderate doses", "start": 14, "end": 16}, {"entity_id": "16882112_5_Ent4", "role": "Treatment", "text": "moderate doses of lithium and venlafaxine", "start": 14, "end": 20}, {"entity_id": "16882112_5_Ent7", "role": "Treatment_Drug", "text": "lithium", "start": 17, "end": 18}, {"entity_id": "16882112_5_Ent9", "role": "Combination_Drug", "text": "lithium", "start": 17, "end": 18}, {"entity_id": "16882112_5_Ent8", "role": "Treatment_Drug", "text": "venlafaxine", "start": 19, "end": 20}, {"entity_id": "16882112_5_Ent10", "role": "Combination_Drug", "text": "venlafaxine", "start": 19, "end": 20}, {"entity_id": "16882112_5_Ent5", "role": "Treatment_Disorder", "text": "refractory depression", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "16882112_5_Ent0", "text": "A 71 - year - old woman", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "16882112_5_Ent1", "text": "71 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "16882112_5_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "16882112_5_Ent3", "text": "serotonin syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16882112_5_Ent6", "text": "moderate doses", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "16882112_5_Ent4", "text": "moderate doses of lithium and venlafaxine", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "16882112_5_Ent7", "text": "lithium", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16882112_5_Ent9", "text": "lithium", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16882112_5_Ent8", "text": "venlafaxine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16882112_5_Ent10", "text": "venlafaxine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16882112_5_Ent5", "text": "refractory depression", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "1688693_3", "wnd_id": "1688693_3_1", "text": "She manifested all the clinical symptoms and signs of caffeine toxicity .", "tokens": ["She", "manifested", "all", "the", "clinical", "symptoms", "and", "signs", "of", "caffeine", "toxicity", "."], "event_mentions": [{"id": "1688693_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "manifested", "start": 1, "end": 2}, "arguments": [{"entity_id": "1688693_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "1688693_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "1688693_3_Ent2", "role": "Effect", "text": "all the clinical symptoms and signs of caffeine toxicity .", "start": 2, "end": 12}, {"entity_id": "1688693_3_Ent3", "role": "Treatment", "text": "caffeine", "start": 9, "end": 10}, {"entity_id": "1688693_3_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "1688693_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1688693_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1688693_3_Ent2", "text": "all the clinical symptoms and signs of caffeine toxicity .", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "1688693_3_Ent3", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1688693_3_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "16901609_1", "wnd_id": "16901609_1_1", "text": "Anaphylaxis to intrathecal diamorphine .", "tokens": ["Anaphylaxis", "to", "intrathecal", "diamorphine", "."], "event_mentions": [{"id": "16901609_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "16901609_1_Ent0", "role": "Effect", "text": "Anaphylaxis", "start": 0, "end": 1}, {"entity_id": "16901609_1_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "16901609_1_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 2, "end": 4}, {"entity_id": "16901609_1_Ent3", "role": "Treatment_Drug", "text": "diamorphine", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "16901609_1_Ent0", "text": "Anaphylaxis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "16901609_1_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "16901609_1_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "16901609_1_Ent3", "text": "diamorphine", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "16901609_2", "wnd_id": "16901609_2_1", "text": "We believe this is the first report of intrathecal diamorphine causing anaphylaxis .", "tokens": ["We", "believe", "this", "is", "the", "first", "report", "of", "intrathecal", "diamorphine", "causing", "anaphylaxis", "."], "event_mentions": [{"id": "16901609_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 10, "end": 11}, "arguments": [{"entity_id": "16901609_2_Ent3", "role": "Treatment_Route", "text": "intrathecal", "start": 8, "end": 9}, {"entity_id": "16901609_2_Ent1", "role": "Treatment", "text": "intrathecal diamorphine", "start": 8, "end": 10}, {"entity_id": "16901609_2_Ent2", "role": "Treatment_Drug", "text": "diamorphine", "start": 9, "end": 10}, {"entity_id": "16901609_2_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16901609_2_Ent3", "text": "intrathecal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "16901609_2_Ent1", "text": "intrathecal diamorphine", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "16901609_2_Ent2", "text": "diamorphine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16901609_2_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "16939867_3", "wnd_id": "16939867_3_1", "text": "This report describes a 13 - year - old female with a right frontal high - grade glioma and complex partial seizures who developed localized purpura after 23 months of lamotrigine monotherapy .", "tokens": ["This", "report", "describes", "a", "13", "-", "year", "-", "old", "female", "with", "a", "right", "frontal", "high", "-", "grade", "glioma", "and", "complex", "partial", "seizures", "who", "developed", "localized", "purpura", "after", "23", "months", "of", "lamotrigine", "monotherapy", "."], "event_mentions": [{"id": "16939867_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 26, "end": 27}, "arguments": [{"entity_id": "16939867_3_Ent0", "role": "Subject", "text": "a 13 - year - old female with a right frontal high - grade glioma and complex partial seizures", "start": 3, "end": 22}, {"entity_id": "16939867_3_Ent1", "role": "Subject_Age", "text": "13 - year - old", "start": 4, "end": 9}, {"entity_id": "16939867_3_Ent2", "role": "Subject_Gender", "text": "female", "start": 9, "end": 10}, {"entity_id": "16939867_3_Ent3", "role": "Subject_Disorder", "text": "right frontal high - grade glioma", "start": 12, "end": 18}, {"entity_id": "16939867_3_Ent8", "role": "Treatment_Disorder", "text": "complex partial seizures", "start": 19, "end": 22}, {"entity_id": "16939867_3_Ent4", "role": "Effect", "text": "localized purpura", "start": 24, "end": 26}, {"entity_id": "16939867_3_Ent7", "role": "Treatment_Disorder", "text": "23 months", "start": 27, "end": 29}, {"entity_id": "16939867_3_Ent5", "role": "Treatment", "text": "23 months of lamotrigine monotherapy", "start": 27, "end": 32}, {"entity_id": "16939867_3_Ent6", "role": "Treatment_Drug", "text": "lamotrigine", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "16939867_3_Ent0", "text": "a 13 - year - old female with a right frontal high - grade glioma and complex partial seizures", "entity_type": "Entity", "start": 3, "end": 22}, {"id": "16939867_3_Ent1", "text": "13 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "16939867_3_Ent2", "text": "female", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16939867_3_Ent3", "text": "right frontal high - grade glioma", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "16939867_3_Ent8", "text": "complex partial seizures", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "16939867_3_Ent4", "text": "localized purpura", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "16939867_3_Ent7", "text": "23 months", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "16939867_3_Ent5", "text": "23 months of lamotrigine monotherapy", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "16939867_3_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "1695794_4", "wnd_id": "1695794_4_1", "text": "She had been taking rifampin prior to admission for acid - fast bacilli .", "tokens": ["She", "had", "been", "taking", "rifampin", "prior", "to", "admission", "for", "acid", "-", "fast", "bacilli", "."], "event_mentions": [{"id": "1695794_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "taking", "start": 3, "end": 4}, "arguments": [{"entity_id": "1695794_4_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "1695794_4_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "1695794_4_Ent2", "role": "Treatment", "text": "rifampin", "start": 4, "end": 5}, {"entity_id": "1695794_4_Ent3", "role": "Treatment_Disorder", "text": "acid - fast bacilli", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "1695794_4_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1695794_4_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1695794_4_Ent2", "text": "rifampin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1695794_4_Ent3", "text": "acid - fast bacilli", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "16960880_1", "wnd_id": "16960880_1_1", "text": "Despite a very low complication rate , several severe arterial thrombotic events have been reported following thrombin injection of pseudoaneurysms .", "tokens": ["Despite", "a", "very", "low", "complication", "rate", ",", "several", "severe", "arterial", "thrombotic", "events", "have", "been", "reported", "following", "thrombin", "injection", "of", "pseudoaneurysms", "."], "event_mentions": [{"id": "16960880_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 15, "end": 16}, "arguments": [{"entity_id": "16960880_1_Ent0", "role": "Effect", "text": "arterial thrombotic", "start": 9, "end": 11}, {"entity_id": "16960880_1_Ent2", "role": "Treatment_Drug", "text": "thrombin", "start": 16, "end": 17}, {"entity_id": "16960880_1_Ent1", "role": "Treatment", "text": "thrombin injection", "start": 16, "end": 18}, {"entity_id": "16960880_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 17, "end": 18}, {"entity_id": "16960880_1_Ent4", "role": "Treatment_Disorder", "text": "pseudoaneurysms", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "16960880_1_Ent0", "text": "arterial thrombotic", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "16960880_1_Ent2", "text": "thrombin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "16960880_1_Ent1", "text": "thrombin injection", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "16960880_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "16960880_1_Ent4", "text": "pseudoaneurysms", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "16968538_1", "wnd_id": "16968538_1_1", "text": "Hemolytic uremic syndrome following the infusion of oxaliplatin : case report .", "tokens": ["Hemolytic", "uremic", "syndrome", "following", "the", "infusion", "of", "oxaliplatin", ":", "case", "report", "."], "event_mentions": [{"id": "16968538_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "16968538_1_Ent0", "role": "Effect", "text": "Hemolytic uremic syndrome", "start": 0, "end": 3}, {"entity_id": "16968538_1_Ent1", "role": "Treatment", "text": "oxaliplatin", "start": 7, "end": 8}, {"entity_id": "16968538_1_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "16968538_1_Ent0", "text": "Hemolytic uremic syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16968538_1_Ent1", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "16968538_1_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "16968538_4", "wnd_id": "16968538_4_1", "text": "We present a case of hemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin .", "tokens": ["We", "present", "a", "case", "of", "hemolytic", "-", "uremic", "syndrome", "that", "developed", "during", "the", "4th", "cycle", "of", "combination", "chemotherapy", "with", "oxaliplatin", ",", "5", "-", "fluorouracil", "and", "leucovorin", "."], "event_mentions": [{"id": "16968538_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "16968538_4_Ent0", "role": "Effect", "text": "hemolytic - uremic syndrome", "start": 5, "end": 9}, {"entity_id": "16968538_4_Ent1", "role": "Treatment", "text": "during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin", "start": 11, "end": 26}, {"entity_id": "16968538_4_Ent2", "role": "Treatment_Drug", "text": "oxaliplatin", "start": 19, "end": 20}, {"entity_id": "16968538_4_Ent3", "role": "Treatment_Drug", "text": "fluorouracil", "start": 23, "end": 24}, {"entity_id": "16968538_4_Ent4", "role": "Treatment_Drug", "text": "leucovorin", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "16968538_4_Ent0", "text": "hemolytic - uremic syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "16968538_4_Ent1", "text": "during the 4th cycle of combination chemotherapy with oxaliplatin , 5 - fluorouracil and leucovorin", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "16968538_4_Ent2", "text": "oxaliplatin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "16968538_4_Ent3", "text": "fluorouracil", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "16968538_4_Ent4", "text": "leucovorin", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "16978752_2", "wnd_id": "16978752_2_1", "text": "Neutropenia and agranulocytosis are risks known to occur with phenothiazines and clozapine .", "tokens": ["Neutropenia", "and", "agranulocytosis", "are", "risks", "known", "to", "occur", "with", "phenothiazines", "and", "clozapine", "."], "event_mentions": [{"id": "16978752_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 7, "end": 8}, "arguments": [{"entity_id": "16978752_2_Ent0", "role": "Effect", "text": "Neutropenia and agranulocytosis", "start": 0, "end": 3}, {"entity_id": "16978752_2_Ent2", "role": "Treatment_Drug", "text": "phenothiazines", "start": 9, "end": 10}, {"entity_id": "16978752_2_Ent1", "role": "Treatment", "text": "phenothiazines and clozapine .", "start": 9, "end": 13}, {"entity_id": "16978752_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "16978752_2_Ent0", "text": "Neutropenia and agranulocytosis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "16978752_2_Ent2", "text": "phenothiazines", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "16978752_2_Ent1", "text": "phenothiazines and clozapine .", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "16978752_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "17009081_1", "wnd_id": "17009081_1_1", "text": "A 43 - year - old woman with multiple sclerosis ( MS ) had nephrotic syndrome 21 months after starting treatment with interferon ( IFN) - beta - 1b ( subcutaneous administration ) .", "tokens": ["A", "43", "-", "year", "-", "old", "woman", "with", "multiple", "sclerosis", "(", "MS", ")", "had", "nephrotic", "syndrome", "21", "months", "after", "starting", "treatment", "with", "interferon", "(", "IFN)", "-", "beta", "-", "1b", "(", "subcutaneous", "administration", ")", "."], "event_mentions": [{"id": "17009081_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 13, "end": 14}, "arguments": [{"entity_id": "17009081_1_Ent0", "role": "Subject", "text": "A 43 - year - old woman with multiple sclerosis ( MS )", "start": 0, "end": 13}, {"entity_id": "17009081_1_Ent1", "role": "Subject_Age", "text": "43 - year - old", "start": 1, "end": 6}, {"entity_id": "17009081_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "17009081_1_Ent5", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 8, "end": 10}, {"entity_id": "17009081_1_Ent3", "role": "Effect", "text": "nephrotic syndrome", "start": 14, "end": 16}, {"entity_id": "17009081_1_Ent7", "role": "Treatment_Time_elapsed", "text": "21 months", "start": 16, "end": 18}, {"entity_id": "17009081_1_Ent4", "role": "Treatment", "text": "21 months after starting treatment with interferon ( IFN) - beta - 1b ( subcutaneous administration )", "start": 16, "end": 33}, {"entity_id": "17009081_1_Ent6", "role": "Treatment_Drug", "text": "interferon ( IFN) - beta - 1b", "start": 22, "end": 29}]}], "entity_mentions": [{"id": "17009081_1_Ent0", "text": "A 43 - year - old woman with multiple sclerosis ( MS )", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "17009081_1_Ent1", "text": "43 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17009081_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17009081_1_Ent5", "text": "multiple sclerosis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17009081_1_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17009081_1_Ent7", "text": "21 months", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17009081_1_Ent4", "text": "21 months after starting treatment with interferon ( IFN) - beta - 1b ( subcutaneous administration )", "entity_type": "Entity", "start": 16, "end": 33}, {"id": "17009081_1_Ent6", "text": "interferon ( IFN) - beta - 1b", "entity_type": "Entity", "start": 22, "end": 29}], "lang": "en"}
{"doc_id": "17026827_2", "wnd_id": "17026827_2_1", "text": "We present a case of severe unilateral posterior scleritis associated with zoledronic acid administration that was recognized and treated in a timely manner .", "tokens": ["We", "present", "a", "case", "of", "severe", "unilateral", "posterior", "scleritis", "associated", "with", "zoledronic", "acid", "administration", "that", "was", "recognized", "and", "treated", "in", "a", "timely", "manner", "."], "event_mentions": [{"id": "17026827_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "17026827_2_Ent0", "role": "Effect", "text": "severe unilateral posterior scleritis", "start": 5, "end": 9}, {"entity_id": "17026827_2_Ent1", "role": "Treatment", "text": "zoledronic acid", "start": 11, "end": 13}, {"entity_id": "17026827_2_Ent2", "role": "Treatment_Drug", "text": "zoledronic acid", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "17026827_2_Ent0", "text": "severe unilateral posterior scleritis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17026827_2_Ent1", "text": "zoledronic acid", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "17026827_2_Ent2", "text": "zoledronic acid", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "17034541_1", "wnd_id": "17034541_1_1", "text": "Late lethal hepatitis B virus reactivation after rituximab treatment of low - grade cutaneous B - cell lymphoma .", "tokens": ["Late", "lethal", "hepatitis", "B", "virus", "reactivation", "after", "rituximab", "treatment", "of", "low", "-", "grade", "cutaneous", "B", "-", "cell", "lymphoma", "."], "event_mentions": [{"id": "17034541_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "17034541_1_Ent0", "role": "Effect", "text": "Late lethal hepatitis B virus reactivation", "start": 0, "end": 6}, {"entity_id": "17034541_1_Ent1", "role": "Treatment", "text": "rituximab", "start": 7, "end": 8}, {"entity_id": "17034541_1_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 7, "end": 8}, {"entity_id": "17034541_1_Ent2", "role": "Treatment_Disorder", "text": "low - grade cutaneous B - cell lymphoma", "start": 10, "end": 18}]}], "entity_mentions": [{"id": "17034541_1_Ent0", "text": "Late lethal hepatitis B virus reactivation", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17034541_1_Ent1", "text": "rituximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17034541_1_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17034541_1_Ent2", "text": "low - grade cutaneous B - cell lymphoma", "entity_type": "Entity", "start": 10, "end": 18}], "lang": "en"}
{"doc_id": "17034541_2", "wnd_id": "17034541_2_1", "text": "Several such HBV reactivations were reported after combined rituximab and multiagent chemotherapy for B - cell lymphomas .", "tokens": ["Several", "such", "HBV", "reactivations", "were", "reported", "after", "combined", "rituximab", "and", "multiagent", "chemotherapy", "for", "B", "-", "cell", "lymphomas", "."], "event_mentions": [{"id": "17034541_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 6, "end": 7}, "arguments": [{"entity_id": "17034541_2_Ent0", "role": "Effect", "text": "Several such HBV reactivations", "start": 0, "end": 4}, {"entity_id": "17034541_2_Ent1", "role": "Treatment", "text": "combined rituximab and multiagent chemotherapy", "start": 7, "end": 12}, {"entity_id": "17034541_2_Ent2", "role": "Treatment_Drug", "text": "rituximab", "start": 8, "end": 9}, {"entity_id": "17034541_2_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 11, "end": 12}, {"entity_id": "17034541_2_Ent3", "role": "Treatment_Disorder", "text": "B - cell lymphomas", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "17034541_2_Ent0", "text": "Several such HBV reactivations", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17034541_2_Ent1", "text": "combined rituximab and multiagent chemotherapy", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17034541_2_Ent2", "text": "rituximab", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17034541_2_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17034541_2_Ent3", "text": "B - cell lymphomas", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "17083890_1", "wnd_id": "17083890_1_1", "text": "Distinct patterns of chromonychia , Beau 's lines , and melanoderma seen with vincristine , adriamycin , dexamethasone therapy for multiple myeloma .", "tokens": ["Distinct", "patterns", "of", "chromonychia", ",", "Beau", "'s", "lines", ",", "and", "melanoderma", "seen", "with", "vincristine", ",", "adriamycin", ",", "dexamethasone", "therapy", "for", "multiple", "myeloma", "."], "event_mentions": [{"id": "17083890_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 11, "end": 12}, "arguments": [{"entity_id": "17083890_1_Ent0", "role": "Effect", "text": "Distinct patterns of chromonychia , Beau 's lines , and melanoderma", "start": 0, "end": 11}, {"entity_id": "17083890_1_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 13, "end": 14}, {"entity_id": "17083890_1_Ent1", "role": "Treatment", "text": "vincristine , adriamycin , dexamethasone", "start": 13, "end": 18}, {"entity_id": "17083890_1_Ent3", "role": "Treatment_Drug", "text": "adriamycin", "start": 15, "end": 16}, {"entity_id": "17083890_1_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 17, "end": 18}, {"entity_id": "17083890_1_Ent5", "role": "Treatment_Disorder", "text": "multiple myeloma", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "17083890_1_Ent0", "text": "Distinct patterns of chromonychia , Beau 's lines , and melanoderma", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "17083890_1_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17083890_1_Ent1", "text": "vincristine , adriamycin , dexamethasone", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "17083890_1_Ent3", "text": "adriamycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17083890_1_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_1_Ent5", "text": "multiple myeloma", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "17083890_8", "wnd_id": "17083890_8_1", "text": "All changes disappeared 4 months after the discontinuation of VAD chemotherapy , which further pointed out towards adriamycin and vincristine as possible etiologic agents .", "tokens": ["All", "changes", "disappeared", "4", "months", "after", "the", "discontinuation", "of", "VAD", "chemotherapy", ",", "which", "further", "pointed", "out", "towards", "adriamycin", "and", "vincristine", "as", "possible", "etiologic", "agents", "."], "event_mentions": [{"id": "17083890_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "etiologic agents", "start": 22, "end": 24}, "arguments": [{"entity_id": "17083890_8_Ent0", "role": "Effect", "text": "All changes", "start": 0, "end": 2}, {"entity_id": "17083890_8_Ent2", "role": "Treatment_Drug", "text": "adriamycin", "start": 17, "end": 18}, {"entity_id": "17083890_8_Ent4", "role": "Combination_Drug", "text": "adriamycin", "start": 17, "end": 18}, {"entity_id": "17083890_8_Ent1", "role": "Treatment", "text": "adriamycin and vincristine", "start": 17, "end": 20}, {"entity_id": "17083890_8_Ent3", "role": "Treatment_Drug", "text": "vincristine", "start": 19, "end": 20}, {"entity_id": "17083890_8_Ent5", "role": "Combination_Drug", "text": "vincristine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17083890_8_Ent0", "text": "All changes", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17083890_8_Ent2", "text": "adriamycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_8_Ent4", "text": "adriamycin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17083890_8_Ent1", "text": "adriamycin and vincristine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17083890_8_Ent3", "text": "vincristine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17083890_8_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17083900_1", "wnd_id": "17083900_1_1", "text": "Acute generalized exanthematous pustulosis induced by nimesulide .", "tokens": ["Acute", "generalized", "exanthematous", "pustulosis", "induced", "by", "nimesulide", "."], "event_mentions": [{"id": "17083900_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17083900_1_Ent0", "role": "Effect", "text": "Acute generalized exanthematous pustulosis", "start": 0, "end": 4}, {"entity_id": "17083900_1_Ent1", "role": "Treatment", "text": "nimesulide", "start": 6, "end": 7}, {"entity_id": "17083900_1_Ent2", "role": "Treatment_Drug", "text": "nimesulide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17083900_1_Ent0", "text": "Acute generalized exanthematous pustulosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17083900_1_Ent1", "text": "nimesulide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17083900_1_Ent2", "text": "nimesulide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17090724_3", "wnd_id": "17090724_3_1", "text": "Use of the Naranjo probability scale indicated a highly probable relationship between the observed cardiac toxicity and amphotericin B deoxycholate therapy in this patient .", "tokens": ["Use", "of", "the", "Naranjo", "probability", "scale", "indicated", "a", "highly", "probable", "relationship", "between", "the", "observed", "cardiac", "toxicity", "and", "amphotericin", "B", "deoxycholate", "therapy", "in", "this", "patient", "."], "event_mentions": [{"id": "17090724_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 10, "end": 11}, "arguments": [{"entity_id": "17090724_3_Ent1", "role": "Effect", "text": "cardiac toxicity", "start": 14, "end": 16}, {"entity_id": "17090724_3_Ent2", "role": "Treatment", "text": "amphotericin B deoxycholate", "start": 17, "end": 20}, {"entity_id": "17090724_3_Ent3", "role": "Treatment_Drug", "text": "amphotericin B deoxycholate", "start": 17, "end": 20}, {"entity_id": "17090724_3_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17090724_3_Ent1", "text": "cardiac toxicity", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "17090724_3_Ent2", "text": "amphotericin B deoxycholate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17090724_3_Ent3", "text": "amphotericin B deoxycholate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "17090724_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "17122225_1", "wnd_id": "17122225_1_1", "text": "Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs .", "tokens": ["Serotonin", "syndrome", "from", "the", "interaction", "of", "cyclobenzaprine", "with", "other", "serotoninergic", "drugs", "."], "event_mentions": [{"id": "17122225_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "17122225_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17122225_1_Ent1", "role": "Treatment", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "start": 4, "end": 11}, {"entity_id": "17122225_1_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 6, "end": 7}, {"entity_id": "17122225_1_Ent3", "role": "Treatment_Drug", "text": "serotoninergic drugs", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17122225_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17122225_1_Ent1", "text": "interaction of cyclobenzaprine with other serotoninergic drugs", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "17122225_1_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17122225_1_Ent3", "text": "serotoninergic drugs", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "17123120_1", "wnd_id": "17123120_1_1", "text": "Tacrolimus - induced HUS : an unusual cause of acute renal failure in nephrotic syndrome .", "tokens": ["Tacrolimus", "-", "induced", "HUS", ":", "an", "unusual", "cause", "of", "acute", "renal", "failure", "in", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "17123120_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17123120_1_Ent1", "role": "Treatment", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent2", "role": "Treatment_Drug", "text": "Tacrolimus", "start": 0, "end": 1}, {"entity_id": "17123120_1_Ent0", "role": "Effect", "text": "HUS", "start": 3, "end": 4}, {"entity_id": "17123120_1_Ent3", "role": "Treatment_Disorder", "text": "nephrotic syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17123120_1_Ent1", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent2", "text": "Tacrolimus", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17123120_1_Ent0", "text": "HUS", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17123120_1_Ent3", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17157086_4", "wnd_id": "17157086_4_1", "text": "Because of chronic asthma , she had been receiving a leukotriene receptor antagonist ( montelukast ) for 5 years before the current presentation ; 1 week before onset she had had 1 week of treatment with two dietary supplements for weight control ; one of these included Garcinia Cambogia , a possible cause of two recent cases of hepatitis in the USA ; in addition , both formulas contained a citrus derivative that interferes cytochrome functions .", "tokens": ["Because", "of", "chronic", "asthma", ",", "she", "had", "been", "receiving", "a", "leukotriene", "receptor", "antagonist", "(", "montelukast", ")", "for", "5", "years", "before", "the", "current", "presentation", ";", "1", "week", "before", "onset", "she", "had", "had", "1", "week", "of", "treatment", "with", "two", "dietary", "supplements", "for", "weight", "control", ";", "one", "of", "these", "included", "Garcinia", "Cambogia", ",", "a", "possible", "cause", "of", "two", "recent", "cases", "of", "hepatitis", "in", "the", "USA", ";", "in", "addition", ",", "both", "formulas", "contained", "a", "citrus", "derivative", "that", "interferes", "cytochrome", "functions", "."], "event_mentions": [{"id": "17157086_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 8, "end": 9}, "arguments": [{"entity_id": "17157086_4_Ent2", "role": "Treatment_Disorder", "text": "chronic asthma", "start": 2, "end": 4}, {"entity_id": "17157086_4_Ent0", "role": "Subject", "text": "she", "start": 5, "end": 6}, {"entity_id": "17157086_4_Ent1", "role": "Treatment", "text": "a leukotriene receptor antagonist ( montelukast ) for 5 years", "start": 9, "end": 19}, {"entity_id": "17157086_4_Ent3", "role": "Treatment_Drug", "text": "montelukast", "start": 14, "end": 15}, {"entity_id": "17157086_4_Ent4", "role": "Treatment_Time_elapsed", "text": "5 years", "start": 17, "end": 19}]}, {"id": "17157086_4_Evt1", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 52, "end": 53}, "arguments": [{"entity_id": "17157086_4_Ent8", "role": "Treatment", "text": "Garcinia Cambogia", "start": 47, "end": 49}, {"entity_id": "17157086_4_Ent9", "role": "Treatment_Drug", "text": "Garcinia Cambogia", "start": 47, "end": 49}, {"entity_id": "17157086_4_Ent6", "role": "Subject_Population", "text": "two", "start": 54, "end": 55}, {"entity_id": "17157086_4_Ent5", "role": "Subject", "text": "two recent cases", "start": 54, "end": 57}, {"entity_id": "17157086_4_Ent7", "role": "Effect", "text": "hepatitis", "start": 58, "end": 59}]}], "entity_mentions": [{"id": "17157086_4_Ent2", "text": "chronic asthma", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "17157086_4_Ent0", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17157086_4_Ent1", "text": "a leukotriene receptor antagonist ( montelukast ) for 5 years", "entity_type": "Entity", "start": 9, "end": 19}, {"id": "17157086_4_Ent3", "text": "montelukast", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17157086_4_Ent4", "text": "5 years", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17157086_4_Ent8", "text": "Garcinia Cambogia", "entity_type": "Entity", "start": 47, "end": 49}, {"id": "17157086_4_Ent9", "text": "Garcinia Cambogia", "entity_type": "Entity", "start": 47, "end": 49}, {"id": "17157086_4_Ent6", "text": "two", "entity_type": "Entity", "start": 54, "end": 55}, {"id": "17157086_4_Ent5", "text": "two recent cases", "entity_type": "Entity", "start": 54, "end": 57}, {"id": "17157086_4_Ent7", "text": "hepatitis", "entity_type": "Entity", "start": 58, "end": 59}], "lang": "en"}
{"doc_id": "17189581_16", "wnd_id": "17189581_16_1", "text": "Serotonin syndrome developed in a patient taking concurrent linezolid and fluoxetine .", "tokens": ["Serotonin", "syndrome", "developed", "in", "a", "patient", "taking", "concurrent", "linezolid", "and", "fluoxetine", "."], "event_mentions": [{"id": "17189581_16_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "17189581_16_Ent1", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "17189581_16_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "17189581_16_Ent2", "role": "Treatment", "text": "concurrent linezolid and fluoxetine", "start": 7, "end": 11}, {"entity_id": "17189581_16_Ent3", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "17189581_16_Ent5", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "17189581_16_Ent4", "role": "Treatment_Drug", "text": "fluoxetine", "start": 10, "end": 11}, {"entity_id": "17189581_16_Ent6", "role": "Combination_Drug", "text": "fluoxetine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17189581_16_Ent1", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17189581_16_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17189581_16_Ent2", "text": "concurrent linezolid and fluoxetine", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "17189581_16_Ent3", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_16_Ent5", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_16_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17189581_16_Ent6", "text": "fluoxetine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17189581_7", "wnd_id": "17189581_7_1", "text": "Despite treatment with levofloxacin , acyclovir , and voriconazole , the patient developed high fevers .", "tokens": ["Despite", "treatment", "with", "levofloxacin", ",", "acyclovir", ",", "and", "voriconazole", ",", "the", "patient", "developed", "high", "fevers", "."], "event_mentions": [{"id": "17189581_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "17189581_7_Ent3", "role": "Treatment_Drug", "text": "levofloxacin", "start": 3, "end": 4}, {"entity_id": "17189581_7_Ent2", "role": "Treatment", "text": "levofloxacin , acyclovir , and voriconazole", "start": 3, "end": 9}, {"entity_id": "17189581_7_Ent4", "role": "Treatment_Drug", "text": "acyclovir", "start": 5, "end": 6}, {"entity_id": "17189581_7_Ent5", "role": "Treatment_Drug", "text": "voriconazole", "start": 8, "end": 9}, {"entity_id": "17189581_7_Ent0", "role": "Subject", "text": "patient", "start": 11, "end": 12}, {"entity_id": "17189581_7_Ent1", "role": "Effect", "text": "high fevers", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17189581_7_Ent3", "text": "levofloxacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17189581_7_Ent2", "text": "levofloxacin , acyclovir , and voriconazole", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "17189581_7_Ent4", "text": "acyclovir", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17189581_7_Ent5", "text": "voriconazole", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17189581_7_Ent0", "text": "patient", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17189581_7_Ent1", "text": "high fevers", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17224428_1", "wnd_id": "17224428_1_1", "text": "Cardiac hypersensitivity and myopericarditis have been reported during long - term treatment with mesalazine .", "tokens": ["Cardiac", "hypersensitivity", "and", "myopericarditis", "have", "been", "reported", "during", "long", "-", "term", "treatment", "with", "mesalazine", "."], "event_mentions": [{"id": "17224428_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 6, "end": 7}, "arguments": [{"entity_id": "17224428_1_Ent0", "role": "Effect", "text": "Cardiac hypersensitivity and myopericarditis", "start": 0, "end": 4}, {"entity_id": "17224428_1_Ent2", "role": "Treatment_Duration", "text": "long - term", "start": 8, "end": 11}, {"entity_id": "17224428_1_Ent1", "role": "Treatment", "text": "long - term treatment with mesalazine", "start": 8, "end": 14}, {"entity_id": "17224428_1_Ent3", "role": "Treatment_Drug", "text": "mesalazine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17224428_1_Ent0", "text": "Cardiac hypersensitivity and myopericarditis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17224428_1_Ent2", "text": "long - term", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "17224428_1_Ent1", "text": "long - term treatment with mesalazine", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "17224428_1_Ent3", "text": "mesalazine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17228132_1", "wnd_id": "17228132_1_1", "text": "Acute drug induced hepatitis due to erlotinib .", "tokens": ["Acute", "drug", "induced", "hepatitis", "due", "to", "erlotinib", "."], "event_mentions": [{"id": "17228132_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 4, "end": 5}, "arguments": [{"entity_id": "17228132_1_Ent0", "role": "Effect", "text": "Acute drug induced hepatitis", "start": 0, "end": 4}, {"entity_id": "17228132_1_Ent1", "role": "Treatment", "text": "erlotinib", "start": 6, "end": 7}, {"entity_id": "17228132_1_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "17228132_1_Ent0", "text": "Acute drug induced hepatitis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "17228132_1_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17228132_1_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "17228132_2", "wnd_id": "17228132_2_1", "text": "CONTEXT : Acute drug induced hepatitis has not been commonly associated with epidermal growth factor receptor ( EGFR ) inhibitors .", "tokens": ["CONTEXT", ":", "Acute", "drug", "induced", "hepatitis", "has", "not", "been", "commonly", "associated", "with", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitors", "."], "event_mentions": [{"id": "17228132_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 10, "end": 11}, "arguments": [{"entity_id": "17228132_2_Ent0", "role": "Effect", "text": "Acute drug induced hepatitis", "start": 2, "end": 6}, {"entity_id": "17228132_2_Ent2", "role": "Treatment_Drug", "text": "epidermal growth factor receptor", "start": 12, "end": 16}, {"entity_id": "17228132_2_Ent1", "role": "Treatment", "text": "epidermal growth factor receptor ( EGFR ) inhibitors", "start": 12, "end": 20}, {"entity_id": "17228132_2_Ent3", "role": "Treatment_Drug", "text": "inhibitors", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17228132_2_Ent0", "text": "Acute drug induced hepatitis", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "17228132_2_Ent2", "text": "epidermal growth factor receptor", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17228132_2_Ent1", "text": "epidermal growth factor receptor ( EGFR ) inhibitors", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "17228132_2_Ent3", "text": "inhibitors", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17228132_3", "wnd_id": "17228132_3_1", "text": "Hepatotoxicity seen with erlotinib , a small molecule tyrosine kinase inhibitor to EGFR , is usually transient with mild elevation of transaminases .", "tokens": ["Hepatotoxicity", "seen", "with", "erlotinib", ",", "a", "small", "molecule", "tyrosine", "kinase", "inhibitor", "to", "EGFR", ",", "is", "usually", "transient", "with", "mild", "elevation", "of", "transaminases", "."], "event_mentions": [{"id": "17228132_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "seen", "start": 1, "end": 2}, "arguments": [{"entity_id": "17228132_3_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "17228132_3_Ent2", "role": "Treatment", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_3_Ent3", "role": "Treatment_Drug", "text": "erlotinib", "start": 3, "end": 4}, {"entity_id": "17228132_3_Ent1", "role": "Effect", "text": "transient with mild elevation of transaminases", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "17228132_3_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17228132_3_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_3_Ent3", "text": "erlotinib", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17228132_3_Ent1", "text": "transient with mild elevation of transaminases", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "1722991_6", "wnd_id": "1722991_6_1", "text": "In the two cases , a combination of iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin - induced platelet aggregation .", "tokens": ["In", "the", "two", "cases", ",", "a", "combination", "of", "iloprost", ",", "a", "stable", "prostacyclin", "analogue", "(", "1", "to", "2", "ng", "/", "kg", "/", "mn", ")", "with", "aspirin", "and", "dipyridamole", "was", "shown", "to", "inhibit", "ex", "vivo", "the", "heparin", "-", "induced", "platelet", "aggregation", "."], "event_mentions": [{"id": "1722991_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "inhibit ex vivo", "start": 31, "end": 34}, "arguments": [{"entity_id": "1722991_6_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "1722991_6_Ent0", "role": "Subject", "text": "two cases", "start": 2, "end": 4}, {"entity_id": "1722991_6_Ent5", "role": "Treatment_Drug", "text": "iloprost", "start": 8, "end": 9}, {"entity_id": "1722991_6_Ent8", "role": "Combination_Drug", "text": "iloprost", "start": 8, "end": 9}, {"entity_id": "1722991_6_Ent2", "role": "Treatment", "text": "iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole", "start": 8, "end": 28}, {"entity_id": "1722991_6_Ent4", "role": "Treatment_Dosage", "text": "1 to 2 ng / kg / mn", "start": 15, "end": 23}, {"entity_id": "1722991_6_Ent6", "role": "Treatment_Drug", "text": "aspirin", "start": 25, "end": 26}, {"entity_id": "1722991_6_Ent9", "role": "Combination_Drug", "text": "aspirin", "start": 25, "end": 26}, {"entity_id": "1722991_6_Ent7", "role": "Treatment_Drug", "text": "dipyridamole", "start": 27, "end": 28}, {"entity_id": "1722991_6_Ent10", "role": "Combination_Drug", "text": "dipyridamole", "start": 27, "end": 28}, {"entity_id": "1722991_6_Ent3", "role": "Treatment_Disorder", "text": "heparin - induced platelet aggregation", "start": 35, "end": 40}]}, {"id": "1722991_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 37, "end": 38}, "arguments": [{"entity_id": "1722991_6_Ent12", "role": "Treatment", "text": "heparin", "start": 35, "end": 36}, {"entity_id": "1722991_6_Ent13", "role": "Treatment_Drug", "text": "heparin", "start": 35, "end": 36}, {"entity_id": "1722991_6_Ent11", "role": "Effect", "text": "platelet aggregation", "start": 38, "end": 40}]}], "entity_mentions": [{"id": "1722991_6_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1722991_6_Ent0", "text": "two cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1722991_6_Ent5", "text": "iloprost", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_6_Ent8", "text": "iloprost", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1722991_6_Ent2", "text": "iloprost , a stable prostacyclin analogue ( 1 to 2 ng / kg / mn ) with aspirin and dipyridamole", "entity_type": "Entity", "start": 8, "end": 28}, {"id": "1722991_6_Ent4", "text": "1 to 2 ng / kg / mn", "entity_type": "Entity", "start": 15, "end": 23}, {"id": "1722991_6_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1722991_6_Ent9", "text": "aspirin", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "1722991_6_Ent7", "text": "dipyridamole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1722991_6_Ent10", "text": "dipyridamole", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "1722991_6_Ent12", "text": "heparin", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1722991_6_Ent13", "text": "heparin", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "1722991_6_Ent3", "text": "heparin - induced platelet aggregation", "entity_type": "Entity", "start": 35, "end": 40}, {"id": "1722991_6_Ent11", "text": "platelet aggregation", "entity_type": "Entity", "start": 38, "end": 40}], "lang": "en"}
{"doc_id": "17241588_1", "wnd_id": "17241588_1_1", "text": "RESULTS : A clinical diagnosis of fixed drug eruption owing to use of the PDE5 inhibitor tadalafil ( Cialis ) was made .", "tokens": ["RESULTS", ":", "A", "clinical", "diagnosis", "of", "fixed", "drug", "eruption", "owing", "to", "use", "of", "the", "PDE5", "inhibitor", "tadalafil", "(", "Cialis", ")", "was", "made", "."], "event_mentions": [{"id": "17241588_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "owing", "start": 9, "end": 10}, "arguments": [{"entity_id": "17241588_1_Ent0", "role": "Effect", "text": "fixed drug eruption", "start": 6, "end": 9}, {"entity_id": "17241588_1_Ent1", "role": "Treatment", "text": "PDE5 inhibitor tadalafil ( Cialis )", "start": 14, "end": 20}, {"entity_id": "17241588_1_Ent2", "role": "Treatment_Drug", "text": "tadalafil", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17241588_1_Ent0", "text": "fixed drug eruption", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "17241588_1_Ent1", "text": "PDE5 inhibitor tadalafil ( Cialis )", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "17241588_1_Ent2", "text": "tadalafil", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17277758_1", "wnd_id": "17277758_1_1", "text": "Acute endophthalmitis following intravitreal bevacizumab ( Avastin ) injection .", "tokens": ["Acute", "endophthalmitis", "following", "intravitreal", "bevacizumab", "(", "Avastin", ")", "injection", "."], "event_mentions": [{"id": "17277758_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "17277758_1_Ent0", "role": "Effect", "text": "Acute endophthalmitis", "start": 0, "end": 2}, {"entity_id": "17277758_1_Ent2", "role": "Treatment_Route", "text": "intravitreal", "start": 3, "end": 4}, {"entity_id": "17277758_1_Ent1", "role": "Treatment", "text": "intravitreal bevacizumab ( Avastin ) injection", "start": 3, "end": 9}, {"entity_id": "17277758_1_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 4, "end": 5}, {"entity_id": "17277758_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "17277758_1_Ent0", "text": "Acute endophthalmitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17277758_1_Ent2", "text": "intravitreal", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17277758_1_Ent1", "text": "intravitreal bevacizumab ( Avastin ) injection", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "17277758_1_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17277758_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17277758_4", "wnd_id": "17277758_4_1", "text": "PURPOSE : To report two cases of acute endophthalmitis following intravitreal bevacizumab injection .", "tokens": ["PURPOSE", ":", "To", "report", "two", "cases", "of", "acute", "endophthalmitis", "following", "intravitreal", "bevacizumab", "injection", "."], "event_mentions": [{"id": "17277758_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "17277758_4_Ent1", "role": "Subject_Population", "text": "two", "start": 4, "end": 5}, {"entity_id": "17277758_4_Ent0", "role": "Subject", "text": "two cases", "start": 4, "end": 6}, {"entity_id": "17277758_4_Ent2", "role": "Effect", "text": "acute endophthalmitis", "start": 7, "end": 9}, {"entity_id": "17277758_4_Ent4", "role": "Treatment_Route", "text": "intravitreal", "start": 10, "end": 11}, {"entity_id": "17277758_4_Ent3", "role": "Treatment", "text": "intravitreal bevacizumab injection", "start": 10, "end": 13}, {"entity_id": "17277758_4_Ent6", "role": "Treatment_Drug", "text": "bevacizumab", "start": 11, "end": 12}, {"entity_id": "17277758_4_Ent5", "role": "Treatment_Route", "text": "injection", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17277758_4_Ent1", "text": "two", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17277758_4_Ent0", "text": "two cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17277758_4_Ent2", "text": "acute endophthalmitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17277758_4_Ent4", "text": "intravitreal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17277758_4_Ent3", "text": "intravitreal bevacizumab injection", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "17277758_4_Ent6", "text": "bevacizumab", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17277758_4_Ent5", "text": "injection", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17285101_2", "wnd_id": "17285101_2_1", "text": "The authors presented a case of pulmonary hypertension during lithium therapy , while she has been on lithium for 6 years .", "tokens": ["The", "authors", "presented", "a", "case", "of", "pulmonary", "hypertension", "during", "lithium", "therapy", ",", "while", "she", "has", "been", "on", "lithium", "for", "6", "years", "."], "event_mentions": [{"id": "17285101_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "17285101_2_Ent2", "role": "Effect", "text": "pulmonary hypertension", "start": 6, "end": 8}, {"entity_id": "17285101_2_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "17285101_2_Ent3", "role": "Treatment", "text": "lithium therapy", "start": 9, "end": 11}, {"entity_id": "17285101_2_Ent0", "role": "Subject", "text": "she", "start": 13, "end": 14}, {"entity_id": "17285101_2_Ent1", "role": "Subject_Gender", "text": "she", "start": 13, "end": 14}, {"entity_id": "17285101_2_Ent5", "role": "Treatment_Duration", "text": "6 years", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "17285101_2_Ent2", "text": "pulmonary hypertension", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17285101_2_Ent4", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17285101_2_Ent3", "text": "lithium therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17285101_2_Ent0", "text": "she", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17285101_2_Ent1", "text": "she", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17285101_2_Ent5", "text": "6 years", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "17301517_1", "wnd_id": "17301517_1_1", "text": "A 32 - year - old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and deep coma after 9 days of treatment with perospirone hydrochloride , a recently developed atypical antipsychotic agent available only in Japan .", "tokens": ["A", "32", "-", "year", "-", "old", "man", "with", "a", "family", "history", "of", "type", "2", "diabetes", "mellitus", "presented", "with", "circulatory", "collapse", "and", "deep", "coma", "after", "9", "days", "of", "treatment", "with", "perospirone", "hydrochloride", ",", "a", "recently", "developed", "atypical", "antipsychotic", "agent", "available", "only", "in", "Japan", "."], "event_mentions": [{"id": "17301517_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "17301517_1_Ent0", "role": "Subject", "text": "A 32 - year - old man with a family history of type 2 diabetes mellitus", "start": 0, "end": 16}, {"entity_id": "17301517_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 1, "end": 6}, {"entity_id": "17301517_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "17301517_1_Ent3", "role": "Subject_Disorder", "text": "type 2 diabetes mellitus", "start": 12, "end": 16}, {"entity_id": "17301517_1_Ent4", "role": "Effect", "text": "circulatory collapse and deep coma", "start": 18, "end": 23}, {"entity_id": "17301517_1_Ent7", "role": "Treatment_Time_elapsed", "text": "after 9 days", "start": 23, "end": 26}, {"entity_id": "17301517_1_Ent5", "role": "Treatment", "text": "9 days of treatment with perospirone hydrochloride", "start": 24, "end": 31}, {"entity_id": "17301517_1_Ent6", "role": "Treatment_Drug", "text": "perospirone hydrochloride", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "17301517_1_Ent0", "text": "A 32 - year - old man with a family history of type 2 diabetes mellitus", "entity_type": "Entity", "start": 0, "end": 16}, {"id": "17301517_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17301517_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17301517_1_Ent3", "text": "type 2 diabetes mellitus", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "17301517_1_Ent4", "text": "circulatory collapse and deep coma", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "17301517_1_Ent7", "text": "after 9 days", "entity_type": "Entity", "start": 23, "end": 26}, {"id": "17301517_1_Ent5", "text": "9 days of treatment with perospirone hydrochloride", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "17301517_1_Ent6", "text": "perospirone hydrochloride", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "17329303_6", "wnd_id": "17329303_6_1", "text": "The second patient was a girl of 6 , already on risperidone for ADHD and borderline intellectual functioning when referred .", "tokens": ["The", "second", "patient", "was", "a", "girl", "of", "6", ",", "already", "on", "risperidone", "for", "ADHD", "and", "borderline", "intellectual", "functioning", "when", "referred", "."], "event_mentions": [{"id": "17329303_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "on", "start": 10, "end": 11}, "arguments": [{"entity_id": "17329303_6_Ent0", "role": "Subject", "text": "a girl of 6", "start": 4, "end": 8}, {"entity_id": "17329303_6_Ent1", "role": "Subject_Gender", "text": "girl", "start": 5, "end": 6}, {"entity_id": "17329303_6_Ent2", "role": "Subject_Age", "text": "6", "start": 7, "end": 8}, {"entity_id": "17329303_6_Ent3", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent4", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "17329303_6_Ent5", "role": "Treatment_Disorder", "text": "ADHD", "start": 13, "end": 14}, {"entity_id": "17329303_6_Ent6", "role": "Treatment_Disorder", "text": "borderline intellectual functioning", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "17329303_6_Ent0", "text": "a girl of 6", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "17329303_6_Ent1", "text": "girl", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17329303_6_Ent2", "text": "6", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17329303_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent4", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17329303_6_Ent5", "text": "ADHD", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17329303_6_Ent6", "text": "borderline intellectual functioning", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "17364199_1", "wnd_id": "17364199_1_1", "text": "Tuberculous uveitis after treatment with etanercept .", "tokens": ["Tuberculous", "uveitis", "after", "treatment", "with", "etanercept", "."], "event_mentions": [{"id": "17364199_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "17364199_1_Ent0", "role": "Effect", "text": "Tuberculous uveitis", "start": 0, "end": 2}, {"entity_id": "17364199_1_Ent1", "role": "Treatment", "text": "etanercept", "start": 5, "end": 6}, {"entity_id": "17364199_1_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "17364199_1_Ent0", "text": "Tuberculous uveitis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17364199_1_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17364199_1_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "17364199_4", "wnd_id": "17364199_4_1", "text": "We report the first case of tuberculous uveitis due to etanercept .", "tokens": ["We", "report", "the", "first", "case", "of", "tuberculous", "uveitis", "due", "to", "etanercept", "."], "event_mentions": [{"id": "17364199_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due to", "start": 8, "end": 10}, "arguments": [{"entity_id": "17364199_4_Ent0", "role": "Effect", "text": "tuberculous uveitis", "start": 6, "end": 8}, {"entity_id": "17364199_4_Ent1", "role": "Treatment", "text": "etanercept", "start": 10, "end": 11}, {"entity_id": "17364199_4_Ent2", "role": "Treatment_Drug", "text": "etanercept", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "17364199_4_Ent0", "text": "tuberculous uveitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "17364199_4_Ent1", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "17364199_4_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "17373180_1", "wnd_id": "17373180_1_1", "text": "Infliximab and its serious adverse effects are discussed , and other cases of osteomyelitis with infliximab use are also reviewed .", "tokens": ["Infliximab", "and", "its", "serious", "adverse", "effects", "are", "discussed", ",", "and", "other", "cases", "of", "osteomyelitis", "with", "infliximab", "use", "are", "also", "reviewed", "."], "event_mentions": [{"id": "17373180_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 14, "end": 15}, "arguments": [{"entity_id": "17373180_1_Ent3", "role": "Treatment_Drug", "text": "Infliximab", "start": 0, "end": 1}, {"entity_id": "17373180_1_Ent0", "role": "Effect", "text": "osteomyelitis", "start": 13, "end": 14}, {"entity_id": "17373180_1_Ent1", "role": "Treatment", "text": "infliximab", "start": 15, "end": 16}, {"entity_id": "17373180_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "17373180_1_Ent3", "text": "Infliximab", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17373180_1_Ent0", "text": "osteomyelitis", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17373180_1_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "17373180_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "17373180_2", "wnd_id": "17373180_2_1", "text": "Osteomyelitis occurring during infliximab treatment of severe psoriasis .", "tokens": ["Osteomyelitis", "occurring", "during", "infliximab", "treatment", "of", "severe", "psoriasis", "."], "event_mentions": [{"id": "17373180_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 4, "end": 5}, "arguments": [{"entity_id": "17373180_2_Ent0", "role": "Effect", "text": "Osteomyelitis", "start": 0, "end": 1}, {"entity_id": "17373180_2_Ent1", "role": "Treatment", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "17373180_2_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 3, "end": 4}, {"entity_id": "17373180_2_Ent3", "role": "Treatment_Disorder", "text": "severe psoriasis", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "17373180_2_Ent0", "text": "Osteomyelitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17373180_2_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17373180_2_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17373180_2_Ent3", "text": "severe psoriasis", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "17381671_8", "wnd_id": "17381671_8_1", "text": "Healthcare professionals should be aware of the possible development of serotonin syndrome as a complication of initiation of fentanyl and other phenylpiperidine opioids in patients treated with SSRIs .", "tokens": ["Healthcare", "professionals", "should", "be", "aware", "of", "the", "possible", "development", "of", "serotonin", "syndrome", "as", "a", "complication", "of", "initiation", "of", "fentanyl", "and", "other", "phenylpiperidine", "opioids", "in", "patients", "treated", "with", "SSRIs", "."], "event_mentions": [{"id": "17381671_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 8, "end": 9}, "arguments": [{"entity_id": "17381671_8_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 10, "end": 12}, {"entity_id": "17381671_8_Ent4", "role": "Treatment_Drug", "text": "fentanyl", "start": 18, "end": 19}, {"entity_id": "17381671_8_Ent8", "role": "Combination_Drug", "text": "fentanyl", "start": 18, "end": 19}, {"entity_id": "17381671_8_Ent2", "role": "Treatment", "text": "fentanyl and other phenylpiperidine opioids", "start": 18, "end": 23}, {"entity_id": "17381671_8_Ent5", "role": "Treatment_Drug", "text": "phenylpiperidine opioids", "start": 21, "end": 23}, {"entity_id": "17381671_8_Ent7", "role": "Combination_Drug", "text": "phenylpiperidine opioids", "start": 21, "end": 23}, {"entity_id": "17381671_8_Ent0", "role": "Subject", "text": "patients", "start": 24, "end": 25}, {"entity_id": "17381671_8_Ent3", "role": "Treatment", "text": "treated with SSRIs", "start": 25, "end": 28}, {"entity_id": "17381671_8_Ent6", "role": "Treatment_Drug", "text": "SSRIs", "start": 27, "end": 28}, {"entity_id": "17381671_8_Ent9", "role": "Combination_Drug", "text": "SSRIs", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "17381671_8_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "17381671_8_Ent4", "text": "fentanyl", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17381671_8_Ent8", "text": "fentanyl", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "17381671_8_Ent2", "text": "fentanyl and other phenylpiperidine opioids", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "17381671_8_Ent5", "text": "phenylpiperidine opioids", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17381671_8_Ent7", "text": "phenylpiperidine opioids", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "17381671_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17381671_8_Ent3", "text": "treated with SSRIs", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "17381671_8_Ent6", "text": "SSRIs", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "17381671_8_Ent9", "text": "SSRIs", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "17383767_2", "wnd_id": "17383767_2_1", "text": "Brain metastases are a frequent finding in patients with advanced non - small cell lung cancer and concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor is necessary in many cases .", "tokens": ["Brain", "metastases", "are", "a", "frequent", "finding", "in", "patients", "with", "advanced", "non", "-", "small", "cell", "lung", "cancer", "and", "concomitant", "administration", "of", "antiepileptic", "and", "chemotherapeutic", "drugs", "or", "epidermal", "growth", "factor", "receptor", "(", "EGFR", ")", "inhibitor", "is", "necessary", "in", "many", "cases", "."], "event_mentions": [{"id": "17383767_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "necessary", "start": 34, "end": 35}, "arguments": [{"entity_id": "17383767_2_Ent6", "role": "Treatment_Disorder", "text": "Brain metastases", "start": 0, "end": 2}, {"entity_id": "17383767_2_Ent0", "role": "Subject", "text": "patients with advanced non - small cell lung cancer", "start": 7, "end": 16}, {"entity_id": "17383767_2_Ent1", "role": "Subject_Disorder", "text": "advanced non - small cell lung cancer", "start": 9, "end": 16}, {"entity_id": "17383767_2_Ent2", "role": "Treatment", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "start": 17, "end": 33}, {"entity_id": "17383767_2_Ent3", "role": "Treatment_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent7", "role": "Combination_Drug", "text": "antiepileptic", "start": 20, "end": 21}, {"entity_id": "17383767_2_Ent4", "role": "Treatment_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent8", "role": "Combination_Drug", "text": "chemotherapeutic", "start": 22, "end": 23}, {"entity_id": "17383767_2_Ent5", "role": "Treatment_Drug", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "start": 25, "end": 33}]}], "entity_mentions": [{"id": "17383767_2_Ent6", "text": "Brain metastases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17383767_2_Ent0", "text": "patients with advanced non - small cell lung cancer", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "17383767_2_Ent1", "text": "advanced non - small cell lung cancer", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17383767_2_Ent2", "text": "concomitant administration of antiepileptic and chemotherapeutic drugs or epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 17, "end": 33}, {"id": "17383767_2_Ent3", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent7", "text": "antiepileptic", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17383767_2_Ent4", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent8", "text": "chemotherapeutic", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "17383767_2_Ent5", "text": "epidermal growth factor receptor ( EGFR ) inhibitor", "entity_type": "Entity", "start": 25, "end": 33}], "lang": "en"}
{"doc_id": "17404582_2", "wnd_id": "17404582_2_1", "text": "Docetaxel - induced Meibomian duct inflammation and blockage leading to chalazion formation .", "tokens": ["Docetaxel", "-", "induced", "Meibomian", "duct", "inflammation", "and", "blockage", "leading", "to", "chalazion", "formation", "."], "event_mentions": [{"id": "17404582_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17404582_2_Ent1", "role": "Treatment", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_2_Ent2", "role": "Treatment_Drug", "text": "Docetaxel", "start": 0, "end": 1}, {"entity_id": "17404582_2_Ent0", "role": "Effect", "text": "Meibomian duct inflammation and blockage leading to chalazion formation", "start": 3, "end": 12}]}], "entity_mentions": [{"id": "17404582_2_Ent1", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_2_Ent2", "text": "Docetaxel", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17404582_2_Ent0", "text": "Meibomian duct inflammation and blockage leading to chalazion formation", "entity_type": "Entity", "start": 3, "end": 12}], "lang": "en"}
{"doc_id": "17406804_1", "wnd_id": "17406804_1_1", "text": "A case of recall pneumonitis induced by gemcitabine is reported .", "tokens": ["A", "case", "of", "recall", "pneumonitis", "induced", "by", "gemcitabine", "is", "reported", "."], "event_mentions": [{"id": "17406804_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "17406804_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "17406804_1_Ent1", "role": "Effect", "text": "recall pneumonitis", "start": 3, "end": 5}, {"entity_id": "17406804_1_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 7, "end": 8}, {"entity_id": "17406804_1_Ent3", "role": "Treatment_Drug", "text": "gemcitabine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "17406804_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17406804_1_Ent1", "text": "recall pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "17406804_1_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17406804_1_Ent3", "text": "gemcitabine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "17406804_3", "wnd_id": "17406804_3_1", "text": "CONCLUSION : Gemcitabine - induced recall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy .", "tokens": ["CONCLUSION", ":", "Gemcitabine", "-", "induced", "recall", "pneumonitis", "is", "a", "rarely", "reported", "phenomenon", "and", "should", "be", "taken", "into", "account", "even", "after", "extended", "time", "interval", "to", "the", "previous", "radiotherapy", "."], "event_mentions": [{"id": "17406804_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "17406804_3_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 2, "end": 3}, {"entity_id": "17406804_3_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 2, "end": 3}, {"entity_id": "17406804_3_Ent0", "role": "Effect", "text": "recall pneumonitis", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17406804_3_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17406804_3_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17406804_3_Ent0", "text": "recall pneumonitis", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17420198_1", "wnd_id": "17420198_1_1", "text": "Potential aripiprazole - mediated extrapyramidal symptoms in an adult with developmental disabilities .", "tokens": ["Potential", "aripiprazole", "-", "mediated", "extrapyramidal", "symptoms", "in", "an", "adult", "with", "developmental", "disabilities", "."], "event_mentions": [{"id": "17420198_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mediated", "start": 3, "end": 4}, "arguments": [{"entity_id": "17420198_1_Ent3", "role": "Treatment", "text": "aripiprazole", "start": 1, "end": 2}, {"entity_id": "17420198_1_Ent4", "role": "Treatment_Drug", "text": "aripiprazole", "start": 1, "end": 2}, {"entity_id": "17420198_1_Ent2", "role": "Effect", "text": "extrapyramidal symptoms", "start": 4, "end": 6}, {"entity_id": "17420198_1_Ent0", "role": "Subject", "text": "an adult with developmental disabilities", "start": 7, "end": 12}, {"entity_id": "17420198_1_Ent1", "role": "Subject_Age", "text": "adult", "start": 8, "end": 9}, {"entity_id": "17420198_1_Ent5", "role": "Treatment_Disorder", "text": "developmental disabilities", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "17420198_1_Ent3", "text": "aripiprazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17420198_1_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17420198_1_Ent2", "text": "extrapyramidal symptoms", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "17420198_1_Ent0", "text": "an adult with developmental disabilities", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17420198_1_Ent1", "text": "adult", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17420198_1_Ent5", "text": "developmental disabilities", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "17420198_2", "wnd_id": "17420198_2_1", "text": "A case of extrapyramidal symptoms ( EPS ) following administration of aripiprazole to a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented .", "tokens": ["A", "case", "of", "extrapyramidal", "symptoms", "(", "EPS", ")", "following", "administration", "of", "aripiprazole", "to", "a", "man", "with", "developmental", "disabilities", "who", "had", "never", "received", "antipsychotic", "medications", "and", "had", "no", "history", "of", "movement", "disorders", "is", "presented", "."], "event_mentions": [{"id": "17420198_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17420198_2_Ent3", "role": "Effect", "text": "extrapyramidal symptoms ( EPS )", "start": 3, "end": 8}, {"entity_id": "17420198_2_Ent4", "role": "Treatment", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent5", "role": "Treatment_Drug", "text": "aripiprazole", "start": 11, "end": 12}, {"entity_id": "17420198_2_Ent0", "role": "Subject", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "start": 13, "end": 33}, {"entity_id": "17420198_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 14, "end": 15}, {"entity_id": "17420198_2_Ent2", "role": "Subject_Disorder", "text": "developmental disabilities", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "17420198_2_Ent3", "text": "extrapyramidal symptoms ( EPS )", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17420198_2_Ent4", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent5", "text": "aripiprazole", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "17420198_2_Ent0", "text": "a man with developmental disabilities who had never received antipsychotic medications and had no history of movement disorders is presented", "entity_type": "Entity", "start": 13, "end": 33}, {"id": "17420198_2_Ent1", "text": "man", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17420198_2_Ent2", "text": "developmental disabilities", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "17426073_2", "wnd_id": "17426073_2_1", "text": "However , a new episode of neutropenia , with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3 , occurred 11 days after teicoplanin initiation .", "tokens": ["However", ",", "a", "new", "episode", "of", "neutropenia", ",", "with", "a", "WBC", "count", "of", "2.8", "x", "10(3)/mm3", "and", "ANC", "of", "0.448", "x", "10(3)/mm3", ",", "occurred", "11", "days", "after", "teicoplanin", "initiation", "."], "event_mentions": [{"id": "17426073_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 23, "end": 24}, "arguments": [{"entity_id": "17426073_2_Ent0", "role": "Effect", "text": "neutropenia , with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3", "start": 6, "end": 22}, {"entity_id": "17426073_2_Ent2", "role": "Treatment_Time_elapsed", "text": "11 days", "start": 24, "end": 26}, {"entity_id": "17426073_2_Ent1", "role": "Treatment", "text": "11 days after teicoplanin initiation", "start": 24, "end": 29}, {"entity_id": "17426073_2_Ent3", "role": "Treatment_Drug", "text": "teicoplanin", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "17426073_2_Ent0", "text": "neutropenia , with a WBC count of 2.8 x 10(3)/mm3 and ANC of 0.448 x 10(3)/mm3", "entity_type": "Entity", "start": 6, "end": 22}, {"id": "17426073_2_Ent2", "text": "11 days", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "17426073_2_Ent1", "text": "11 days after teicoplanin initiation", "entity_type": "Entity", "start": 24, "end": 29}, {"id": "17426073_2_Ent3", "text": "teicoplanin", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "1743388_1", "wnd_id": "1743388_1_1", "text": "Cutaneous ulceration : an unusual complication of intravenous pentamidine therapy .", "tokens": ["Cutaneous", "ulceration", ":", "an", "unusual", "complication", "of", "intravenous", "pentamidine", "therapy", "."], "event_mentions": [{"id": "1743388_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 5, "end": 6}, "arguments": [{"entity_id": "1743388_1_Ent0", "role": "Effect", "text": "Cutaneous ulceration", "start": 0, "end": 2}, {"entity_id": "1743388_1_Ent3", "role": "Treatment_Route", "text": "intravenous", "start": 7, "end": 8}, {"entity_id": "1743388_1_Ent1", "role": "Treatment", "text": "intravenous pentamidine", "start": 7, "end": 9}, {"entity_id": "1743388_1_Ent2", "role": "Treatment_Drug", "text": "pentamidine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1743388_1_Ent0", "text": "Cutaneous ulceration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1743388_1_Ent3", "text": "intravenous", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1743388_1_Ent1", "text": "intravenous pentamidine", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "1743388_1_Ent2", "text": "pentamidine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "17444802_4", "wnd_id": "17444802_4_1", "text": "RESULTS : An 81 - year - old man with a history of neoplasies of the colon and prostate and anticoagulant treatment was referred for treatment of an ocular surface neoplasia on his left eye .", "tokens": ["RESULTS", ":", "An", "81", "-", "year", "-", "old", "man", "with", "a", "history", "of", "neoplasies", "of", "the", "colon", "and", "prostate", "and", "anticoagulant", "treatment", "was", "referred", "for", "treatment", "of", "an", "ocular", "surface", "neoplasia", "on", "his", "left", "eye", "."], "event_mentions": [{"id": "17444802_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "referred", "start": 23, "end": 24}, "arguments": [{"entity_id": "17444802_4_Ent0", "role": "Subject", "text": "An 81 - year - old man with a history of neoplasies of the colon and prostate", "start": 2, "end": 19}, {"entity_id": "17444802_4_Ent1", "role": "Subject_Age", "text": "81 - year - old", "start": 3, "end": 8}, {"entity_id": "17444802_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "17444802_4_Ent6", "role": "Treatment_Disorder", "text": "neoplasies of the colon and prostate", "start": 13, "end": 19}, {"entity_id": "17444802_4_Ent4", "role": "Treatment", "text": "anticoagulant", "start": 20, "end": 21}, {"entity_id": "17444802_4_Ent5", "role": "Treatment_Drug", "text": "anticoagulant", "start": 20, "end": 21}, {"entity_id": "17444802_4_Ent3", "role": "Effect", "text": "an ocular surface neoplasia on his left eye", "start": 27, "end": 35}]}], "entity_mentions": [{"id": "17444802_4_Ent0", "text": "An 81 - year - old man with a history of neoplasies of the colon and prostate", "entity_type": "Entity", "start": 2, "end": 19}, {"id": "17444802_4_Ent1", "text": "81 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "17444802_4_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17444802_4_Ent6", "text": "neoplasies of the colon and prostate", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "17444802_4_Ent4", "text": "anticoagulant", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17444802_4_Ent5", "text": "anticoagulant", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17444802_4_Ent3", "text": "an ocular surface neoplasia on his left eye", "entity_type": "Entity", "start": 27, "end": 35}], "lang": "en"}
{"doc_id": "17448102_4", "wnd_id": "17448102_4_1", "text": "Hypertonic sodium bicarbonate is recognized as effective therapy for hypotension and arrhythmias .", "tokens": ["Hypertonic", "sodium", "bicarbonate", "is", "recognized", "as", "effective", "therapy", "for", "hypotension", "and", "arrhythmias", "."], "event_mentions": [{"id": "17448102_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "effective", "start": 6, "end": 7}, "arguments": [{"entity_id": "17448102_4_Ent0", "role": "Treatment", "text": "Hypertonic sodium bicarbonate", "start": 0, "end": 3}, {"entity_id": "17448102_4_Ent2", "role": "Treatment_Drug", "text": "sodium bicarbonate", "start": 1, "end": 3}, {"entity_id": "17448102_4_Ent1", "role": "Treatment_Disorder", "text": "hypotension and arrhythmias", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17448102_4_Ent0", "text": "Hypertonic sodium bicarbonate", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "17448102_4_Ent2", "text": "sodium bicarbonate", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "17448102_4_Ent1", "text": "hypotension and arrhythmias", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17458405_1", "wnd_id": "17458405_1_1", "text": "Ezetimibe - induced acute pancreatitis .", "tokens": ["Ezetimibe", "-", "induced", "acute", "pancreatitis", "."], "event_mentions": [{"id": "17458405_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17458405_1_Ent1", "role": "Treatment", "text": "Ezetimibe", "start": 0, "end": 1}, {"entity_id": "17458405_1_Ent2", "role": "Treatment_Drug", "text": "Ezetimibe", "start": 0, "end": 1}, {"entity_id": "17458405_1_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "17458405_1_Ent1", "text": "Ezetimibe", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17458405_1_Ent2", "text": "Ezetimibe", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17458405_1_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "17473920_8", "wnd_id": "17473920_8_1", "text": "After starting nevirapine treatment , nine out of ten patients experienced symptoms of abstinence syndrome , and methadone dose had to be increased by 20 % on average during the course of the study .", "tokens": ["After", "starting", "nevirapine", "treatment", ",", "nine", "out", "of", "ten", "patients", "experienced", "symptoms", "of", "abstinence", "syndrome", ",", "and", "methadone", "dose", "had", "to", "be", "increased", "by", "20", "%", "on", "average", "during", "the", "course", "of", "the", "study", "."], "event_mentions": [{"id": "17473920_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "17473920_8_Ent3", "role": "Treatment", "text": "nevirapine", "start": 2, "end": 3}, {"entity_id": "17473920_8_Ent4", "role": "Treatment_Drug", "text": "nevirapine", "start": 2, "end": 3}, {"entity_id": "17473920_8_Ent1", "role": "Subject_Population", "text": "nine out of ten", "start": 5, "end": 9}, {"entity_id": "17473920_8_Ent0", "role": "Subject", "text": "nine out of ten patients", "start": 5, "end": 10}, {"entity_id": "17473920_8_Ent2", "role": "Effect", "text": "abstinence syndrome", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "17473920_8_Ent3", "text": "nevirapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_8_Ent4", "text": "nevirapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17473920_8_Ent1", "text": "nine out of ten", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "17473920_8_Ent0", "text": "nine out of ten patients", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "17473920_8_Ent2", "text": "abstinence syndrome", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "17504225_3", "wnd_id": "17504225_3_1", "text": "In this paper it is reported an evidence of pharmacokinetic interaction between clarithromycin and sirolimus in a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae .", "tokens": ["In", "this", "paper", "it", "is", "reported", "an", "evidence", "of", "pharmacokinetic", "interaction", "between", "clarithromycin", "and", "sirolimus", "in", "a", "kidney", "transplanted", "woman", ",", "suffering", "from", "pulmonary", "infection", "sustained", "by", "a", "bacterial", "pathogen", ",", "in", "particular", "Hemophilus", "Influenzae", "."], "event_mentions": [{"id": "17504225_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 11, "end": 12}, "arguments": [{"entity_id": "17504225_3_Ent3", "role": "Effect", "text": "pharmacokinetic interaction", "start": 9, "end": 11}, {"entity_id": "17504225_3_Ent5", "role": "Treatment_Drug", "text": "clarithromycin", "start": 12, "end": 13}, {"entity_id": "17504225_3_Ent8", "role": "Combination_Drug", "text": "clarithromycin", "start": 12, "end": 13}, {"entity_id": "17504225_3_Ent4", "role": "Treatment", "text": "clarithromycin and sirolimus", "start": 12, "end": 15}, {"entity_id": "17504225_3_Ent6", "role": "Treatment_Drug", "text": "sirolimus", "start": 14, "end": 15}, {"entity_id": "17504225_3_Ent9", "role": "Combination_Drug", "text": "sirolimus", "start": 14, "end": 15}, {"entity_id": "17504225_3_Ent0", "role": "Subject", "text": "a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae", "start": 16, "end": 35}, {"entity_id": "17504225_3_Ent1", "role": "Subject_Disorder", "text": "kidney transplanted", "start": 17, "end": 19}, {"entity_id": "17504225_3_Ent2", "role": "Subject_Gender", "text": "woman", "start": 19, "end": 20}, {"entity_id": "17504225_3_Ent7", "role": "Treatment_Disorder", "text": "pulmonary infection", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "17504225_3_Ent3", "text": "pharmacokinetic interaction", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17504225_3_Ent5", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17504225_3_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17504225_3_Ent4", "text": "clarithromycin and sirolimus", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "17504225_3_Ent6", "text": "sirolimus", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17504225_3_Ent9", "text": "sirolimus", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17504225_3_Ent0", "text": "a kidney transplanted woman , suffering from pulmonary infection sustained by a bacterial pathogen , in particular Hemophilus Influenzae", "entity_type": "Entity", "start": 16, "end": 35}, {"id": "17504225_3_Ent1", "text": "kidney transplanted", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "17504225_3_Ent2", "text": "woman", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17504225_3_Ent7", "text": "pulmonary infection", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "17505739_1", "wnd_id": "17505739_1_1", "text": "Intravitreal triamcinolone may have had an influence on the exacerbation of retinochoroiditis in the posterior pole of the patient .", "tokens": ["Intravitreal", "triamcinolone", "may", "have", "had", "an", "influence", "on", "the", "exacerbation", "of", "retinochoroiditis", "in", "the", "posterior", "pole", "of", "the", "patient", "."], "event_mentions": [{"id": "17505739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "influence", "start": 6, "end": 7}, "arguments": [{"entity_id": "17505739_1_Ent4", "role": "Treatment_Route", "text": "Intravitreal", "start": 0, "end": 1}, {"entity_id": "17505739_1_Ent2", "role": "Treatment", "text": "Intravitreal triamcinolone", "start": 0, "end": 2}, {"entity_id": "17505739_1_Ent3", "role": "Treatment_Drug", "text": "triamcinolone", "start": 1, "end": 2}, {"entity_id": "17505739_1_Ent1", "role": "Effect", "text": "exacerbation of retinochoroiditis in the posterior pole", "start": 9, "end": 16}, {"entity_id": "17505739_1_Ent0", "role": "Subject", "text": "the patient", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "17505739_1_Ent4", "text": "Intravitreal", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17505739_1_Ent2", "text": "Intravitreal triamcinolone", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17505739_1_Ent3", "text": "triamcinolone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17505739_1_Ent1", "text": "exacerbation of retinochoroiditis in the posterior pole", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "17505739_1_Ent0", "text": "the patient", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "17526968_4", "wnd_id": "17526968_4_1", "text": "The hyperpigmentation was diffuse scattered , flagellate like and linear streaking which was thought to be mainly related to the skin toxicity of bleomycin .", "tokens": ["The", "hyperpigmentation", "was", "diffuse", "scattered", ",", "flagellate", "like", "and", "linear", "streaking", "which", "was", "thought", "to", "be", "mainly", "related", "to", "the", "skin", "toxicity", "of", "bleomycin", "."], "event_mentions": [{"id": "17526968_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 21, "end": 22}, "arguments": [{"entity_id": "17526968_4_Ent0", "role": "Effect", "text": "hyperpigmentation was diffuse scattered , flagellate like and linear streaking", "start": 1, "end": 11}, {"entity_id": "17526968_4_Ent1", "role": "Treatment", "text": "bleomycin", "start": 23, "end": 24}, {"entity_id": "17526968_4_Ent2", "role": "Treatment_Drug", "text": "bleomycin", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "17526968_4_Ent0", "text": "hyperpigmentation was diffuse scattered , flagellate like and linear streaking", "entity_type": "Entity", "start": 1, "end": 11}, {"id": "17526968_4_Ent1", "text": "bleomycin", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "17526968_4_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "17536204_1", "wnd_id": "17536204_1_1", "text": "A cause - effect relationship to capecitabine was suggested due to resolution of headache with capecitabine withdrawal and reappearance with capecitabine rechallenge .", "tokens": ["A", "cause", "-", "effect", "relationship", "to", "capecitabine", "was", "suggested", "due", "to", "resolution", "of", "headache", "with", "capecitabine", "withdrawal", "and", "reappearance", "with", "capecitabine", "rechallenge", "."], "event_mentions": [{"id": "17536204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship to", "start": 4, "end": 6}, "arguments": [{"entity_id": "17536204_1_Ent1", "role": "Treatment", "text": "capecitabine", "start": 6, "end": 7}, {"entity_id": "17536204_1_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 6, "end": 7}, {"entity_id": "17536204_1_Ent0", "role": "Effect", "text": "headache", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "17536204_1_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17536204_1_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17536204_1_Ent0", "text": "headache", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "17536204_2", "wnd_id": "17536204_2_1", "text": "BACKGROUND : Headaches have been reported as a potential side effect of capecitabine therapy .", "tokens": ["BACKGROUND", ":", "Headaches", "have", "been", "reported", "as", "a", "potential", "side", "effect", "of", "capecitabine", "therapy", "."], "event_mentions": [{"id": "17536204_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 11, "end": 12}, "arguments": [{"entity_id": "17536204_2_Ent0", "role": "Effect", "text": "Headaches", "start": 2, "end": 3}, {"entity_id": "17536204_2_Ent1", "role": "Treatment", "text": "capecitabine", "start": 12, "end": 13}, {"entity_id": "17536204_2_Ent2", "role": "Treatment_Drug", "text": "capecitabine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17536204_2_Ent0", "text": "Headaches", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17536204_2_Ent1", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "17536204_2_Ent2", "text": "capecitabine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17556909_2", "wnd_id": "17556909_2_1", "text": "Paralytic ileus in patients undergoing bortezomib treatment has been reported , although a definite attribution to bortezomib administration has not been established .", "tokens": ["Paralytic", "ileus", "in", "patients", "undergoing", "bortezomib", "treatment", "has", "been", "reported", ",", "although", "a", "definite", "attribution", "to", "bortezomib", "administration", "has", "not", "been", "established", "."], "event_mentions": [{"id": "17556909_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reported", "start": 9, "end": 10}, "arguments": [{"entity_id": "17556909_2_Ent1", "role": "Effect", "text": "Paralytic ileus", "start": 0, "end": 2}, {"entity_id": "17556909_2_Ent0", "role": "Subject", "text": "patients", "start": 3, "end": 4}, {"entity_id": "17556909_2_Ent3", "role": "Treatment_Drug", "text": "bortezomib", "start": 5, "end": 6}, {"entity_id": "17556909_2_Ent2", "role": "Treatment", "text": "bortezomib treatment", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "17556909_2_Ent1", "text": "Paralytic ileus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "17556909_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17556909_2_Ent3", "text": "bortezomib", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "17556909_2_Ent2", "text": "bortezomib treatment", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "17655517_1", "wnd_id": "17655517_1_1", "text": "Linezolid - associated peripheral and optic neuropathy , lactic acidosis , and serotonin syndrome .", "tokens": ["Linezolid", "-", "associated", "peripheral", "and", "optic", "neuropathy", ",", "lactic", "acidosis", ",", "and", "serotonin", "syndrome", "."], "event_mentions": [{"id": "17655517_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "17655517_1_Ent1", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_1_Ent2", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_1_Ent0", "role": "Effect", "text": "peripheral and optic neuropathy , lactic acidosis , and serotonin syndrome .", "start": 3, "end": 15}]}], "entity_mentions": [{"id": "17655517_1_Ent1", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_1_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_1_Ent0", "text": "peripheral and optic neuropathy , lactic acidosis , and serotonin syndrome .", "entity_type": "Entity", "start": 3, "end": 15}], "lang": "en"}
{"doc_id": "17655517_8", "wnd_id": "17655517_8_1", "text": "Linezolid should be discontinued immediately in patients experiencing these adverse effects .", "tokens": ["Linezolid", "should", "be", "discontinued", "immediately", "in", "patients", "experiencing", "these", "adverse", "effects", "."], "event_mentions": [{"id": "17655517_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinued", "start": 3, "end": 4}, "arguments": [{"entity_id": "17655517_8_Ent2", "role": "Treatment", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_8_Ent3", "role": "Treatment_Drug", "text": "Linezolid", "start": 0, "end": 1}, {"entity_id": "17655517_8_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "17655517_8_Ent1", "role": "Effect", "text": "adverse effects", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "17655517_8_Ent2", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_8_Ent3", "text": "Linezolid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17655517_8_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17655517_8_Ent1", "text": "adverse effects", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "1765991_4", "wnd_id": "1765991_4_1", "text": "We assume that rIFN - gamma induced the de novo development of SLE in our patient .", "tokens": ["We", "assume", "that", "rIFN", "-", "gamma", "induced", "the", "de", "novo", "development", "of", "SLE", "in", "our", "patient", "."], "event_mentions": [{"id": "1765991_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "1765991_4_Ent2", "role": "Treatment", "text": "rIFN - gamma", "start": 3, "end": 6}, {"entity_id": "1765991_4_Ent3", "role": "Treatment_Drug", "text": "rIFN - gamma", "start": 3, "end": 6}, {"entity_id": "1765991_4_Ent1", "role": "Effect", "text": "the de novo development of SLE", "start": 7, "end": 13}, {"entity_id": "1765991_4_Ent0", "role": "Subject", "text": "our patient", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "1765991_4_Ent2", "text": "rIFN - gamma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_4_Ent3", "text": "rIFN - gamma", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "1765991_4_Ent1", "text": "the de novo development of SLE", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "1765991_4_Ent0", "text": "our patient", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "17665812_2", "wnd_id": "17665812_2_1", "text": "Drug - induced eosinophilia is a non - dose - dependent side effect of clozapine .", "tokens": ["Drug", "-", "induced", "eosinophilia", "is", "a", "non", "-", "dose", "-", "dependent", "side", "effect", "of", "clozapine", "."], "event_mentions": [{"id": "17665812_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17665812_2_Ent0", "role": "Effect", "text": "eosinophilia", "start": 3, "end": 4}, {"entity_id": "17665812_2_Ent3", "role": "Treatment_Dosage", "text": "non - dose - dependent", "start": 6, "end": 11}, {"entity_id": "17665812_2_Ent1", "role": "Treatment", "text": "clozapine", "start": 14, "end": 15}, {"entity_id": "17665812_2_Ent2", "role": "Treatment_Drug", "text": "clozapine", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "17665812_2_Ent0", "text": "eosinophilia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "17665812_2_Ent3", "text": "non - dose - dependent", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "17665812_2_Ent1", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "17665812_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "17667887_2", "wnd_id": "17667887_2_1", "text": "We report two cases of serotonin syndrome in elderly patients during treatment of psychotic depression with atypical antipsychotics and antidepressants .", "tokens": ["We", "report", "two", "cases", "of", "serotonin", "syndrome", "in", "elderly", "patients", "during", "treatment", "of", "psychotic", "depression", "with", "atypical", "antipsychotics", "and", "antidepressants", "."], "event_mentions": [{"id": "17667887_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 10, "end": 11}, "arguments": [{"entity_id": "17667887_2_Ent2", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "17667887_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 8, "end": 9}, {"entity_id": "17667887_2_Ent0", "role": "Subject", "text": "elderly patients", "start": 8, "end": 10}, {"entity_id": "17667887_2_Ent4", "role": "Treatment_Disorder", "text": "psychotic depression", "start": 13, "end": 15}, {"entity_id": "17667887_2_Ent5", "role": "Treatment_Drug", "text": "atypical antipsychotics", "start": 16, "end": 18}, {"entity_id": "17667887_2_Ent7", "role": "Combination_Drug", "text": "atypical antipsychotics", "start": 16, "end": 18}, {"entity_id": "17667887_2_Ent3", "role": "Treatment", "text": "atypical antipsychotics and antidepressants", "start": 16, "end": 20}, {"entity_id": "17667887_2_Ent6", "role": "Treatment_Drug", "text": "antidepressants", "start": 19, "end": 20}, {"entity_id": "17667887_2_Ent8", "role": "Combination_Drug", "text": "antidepressants", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "17667887_2_Ent2", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "17667887_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "17667887_2_Ent0", "text": "elderly patients", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "17667887_2_Ent4", "text": "psychotic depression", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "17667887_2_Ent5", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17667887_2_Ent7", "text": "atypical antipsychotics", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "17667887_2_Ent3", "text": "atypical antipsychotics and antidepressants", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "17667887_2_Ent6", "text": "antidepressants", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "17667887_2_Ent8", "text": "antidepressants", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "17667887_9", "wnd_id": "17667887_9_1", "text": "There have been several case reports of serotonin syndrome from similar combinations of antidepressant and atypical antipsychotic treatment .", "tokens": ["There", "have", "been", "several", "case", "reports", "of", "serotonin", "syndrome", "from", "similar", "combinations", "of", "antidepressant", "and", "atypical", "antipsychotic", "treatment", "."], "event_mentions": [{"id": "17667887_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 9, "end": 10}, "arguments": [{"entity_id": "17667887_9_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 7, "end": 9}, {"entity_id": "17667887_9_Ent1", "role": "Treatment", "text": "combinations of antidepressant and atypical antipsychotic treatment", "start": 11, "end": 18}, {"entity_id": "17667887_9_Ent2", "role": "Treatment_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "17667887_9_Ent4", "role": "Combination_Drug", "text": "antidepressant", "start": 13, "end": 14}, {"entity_id": "17667887_9_Ent3", "role": "Treatment_Drug", "text": "antipsychotic", "start": 16, "end": 17}, {"entity_id": "17667887_9_Ent5", "role": "Combination_Drug", "text": "antipsychotic", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "17667887_9_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "17667887_9_Ent1", "text": "combinations of antidepressant and atypical antipsychotic treatment", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "17667887_9_Ent2", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17667887_9_Ent4", "text": "antidepressant", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "17667887_9_Ent3", "text": "antipsychotic", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17667887_9_Ent5", "text": "antipsychotic", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "17675030_4", "wnd_id": "17675030_4_1", "text": "We describe in detail the first U.S. case report , of a 4(1/2) - year - old boy who experienced angioedema during treatment with oxcarbazepine .", "tokens": ["We", "describe", "in", "detail", "the", "first", "U.S.", "case", "report", ",", "of", "a", "4(1/2)", "-", "year", "-", "old", "boy", "who", "experienced", "angioedema", "during", "treatment", "with", "oxcarbazepine", "."], "event_mentions": [{"id": "17675030_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment", "start": 22, "end": 23}, "arguments": [{"entity_id": "17675030_4_Ent0", "role": "Subject", "text": "a 4(1/2) - year - old boy", "start": 11, "end": 18}, {"entity_id": "17675030_4_Ent1", "role": "Subject_Age", "text": "4(1/2) - year - old", "start": 12, "end": 17}, {"entity_id": "17675030_4_Ent2", "role": "Subject_Gender", "text": "boy", "start": 17, "end": 18}, {"entity_id": "17675030_4_Ent3", "role": "Effect", "text": "angioedema", "start": 20, "end": 21}, {"entity_id": "17675030_4_Ent4", "role": "Treatment", "text": "oxcarbazepine", "start": 24, "end": 25}, {"entity_id": "17675030_4_Ent5", "role": "Treatment_Drug", "text": "oxcarbazepine", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "17675030_4_Ent0", "text": "a 4(1/2) - year - old boy", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "17675030_4_Ent1", "text": "4(1/2) - year - old", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "17675030_4_Ent2", "text": "boy", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "17675030_4_Ent3", "text": "angioedema", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "17675030_4_Ent4", "text": "oxcarbazepine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "17675030_4_Ent5", "text": "oxcarbazepine", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "17710018_2", "wnd_id": "17710018_2_1", "text": "Because etoposide - induced pulmonary toxicity is an uncommon but serious adverse event , clinicians must be vigilant about the possibility of it , so that the optimal treatment can start as soon as possible .", "tokens": ["Because", "etoposide", "-", "induced", "pulmonary", "toxicity", "is", "an", "uncommon", "but", "serious", "adverse", "event", ",", "clinicians", "must", "be", "vigilant", "about", "the", "possibility", "of", "it", ",", "so", "that", "the", "optimal", "treatment", "can", "start", "as", "soon", "as", "possible", "."], "event_mentions": [{"id": "17710018_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "17710018_2_Ent1", "role": "Treatment", "text": "etoposide", "start": 1, "end": 2}, {"entity_id": "17710018_2_Ent2", "role": "Treatment_Drug", "text": "etoposide", "start": 1, "end": 2}, {"entity_id": "17710018_2_Ent0", "role": "Effect", "text": "pulmonary toxicity", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "17710018_2_Ent1", "text": "etoposide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17710018_2_Ent2", "text": "etoposide", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "17710018_2_Ent0", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "1772299_1", "wnd_id": "1772299_1_1", "text": "Detection of antineutrophil cytoplasmic antibody in a patient with L - tryptophan induced eosinophilia - myalgia syndrome .", "tokens": ["Detection", "of", "antineutrophil", "cytoplasmic", "antibody", "in", "a", "patient", "with", "L", "-", "tryptophan", "induced", "eosinophilia", "-", "myalgia", "syndrome", "."], "event_mentions": [{"id": "1772299_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "1772299_1_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "1772299_1_Ent2", "role": "Treatment", "text": "L - tryptophan", "start": 9, "end": 12}, {"entity_id": "1772299_1_Ent3", "role": "Treatment_Drug", "text": "L - tryptophan", "start": 9, "end": 12}, {"entity_id": "1772299_1_Ent1", "role": "Effect", "text": "eosinophilia - myalgia syndrome", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "1772299_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1772299_1_Ent2", "text": "L - tryptophan", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1772299_1_Ent3", "text": "L - tryptophan", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "1772299_1_Ent1", "text": "eosinophilia - myalgia syndrome", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "17725438_1", "wnd_id": "17725438_1_1", "text": "Here , we report a case of RFP - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Here", ",", "we", "report", "a", "case", "of", "RFP", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "17725438_1_Ent1", "role": "Treatment", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent2", "role": "Treatment_Drug", "text": "RFP", "start": 7, "end": 8}, {"entity_id": "17725438_1_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "17725438_1_Ent1", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent2", "text": "RFP", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17725438_1_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "17725438_2", "wnd_id": "17725438_2_1", "text": "Rifampin - induced hypothyroidism without underlying thyroid disease .", "tokens": ["Rifampin", "-", "induced", "hypothyroidism", "without", "underlying", "thyroid", "disease", "."], "event_mentions": [{"id": "17725438_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "17725438_2_Ent1", "role": "Treatment", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "17725438_2_Ent2", "role": "Treatment_Drug", "text": "Rifampin", "start": 0, "end": 1}, {"entity_id": "17725438_2_Ent0", "role": "Effect", "text": "hypothyroidism without underlying thyroid disease", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "17725438_2_Ent1", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17725438_2_Ent2", "text": "Rifampin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "17725438_2_Ent0", "text": "hypothyroidism without underlying thyroid disease", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "17763133_2", "wnd_id": "17763133_2_1", "text": "Discontinuation of simvastatin and cyclosporine resulted in resolution of rhabdomyolysis and normalization of renal function .", "tokens": ["Discontinuation", "of", "simvastatin", "and", "cyclosporine", "resulted", "in", "resolution", "of", "rhabdomyolysis", "and", "normalization", "of", "renal", "function", "."], "event_mentions": [{"id": "17763133_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resulted", "start": 5, "end": 6}, "arguments": [{"entity_id": "17763133_2_Ent1", "role": "Treatment", "text": "Discontinuation of simvastatin and cyclosporine", "start": 0, "end": 5}, {"entity_id": "17763133_2_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 2, "end": 3}, {"entity_id": "17763133_2_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 4, "end": 5}, {"entity_id": "17763133_2_Ent2", "role": "Treatment_Disorder", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "17763133_2_Ent0", "role": "Effect", "text": "normalization of renal function", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "17763133_2_Ent1", "text": "Discontinuation of simvastatin and cyclosporine", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "17763133_2_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17763133_2_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17763133_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17763133_2_Ent0", "text": "normalization of renal function", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "17823522_1", "wnd_id": "17823522_1_1", "text": "Generalized lichen nitidus with involvement of the palms following interferon alpha treatment .", "tokens": ["Generalized", "lichen", "nitidus", "with", "involvement", "of", "the", "palms", "following", "interferon", "alpha", "treatment", "."], "event_mentions": [{"id": "17823522_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 8, "end": 9}, "arguments": [{"entity_id": "17823522_1_Ent0", "role": "Effect", "text": "Generalized lichen nitidus with involvement of the palms", "start": 0, "end": 8}, {"entity_id": "17823522_1_Ent2", "role": "Treatment_Drug", "text": "interferon alpha", "start": 9, "end": 11}, {"entity_id": "17823522_1_Ent1", "role": "Treatment", "text": "interferon alpha treatment", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "17823522_1_Ent0", "text": "Generalized lichen nitidus with involvement of the palms", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "17823522_1_Ent2", "text": "interferon alpha", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "17823522_1_Ent1", "text": "interferon alpha treatment", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "17852449_1", "wnd_id": "17852449_1_1", "text": "Outcome of pregnancy in women treated with all - trans retinoic acid ; a case report and review of literature .", "tokens": ["Outcome", "of", "pregnancy", "in", "women", "treated", "with", "all", "-", "trans", "retinoic", "acid", ";", "a", "case", "report", "and", "review", "of", "literature", "."], "event_mentions": [{"id": "17852449_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 5, "end": 6}, "arguments": [{"entity_id": "17852449_1_Ent4", "role": "Treatment_Disorder", "text": "pregnancy", "start": 2, "end": 3}, {"entity_id": "17852449_1_Ent0", "role": "Subject", "text": "pregnancy in women", "start": 2, "end": 5}, {"entity_id": "17852449_1_Ent1", "role": "Subject_Gender", "text": "women", "start": 4, "end": 5}, {"entity_id": "17852449_1_Ent2", "role": "Treatment", "text": "all - trans retinoic acid", "start": 7, "end": 12}, {"entity_id": "17852449_1_Ent3", "role": "Treatment_Drug", "text": "all - trans retinoic acid", "start": 7, "end": 12}]}], "entity_mentions": [{"id": "17852449_1_Ent4", "text": "pregnancy", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "17852449_1_Ent0", "text": "pregnancy in women", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "17852449_1_Ent1", "text": "women", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "17852449_1_Ent2", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "17852449_1_Ent3", "text": "all - trans retinoic acid", "entity_type": "Entity", "start": 7, "end": 12}], "lang": "en"}
{"doc_id": "17873198_1", "wnd_id": "17873198_1_1", "text": "Interstitial lung disease ( ILD ) related to therapy with the drug gefitinib has been well reported .", "tokens": ["Interstitial", "lung", "disease", "(", "ILD", ")", "related", "to", "therapy", "with", "the", "drug", "gefitinib", "has", "been", "well", "reported", "."], "event_mentions": [{"id": "17873198_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 6, "end": 7}, "arguments": [{"entity_id": "17873198_1_Ent0", "role": "Effect", "text": "Interstitial lung disease ( ILD )", "start": 0, "end": 6}, {"entity_id": "17873198_1_Ent1", "role": "Treatment", "text": "therapy with the drug gefitinib", "start": 8, "end": 13}, {"entity_id": "17873198_1_Ent2", "role": "Treatment_Drug", "text": "gefitinib", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "17873198_1_Ent0", "text": "Interstitial lung disease ( ILD )", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "17873198_1_Ent1", "text": "therapy with the drug gefitinib", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17873198_1_Ent2", "text": "gefitinib", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "17921794_3", "wnd_id": "17921794_3_1", "text": "The concomitant use , however , of colchicine and statin has been associated with the rapid onset of muscle weakness .", "tokens": ["The", "concomitant", "use", ",", "however", ",", "of", "colchicine", "and", "statin", "has", "been", "associated", "with", "the", "rapid", "onset", "of", "muscle", "weakness", "."], "event_mentions": [{"id": "17921794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 12, "end": 13}, "arguments": [{"entity_id": "17921794_3_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "17921794_3_Ent4", "role": "Combination_Drug", "text": "colchicine", "start": 7, "end": 8}, {"entity_id": "17921794_3_Ent1", "role": "Treatment", "text": "colchicine and statin", "start": 7, "end": 10}, {"entity_id": "17921794_3_Ent3", "role": "Treatment_Drug", "text": "statin", "start": 9, "end": 10}, {"entity_id": "17921794_3_Ent5", "role": "Combination_Drug", "text": "statin", "start": 9, "end": 10}, {"entity_id": "17921794_3_Ent0", "role": "Effect", "text": "the rapid onset of muscle weakness", "start": 14, "end": 20}]}], "entity_mentions": [{"id": "17921794_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17921794_3_Ent4", "text": "colchicine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "17921794_3_Ent1", "text": "colchicine and statin", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "17921794_3_Ent3", "text": "statin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17921794_3_Ent5", "text": "statin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "17921794_3_Ent0", "text": "the rapid onset of muscle weakness", "entity_type": "Entity", "start": 14, "end": 20}], "lang": "en"}
{"doc_id": "17921794_4", "wnd_id": "17921794_4_1", "text": "We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "mild", "chronic", "renal", "insufficiency", "who", "had", "been", "taking", "simvastatin", "for", "over", "a", "year", "and", "developed", "acute", "weakness", "within", "3", "weeks", "after", "the", "start", "of", "treatment", "with", "colchicine", "for", "acute", "gouty", "bursitis", "."], "event_mentions": [{"id": "17921794_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 22, "end": 23}, "arguments": [{"entity_id": "17921794_4_Ent0", "role": "Subject", "text": "a patient with mild chronic renal insufficiency", "start": 5, "end": 12}, {"entity_id": "17921794_4_Ent1", "role": "Subject_Disorder", "text": "mild chronic renal insufficiency", "start": 8, "end": 12}, {"entity_id": "17921794_4_Ent3", "role": "Treatment", "text": "taking simvastatin for over a year", "start": 15, "end": 21}, {"entity_id": "17921794_4_Ent6", "role": "Treatment_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent10", "role": "Combination_Drug", "text": "simvastatin", "start": 16, "end": 17}, {"entity_id": "17921794_4_Ent8", "role": "Treatment_Time_elapsed", "text": "over a year", "start": 18, "end": 21}, {"entity_id": "17921794_4_Ent2", "role": "Effect", "text": "acute weakness", "start": 23, "end": 25}, {"entity_id": "17921794_4_Ent9", "role": "Treatment_Time_elapsed", "text": "3 weeks", "start": 26, "end": 28}, {"entity_id": "17921794_4_Ent4", "role": "Treatment", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "start": 26, "end": 39}, {"entity_id": "17921794_4_Ent7", "role": "Treatment_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent11", "role": "Combination_Drug", "text": "colchicine", "start": 34, "end": 35}, {"entity_id": "17921794_4_Ent5", "role": "Treatment_Disorder", "text": "acute gouty bursitis", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "17921794_4_Ent0", "text": "a patient with mild chronic renal insufficiency", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "17921794_4_Ent1", "text": "mild chronic renal insufficiency", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "17921794_4_Ent3", "text": "taking simvastatin for over a year", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "17921794_4_Ent6", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent10", "text": "simvastatin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "17921794_4_Ent8", "text": "over a year", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "17921794_4_Ent2", "text": "acute weakness", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "17921794_4_Ent9", "text": "3 weeks", "entity_type": "Entity", "start": 26, "end": 28}, {"id": "17921794_4_Ent4", "text": "3 weeks after the start of treatment with colchicine for acute gouty bursitis", "entity_type": "Entity", "start": 26, "end": 39}, {"id": "17921794_4_Ent7", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent11", "text": "colchicine", "entity_type": "Entity", "start": 34, "end": 35}, {"id": "17921794_4_Ent5", "text": "acute gouty bursitis", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "1792646_2", "wnd_id": "1792646_2_1", "text": "Pneumocystis pneumonia should be considered in asthmatic patients taking methotrexate who present with fever , pulmonary infiltrates , and hypoxia .", "tokens": ["Pneumocystis", "pneumonia", "should", "be", "considered", "in", "asthmatic", "patients", "taking", "methotrexate", "who", "present", "with", "fever", ",", "pulmonary", "infiltrates", ",", "and", "hypoxia", "."], "event_mentions": [{"id": "1792646_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 8, "end": 9}, "arguments": [{"entity_id": "1792646_2_Ent1", "role": "Effect", "text": "Pneumocystis pneumonia", "start": 0, "end": 2}, {"entity_id": "1792646_2_Ent5", "role": "Treatment_Disorder", "text": "asthmatic", "start": 6, "end": 7}, {"entity_id": "1792646_2_Ent0", "role": "Subject", "text": "asthmatic patients", "start": 6, "end": 8}, {"entity_id": "1792646_2_Ent3", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "1792646_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "1792646_2_Ent2", "role": "Effect", "text": "fever , pulmonary infiltrates , and hypoxia", "start": 13, "end": 20}]}], "entity_mentions": [{"id": "1792646_2_Ent1", "text": "Pneumocystis pneumonia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1792646_2_Ent5", "text": "asthmatic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "1792646_2_Ent0", "text": "asthmatic patients", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "1792646_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1792646_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "1792646_2_Ent2", "text": "fever , pulmonary infiltrates , and hypoxia", "entity_type": "Entity", "start": 13, "end": 20}], "lang": "en"}
{"doc_id": "17952482_1", "wnd_id": "17952482_1_1", "text": "A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever , skin eruptions , leukocytopenia , and thrombocytopenia , 3 weeks after treatment with sulfasalazine .", "tokens": ["A", "58", "-", "year", "-", "old", "woman", "with", "rheumatoid", "arthritis", "(", "RA", ")", "developed", "fever", ",", "skin", "eruptions", ",", "leukocytopenia", ",", "and", "thrombocytopenia", ",", "3", "weeks", "after", "treatment", "with", "sulfasalazine", "."], "event_mentions": [{"id": "17952482_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "17952482_1_Ent1", "role": "Subject_Age", "text": "58 - year - old", "start": 1, "end": 6}, {"entity_id": "17952482_1_Ent0", "role": "Subject", "text": "58 - year - old woman with rheumatoid arthritis ( RA )", "start": 1, "end": 13}, {"entity_id": "17952482_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "17952482_1_Ent7", "role": "Treatment_Disorder", "text": "rheumatoid arthritis ( RA )", "start": 8, "end": 13}, {"entity_id": "17952482_1_Ent3", "role": "Effect", "text": "fever , skin eruptions , leukocytopenia , and thrombocytopenia", "start": 14, "end": 23}, {"entity_id": "17952482_1_Ent6", "role": "Treatment_Time_elapsed", "text": "3 weeks after", "start": 24, "end": 27}, {"entity_id": "17952482_1_Ent4", "role": "Treatment", "text": "3 weeks after treatment with sulfasalazine", "start": 24, "end": 30}, {"entity_id": "17952482_1_Ent5", "role": "Treatment_Drug", "text": "sulfasalazine", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "17952482_1_Ent1", "text": "58 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "17952482_1_Ent0", "text": "58 - year - old woman with rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 1, "end": 13}, {"id": "17952482_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "17952482_1_Ent7", "text": "rheumatoid arthritis ( RA )", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "17952482_1_Ent3", "text": "fever , skin eruptions , leukocytopenia , and thrombocytopenia", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "17952482_1_Ent6", "text": "3 weeks after", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "17952482_1_Ent4", "text": "3 weeks after treatment with sulfasalazine", "entity_type": "Entity", "start": 24, "end": 30}, {"id": "17952482_1_Ent5", "text": "sulfasalazine", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "18034202_1", "wnd_id": "18034202_1_1", "text": "We report a case of a patient with rheumatoid arthritis treated with low - dose methotrexate ( 15 mg / week ) who developed infection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip .", "tokens": ["We", "report", "a", "case", "of", "a", "patient", "with", "rheumatoid", "arthritis", "treated", "with", "low", "-", "dose", "methotrexate", "(", "15", "mg", "/", "week", ")", "who", "developed", "infection", "with", "both", "M.", "tuberculosis", "and", "M.", "chelonae", "after", "the", "revision", "of", "a", "prosthetic", "hip", "."], "event_mentions": [{"id": "18034202_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "18034202_1_Ent0", "role": "Subject", "text": "patient with rheumatoid arthritis", "start": 6, "end": 10}, {"entity_id": "18034202_1_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 8, "end": 10}, {"entity_id": "18034202_1_Ent2", "role": "Treatment", "text": "low - dose methotrexate ( 15 mg / week )", "start": 12, "end": 22}, {"entity_id": "18034202_1_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 15, "end": 16}, {"entity_id": "18034202_1_Ent3", "role": "Treatment_Dosage", "text": "15 mg / week", "start": 17, "end": 21}, {"entity_id": "18034202_1_Ent1", "role": "Effect", "text": "infection with both M. tuberculosis and M. chelonae", "start": 24, "end": 32}]}], "entity_mentions": [{"id": "18034202_1_Ent0", "text": "patient with rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "18034202_1_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18034202_1_Ent2", "text": "low - dose methotrexate ( 15 mg / week )", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "18034202_1_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18034202_1_Ent3", "text": "15 mg / week", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "18034202_1_Ent1", "text": "infection with both M. tuberculosis and M. chelonae", "entity_type": "Entity", "start": 24, "end": 32}], "lang": "en"}
{"doc_id": "18079582_3", "wnd_id": "18079582_3_1", "text": "We report such a series of patients who had transient asymptomatic bradycardia after being treated with continuous infusion 5 - FU .", "tokens": ["We", "report", "such", "a", "series", "of", "patients", "who", "had", "transient", "asymptomatic", "bradycardia", "after", "being", "treated", "with", "continuous", "infusion", "5", "-", "FU", "."], "event_mentions": [{"id": "18079582_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "18079582_3_Ent1", "role": "Subject_Population", "text": "a series", "start": 3, "end": 5}, {"entity_id": "18079582_3_Ent0", "role": "Subject", "text": "a series of patients", "start": 3, "end": 7}, {"entity_id": "18079582_3_Ent2", "role": "Effect", "text": "transient asymptomatic bradycardia", "start": 9, "end": 12}, {"entity_id": "18079582_3_Ent4", "role": "Treatment_Freq", "text": "continuous", "start": 16, "end": 17}, {"entity_id": "18079582_3_Ent3", "role": "Treatment", "text": "continuous infusion 5 - FU", "start": 16, "end": 21}, {"entity_id": "18079582_3_Ent6", "role": "Treatment_Route", "text": "infusion", "start": 17, "end": 18}, {"entity_id": "18079582_3_Ent5", "role": "Treatment_Drug", "text": "5 - FU", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "18079582_3_Ent1", "text": "a series", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18079582_3_Ent0", "text": "a series of patients", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "18079582_3_Ent2", "text": "transient asymptomatic bradycardia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18079582_3_Ent4", "text": "continuous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18079582_3_Ent3", "text": "continuous infusion 5 - FU", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "18079582_3_Ent6", "text": "infusion", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18079582_3_Ent5", "text": "5 - FU", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "18094347_1", "wnd_id": "18094347_1_1", "text": "According to the Naranjo probability scale , the papular eruption was probably caused by methotrexate .", "tokens": ["According", "to", "the", "Naranjo", "probability", "scale", ",", "the", "papular", "eruption", "was", "probably", "caused", "by", "methotrexate", "."], "event_mentions": [{"id": "18094347_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "18094347_1_Ent0", "role": "Effect", "text": "papular eruption", "start": 8, "end": 10}, {"entity_id": "18094347_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "18094347_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "18094347_1_Ent0", "text": "papular eruption", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18094347_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18094347_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "18094347_8", "wnd_id": "18094347_8_1", "text": "Ten hours after the second methotrexate injection , the patient experienced a diffuse pruritic papular eruption located mainly on the limbs .", "tokens": ["Ten", "hours", "after", "the", "second", "methotrexate", "injection", ",", "the", "patient", "experienced", "a", "diffuse", "pruritic", "papular", "eruption", "located", "mainly", "on", "the", "limbs", "."], "event_mentions": [{"id": "18094347_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 10, "end": 11}, "arguments": [{"entity_id": "18094347_8_Ent5", "role": "Treatment_Time_elapsed", "text": "Ten hours", "start": 0, "end": 2}, {"entity_id": "18094347_8_Ent2", "role": "Treatment", "text": "Ten hours after the second methotrexate injection", "start": 0, "end": 7}, {"entity_id": "18094347_8_Ent6", "role": "Treatment_Time_elapsed", "text": "second", "start": 4, "end": 5}, {"entity_id": "18094347_8_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 5, "end": 6}, {"entity_id": "18094347_8_Ent4", "role": "Treatment_Route", "text": "injection", "start": 6, "end": 7}, {"entity_id": "18094347_8_Ent0", "role": "Subject", "text": "the patient", "start": 8, "end": 10}, {"entity_id": "18094347_8_Ent1", "role": "Effect", "text": "diffuse pruritic papular eruption located mainly on the limbs", "start": 12, "end": 21}]}], "entity_mentions": [{"id": "18094347_8_Ent5", "text": "Ten hours", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18094347_8_Ent2", "text": "Ten hours after the second methotrexate injection", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "18094347_8_Ent6", "text": "second", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18094347_8_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18094347_8_Ent4", "text": "injection", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18094347_8_Ent0", "text": "the patient", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "18094347_8_Ent1", "text": "diffuse pruritic papular eruption located mainly on the limbs", "entity_type": "Entity", "start": 12, "end": 21}], "lang": "en"}
{"doc_id": "1814986_1", "wnd_id": "1814986_1_1", "text": "Metabolic acidosis induced by acetazolamide .", "tokens": ["Metabolic", "acidosis", "induced", "by", "acetazolamide", "."], "event_mentions": [{"id": "1814986_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1814986_1_Ent0", "role": "Effect", "text": "Metabolic acidosis", "start": 0, "end": 2}, {"entity_id": "1814986_1_Ent1", "role": "Treatment", "text": "acetazolamide", "start": 4, "end": 5}, {"entity_id": "1814986_1_Ent2", "role": "Treatment_Drug", "text": "acetazolamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "1814986_1_Ent0", "text": "Metabolic acidosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1814986_1_Ent1", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "1814986_1_Ent2", "text": "acetazolamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "18160579_1", "wnd_id": "18160579_1_1", "text": "Pericardial hemorrhage due to acetylsalicylic acid in a patient with essential thrombocythemia .", "tokens": ["Pericardial", "hemorrhage", "due", "to", "acetylsalicylic", "acid", "in", "a", "patient", "with", "essential", "thrombocythemia", "."], "event_mentions": [{"id": "18160579_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "18160579_1_Ent0", "role": "Effect", "text": "Pericardial hemorrhage", "start": 0, "end": 2}, {"entity_id": "18160579_1_Ent1", "role": "Treatment", "text": "acetylsalicylic acid", "start": 4, "end": 6}, {"entity_id": "18160579_1_Ent2", "role": "Treatment_Drug", "text": "acetylsalicylic acid", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "18160579_1_Ent0", "text": "Pericardial hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18160579_1_Ent1", "text": "acetylsalicylic acid", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18160579_1_Ent2", "text": "acetylsalicylic acid", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "18171260_1", "wnd_id": "18171260_1_1", "text": "Serotonin syndrome after concomitant treatment with linezolid and meperidine .", "tokens": ["Serotonin", "syndrome", "after", "concomitant", "treatment", "with", "linezolid", "and", "meperidine", "."], "event_mentions": [{"id": "18171260_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "18171260_1_Ent0", "role": "Effect", "text": "Serotonin syndrome", "start": 0, "end": 2}, {"entity_id": "18171260_1_Ent1", "role": "Treatment", "text": "concomitant treatment with linezolid and meperidine", "start": 3, "end": 9}, {"entity_id": "18171260_1_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "18171260_1_Ent4", "role": "Combination_Drug", "text": "linezolid", "start": 6, "end": 7}, {"entity_id": "18171260_1_Ent3", "role": "Treatment_Drug", "text": "meperidine", "start": 8, "end": 9}, {"entity_id": "18171260_1_Ent5", "role": "Combination_Drug", "text": "meperidine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18171260_1_Ent0", "text": "Serotonin syndrome", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18171260_1_Ent1", "text": "concomitant treatment with linezolid and meperidine", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "18171260_1_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18171260_1_Ent4", "text": "linezolid", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18171260_1_Ent3", "text": "meperidine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_1_Ent5", "text": "meperidine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18171260_5", "wnd_id": "18171260_5_1", "text": "We describe serotonin syndrome after concomitant use of linezolid and meperidine in a 27 - year - old man with acute leukemia .", "tokens": ["We", "describe", "serotonin", "syndrome", "after", "concomitant", "use", "of", "linezolid", "and", "meperidine", "in", "a", "27", "-", "year", "-", "old", "man", "with", "acute", "leukemia", "."], "event_mentions": [{"id": "18171260_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18171260_5_Ent4", "role": "Effect", "text": "serotonin syndrome", "start": 2, "end": 4}, {"entity_id": "18171260_5_Ent5", "role": "Treatment", "text": "concomitant use of linezolid and meperidine", "start": 5, "end": 11}, {"entity_id": "18171260_5_Ent6", "role": "Treatment_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_5_Ent8", "role": "Combination_Drug", "text": "linezolid", "start": 8, "end": 9}, {"entity_id": "18171260_5_Ent7", "role": "Treatment_Drug", "text": "meperidine", "start": 10, "end": 11}, {"entity_id": "18171260_5_Ent9", "role": "Combination_Drug", "text": "meperidine", "start": 10, "end": 11}, {"entity_id": "18171260_5_Ent0", "role": "Subject", "text": "a 27 - year - old man with acute leukemia", "start": 12, "end": 22}, {"entity_id": "18171260_5_Ent2", "role": "Subject_Age", "text": "27 - year - old", "start": 13, "end": 18}, {"entity_id": "18171260_5_Ent3", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}, {"entity_id": "18171260_5_Ent1", "role": "Subject_Disorder", "text": "acute leukemia", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "18171260_5_Ent4", "text": "serotonin syndrome", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18171260_5_Ent5", "text": "concomitant use of linezolid and meperidine", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "18171260_5_Ent6", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_5_Ent8", "text": "linezolid", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18171260_5_Ent7", "text": "meperidine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18171260_5_Ent9", "text": "meperidine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18171260_5_Ent0", "text": "a 27 - year - old man with acute leukemia", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "18171260_5_Ent2", "text": "27 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "18171260_5_Ent3", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "18171260_5_Ent1", "text": "acute leukemia", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "18176653_12", "wnd_id": "18176653_12_1", "text": "Although HAART is very important in the treatment of HIV , its side effects are responsible for patients ' non - adherence to medications .", "tokens": ["Although", "HAART", "is", "very", "important", "in", "the", "treatment", "of", "HIV", ",", "its", "side", "effects", "are", "responsible", "for", "patients", "'", "non", "-", "adherence", "to", "medications", "."], "event_mentions": [{"id": "18176653_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 12, "end": 14}, "arguments": [{"entity_id": "18176653_12_Ent2", "role": "Treatment", "text": "HAART", "start": 1, "end": 2}, {"entity_id": "18176653_12_Ent4", "role": "Treatment_Drug", "text": "HAART", "start": 1, "end": 2}, {"entity_id": "18176653_12_Ent3", "role": "Treatment_Disorder", "text": "HIV", "start": 9, "end": 10}, {"entity_id": "18176653_12_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "18176653_12_Ent1", "role": "Effect", "text": "non - adherence to medications", "start": 19, "end": 24}]}], "entity_mentions": [{"id": "18176653_12_Ent2", "text": "HAART", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18176653_12_Ent4", "text": "HAART", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18176653_12_Ent3", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18176653_12_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18176653_12_Ent1", "text": "non - adherence to medications", "entity_type": "Entity", "start": 19, "end": 24}], "lang": "en"}
{"doc_id": "18176653_3", "wnd_id": "18176653_3_1", "text": "BACKGROUND : NVP is a non - nucleoside reverse transcriptase inhibitor used in the treatment of Human Immunodeficiency Virus ( HIV ) infection .", "tokens": ["BACKGROUND", ":", "NVP", "is", "a", "non", "-", "nucleoside", "reverse", "transcriptase", "inhibitor", "used", "in", "the", "treatment", "of", "Human", "Immunodeficiency", "Virus", "(", "HIV", ")", "infection", "."], "event_mentions": [{"id": "18176653_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used", "start": 11, "end": 12}, "arguments": [{"entity_id": "18176653_3_Ent0", "role": "Treatment", "text": "NVP", "start": 2, "end": 3}, {"entity_id": "18176653_3_Ent2", "role": "Treatment_Drug", "text": "NVP", "start": 2, "end": 3}, {"entity_id": "18176653_3_Ent1", "role": "Treatment_Disorder", "text": "Human Immunodeficiency Virus ( HIV ) infection", "start": 16, "end": 23}]}], "entity_mentions": [{"id": "18176653_3_Ent0", "text": "NVP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18176653_3_Ent2", "text": "NVP", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18176653_3_Ent1", "text": "Human Immunodeficiency Virus ( HIV ) infection", "entity_type": "Entity", "start": 16, "end": 23}], "lang": "en"}
{"doc_id": "18258513_1", "wnd_id": "18258513_1_1", "text": "While doxorubicin was administered , the patient presented thoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum .", "tokens": ["While", "doxorubicin", "was", "administered", ",", "the", "patient", "presented", "thoracic", "pain", "and", "breathing", "distress", "due", "to", "superior", "vena", "cava", "perforation", "by", "the", "central", "catheter", "and", "subsequent", "extravasation", "of", "the", "drug", "into", "the", "mediastinum", "."], "event_mentions": [{"id": "18258513_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 7, "end": 8}, "arguments": [{"entity_id": "18258513_1_Ent2", "role": "Treatment", "text": "doxorubicin", "start": 1, "end": 2}, {"entity_id": "18258513_1_Ent3", "role": "Treatment_Drug", "text": "doxorubicin", "start": 1, "end": 2}, {"entity_id": "18258513_1_Ent0", "role": "Subject", "text": "patient", "start": 6, "end": 7}, {"entity_id": "18258513_1_Ent1", "role": "Effect", "text": "thoracic pain and breathing distress", "start": 8, "end": 13}]}], "entity_mentions": [{"id": "18258513_1_Ent2", "text": "doxorubicin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18258513_1_Ent3", "text": "doxorubicin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "18258513_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18258513_1_Ent1", "text": "thoracic pain and breathing distress", "entity_type": "Entity", "start": 8, "end": 13}], "lang": "en"}
{"doc_id": "18262450_10", "wnd_id": "18262450_10_1", "text": "Oxycodone - gabapentin also significantly improved pain relief vs gabapentin alone ( P = 0.003 ) .", "tokens": ["Oxycodone", "-", "gabapentin", "also", "significantly", "improved", "pain", "relief", "vs", "gabapentin", "alone", "(", "P", "=", "0.003", ")", "."], "event_mentions": [{"id": "18262450_10_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 5, "end": 6}, "arguments": [{"entity_id": "18262450_10_Ent2", "role": "Treatment_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_10_Ent4", "role": "Combination_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_10_Ent0", "role": "Treatment", "text": "Oxycodone - gabapentin", "start": 0, "end": 3}, {"entity_id": "18262450_10_Ent3", "role": "Treatment_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_10_Ent5", "role": "Combination_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_10_Ent1", "role": "Treatment_Disorder", "text": "pain", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18262450_10_Ent2", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_10_Ent4", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_10_Ent0", "text": "Oxycodone - gabapentin", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18262450_10_Ent3", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_10_Ent5", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_10_Ent1", "text": "pain", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18262450_11", "wnd_id": "18262450_11_1", "text": "Oxycodone - gabapentin co - administration was associated with less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P < 0.05 ) .", "tokens": ["Oxycodone", "-", "gabapentin", "co", "-", "administration", "was", "associated", "with", "less", "escape", "medication", "use", "(", "P", "=", "0.03", ")", "and", "fewer", "nights", "of", "disturbed", "sleep", "(", "P", "<", "0.05", ")", "."], "event_mentions": [{"id": "18262450_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "18262450_11_Ent3", "role": "Treatment_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_11_Ent4", "role": "Combination_Drug", "text": "Oxycodone", "start": 0, "end": 1}, {"entity_id": "18262450_11_Ent1", "role": "Treatment", "text": "Oxycodone - gabapentin co - administration", "start": 0, "end": 6}, {"entity_id": "18262450_11_Ent2", "role": "Treatment_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_11_Ent5", "role": "Combination_Drug", "text": "gabapentin", "start": 2, "end": 3}, {"entity_id": "18262450_11_Ent0", "role": "Effect", "text": "less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P < 0.05 )", "start": 9, "end": 29}]}], "entity_mentions": [{"id": "18262450_11_Ent3", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_11_Ent4", "text": "Oxycodone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18262450_11_Ent1", "text": "Oxycodone - gabapentin co - administration", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "18262450_11_Ent2", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_11_Ent5", "text": "gabapentin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18262450_11_Ent0", "text": "less escape medication use ( P = 0.03 ) and fewer nights of disturbed sleep ( P < 0.05 )", "entity_type": "Entity", "start": 9, "end": 29}], "lang": "en"}
{"doc_id": "1827039_1", "wnd_id": "1827039_1_1", "text": "Severe hepatocellular dysfunction following cyproterone acetate therapy .", "tokens": ["Severe", "hepatocellular", "dysfunction", "following", "cyproterone", "acetate", "therapy", "."], "event_mentions": [{"id": "1827039_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "1827039_1_Ent0", "role": "Effect", "text": "Severe hepatocellular dysfunction", "start": 0, "end": 3}, {"entity_id": "1827039_1_Ent1", "role": "Treatment", "text": "cyproterone acetate", "start": 4, "end": 6}, {"entity_id": "1827039_1_Ent2", "role": "Treatment_Drug", "text": "cyproterone acetate", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "1827039_1_Ent0", "text": "Severe hepatocellular dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1827039_1_Ent1", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "1827039_1_Ent2", "text": "cyproterone acetate", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "1827039_2", "wnd_id": "1827039_2_1", "text": "We report 3 patients with severe hepatocellular damage due to CPA therapy , 2 with fatal fulminant hepatitis .", "tokens": ["We", "report", "3", "patients", "with", "severe", "hepatocellular", "damage", "due", "to", "CPA", "therapy", ",", "2", "with", "fatal", "fulminant", "hepatitis", "."], "event_mentions": [{"id": "1827039_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "1827039_2_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "1827039_2_Ent0", "role": "Subject", "text": "3 patients", "start": 2, "end": 4}, {"entity_id": "1827039_2_Ent2", "role": "Effect", "text": "severe hepatocellular damage", "start": 5, "end": 8}, {"entity_id": "1827039_2_Ent3", "role": "Treatment", "text": "CPA", "start": 10, "end": 11}, {"entity_id": "1827039_2_Ent4", "role": "Treatment_Drug", "text": "CPA", "start": 10, "end": 11}]}, {"id": "1827039_2_Evt1", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 8, "end": 9}, "arguments": [{"entity_id": "1827039_2_Ent8", "role": "Treatment", "text": "CPA", "start": 10, "end": 11}, {"entity_id": "1827039_2_Ent9", "role": "Treatment_Drug", "text": "CPA", "start": 10, "end": 11}, {"entity_id": "1827039_2_Ent5", "role": "Subject", "text": "2", "start": 13, "end": 14}, {"entity_id": "1827039_2_Ent6", "role": "Subject_Population", "text": "2", "start": 13, "end": 14}, {"entity_id": "1827039_2_Ent7", "role": "Effect", "text": "fatal fulminant hepatitis", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "1827039_2_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "1827039_2_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1827039_2_Ent2", "text": "severe hepatocellular damage", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "1827039_2_Ent3", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent4", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent8", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent9", "text": "CPA", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "1827039_2_Ent5", "text": "2", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1827039_2_Ent6", "text": "2", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "1827039_2_Ent7", "text": "fatal fulminant hepatitis", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "18294121_1", "wnd_id": "18294121_1_1", "text": "According to the Naranjo adverse drug reaction probability scale , the likelihood that temozolomide was responsible for the adverse drug reaction of fever was probable ( score of 6 ) .", "tokens": ["According", "to", "the", "Naranjo", "adverse", "drug", "reaction", "probability", "scale", ",", "the", "likelihood", "that", "temozolomide", "was", "responsible", "for", "the", "adverse", "drug", "reaction", "of", "fever", "was", "probable", "(", "score", "of", "6", ")", "."], "event_mentions": [{"id": "18294121_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse drug reaction", "start": 18, "end": 21}, "arguments": [{"entity_id": "18294121_1_Ent1", "role": "Treatment", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 13, "end": 14}, {"entity_id": "18294121_1_Ent0", "role": "Effect", "text": "fever", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18294121_1_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18294121_1_Ent0", "text": "fever", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18294121_3", "wnd_id": "18294121_3_1", "text": "Due to the severity of the rash , temozolomide was permanently discontinued .", "tokens": ["Due", "to", "the", "severity", "of", "the", "rash", ",", "temozolomide", "was", "permanently", "discontinued", "."], "event_mentions": [{"id": "18294121_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Due", "start": 0, "end": 1}, "arguments": [{"entity_id": "18294121_3_Ent0", "role": "Effect", "text": "rash", "start": 6, "end": 7}, {"entity_id": "18294121_3_Ent1", "role": "Treatment", "text": "temozolomide", "start": 8, "end": 9}, {"entity_id": "18294121_3_Ent2", "role": "Treatment_Drug", "text": "temozolomide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18294121_3_Ent0", "text": "rash", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18294121_3_Ent1", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18294121_3_Ent2", "text": "temozolomide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18315788_1", "wnd_id": "18315788_1_1", "text": "Phenytoin toxicity : an easily missed cause of cerebellar syndrome .", "tokens": ["Phenytoin", "toxicity", ":", "an", "easily", "missed", "cause", "of", "cerebellar", "syndrome", "."], "event_mentions": [{"id": "18315788_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "18315788_1_Ent1", "role": "Treatment", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "18315788_1_Ent2", "role": "Treatment_Drug", "text": "Phenytoin", "start": 0, "end": 1}, {"entity_id": "18315788_1_Ent0", "role": "Effect", "text": "cerebellar syndrome", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "18315788_1_Ent1", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18315788_1_Ent2", "text": "Phenytoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18315788_1_Ent0", "text": "cerebellar syndrome", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "18344455_3", "wnd_id": "18344455_3_1", "text": "This article presents a 3(1/2) - year - old child on valproic acid , lamotrigine , and phenytoin who developed simultaneous hepatotoxicity and bone marrow toxicity during a parainfluenza virus type 3 infection .", "tokens": ["This", "article", "presents", "a", "3(1/2)", "-", "year", "-", "old", "child", "on", "valproic", "acid", ",", "lamotrigine", ",", "and", "phenytoin", "who", "developed", "simultaneous", "hepatotoxicity", "and", "bone", "marrow", "toxicity", "during", "a", "parainfluenza", "virus", "type", "3", "infection", "."], "event_mentions": [{"id": "18344455_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "18344455_3_Ent0", "role": "Subject", "text": "a 3(1/2) - year - old child", "start": 3, "end": 10}, {"entity_id": "18344455_3_Ent1", "role": "Subject_Age", "text": "3(1/2) - year - old", "start": 4, "end": 9}, {"entity_id": "18344455_3_Ent2", "role": "Subject_Age", "text": "child", "start": 9, "end": 10}, {"entity_id": "18344455_3_Ent5", "role": "Treatment_Drug", "text": "valproic acid", "start": 11, "end": 13}, {"entity_id": "18344455_3_Ent10", "role": "Combination_Drug", "text": "valproic acid", "start": 11, "end": 13}, {"entity_id": "18344455_3_Ent4", "role": "Treatment", "text": "valproic acid , lamotrigine , and phenytoin", "start": 11, "end": 18}, {"entity_id": "18344455_3_Ent6", "role": "Treatment_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "18344455_3_Ent9", "role": "Combination_Drug", "text": "lamotrigine", "start": 14, "end": 15}, {"entity_id": "18344455_3_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 17, "end": 18}, {"entity_id": "18344455_3_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 17, "end": 18}, {"entity_id": "18344455_3_Ent3", "role": "Effect", "text": "simultaneous hepatotoxicity and bone marrow toxicity", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18344455_3_Ent0", "text": "a 3(1/2) - year - old child", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "18344455_3_Ent1", "text": "3(1/2) - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18344455_3_Ent2", "text": "child", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18344455_3_Ent5", "text": "valproic acid", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18344455_3_Ent10", "text": "valproic acid", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18344455_3_Ent4", "text": "valproic acid , lamotrigine , and phenytoin", "entity_type": "Entity", "start": 11, "end": 18}, {"id": "18344455_3_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18344455_3_Ent9", "text": "lamotrigine", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18344455_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18344455_3_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18344455_3_Ent3", "text": "simultaneous hepatotoxicity and bone marrow toxicity", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18347524_2", "wnd_id": "18347524_2_1", "text": "We report the case of a young man , affected by rheumatoid arthritis who developed a rapid - onset short - of - breath , hemoptysis , and severe weakness , about 2 weeks after the administration of leflunomide .", "tokens": ["We", "report", "the", "case", "of", "a", "young", "man", ",", "affected", "by", "rheumatoid", "arthritis", "who", "developed", "a", "rapid", "-", "onset", "short", "-", "of", "-", "breath", ",", "hemoptysis", ",", "and", "severe", "weakness", ",", "about", "2", "weeks", "after", "the", "administration", "of", "leflunomide", "."], "event_mentions": [{"id": "18347524_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "18347524_2_Ent0", "role": "Subject", "text": "a young man", "start": 5, "end": 8}, {"entity_id": "18347524_2_Ent1", "role": "Subject_Age", "text": "young", "start": 6, "end": 7}, {"entity_id": "18347524_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 11, "end": 13}, {"entity_id": "18347524_2_Ent2", "role": "Effect", "text": "a rapid - onset short - of - breath , hemoptysis , and severe weakness", "start": 15, "end": 30}, {"entity_id": "18347524_2_Ent3", "role": "Treatment", "text": "about 2 weeks after the administration of leflunomide", "start": 31, "end": 39}, {"entity_id": "18347524_2_Ent6", "role": "Treatment_Time_elapsed", "text": "2 weeks", "start": 32, "end": 34}, {"entity_id": "18347524_2_Ent7", "role": "Treatment_Route", "text": "the administration", "start": 35, "end": 37}, {"entity_id": "18347524_2_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "18347524_2_Ent0", "text": "a young man", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18347524_2_Ent1", "text": "young", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18347524_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18347524_2_Ent2", "text": "a rapid - onset short - of - breath , hemoptysis , and severe weakness", "entity_type": "Entity", "start": 15, "end": 30}, {"id": "18347524_2_Ent3", "text": "about 2 weeks after the administration of leflunomide", "entity_type": "Entity", "start": 31, "end": 39}, {"id": "18347524_2_Ent6", "text": "2 weeks", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "18347524_2_Ent7", "text": "the administration", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "18347524_2_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "18354950_1", "wnd_id": "18354950_1_1", "text": "Hyponatraemia developed after rechallenge with controlled release carbamazepine .", "tokens": ["Hyponatraemia", "developed", "after", "rechallenge", "with", "controlled", "release", "carbamazepine", "."], "event_mentions": [{"id": "18354950_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 1, "end": 2}, "arguments": [{"entity_id": "18354950_1_Ent0", "role": "Effect", "text": "Hyponatraemia", "start": 0, "end": 1}, {"entity_id": "18354950_1_Ent1", "role": "Treatment", "text": "rechallenge with controlled release carbamazepine", "start": 3, "end": 8}, {"entity_id": "18354950_1_Ent2", "role": "Treatment_Drug", "text": "carbamazepine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "18354950_1_Ent0", "text": "Hyponatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18354950_1_Ent1", "text": "rechallenge with controlled release carbamazepine", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "18354950_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "18354950_2", "wnd_id": "18354950_2_1", "text": "Hyponatraemia during low - dose carbamazepine therapy .", "tokens": ["Hyponatraemia", "during", "low", "-", "dose", "carbamazepine", "therapy", "."], "event_mentions": [{"id": "18354950_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 1, "end": 2}, "arguments": [{"entity_id": "18354950_2_Ent0", "role": "Effect", "text": "Hyponatraemia", "start": 0, "end": 1}, {"entity_id": "18354950_2_Ent1", "role": "Treatment", "text": "low - dose carbamazepine", "start": 2, "end": 6}, {"entity_id": "18354950_2_Ent2", "role": "Treatment_Drug", "text": "low - dose carbamazepine", "start": 2, "end": 6}]}], "entity_mentions": [{"id": "18354950_2_Ent0", "text": "Hyponatraemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18354950_2_Ent1", "text": "low - dose carbamazepine", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "18354950_2_Ent2", "text": "low - dose carbamazepine", "entity_type": "Entity", "start": 2, "end": 6}], "lang": "en"}
{"doc_id": "18362995_2", "wnd_id": "18362995_2_1", "text": "Imatinib mesylate - related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection .", "tokens": ["Imatinib", "mesylate", "-", "related", "fatal", "acute", "hepatic", "failure", "in", "a", "patient", "with", "chronic", "myeloid", "leukaemia", "and", "chronic", "hepatitis", "B", "infection", "."], "event_mentions": [{"id": "18362995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 3, "end": 4}, "arguments": [{"entity_id": "18362995_2_Ent3", "role": "Treatment", "text": "Imatinib mesylate", "start": 0, "end": 2}, {"entity_id": "18362995_2_Ent4", "role": "Treatment_Drug", "text": "Imatinib mesylate", "start": 0, "end": 2}, {"entity_id": "18362995_2_Ent2", "role": "Effect", "text": "fatal acute hepatic failure", "start": 4, "end": 8}, {"entity_id": "18362995_2_Ent0", "role": "Subject", "text": "a patient with chronic myeloid leukaemia and chronic hepatitis B infection", "start": 9, "end": 20}, {"entity_id": "18362995_2_Ent5", "role": "Treatment_Disorder", "text": "chronic myeloid leukaemia", "start": 12, "end": 15}, {"entity_id": "18362995_2_Ent1", "role": "Subject_Disorder", "text": "chronic hepatitis B infection", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "18362995_2_Ent3", "text": "Imatinib mesylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18362995_2_Ent4", "text": "Imatinib mesylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18362995_2_Ent2", "text": "fatal acute hepatic failure", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "18362995_2_Ent0", "text": "a patient with chronic myeloid leukaemia and chronic hepatitis B infection", "entity_type": "Entity", "start": 9, "end": 20}, {"id": "18362995_2_Ent5", "text": "chronic myeloid leukaemia", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18362995_2_Ent1", "text": "chronic hepatitis B infection", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "18364401_3", "wnd_id": "18364401_3_1", "text": "Rapidly developing hyperglycemia during treatment with olanzapine .", "tokens": ["Rapidly", "developing", "hyperglycemia", "during", "treatment", "with", "olanzapine", "."], "event_mentions": [{"id": "18364401_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "18364401_3_Ent0", "role": "Effect", "text": "Rapidly developing hyperglycemia", "start": 0, "end": 3}, {"entity_id": "18364401_3_Ent1", "role": "Treatment", "text": "olanzapine", "start": 6, "end": 7}, {"entity_id": "18364401_3_Ent2", "role": "Treatment_Drug", "text": "olanzapine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "18364401_3_Ent0", "text": "Rapidly developing hyperglycemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18364401_3_Ent1", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18364401_3_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "18371508_1", "wnd_id": "18371508_1_1", "text": "Adult respiratory distress syndrome after treatment with pegylated interferon alpha - 2a and ribavirin .", "tokens": ["Adult", "respiratory", "distress", "syndrome", "after", "treatment", "with", "pegylated", "interferon", "alpha", "-", "2a", "and", "ribavirin", "."], "event_mentions": [{"id": "18371508_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "18371508_1_Ent0", "role": "Effect", "text": "Adult respiratory distress syndrome", "start": 0, "end": 4}, {"entity_id": "18371508_1_Ent2", "role": "Treatment_Drug", "text": "pegylated interferon alpha - 2a", "start": 7, "end": 12}, {"entity_id": "18371508_1_Ent4", "role": "Combination_Drug", "text": "pegylated interferon alpha - 2a", "start": 7, "end": 12}, {"entity_id": "18371508_1_Ent1", "role": "Treatment", "text": "pegylated interferon alpha - 2a and ribavirin", "start": 7, "end": 14}, {"entity_id": "18371508_1_Ent3", "role": "Treatment_Drug", "text": "ribavirin", "start": 13, "end": 14}, {"entity_id": "18371508_1_Ent5", "role": "Combination_Drug", "text": "ribavirin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18371508_1_Ent0", "text": "Adult respiratory distress syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "18371508_1_Ent2", "text": "pegylated interferon alpha - 2a", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18371508_1_Ent4", "text": "pegylated interferon alpha - 2a", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18371508_1_Ent1", "text": "pegylated interferon alpha - 2a and ribavirin", "entity_type": "Entity", "start": 7, "end": 14}, {"id": "18371508_1_Ent3", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18371508_1_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18379937_1", "wnd_id": "18379937_1_1", "text": "Bilateral anterior uveitis associated with clomiphene citrate .", "tokens": ["Bilateral", "anterior", "uveitis", "associated", "with", "clomiphene", "citrate", "."], "event_mentions": [{"id": "18379937_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "18379937_1_Ent0", "role": "Effect", "text": "Bilateral anterior uveitis", "start": 0, "end": 3}, {"entity_id": "18379937_1_Ent1", "role": "Treatment", "text": "clomiphene citrate", "start": 5, "end": 7}, {"entity_id": "18379937_1_Ent2", "role": "Treatment_Drug", "text": "clomiphene citrate", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18379937_1_Ent0", "text": "Bilateral anterior uveitis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18379937_1_Ent1", "text": "clomiphene citrate", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18379937_1_Ent2", "text": "clomiphene citrate", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18408649_2", "wnd_id": "18408649_2_1", "text": "There are , however , case studies describing patients experiencing recurrences of tics following treatment with atomoxetine .", "tokens": ["There", "are", ",", "however", ",", "case", "studies", "describing", "patients", "experiencing", "recurrences", "of", "tics", "following", "treatment", "with", "atomoxetine", "."], "event_mentions": [{"id": "18408649_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 13, "end": 14}, "arguments": [{"entity_id": "18408649_2_Ent0", "role": "Effect", "text": "recurrences of tics", "start": 10, "end": 13}, {"entity_id": "18408649_2_Ent1", "role": "Treatment", "text": "treatment with atomoxetine", "start": 14, "end": 17}, {"entity_id": "18408649_2_Ent2", "role": "Treatment_Drug", "text": "atomoxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18408649_2_Ent0", "text": "recurrences of tics", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18408649_2_Ent1", "text": "treatment with atomoxetine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "18408649_2_Ent2", "text": "atomoxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18425523_2", "wnd_id": "18425523_2_1", "text": "CONCLUSION : Severe and sustained ocular hypertension may occur after intravitreal ranibizumab .", "tokens": ["CONCLUSION", ":", "Severe", "and", "sustained", "ocular", "hypertension", "may", "occur", "after", "intravitreal", "ranibizumab", "."], "event_mentions": [{"id": "18425523_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "18425523_2_Ent0", "role": "Effect", "text": "Severe and sustained ocular hypertension", "start": 2, "end": 7}, {"entity_id": "18425523_2_Ent3", "role": "Treatment_Route", "text": "intravitreal", "start": 10, "end": 11}, {"entity_id": "18425523_2_Ent1", "role": "Treatment", "text": "intravitreal ranibizumab", "start": 10, "end": 12}, {"entity_id": "18425523_2_Ent2", "role": "Treatment_Drug", "text": "ranibizumab", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "18425523_2_Ent0", "text": "Severe and sustained ocular hypertension", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18425523_2_Ent3", "text": "intravitreal", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18425523_2_Ent1", "text": "intravitreal ranibizumab", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18425523_2_Ent2", "text": "ranibizumab", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "18425523_4", "wnd_id": "18425523_4_1", "text": "Persisent ocular hypertension following intravitreal ranibizumab .", "tokens": ["Persisent", "ocular", "hypertension", "following", "intravitreal", "ranibizumab", "."], "event_mentions": [{"id": "18425523_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "18425523_4_Ent0", "role": "Effect", "text": "Persisent ocular hypertension", "start": 0, "end": 3}, {"entity_id": "18425523_4_Ent1", "role": "Treatment", "text": "intravitreal ranibizumab", "start": 4, "end": 6}, {"entity_id": "18425523_4_Ent2", "role": "Treatment_Drug", "text": "ranibizumab", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "18425523_4_Ent0", "text": "Persisent ocular hypertension", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18425523_4_Ent1", "text": "intravitreal ranibizumab", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18425523_4_Ent2", "text": "ranibizumab", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "18431096_1", "wnd_id": "18431096_1_1", "text": "Methylphenidate and dextroamphetamine - induced peripheral vasculopathy .", "tokens": ["Methylphenidate", "and", "dextroamphetamine", "-", "induced", "peripheral", "vasculopathy", "."], "event_mentions": [{"id": "18431096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18431096_1_Ent3", "role": "Treatment_Drug", "text": "Methylphenidate", "start": 0, "end": 1}, {"entity_id": "18431096_1_Ent1", "role": "Treatment", "text": "Methylphenidate and dextroamphetamine", "start": 0, "end": 3}, {"entity_id": "18431096_1_Ent2", "role": "Treatment_Drug", "text": "dextroamphetamine", "start": 2, "end": 3}, {"entity_id": "18431096_1_Ent0", "role": "Effect", "text": "peripheral vasculopathy", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "18431096_1_Ent3", "text": "Methylphenidate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18431096_1_Ent1", "text": "Methylphenidate and dextroamphetamine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18431096_1_Ent2", "text": "dextroamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18431096_1_Ent0", "text": "peripheral vasculopathy", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "18504683_1", "wnd_id": "18504683_1_1", "text": "L - asparaginase - induced posterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children .", "tokens": ["L", "-", "asparaginase", "-", "induced", "posterior", "reversible", "encephalopathy", "syndrome", "during", "acute", "lymphoblastic", "leukemia", "treatment", "in", "children", "."], "event_mentions": [{"id": "18504683_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "18504683_1_Ent3", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "18504683_1_Ent4", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "18504683_1_Ent2", "role": "Effect", "text": "posterior reversible encephalopathy syndrome", "start": 5, "end": 9}, {"entity_id": "18504683_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 10, "end": 13}, {"entity_id": "18504683_1_Ent0", "role": "Subject", "text": "children", "start": 15, "end": 16}, {"entity_id": "18504683_1_Ent1", "role": "Subject_Age", "text": "children", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18504683_1_Ent3", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18504683_1_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18504683_1_Ent2", "text": "posterior reversible encephalopathy syndrome", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "18504683_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18504683_1_Ent0", "text": "children", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18504683_1_Ent1", "text": "children", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18504683_3", "wnd_id": "18504683_3_1", "text": "We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and altered sensorium after L - asparaginase therapy .", "tokens": ["We", "report", "3", "cases", "of", "children", "with", "acute", "lymphoblastic", "leukemia", "who", "developed", "seizures", "and", "altered", "sensorium", "after", "L", "-", "asparaginase", "therapy", "."], "event_mentions": [{"id": "18504683_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "18504683_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "18504683_3_Ent0", "role": "Subject", "text": "3 cases of children with acute lymphoblastic leukemia", "start": 2, "end": 10}, {"entity_id": "18504683_3_Ent2", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "18504683_3_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 7, "end": 10}, {"entity_id": "18504683_3_Ent3", "role": "Effect", "text": "seizures and altered sensorium", "start": 12, "end": 16}, {"entity_id": "18504683_3_Ent4", "role": "Treatment", "text": "L - asparaginase", "start": 17, "end": 20}, {"entity_id": "18504683_3_Ent6", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "18504683_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18504683_3_Ent0", "text": "3 cases of children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 10}, {"id": "18504683_3_Ent2", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18504683_3_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "18504683_3_Ent3", "text": "seizures and altered sensorium", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "18504683_3_Ent4", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18504683_3_Ent6", "text": "L - asparaginase", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "18505911_9", "wnd_id": "18505911_9_1", "text": "Azathioprine was the probable causative agent of warfarin resistance according to the Naranjo probability scale , and a possible causative agent according to the Drug Interaction Probability Scale .", "tokens": ["Azathioprine", "was", "the", "probable", "causative", "agent", "of", "warfarin", "resistance", "according", "to", "the", "Naranjo", "probability", "scale", ",", "and", "a", "possible", "causative", "agent", "according", "to", "the", "Drug", "Interaction", "Probability", "Scale", "."], "event_mentions": [{"id": "18505911_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causative agent", "start": 4, "end": 6}, "arguments": [{"entity_id": "18505911_9_Ent1", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_9_Ent2", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "18505911_9_Ent0", "role": "Effect", "text": "warfarin resistance", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "18505911_9_Ent1", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_9_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18505911_9_Ent0", "text": "warfarin resistance", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "18523232_1", "wnd_id": "18523232_1_1", "text": "CASE SUMMARY : A 61 - year - old woman with no apparent risk factors for liver injury developed acute hepatitis one week after the final dose of a long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk ) for onychomycosis .", "tokens": ["CASE", "SUMMARY", ":", "A", "61", "-", "year", "-", "old", "woman", "with", "no", "apparent", "risk", "factors", "for", "liver", "injury", "developed", "acute", "hepatitis", "one", "week", "after", "the", "final", "dose", "of", "a", "long", "-", "term", "course", "of", "pulse", "itraconazole", "therapy", "(", "200", "mg", "orally", "twice", "daily", ",", "1", "wk", "on", ",", "3", "wk", "off", ",", "for", "24", "wk", ")", "for", "onychomycosis", "."], "event_mentions": [{"id": "18523232_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "18523232_1_Ent0", "role": "Subject", "text": "A 61 - year - old woman with no apparent risk factors for liver injury", "start": 3, "end": 18}, {"entity_id": "18523232_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 4, "end": 9}, {"entity_id": "18523232_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "18523232_1_Ent3", "role": "Effect", "text": "acute hepatitis", "start": 19, "end": 21}, {"entity_id": "18523232_1_Ent4", "role": "Treatment", "text": "long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk )", "start": 29, "end": 56}, {"entity_id": "18523232_1_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 35, "end": 36}, {"entity_id": "18523232_1_Ent7", "role": "Treatment_Dosage", "text": "200 mg", "start": 38, "end": 40}, {"entity_id": "18523232_1_Ent8", "role": "Treatment_Route", "text": "orally", "start": 40, "end": 41}, {"entity_id": "18523232_1_Ent9", "role": "Treatment_Freq", "text": "twice daily", "start": 41, "end": 43}, {"entity_id": "18523232_1_Ent5", "role": "Treatment_Disorder", "text": "onychomycosis", "start": 57, "end": 58}]}], "entity_mentions": [{"id": "18523232_1_Ent0", "text": "A 61 - year - old woman with no apparent risk factors for liver injury", "entity_type": "Entity", "start": 3, "end": 18}, {"id": "18523232_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "18523232_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18523232_1_Ent3", "text": "acute hepatitis", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "18523232_1_Ent4", "text": "long - term course of pulse itraconazole therapy ( 200 mg orally twice daily , 1 wk on , 3 wk off , for 24 wk )", "entity_type": "Entity", "start": 29, "end": 56}, {"id": "18523232_1_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "18523232_1_Ent7", "text": "200 mg", "entity_type": "Entity", "start": 38, "end": 40}, {"id": "18523232_1_Ent8", "text": "orally", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "18523232_1_Ent9", "text": "twice daily", "entity_type": "Entity", "start": 41, "end": 43}, {"id": "18523232_1_Ent5", "text": "onychomycosis", "entity_type": "Entity", "start": 57, "end": 58}], "lang": "en"}
{"doc_id": "18523232_2", "wnd_id": "18523232_2_1", "text": "CONCLUSIONS : Prolonged exposure to itraconazole , administered either continuously or intermittently , may precipitate severe and irreversible hepatotoxic events .", "tokens": ["CONCLUSIONS", ":", "Prolonged", "exposure", "to", "itraconazole", ",", "administered", "either", "continuously", "or", "intermittently", ",", "may", "precipitate", "severe", "and", "irreversible", "hepatotoxic", "events", "."], "event_mentions": [{"id": "18523232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "precipitate", "start": 14, "end": 15}, "arguments": [{"entity_id": "18523232_2_Ent3", "role": "Treatment_Dosage", "text": "Prolonged exposure", "start": 2, "end": 4}, {"entity_id": "18523232_2_Ent1", "role": "Treatment", "text": "Prolonged exposure to itraconazole , administered either continuously or intermittently", "start": 2, "end": 12}, {"entity_id": "18523232_2_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 5, "end": 6}, {"entity_id": "18523232_2_Ent4", "role": "Treatment_Route", "text": "continuously or intermittently", "start": 9, "end": 12}, {"entity_id": "18523232_2_Ent0", "role": "Effect", "text": "severe and irreversible hepatotoxic events", "start": 15, "end": 20}]}], "entity_mentions": [{"id": "18523232_2_Ent3", "text": "Prolonged exposure", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18523232_2_Ent1", "text": "Prolonged exposure to itraconazole , administered either continuously or intermittently", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "18523232_2_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "18523232_2_Ent4", "text": "continuously or intermittently", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "18523232_2_Ent0", "text": "severe and irreversible hepatotoxic events", "entity_type": "Entity", "start": 15, "end": 20}], "lang": "en"}
{"doc_id": "18562412_3", "wnd_id": "18562412_3_1", "text": "The fifth patient exhibited paraesthesia and agitation caused by olanzapine that was misdiagnosed as psychotic agitation .", "tokens": ["The", "fifth", "patient", "exhibited", "paraesthesia", "and", "agitation", "caused", "by", "olanzapine", "that", "was", "misdiagnosed", "as", "psychotic", "agitation", "."], "event_mentions": [{"id": "18562412_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 7, "end": 8}, "arguments": [{"entity_id": "18562412_3_Ent0", "role": "Subject", "text": "The fifth patient", "start": 0, "end": 3}, {"entity_id": "18562412_3_Ent1", "role": "Effect", "text": "paraesthesia and agitation", "start": 4, "end": 7}, {"entity_id": "18562412_3_Ent2", "role": "Treatment", "text": "olanzapine", "start": 9, "end": 10}, {"entity_id": "18562412_3_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "18562412_3_Ent0", "text": "The fifth patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_3_Ent1", "text": "paraesthesia and agitation", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "18562412_3_Ent2", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "18562412_3_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "18562412_4", "wnd_id": "18562412_4_1", "text": "The fourth patient showed RLS symptoms that were initially caused by a 20 - mg daily olanzapine dosage and were later mitigated when olanzapine was reduced and ropinirole was administered .", "tokens": ["The", "fourth", "patient", "showed", "RLS", "symptoms", "that", "were", "initially", "caused", "by", "a", "20", "-", "mg", "daily", "olanzapine", "dosage", "and", "were", "later", "mitigated", "when", "olanzapine", "was", "reduced", "and", "ropinirole", "was", "administered", "."], "event_mentions": [{"id": "18562412_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 9, "end": 10}, "arguments": [{"entity_id": "18562412_4_Ent0", "role": "Subject", "text": "The fourth patient", "start": 0, "end": 3}, {"entity_id": "18562412_4_Ent1", "role": "Effect", "text": "RLS symptoms", "start": 4, "end": 6}, {"entity_id": "18562412_4_Ent3", "role": "Treatment_Dosage", "text": "20 - mg", "start": 12, "end": 15}, {"entity_id": "18562412_4_Ent2", "role": "Treatment", "text": "20 - mg daily olanzapine dosage", "start": 12, "end": 18}, {"entity_id": "18562412_4_Ent4", "role": "Treatment_Freq", "text": "daily", "start": 15, "end": 16}, {"entity_id": "18562412_4_Ent5", "role": "Treatment_Drug", "text": "olanzapine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18562412_4_Ent0", "text": "The fourth patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_4_Ent1", "text": "RLS symptoms", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18562412_4_Ent3", "text": "20 - mg", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18562412_4_Ent2", "text": "20 - mg daily olanzapine dosage", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "18562412_4_Ent4", "text": "daily", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "18562412_4_Ent5", "text": "olanzapine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18562412_5", "wnd_id": "18562412_5_1", "text": "The second patient exhibited sudden PLMS following olanzapine injection .", "tokens": ["The", "second", "patient", "exhibited", "sudden", "PLMS", "following", "olanzapine", "injection", "."], "event_mentions": [{"id": "18562412_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "18562412_5_Ent0", "role": "Subject", "text": "The second patient", "start": 0, "end": 3}, {"entity_id": "18562412_5_Ent1", "role": "Effect", "text": "sudden PLMS", "start": 4, "end": 6}, {"entity_id": "18562412_5_Ent3", "role": "Treatment_Drug", "text": "olanzapine", "start": 7, "end": 8}, {"entity_id": "18562412_5_Ent2", "role": "Treatment", "text": "olanzapine injection", "start": 7, "end": 9}, {"entity_id": "18562412_5_Ent4", "role": "Treatment_Route", "text": "injection", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "18562412_5_Ent0", "text": "The second patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_5_Ent1", "text": "sudden PLMS", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "18562412_5_Ent3", "text": "olanzapine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18562412_5_Ent2", "text": "olanzapine injection", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "18562412_5_Ent4", "text": "injection", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18562412_6", "wnd_id": "18562412_6_1", "text": "The third patient had been suffering from serious akathisia while on risperidone , and was cured after switching to olanzapine , but thereafter the patient suffered from RLS at nighttime .", "tokens": ["The", "third", "patient", "had", "been", "suffering", "from", "serious", "akathisia", "while", "on", "risperidone", ",", "and", "was", "cured", "after", "switching", "to", "olanzapine", ",", "but", "thereafter", "the", "patient", "suffered", "from", "RLS", "at", "nighttime", "."], "event_mentions": [{"id": "18562412_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering", "start": 5, "end": 6}, "arguments": [{"entity_id": "18562412_6_Ent0", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent1", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent2", "role": "Treatment", "text": "risperidone", "start": 11, "end": 12}, {"entity_id": "18562412_6_Ent3", "role": "Treatment_Drug", "text": "risperidone", "start": 11, "end": 12}]}, {"id": "18562412_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 25, "end": 26}, "arguments": [{"entity_id": "18562412_6_Ent4", "role": "Subject", "text": "The third patient", "start": 0, "end": 3}, {"entity_id": "18562412_6_Ent7", "role": "Treatment_Disorder", "text": "akathisia", "start": 8, "end": 9}, {"entity_id": "18562412_6_Ent6", "role": "Treatment", "text": "switching to olanzapine", "start": 17, "end": 20}, {"entity_id": "18562412_6_Ent8", "role": "Treatment_Drug", "text": "olanzapine", "start": 19, "end": 20}, {"entity_id": "18562412_6_Ent5", "role": "Effect", "text": "RLS at nighttime", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "18562412_6_Ent0", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent4", "text": "The third patient", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "18562412_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent7", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18562412_6_Ent2", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent3", "text": "risperidone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "18562412_6_Ent6", "text": "switching to olanzapine", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "18562412_6_Ent8", "text": "olanzapine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18562412_6_Ent5", "text": "RLS at nighttime", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "18585545_3", "wnd_id": "18585545_3_1", "text": "Here , we describe levofloxacin - induced delirium with psychotic features in a relatively young , otherwise healthy female .", "tokens": ["Here", ",", "we", "describe", "levofloxacin", "-", "induced", "delirium", "with", "psychotic", "features", "in", "a", "relatively", "young", ",", "otherwise", "healthy", "female", "."], "event_mentions": [{"id": "18585545_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "18585545_3_Ent2", "role": "Treatment", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_3_Ent3", "role": "Treatment_Drug", "text": "levofloxacin", "start": 4, "end": 5}, {"entity_id": "18585545_3_Ent1", "role": "Effect", "text": "delirium with psychotic features", "start": 7, "end": 11}, {"entity_id": "18585545_3_Ent0", "role": "Subject", "text": "relatively young , otherwise healthy female", "start": 13, "end": 19}]}], "entity_mentions": [{"id": "18585545_3_Ent2", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_3_Ent3", "text": "levofloxacin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18585545_3_Ent1", "text": "delirium with psychotic features", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "18585545_3_Ent0", "text": "relatively young , otherwise healthy female", "entity_type": "Entity", "start": 13, "end": 19}], "lang": "en"}
{"doc_id": "18607107_2", "wnd_id": "18607107_2_1", "text": "Development of Crohn 's disease in a patient with multiple sclerosis treated with copaxone .", "tokens": ["Development", "of", "Crohn", "'s", "disease", "in", "a", "patient", "with", "multiple", "sclerosis", "treated", "with", "copaxone", "."], "event_mentions": [{"id": "18607107_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "18607107_2_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 2, "end": 5}, {"entity_id": "18607107_2_Ent0", "role": "Subject", "text": "a patient with multiple sclerosis", "start": 6, "end": 11}, {"entity_id": "18607107_2_Ent3", "role": "Treatment_Disorder", "text": "multiple sclerosis", "start": 9, "end": 11}, {"entity_id": "18607107_2_Ent2", "role": "Treatment", "text": "copaxone", "start": 13, "end": 14}, {"entity_id": "18607107_2_Ent4", "role": "Treatment_Drug", "text": "copaxone", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18607107_2_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "18607107_2_Ent0", "text": "a patient with multiple sclerosis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18607107_2_Ent3", "text": "multiple sclerosis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18607107_2_Ent2", "text": "copaxone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18607107_2_Ent4", "text": "copaxone", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18607107_3", "wnd_id": "18607107_3_1", "text": "RESULTS : Our patient developed Crohn 's disease while on Copaxone treatment as a consequence of long - term immunosuppression .", "tokens": ["RESULTS", ":", "Our", "patient", "developed", "Crohn", "'s", "disease", "while", "on", "Copaxone", "treatment", "as", "a", "consequence", "of", "long", "-", "term", "immunosuppression", "."], "event_mentions": [{"id": "18607107_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 4, "end": 5}, "arguments": [{"entity_id": "18607107_3_Ent0", "role": "Subject", "text": "patient", "start": 3, "end": 4}, {"entity_id": "18607107_3_Ent1", "role": "Effect", "text": "Crohn 's disease", "start": 5, "end": 8}, {"entity_id": "18607107_3_Ent3", "role": "Treatment", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent4", "role": "Treatment_Drug", "text": "Copaxone", "start": 10, "end": 11}, {"entity_id": "18607107_3_Ent2", "role": "Effect", "text": "long - term immunosuppression", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "18607107_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18607107_3_Ent1", "text": "Crohn 's disease", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18607107_3_Ent3", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent4", "text": "Copaxone", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "18607107_3_Ent2", "text": "long - term immunosuppression", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "18633310_1", "wnd_id": "18633310_1_1", "text": "Multiple seizures after bupropion overdose in a small child .", "tokens": ["Multiple", "seizures", "after", "bupropion", "overdose", "in", "a", "small", "child", "."], "event_mentions": [{"id": "18633310_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "18633310_1_Ent2", "role": "Effect", "text": "Multiple seizures", "start": 0, "end": 2}, {"entity_id": "18633310_1_Ent4", "role": "Treatment_Drug", "text": "bupropion", "start": 3, "end": 4}, {"entity_id": "18633310_1_Ent3", "role": "Treatment", "text": "bupropion overdose", "start": 3, "end": 5}, {"entity_id": "18633310_1_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "18633310_1_Ent0", "role": "Subject", "text": "a small child", "start": 6, "end": 9}, {"entity_id": "18633310_1_Ent1", "role": "Subject_Age", "text": "small child", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "18633310_1_Ent2", "text": "Multiple seizures", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18633310_1_Ent4", "text": "bupropion", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18633310_1_Ent3", "text": "bupropion overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "18633310_1_Ent5", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18633310_1_Ent0", "text": "a small child", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "18633310_1_Ent1", "text": "small child", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "18675768_1", "wnd_id": "18675768_1_1", "text": "Adverse effects of propafenone after long - term therapy with the addition of citalopram .", "tokens": ["Adverse", "effects", "of", "propafenone", "after", "long", "-", "term", "therapy", "with", "the", "addition", "of", "citalopram", "."], "event_mentions": [{"id": "18675768_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "18675768_1_Ent0", "role": "Effect", "text": "Adverse effects", "start": 0, "end": 2}, {"entity_id": "18675768_1_Ent2", "role": "Treatment_Drug", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "18675768_1_Ent6", "role": "Combination_Drug", "text": "propafenone", "start": 3, "end": 4}, {"entity_id": "18675768_1_Ent4", "role": "Treatment_Time_elapsed", "text": "long - term", "start": 5, "end": 8}, {"entity_id": "18675768_1_Ent1", "role": "Treatment", "text": "long - term therapy with the addition of citalopram", "start": 5, "end": 14}, {"entity_id": "18675768_1_Ent3", "role": "Treatment_Drug", "text": "citalopram", "start": 13, "end": 14}, {"entity_id": "18675768_1_Ent5", "role": "Combination_Drug", "text": "citalopram", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "18675768_1_Ent0", "text": "Adverse effects", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18675768_1_Ent2", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18675768_1_Ent6", "text": "propafenone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "18675768_1_Ent4", "text": "long - term", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "18675768_1_Ent1", "text": "long - term therapy with the addition of citalopram", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "18675768_1_Ent3", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18675768_1_Ent5", "text": "citalopram", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "18675768_5", "wnd_id": "18675768_5_1", "text": "An 80 - year - old white female , followed up at the Memory Clinic for mild cognitive impairment , had been taking propafenone 900 mg / d for > 10 years for paroxysmal atrial fibrillation without adverse effects .", "tokens": ["An", "80", "-", "year", "-", "old", "white", "female", ",", "followed", "up", "at", "the", "Memory", "Clinic", "for", "mild", "cognitive", "impairment", ",", "had", "been", "taking", "propafenone", "900", "mg", "/", "d", "for", ">", "10", "years", "for", "paroxysmal", "atrial", "fibrillation", "without", "adverse", "effects", "."], "event_mentions": [{"id": "18675768_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 32, "end": 33}, "arguments": [{"entity_id": "18675768_5_Ent0", "role": "Subject", "text": "An 80 - year - old white female", "start": 0, "end": 8}, {"entity_id": "18675768_5_Ent1", "role": "Subject_Age", "text": "80 - year - old", "start": 1, "end": 6}, {"entity_id": "18675768_5_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "18675768_5_Ent3", "role": "Subject_Gender", "text": "female", "start": 7, "end": 8}, {"entity_id": "18675768_5_Ent4", "role": "Subject_Disorder", "text": "mild cognitive impairment", "start": 16, "end": 19}, {"entity_id": "18675768_5_Ent7", "role": "Treatment_Drug", "text": "propafenone", "start": 23, "end": 24}, {"entity_id": "18675768_5_Ent5", "role": "Treatment", "text": "propafenone 900 mg / d for > 10 years", "start": 23, "end": 32}, {"entity_id": "18675768_5_Ent8", "role": "Treatment_Dosage", "text": "900 mg / d", "start": 24, "end": 28}, {"entity_id": "18675768_5_Ent9", "role": "Treatment_Duration", "text": "> 10 years", "start": 29, "end": 32}, {"entity_id": "18675768_5_Ent6", "role": "Treatment_Disorder", "text": "paroxysmal atrial fibrillation", "start": 33, "end": 36}]}], "entity_mentions": [{"id": "18675768_5_Ent0", "text": "An 80 - year - old white female", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "18675768_5_Ent1", "text": "80 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "18675768_5_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18675768_5_Ent3", "text": "female", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "18675768_5_Ent4", "text": "mild cognitive impairment", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "18675768_5_Ent7", "text": "propafenone", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "18675768_5_Ent5", "text": "propafenone 900 mg / d for > 10 years", "entity_type": "Entity", "start": 23, "end": 32}, {"id": "18675768_5_Ent8", "text": "900 mg / d", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "18675768_5_Ent9", "text": "> 10 years", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "18675768_5_Ent6", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 33, "end": 36}], "lang": "en"}
{"doc_id": "18682542_1", "wnd_id": "18682542_1_1", "text": "CONCLUSIONS : Clinicians should be aware of this adverse reaction when facing similar complex neurologic symptoms in patients who are receiving the antibiotic treatment described here , especially vancomycin .", "tokens": ["CONCLUSIONS", ":", "Clinicians", "should", "be", "aware", "of", "this", "adverse", "reaction", "when", "facing", "similar", "complex", "neurologic", "symptoms", "in", "patients", "who", "are", "receiving", "the", "antibiotic", "treatment", "described", "here", ",", "especially", "vancomycin", "."], "event_mentions": [{"id": "18682542_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse reaction", "start": 8, "end": 10}, "arguments": [{"entity_id": "18682542_1_Ent1", "role": "Effect", "text": "neurologic symptoms", "start": 14, "end": 16}, {"entity_id": "18682542_1_Ent0", "role": "Subject", "text": "patients", "start": 17, "end": 18}, {"entity_id": "18682542_1_Ent2", "role": "Treatment", "text": "vancomycin", "start": 28, "end": 29}, {"entity_id": "18682542_1_Ent3", "role": "Treatment_Drug", "text": "vancomycin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "18682542_1_Ent1", "text": "neurologic symptoms", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18682542_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18682542_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "18682542_1_Ent3", "text": "vancomycin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "18691992_1", "wnd_id": "18691992_1_1", "text": "BACKGROUND : Hydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and nail hyperpigmentation .", "tokens": ["BACKGROUND", ":", "Hydroxyurea", "is", "a", "cytostatic", "agent", "used", "to", "treat", "myeloproliferative", "disorders", "and", "long", "-", "term", "treatment", "is", "associated", "with", "mucocutaneous", "adverse", "events", "and", "nail", "hyperpigmentation", "."], "event_mentions": [{"id": "18691992_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 18, "end": 19}, "arguments": [{"entity_id": "18691992_1_Ent2", "role": "Treatment_Drug", "text": "Hydroxyurea", "start": 2, "end": 3}, {"entity_id": "18691992_1_Ent1", "role": "Treatment", "text": "Hydroxyurea is a cytostatic agent", "start": 2, "end": 7}, {"entity_id": "18691992_1_Ent3", "role": "Treatment_Disorder", "text": "myeloproliferative disorders", "start": 10, "end": 12}, {"entity_id": "18691992_1_Ent0", "role": "Effect", "text": "mucocutaneous adverse events and nail hyperpigmentation", "start": 20, "end": 26}]}], "entity_mentions": [{"id": "18691992_1_Ent2", "text": "Hydroxyurea", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18691992_1_Ent1", "text": "Hydroxyurea is a cytostatic agent", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18691992_1_Ent3", "text": "myeloproliferative disorders", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18691992_1_Ent0", "text": "mucocutaneous adverse events and nail hyperpigmentation", "entity_type": "Entity", "start": 20, "end": 26}], "lang": "en"}
{"doc_id": "18691992_6", "wnd_id": "18691992_6_1", "text": "OBJECTIVE : The purpose of this study was to report the concomitant occurrence of multiple squamous cell carcinomas and diffuse nail hyperpigmentation associated with hydroxyurea treatment , and to describe a successful therapeutic approach using imiquimod 5 % .", "tokens": ["OBJECTIVE", ":", "The", "purpose", "of", "this", "study", "was", "to", "report", "the", "concomitant", "occurrence", "of", "multiple", "squamous", "cell", "carcinomas", "and", "diffuse", "nail", "hyperpigmentation", "associated", "with", "hydroxyurea", "treatment", ",", "and", "to", "describe", "a", "successful", "therapeutic", "approach", "using", "imiquimod", "5", "%", "."], "event_mentions": [{"id": "18691992_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 22, "end": 23}, "arguments": [{"entity_id": "18691992_6_Ent0", "role": "Effect", "text": "multiple squamous cell carcinomas and diffuse nail hyperpigmentation", "start": 14, "end": 22}, {"entity_id": "18691992_6_Ent1", "role": "Treatment", "text": "hydroxyurea", "start": 24, "end": 25}, {"entity_id": "18691992_6_Ent2", "role": "Treatment_Drug", "text": "hydroxyurea", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "18691992_6_Ent0", "text": "multiple squamous cell carcinomas and diffuse nail hyperpigmentation", "entity_type": "Entity", "start": 14, "end": 22}, {"id": "18691992_6_Ent1", "text": "hydroxyurea", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18691992_6_Ent2", "text": "hydroxyurea", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "18707772_1", "wnd_id": "18707772_1_1", "text": "A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for intracranial bleeding while receiving aspirin and clopidogrel .", "tokens": ["A", "64", "year", "old", "woman", "with", "previous", "history", "of", "coronary", "stenting", "five", "days", "before", "was", "admitted", "in", "our", "institution", "for", "intracranial", "bleeding", "while", "receiving", "aspirin", "and", "clopidogrel", "."], "event_mentions": [{"id": "18707772_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 23, "end": 24}, "arguments": [{"entity_id": "18707772_1_Ent0", "role": "Subject", "text": "A 64 year old woman with previous history of coronary stenting", "start": 0, "end": 11}, {"entity_id": "18707772_1_Ent1", "role": "Subject_Age", "text": "64 year old", "start": 1, "end": 4}, {"entity_id": "18707772_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 4, "end": 5}, {"entity_id": "18707772_1_Ent8", "role": "Treatment_Disorder", "text": "coronary stenting", "start": 9, "end": 11}, {"entity_id": "18707772_1_Ent9", "role": "Treatment_Time_elapsed", "text": "five days", "start": 11, "end": 13}, {"entity_id": "18707772_1_Ent4", "role": "Treatment", "text": "five days before", "start": 11, "end": 14}, {"entity_id": "18707772_1_Ent3", "role": "Effect", "text": "intracranial bleeding", "start": 20, "end": 22}, {"entity_id": "18707772_1_Ent7", "role": "Treatment_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent10", "role": "Combination_Drug", "text": "aspirin", "start": 24, "end": 25}, {"entity_id": "18707772_1_Ent5", "role": "Treatment", "text": "aspirin and clopidogrel", "start": 24, "end": 27}, {"entity_id": "18707772_1_Ent6", "role": "Treatment_Drug", "text": "clopidogrel", "start": 26, "end": 27}, {"entity_id": "18707772_1_Ent11", "role": "Combination_Drug", "text": "clopidogrel", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "18707772_1_Ent0", "text": "A 64 year old woman with previous history of coronary stenting", "entity_type": "Entity", "start": 0, "end": 11}, {"id": "18707772_1_Ent1", "text": "64 year old", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "18707772_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "18707772_1_Ent8", "text": "coronary stenting", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "18707772_1_Ent9", "text": "five days", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18707772_1_Ent4", "text": "five days before", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "18707772_1_Ent3", "text": "intracranial bleeding", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "18707772_1_Ent7", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent10", "text": "aspirin", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "18707772_1_Ent5", "text": "aspirin and clopidogrel", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "18707772_1_Ent6", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18707772_1_Ent11", "text": "clopidogrel", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "18717612_3", "wnd_id": "18717612_3_1", "text": "We report the first case of a 54 - year - old Turkish woman who presented with ceftriaxone - induced FDE .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "54", "-", "year", "-", "old", "Turkish", "woman", "who", "presented", "with", "ceftriaxone", "-", "induced", "FDE", "."], "event_mentions": [{"id": "18717612_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "18717612_3_Ent0", "role": "Subject", "text": "a 54 - year - old Turkish woman", "start": 6, "end": 14}, {"entity_id": "18717612_3_Ent1", "role": "Subject_Age", "text": "54 - year - old", "start": 7, "end": 12}, {"entity_id": "18717612_3_Ent2", "role": "Subject_Race", "text": "Turkish", "start": 12, "end": 13}, {"entity_id": "18717612_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 13, "end": 14}, {"entity_id": "18717612_3_Ent5", "role": "Treatment", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent6", "role": "Treatment_Drug", "text": "ceftriaxone", "start": 17, "end": 18}, {"entity_id": "18717612_3_Ent4", "role": "Effect", "text": "FDE", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18717612_3_Ent0", "text": "a 54 - year - old Turkish woman", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "18717612_3_Ent1", "text": "54 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18717612_3_Ent2", "text": "Turkish", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "18717612_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "18717612_3_Ent5", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent6", "text": "ceftriaxone", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18717612_3_Ent4", "text": "FDE", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "18721173_3", "wnd_id": "18721173_3_1", "text": "OBJECTIVE : This case report outlines a significant type of morbidity due to continued use of gabapentin during an episode of acute renal failure .", "tokens": ["OBJECTIVE", ":", "This", "case", "report", "outlines", "a", "significant", "type", "of", "morbidity", "due", "to", "continued", "use", "of", "gabapentin", "during", "an", "episode", "of", "acute", "renal", "failure", "."], "event_mentions": [{"id": "18721173_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "use", "start": 14, "end": 15}, "arguments": [{"entity_id": "18721173_3_Ent0", "role": "Subject", "text": "This case", "start": 2, "end": 4}, {"entity_id": "18721173_3_Ent1", "role": "Effect", "text": "a significant type of morbidity", "start": 6, "end": 11}, {"entity_id": "18721173_3_Ent2", "role": "Treatment", "text": "gabapentin", "start": 16, "end": 17}, {"entity_id": "18721173_3_Ent3", "role": "Treatment_Drug", "text": "gabapentin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "18721173_3_Ent0", "text": "This case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "18721173_3_Ent1", "text": "a significant type of morbidity", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "18721173_3_Ent2", "text": "gabapentin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "18721173_3_Ent3", "text": "gabapentin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "18751717_4", "wnd_id": "18751717_4_1", "text": "RESULTS : Two patients with ocular inflammation of unknown origin developed severe chorioretinitis after IVTA injection .", "tokens": ["RESULTS", ":", "Two", "patients", "with", "ocular", "inflammation", "of", "unknown", "origin", "developed", "severe", "chorioretinitis", "after", "IVTA", "injection", "."], "event_mentions": [{"id": "18751717_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "18751717_4_Ent2", "role": "Subject_Population", "text": "Two", "start": 2, "end": 3}, {"entity_id": "18751717_4_Ent0", "role": "Subject", "text": "Two patients with ocular inflammation", "start": 2, "end": 7}, {"entity_id": "18751717_4_Ent1", "role": "Subject_Disorder", "text": "ocular inflammation", "start": 5, "end": 7}, {"entity_id": "18751717_4_Ent3", "role": "Effect", "text": "severe chorioretinitis", "start": 11, "end": 13}, {"entity_id": "18751717_4_Ent5", "role": "Treatment_Drug", "text": "IVTA", "start": 14, "end": 15}, {"entity_id": "18751717_4_Ent4", "role": "Treatment", "text": "IVTA injection", "start": 14, "end": 16}, {"entity_id": "18751717_4_Ent6", "role": "Treatment_Route", "text": "injection", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "18751717_4_Ent2", "text": "Two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "18751717_4_Ent0", "text": "Two patients with ocular inflammation", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "18751717_4_Ent1", "text": "ocular inflammation", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "18751717_4_Ent3", "text": "severe chorioretinitis", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "18751717_4_Ent5", "text": "IVTA", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18751717_4_Ent4", "text": "IVTA injection", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "18751717_4_Ent6", "text": "injection", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "18765315_4", "wnd_id": "18765315_4_1", "text": "The occurrence of symptoms that could be ascribed to an acute coronary syndrome should always be taken seriously during the first rituximab infusion and investigated aggressively .", "tokens": ["The", "occurrence", "of", "symptoms", "that", "could", "be", "ascribed", "to", "an", "acute", "coronary", "syndrome", "should", "always", "be", "taken", "seriously", "during", "the", "first", "rituximab", "infusion", "and", "investigated", "aggressively", "."], "event_mentions": [{"id": "18765315_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 18, "end": 19}, "arguments": [{"entity_id": "18765315_4_Ent0", "role": "Effect", "text": "acute coronary syndrome", "start": 10, "end": 13}, {"entity_id": "18765315_4_Ent2", "role": "Treatment_Duration", "text": "first", "start": 20, "end": 21}, {"entity_id": "18765315_4_Ent1", "role": "Treatment", "text": "first rituximab infusion", "start": 20, "end": 23}, {"entity_id": "18765315_4_Ent3", "role": "Treatment_Drug", "text": "rituximab", "start": 21, "end": 22}, {"entity_id": "18765315_4_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "18765315_4_Ent0", "text": "acute coronary syndrome", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "18765315_4_Ent2", "text": "first", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "18765315_4_Ent1", "text": "first rituximab infusion", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "18765315_4_Ent3", "text": "rituximab", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "18765315_4_Ent4", "text": "infusion", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "18775393_2", "wnd_id": "18775393_2_1", "text": "Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion .", "tokens": ["Laryngeal", "dyspnea", "in", "relation", "to", "an", "interaction", "between", "acenocoumarol", "and", "topical", "econazole", "lotion", "."], "event_mentions": [{"id": "18775393_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relation", "start": 3, "end": 4}, "arguments": [{"entity_id": "18775393_2_Ent0", "role": "Effect", "text": "Laryngeal dyspnea", "start": 0, "end": 2}, {"entity_id": "18775393_2_Ent1", "role": "Treatment", "text": "acenocoumarol", "start": 8, "end": 9}, {"entity_id": "18775393_2_Ent3", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 8, "end": 9}, {"entity_id": "18775393_2_Ent5", "role": "Combination_Drug", "text": "acenocoumarol", "start": 8, "end": 9}, {"entity_id": "18775393_2_Ent4", "role": "Treatment_Drug", "text": "topical econazole", "start": 10, "end": 12}, {"entity_id": "18775393_2_Ent6", "role": "Combination_Drug", "text": "topical econazole", "start": 10, "end": 12}, {"entity_id": "18775393_2_Ent2", "role": "Treatment", "text": "topical econazole lotion", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "18775393_2_Ent0", "text": "Laryngeal dyspnea", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "18775393_2_Ent1", "text": "acenocoumarol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18775393_2_Ent3", "text": "acenocoumarol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18775393_2_Ent5", "text": "acenocoumarol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "18775393_2_Ent4", "text": "topical econazole", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18775393_2_Ent6", "text": "topical econazole", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "18775393_2_Ent2", "text": "topical econazole lotion", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "18805724_2", "wnd_id": "18805724_2_1", "text": "Leflunomide - induced toxic epidermal necrolysis in a patient with rheumatoid arthritis .", "tokens": ["Leflunomide", "-", "induced", "toxic", "epidermal", "necrolysis", "in", "a", "patient", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "18805724_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "18805724_2_Ent2", "role": "Treatment", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "18805724_2_Ent4", "role": "Treatment_Drug", "text": "Leflunomide", "start": 0, "end": 1}, {"entity_id": "18805724_2_Ent1", "role": "Effect", "text": "toxic epidermal necrolysis", "start": 3, "end": 6}, {"entity_id": "18805724_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 7, "end": 12}, {"entity_id": "18805724_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "18805724_2_Ent2", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18805724_2_Ent4", "text": "Leflunomide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "18805724_2_Ent1", "text": "toxic epidermal necrolysis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "18805724_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18805724_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "18855892_5", "wnd_id": "18855892_5_1", "text": "We report the case of a child with metastatic osteosarcoma , who experienced an anaphylactic / anaphylactoid reaction to methotrexate .", "tokens": ["We", "report", "the", "case", "of", "a", "child", "with", "metastatic", "osteosarcoma", ",", "who", "experienced", "an", "anaphylactic", "/", "anaphylactoid", "reaction", "to", "methotrexate", "."], "event_mentions": [{"id": "18855892_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 12, "end": 13}, "arguments": [{"entity_id": "18855892_5_Ent0", "role": "Subject", "text": "a child with metastatic osteosarcoma", "start": 5, "end": 10}, {"entity_id": "18855892_5_Ent1", "role": "Subject_Age", "text": "child", "start": 6, "end": 7}, {"entity_id": "18855892_5_Ent2", "role": "Effect", "text": "anaphylactic / anaphylactoid reaction", "start": 14, "end": 18}, {"entity_id": "18855892_5_Ent3", "role": "Treatment", "text": "methotrexate", "start": 19, "end": 20}, {"entity_id": "18855892_5_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "18855892_5_Ent0", "text": "a child with metastatic osteosarcoma", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "18855892_5_Ent1", "text": "child", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "18855892_5_Ent2", "text": "anaphylactic / anaphylactoid reaction", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "18855892_5_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "18855892_5_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "18855892_8", "wnd_id": "18855892_8_1", "text": "Thus , we confirm that desensitization may be a safe procedure in patients with cancer who experience methotrexate - induced anaphylaxis .", "tokens": ["Thus", ",", "we", "confirm", "that", "desensitization", "may", "be", "a", "safe", "procedure", "in", "patients", "with", "cancer", "who", "experience", "methotrexate", "-", "induced", "anaphylaxis", "."], "event_mentions": [{"id": "18855892_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "18855892_8_Ent0", "role": "Subject", "text": "patients with cancer", "start": 12, "end": 15}, {"entity_id": "18855892_8_Ent1", "role": "Subject_Disorder", "text": "cancer", "start": 14, "end": 15}, {"entity_id": "18855892_8_Ent3", "role": "Treatment", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "18855892_8_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 17, "end": 18}, {"entity_id": "18855892_8_Ent2", "role": "Effect", "text": "anaphylaxis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "18855892_8_Ent0", "text": "patients with cancer", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "18855892_8_Ent1", "text": "cancer", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "18855892_8_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18855892_8_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "18855892_8_Ent2", "text": "anaphylaxis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "1893404_1", "wnd_id": "1893404_1_1", "text": "Carbamazepine - induced Diabetes mellitus .", "tokens": ["Carbamazepine", "-", "induced", "Diabetes", "mellitus", "."], "event_mentions": [{"id": "1893404_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "1893404_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "1893404_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "1893404_1_Ent0", "role": "Effect", "text": "Diabetes mellitus", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "1893404_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1893404_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "1893404_1_Ent0", "text": "Diabetes mellitus", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "1893404_2", "wnd_id": "1893404_2_1", "text": "Diabetes Mellitus was observed in a patient given carbamazepine .", "tokens": ["Diabetes", "Mellitus", "was", "observed", "in", "a", "patient", "given", "carbamazepine", "."], "event_mentions": [{"id": "1893404_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "given", "start": 7, "end": 8}, "arguments": [{"entity_id": "1893404_2_Ent1", "role": "Effect", "text": "Diabetes Mellitus", "start": 0, "end": 2}, {"entity_id": "1893404_2_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "1893404_2_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 8, "end": 9}, {"entity_id": "1893404_2_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "1893404_2_Ent1", "text": "Diabetes Mellitus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "1893404_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "1893404_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "1893404_2_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "18991509_2", "wnd_id": "18991509_2_1", "text": "We report the first case of a human immunodeficiency virus type 1 ( HIV - 1) - infected individual receiving combination antiretroviral therapy , which included ritonavir , who developed Cushing syndrome with profound complications after epidural triamcinolone injections .", "tokens": ["We", "report", "the", "first", "case", "of", "a", "human", "immunodeficiency", "virus", "type", "1", "(", "HIV", "-", "1)", "-", "infected", "individual", "receiving", "combination", "antiretroviral", "therapy", ",", "which", "included", "ritonavir", ",", "who", "developed", "Cushing", "syndrome", "with", "profound", "complications", "after", "epidural", "triamcinolone", "injections", "."], "event_mentions": [{"id": "18991509_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 29, "end": 30}, "arguments": [{"entity_id": "18991509_2_Ent0", "role": "Subject", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "start": 6, "end": 19}, {"entity_id": "18991509_2_Ent4", "role": "Treatment_Disorder", "text": "human immunodeficiency virus type 1", "start": 7, "end": 12}, {"entity_id": "18991509_2_Ent2", "role": "Treatment", "text": "combination antiretroviral therapy , which included ritonavir", "start": 20, "end": 27}, {"entity_id": "18991509_2_Ent6", "role": "Treatment_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent9", "role": "Combination_Drug", "text": "ritonavir", "start": 26, "end": 27}, {"entity_id": "18991509_2_Ent1", "role": "Effect", "text": "Cushing syndrome", "start": 30, "end": 32}, {"entity_id": "18991509_2_Ent7", "role": "Treatment_Route", "text": "epidural", "start": 36, "end": 37}, {"entity_id": "18991509_2_Ent3", "role": "Treatment", "text": "epidural triamcinolone injections", "start": 36, "end": 39}, {"entity_id": "18991509_2_Ent5", "role": "Treatment_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent10", "role": "Combination_Drug", "text": "triamcinolone", "start": 37, "end": 38}, {"entity_id": "18991509_2_Ent8", "role": "Treatment_Route", "text": "injections", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "18991509_2_Ent0", "text": "a human immunodeficiency virus type 1 ( HIV - 1) - infected individual", "entity_type": "Entity", "start": 6, "end": 19}, {"id": "18991509_2_Ent4", "text": "human immunodeficiency virus type 1", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "18991509_2_Ent2", "text": "combination antiretroviral therapy , which included ritonavir", "entity_type": "Entity", "start": 20, "end": 27}, {"id": "18991509_2_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent9", "text": "ritonavir", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "18991509_2_Ent1", "text": "Cushing syndrome", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "18991509_2_Ent7", "text": "epidural", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "18991509_2_Ent3", "text": "epidural triamcinolone injections", "entity_type": "Entity", "start": 36, "end": 39}, {"id": "18991509_2_Ent5", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent10", "text": "triamcinolone", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "18991509_2_Ent8", "text": "injections", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "19017039_2", "wnd_id": "19017039_2_1", "text": "Syringotropic hypersensitivity reaction associated with infliximab and leflunomide combination therapy in a child with psoriatic arthritis .", "tokens": ["Syringotropic", "hypersensitivity", "reaction", "associated", "with", "infliximab", "and", "leflunomide", "combination", "therapy", "in", "a", "child", "with", "psoriatic", "arthritis", "."], "event_mentions": [{"id": "19017039_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19017039_2_Ent2", "role": "Effect", "text": "Syringotropic hypersensitivity reaction", "start": 0, "end": 3}, {"entity_id": "19017039_2_Ent4", "role": "Treatment_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent8", "role": "Combination_Drug", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19017039_2_Ent3", "role": "Treatment", "text": "infliximab and leflunomide combination therapy", "start": 5, "end": 10}, {"entity_id": "19017039_2_Ent5", "role": "Treatment_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent7", "role": "Combination_Drug", "text": "leflunomide", "start": 7, "end": 8}, {"entity_id": "19017039_2_Ent0", "role": "Subject", "text": "a child with psoriatic arthritis", "start": 11, "end": 16}, {"entity_id": "19017039_2_Ent1", "role": "Subject_Age", "text": "child", "start": 12, "end": 13}, {"entity_id": "19017039_2_Ent6", "role": "Treatment_Disorder", "text": "psoriatic arthritis", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19017039_2_Ent2", "text": "Syringotropic hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19017039_2_Ent4", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent8", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19017039_2_Ent3", "text": "infliximab and leflunomide combination therapy", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19017039_2_Ent5", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent7", "text": "leflunomide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19017039_2_Ent0", "text": "a child with psoriatic arthritis", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19017039_2_Ent1", "text": "child", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19017039_2_Ent6", "text": "psoriatic arthritis", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19034138_4", "wnd_id": "19034138_4_1", "text": "Corneal endothelial dysfunction associated with amantadine toxicity .", "tokens": ["Corneal", "endothelial", "dysfunction", "associated", "with", "amantadine", "toxicity", "."], "event_mentions": [{"id": "19034138_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 3, "end": 4}, "arguments": [{"entity_id": "19034138_4_Ent0", "role": "Effect", "text": "Corneal endothelial dysfunction", "start": 0, "end": 3}, {"entity_id": "19034138_4_Ent1", "role": "Treatment", "text": "amantadine", "start": 5, "end": 6}, {"entity_id": "19034138_4_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "19034138_4_Ent0", "text": "Corneal endothelial dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19034138_4_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19034138_4_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "19034138_5", "wnd_id": "19034138_5_1", "text": "PURPOSE : To describe bilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term amantadine .", "tokens": ["PURPOSE", ":", "To", "describe", "bilateral", "corneal", "endothelial", "dysfunction", "in", "a", "patient", "with", "Parkinson", "disease", "who", "was", "treated", "with", "long", "-", "term", "amantadine", "."], "event_mentions": [{"id": "19034138_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "19034138_5_Ent1", "role": "Effect", "text": "bilateral corneal endothelial dysfunction", "start": 4, "end": 8}, {"entity_id": "19034138_5_Ent0", "role": "Subject", "text": "a patient with Parkinson disease", "start": 9, "end": 14}, {"entity_id": "19034138_5_Ent3", "role": "Treatment_Disorder", "text": "Parkinson disease", "start": 12, "end": 14}, {"entity_id": "19034138_5_Ent5", "role": "Treatment_Duration", "text": "long - term", "start": 18, "end": 21}, {"entity_id": "19034138_5_Ent2", "role": "Treatment", "text": "long - term amantadine", "start": 18, "end": 22}, {"entity_id": "19034138_5_Ent4", "role": "Treatment_Drug", "text": "amantadine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19034138_5_Ent1", "text": "bilateral corneal endothelial dysfunction", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19034138_5_Ent0", "text": "a patient with Parkinson disease", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "19034138_5_Ent3", "text": "Parkinson disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "19034138_5_Ent5", "text": "long - term", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19034138_5_Ent2", "text": "long - term amantadine", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "19034138_5_Ent4", "text": "amantadine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "19034138_7", "wnd_id": "19034138_7_1", "text": "Therefore , amantadine was permanently discontinued and the cornea cleared again .", "tokens": ["Therefore", ",", "amantadine", "was", "permanently", "discontinued", "and", "the", "cornea", "cleared", "again", "."], "event_mentions": [{"id": "19034138_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "was", "start": 3, "end": 4}, "arguments": [{"entity_id": "19034138_7_Ent1", "role": "Treatment", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "19034138_7_Ent2", "role": "Treatment_Drug", "text": "amantadine", "start": 2, "end": 3}, {"entity_id": "19034138_7_Ent0", "role": "Effect", "text": "cornea cleared", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "19034138_7_Ent1", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19034138_7_Ent2", "text": "amantadine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19034138_7_Ent0", "text": "cornea cleared", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "19071894_7", "wnd_id": "19071894_7_1", "text": "Renal toxicity signs , induced by amphotericin B , progression of infection after fluconazole , and likely in vivo resistance to this triazole made this case difficult to treat .", "tokens": ["Renal", "toxicity", "signs", ",", "induced", "by", "amphotericin", "B", ",", "progression", "of", "infection", "after", "fluconazole", ",", "and", "likely", "in", "vivo", "resistance", "to", "this", "triazole", "made", "this", "case", "difficult", "to", "treat", "."], "event_mentions": [{"id": "19071894_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "19071894_7_Ent0", "role": "Effect", "text": "Renal toxicity signs", "start": 0, "end": 3}, {"entity_id": "19071894_7_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 6, "end": 8}, {"entity_id": "19071894_7_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 6, "end": 8}]}, {"id": "19071894_7_Evt1", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "19071894_7_Ent3", "role": "Effect", "text": "infection", "start": 11, "end": 12}, {"entity_id": "19071894_7_Ent4", "role": "Treatment", "text": "fluconazole", "start": 13, "end": 14}, {"entity_id": "19071894_7_Ent5", "role": "Treatment_Drug", "text": "fluconazole", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "19071894_7_Ent0", "text": "Renal toxicity signs", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19071894_7_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19071894_7_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "19071894_7_Ent3", "text": "infection", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19071894_7_Ent4", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19071894_7_Ent5", "text": "fluconazole", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "19097599_1", "wnd_id": "19097599_1_1", "text": "Only 3 cases of imatinib - induced tumor lysis syndrome have been reported .", "tokens": ["Only", "3", "cases", "of", "imatinib", "-", "induced", "tumor", "lysis", "syndrome", "have", "been", "reported", "."], "event_mentions": [{"id": "19097599_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "19097599_1_Ent1", "role": "Treatment", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "19097599_1_Ent2", "role": "Treatment_Drug", "text": "imatinib", "start": 4, "end": 5}, {"entity_id": "19097599_1_Ent0", "role": "Effect", "text": "tumor lysis syndrome", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "19097599_1_Ent1", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19097599_1_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19097599_1_Ent0", "text": "tumor lysis syndrome", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "19116715_1", "wnd_id": "19116715_1_1", "text": "Gemcitabine is a known risk factor for hemolytic uremic syndrome ( HUS ) , which can often have a rapidly fatal clinical course despite intervention with steroids , plasmapheresis and hemodialysis .", "tokens": ["Gemcitabine", "is", "a", "known", "risk", "factor", "for", "hemolytic", "uremic", "syndrome", "(", "HUS", ")", ",", "which", "can", "often", "have", "a", "rapidly", "fatal", "clinical", "course", "despite", "intervention", "with", "steroids", ",", "plasmapheresis", "and", "hemodialysis", "."], "event_mentions": [{"id": "19116715_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "risk", "start": 4, "end": 5}, "arguments": [{"entity_id": "19116715_1_Ent1", "role": "Treatment", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19116715_1_Ent2", "role": "Treatment_Drug", "text": "Gemcitabine", "start": 0, "end": 1}, {"entity_id": "19116715_1_Ent0", "role": "Effect", "text": "hemolytic uremic syndrome", "start": 7, "end": 10}]}, {"id": "19116715_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "intervention", "start": 24, "end": 25}, "arguments": [{"entity_id": "19116715_1_Ent7", "role": "Treatment_Disorder", "text": "a rapidly fatal", "start": 18, "end": 21}, {"entity_id": "19116715_1_Ent3", "role": "Treatment", "text": "with steroids , plasmapheresis and hemodialysis", "start": 25, "end": 31}, {"entity_id": "19116715_1_Ent4", "role": "Treatment_Drug", "text": "steroids", "start": 26, "end": 27}, {"entity_id": "19116715_1_Ent5", "role": "Treatment_Drug", "text": "plasmapheresis", "start": 28, "end": 29}, {"entity_id": "19116715_1_Ent6", "role": "Treatment_Drug", "text": "hemodialysis", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19116715_1_Ent1", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19116715_1_Ent2", "text": "Gemcitabine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19116715_1_Ent0", "text": "hemolytic uremic syndrome", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "19116715_1_Ent7", "text": "a rapidly fatal", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "19116715_1_Ent3", "text": "with steroids , plasmapheresis and hemodialysis", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "19116715_1_Ent4", "text": "steroids", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19116715_1_Ent5", "text": "plasmapheresis", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "19116715_1_Ent6", "text": "hemodialysis", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "19122478_5", "wnd_id": "19122478_5_1", "text": "We report the first case of chlorambucil - induced DRESS syndrome in a 70 - year - old man recently diagnosed with chronic lymphocytic leukaemia .", "tokens": ["We", "report", "the", "first", "case", "of", "chlorambucil", "-", "induced", "DRESS", "syndrome", "in", "a", "70", "-", "year", "-", "old", "man", "recently", "diagnosed", "with", "chronic", "lymphocytic", "leukaemia", "."], "event_mentions": [{"id": "19122478_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19122478_5_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "19122478_5_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "19122478_5_Ent3", "role": "Effect", "text": "DRESS syndrome", "start": 9, "end": 11}, {"entity_id": "19122478_5_Ent0", "role": "Subject", "text": "a 70 - year - old man", "start": 12, "end": 19}, {"entity_id": "19122478_5_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 13, "end": 18}, {"entity_id": "19122478_5_Ent2", "role": "Subject_Gender", "text": "man", "start": 18, "end": 19}, {"entity_id": "19122478_5_Ent6", "role": "Treatment_Disorder", "text": "chronic lymphocytic leukaemia", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "19122478_5_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19122478_5_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19122478_5_Ent3", "text": "DRESS syndrome", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "19122478_5_Ent0", "text": "a 70 - year - old man", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "19122478_5_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 13, "end": 18}, {"id": "19122478_5_Ent2", "text": "man", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "19122478_5_Ent6", "text": "chronic lymphocytic leukaemia", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "19122478_7", "wnd_id": "19122478_7_1", "text": "The condition improved slowly after stopping medication and systemic steroids .", "tokens": ["The", "condition", "improved", "slowly", "after", "stopping", "medication", "and", "systemic", "steroids", "."], "event_mentions": [{"id": "19122478_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "stopping", "start": 5, "end": 6}, "arguments": [{"entity_id": "19122478_7_Ent0", "role": "Effect", "text": "condition improved", "start": 1, "end": 3}, {"entity_id": "19122478_7_Ent1", "role": "Treatment", "text": "steroids", "start": 9, "end": 10}, {"entity_id": "19122478_7_Ent2", "role": "Treatment_Drug", "text": "steroids", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19122478_7_Ent0", "text": "condition improved", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19122478_7_Ent1", "text": "steroids", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19122478_7_Ent2", "text": "steroids", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19145124_2", "wnd_id": "19145124_2_1", "text": "These are the first reported patients to show mfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that ethambutol damages the retina .", "tokens": ["These", "are", "the", "first", "reported", "patients", "to", "show", "mfERG", "abnormalities", "that", "correspond", "to", "bitemporal", "visual", "field", "defects", "and", "add", "to", "the", "growing", "evidence", "that", "ethambutol", "damages", "the", "retina", "."], "event_mentions": [{"id": "19145124_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "evidence", "start": 22, "end": 23}, "arguments": [{"entity_id": "19145124_2_Ent1", "role": "Treatment", "text": "ethambutol", "start": 24, "end": 25}, {"entity_id": "19145124_2_Ent2", "role": "Treatment_Drug", "text": "ethambutol", "start": 24, "end": 25}, {"entity_id": "19145124_2_Ent0", "role": "Effect", "text": "damages the retina", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "19145124_2_Ent1", "text": "ethambutol", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19145124_2_Ent2", "text": "ethambutol", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19145124_2_Ent0", "text": "damages the retina", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "19183077_1", "wnd_id": "19183077_1_1", "text": "Tenofovir - associated nephrotoxicity in two HIV - infected adolescent males .", "tokens": ["Tenofovir", "-", "associated", "nephrotoxicity", "in", "two", "HIV", "-", "infected", "adolescent", "males", "."], "event_mentions": [{"id": "19183077_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "19183077_1_Ent5", "role": "Treatment", "text": "Tenofovir", "start": 0, "end": 1}, {"entity_id": "19183077_1_Ent6", "role": "Treatment_Drug", "text": "Tenofovir", "start": 0, "end": 1}, {"entity_id": "19183077_1_Ent4", "role": "Effect", "text": "nephrotoxicity", "start": 3, "end": 4}, {"entity_id": "19183077_1_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "19183077_1_Ent0", "role": "Subject", "text": "two HIV - infected adolescent males", "start": 5, "end": 11}, {"entity_id": "19183077_1_Ent7", "role": "Treatment_Disorder", "text": "HIV - infected", "start": 6, "end": 9}, {"entity_id": "19183077_1_Ent2", "role": "Subject_Age", "text": "adolescent", "start": 9, "end": 10}, {"entity_id": "19183077_1_Ent3", "role": "Subject_Gender", "text": "males", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19183077_1_Ent5", "text": "Tenofovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19183077_1_Ent6", "text": "Tenofovir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19183077_1_Ent4", "text": "nephrotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19183077_1_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19183077_1_Ent0", "text": "two HIV - infected adolescent males", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "19183077_1_Ent7", "text": "HIV - infected", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19183077_1_Ent2", "text": "adolescent", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19183077_1_Ent3", "text": "males", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19203515_1", "wnd_id": "19203515_1_1", "text": "Acute renal failure following intravenous immunoglobulin therapy in a HIV - infected patient .", "tokens": ["Acute", "renal", "failure", "following", "intravenous", "immunoglobulin", "therapy", "in", "a", "HIV", "-", "infected", "patient", "."], "event_mentions": [{"id": "19203515_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19203515_1_Ent2", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "19203515_1_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 4, "end": 5}, {"entity_id": "19203515_1_Ent3", "role": "Treatment", "text": "intravenous immunoglobulin therapy", "start": 4, "end": 7}, {"entity_id": "19203515_1_Ent4", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 5, "end": 6}, {"entity_id": "19203515_1_Ent0", "role": "Subject", "text": "a HIV - infected patient", "start": 8, "end": 13}, {"entity_id": "19203515_1_Ent1", "role": "Subject_Disorder", "text": "HIV", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "19203515_1_Ent2", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19203515_1_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19203515_1_Ent3", "text": "intravenous immunoglobulin therapy", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "19203515_1_Ent4", "text": "immunoglobulin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19203515_1_Ent0", "text": "a HIV - infected patient", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "19203515_1_Ent1", "text": "HIV", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "19203515_2", "wnd_id": "19203515_2_1", "text": "Acute renal failure is a rare complication following the administration of intravenous immunoglobulin ( IVIG ) .", "tokens": ["Acute", "renal", "failure", "is", "a", "rare", "complication", "following", "the", "administration", "of", "intravenous", "immunoglobulin", "(", "IVIG", ")", "."], "event_mentions": [{"id": "19203515_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 6, "end": 7}, "arguments": [{"entity_id": "19203515_2_Ent0", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "19203515_2_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 11, "end": 12}, {"entity_id": "19203515_2_Ent1", "role": "Treatment", "text": "intravenous immunoglobulin ( IVIG )", "start": 11, "end": 16}, {"entity_id": "19203515_2_Ent3", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19203515_2_Ent0", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19203515_2_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19203515_2_Ent1", "text": "intravenous immunoglobulin ( IVIG )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19203515_2_Ent3", "text": "immunoglobulin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19224802_5", "wnd_id": "19224802_5_1", "text": "We report on three cases wherein treatment of dexmedetomidine - induced bradycardia with i.v .", "tokens": ["We", "report", "on", "three", "cases", "wherein", "treatment", "of", "dexmedetomidine", "-", "induced", "bradycardia", "with", "i.v", "."], "event_mentions": [{"id": "19224802_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19224802_5_Ent1", "role": "Treatment", "text": "treatment of dexmedetomidine", "start": 6, "end": 9}, {"entity_id": "19224802_5_Ent2", "role": "Treatment_Drug", "text": "dexmedetomidine", "start": 8, "end": 9}, {"entity_id": "19224802_5_Ent0", "role": "Effect", "text": "bradycardia with i.v", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19224802_5_Ent1", "text": "treatment of dexmedetomidine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19224802_5_Ent2", "text": "dexmedetomidine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19224802_5_Ent0", "text": "bradycardia with i.v", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19224802_6", "wnd_id": "19224802_6_1", "text": "glycopyrrolate ( 5.0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure .", "tokens": ["glycopyrrolate", "(", "5.0", "microg", "/", "kg", ")", "not", "only", "resulting", "in", "resolution", "of", "bradycardia", "but", "also", "resulting", "in", "an", "exaggerated", "increase", "of", "arterial", "blood", "pressure", "."], "event_mentions": [{"id": "19224802_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 9, "end": 10}, "arguments": [{"entity_id": "19224802_6_Ent3", "role": "Treatment_Drug", "text": "glycopyrrolate", "start": 0, "end": 1}, {"entity_id": "19224802_6_Ent2", "role": "Treatment", "text": "glycopyrrolate ( 5.0 microg / kg )", "start": 0, "end": 7}, {"entity_id": "19224802_6_Ent4", "role": "Treatment_Dosage", "text": "5.0 microg / kg", "start": 2, "end": 6}, {"entity_id": "19224802_6_Ent0", "role": "Effect", "text": "resolution of bradycardia", "start": 11, "end": 14}, {"entity_id": "19224802_6_Ent1", "role": "Effect", "text": "an exaggerated increase of arterial blood pressure", "start": 18, "end": 25}]}], "entity_mentions": [{"id": "19224802_6_Ent3", "text": "glycopyrrolate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19224802_6_Ent2", "text": "glycopyrrolate ( 5.0 microg / kg )", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19224802_6_Ent4", "text": "5.0 microg / kg", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19224802_6_Ent0", "text": "resolution of bradycardia", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "19224802_6_Ent1", "text": "an exaggerated increase of arterial blood pressure", "entity_type": "Entity", "start": 18, "end": 25}], "lang": "en"}
{"doc_id": "19235747_1", "wnd_id": "19235747_1_1", "text": "Bisphosphonate - related osteonecrosis of the jaw ( BRONJ ) is reported in up to 18.6 % of patients treated with intravenous bisphosphonates and can result in significant morbidity .", "tokens": ["Bisphosphonate", "-", "related", "osteonecrosis", "of", "the", "jaw", "(", "BRONJ", ")", "is", "reported", "in", "up", "to", "18.6", "%", "of", "patients", "treated", "with", "intravenous", "bisphosphonates", "and", "can", "result", "in", "significant", "morbidity", "."], "event_mentions": [{"id": "19235747_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 2, "end": 3}, "arguments": [{"entity_id": "19235747_1_Ent4", "role": "Treatment_Drug", "text": "Bisphosphonate", "start": 0, "end": 1}, {"entity_id": "19235747_1_Ent2", "role": "Effect", "text": "osteonecrosis of the jaw ( BRONJ )", "start": 3, "end": 10}, {"entity_id": "19235747_1_Ent1", "role": "Subject_Population", "text": "18.6 %", "start": 15, "end": 17}, {"entity_id": "19235747_1_Ent0", "role": "Subject", "text": "18.6 % of patients", "start": 15, "end": 19}, {"entity_id": "19235747_1_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 21, "end": 22}, {"entity_id": "19235747_1_Ent3", "role": "Treatment", "text": "intravenous bisphosphonates", "start": 21, "end": 23}, {"entity_id": "19235747_1_Ent5", "role": "Treatment_Drug", "text": "bisphosphonates", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19235747_1_Ent4", "text": "Bisphosphonate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19235747_1_Ent2", "text": "osteonecrosis of the jaw ( BRONJ )", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "19235747_1_Ent1", "text": "18.6 %", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "19235747_1_Ent0", "text": "18.6 % of patients", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19235747_1_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19235747_1_Ent3", "text": "intravenous bisphosphonates", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "19235747_1_Ent5", "text": "bisphosphonates", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19260037_2", "wnd_id": "19260037_2_1", "text": "A retrospective review of TTP patients with quinine - associated thrombotic microangiopathy ( TMA ) for whom ADAMTS13 was measured before plasma exchange was performed .", "tokens": ["A", "retrospective", "review", "of", "TTP", "patients", "with", "quinine", "-", "associated", "thrombotic", "microangiopathy", "(", "TMA", ")", "for", "whom", "ADAMTS13", "was", "measured", "before", "plasma", "exchange", "was", "performed", "."], "event_mentions": [{"id": "19260037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "19260037_2_Ent1", "role": "Subject_Disorder", "text": "TTP", "start": 4, "end": 5}, {"entity_id": "19260037_2_Ent0", "role": "Subject", "text": "TTP patients", "start": 4, "end": 6}, {"entity_id": "19260037_2_Ent3", "role": "Treatment", "text": "quinine", "start": 7, "end": 8}, {"entity_id": "19260037_2_Ent4", "role": "Treatment_Drug", "text": "quinine", "start": 7, "end": 8}, {"entity_id": "19260037_2_Ent2", "role": "Effect", "text": "thrombotic microangiopathy ( TMA )", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "19260037_2_Ent1", "text": "TTP", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19260037_2_Ent0", "text": "TTP patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "19260037_2_Ent3", "text": "quinine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19260037_2_Ent4", "text": "quinine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19260037_2_Ent2", "text": "thrombotic microangiopathy ( TMA )", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "19275460_6", "wnd_id": "19275460_6_1", "text": "Despite aggressive medical management , including intravenous hydration and broad - spectrum antibiotics , the patient continued to become more confused , agitated , and despondent over the subsequent 24 hours .", "tokens": ["Despite", "aggressive", "medical", "management", ",", "including", "intravenous", "hydration", "and", "broad", "-", "spectrum", "antibiotics", ",", "the", "patient", "continued", "to", "become", "more", "confused", ",", "agitated", ",", "and", "despondent", "over", "the", "subsequent", "24", "hours", "."], "event_mentions": [{"id": "19275460_6_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "continued", "start": 16, "end": 17}, "arguments": [{"entity_id": "19275460_6_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 6, "end": 7}, {"entity_id": "19275460_6_Ent2", "role": "Treatment", "text": "intravenous hydration and broad - spectrum antibiotics", "start": 6, "end": 13}, {"entity_id": "19275460_6_Ent3", "role": "Treatment_Drug", "text": "hydration", "start": 7, "end": 8}, {"entity_id": "19275460_6_Ent6", "role": "Combination_Drug", "text": "hydration", "start": 7, "end": 8}, {"entity_id": "19275460_6_Ent4", "role": "Treatment_Drug", "text": "broad - spectrum antibiotics", "start": 9, "end": 13}, {"entity_id": "19275460_6_Ent7", "role": "Combination_Drug", "text": "broad - spectrum antibiotics", "start": 9, "end": 13}, {"entity_id": "19275460_6_Ent0", "role": "Subject", "text": "patient", "start": 15, "end": 16}, {"entity_id": "19275460_6_Ent1", "role": "Effect", "text": "become more confused , agitated , and despondent over the subsequent 24 hours", "start": 18, "end": 31}]}], "entity_mentions": [{"id": "19275460_6_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19275460_6_Ent2", "text": "intravenous hydration and broad - spectrum antibiotics", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "19275460_6_Ent3", "text": "hydration", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19275460_6_Ent6", "text": "hydration", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19275460_6_Ent4", "text": "broad - spectrum antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19275460_6_Ent7", "text": "broad - spectrum antibiotics", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "19275460_6_Ent0", "text": "patient", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "19275460_6_Ent1", "text": "become more confused , agitated , and despondent over the subsequent 24 hours", "entity_type": "Entity", "start": 18, "end": 31}], "lang": "en"}
{"doc_id": "19281746_1", "wnd_id": "19281746_1_1", "text": "Aliskiren - associated acute renal failure with hyperkalemia .", "tokens": ["Aliskiren", "-", "associated", "acute", "renal", "failure", "with", "hyperkalemia", "."], "event_mentions": [{"id": "19281746_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "19281746_1_Ent1", "role": "Treatment", "text": "Aliskiren", "start": 0, "end": 1}, {"entity_id": "19281746_1_Ent2", "role": "Treatment_Drug", "text": "Aliskiren", "start": 0, "end": 1}, {"entity_id": "19281746_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "19281746_1_Ent1", "text": "Aliskiren", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19281746_1_Ent2", "text": "Aliskiren", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19281746_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "19296063_3", "wnd_id": "19296063_3_1", "text": "We report the case of a 17 - year - old male who developed chest pain , elevated cardiac biomarkers , and acute left ventricular dysfunction following a single dose of methylphenidate .", "tokens": ["We", "report", "the", "case", "of", "a", "17", "-", "year", "-", "old", "male", "who", "developed", "chest", "pain", ",", "elevated", "cardiac", "biomarkers", ",", "and", "acute", "left", "ventricular", "dysfunction", "following", "a", "single", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "19296063_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 26, "end": 27}, "arguments": [{"entity_id": "19296063_3_Ent0", "role": "Subject", "text": "a 17 - year - old male", "start": 5, "end": 12}, {"entity_id": "19296063_3_Ent2", "role": "Subject_Age", "text": "17 - year - old", "start": 6, "end": 11}, {"entity_id": "19296063_3_Ent1", "role": "Subject_Gender", "text": "male", "start": 11, "end": 12}, {"entity_id": "19296063_3_Ent3", "role": "Effect", "text": "chest pain , elevated cardiac biomarkers , and acute left ventricular dysfunction", "start": 14, "end": 26}, {"entity_id": "19296063_3_Ent5", "role": "Treatment_Dosage", "text": "a single dose", "start": 27, "end": 30}, {"entity_id": "19296063_3_Ent4", "role": "Treatment", "text": "a single dose of methylphenidate", "start": 27, "end": 32}, {"entity_id": "19296063_3_Ent6", "role": "Treatment_Drug", "text": "methylphenidate", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "19296063_3_Ent0", "text": "a 17 - year - old male", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19296063_3_Ent2", "text": "17 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "19296063_3_Ent1", "text": "male", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "19296063_3_Ent3", "text": "chest pain , elevated cardiac biomarkers , and acute left ventricular dysfunction", "entity_type": "Entity", "start": 14, "end": 26}, {"id": "19296063_3_Ent5", "text": "a single dose", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "19296063_3_Ent4", "text": "a single dose of methylphenidate", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "19296063_3_Ent6", "text": "methylphenidate", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "19299370_2", "wnd_id": "19299370_2_1", "text": "CONCLUSION : A woman receiving enoxaparin every 12 hours developed signs and symptoms of hepatotoxicity after the second dose .", "tokens": ["CONCLUSION", ":", "A", "woman", "receiving", "enoxaparin", "every", "12", "hours", "developed", "signs", "and", "symptoms", "of", "hepatotoxicity", "after", "the", "second", "dose", "."], "event_mentions": [{"id": "19299370_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19299370_2_Ent0", "role": "Subject", "text": "A woman", "start": 2, "end": 4}, {"entity_id": "19299370_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 3, "end": 4}, {"entity_id": "19299370_2_Ent5", "role": "Treatment_Drug", "text": "enoxaparin", "start": 5, "end": 6}, {"entity_id": "19299370_2_Ent3", "role": "Treatment", "text": "enoxaparin every 12 hours", "start": 5, "end": 9}, {"entity_id": "19299370_2_Ent6", "role": "Treatment_Freq", "text": "every 12 hours", "start": 6, "end": 9}, {"entity_id": "19299370_2_Ent2", "role": "Effect", "text": "signs and symptoms of hepatotoxicity", "start": 10, "end": 15}, {"entity_id": "19299370_2_Ent4", "role": "Treatment", "text": "after the second dose", "start": 15, "end": 19}, {"entity_id": "19299370_2_Ent7", "role": "Treatment_Dosage", "text": "the second dose .", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "19299370_2_Ent0", "text": "A woman", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19299370_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19299370_2_Ent5", "text": "enoxaparin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19299370_2_Ent3", "text": "enoxaparin every 12 hours", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19299370_2_Ent6", "text": "every 12 hours", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19299370_2_Ent2", "text": "signs and symptoms of hepatotoxicity", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "19299370_2_Ent4", "text": "after the second dose", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19299370_2_Ent7", "text": "the second dose .", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "19307676_2", "wnd_id": "19307676_2_1", "text": "The addition of intrathecal methotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of neurotoxicity .", "tokens": ["The", "addition", "of", "intrathecal", "methotrexate", "to", "treatment", "protocols", "has", "increased", "survival", "rates", "in", "children", "with", "acute", "lymphoblastic", "leukemia", "but", "is", "also", "associated", "with", "varying", "degrees", "of", "neurotoxicity", "."], "event_mentions": [{"id": "19307676_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 21, "end": 22}, "arguments": [{"entity_id": "19307676_2_Ent3", "role": "Treatment", "text": "The addition of intrathecal methotrexate to treatment protocols", "start": 0, "end": 8}, {"entity_id": "19307676_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 4, "end": 5}, {"entity_id": "19307676_2_Ent0", "role": "Subject", "text": "in children with acute lymphoblastic leukemia", "start": 12, "end": 18}, {"entity_id": "19307676_2_Ent1", "role": "Subject_Age", "text": "children", "start": 13, "end": 14}, {"entity_id": "19307676_2_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 15, "end": 18}, {"entity_id": "19307676_2_Ent2", "role": "Effect", "text": "varying degrees of neurotoxicity", "start": 23, "end": 27}]}], "entity_mentions": [{"id": "19307676_2_Ent3", "text": "The addition of intrathecal methotrexate to treatment protocols", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "19307676_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19307676_2_Ent0", "text": "in children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19307676_2_Ent1", "text": "children", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19307676_2_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "19307676_2_Ent2", "text": "varying degrees of neurotoxicity", "entity_type": "Entity", "start": 23, "end": 27}], "lang": "en"}
{"doc_id": "19318596_1", "wnd_id": "19318596_1_1", "text": "Cyclosporine - induced pain syndrome in a child undergoing hematopoietic stem cell transplant .", "tokens": ["Cyclosporine", "-", "induced", "pain", "syndrome", "in", "a", "child", "undergoing", "hematopoietic", "stem", "cell", "transplant", "."], "event_mentions": [{"id": "19318596_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19318596_1_Ent4", "role": "Treatment", "text": "Cyclosporine", "start": 0, "end": 1}, {"entity_id": "19318596_1_Ent5", "role": "Treatment_Drug", "text": "Cyclosporine", "start": 0, "end": 1}, {"entity_id": "19318596_1_Ent3", "role": "Effect", "text": "pain syndrome", "start": 3, "end": 5}, {"entity_id": "19318596_1_Ent0", "role": "Subject", "text": "a child undergoing hematopoietic stem cell transplant", "start": 6, "end": 13}, {"entity_id": "19318596_1_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}, {"entity_id": "19318596_1_Ent2", "role": "Subject_Disorder", "text": "hematopoietic stem cell transplant", "start": 9, "end": 13}]}], "entity_mentions": [{"id": "19318596_1_Ent4", "text": "Cyclosporine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_1_Ent5", "text": "Cyclosporine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19318596_1_Ent3", "text": "pain syndrome", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19318596_1_Ent0", "text": "a child undergoing hematopoietic stem cell transplant", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "19318596_1_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19318596_1_Ent2", "text": "hematopoietic stem cell transplant", "entity_type": "Entity", "start": 9, "end": 13}], "lang": "en"}
{"doc_id": "19357764_2", "wnd_id": "19357764_2_1", "text": "DISCUSSION : This case shows that switching to zidovudine potentially can lead to a hyperlactatemia relapse .", "tokens": ["DISCUSSION", ":", "This", "case", "shows", "that", "switching", "to", "zidovudine", "potentially", "can", "lead", "to", "a", "hyperlactatemia", "relapse", "."], "event_mentions": [{"id": "19357764_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 11, "end": 12}, "arguments": [{"entity_id": "19357764_2_Ent0", "role": "Subject", "text": "This case", "start": 2, "end": 4}, {"entity_id": "19357764_2_Ent2", "role": "Treatment", "text": "zidovudine", "start": 8, "end": 9}, {"entity_id": "19357764_2_Ent3", "role": "Treatment_Drug", "text": "zidovudine", "start": 8, "end": 9}, {"entity_id": "19357764_2_Ent1", "role": "Effect", "text": "hyperlactatemia relapse", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19357764_2_Ent0", "text": "This case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19357764_2_Ent2", "text": "zidovudine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19357764_2_Ent3", "text": "zidovudine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19357764_2_Ent1", "text": "hyperlactatemia relapse", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19402273_1", "wnd_id": "19402273_1_1", "text": "Isoniazid causing breast tissue enlargement has been very rarely reported .", "tokens": ["Isoniazid", "causing", "breast", "tissue", "enlargement", "has", "been", "very", "rarely", "reported", "."], "event_mentions": [{"id": "19402273_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 1, "end": 2}, "arguments": [{"entity_id": "19402273_1_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_1_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_1_Ent0", "role": "Effect", "text": "breast tissue enlargement", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "19402273_1_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_1_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_1_Ent0", "text": "breast tissue enlargement", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "19402273_2", "wnd_id": "19402273_2_1", "text": "Isoniazid induced gynaecomastia : a case report .", "tokens": ["Isoniazid", "induced", "gynaecomastia", ":", "a", "case", "report", "."], "event_mentions": [{"id": "19402273_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "19402273_2_Ent1", "role": "Treatment", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_2_Ent2", "role": "Treatment_Drug", "text": "Isoniazid", "start": 0, "end": 1}, {"entity_id": "19402273_2_Ent0", "role": "Effect", "text": "gynaecomastia", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "19402273_2_Ent1", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_2_Ent2", "text": "Isoniazid", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19402273_2_Ent0", "text": "gynaecomastia", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "19474653_2", "wnd_id": "19474653_2_1", "text": "We report the first case of rhabdomyolysis related to the administration of clarithromycin without concurrent use of other medications .", "tokens": ["We", "report", "the", "first", "case", "of", "rhabdomyolysis", "related", "to", "the", "administration", "of", "clarithromycin", "without", "concurrent", "use", "of", "other", "medications", "."], "event_mentions": [{"id": "19474653_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 7, "end": 9}, "arguments": [{"entity_id": "19474653_2_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 6, "end": 7}, {"entity_id": "19474653_2_Ent1", "role": "Treatment", "text": "administration of clarithromycin without concurrent use of other medications", "start": 10, "end": 19}, {"entity_id": "19474653_2_Ent2", "role": "Treatment_Drug", "text": "clarithromycin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19474653_2_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19474653_2_Ent1", "text": "administration of clarithromycin without concurrent use of other medications", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "19474653_2_Ent2", "text": "clarithromycin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19499966_2", "wnd_id": "19499966_2_1", "text": "However , re - initiation of sunitinib treatment was followed by bilateral breast enlargement again .", "tokens": ["However", ",", "re", "-", "initiation", "of", "sunitinib", "treatment", "was", "followed", "by", "bilateral", "breast", "enlargement", "again", "."], "event_mentions": [{"id": "19499966_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "followed", "start": 9, "end": 10}, "arguments": [{"entity_id": "19499966_2_Ent1", "role": "Treatment", "text": "sunitinib", "start": 6, "end": 7}, {"entity_id": "19499966_2_Ent2", "role": "Treatment_Drug", "text": "sunitinib", "start": 6, "end": 7}, {"entity_id": "19499966_2_Ent0", "role": "Effect", "text": "bilateral breast enlargement", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "19499966_2_Ent1", "text": "sunitinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19499966_2_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19499966_2_Ent0", "text": "bilateral breast enlargement", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "19499966_4", "wnd_id": "19499966_4_1", "text": "The mechanism by which sunitinib induces gynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors .", "tokens": ["The", "mechanism", "by", "which", "sunitinib", "induces", "gynaecomastia", "is", "thought", "to", "be", "associated", "with", "an", "unknown", "direct", "action", "on", "breast", "hormonal", "receptors", "."], "event_mentions": [{"id": "19499966_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induces", "start": 5, "end": 6}, "arguments": [{"entity_id": "19499966_4_Ent1", "role": "Treatment", "text": "sunitinib", "start": 4, "end": 5}, {"entity_id": "19499966_4_Ent2", "role": "Treatment_Drug", "text": "sunitinib", "start": 4, "end": 5}, {"entity_id": "19499966_4_Ent0", "role": "Effect", "text": "gynaecomastia", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "19499966_4_Ent1", "text": "sunitinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19499966_4_Ent2", "text": "sunitinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19499966_4_Ent0", "text": "gynaecomastia", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "19531695_10", "wnd_id": "19531695_10_1", "text": "Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients .", "tokens": ["Flecainide", "and", "pharmacologically", "similar", "agents", "that", "interact", "with", "sodium", "channels", "may", "cause", "delirium", "in", "susceptible", "patients", "."], "event_mentions": [{"id": "19531695_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531695_10_Ent3", "role": "Treatment_Drug", "text": "Flecainide", "start": 0, "end": 1}, {"entity_id": "19531695_10_Ent2", "role": "Treatment", "text": "Flecainide and pharmacologically similar agents that interact with sodium channels", "start": 0, "end": 10}, {"entity_id": "19531695_10_Ent1", "role": "Effect", "text": "delirium", "start": 12, "end": 13}, {"entity_id": "19531695_10_Ent0", "role": "Subject", "text": "susceptible patients", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "19531695_10_Ent3", "text": "Flecainide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19531695_10_Ent2", "text": "Flecainide and pharmacologically similar agents that interact with sodium channels", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "19531695_10_Ent1", "text": "delirium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19531695_10_Ent0", "text": "susceptible patients", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "19531695_2", "wnd_id": "19531695_2_1", "text": "To describe a case of flecainide - induced delirium associated with a pharmacokinetic drug interaction with paroxetine .", "tokens": ["To", "describe", "a", "case", "of", "flecainide", "-", "induced", "delirium", "associated", "with", "a", "pharmacokinetic", "drug", "interaction", "with", "paroxetine", "."], "event_mentions": [{"id": "19531695_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "19531695_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "19531695_2_Ent2", "role": "Treatment", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent7", "role": "Combination_Drug", "text": "flecainide", "start": 5, "end": 6}, {"entity_id": "19531695_2_Ent1", "role": "Effect", "text": "delirium", "start": 8, "end": 9}, {"entity_id": "19531695_2_Ent3", "role": "Treatment", "text": "interaction with paroxetine", "start": 14, "end": 17}, {"entity_id": "19531695_2_Ent5", "role": "Treatment_Drug", "text": "paroxetine", "start": 16, "end": 17}, {"entity_id": "19531695_2_Ent6", "role": "Combination_Drug", "text": "paroxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "19531695_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19531695_2_Ent2", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent7", "text": "flecainide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19531695_2_Ent1", "text": "delirium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531695_2_Ent3", "text": "interaction with paroxetine", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "19531695_2_Ent5", "text": "paroxetine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19531695_2_Ent6", "text": "paroxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "19531696_2", "wnd_id": "19531696_2_1", "text": "To report a probable interaction between warfarin and marijuana smoking , resulting in increased international normalized ratio ( INR ) values and bleeding complications .", "tokens": ["To", "report", "a", "probable", "interaction", "between", "warfarin", "and", "marijuana", "smoking", ",", "resulting", "in", "increased", "international", "normalized", "ratio", "(", "INR", ")", "values", "and", "bleeding", "complications", "."], "event_mentions": [{"id": "19531696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 11, "end": 12}, "arguments": [{"entity_id": "19531696_2_Ent1", "role": "Treatment", "text": "interaction between warfarin and marijuana smoking", "start": 4, "end": 10}, {"entity_id": "19531696_2_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 6, "end": 7}, {"entity_id": "19531696_2_Ent3", "role": "Treatment_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent6", "role": "Combination_Drug", "text": "marijuana", "start": 8, "end": 9}, {"entity_id": "19531696_2_Ent4", "role": "Treatment_Route", "text": "smoking", "start": 9, "end": 10}, {"entity_id": "19531696_2_Ent0", "role": "Effect", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "start": 13, "end": 24}]}], "entity_mentions": [{"id": "19531696_2_Ent1", "text": "interaction between warfarin and marijuana smoking", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "19531696_2_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_2_Ent3", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent6", "text": "marijuana", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19531696_2_Ent4", "text": "smoking", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19531696_2_Ent0", "text": "increased international normalized ratio ( INR ) values and bleeding complications", "entity_type": "Entity", "start": 13, "end": 24}], "lang": "en"}
{"doc_id": "19531696_3", "wnd_id": "19531696_3_1", "text": "A 56 - year - old white male had been receiving chronic warfarin therapy for 11 years after mechanical heart valve replacement .", "tokens": ["A", "56", "-", "year", "-", "old", "white", "male", "had", "been", "receiving", "chronic", "warfarin", "therapy", "for", "11", "years", "after", "mechanical", "heart", "valve", "replacement", "."], "event_mentions": [{"id": "19531696_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 10, "end": 11}, "arguments": [{"entity_id": "19531696_3_Ent0", "role": "Subject", "text": "A 56 - year - old white male", "start": 0, "end": 8}, {"entity_id": "19531696_3_Ent1", "role": "Subject_Age", "text": "56 - year - old", "start": 1, "end": 6}, {"entity_id": "19531696_3_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "19531696_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "19531696_3_Ent4", "role": "Treatment", "text": "chronic warfarin therapy for 11 years after mechanical heart valve replacement", "start": 11, "end": 22}, {"entity_id": "19531696_3_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "19531696_3_Ent0", "text": "A 56 - year - old white male", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "19531696_3_Ent1", "text": "56 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "19531696_3_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19531696_3_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19531696_3_Ent4", "text": "chronic warfarin therapy for 11 years after mechanical heart valve replacement", "entity_type": "Entity", "start": 11, "end": 22}, {"id": "19531696_3_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "19537383_1", "wnd_id": "19537383_1_1", "text": "Localized dyskeratotic plaque with milia associated with sorafenib .", "tokens": ["Localized", "dyskeratotic", "plaque", "with", "milia", "associated", "with", "sorafenib", "."], "event_mentions": [{"id": "19537383_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "19537383_1_Ent0", "role": "Effect", "text": "Localized dyskeratotic plaque with milia", "start": 0, "end": 5}, {"entity_id": "19537383_1_Ent1", "role": "Treatment", "text": "sorafenib", "start": 7, "end": 8}, {"entity_id": "19537383_1_Ent2", "role": "Treatment_Drug", "text": "sorafenib", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "19537383_1_Ent0", "text": "Localized dyskeratotic plaque with milia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "19537383_1_Ent1", "text": "sorafenib", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19537383_1_Ent2", "text": "sorafenib", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19537383_2", "wnd_id": "19537383_2_1", "text": "Sorafenib , a multitargeted kinase inhibitor used for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinomas , received FDA approval in 2005 .", "tokens": ["Sorafenib", ",", "a", "multitargeted", "kinase", "inhibitor", "used", "for", "the", "treatment", "of", "unresectable", "hepatocellular", "carcinoma", "and", "advanced", "renal", "cell", "carcinomas", ",", "received", "FDA", "approval", "in", "2005", "."], "event_mentions": [{"id": "19537383_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 9, "end": 10}, "arguments": [{"entity_id": "19537383_2_Ent0", "role": "Treatment", "text": "Sorafenib", "start": 0, "end": 1}, {"entity_id": "19537383_2_Ent2", "role": "Treatment_Drug", "text": "Sorafenib", "start": 0, "end": 1}, {"entity_id": "19537383_2_Ent1", "role": "Treatment", "text": "a multitargeted kinase inhibitor", "start": 2, "end": 6}, {"entity_id": "19537383_2_Ent3", "role": "Treatment_Disorder", "text": "unresectable hepatocellular carcinoma", "start": 11, "end": 14}, {"entity_id": "19537383_2_Ent4", "role": "Treatment_Disorder", "text": "advanced renal cell carcinomas", "start": 15, "end": 19}]}], "entity_mentions": [{"id": "19537383_2_Ent0", "text": "Sorafenib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19537383_2_Ent2", "text": "Sorafenib", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19537383_2_Ent1", "text": "a multitargeted kinase inhibitor", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "19537383_2_Ent3", "text": "unresectable hepatocellular carcinoma", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "19537383_2_Ent4", "text": "advanced renal cell carcinomas", "entity_type": "Entity", "start": 15, "end": 19}], "lang": "en"}
{"doc_id": "19540093_2", "wnd_id": "19540093_2_1", "text": "Following 7 days of tigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis .", "tokens": ["Following", "7", "days", "of", "tigecycline", "she", "developed", "severe", "abdominal", "pain", "and", "elevated", "pancreatic", "enzymes", "suggesting", "acute", "pancreatitis", "."], "event_mentions": [{"id": "19540093_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "19540093_2_Ent3", "role": "Treatment_Time_elapsed", "text": "7 days", "start": 1, "end": 3}, {"entity_id": "19540093_2_Ent2", "role": "Treatment", "text": "7 days of tigecycline", "start": 1, "end": 5}, {"entity_id": "19540093_2_Ent4", "role": "Treatment_Drug", "text": "tigecycline", "start": 4, "end": 5}, {"entity_id": "19540093_2_Ent0", "role": "Subject", "text": "she", "start": 5, "end": 6}, {"entity_id": "19540093_2_Ent1", "role": "Effect", "text": "abdominal pain and elevated pancreatic enzymes", "start": 8, "end": 14}]}], "entity_mentions": [{"id": "19540093_2_Ent3", "text": "7 days", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "19540093_2_Ent2", "text": "7 days of tigecycline", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "19540093_2_Ent4", "text": "tigecycline", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19540093_2_Ent0", "text": "she", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19540093_2_Ent1", "text": "abdominal pain and elevated pancreatic enzymes", "entity_type": "Entity", "start": 8, "end": 14}], "lang": "en"}
{"doc_id": "1954704_1", "wnd_id": "1954704_1_1", "text": "Drug induced polymyositis secondary to leuprolide acetate ( Lupron ) therapy for prostate carcinoma .", "tokens": ["Drug", "induced", "polymyositis", "secondary", "to", "leuprolide", "acetate", "(", "Lupron", ")", "therapy", "for", "prostate", "carcinoma", "."], "event_mentions": [{"id": "1954704_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 3, "end": 5}, "arguments": [{"entity_id": "1954704_1_Ent0", "role": "Effect", "text": "Drug induced polymyositis", "start": 0, "end": 3}, {"entity_id": "1954704_1_Ent3", "role": "Treatment_Drug", "text": "leuprolide acetate ( Lupron )", "start": 5, "end": 10}, {"entity_id": "1954704_1_Ent1", "role": "Treatment", "text": "leuprolide acetate ( Lupron ) therapy", "start": 5, "end": 11}, {"entity_id": "1954704_1_Ent2", "role": "Treatment_Disorder", "text": "prostate carcinoma", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "1954704_1_Ent0", "text": "Drug induced polymyositis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1954704_1_Ent3", "text": "leuprolide acetate ( Lupron )", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "1954704_1_Ent1", "text": "leuprolide acetate ( Lupron ) therapy", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "1954704_1_Ent2", "text": "prostate carcinoma", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "1954704_2", "wnd_id": "1954704_2_1", "text": "We report a case of biopsy proven myositis whose symptoms began within 10 days of receiving leuprolide acetate therapy for prostate cancer .", "tokens": ["We", "report", "a", "case", "of", "biopsy", "proven", "myositis", "whose", "symptoms", "began", "within", "10", "days", "of", "receiving", "leuprolide", "acetate", "therapy", "for", "prostate", "cancer", "."], "event_mentions": [{"id": "1954704_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptoms began", "start": 9, "end": 11}, "arguments": [{"entity_id": "1954704_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "1954704_2_Ent1", "role": "Effect", "text": "myositis", "start": 7, "end": 8}, {"entity_id": "1954704_2_Ent2", "role": "Treatment", "text": "within 10 days of receiving leuprolide acetate therapy", "start": 11, "end": 19}, {"entity_id": "1954704_2_Ent4", "role": "Treatment_Time_elapsed", "text": "10 days", "start": 12, "end": 14}, {"entity_id": "1954704_2_Ent3", "role": "Treatment_Drug", "text": "leuprolide acetate", "start": 16, "end": 18}, {"entity_id": "1954704_2_Ent5", "role": "Treatment_Disorder", "text": "prostate cancer", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "1954704_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "1954704_2_Ent1", "text": "myositis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1954704_2_Ent2", "text": "within 10 days of receiving leuprolide acetate therapy", "entity_type": "Entity", "start": 11, "end": 19}, {"id": "1954704_2_Ent4", "text": "10 days", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "1954704_2_Ent3", "text": "leuprolide acetate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "1954704_2_Ent5", "text": "prostate cancer", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "19567656_1", "wnd_id": "19567656_1_1", "text": "CONCLUSIONS : This patient 's rhabdomyolysis was probably induced by sertraline therapy .", "tokens": ["CONCLUSIONS", ":", "This", "patient", "'s", "rhabdomyolysis", "was", "probably", "induced", "by", "sertraline", "therapy", "."], "event_mentions": [{"id": "19567656_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "19567656_1_Ent0", "role": "Subject", "text": "This patient", "start": 2, "end": 4}, {"entity_id": "19567656_1_Ent1", "role": "Effect", "text": "rhabdomyolysis", "start": 5, "end": 6}, {"entity_id": "19567656_1_Ent2", "role": "Treatment", "text": "sertraline", "start": 10, "end": 11}, {"entity_id": "19567656_1_Ent3", "role": "Treatment_Drug", "text": "sertraline", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "19567656_1_Ent0", "text": "This patient", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19567656_1_Ent1", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19567656_1_Ent2", "text": "sertraline", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19567656_1_Ent3", "text": "sertraline", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "19567656_4", "wnd_id": "19567656_4_1", "text": "Sertraline - induced rhabdomyolysis in an elderly patient with dementia and comorbidities .", "tokens": ["Sertraline", "-", "induced", "rhabdomyolysis", "in", "an", "elderly", "patient", "with", "dementia", "and", "comorbidities", "."], "event_mentions": [{"id": "19567656_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19567656_4_Ent5", "role": "Treatment", "text": "Sertraline", "start": 0, "end": 1}, {"entity_id": "19567656_4_Ent6", "role": "Treatment_Drug", "text": "Sertraline", "start": 0, "end": 1}, {"entity_id": "19567656_4_Ent4", "role": "Effect", "text": "rhabdomyolysis", "start": 3, "end": 4}, {"entity_id": "19567656_4_Ent0", "role": "Subject", "text": "an elderly patient with dementia and comorbidities", "start": 5, "end": 12}, {"entity_id": "19567656_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "19567656_4_Ent2", "role": "Subject_Disorder", "text": "dementia", "start": 9, "end": 10}, {"entity_id": "19567656_4_Ent3", "role": "Subject_Disorder", "text": "comorbidities", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "19567656_4_Ent5", "text": "Sertraline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19567656_4_Ent6", "text": "Sertraline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19567656_4_Ent4", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19567656_4_Ent0", "text": "an elderly patient with dementia and comorbidities", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "19567656_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19567656_4_Ent2", "text": "dementia", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "19567656_4_Ent3", "text": "comorbidities", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "19583682_3", "wnd_id": "19583682_3_1", "text": "We report a case of serotonin syndrome induced by pharmacokinetic and pharmacodynamic interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin .", "tokens": ["We", "report", "a", "case", "of", "serotonin", "syndrome", "induced", "by", "pharmacokinetic", "and", "pharmacodynamic", "interactions", "between", "three", "different", "selective", "serotonin", "-", "reuptake", "inhibitors", "(", "SSRI", ")", "and", "possibly", "ciprofloxacin", "."], "event_mentions": [{"id": "19583682_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "19583682_3_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "19583682_3_Ent1", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "19583682_3_Ent2", "role": "Treatment", "text": "interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin", "start": 12, "end": 27}, {"entity_id": "19583682_3_Ent3", "role": "Treatment_Drug", "text": "selective serotonin - reuptake inhibitors", "start": 16, "end": 21}, {"entity_id": "19583682_3_Ent6", "role": "Combination_Drug", "text": "selective serotonin - reuptake inhibitors", "start": 16, "end": 21}, {"entity_id": "19583682_3_Ent4", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 26, "end": 27}, {"entity_id": "19583682_3_Ent5", "role": "Combination_Drug", "text": "ciprofloxacin", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "19583682_3_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19583682_3_Ent1", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "19583682_3_Ent2", "text": "interactions between three different selective serotonin - reuptake inhibitors ( SSRI ) and possibly ciprofloxacin", "entity_type": "Entity", "start": 12, "end": 27}, {"id": "19583682_3_Ent3", "text": "selective serotonin - reuptake inhibitors", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19583682_3_Ent6", "text": "selective serotonin - reuptake inhibitors", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "19583682_3_Ent4", "text": "ciprofloxacin", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "19583682_3_Ent5", "text": "ciprofloxacin", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "19660974_1", "wnd_id": "19660974_1_1", "text": "Colitis as a manifestation of infliximab - associated disseminated cryptococcosis .", "tokens": ["Colitis", "as", "a", "manifestation", "of", "infliximab", "-", "associated", "disseminated", "cryptococcosis", "."], "event_mentions": [{"id": "19660974_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "19660974_1_Ent0", "role": "Effect", "text": "Colitis", "start": 0, "end": 1}, {"entity_id": "19660974_1_Ent1", "role": "Treatment", "text": "infliximab", "start": 5, "end": 6}, {"entity_id": "19660974_1_Ent2", "role": "Treatment_Drug", "text": "infliximab", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "19660974_1_Ent0", "text": "Colitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19660974_1_Ent1", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19660974_1_Ent2", "text": "infliximab", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "19667003_1", "wnd_id": "19667003_1_1", "text": "Carbamazepine - induced hyperammonemia .", "tokens": ["Carbamazepine", "-", "induced", "hyperammonemia", "."], "event_mentions": [{"id": "19667003_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "19667003_1_Ent1", "role": "Treatment", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "19667003_1_Ent2", "role": "Treatment_Drug", "text": "Carbamazepine", "start": 0, "end": 1}, {"entity_id": "19667003_1_Ent0", "role": "Effect", "text": "hyperammonemia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "19667003_1_Ent1", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_1_Ent2", "text": "Carbamazepine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_1_Ent0", "text": "hyperammonemia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "19667003_15", "wnd_id": "19667003_15_1", "text": "He had also developed elevated serum ammonia levels while on valproic acid .", "tokens": ["He", "had", "also", "developed", "elevated", "serum", "ammonia", "levels", "while", "on", "valproic", "acid", "."], "event_mentions": [{"id": "19667003_15_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "19667003_15_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "19667003_15_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "19667003_15_Ent2", "role": "Effect", "text": "elevated serum ammonia levels", "start": 4, "end": 8}, {"entity_id": "19667003_15_Ent3", "role": "Treatment", "text": "valproic acid", "start": 10, "end": 12}, {"entity_id": "19667003_15_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "19667003_15_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_15_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19667003_15_Ent2", "text": "elevated serum ammonia levels", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "19667003_15_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19667003_15_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "19690222_3", "wnd_id": "19690222_3_1", "text": "Spontaneous hemothorax following anticoagulation with low - molecular - weight heparin .", "tokens": ["Spontaneous", "hemothorax", "following", "anticoagulation", "with", "low", "-", "molecular", "-", "weight", "heparin", "."], "event_mentions": [{"id": "19690222_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 4, "end": 5}, "arguments": [{"entity_id": "19690222_3_Ent0", "role": "Effect", "text": "Spontaneous hemothorax following anticoagulation", "start": 0, "end": 4}, {"entity_id": "19690222_3_Ent1", "role": "Treatment", "text": "low - molecular - weight heparin", "start": 5, "end": 11}, {"entity_id": "19690222_3_Ent2", "role": "Treatment_Drug", "text": "low - molecular - weight heparin", "start": 5, "end": 11}]}], "entity_mentions": [{"id": "19690222_3_Ent0", "text": "Spontaneous hemothorax following anticoagulation", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "19690222_3_Ent1", "text": "low - molecular - weight heparin", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "19690222_3_Ent2", "text": "low - molecular - weight heparin", "entity_type": "Entity", "start": 5, "end": 11}], "lang": "en"}
{"doc_id": "19707032_3", "wnd_id": "19707032_3_1", "text": "AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and stroke after intravitreal injection of bevacizumab .", "tokens": ["AIM", ":", "To", "report", "a", "patient", "with", "diabetic", "rubeosis", "who", "suffered", "from", "acute", "retinal", "ischemic", "change", "and", "stroke", "after", "intravitreal", "injection", "of", "bevacizumab", "."], "event_mentions": [{"id": "19707032_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffered", "start": 10, "end": 11}, "arguments": [{"entity_id": "19707032_3_Ent0", "role": "Subject", "text": "patient with diabetic rubeosis", "start": 5, "end": 9}, {"entity_id": "19707032_3_Ent3", "role": "Treatment_Disorder", "text": "diabetic rubeosis", "start": 7, "end": 9}, {"entity_id": "19707032_3_Ent1", "role": "Effect", "text": "acute retinal ischemic change and stroke", "start": 12, "end": 18}, {"entity_id": "19707032_3_Ent5", "role": "Treatment_Route", "text": "intravitreal injection", "start": 19, "end": 21}, {"entity_id": "19707032_3_Ent2", "role": "Treatment", "text": "intravitreal injection of bevacizumab", "start": 19, "end": 23}, {"entity_id": "19707032_3_Ent4", "role": "Treatment_Drug", "text": "bevacizumab", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "19707032_3_Ent0", "text": "patient with diabetic rubeosis", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19707032_3_Ent3", "text": "diabetic rubeosis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "19707032_3_Ent1", "text": "acute retinal ischemic change and stroke", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "19707032_3_Ent5", "text": "intravitreal injection", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "19707032_3_Ent2", "text": "intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "19707032_3_Ent4", "text": "bevacizumab", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "19707032_5", "wnd_id": "19707032_5_1", "text": "Three days after intravitreal injection of bevacizumab , acute ocular ischemic syndrome occurred .", "tokens": ["Three", "days", "after", "intravitreal", "injection", "of", "bevacizumab", ",", "acute", "ocular", "ischemic", "syndrome", "occurred", "."], "event_mentions": [{"id": "19707032_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 12, "end": 13}, "arguments": [{"entity_id": "19707032_5_Ent4", "role": "Treatment_Time_elapsed", "text": "Three days", "start": 0, "end": 2}, {"entity_id": "19707032_5_Ent1", "role": "Treatment", "text": "Three days after intravitreal injection of bevacizumab", "start": 0, "end": 7}, {"entity_id": "19707032_5_Ent3", "role": "Treatment_Route", "text": "intravitreal injection", "start": 3, "end": 5}, {"entity_id": "19707032_5_Ent2", "role": "Treatment_Drug", "text": "bevacizumab", "start": 6, "end": 7}, {"entity_id": "19707032_5_Ent0", "role": "Effect", "text": "acute ocular ischemic syndrome", "start": 8, "end": 12}]}], "entity_mentions": [{"id": "19707032_5_Ent4", "text": "Three days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19707032_5_Ent1", "text": "Three days after intravitreal injection of bevacizumab", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19707032_5_Ent3", "text": "intravitreal injection", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "19707032_5_Ent2", "text": "bevacizumab", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19707032_5_Ent0", "text": "acute ocular ischemic syndrome", "entity_type": "Entity", "start": 8, "end": 12}], "lang": "en"}
{"doc_id": "19733945_3", "wnd_id": "19733945_3_1", "text": "This case of linezolid - associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug .", "tokens": ["This", "case", "of", "linezolid", "-", "associated", "acute", "interstitial", "nephritis", "within", "the", "context", "of", "a", "drug", "rash", "with", "eosinophilia", "and", "systemic", "symptoms", "(", "DRESS", ")", "syndrome", "in", "a", "patient", "treated", "with", "linezolid", "raises", "concerns", "about", "the", "presumed", "renal", "safety", "of", "this", "drug", "."], "event_mentions": [{"id": "19733945_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "19733945_3_Ent1", "role": "Treatment", "text": "linezolid", "start": 3, "end": 4}, {"entity_id": "19733945_3_Ent2", "role": "Treatment_Drug", "text": "linezolid", "start": 3, "end": 4}, {"entity_id": "19733945_3_Ent0", "role": "Effect", "text": "acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome", "start": 6, "end": 25}]}], "entity_mentions": [{"id": "19733945_3_Ent1", "text": "linezolid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19733945_3_Ent2", "text": "linezolid", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "19733945_3_Ent0", "text": "acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome", "entity_type": "Entity", "start": 6, "end": 25}], "lang": "en"}
{"doc_id": "19745701_3", "wnd_id": "19745701_3_1", "text": "She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to immunodeficiency caused by MTX administration .", "tokens": ["She", "was", "diagnosed", "with", "Epstein", "-", "Barr", "virus", "-", "associated", "polymorphic", "lymphoproliferative", "disorder", "(", "LPD", ")", "due", "to", "immunodeficiency", "caused", "by", "MTX", "administration", "."], "event_mentions": [{"id": "19745701_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 16, "end": 17}, "arguments": [{"entity_id": "19745701_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "19745701_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "19745701_3_Ent2", "role": "Effect", "text": "Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD )", "start": 4, "end": 16}, {"entity_id": "19745701_3_Ent3", "role": "Treatment", "text": "immunodeficiency caused by MTX administration", "start": 18, "end": 23}, {"entity_id": "19745701_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "19745701_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19745701_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "19745701_3_Ent2", "text": "Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD )", "entity_type": "Entity", "start": 4, "end": 16}, {"id": "19745701_3_Ent3", "text": "immunodeficiency caused by MTX administration", "entity_type": "Entity", "start": 18, "end": 23}, {"id": "19745701_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "1977935_1", "wnd_id": "1977935_1_1", "text": "Torsades de pointes occurring in association with terfenadine use .", "tokens": ["Torsades", "de", "pointes", "occurring", "in", "association", "with", "terfenadine", "use", "."], "event_mentions": [{"id": "1977935_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 5, "end": 6}, "arguments": [{"entity_id": "1977935_1_Ent0", "role": "Effect", "text": "Torsades de pointes", "start": 0, "end": 3}, {"entity_id": "1977935_1_Ent1", "role": "Treatment", "text": "terfenadine", "start": 7, "end": 8}, {"entity_id": "1977935_1_Ent2", "role": "Treatment_Drug", "text": "terfenadine", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "1977935_1_Ent0", "text": "Torsades de pointes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "1977935_1_Ent1", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "1977935_1_Ent2", "text": "terfenadine", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "19782276_1", "wnd_id": "19782276_1_1", "text": "Fulminant fatal cardiotoxicity following cyclophosphamide therapy .", "tokens": ["Fulminant", "fatal", "cardiotoxicity", "following", "cyclophosphamide", "therapy", "."], "event_mentions": [{"id": "19782276_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "19782276_1_Ent0", "role": "Effect", "text": "Fulminant fatal cardiotoxicity", "start": 0, "end": 3}, {"entity_id": "19782276_1_Ent1", "role": "Treatment", "text": "cyclophosphamide", "start": 4, "end": 5}, {"entity_id": "19782276_1_Ent2", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "19782276_1_Ent0", "text": "Fulminant fatal cardiotoxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "19782276_1_Ent1", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "19782276_1_Ent2", "text": "cyclophosphamide", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "19789166_1", "wnd_id": "19789166_1_1", "text": "Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels , restoring most of them to normal , we concluded that this was probably the case of toxic liver damage caused by nitrofurantoin .", "tokens": ["Given", "that", "discontinuation", "of", "nitrofurantoin", "and", "introduction", "of", "methylprednisolon", "therapy", "significantly", "lowered", "liver", "enzyme", "levels", ",", "restoring", "most", "of", "them", "to", "normal", ",", "we", "concluded", "that", "this", "was", "probably", "the", "case", "of", "toxic", "liver", "damage", "caused", "by", "nitrofurantoin", "."], "event_mentions": [{"id": "19789166_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 35, "end": 36}, "arguments": [{"entity_id": "19789166_1_Ent0", "role": "Effect", "text": "toxic liver damage", "start": 32, "end": 35}, {"entity_id": "19789166_1_Ent1", "role": "Treatment", "text": "nitrofurantoin", "start": 37, "end": 38}, {"entity_id": "19789166_1_Ent2", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 37, "end": 38}]}], "entity_mentions": [{"id": "19789166_1_Ent0", "text": "toxic liver damage", "entity_type": "Entity", "start": 32, "end": 35}, {"id": "19789166_1_Ent1", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "19789166_1_Ent2", "text": "nitrofurantoin", "entity_type": "Entity", "start": 37, "end": 38}], "lang": "en"}
{"doc_id": "19789372_6", "wnd_id": "19789372_6_1", "text": "Of the 15 patients treated with tizanidine and mexiletine , 4 suffered tizanidine - induced adverse effects such as drowsiness and dry mouth in the retrospective survey .", "tokens": ["Of", "the", "15", "patients", "treated", "with", "tizanidine", "and", "mexiletine", ",", "4", "suffered", "tizanidine", "-", "induced", "adverse", "effects", "such", "as", "drowsiness", "and", "dry", "mouth", "in", "the", "retrospective", "survey", "."], "event_mentions": [{"id": "19789372_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "19789372_6_Ent2", "role": "Subject_Population", "text": "15", "start": 2, "end": 3}, {"entity_id": "19789372_6_Ent0", "role": "Subject", "text": "15 patients", "start": 2, "end": 4}, {"entity_id": "19789372_6_Ent5", "role": "Treatment_Drug", "text": "tizanidine", "start": 6, "end": 7}, {"entity_id": "19789372_6_Ent8", "role": "Combination_Drug", "text": "tizanidine", "start": 6, "end": 7}, {"entity_id": "19789372_6_Ent4", "role": "Treatment", "text": "tizanidine and mexiletine", "start": 6, "end": 9}, {"entity_id": "19789372_6_Ent6", "role": "Treatment_Drug", "text": "mexiletine", "start": 8, "end": 9}, {"entity_id": "19789372_6_Ent9", "role": "Combination_Drug", "text": "mexiletine", "start": 8, "end": 9}, {"entity_id": "19789372_6_Ent1", "role": "Subject", "text": "4", "start": 10, "end": 11}, {"entity_id": "19789372_6_Ent7", "role": "Treatment_Drug", "text": "tizanidine", "start": 12, "end": 13}, {"entity_id": "19789372_6_Ent3", "role": "Effect", "text": "drowsiness and dry mouth", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19789372_6_Ent2", "text": "15", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19789372_6_Ent0", "text": "15 patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19789372_6_Ent5", "text": "tizanidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19789372_6_Ent8", "text": "tizanidine", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19789372_6_Ent4", "text": "tizanidine and mexiletine", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19789372_6_Ent6", "text": "mexiletine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19789372_6_Ent9", "text": "mexiletine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19789372_6_Ent1", "text": "4", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19789372_6_Ent7", "text": "tizanidine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "19789372_6_Ent3", "text": "drowsiness and dry mouth", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19838099_1", "wnd_id": "19838099_1_1", "text": "Although there have been numerous reports of effusions , none have provided complete pleural fluid analysis ; therefore , we report 2 patients with dasatinib - induced pleural effusion with complete pleural fluid analysis .", "tokens": ["Although", "there", "have", "been", "numerous", "reports", "of", "effusions", ",", "none", "have", "provided", "complete", "pleural", "fluid", "analysis", ";", "therefore", ",", "we", "report", "2", "patients", "with", "dasatinib", "-", "induced", "pleural", "effusion", "with", "complete", "pleural", "fluid", "analysis", "."], "event_mentions": [{"id": "19838099_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 26, "end": 27}, "arguments": [{"entity_id": "19838099_1_Ent1", "role": "Subject_Population", "text": "2", "start": 21, "end": 22}, {"entity_id": "19838099_1_Ent0", "role": "Subject", "text": "2 patients", "start": 21, "end": 23}, {"entity_id": "19838099_1_Ent3", "role": "Treatment", "text": "dasatinib", "start": 24, "end": 25}, {"entity_id": "19838099_1_Ent4", "role": "Treatment_Drug", "text": "dasatinib", "start": 24, "end": 25}, {"entity_id": "19838099_1_Ent2", "role": "Effect", "text": "pleural effusion", "start": 27, "end": 29}]}], "entity_mentions": [{"id": "19838099_1_Ent1", "text": "2", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19838099_1_Ent0", "text": "2 patients", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "19838099_1_Ent3", "text": "dasatinib", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19838099_1_Ent4", "text": "dasatinib", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "19838099_1_Ent2", "text": "pleural effusion", "entity_type": "Entity", "start": 27, "end": 29}], "lang": "en"}
{"doc_id": "19844714_1", "wnd_id": "19844714_1_1", "text": "RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a carboplatin - based regimen , developed a platinum hypersensitivity .", "tokens": ["RESULTS", ":", "One", "case", "of", "recurrent", "primary", "peritoneal", "carcinoma", "previously", "treated", "with", "a", "carboplatin", "-", "based", "regimen", ",", "developed", "a", "platinum", "hypersensitivity", "."], "event_mentions": [{"id": "19844714_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "19844714_1_Ent3", "role": "Treatment_Disorder", "text": "recurrent primary peritoneal carcinoma", "start": 5, "end": 9}, {"entity_id": "19844714_1_Ent1", "role": "Treatment", "text": "a carboplatin - based regimen", "start": 12, "end": 17}, {"entity_id": "19844714_1_Ent2", "role": "Treatment_Drug", "text": "carboplatin", "start": 13, "end": 14}, {"entity_id": "19844714_1_Ent0", "role": "Effect", "text": "a platinum hypersensitivity", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "19844714_1_Ent3", "text": "recurrent primary peritoneal carcinoma", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "19844714_1_Ent1", "text": "a carboplatin - based regimen", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "19844714_1_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "19844714_1_Ent0", "text": "a platinum hypersensitivity", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "19857154_4", "wnd_id": "19857154_4_1", "text": "We describe two patients who experienced serious quetiapine adverse effects potentially mediated through an interaction with ritonavir - boosted atazanavir .", "tokens": ["We", "describe", "two", "patients", "who", "experienced", "serious", "quetiapine", "adverse", "effects", "potentially", "mediated", "through", "an", "interaction", "with", "ritonavir", "-", "boosted", "atazanavir", "."], "event_mentions": [{"id": "19857154_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 5, "end": 6}, "arguments": [{"entity_id": "19857154_4_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "19857154_4_Ent0", "role": "Subject", "text": "two patients", "start": 2, "end": 4}, {"entity_id": "19857154_4_Ent2", "role": "Effect", "text": "serious quetiapine adverse effects", "start": 6, "end": 10}, {"entity_id": "19857154_4_Ent4", "role": "Treatment_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "19857154_4_Ent6", "role": "Combination_Drug", "text": "ritonavir", "start": 16, "end": 17}, {"entity_id": "19857154_4_Ent3", "role": "Treatment", "text": "ritonavir - boosted atazanavir", "start": 16, "end": 20}, {"entity_id": "19857154_4_Ent5", "role": "Treatment_Drug", "text": "atazanavir", "start": 19, "end": 20}, {"entity_id": "19857154_4_Ent7", "role": "Combination_Drug", "text": "atazanavir", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "19857154_4_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19857154_4_Ent0", "text": "two patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "19857154_4_Ent2", "text": "serious quetiapine adverse effects", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "19857154_4_Ent4", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19857154_4_Ent6", "text": "ritonavir", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19857154_4_Ent3", "text": "ritonavir - boosted atazanavir", "entity_type": "Entity", "start": 16, "end": 20}, {"id": "19857154_4_Ent5", "text": "atazanavir", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "19857154_4_Ent7", "text": "atazanavir", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "19897274_3", "wnd_id": "19897274_3_1", "text": "In this article , we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma .", "tokens": ["In", "this", "article", ",", "we", "describe", "a", "Japanese", "patient", "with", "severe", "interstitial", "pneumonia", "probably", "caused", "by", "sorafenib", "treatment", "for", "metastatic", "renal", "cell", "carcinoma", "."], "event_mentions": [{"id": "19897274_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 14, "end": 15}, "arguments": [{"entity_id": "19897274_3_Ent0", "role": "Subject", "text": "a Japanese patient", "start": 6, "end": 9}, {"entity_id": "19897274_3_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 7, "end": 8}, {"entity_id": "19897274_3_Ent2", "role": "Effect", "text": "severe interstitial pneumonia", "start": 10, "end": 13}, {"entity_id": "19897274_3_Ent3", "role": "Treatment", "text": "sorafenib", "start": 16, "end": 17}, {"entity_id": "19897274_3_Ent5", "role": "Treatment_Drug", "text": "sorafenib", "start": 16, "end": 17}, {"entity_id": "19897274_3_Ent4", "role": "Treatment_Disorder", "text": "metastatic renal cell carcinoma", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "19897274_3_Ent0", "text": "a Japanese patient", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19897274_3_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "19897274_3_Ent2", "text": "severe interstitial pneumonia", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "19897274_3_Ent3", "text": "sorafenib", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19897274_3_Ent5", "text": "sorafenib", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "19897274_3_Ent4", "text": "metastatic renal cell carcinoma", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "19904536_10", "wnd_id": "19904536_10_1", "text": "A helicoidal CT scan showed diffuse and severe interstitial pneumonitis , and lung biopsy confirmed accelerated usual interstitial pneumonia consistent with drug - induced toxicity .", "tokens": ["A", "helicoidal", "CT", "scan", "showed", "diffuse", "and", "severe", "interstitial", "pneumonitis", ",", "and", "lung", "biopsy", "confirmed", "accelerated", "usual", "interstitial", "pneumonia", "consistent", "with", "drug", "-", "induced", "toxicity", "."], "event_mentions": [{"id": "19904536_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 23, "end": 24}, "arguments": [{"entity_id": "19904536_10_Ent0", "role": "Effect", "text": "diffuse and severe interstitial pneumonitis", "start": 5, "end": 10}, {"entity_id": "19904536_10_Ent1", "role": "Effect", "text": "accelerated usual interstitial pneumonia", "start": 15, "end": 19}, {"entity_id": "19904536_10_Ent3", "role": "Treatment", "text": "drug", "start": 21, "end": 22}, {"entity_id": "19904536_10_Ent4", "role": "Treatment_Drug", "text": "drug", "start": 21, "end": 22}, {"entity_id": "19904536_10_Ent2", "role": "Effect", "text": "toxicity", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "19904536_10_Ent0", "text": "diffuse and severe interstitial pneumonitis", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "19904536_10_Ent1", "text": "accelerated usual interstitial pneumonia", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "19904536_10_Ent3", "text": "drug", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19904536_10_Ent4", "text": "drug", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "19904536_10_Ent2", "text": "toxicity", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "19904536_3", "wnd_id": "19904536_3_1", "text": "In this report , we describe a fatal gemcitabine - induced pulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma .", "tokens": ["In", "this", "report", ",", "we", "describe", "a", "fatal", "gemcitabine", "-", "induced", "pulmonary", "toxicity", "in", "a", "patient", "with", "gallbladder", "metastatic", "adenocarcinoma", "."], "event_mentions": [{"id": "19904536_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "19904536_3_Ent2", "role": "Treatment", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "19904536_3_Ent4", "role": "Treatment_Drug", "text": "gemcitabine", "start": 8, "end": 9}, {"entity_id": "19904536_3_Ent1", "role": "Effect", "text": "pulmonary toxicity", "start": 11, "end": 13}, {"entity_id": "19904536_3_Ent0", "role": "Subject", "text": "a patient with gallbladder metastatic adenocarcinoma", "start": 14, "end": 20}, {"entity_id": "19904536_3_Ent3", "role": "Treatment_Disorder", "text": "gallbladder metastatic adenocarcinoma", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "19904536_3_Ent2", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19904536_3_Ent4", "text": "gemcitabine", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19904536_3_Ent1", "text": "pulmonary toxicity", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "19904536_3_Ent0", "text": "a patient with gallbladder metastatic adenocarcinoma", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "19904536_3_Ent3", "text": "gallbladder metastatic adenocarcinoma", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "19949685_3", "wnd_id": "19949685_3_1", "text": "Two days after administration of Kalimate enema , he had profuse hematochezia , and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon .", "tokens": ["Two", "days", "after", "administration", "of", "Kalimate", "enema", ",", "he", "had", "profuse", "hematochezia", ",", "and", "a", "sigmoidoscopy", "showed", "diffuse", "colonic", "mucosal", "necrosis", "in", "the", "rectum", "and", "sigmoid", "colon", "."], "event_mentions": [{"id": "19949685_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "19949685_3_Ent7", "role": "Treatment_Time_elapsed", "text": "Two days", "start": 0, "end": 2}, {"entity_id": "19949685_3_Ent4", "role": "Treatment", "text": "Two days after administration of Kalimate enema", "start": 0, "end": 7}, {"entity_id": "19949685_3_Ent6", "role": "Treatment_Drug", "text": "Kalimate", "start": 5, "end": 6}, {"entity_id": "19949685_3_Ent5", "role": "Treatment_Route", "text": "enema", "start": 6, "end": 7}, {"entity_id": "19949685_3_Ent0", "role": "Subject", "text": "he", "start": 8, "end": 9}, {"entity_id": "19949685_3_Ent1", "role": "Subject_Gender", "text": "he", "start": 8, "end": 9}, {"entity_id": "19949685_3_Ent2", "role": "Effect", "text": "profuse hematochezia", "start": 10, "end": 12}, {"entity_id": "19949685_3_Ent3", "role": "Effect", "text": "diffuse colonic mucosal necrosis in the rectum", "start": 17, "end": 24}]}], "entity_mentions": [{"id": "19949685_3_Ent7", "text": "Two days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "19949685_3_Ent4", "text": "Two days after administration of Kalimate enema", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "19949685_3_Ent6", "text": "Kalimate", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "19949685_3_Ent5", "text": "enema", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "19949685_3_Ent0", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19949685_3_Ent1", "text": "he", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "19949685_3_Ent2", "text": "profuse hematochezia", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "19949685_3_Ent3", "text": "diffuse colonic mucosal necrosis in the rectum", "entity_type": "Entity", "start": 17, "end": 24}], "lang": "en"}
{"doc_id": "19949685_4", "wnd_id": "19949685_4_1", "text": "We report a rare case of colonic mucosal necrosis following Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol in a 34 - yr - old man .", "tokens": ["We", "report", "a", "rare", "case", "of", "colonic", "mucosal", "necrosis", "following", "Kalimate", "(", "calcium", "polystryrene", "sulfonate", ")", ",", "an", "analogue", "of", "Kayexalate", "without", "sorbitol", "in", "a", "34", "-", "yr", "-", "old", "man", "."], "event_mentions": [{"id": "19949685_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "19949685_4_Ent3", "role": "Effect", "text": "colonic mucosal necrosis", "start": 6, "end": 9}, {"entity_id": "19949685_4_Ent5", "role": "Treatment_Drug", "text": "Kalimate", "start": 10, "end": 11}, {"entity_id": "19949685_4_Ent4", "role": "Treatment", "text": "Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol", "start": 10, "end": 23}, {"entity_id": "19949685_4_Ent6", "role": "Treatment_Drug", "text": "( calcium polystryrene sulfonate )", "start": 11, "end": 16}, {"entity_id": "19949685_4_Ent7", "role": "Treatment_Drug", "text": "Kayexalate", "start": 20, "end": 21}, {"entity_id": "19949685_4_Ent0", "role": "Subject", "text": "a 34 - yr - old man", "start": 24, "end": 31}, {"entity_id": "19949685_4_Ent1", "role": "Subject_Age", "text": "34 - yr - old", "start": 25, "end": 30}, {"entity_id": "19949685_4_Ent2", "role": "Subject_Gender", "text": "man", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "19949685_4_Ent3", "text": "colonic mucosal necrosis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "19949685_4_Ent5", "text": "Kalimate", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "19949685_4_Ent4", "text": "Kalimate ( calcium polystryrene sulfonate ) , an analogue of Kayexalate without sorbitol", "entity_type": "Entity", "start": 10, "end": 23}, {"id": "19949685_4_Ent6", "text": "( calcium polystryrene sulfonate )", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "19949685_4_Ent7", "text": "Kayexalate", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "19949685_4_Ent0", "text": "a 34 - yr - old man", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "19949685_4_Ent1", "text": "34 - yr - old", "entity_type": "Entity", "start": 25, "end": 30}, {"id": "19949685_4_Ent2", "text": "man", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "19995222_4", "wnd_id": "19995222_4_1", "text": "OBJECTIVE : Clozapine causes few extrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia ( TD ) .", "tokens": ["OBJECTIVE", ":", "Clozapine", "causes", "few", "extrapyramidal", "symptoms", "and", "is", "recommended", "as", "a", "treatment", "drug", "for", "severe", "tardive", "dyskinesia", "(", "TD", ")", "."], "event_mentions": [{"id": "19995222_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 3, "end": 4}, "arguments": [{"entity_id": "19995222_4_Ent1", "role": "Treatment", "text": "Clozapine", "start": 2, "end": 3}, {"entity_id": "19995222_4_Ent2", "role": "Treatment_Drug", "text": "Clozapine", "start": 2, "end": 3}, {"entity_id": "19995222_4_Ent0", "role": "Effect", "text": "few extrapyramidal symptoms", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "19995222_4_Ent1", "text": "Clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19995222_4_Ent2", "text": "Clozapine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "19995222_4_Ent0", "text": "few extrapyramidal symptoms", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "20020238_3", "wnd_id": "20020238_3_1", "text": "Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin .", "tokens": ["Retinopathy", "in", "hepatitis", "C", "patients", "due", "to", "combination", "therapy", "with", "pegylated", "interferon", "and", "ribavirin", "."], "event_mentions": [{"id": "20020238_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 5, "end": 6}, "arguments": [{"entity_id": "20020238_3_Ent1", "role": "Effect", "text": "Retinopathy", "start": 0, "end": 1}, {"entity_id": "20020238_3_Ent3", "role": "Treatment_Disorder", "text": "hepatitis C", "start": 2, "end": 4}, {"entity_id": "20020238_3_Ent0", "role": "Subject", "text": "hepatitis C patients", "start": 2, "end": 5}, {"entity_id": "20020238_3_Ent4", "role": "Treatment_Drug", "text": "pegylated interferon", "start": 10, "end": 12}, {"entity_id": "20020238_3_Ent6", "role": "Combination_Drug", "text": "pegylated interferon", "start": 10, "end": 12}, {"entity_id": "20020238_3_Ent2", "role": "Treatment", "text": "pegylated interferon and ribavirin", "start": 10, "end": 14}, {"entity_id": "20020238_3_Ent5", "role": "Treatment_Drug", "text": "ribavirin", "start": 13, "end": 14}, {"entity_id": "20020238_3_Ent7", "role": "Combination_Drug", "text": "ribavirin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "20020238_3_Ent1", "text": "Retinopathy", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20020238_3_Ent3", "text": "hepatitis C", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "20020238_3_Ent0", "text": "hepatitis C patients", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "20020238_3_Ent4", "text": "pegylated interferon", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20020238_3_Ent6", "text": "pegylated interferon", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "20020238_3_Ent2", "text": "pegylated interferon and ribavirin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "20020238_3_Ent5", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "20020238_3_Ent7", "text": "ribavirin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "20038831_2", "wnd_id": "20038831_2_1", "text": "Hypersensitivity to carboplatin has been reported in up to 44 % of patients receiving this antineoplastic agent , usually occurring after several courses of treatment .", "tokens": ["Hypersensitivity", "to", "carboplatin", "has", "been", "reported", "in", "up", "to", "44", "%", "of", "patients", "receiving", "this", "antineoplastic", "agent", ",", "usually", "occurring", "after", "several", "courses", "of", "treatment", "."], "event_mentions": [{"id": "20038831_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 1, "end": 2}, "arguments": [{"entity_id": "20038831_2_Ent1", "role": "Effect", "text": "Hypersensitivity", "start": 0, "end": 1}, {"entity_id": "20038831_2_Ent2", "role": "Treatment", "text": "carboplatin", "start": 2, "end": 3}, {"entity_id": "20038831_2_Ent4", "role": "Treatment_Drug", "text": "carboplatin", "start": 2, "end": 3}, {"entity_id": "20038831_2_Ent0", "role": "Subject", "text": "44 % of patients", "start": 9, "end": 13}, {"entity_id": "20038831_2_Ent3", "role": "Treatment", "text": "after several courses of treatment", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "20038831_2_Ent1", "text": "Hypersensitivity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20038831_2_Ent2", "text": "carboplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20038831_2_Ent4", "text": "carboplatin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20038831_2_Ent0", "text": "44 % of patients", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "20038831_2_Ent3", "text": "after several courses of treatment", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "20076952_11", "wnd_id": "20076952_11_1", "text": "The clinical use of itraconazole in patients receiving multiple doses of oxycodone for pain relief may increase the risk of opioid - associated adverse effects .", "tokens": ["The", "clinical", "use", "of", "itraconazole", "in", "patients", "receiving", "multiple", "doses", "of", "oxycodone", "for", "pain", "relief", "may", "increase", "the", "risk", "of", "opioid", "-", "associated", "adverse", "effects", "."], "event_mentions": [{"id": "20076952_11_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increase", "start": 16, "end": 17}, "arguments": [{"entity_id": "20076952_11_Ent2", "role": "Treatment", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent6", "role": "Treatment_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent8", "role": "Combination_Drug", "text": "itraconazole", "start": 4, "end": 5}, {"entity_id": "20076952_11_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "20076952_11_Ent3", "role": "Treatment", "text": "receiving multiple doses of oxycodone", "start": 7, "end": 12}, {"entity_id": "20076952_11_Ent7", "role": "Treatment_Dosage", "text": "multiple doses", "start": 8, "end": 10}, {"entity_id": "20076952_11_Ent5", "role": "Treatment_Drug", "text": "oxycodone", "start": 11, "end": 12}, {"entity_id": "20076952_11_Ent9", "role": "Combination_Drug", "text": "oxycodone", "start": 11, "end": 12}, {"entity_id": "20076952_11_Ent4", "role": "Treatment_Disorder", "text": "pain relief", "start": 13, "end": 15}, {"entity_id": "20076952_11_Ent1", "role": "Effect", "text": "opioid - associated adverse effects", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "20076952_11_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent6", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent8", "text": "itraconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20076952_11_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "20076952_11_Ent3", "text": "receiving multiple doses of oxycodone", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "20076952_11_Ent7", "text": "multiple doses", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "20076952_11_Ent5", "text": "oxycodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20076952_11_Ent9", "text": "oxycodone", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20076952_11_Ent4", "text": "pain relief", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "20076952_11_Ent1", "text": "opioid - associated adverse effects", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "20110001_4", "wnd_id": "20110001_4_1", "text": "OBJECTIVE : We report a case of cutaneous KS lesions in a patient affected by CML treated with imatinib .", "tokens": ["OBJECTIVE", ":", "We", "report", "a", "case", "of", "cutaneous", "KS", "lesions", "in", "a", "patient", "affected", "by", "CML", "treated", "with", "imatinib", "."], "event_mentions": [{"id": "20110001_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated with", "start": 16, "end": 18}, "arguments": [{"entity_id": "20110001_4_Ent1", "role": "Effect", "text": "cutaneous KS lesions", "start": 7, "end": 10}, {"entity_id": "20110001_4_Ent0", "role": "Subject", "text": "a patient affected by CML", "start": 11, "end": 16}, {"entity_id": "20110001_4_Ent4", "role": "Treatment_Disorder", "text": "CML", "start": 15, "end": 16}, {"entity_id": "20110001_4_Ent2", "role": "Treatment", "text": "imatinib", "start": 18, "end": 19}, {"entity_id": "20110001_4_Ent3", "role": "Treatment_Drug", "text": "imatinib", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "20110001_4_Ent1", "text": "cutaneous KS lesions", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "20110001_4_Ent0", "text": "a patient affected by CML", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "20110001_4_Ent4", "text": "CML", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "20110001_4_Ent2", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20110001_4_Ent3", "text": "imatinib", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "2011096_1", "wnd_id": "2011096_1_1", "text": "Bulbar and pseudobulbar palsy complicating therapy with high - dose cytosine arabinoside in children with leukemia .", "tokens": ["Bulbar", "and", "pseudobulbar", "palsy", "complicating", "therapy", "with", "high", "-", "dose", "cytosine", "arabinoside", "in", "children", "with", "leukemia", "."], "event_mentions": [{"id": "2011096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicating", "start": 4, "end": 5}, "arguments": [{"entity_id": "2011096_1_Ent2", "role": "Effect", "text": "Bulbar and pseudobulbar palsy", "start": 0, "end": 4}, {"entity_id": "2011096_1_Ent5", "role": "Treatment_Dosage", "text": "high - dose", "start": 7, "end": 10}, {"entity_id": "2011096_1_Ent3", "role": "Treatment", "text": "high - dose cytosine arabinoside", "start": 7, "end": 12}, {"entity_id": "2011096_1_Ent4", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 10, "end": 12}, {"entity_id": "2011096_1_Ent1", "role": "Subject_Age", "text": "children", "start": 13, "end": 14}, {"entity_id": "2011096_1_Ent0", "role": "Subject", "text": "children with leukemia", "start": 13, "end": 16}, {"entity_id": "2011096_1_Ent6", "role": "Treatment_Disorder", "text": "leukemia", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2011096_1_Ent2", "text": "Bulbar and pseudobulbar palsy", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2011096_1_Ent5", "text": "high - dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2011096_1_Ent3", "text": "high - dose cytosine arabinoside", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2011096_1_Ent4", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2011096_1_Ent1", "text": "children", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2011096_1_Ent0", "text": "children with leukemia", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "2011096_1_Ent6", "text": "leukemia", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "20120657_1", "wnd_id": "20120657_1_1", "text": "CONCLUSION : Zidovudine is well a known cause of anaemia and thus should be used with caution in the initiation of antiretroviral therapy .", "tokens": ["CONCLUSION", ":", "Zidovudine", "is", "well", "a", "known", "cause", "of", "anaemia", "and", "thus", "should", "be", "used", "with", "caution", "in", "the", "initiation", "of", "antiretroviral", "therapy", "."], "event_mentions": [{"id": "20120657_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 7, "end": 8}, "arguments": [{"entity_id": "20120657_1_Ent1", "role": "Treatment", "text": "Zidovudine", "start": 2, "end": 3}, {"entity_id": "20120657_1_Ent2", "role": "Treatment_Drug", "text": "Zidovudine", "start": 2, "end": 3}, {"entity_id": "20120657_1_Ent0", "role": "Effect", "text": "anaemia", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "20120657_1_Ent1", "text": "Zidovudine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20120657_1_Ent2", "text": "Zidovudine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "20120657_1_Ent0", "text": "anaemia", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "20126479_3", "wnd_id": "20126479_3_1", "text": "Spectral - domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss .", "tokens": ["Spectral", "-", "domain", "optical", "coherence", "tomography", "and", "adaptive", "optics", "may", "detect", "hydroxychloroquine", "retinal", "toxicity", "before", "symptomatic", "vision", "loss", "."], "event_mentions": [{"id": "20126479_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "before", "start": 14, "end": 15}, "arguments": [{"entity_id": "20126479_3_Ent1", "role": "Treatment", "text": "hydroxychloroquine", "start": 11, "end": 12}, {"entity_id": "20126479_3_Ent2", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 11, "end": 12}, {"entity_id": "20126479_3_Ent0", "role": "Effect", "text": "symptomatic vision loss", "start": 15, "end": 18}]}], "entity_mentions": [{"id": "20126479_3_Ent1", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20126479_3_Ent2", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20126479_3_Ent0", "text": "symptomatic vision loss", "entity_type": "Entity", "start": 15, "end": 18}], "lang": "en"}
{"doc_id": "2012922_1", "wnd_id": "2012922_1_1", "text": "Transient trazodone - induced hypomanic symptoms occurred in three depressed patients .", "tokens": ["Transient", "trazodone", "-", "induced", "hypomanic", "symptoms", "occurred", "in", "three", "depressed", "patients", "."], "event_mentions": [{"id": "2012922_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2012922_1_Ent3", "role": "Treatment", "text": "trazodone", "start": 1, "end": 2}, {"entity_id": "2012922_1_Ent5", "role": "Treatment_Drug", "text": "trazodone", "start": 1, "end": 2}, {"entity_id": "2012922_1_Ent2", "role": "Effect", "text": "hypomanic symptoms", "start": 4, "end": 6}, {"entity_id": "2012922_1_Ent1", "role": "Subject_Population", "text": "three", "start": 8, "end": 9}, {"entity_id": "2012922_1_Ent0", "role": "Subject", "text": "three depressed patients", "start": 8, "end": 11}, {"entity_id": "2012922_1_Ent4", "role": "Treatment_Disorder", "text": "depressed", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2012922_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2012922_1_Ent5", "text": "trazodone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2012922_1_Ent2", "text": "hypomanic symptoms", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2012922_1_Ent1", "text": "three", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2012922_1_Ent0", "text": "three depressed patients", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2012922_1_Ent4", "text": "depressed", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "20130478_2", "wnd_id": "20130478_2_1", "text": "Reversible heart failure in a patient receiving etanercept for ankylosing spondylitis .", "tokens": ["Reversible", "heart", "failure", "in", "a", "patient", "receiving", "etanercept", "for", "ankylosing", "spondylitis", "."], "event_mentions": [{"id": "20130478_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "20130478_2_Ent1", "role": "Effect", "text": "Reversible heart failure", "start": 0, "end": 3}, {"entity_id": "20130478_2_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "20130478_2_Ent2", "role": "Treatment", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "20130478_2_Ent3", "role": "Treatment_Drug", "text": "etanercept", "start": 7, "end": 8}, {"entity_id": "20130478_2_Ent4", "role": "Treatment_Disorder", "text": "ankylosing spondylitis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "20130478_2_Ent1", "text": "Reversible heart failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "20130478_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "20130478_2_Ent2", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20130478_2_Ent3", "text": "etanercept", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20130478_2_Ent4", "text": "ankylosing spondylitis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "20185472_2", "wnd_id": "20185472_2_1", "text": "Tremor : a newly described adverse event with long - term itraconazole therapy .", "tokens": ["Tremor", ":", "a", "newly", "described", "adverse", "event", "with", "long", "-", "term", "itraconazole", "therapy", "."], "event_mentions": [{"id": "20185472_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 7, "end": 8}, "arguments": [{"entity_id": "20185472_2_Ent0", "role": "Effect", "text": "Tremor", "start": 0, "end": 1}, {"entity_id": "20185472_2_Ent3", "role": "Treatment_Duration", "text": "long - term", "start": 8, "end": 11}, {"entity_id": "20185472_2_Ent1", "role": "Treatment", "text": "long - term itraconazole therapy", "start": 8, "end": 13}, {"entity_id": "20185472_2_Ent2", "role": "Treatment_Drug", "text": "itraconazole", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "20185472_2_Ent0", "text": "Tremor", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20185472_2_Ent3", "text": "long - term", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "20185472_2_Ent1", "text": "long - term itraconazole therapy", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "20185472_2_Ent2", "text": "itraconazole", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "20202988_8", "wnd_id": "20202988_8_1", "text": "In two other patients ( one after OLTX and one with Crohn 's disease ) , a raltegravir - based HIV therapy was started while patients received 1 or 2 mg of tacrolimus twice daily .", "tokens": ["In", "two", "other", "patients", "(", "one", "after", "OLTX", "and", "one", "with", "Crohn", "'s", "disease", ")", ",", "a", "raltegravir", "-", "based", "HIV", "therapy", "was", "started", "while", "patients", "received", "1", "or", "2", "mg", "of", "tacrolimus", "twice", "daily", "."], "event_mentions": [{"id": "20202988_8_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 26, "end": 27}, "arguments": [{"entity_id": "20202988_8_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "20202988_8_Ent0", "role": "Subject", "text": "two other patients ( one after OLTX and one with Crohn 's disease )", "start": 1, "end": 15}, {"entity_id": "20202988_8_Ent6", "role": "Treatment_Disorder", "text": "OLTX", "start": 7, "end": 8}, {"entity_id": "20202988_8_Ent5", "role": "Treatment_Disorder", "text": "Crohn 's disease", "start": 11, "end": 14}, {"entity_id": "20202988_8_Ent2", "role": "Treatment", "text": "raltegravir", "start": 17, "end": 18}, {"entity_id": "20202988_8_Ent7", "role": "Treatment_Drug", "text": "raltegravir", "start": 17, "end": 18}, {"entity_id": "20202988_8_Ent11", "role": "Combination_Drug", "text": "raltegravir", "start": 17, "end": 18}, {"entity_id": "20202988_8_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 20, "end": 21}, {"entity_id": "20202988_8_Ent9", "role": "Treatment_Dosage", "text": "1 or 2 mg", "start": 27, "end": 31}, {"entity_id": "20202988_8_Ent3", "role": "Treatment", "text": "1 or 2 mg of tacrolimus twice daily .", "start": 27, "end": 36}, {"entity_id": "20202988_8_Ent8", "role": "Treatment_Drug", "text": "tacrolimus", "start": 32, "end": 33}, {"entity_id": "20202988_8_Ent12", "role": "Combination_Drug", "text": "tacrolimus", "start": 32, "end": 33}, {"entity_id": "20202988_8_Ent10", "role": "Treatment_Freq", "text": "twice daily", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "20202988_8_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20202988_8_Ent0", "text": "two other patients ( one after OLTX and one with Crohn 's disease )", "entity_type": "Entity", "start": 1, "end": 15}, {"id": "20202988_8_Ent6", "text": "OLTX", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "20202988_8_Ent5", "text": "Crohn 's disease", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "20202988_8_Ent2", "text": "raltegravir", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20202988_8_Ent7", "text": "raltegravir", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20202988_8_Ent11", "text": "raltegravir", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20202988_8_Ent4", "text": "HIV", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "20202988_8_Ent9", "text": "1 or 2 mg", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "20202988_8_Ent3", "text": "1 or 2 mg of tacrolimus twice daily .", "entity_type": "Entity", "start": 27, "end": 36}, {"id": "20202988_8_Ent8", "text": "tacrolimus", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "20202988_8_Ent12", "text": "tacrolimus", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "20202988_8_Ent10", "text": "twice daily", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "20203465_3", "wnd_id": "20203465_3_1", "text": "We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea , shortness of breath , azotemia , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( IVIG ) .", "tokens": ["We", "report", "the", "case", "of", "an", "87", "-", "year", "-", "old", "white", "woman", "with", "myasthenia", "gravis", "who", "presented", "with", "nausea", ",", "shortness", "of", "breath", ",", "azotemia", ",", "and", "hyperkalemia", "shortly", "after", "completing", "a", "course", "of", "intravenous", "immunoglobulin", "(", "IVIG", ")", "."], "event_mentions": [{"id": "20203465_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presented", "start": 17, "end": 18}, "arguments": [{"entity_id": "20203465_3_Ent0", "role": "Subject", "text": "an 87 - year - old white woman with myasthenia gravis", "start": 5, "end": 16}, {"entity_id": "20203465_3_Ent1", "role": "Subject_Age", "text": "87 - year - old", "start": 6, "end": 11}, {"entity_id": "20203465_3_Ent2", "role": "Subject_Race", "text": "white", "start": 11, "end": 12}, {"entity_id": "20203465_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 12, "end": 13}, {"entity_id": "20203465_3_Ent7", "role": "Treatment_Disorder", "text": "myasthenia gravis", "start": 14, "end": 16}, {"entity_id": "20203465_3_Ent4", "role": "Effect", "text": "nausea , shortness of breath , azotemia , and hyperkalemia", "start": 19, "end": 29}, {"entity_id": "20203465_3_Ent8", "role": "Treatment_Route", "text": "intravenous", "start": 35, "end": 36}, {"entity_id": "20203465_3_Ent5", "role": "Treatment", "text": "intravenous immunoglobulin", "start": 35, "end": 37}, {"entity_id": "20203465_3_Ent6", "role": "Treatment_Drug", "text": "immunoglobulin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "20203465_3_Ent0", "text": "an 87 - year - old white woman with myasthenia gravis", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "20203465_3_Ent1", "text": "87 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20203465_3_Ent2", "text": "white", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "20203465_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20203465_3_Ent7", "text": "myasthenia gravis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "20203465_3_Ent4", "text": "nausea , shortness of breath , azotemia , and hyperkalemia", "entity_type": "Entity", "start": 19, "end": 29}, {"id": "20203465_3_Ent8", "text": "intravenous", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "20203465_3_Ent5", "text": "intravenous immunoglobulin", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "20203465_3_Ent6", "text": "immunoglobulin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "2022118_1", "wnd_id": "2022118_1_1", "text": "However , the use of lithium should be avoided with any patient who is purging , since it may exacerbate the loss of intracellular potassium , thereby increasing the risk of cardiac toxicity .", "tokens": ["However", ",", "the", "use", "of", "lithium", "should", "be", "avoided", "with", "any", "patient", "who", "is", "purging", ",", "since", "it", "may", "exacerbate", "the", "loss", "of", "intracellular", "potassium", ",", "thereby", "increasing", "the", "risk", "of", "cardiac", "toxicity", "."], "event_mentions": [{"id": "2022118_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exacerbate", "start": 19, "end": 20}, "arguments": [{"entity_id": "2022118_1_Ent3", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "2022118_1_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "2022118_1_Ent0", "role": "Subject", "text": "patient who is purging", "start": 11, "end": 15}, {"entity_id": "2022118_1_Ent1", "role": "Effect", "text": "loss of intracellular potassium", "start": 21, "end": 25}, {"entity_id": "2022118_1_Ent2", "role": "Effect", "text": "increasing the risk of cardiac toxicity", "start": 27, "end": 33}]}], "entity_mentions": [{"id": "2022118_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2022118_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2022118_1_Ent0", "text": "patient who is purging", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "2022118_1_Ent1", "text": "loss of intracellular potassium", "entity_type": "Entity", "start": 21, "end": 25}, {"id": "2022118_1_Ent2", "text": "increasing the risk of cardiac toxicity", "entity_type": "Entity", "start": 27, "end": 33}], "lang": "en"}
{"doc_id": "20234160_1", "wnd_id": "20234160_1_1", "text": "Severe vancomycin - induced anaphylactic reaction .", "tokens": ["Severe", "vancomycin", "-", "induced", "anaphylactic", "reaction", "."], "event_mentions": [{"id": "20234160_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "20234160_1_Ent1", "role": "Treatment", "text": "vancomycin", "start": 1, "end": 2}, {"entity_id": "20234160_1_Ent2", "role": "Treatment_Drug", "text": "vancomycin", "start": 1, "end": 2}, {"entity_id": "20234160_1_Ent0", "role": "Effect", "text": "anaphylactic reaction", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "20234160_1_Ent1", "text": "vancomycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20234160_1_Ent2", "text": "vancomycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "20234160_1_Ent0", "text": "anaphylactic reaction", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "20234160_2", "wnd_id": "20234160_2_1", "text": "Vancomycin is widely used against methicillin - resistant Staphylococcus aureus infections , but it is associated with many adverse effects such as nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis .", "tokens": ["Vancomycin", "is", "widely", "used", "against", "methicillin", "-", "resistant", "Staphylococcus", "aureus", "infections", ",", "but", "it", "is", "associated", "with", "many", "adverse", "effects", "such", "as", "nephrotoxicity", ",", "ototoxicity", ",", "gastrointestinal", "disturbances", ",", "blood", "disorders", ",", "and", "two", "types", "of", "hypersensitivity", "reactions", "-", "an", "anaphylactoid", "reaction", "known", "as", "\"", "red", "man", "syndrome", "\"", "and", "anaphylaxis", "."], "event_mentions": [{"id": "20234160_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "20234160_2_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "20234160_2_Ent3", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "20234160_2_Ent2", "role": "Treatment_Disorder", "text": "methicillin - resistant Staphylococcus aureus infections", "start": 5, "end": 11}, {"entity_id": "20234160_2_Ent0", "role": "Effect", "text": "nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis", "start": 22, "end": 51}]}], "entity_mentions": [{"id": "20234160_2_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20234160_2_Ent3", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20234160_2_Ent2", "text": "methicillin - resistant Staphylococcus aureus infections", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "20234160_2_Ent0", "text": "nephrotoxicity , ototoxicity , gastrointestinal disturbances , blood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as \" red man syndrome \" and anaphylaxis", "entity_type": "Entity", "start": 22, "end": 51}], "lang": "en"}
{"doc_id": "2028358_1", "wnd_id": "2028358_1_1", "text": "Four patients in whom pulmonary oedema developed during tocolysis with hexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed .", "tokens": ["Four", "patients", "in", "whom", "pulmonary", "oedema", "developed", "during", "tocolysis", "with", "hexoprenaline", "are", "described", "and", "the", "aetiological", "factors", "and", "pathogenesis", "of", "this", "potentially", "lethal", "complication", "discussed", "."], "event_mentions": [{"id": "2028358_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "2028358_1_Ent1", "role": "Subject_Population", "text": "Four", "start": 0, "end": 1}, {"entity_id": "2028358_1_Ent0", "role": "Subject", "text": "Four patients", "start": 0, "end": 2}, {"entity_id": "2028358_1_Ent2", "role": "Effect", "text": "pulmonary oedema", "start": 4, "end": 6}, {"entity_id": "2028358_1_Ent3", "role": "Treatment", "text": "tocolysis with hexoprenaline", "start": 8, "end": 11}, {"entity_id": "2028358_1_Ent4", "role": "Treatment_Drug", "text": "hexoprenaline", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "2028358_1_Ent1", "text": "Four", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2028358_1_Ent0", "text": "Four patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2028358_1_Ent2", "text": "pulmonary oedema", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2028358_1_Ent3", "text": "tocolysis with hexoprenaline", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2028358_1_Ent4", "text": "hexoprenaline", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20298401_10", "wnd_id": "20298401_10_1", "text": "CONCLUSION : Our case shows a fatal side effect of erlotinib .", "tokens": ["CONCLUSION", ":", "Our", "case", "shows", "a", "fatal", "side", "effect", "of", "erlotinib", "."], "event_mentions": [{"id": "20298401_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 9, "end": 10}, "arguments": [{"entity_id": "20298401_10_Ent0", "role": "Effect", "text": "side effect", "start": 7, "end": 9}, {"entity_id": "20298401_10_Ent1", "role": "Treatment", "text": "erlotinib", "start": 10, "end": 11}, {"entity_id": "20298401_10_Ent2", "role": "Treatment_Drug", "text": "erlotinib", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20298401_10_Ent0", "text": "side effect", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20298401_10_Ent1", "text": "erlotinib", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20298401_10_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20298401_7", "wnd_id": "20298401_7_1", "text": "Six days after taking erlotinib , a chest radiograph showed rapid progression of reticular infiltration in both lung fields .", "tokens": ["Six", "days", "after", "taking", "erlotinib", ",", "a", "chest", "radiograph", "showed", "rapid", "progression", "of", "reticular", "infiltration", "in", "both", "lung", "fields", "."], "event_mentions": [{"id": "20298401_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "20298401_7_Ent1", "role": "Treatment", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent3", "role": "Treatment_Time_elapsed", "text": "Six days", "start": 0, "end": 2}, {"entity_id": "20298401_7_Ent2", "role": "Treatment", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent4", "role": "Treatment_Drug", "text": "erlotinib", "start": 4, "end": 5}, {"entity_id": "20298401_7_Ent0", "role": "Effect", "text": "rapid progression of reticular infiltration in both lung fields", "start": 10, "end": 19}]}], "entity_mentions": [{"id": "20298401_7_Ent1", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent3", "text": "Six days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "20298401_7_Ent2", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent4", "text": "erlotinib", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "20298401_7_Ent0", "text": "rapid progression of reticular infiltration in both lung fields", "entity_type": "Entity", "start": 10, "end": 19}], "lang": "en"}
{"doc_id": "20367573_2", "wnd_id": "20367573_2_1", "text": "Thrombocytosis associated with enoxaparin : A very rare cause in newborns .", "tokens": ["Thrombocytosis", "associated", "with", "enoxaparin", ":", "A", "very", "rare", "cause", "in", "newborns", "."], "event_mentions": [{"id": "20367573_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "20367573_2_Ent2", "role": "Effect", "text": "Thrombocytosis", "start": 0, "end": 1}, {"entity_id": "20367573_2_Ent3", "role": "Treatment", "text": "enoxaparin", "start": 3, "end": 4}, {"entity_id": "20367573_2_Ent4", "role": "Treatment_Drug", "text": "enoxaparin", "start": 3, "end": 4}, {"entity_id": "20367573_2_Ent0", "role": "Subject", "text": "newborns", "start": 10, "end": 11}, {"entity_id": "20367573_2_Ent1", "role": "Subject_Age", "text": "newborns", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "20367573_2_Ent2", "text": "Thrombocytosis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20367573_2_Ent3", "text": "enoxaparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20367573_2_Ent4", "text": "enoxaparin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20367573_2_Ent0", "text": "newborns", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "20367573_2_Ent1", "text": "newborns", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "20378385_1", "wnd_id": "20378385_1_1", "text": "OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving adalimumab who developed fever , pancytopenia , splenomegaly , and extreme hyperferritinemia .", "tokens": ["OBJECTIVE", ":", "1", ")", "To", "describe", "a", "patient", "with", "rheumatoid", "arthritis", "receiving", "adalimumab", "who", "developed", "fever", ",", "pancytopenia", ",", "splenomegaly", ",", "and", "extreme", "hyperferritinemia", "."], "event_mentions": [{"id": "20378385_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 14, "end": 15}, "arguments": [{"entity_id": "20378385_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 6, "end": 11}, {"entity_id": "20378385_1_Ent1", "role": "Subject_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}, {"entity_id": "20378385_1_Ent3", "role": "Treatment", "text": "adalimumab", "start": 12, "end": 13}, {"entity_id": "20378385_1_Ent4", "role": "Treatment_Drug", "text": "adalimumab", "start": 12, "end": 13}, {"entity_id": "20378385_1_Ent2", "role": "Effect", "text": "fever , pancytopenia , splenomegaly , and extreme hyperferritinemia", "start": 15, "end": 24}]}], "entity_mentions": [{"id": "20378385_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "20378385_1_Ent1", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "20378385_1_Ent3", "text": "adalimumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20378385_1_Ent4", "text": "adalimumab", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "20378385_1_Ent2", "text": "fever , pancytopenia , splenomegaly , and extreme hyperferritinemia", "entity_type": "Entity", "start": 15, "end": 24}], "lang": "en"}
{"doc_id": "20397038_1", "wnd_id": "20397038_1_1", "text": "Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe hydroxychloroquine retinopathy with 19 years follow - up .", "tokens": ["Normalization", "of", "generalized", "retinal", "function", "and", "progression", "of", "maculopathy", "after", "cessation", "of", "therapy", "in", "a", "case", "of", "severe", "hydroxychloroquine", "retinopathy", "with", "19", "years", "follow", "-", "up", "."], "event_mentions": [{"id": "20397038_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "20397038_1_Ent1", "role": "Effect", "text": "Normalization of generalized retinal function and progression of maculopathy", "start": 0, "end": 9}, {"entity_id": "20397038_1_Ent2", "role": "Treatment", "text": "cessation of therapy", "start": 10, "end": 13}, {"entity_id": "20397038_1_Ent0", "role": "Subject", "text": "a case of severe hydroxychloroquine retinopathy", "start": 14, "end": 20}, {"entity_id": "20397038_1_Ent3", "role": "Treatment", "text": "hydroxychloroquine", "start": 18, "end": 19}, {"entity_id": "20397038_1_Ent4", "role": "Treatment_Drug", "text": "hydroxychloroquine", "start": 18, "end": 19}, {"entity_id": "20397038_1_Ent5", "role": "Treatment_Disorder", "text": "hydroxychloroquine retinopathy", "start": 18, "end": 20}, {"entity_id": "20397038_1_Ent6", "role": "Treatment_Time_elapsed", "text": "19 years", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "20397038_1_Ent1", "text": "Normalization of generalized retinal function and progression of maculopathy", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "20397038_1_Ent2", "text": "cessation of therapy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "20397038_1_Ent0", "text": "a case of severe hydroxychloroquine retinopathy", "entity_type": "Entity", "start": 14, "end": 20}, {"id": "20397038_1_Ent3", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20397038_1_Ent4", "text": "hydroxychloroquine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "20397038_1_Ent5", "text": "hydroxychloroquine retinopathy", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "20397038_1_Ent6", "text": "19 years", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "2051906_2", "wnd_id": "2051906_2_1", "text": "It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .", "tokens": ["It", "is", "believed", "that", "this", "is", "the", "first", "reported", "case", "of", "reversible", "azathioprine", "-", "induced", "cholestasis", "associated", "with", "histological", "evidence", "of", "bile", "duct", "injury", "."], "event_mentions": [{"id": "2051906_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "2051906_2_Ent1", "role": "Treatment", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "2051906_2_Ent2", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "2051906_2_Ent0", "role": "Effect", "text": "cholestasis", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "2051906_2_Ent1", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2051906_2_Ent2", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2051906_2_Ent0", "text": "cholestasis", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "2063999_1", "wnd_id": "2063999_1_1", "text": "A case of the Rett syndrome with acute encephalopathy induced during calcium hopantenate treatment .", "tokens": ["A", "case", "of", "the", "Rett", "syndrome", "with", "acute", "encephalopathy", "induced", "during", "calcium", "hopantenate", "treatment", "."], "event_mentions": [{"id": "2063999_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2063999_1_Ent0", "role": "Subject", "text": "A case of the Rett syndrome", "start": 0, "end": 6}, {"entity_id": "2063999_1_Ent4", "role": "Treatment_Disorder", "text": "Rett syndrome", "start": 4, "end": 6}, {"entity_id": "2063999_1_Ent1", "role": "Effect", "text": "acute encephalopathy", "start": 7, "end": 9}, {"entity_id": "2063999_1_Ent3", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 11, "end": 13}, {"entity_id": "2063999_1_Ent2", "role": "Treatment", "text": "calcium hopantenate treatment", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "2063999_1_Ent0", "text": "A case of the Rett syndrome", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2063999_1_Ent4", "text": "Rett syndrome", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2063999_1_Ent1", "text": "acute encephalopathy", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2063999_1_Ent3", "text": "calcium hopantenate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "2063999_1_Ent2", "text": "calcium hopantenate treatment", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "20666169_1", "wnd_id": "20666169_1_1", "text": "Atorvastatin induced multiple organ failure .", "tokens": ["Atorvastatin", "induced", "multiple", "organ", "failure", "."], "event_mentions": [{"id": "20666169_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 1, "end": 2}, "arguments": [{"entity_id": "20666169_1_Ent1", "role": "Treatment", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "20666169_1_Ent2", "role": "Treatment_Drug", "text": "Atorvastatin", "start": 0, "end": 1}, {"entity_id": "20666169_1_Ent0", "role": "Effect", "text": "multiple organ failure", "start": 2, "end": 5}]}], "entity_mentions": [{"id": "20666169_1_Ent1", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20666169_1_Ent2", "text": "Atorvastatin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "20666169_1_Ent0", "text": "multiple organ failure", "entity_type": "Entity", "start": 2, "end": 5}], "lang": "en"}
{"doc_id": "20925534_12", "wnd_id": "20925534_12_1", "text": "A total of 109 patients had a cardiovascular event , with event rates of 4.9 % with omeprazole and 5.7 % with placebo ( hazard ratio with omeprazole , 0.99 ; 95 % CI , 0.68 to 1.44 ; P = 0.96 ) ; high - risk subgroups did not show significant heterogeneity .", "tokens": ["A", "total", "of", "109", "patients", "had", "a", "cardiovascular", "event", ",", "with", "event", "rates", "of", "4.9", "%", "with", "omeprazole", "and", "5.7", "%", "with", "placebo", "(", "hazard", "ratio", "with", "omeprazole", ",", "0.99", ";", "95", "%", "CI", ",", "0.68", "to", "1.44", ";", "P", "=", "0.96", ")", ";", "high", "-", "risk", "subgroups", "did", "not", "show", "significant", "heterogeneity", "."], "event_mentions": [{"id": "20925534_12_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 5, "end": 6}, "arguments": [{"entity_id": "20925534_12_Ent1", "role": "Subject_Population", "text": "109", "start": 3, "end": 4}, {"entity_id": "20925534_12_Ent0", "role": "Subject", "text": "109 patients", "start": 3, "end": 5}, {"entity_id": "20925534_12_Ent2", "role": "Effect", "text": "cardiovascular event", "start": 7, "end": 9}, {"entity_id": "20925534_12_Ent3", "role": "Treatment", "text": "4.9 % with omeprazole and 5.7 % with placebo", "start": 14, "end": 23}, {"entity_id": "20925534_12_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 17, "end": 18}, {"entity_id": "20925534_12_Ent5", "role": "Treatment_Drug", "text": "placebo", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "20925534_12_Ent1", "text": "109", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "20925534_12_Ent0", "text": "109 patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "20925534_12_Ent2", "text": "cardiovascular event", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "20925534_12_Ent3", "text": "4.9 % with omeprazole and 5.7 % with placebo", "entity_type": "Entity", "start": 14, "end": 23}, {"id": "20925534_12_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "20925534_12_Ent5", "text": "placebo", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "2104570_1", "wnd_id": "2104570_1_1", "text": "Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma .", "tokens": ["Secondary", "hematologic", "neoplasm", "after", "intravesical", "chemotherapy", "for", "superficial", "bladder", "carcinoma", "."], "event_mentions": [{"id": "2104570_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 3, "end": 4}, "arguments": [{"entity_id": "2104570_1_Ent0", "role": "Effect", "text": "Secondary hematologic neoplasm", "start": 0, "end": 3}, {"entity_id": "2104570_1_Ent3", "role": "Treatment_Drug", "text": "intravesical", "start": 4, "end": 5}, {"entity_id": "2104570_1_Ent1", "role": "Treatment", "text": "intravesical chemotherapy", "start": 4, "end": 6}, {"entity_id": "2104570_1_Ent4", "role": "Treatment_Route", "text": "chemotherapy", "start": 5, "end": 6}, {"entity_id": "2104570_1_Ent2", "role": "Treatment_Disorder", "text": "bladder carcinoma", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "2104570_1_Ent0", "text": "Secondary hematologic neoplasm", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2104570_1_Ent3", "text": "intravesical", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2104570_1_Ent1", "text": "intravesical chemotherapy", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2104570_1_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2104570_1_Ent2", "text": "bladder carcinoma", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2116935_1", "wnd_id": "2116935_1_1", "text": "Splenic hemorrhage : a complication of tissue plasminogen activator treatment .", "tokens": ["Splenic", "hemorrhage", ":", "a", "complication", "of", "tissue", "plasminogen", "activator", "treatment", "."], "event_mentions": [{"id": "2116935_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication of", "start": 4, "end": 6}, "arguments": [{"entity_id": "2116935_1_Ent0", "role": "Effect", "text": "Splenic hemorrhage", "start": 0, "end": 2}, {"entity_id": "2116935_1_Ent2", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 6, "end": 9}, {"entity_id": "2116935_1_Ent1", "role": "Treatment", "text": "tissue plasminogen activator treatment", "start": 6, "end": 10}]}], "entity_mentions": [{"id": "2116935_1_Ent0", "text": "Splenic hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2116935_1_Ent2", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2116935_1_Ent1", "text": "tissue plasminogen activator treatment", "entity_type": "Entity", "start": 6, "end": 10}], "lang": "en"}
{"doc_id": "21350204_1", "wnd_id": "21350204_1_1", "text": "Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator .", "tokens": ["Subtherapeutic", "warfarin", "is", "not", "associated", "with", "increased", "hemorrhage", "rates", "in", "ischemic", "strokes", "treated", "with", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "21350204_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "21350204_1_Ent1", "role": "Treatment", "text": "Subtherapeutic warfarin", "start": 0, "end": 2}, {"entity_id": "21350204_1_Ent5", "role": "Treatment_Drug", "text": "warfarin", "start": 1, "end": 2}, {"entity_id": "21350204_1_Ent6", "role": "Combination_Drug", "text": "warfarin", "start": 1, "end": 2}, {"entity_id": "21350204_1_Ent0", "role": "Effect", "text": "increased hemorrhage rates", "start": 6, "end": 9}, {"entity_id": "21350204_1_Ent3", "role": "Treatment_Disorder", "text": "ischemic strokes", "start": 10, "end": 12}, {"entity_id": "21350204_1_Ent2", "role": "Treatment", "text": "treated with tissue plasminogen activator", "start": 12, "end": 17}, {"entity_id": "21350204_1_Ent4", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 14, "end": 17}, {"entity_id": "21350204_1_Ent7", "role": "Combination_Drug", "text": "tissue plasminogen activator", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "21350204_1_Ent1", "text": "Subtherapeutic warfarin", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21350204_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21350204_1_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "21350204_1_Ent0", "text": "increased hemorrhage rates", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "21350204_1_Ent3", "text": "ischemic strokes", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "21350204_1_Ent2", "text": "treated with tissue plasminogen activator", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "21350204_1_Ent4", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "21350204_1_Ent7", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "2144305_1", "wnd_id": "2144305_1_1", "text": "A unique case of a transient , nonpigmenting fixed drug eruption caused by the radiopaque contrast medium iothalamate is reported .", "tokens": ["A", "unique", "case", "of", "a", "transient", ",", "nonpigmenting", "fixed", "drug", "eruption", "caused", "by", "the", "radiopaque", "contrast", "medium", "iothalamate", "is", "reported", "."], "event_mentions": [{"id": "2144305_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 11, "end": 12}, "arguments": [{"entity_id": "2144305_1_Ent0", "role": "Effect", "text": "a transient , nonpigmenting fixed drug eruption", "start": 4, "end": 11}, {"entity_id": "2144305_1_Ent1", "role": "Treatment", "text": "iothalamate", "start": 17, "end": 18}, {"entity_id": "2144305_1_Ent2", "role": "Treatment_Drug", "text": "iothalamate", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "2144305_1_Ent0", "text": "a transient , nonpigmenting fixed drug eruption", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "2144305_1_Ent1", "text": "iothalamate", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2144305_1_Ent2", "text": "iothalamate", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "21448111_6", "wnd_id": "21448111_6_1", "text": "We can conclude that in this case , as in many others , akathisia as a possible adverse effect of psychopharmacs was very hard to identify .", "tokens": ["We", "can", "conclude", "that", "in", "this", "case", ",", "as", "in", "many", "others", ",", "akathisia", "as", "a", "possible", "adverse", "effect", "of", "psychopharmacs", "was", "very", "hard", "to", "identify", "."], "event_mentions": [{"id": "21448111_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse effect", "start": 17, "end": 19}, "arguments": [{"entity_id": "21448111_6_Ent0", "role": "Subject", "text": "this case", "start": 5, "end": 7}, {"entity_id": "21448111_6_Ent1", "role": "Effect", "text": "akathisia", "start": 13, "end": 14}, {"entity_id": "21448111_6_Ent2", "role": "Treatment", "text": "psychopharmacs", "start": 20, "end": 21}, {"entity_id": "21448111_6_Ent3", "role": "Treatment_Drug", "text": "psychopharmacs", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "21448111_6_Ent0", "text": "this case", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "21448111_6_Ent1", "text": "akathisia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "21448111_6_Ent2", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "21448111_6_Ent3", "text": "psychopharmacs", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "21515865_4", "wnd_id": "21515865_4_1", "text": "On the day before this visit , he had received the third of six serial weekly BCG bladder instillations for the treatment of bladder cancer .", "tokens": ["On", "the", "day", "before", "this", "visit", ",", "he", "had", "received", "the", "third", "of", "six", "serial", "weekly", "BCG", "bladder", "instillations", "for", "the", "treatment", "of", "bladder", "cancer", "."], "event_mentions": [{"id": "21515865_4_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 9, "end": 10}, "arguments": [{"entity_id": "21515865_4_Ent0", "role": "Subject", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent2", "role": "Subject_Gender", "text": "he", "start": 7, "end": 8}, {"entity_id": "21515865_4_Ent3", "role": "Treatment", "text": "the third of six serial weekly BCG bladder instillations", "start": 10, "end": 19}, {"entity_id": "21515865_4_Ent7", "role": "Treatment_Freq", "text": "weekly", "start": 15, "end": 16}, {"entity_id": "21515865_4_Ent6", "role": "Treatment_Drug", "text": "BCG", "start": 16, "end": 17}, {"entity_id": "21515865_4_Ent4", "role": "Treatment_Route", "text": "bladder instillations", "start": 17, "end": 19}, {"entity_id": "21515865_4_Ent1", "role": "Subject", "text": "bladder cancer", "start": 23, "end": 25}, {"entity_id": "21515865_4_Ent5", "role": "Treatment_Disorder", "text": "bladder cancer", "start": 23, "end": 25}]}], "entity_mentions": [{"id": "21515865_4_Ent0", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent2", "text": "he", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21515865_4_Ent3", "text": "the third of six serial weekly BCG bladder instillations", "entity_type": "Entity", "start": 10, "end": 19}, {"id": "21515865_4_Ent7", "text": "weekly", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21515865_4_Ent6", "text": "BCG", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "21515865_4_Ent4", "text": "bladder instillations", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "21515865_4_Ent1", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "21515865_4_Ent5", "text": "bladder cancer", "entity_type": "Entity", "start": 23, "end": 25}], "lang": "en"}
{"doc_id": "2154663_1", "wnd_id": "2154663_1_1", "text": "Aminoglutethimide was discontinued until completion of radiotherapy , and the rash resolved .", "tokens": ["Aminoglutethimide", "was", "discontinued", "until", "completion", "of", "radiotherapy", ",", "and", "the", "rash", "resolved", "."], "event_mentions": [{"id": "2154663_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "and", "start": 8, "end": 9}, "arguments": [{"entity_id": "2154663_1_Ent2", "role": "Treatment_Drug", "text": "Aminoglutethimide", "start": 0, "end": 1}, {"entity_id": "2154663_1_Ent1", "role": "Treatment", "text": "Aminoglutethimide was discontinued until completion of radiotherapy", "start": 0, "end": 7}, {"entity_id": "2154663_1_Ent0", "role": "Effect", "text": "the rash resolved", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "2154663_1_Ent2", "text": "Aminoglutethimide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2154663_1_Ent1", "text": "Aminoglutethimide was discontinued until completion of radiotherapy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "2154663_1_Ent0", "text": "the rash resolved", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "21630612_4", "wnd_id": "21630612_4_1", "text": "We report a case of severe simvastatin - induced rhabdomyolysis triggered by the addition of amiodarone to previously well - tolerated chronic statin therapy .", "tokens": ["We", "report", "a", "case", "of", "severe", "simvastatin", "-", "induced", "rhabdomyolysis", "triggered", "by", "the", "addition", "of", "amiodarone", "to", "previously", "well", "-", "tolerated", "chronic", "statin", "therapy", "."], "event_mentions": [{"id": "21630612_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "21630612_4_Ent1", "role": "Treatment", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent3", "role": "Treatment_Drug", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent8", "role": "Combination_Drug", "text": "simvastatin", "start": 6, "end": 7}, {"entity_id": "21630612_4_Ent0", "role": "Effect", "text": "rhabdomyolysis", "start": 9, "end": 10}, {"entity_id": "21630612_4_Ent2", "role": "Treatment", "text": "the addition of amiodarone to previously well - tolerated chronic statin therapy", "start": 12, "end": 24}, {"entity_id": "21630612_4_Ent4", "role": "Treatment_Drug", "text": "amiodarone", "start": 15, "end": 16}, {"entity_id": "21630612_4_Ent7", "role": "Combination_Drug", "text": "amiodarone", "start": 15, "end": 16}, {"entity_id": "21630612_4_Ent6", "role": "Treatment_Time_elapsed", "text": "chronic", "start": 21, "end": 22}, {"entity_id": "21630612_4_Ent5", "role": "Treatment_Drug", "text": "statin", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "21630612_4_Ent1", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent3", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent8", "text": "simvastatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21630612_4_Ent0", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21630612_4_Ent2", "text": "the addition of amiodarone to previously well - tolerated chronic statin therapy", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "21630612_4_Ent4", "text": "amiodarone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_4_Ent7", "text": "amiodarone", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "21630612_4_Ent6", "text": "chronic", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "21630612_4_Ent5", "text": "statin", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "21658326_5", "wnd_id": "21658326_5_1", "text": "To date , no relation has ever been suggested between TNF - alpha inhibitors and increased susceptibility to developing exaggerated ASRs with imiquimod .", "tokens": ["To", "date", ",", "no", "relation", "has", "ever", "been", "suggested", "between", "TNF", "-", "alpha", "inhibitors", "and", "increased", "susceptibility", "to", "developing", "exaggerated", "ASRs", "with", "imiquimod", "."], "event_mentions": [{"id": "21658326_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 18, "end": 19}, "arguments": [{"entity_id": "21658326_5_Ent1", "role": "Treatment", "text": "TNF - alpha inhibitors", "start": 10, "end": 14}, {"entity_id": "21658326_5_Ent3", "role": "Treatment_Drug", "text": "TNF - alpha inhibitors", "start": 10, "end": 14}, {"entity_id": "21658326_5_Ent5", "role": "Combination_Drug", "text": "TNF - alpha inhibitors", "start": 10, "end": 14}, {"entity_id": "21658326_5_Ent0", "role": "Effect", "text": "exaggerated ASRs", "start": 19, "end": 21}, {"entity_id": "21658326_5_Ent2", "role": "Treatment", "text": "imiquimod", "start": 22, "end": 23}, {"entity_id": "21658326_5_Ent4", "role": "Treatment_Drug", "text": "imiquimod", "start": 22, "end": 23}, {"entity_id": "21658326_5_Ent6", "role": "Combination_Drug", "text": "imiquimod", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "21658326_5_Ent1", "text": "TNF - alpha inhibitors", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "21658326_5_Ent3", "text": "TNF - alpha inhibitors", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "21658326_5_Ent5", "text": "TNF - alpha inhibitors", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "21658326_5_Ent0", "text": "exaggerated ASRs", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "21658326_5_Ent2", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21658326_5_Ent4", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21658326_5_Ent6", "text": "imiquimod", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "21712512_6", "wnd_id": "21712512_6_1", "text": "Three days after starting fluconazole , she developed polyuria and polydipsia and was found to have severe hyperglycemia , which led to the diagnosis of Cushing syndrome .", "tokens": ["Three", "days", "after", "starting", "fluconazole", ",", "she", "developed", "polyuria", "and", "polydipsia", "and", "was", "found", "to", "have", "severe", "hyperglycemia", ",", "which", "led", "to", "the", "diagnosis", "of", "Cushing", "syndrome", "."], "event_mentions": [{"id": "21712512_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "21712512_6_Ent3", "role": "Treatment_Time_elapsed", "text": "Three days", "start": 0, "end": 2}, {"entity_id": "21712512_6_Ent1", "role": "Treatment", "text": "Three days after starting fluconazole", "start": 0, "end": 5}, {"entity_id": "21712512_6_Ent2", "role": "Treatment_Drug", "text": "fluconazole", "start": 4, "end": 5}, {"entity_id": "21712512_6_Ent0", "role": "Effect", "text": "polyuria and polydipsia and was found to have severe hyperglycemia , which led to the diagnosis of Cushing syndrome", "start": 8, "end": 27}]}], "entity_mentions": [{"id": "21712512_6_Ent3", "text": "Three days", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "21712512_6_Ent1", "text": "Three days after starting fluconazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "21712512_6_Ent2", "text": "fluconazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21712512_6_Ent0", "text": "polyuria and polydipsia and was found to have severe hyperglycemia , which led to the diagnosis of Cushing syndrome", "entity_type": "Entity", "start": 8, "end": 27}], "lang": "en"}
{"doc_id": "21751542_4", "wnd_id": "21751542_4_1", "text": "Angiotensin converting enzyme blockers and their influence on the endothelial dysfunction , but the risk of hyperpotassemia are showed .", "tokens": ["Angiotensin", "converting", "enzyme", "blockers", "and", "their", "influence", "on", "the", "endothelial", "dysfunction", ",", "but", "the", "risk", "of", "hyperpotassemia", "are", "showed", "."], "event_mentions": [{"id": "21751542_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 18, "end": 19}, "arguments": [{"entity_id": "21751542_4_Ent1", "role": "Treatment", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent2", "role": "Treatment_Drug", "text": "Angiotensin converting enzyme blockers", "start": 0, "end": 4}, {"entity_id": "21751542_4_Ent0", "role": "Effect", "text": "hyperpotassemia", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "21751542_4_Ent1", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent2", "text": "Angiotensin converting enzyme blockers", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21751542_4_Ent0", "text": "hyperpotassemia", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "21751666_5", "wnd_id": "21751666_5_1", "text": "Oseltamivir was effective for post - exposure prophylaxis of H1N1 in close contact .", "tokens": ["Oseltamivir", "was", "effective", "for", "post", "-", "exposure", "prophylaxis", "of", "H1N1", "in", "close", "contact", "."], "event_mentions": [{"id": "21751666_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "post - exposure prophylaxis", "start": 4, "end": 8}, "arguments": [{"entity_id": "21751666_5_Ent0", "role": "Treatment", "text": "Oseltamivir", "start": 0, "end": 1}, {"entity_id": "21751666_5_Ent2", "role": "Treatment_Drug", "text": "Oseltamivir", "start": 0, "end": 1}, {"entity_id": "21751666_5_Ent1", "role": "Treatment_Disorder", "text": "H1N1", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "21751666_5_Ent0", "text": "Oseltamivir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21751666_5_Ent2", "text": "Oseltamivir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "21751666_5_Ent1", "text": "H1N1", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "21802143_1", "wnd_id": "21802143_1_1", "text": "Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations .", "tokens": ["Hepatic", "drug", "interaction", "between", "tacrolimus", "and", "lansoprazole", "in", "a", "bone", "marrow", "transplant", "patient", "receiving", "voriconazole", "and", "harboring", "CYP2C19", "and", "CYP3A5", "heterozygous", "mutations", "."], "event_mentions": [{"id": "21802143_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "between", "start": 3, "end": 4}, "arguments": [{"entity_id": "21802143_1_Ent2", "role": "Effect", "text": "Hepatic drug interaction", "start": 0, "end": 3}, {"entity_id": "21802143_1_Ent6", "role": "Treatment_Drug", "text": "tacrolimus", "start": 4, "end": 5}, {"entity_id": "21802143_1_Ent9", "role": "Combination_Drug", "text": "tacrolimus", "start": 4, "end": 5}, {"entity_id": "21802143_1_Ent3", "role": "Treatment", "text": "tacrolimus and lansoprazole", "start": 4, "end": 7}, {"entity_id": "21802143_1_Ent7", "role": "Treatment_Drug", "text": "lansoprazole", "start": 6, "end": 7}, {"entity_id": "21802143_1_Ent10", "role": "Combination_Drug", "text": "lansoprazole", "start": 6, "end": 7}, {"entity_id": "21802143_1_Ent0", "role": "Subject", "text": "a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations", "start": 8, "end": 22}, {"entity_id": "21802143_1_Ent5", "role": "Treatment_Disorder", "text": "bone marrow transplant", "start": 9, "end": 12}, {"entity_id": "21802143_1_Ent4", "role": "Treatment", "text": "voriconazole", "start": 14, "end": 15}, {"entity_id": "21802143_1_Ent8", "role": "Treatment_Drug", "text": "voriconazole", "start": 14, "end": 15}, {"entity_id": "21802143_1_Ent11", "role": "Combination_Drug", "text": "voriconazole", "start": 14, "end": 15}, {"entity_id": "21802143_1_Ent1", "role": "Subject_Disorder", "text": "CYP2C19 and CYP3A5 heterozygous mutations", "start": 17, "end": 22}]}], "entity_mentions": [{"id": "21802143_1_Ent2", "text": "Hepatic drug interaction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21802143_1_Ent6", "text": "tacrolimus", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21802143_1_Ent9", "text": "tacrolimus", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "21802143_1_Ent3", "text": "tacrolimus and lansoprazole", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "21802143_1_Ent7", "text": "lansoprazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21802143_1_Ent10", "text": "lansoprazole", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21802143_1_Ent0", "text": "a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations", "entity_type": "Entity", "start": 8, "end": 22}, {"id": "21802143_1_Ent5", "text": "bone marrow transplant", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "21802143_1_Ent4", "text": "voriconazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21802143_1_Ent8", "text": "voriconazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21802143_1_Ent11", "text": "voriconazole", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "21802143_1_Ent1", "text": "CYP2C19 and CYP3A5 heterozygous mutations", "entity_type": "Entity", "start": 17, "end": 22}], "lang": "en"}
{"doc_id": "21802143_5", "wnd_id": "21802143_5_1", "text": "An 18 - year - old Japanese man weighing 53 kg with an anaplastic large cell lymphoma received continuous IV administration of TAC as post - transplantation prophylaxis against graft - versus - host disease ( GVHD ) after an allogeneic bone marrow transplantation ( BMT ) .", "tokens": ["An", "18", "-", "year", "-", "old", "Japanese", "man", "weighing", "53", "kg", "with", "an", "anaplastic", "large", "cell", "lymphoma", "received", "continuous", "IV", "administration", "of", "TAC", "as", "post", "-", "transplantation", "prophylaxis", "against", "graft", "-", "versus", "-", "host", "disease", "(", "GVHD", ")", "after", "an", "allogeneic", "bone", "marrow", "transplantation", "(", "BMT", ")", "."], "event_mentions": [{"id": "21802143_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylaxis", "start": 27, "end": 28}, "arguments": [{"entity_id": "21802143_5_Ent0", "role": "Subject", "text": "An 18 - year - old Japanese man weighing 53 kg with an anaplastic large cell lymphoma", "start": 0, "end": 17}, {"entity_id": "21802143_5_Ent2", "role": "Subject_Age", "text": "18 - year - old", "start": 1, "end": 6}, {"entity_id": "21802143_5_Ent1", "role": "Subject_Race", "text": "Japanese", "start": 6, "end": 7}, {"entity_id": "21802143_5_Ent3", "role": "Subject_Gender", "text": "man", "start": 7, "end": 8}, {"entity_id": "21802143_5_Ent7", "role": "Treatment_Disorder", "text": "cell lymphoma", "start": 15, "end": 17}, {"entity_id": "21802143_5_Ent5", "role": "Treatment", "text": "received continuous IV administration of TAC", "start": 17, "end": 23}, {"entity_id": "21802143_5_Ent9", "role": "Treatment_Route", "text": "IV administration", "start": 19, "end": 21}, {"entity_id": "21802143_5_Ent8", "role": "Treatment_Drug", "text": "TAC", "start": 22, "end": 23}, {"entity_id": "21802143_5_Ent4", "role": "Effect", "text": "graft - versus - host disease ( GVHD )", "start": 29, "end": 38}, {"entity_id": "21802143_5_Ent6", "role": "Treatment", "text": "allogeneic bone marrow transplantation ( BMT )", "start": 40, "end": 47}]}], "entity_mentions": [{"id": "21802143_5_Ent0", "text": "An 18 - year - old Japanese man weighing 53 kg with an anaplastic large cell lymphoma", "entity_type": "Entity", "start": 0, "end": 17}, {"id": "21802143_5_Ent2", "text": "18 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "21802143_5_Ent1", "text": "Japanese", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "21802143_5_Ent3", "text": "man", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21802143_5_Ent7", "text": "cell lymphoma", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "21802143_5_Ent5", "text": "received continuous IV administration of TAC", "entity_type": "Entity", "start": 17, "end": 23}, {"id": "21802143_5_Ent9", "text": "IV administration", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "21802143_5_Ent8", "text": "TAC", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "21802143_5_Ent4", "text": "graft - versus - host disease ( GVHD )", "entity_type": "Entity", "start": 29, "end": 38}, {"id": "21802143_5_Ent6", "text": "allogeneic bone marrow transplantation ( BMT )", "entity_type": "Entity", "start": 40, "end": 47}], "lang": "en"}
{"doc_id": "21887897_2", "wnd_id": "21887897_2_1", "text": "A fatal poisoning case involving etizolam , phenobarbital , promethazine and chlorpromazine is presented .", "tokens": ["A", "fatal", "poisoning", "case", "involving", "etizolam", ",", "phenobarbital", ",", "promethazine", "and", "chlorpromazine", "is", "presented", "."], "event_mentions": [{"id": "21887897_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "involving", "start": 4, "end": 5}, "arguments": [{"entity_id": "21887897_2_Ent1", "role": "Effect", "text": "A fatal poisoning", "start": 0, "end": 3}, {"entity_id": "21887897_2_Ent0", "role": "Subject", "text": "A fatal poisoning case", "start": 0, "end": 4}, {"entity_id": "21887897_2_Ent3", "role": "Treatment_Drug", "text": "etizolam", "start": 5, "end": 6}, {"entity_id": "21887897_2_Ent2", "role": "Treatment", "text": "etizolam , phenobarbital , promethazine and chlorpromazine", "start": 5, "end": 12}, {"entity_id": "21887897_2_Ent4", "role": "Treatment_Drug", "text": "phenobarbital", "start": 7, "end": 8}, {"entity_id": "21887897_2_Ent5", "role": "Treatment_Drug", "text": "promethazine", "start": 9, "end": 10}, {"entity_id": "21887897_2_Ent6", "role": "Treatment_Drug", "text": "chlorpromazine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "21887897_2_Ent1", "text": "A fatal poisoning", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "21887897_2_Ent0", "text": "A fatal poisoning case", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "21887897_2_Ent3", "text": "etizolam", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "21887897_2_Ent2", "text": "etizolam , phenobarbital , promethazine and chlorpromazine", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "21887897_2_Ent4", "text": "phenobarbital", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "21887897_2_Ent5", "text": "promethazine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "21887897_2_Ent6", "text": "chlorpromazine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "2196696_2", "wnd_id": "2196696_2_1", "text": "Our patient had headache , mild fever , nausea , vomiting , rash , and eosinophilia after 3 weeks of disulfiram therapy .", "tokens": ["Our", "patient", "had", "headache", ",", "mild", "fever", ",", "nausea", ",", "vomiting", ",", "rash", ",", "and", "eosinophilia", "after", "3", "weeks", "of", "disulfiram", "therapy", "."], "event_mentions": [{"id": "2196696_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "2196696_2_Ent0", "role": "Effect", "text": "headache , mild fever , nausea , vomiting , rash , and eosinophilia", "start": 3, "end": 16}, {"entity_id": "2196696_2_Ent3", "role": "Treatment_Time_elapsed", "text": "after 3 weeks", "start": 16, "end": 19}, {"entity_id": "2196696_2_Ent1", "role": "Treatment", "text": "after 3 weeks of disulfiram", "start": 16, "end": 21}, {"entity_id": "2196696_2_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2196696_2_Ent0", "text": "headache , mild fever , nausea , vomiting , rash , and eosinophilia", "entity_type": "Entity", "start": 3, "end": 16}, {"id": "2196696_2_Ent3", "text": "after 3 weeks", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2196696_2_Ent1", "text": "after 3 weeks of disulfiram", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "2196696_2_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "22010004_8", "wnd_id": "22010004_8_1", "text": "The mechanism of niacin - induced coagulopathy is theorized to be related to diminished coagulation factors , and limited data suggest that this may be more pronounced with extended - release niacin .", "tokens": ["The", "mechanism", "of", "niacin", "-", "induced", "coagulopathy", "is", "theorized", "to", "be", "related", "to", "diminished", "coagulation", "factors", ",", "and", "limited", "data", "suggest", "that", "this", "may", "be", "more", "pronounced", "with", "extended", "-", "release", "niacin", "."], "event_mentions": [{"id": "22010004_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "22010004_8_Ent1", "role": "Treatment", "text": "niacin", "start": 3, "end": 4}, {"entity_id": "22010004_8_Ent2", "role": "Treatment_Drug", "text": "niacin", "start": 3, "end": 4}, {"entity_id": "22010004_8_Ent0", "role": "Effect", "text": "coagulopathy", "start": 6, "end": 7}, {"entity_id": "22010004_8_Ent3", "role": "Treatment_Drug", "text": "extended - release niacin", "start": 28, "end": 32}]}], "entity_mentions": [{"id": "22010004_8_Ent1", "text": "niacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22010004_8_Ent2", "text": "niacin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "22010004_8_Ent0", "text": "coagulopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_8_Ent3", "text": "extended - release niacin", "entity_type": "Entity", "start": 28, "end": 32}], "lang": "en"}
{"doc_id": "22010004_9", "wnd_id": "22010004_9_1", "text": "Because of the described effects of niacin on the coagulation cascade and the possibility for pharmacokinetic interactions , there is a potential for synergistic coagulopathy when combined with warfarin therapy .", "tokens": ["Because", "of", "the", "described", "effects", "of", "niacin", "on", "the", "coagulation", "cascade", "and", "the", "possibility", "for", "pharmacokinetic", "interactions", ",", "there", "is", "a", "potential", "for", "synergistic", "coagulopathy", "when", "combined", "with", "warfarin", "therapy", "."], "event_mentions": [{"id": "22010004_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 21, "end": 22}, "arguments": [{"entity_id": "22010004_9_Ent1", "role": "Treatment", "text": "niacin", "start": 6, "end": 7}, {"entity_id": "22010004_9_Ent3", "role": "Treatment_Drug", "text": "niacin", "start": 6, "end": 7}, {"entity_id": "22010004_9_Ent6", "role": "Combination_Drug", "text": "niacin", "start": 6, "end": 7}, {"entity_id": "22010004_9_Ent0", "role": "Effect", "text": "synergistic coagulopathy", "start": 23, "end": 25}, {"entity_id": "22010004_9_Ent2", "role": "Treatment", "text": "combined with warfarin therapy", "start": 26, "end": 30}, {"entity_id": "22010004_9_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 28, "end": 29}, {"entity_id": "22010004_9_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "22010004_9_Ent1", "text": "niacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_9_Ent3", "text": "niacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_9_Ent6", "text": "niacin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22010004_9_Ent0", "text": "synergistic coagulopathy", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "22010004_9_Ent2", "text": "combined with warfarin therapy", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "22010004_9_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "22010004_9_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "2204409_1", "wnd_id": "2204409_1_1", "text": "An episode of leukoencephalopathy is reported in a 13 - year - old girl who , after standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate .", "tokens": ["An", "episode", "of", "leukoencephalopathy", "is", "reported", "in", "a", "13", "-", "year", "-", "old", "girl", "who", ",", "after", "standard", "radiotherapy", "for", "a", "posterior", "fossa", "medulloblastoma", ",", "received", "8", "treatments", "with", "a", "protocol", "containing", "a", "4", "-", "hour", "infusion", "of", "500", "mg", "/", "m2", "methotrexate", "and", "12", "mg", "intrathecal", "methotrexate", "."], "event_mentions": [{"id": "2204409_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "2204409_1_Ent3", "role": "Effect", "text": "leukoencephalopathy", "start": 3, "end": 4}, {"entity_id": "2204409_1_Ent1", "role": "Subject_Age", "text": "13 - year - old", "start": 8, "end": 13}, {"entity_id": "2204409_1_Ent0", "role": "Subject", "text": "13 - year - old girl who", "start": 8, "end": 15}, {"entity_id": "2204409_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 13, "end": 14}, {"entity_id": "2204409_1_Ent4", "role": "Treatment", "text": "standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate", "start": 17, "end": 48}, {"entity_id": "2204409_1_Ent5", "role": "Treatment_Drug", "text": "radiotherapy", "start": 18, "end": 19}, {"entity_id": "2204409_1_Ent8", "role": "Treatment_Route", "text": "infusion", "start": 36, "end": 37}, {"entity_id": "2204409_1_Ent9", "role": "Treatment_Dosage", "text": "500 mg / m2", "start": 38, "end": 42}, {"entity_id": "2204409_1_Ent6", "role": "Treatment_Drug", "text": "methotrexate", "start": 42, "end": 43}, {"entity_id": "2204409_1_Ent10", "role": "Treatment_Dosage", "text": "12 mg", "start": 44, "end": 46}, {"entity_id": "2204409_1_Ent7", "role": "Treatment_Drug", "text": "intrathecal methotrexate", "start": 46, "end": 48}]}], "entity_mentions": [{"id": "2204409_1_Ent3", "text": "leukoencephalopathy", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2204409_1_Ent1", "text": "13 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "2204409_1_Ent0", "text": "13 - year - old girl who", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "2204409_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2204409_1_Ent4", "text": "standard radiotherapy for a posterior fossa medulloblastoma , received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal methotrexate", "entity_type": "Entity", "start": 17, "end": 48}, {"id": "2204409_1_Ent5", "text": "radiotherapy", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "2204409_1_Ent8", "text": "infusion", "entity_type": "Entity", "start": 36, "end": 37}, {"id": "2204409_1_Ent9", "text": "500 mg / m2", "entity_type": "Entity", "start": 38, "end": 42}, {"id": "2204409_1_Ent6", "text": "methotrexate", "entity_type": "Entity", "start": 42, "end": 43}, {"id": "2204409_1_Ent10", "text": "12 mg", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "2204409_1_Ent7", "text": "intrathecal methotrexate", "entity_type": "Entity", "start": 46, "end": 48}], "lang": "en"}
{"doc_id": "2212262_1", "wnd_id": "2212262_1_1", "text": "Severe heparin associated thrombocytopenia is a rare complication of heparin therapy .", "tokens": ["Severe", "heparin", "associated", "thrombocytopenia", "is", "a", "rare", "complication", "of", "heparin", "therapy", "."], "event_mentions": [{"id": "2212262_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "2212262_1_Ent1", "role": "Treatment", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "2212262_1_Ent2", "role": "Treatment_Drug", "text": "heparin", "start": 1, "end": 2}, {"entity_id": "2212262_1_Ent0", "role": "Effect", "text": "thrombocytopenia", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2212262_1_Ent1", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2212262_1_Ent2", "text": "heparin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "2212262_1_Ent0", "text": "thrombocytopenia", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2224786_1", "wnd_id": "2224786_1_1", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related hemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate .", "tokens": ["A", "62", "-", "year", "-", "old", "woman", "who", "was", "being", "treated", "for", "squamous", "cell", "carcinoma", "of", "the", "head", "and", "neck", "developed", "a", "chemotherapy", "-", "related", "hemolytic", "-", "uremic", "syndrome", "during", "the", "second", "cycle", "of", "neoadjuvant", "chemotherapy", "consisting", "of", "cisplatin", ",", "bleomycin", ",", "and", "methotrexate", "."], "event_mentions": [{"id": "2224786_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2224786_1_Ent0", "role": "Subject", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck", "start": 0, "end": 20}, {"entity_id": "2224786_1_Ent1", "role": "Subject_Age", "text": "62 - year - old", "start": 1, "end": 6}, {"entity_id": "2224786_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2224786_1_Ent5", "role": "Treatment_Disorder", "text": "squamous cell carcinoma of the head and neck", "start": 12, "end": 20}, {"entity_id": "2224786_1_Ent3", "role": "Effect", "text": "a chemotherapy - related hemolytic - uremic syndrome", "start": 21, "end": 29}, {"entity_id": "2224786_1_Ent4", "role": "Treatment", "text": "the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate", "start": 30, "end": 44}, {"entity_id": "2224786_1_Ent6", "role": "Treatment_Dosage", "text": "second cycle", "start": 31, "end": 33}, {"entity_id": "2224786_1_Ent7", "role": "Treatment_Drug", "text": "cisplatin", "start": 38, "end": 39}, {"entity_id": "2224786_1_Ent10", "role": "Combination_Drug", "text": "cisplatin", "start": 38, "end": 39}, {"entity_id": "2224786_1_Ent8", "role": "Treatment_Drug", "text": "bleomycin", "start": 40, "end": 41}, {"entity_id": "2224786_1_Ent11", "role": "Combination_Drug", "text": "bleomycin", "start": 40, "end": 41}, {"entity_id": "2224786_1_Ent9", "role": "Treatment_Drug", "text": "methotrexate", "start": 43, "end": 44}, {"entity_id": "2224786_1_Ent12", "role": "Combination_Drug", "text": "methotrexate", "start": 43, "end": 44}]}], "entity_mentions": [{"id": "2224786_1_Ent0", "text": "A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 0, "end": 20}, {"id": "2224786_1_Ent1", "text": "62 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2224786_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2224786_1_Ent5", "text": "squamous cell carcinoma of the head and neck", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "2224786_1_Ent3", "text": "a chemotherapy - related hemolytic - uremic syndrome", "entity_type": "Entity", "start": 21, "end": 29}, {"id": "2224786_1_Ent4", "text": "the second cycle of neoadjuvant chemotherapy consisting of cisplatin , bleomycin , and methotrexate", "entity_type": "Entity", "start": 30, "end": 44}, {"id": "2224786_1_Ent6", "text": "second cycle", "entity_type": "Entity", "start": 31, "end": 33}, {"id": "2224786_1_Ent7", "text": "cisplatin", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "2224786_1_Ent10", "text": "cisplatin", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "2224786_1_Ent8", "text": "bleomycin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "2224786_1_Ent11", "text": "bleomycin", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "2224786_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "2224786_1_Ent12", "text": "methotrexate", "entity_type": "Entity", "start": 43, "end": 44}], "lang": "en"}
{"doc_id": "2241449_1", "wnd_id": "2241449_1_1", "text": "Physicians using this \" new \" drug must be aware of the potential danger of sulfonamide - induced injury to the urinary tract .", "tokens": ["Physicians", "using", "this", "\"", "new", "\"", "drug", "must", "be", "aware", "of", "the", "potential", "danger", "of", "sulfonamide", "-", "induced", "injury", "to", "the", "urinary", "tract", "."], "event_mentions": [{"id": "2241449_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 17, "end": 18}, "arguments": [{"entity_id": "2241449_1_Ent1", "role": "Treatment", "text": "sulfonamide", "start": 15, "end": 16}, {"entity_id": "2241449_1_Ent2", "role": "Treatment_Drug", "text": "sulfonamide", "start": 15, "end": 16}, {"entity_id": "2241449_1_Ent0", "role": "Effect", "text": "injury to the urinary tract", "start": 18, "end": 23}]}], "entity_mentions": [{"id": "2241449_1_Ent1", "text": "sulfonamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2241449_1_Ent2", "text": "sulfonamide", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2241449_1_Ent0", "text": "injury to the urinary tract", "entity_type": "Entity", "start": 18, "end": 23}], "lang": "en"}
{"doc_id": "22550162_3", "wnd_id": "22550162_3_1", "text": "The patient was placed on omeprazole after his first cycle of high - dose methotrexate for stress ulcer prophylaxis , and it was discontinued before the start of the first day of the patient 's second round of high - dose methotrexate .", "tokens": ["The", "patient", "was", "placed", "on", "omeprazole", "after", "his", "first", "cycle", "of", "high", "-", "dose", "methotrexate", "for", "stress", "ulcer", "prophylaxis", ",", "and", "it", "was", "discontinued", "before", "the", "start", "of", "the", "first", "day", "of", "the", "patient", "'s", "second", "round", "of", "high", "-", "dose", "methotrexate", "."], "event_mentions": [{"id": "22550162_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prophylaxis", "start": 18, "end": 19}, "arguments": [{"entity_id": "22550162_3_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "22550162_3_Ent5", "role": "Treatment_Drug", "text": "omeprazole", "start": 5, "end": 6}, {"entity_id": "22550162_3_Ent6", "role": "Treatment_Dosage", "text": "high - dose", "start": 11, "end": 14}, {"entity_id": "22550162_3_Ent1", "role": "Treatment", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "22550162_3_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 14, "end": 15}, {"entity_id": "22550162_3_Ent2", "role": "Treatment_Disorder", "text": "stress ulcer", "start": 16, "end": 18}, {"entity_id": "22550162_3_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 41, "end": 42}]}], "entity_mentions": [{"id": "22550162_3_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "22550162_3_Ent5", "text": "omeprazole", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "22550162_3_Ent6", "text": "high - dose", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "22550162_3_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22550162_3_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "22550162_3_Ent2", "text": "stress ulcer", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "22550162_3_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 41, "end": 42}], "lang": "en"}
{"doc_id": "22677303_3", "wnd_id": "22677303_3_1", "text": "A 70 - year - old man had been treated with warfarin for atrial fibrillation .", "tokens": ["A", "70", "-", "year", "-", "old", "man", "had", "been", "treated", "with", "warfarin", "for", "atrial", "fibrillation", "."], "event_mentions": [{"id": "22677303_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 9, "end": 10}, "arguments": [{"entity_id": "22677303_3_Ent0", "role": "Subject", "text": "A 70 - year - old man", "start": 0, "end": 7}, {"entity_id": "22677303_3_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 1, "end": 6}, {"entity_id": "22677303_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "22677303_3_Ent3", "role": "Treatment", "text": "warfarin", "start": 11, "end": 12}, {"entity_id": "22677303_3_Ent4", "role": "Treatment_Drug", "text": "warfarin", "start": 11, "end": 12}, {"entity_id": "22677303_3_Ent5", "role": "Treatment_Disorder", "text": "atrial fibrillation", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "22677303_3_Ent0", "text": "A 70 - year - old man", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "22677303_3_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "22677303_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "22677303_3_Ent3", "text": "warfarin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "22677303_3_Ent4", "text": "warfarin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "22677303_3_Ent5", "text": "atrial fibrillation", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "2276822_1", "wnd_id": "2276822_1_1", "text": "Because of a hypersensitivity reaction , initial therapy with penicillin G and gentamicin was stopped and substituted with cefazolin .", "tokens": ["Because", "of", "a", "hypersensitivity", "reaction", ",", "initial", "therapy", "with", "penicillin", "G", "and", "gentamicin", "was", "stopped", "and", "substituted", "with", "cefazolin", "."], "event_mentions": [{"id": "2276822_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 8, "end": 9}, "arguments": [{"entity_id": "2276822_1_Ent0", "role": "Effect", "text": "hypersensitivity reaction", "start": 3, "end": 5}, {"entity_id": "2276822_1_Ent1", "role": "Treatment", "text": "penicillin G", "start": 9, "end": 11}, {"entity_id": "2276822_1_Ent3", "role": "Treatment_Drug", "text": "penicillin G", "start": 9, "end": 11}, {"entity_id": "2276822_1_Ent6", "role": "Combination_Drug", "text": "penicillin G", "start": 9, "end": 11}, {"entity_id": "2276822_1_Ent2", "role": "Treatment", "text": "gentamicin", "start": 12, "end": 13}, {"entity_id": "2276822_1_Ent4", "role": "Treatment_Drug", "text": "gentamicin", "start": 12, "end": 13}, {"entity_id": "2276822_1_Ent7", "role": "Combination_Drug", "text": "gentamicin", "start": 12, "end": 13}, {"entity_id": "2276822_1_Ent5", "role": "Treatment_Drug", "text": "cefazolin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "2276822_1_Ent0", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2276822_1_Ent1", "text": "penicillin G", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2276822_1_Ent3", "text": "penicillin G", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2276822_1_Ent6", "text": "penicillin G", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "2276822_1_Ent2", "text": "gentamicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2276822_1_Ent4", "text": "gentamicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2276822_1_Ent7", "text": "gentamicin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2276822_1_Ent5", "text": "cefazolin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "22791547_3", "wnd_id": "22791547_3_1", "text": "In this article , the authors report a 7 - year - old male patient who presented with orofacial and limb dyskinesia after his first dose of methylphenidate treatment for a diagnosis of attention - deficit / hyperactivity disorder ; he was also receiving sodium valproate treatment for epilepsy .", "tokens": ["In", "this", "article", ",", "the", "authors", "report", "a", "7", "-", "year", "-", "old", "male", "patient", "who", "presented", "with", "orofacial", "and", "limb", "dyskinesia", "after", "his", "first", "dose", "of", "methylphenidate", "treatment", "for", "a", "diagnosis", "of", "attention", "-", "deficit", "/", "hyperactivity", "disorder", ";", "he", "was", "also", "receiving", "sodium", "valproate", "treatment", "for", "epilepsy", "."], "event_mentions": [{"id": "22791547_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 22, "end": 23}, "arguments": [{"entity_id": "22791547_3_Ent0", "role": "Subject", "text": "a 7 - year - old male patient", "start": 7, "end": 15}, {"entity_id": "22791547_3_Ent1", "role": "Subject_Age", "text": "7 - year - old", "start": 8, "end": 13}, {"entity_id": "22791547_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "22791547_3_Ent3", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 18, "end": 22}, {"entity_id": "22791547_3_Ent6", "role": "Treatment_Time_elapsed", "text": "first dose", "start": 24, "end": 26}, {"entity_id": "22791547_3_Ent4", "role": "Treatment", "text": "first dose of methylphenidate", "start": 24, "end": 28}, {"entity_id": "22791547_3_Ent7", "role": "Treatment_Drug", "text": "methylphenidate", "start": 27, "end": 28}, {"entity_id": "22791547_3_Ent5", "role": "Treatment_Disorder", "text": "attention - deficit / hyperactivity disorder", "start": 33, "end": 39}]}, {"id": "22791547_3_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 43, "end": 44}, "arguments": [{"entity_id": "22791547_3_Ent8", "role": "Subject", "text": "a 7 - year - old male patient", "start": 7, "end": 15}, {"entity_id": "22791547_3_Ent9", "role": "Subject_Age", "text": "7 - year - old", "start": 8, "end": 13}, {"entity_id": "22791547_3_Ent10", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "22791547_3_Ent11", "role": "Treatment", "text": "sodium valproate", "start": 44, "end": 46}, {"entity_id": "22791547_3_Ent13", "role": "Treatment_Drug", "text": "sodium valproate", "start": 44, "end": 46}, {"entity_id": "22791547_3_Ent12", "role": "Treatment_Disorder", "text": "epilepsy", "start": 48, "end": 49}]}], "entity_mentions": [{"id": "22791547_3_Ent0", "text": "a 7 - year - old male patient", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "22791547_3_Ent8", "text": "a 7 - year - old male patient", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "22791547_3_Ent1", "text": "7 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "22791547_3_Ent9", "text": "7 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "22791547_3_Ent2", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22791547_3_Ent10", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "22791547_3_Ent3", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "22791547_3_Ent6", "text": "first dose", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "22791547_3_Ent4", "text": "first dose of methylphenidate", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "22791547_3_Ent7", "text": "methylphenidate", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "22791547_3_Ent5", "text": "attention - deficit / hyperactivity disorder", "entity_type": "Entity", "start": 33, "end": 39}, {"id": "22791547_3_Ent11", "text": "sodium valproate", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "22791547_3_Ent13", "text": "sodium valproate", "entity_type": "Entity", "start": 44, "end": 46}, {"id": "22791547_3_Ent12", "text": "epilepsy", "entity_type": "Entity", "start": 48, "end": 49}], "lang": "en"}
{"doc_id": "22791547_5", "wnd_id": "22791547_5_1", "text": "Although limb dyskinesia after methylphenidate is a commonly reported side effect , to the authors ' knowledge this is only the second reported case to develop both orofacial and limb dyskinesia in the acute period after the first dose of methylphenidate .", "tokens": ["Although", "limb", "dyskinesia", "after", "methylphenidate", "is", "a", "commonly", "reported", "side", "effect", ",", "to", "the", "authors", "'", "knowledge", "this", "is", "only", "the", "second", "reported", "case", "to", "develop", "both", "orofacial", "and", "limb", "dyskinesia", "in", "the", "acute", "period", "after", "the", "first", "dose", "of", "methylphenidate", "."], "event_mentions": [{"id": "22791547_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "develop", "start": 25, "end": 26}, "arguments": [{"entity_id": "22791547_5_Ent3", "role": "Treatment_Drug", "text": "methylphenidate", "start": 4, "end": 5}, {"entity_id": "22791547_5_Ent0", "role": "Subject", "text": "the second reported case", "start": 20, "end": 24}, {"entity_id": "22791547_5_Ent1", "role": "Effect", "text": "orofacial and limb dyskinesia", "start": 27, "end": 31}, {"entity_id": "22791547_5_Ent2", "role": "Treatment", "text": "methylphenidate", "start": 40, "end": 41}, {"entity_id": "22791547_5_Ent4", "role": "Treatment_Drug", "text": "methylphenidate", "start": 40, "end": 41}]}], "entity_mentions": [{"id": "22791547_5_Ent3", "text": "methylphenidate", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "22791547_5_Ent0", "text": "the second reported case", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "22791547_5_Ent1", "text": "orofacial and limb dyskinesia", "entity_type": "Entity", "start": 27, "end": 31}, {"id": "22791547_5_Ent2", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}, {"id": "22791547_5_Ent4", "text": "methylphenidate", "entity_type": "Entity", "start": 40, "end": 41}], "lang": "en"}
{"doc_id": "2292051_2", "wnd_id": "2292051_2_1", "text": "Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / infarction shortly after cis - diamine - dichloroplatinum II ( cisplatin ) -based chemotherapy .", "tokens": ["Six", "patients", "with", "no", "previous", "signs", "or", "symptoms", "suggestive", "of", "coronary", "artery", "disease", "developed", "acute", "coronary", "ischemia", "/", "infarction", "shortly", "after", "cis", "-", "diamine", "-", "dichloroplatinum", "II", "(", "cisplatin", ")", "-based", "chemotherapy", "."], "event_mentions": [{"id": "2292051_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "2292051_2_Ent1", "role": "Subject_Population", "text": "Six", "start": 0, "end": 1}, {"entity_id": "2292051_2_Ent0", "role": "Subject", "text": "Six patients with no previous signs or symptoms suggestive of coronary artery disease", "start": 0, "end": 13}, {"entity_id": "2292051_2_Ent2", "role": "Effect", "text": "acute coronary ischemia / infarction", "start": 14, "end": 19}, {"entity_id": "2292051_2_Ent4", "role": "Treatment_Drug", "text": "cis - diamine - dichloroplatinum II", "start": 21, "end": 27}, {"entity_id": "2292051_2_Ent3", "role": "Treatment", "text": "cis - diamine - dichloroplatinum II ( cisplatin ) -based chemotherapy", "start": 21, "end": 32}, {"entity_id": "2292051_2_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "2292051_2_Ent1", "text": "Six", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2292051_2_Ent0", "text": "Six patients with no previous signs or symptoms suggestive of coronary artery disease", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "2292051_2_Ent2", "text": "acute coronary ischemia / infarction", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "2292051_2_Ent4", "text": "cis - diamine - dichloroplatinum II", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "2292051_2_Ent3", "text": "cis - diamine - dichloroplatinum II ( cisplatin ) -based chemotherapy", "entity_type": "Entity", "start": 21, "end": 32}, {"id": "2292051_2_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "2295443_3", "wnd_id": "2295443_3_1", "text": "This report presents a case of colon perforation which occurred 4 months after treatment with intraperitoneal chromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma .", "tokens": ["This", "report", "presents", "a", "case", "of", "colon", "perforation", "which", "occurred", "4", "months", "after", "treatment", "with", "intraperitoneal", "chromic", "phosphate", "for", "stage", "IB", "ovarian", "papillary", "serous", "cystadenocarcinoma", "."], "event_mentions": [{"id": "2295443_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 9, "end": 10}, "arguments": [{"entity_id": "2295443_3_Ent0", "role": "Effect", "text": "colon perforation", "start": 6, "end": 8}, {"entity_id": "2295443_3_Ent3", "role": "Treatment_Time_elapsed", "text": "4 months", "start": 10, "end": 12}, {"entity_id": "2295443_3_Ent4", "role": "Treatment_Route", "text": "intraperitoneal", "start": 15, "end": 16}, {"entity_id": "2295443_3_Ent1", "role": "Treatment", "text": "intraperitoneal chromic phosphate", "start": 15, "end": 18}, {"entity_id": "2295443_3_Ent2", "role": "Treatment_Drug", "text": "chromic phosphate", "start": 16, "end": 18}, {"entity_id": "2295443_3_Ent5", "role": "Treatment_Disorder", "text": "stage IB ovarian papillary serous cystadenocarcinoma", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "2295443_3_Ent0", "text": "colon perforation", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "2295443_3_Ent3", "text": "4 months", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "2295443_3_Ent4", "text": "intraperitoneal", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2295443_3_Ent1", "text": "intraperitoneal chromic phosphate", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "2295443_3_Ent2", "text": "chromic phosphate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "2295443_3_Ent5", "text": "stage IB ovarian papillary serous cystadenocarcinoma", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "2299784_1", "wnd_id": "2299784_1_1", "text": "A 59 - year - old woman with myasthenia gravis who received a large dose of pyridostigmine bromide developed postoperative psychosis and was diagnosed as having bromide intoxication .", "tokens": ["A", "59", "-", "year", "-", "old", "woman", "with", "myasthenia", "gravis", "who", "received", "a", "large", "dose", "of", "pyridostigmine", "bromide", "developed", "postoperative", "psychosis", "and", "was", "diagnosed", "as", "having", "bromide", "intoxication", "."], "event_mentions": [{"id": "2299784_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 18, "end": 19}, "arguments": [{"entity_id": "2299784_1_Ent0", "role": "Subject", "text": "A 59 - year - old woman with myasthenia gravis", "start": 0, "end": 10}, {"entity_id": "2299784_1_Ent1", "role": "Subject_Age", "text": "59 - year - old", "start": 1, "end": 6}, {"entity_id": "2299784_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "2299784_1_Ent6", "role": "Treatment_Disorder", "text": "myasthenia gravis", "start": 8, "end": 10}, {"entity_id": "2299784_1_Ent7", "role": "Treatment_Dosage", "text": "a large dose", "start": 12, "end": 15}, {"entity_id": "2299784_1_Ent4", "role": "Treatment", "text": "a large dose of pyridostigmine bromide", "start": 12, "end": 18}, {"entity_id": "2299784_1_Ent5", "role": "Treatment_Drug", "text": "pyridostigmine bromide", "start": 16, "end": 18}, {"entity_id": "2299784_1_Ent3", "role": "Effect", "text": "postoperative psychosis and was diagnosed as having bromide intoxication .", "start": 19, "end": 29}]}], "entity_mentions": [{"id": "2299784_1_Ent0", "text": "A 59 - year - old woman with myasthenia gravis", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "2299784_1_Ent1", "text": "59 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "2299784_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2299784_1_Ent6", "text": "myasthenia gravis", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "2299784_1_Ent7", "text": "a large dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "2299784_1_Ent4", "text": "a large dose of pyridostigmine bromide", "entity_type": "Entity", "start": 12, "end": 18}, {"id": "2299784_1_Ent5", "text": "pyridostigmine bromide", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "2299784_1_Ent3", "text": "postoperative psychosis and was diagnosed as having bromide intoxication .", "entity_type": "Entity", "start": 19, "end": 29}], "lang": "en"}
{"doc_id": "23115227_3", "wnd_id": "23115227_3_1", "text": "In January 2010 , a 50 - year - old transgender female with HIV infection and recurrent deep vein thrombosis began treatment with the TRIO study regimen .", "tokens": ["In", "January", "2010", ",", "a", "50", "-", "year", "-", "old", "transgender", "female", "with", "HIV", "infection", "and", "recurrent", "deep", "vein", "thrombosis", "began", "treatment", "with", "the", "TRIO", "study", "regimen", "."], "event_mentions": [{"id": "23115227_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 21, "end": 22}, "arguments": [{"entity_id": "23115227_3_Ent0", "role": "Subject", "text": "a 50 - year - old transgender female", "start": 4, "end": 12}, {"entity_id": "23115227_3_Ent1", "role": "Subject_Age", "text": "50 - year - old", "start": 5, "end": 10}, {"entity_id": "23115227_3_Ent2", "role": "Subject_Gender", "text": "transgender female", "start": 10, "end": 12}, {"entity_id": "23115227_3_Ent5", "role": "Treatment_Disorder", "text": "HIV infection and recurrent deep vein thrombosis", "start": 13, "end": 20}, {"entity_id": "23115227_3_Ent3", "role": "Treatment", "text": "TRIO", "start": 24, "end": 25}, {"entity_id": "23115227_3_Ent4", "role": "Treatment_Drug", "text": "TRIO", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "23115227_3_Ent0", "text": "a 50 - year - old transgender female", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "23115227_3_Ent1", "text": "50 - year - old", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "23115227_3_Ent2", "text": "transgender female", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "23115227_3_Ent5", "text": "HIV infection and recurrent deep vein thrombosis", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "23115227_3_Ent3", "text": "TRIO", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "23115227_3_Ent4", "text": "TRIO", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "2316232_2", "wnd_id": "2316232_2_1", "text": "Symptomatic hypoglycemia secondary to a glipizide - trimethoprim / sulfamethoxazole drug interaction .", "tokens": ["Symptomatic", "hypoglycemia", "secondary", "to", "a", "glipizide", "-", "trimethoprim", "/", "sulfamethoxazole", "drug", "interaction", "."], "event_mentions": [{"id": "2316232_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 2, "end": 4}, "arguments": [{"entity_id": "2316232_2_Ent0", "role": "Effect", "text": "Symptomatic hypoglycemia", "start": 0, "end": 2}, {"entity_id": "2316232_2_Ent2", "role": "Treatment_Drug", "text": "glipizide", "start": 5, "end": 6}, {"entity_id": "2316232_2_Ent5", "role": "Combination_Drug", "text": "glipizide", "start": 5, "end": 6}, {"entity_id": "2316232_2_Ent1", "role": "Treatment", "text": "glipizide - trimethoprim / sulfamethoxazole drug interaction", "start": 5, "end": 12}, {"entity_id": "2316232_2_Ent3", "role": "Treatment_Drug", "text": "trimethoprim", "start": 7, "end": 8}, {"entity_id": "2316232_2_Ent6", "role": "Combination_Drug", "text": "trimethoprim", "start": 7, "end": 8}, {"entity_id": "2316232_2_Ent4", "role": "Treatment_Drug", "text": "sulfamethoxazole", "start": 9, "end": 10}, {"entity_id": "2316232_2_Ent7", "role": "Combination_Drug", "text": "sulfamethoxazole", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2316232_2_Ent0", "text": "Symptomatic hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2316232_2_Ent2", "text": "glipizide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2316232_2_Ent5", "text": "glipizide", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2316232_2_Ent1", "text": "glipizide - trimethoprim / sulfamethoxazole drug interaction", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "2316232_2_Ent3", "text": "trimethoprim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2316232_2_Ent6", "text": "trimethoprim", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2316232_2_Ent4", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2316232_2_Ent7", "text": "sulfamethoxazole", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2320800_6", "wnd_id": "2320800_6_1", "text": "Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .", "tokens": ["Ifosfamide", "is", "a", "known", "nephrotoxic", "drug", "with", "demonstrated", "tubulopathies", "."], "event_mentions": [{"id": "2320800_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 6, "end": 7}, "arguments": [{"entity_id": "2320800_6_Ent1", "role": "Treatment", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent2", "role": "Treatment_Drug", "text": "Ifosfamide", "start": 0, "end": 1}, {"entity_id": "2320800_6_Ent0", "role": "Effect", "text": "tubulopathies", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "2320800_6_Ent1", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent2", "text": "Ifosfamide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2320800_6_Ent0", "text": "tubulopathies", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "2327115_4", "wnd_id": "2327115_4_1", "text": "This article describes a patient with suspected ciprofloxacin - induced interstitial nephritis .", "tokens": ["This", "article", "describes", "a", "patient", "with", "suspected", "ciprofloxacin", "-", "induced", "interstitial", "nephritis", "."], "event_mentions": [{"id": "2327115_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 9, "end": 10}, "arguments": [{"entity_id": "2327115_4_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "2327115_4_Ent2", "role": "Treatment", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "2327115_4_Ent3", "role": "Treatment_Drug", "text": "ciprofloxacin", "start": 7, "end": 8}, {"entity_id": "2327115_4_Ent1", "role": "Effect", "text": "interstitial nephritis", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "2327115_4_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2327115_4_Ent2", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2327115_4_Ent3", "text": "ciprofloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2327115_4_Ent1", "text": "interstitial nephritis", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "2329972_1", "wnd_id": "2329972_1_1", "text": "In a female with acute lymphoblastic leukemia , inadvertent doxorubicin administration intrathecally caused severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus .", "tokens": ["In", "a", "female", "with", "acute", "lymphoblastic", "leukemia", ",", "inadvertent", "doxorubicin", "administration", "intrathecally", "caused", "severe", ",", "life", "-", "threatening", ",", "acute", "encephalopathy", "with", "high", "-", "pressure", "hydrocephalus", "."], "event_mentions": [{"id": "2329972_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 12, "end": 13}, "arguments": [{"entity_id": "2329972_1_Ent1", "role": "Subject_Gender", "text": "female", "start": 2, "end": 3}, {"entity_id": "2329972_1_Ent0", "role": "Subject", "text": "female with acute lymphoblastic leukemia", "start": 2, "end": 7}, {"entity_id": "2329972_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 4, "end": 7}, {"entity_id": "2329972_1_Ent3", "role": "Treatment", "text": "inadvertent doxorubicin administration intrathecally", "start": 8, "end": 12}, {"entity_id": "2329972_1_Ent4", "role": "Treatment_Drug", "text": "doxorubicin", "start": 9, "end": 10}, {"entity_id": "2329972_1_Ent6", "role": "Treatment_Route", "text": "intrathecally", "start": 11, "end": 12}, {"entity_id": "2329972_1_Ent2", "role": "Effect", "text": "severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus", "start": 13, "end": 26}]}], "entity_mentions": [{"id": "2329972_1_Ent1", "text": "female", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "2329972_1_Ent0", "text": "female with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "2329972_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2329972_1_Ent3", "text": "inadvertent doxorubicin administration intrathecally", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "2329972_1_Ent4", "text": "doxorubicin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2329972_1_Ent6", "text": "intrathecally", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2329972_1_Ent2", "text": "severe , life - threatening , acute encephalopathy with high - pressure hydrocephalus", "entity_type": "Entity", "start": 13, "end": 26}], "lang": "en"}
{"doc_id": "23471710_1", "wnd_id": "23471710_1_1", "text": "Severe hypoglycemia from Helicobacter pylori triple - drug therapy and insulin detemir drug interaction .", "tokens": ["Severe", "hypoglycemia", "from", "Helicobacter", "pylori", "triple", "-", "drug", "therapy", "and", "insulin", "detemir", "drug", "interaction", "."], "event_mentions": [{"id": "23471710_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "from", "start": 2, "end": 3}, "arguments": [{"entity_id": "23471710_1_Ent0", "role": "Effect", "text": "Severe hypoglycemia", "start": 0, "end": 2}, {"entity_id": "23471710_1_Ent2", "role": "Treatment_Drug", "text": "Helicobacter pylori triple - drug", "start": 3, "end": 8}, {"entity_id": "23471710_1_Ent5", "role": "Combination_Drug", "text": "Helicobacter pylori triple - drug", "start": 3, "end": 8}, {"entity_id": "23471710_1_Ent1", "role": "Treatment", "text": "Helicobacter pylori triple - drug therapy and insulin detemir drug interaction", "start": 3, "end": 14}, {"entity_id": "23471710_1_Ent3", "role": "Treatment_Drug", "text": "insulin detemir drug", "start": 10, "end": 13}, {"entity_id": "23471710_1_Ent4", "role": "Combination_Drug", "text": "insulin detemir drug", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "23471710_1_Ent0", "text": "Severe hypoglycemia", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "23471710_1_Ent2", "text": "Helicobacter pylori triple - drug", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "23471710_1_Ent5", "text": "Helicobacter pylori triple - drug", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "23471710_1_Ent1", "text": "Helicobacter pylori triple - drug therapy and insulin detemir drug interaction", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "23471710_1_Ent3", "text": "insulin detemir drug", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "23471710_1_Ent4", "text": "insulin detemir drug", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "23552010_1", "wnd_id": "23552010_1_1", "text": "Acute angioedema response to topical 5 - fluorouracil therapy .", "tokens": ["Acute", "angioedema", "response", "to", "topical", "5", "-", "fluorouracil", "therapy", "."], "event_mentions": [{"id": "23552010_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "response", "start": 2, "end": 3}, "arguments": [{"entity_id": "23552010_1_Ent0", "role": "Effect", "text": "angioedema", "start": 1, "end": 2}, {"entity_id": "23552010_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 5, "end": 8}, {"entity_id": "23552010_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 5, "end": 8}]}], "entity_mentions": [{"id": "23552010_1_Ent0", "text": "angioedema", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "23552010_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "23552010_1_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 5, "end": 8}], "lang": "en"}
{"doc_id": "23552010_2", "wnd_id": "23552010_2_1", "text": "This is a case report involving a patient who was treated with topical 5 - FU cream and subsequently developed a severe case of angioedema .", "tokens": ["This", "is", "a", "case", "report", "involving", "a", "patient", "who", "was", "treated", "with", "topical", "5", "-", "FU", "cream", "and", "subsequently", "developed", "a", "severe", "case", "of", "angioedema", "."], "event_mentions": [{"id": "23552010_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "23552010_2_Ent0", "role": "Subject", "text": "a patient", "start": 6, "end": 8}, {"entity_id": "23552010_2_Ent3", "role": "Treatment_Route", "text": "topical", "start": 12, "end": 13}, {"entity_id": "23552010_2_Ent2", "role": "Treatment", "text": "topical 5 - FU cream", "start": 12, "end": 17}, {"entity_id": "23552010_2_Ent4", "role": "Treatment_Drug", "text": "5 - FU", "start": 13, "end": 16}, {"entity_id": "23552010_2_Ent1", "role": "Effect", "text": "a severe case of angioedema", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "23552010_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23552010_2_Ent3", "text": "topical", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "23552010_2_Ent2", "text": "topical 5 - FU cream", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "23552010_2_Ent4", "text": "5 - FU", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "23552010_2_Ent1", "text": "a severe case of angioedema", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "23552010_3", "wnd_id": "23552010_3_1", "text": "This case presents the possibility of anaphylaxis to topical 5 - FU treatments and/or the interaction with angiotensin converting enzyme inhibitors .", "tokens": ["This", "case", "presents", "the", "possibility", "of", "anaphylaxis", "to", "topical", "5", "-", "FU", "treatments", "and/or", "the", "interaction", "with", "angiotensin", "converting", "enzyme", "inhibitors", "."], "event_mentions": [{"id": "23552010_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 7, "end": 8}, "arguments": [{"entity_id": "23552010_3_Ent0", "role": "Effect", "text": "anaphylaxis", "start": 6, "end": 7}, {"entity_id": "23552010_3_Ent1", "role": "Treatment", "text": "5 - FU", "start": 9, "end": 12}, {"entity_id": "23552010_3_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 9, "end": 12}, {"entity_id": "23552010_3_Ent6", "role": "Combination_Drug", "text": "5 - FU", "start": 9, "end": 12}, {"entity_id": "23552010_3_Ent2", "role": "Treatment", "text": "angiotensin converting enzyme inhibitors", "start": 17, "end": 21}, {"entity_id": "23552010_3_Ent4", "role": "Treatment_Drug", "text": "angiotensin converting enzyme inhibitors", "start": 17, "end": 21}, {"entity_id": "23552010_3_Ent5", "role": "Combination_Drug", "text": "angiotensin converting enzyme inhibitors", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "23552010_3_Ent0", "text": "anaphylaxis", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23552010_3_Ent1", "text": "5 - FU", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "23552010_3_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "23552010_3_Ent6", "text": "5 - FU", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "23552010_3_Ent2", "text": "angiotensin converting enzyme inhibitors", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "23552010_3_Ent4", "text": "angiotensin converting enzyme inhibitors", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "23552010_3_Ent5", "text": "angiotensin converting enzyme inhibitors", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "2369419_1", "wnd_id": "2369419_1_1", "text": "A patient with seropositive rheumatoid arthritis developed ascites while taking weekly doses of methotrexate ( MTX ) .", "tokens": ["A", "patient", "with", "seropositive", "rheumatoid", "arthritis", "developed", "ascites", "while", "taking", "weekly", "doses", "of", "methotrexate", "(", "MTX", ")", "."], "event_mentions": [{"id": "2369419_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "2369419_1_Ent0", "role": "Subject", "text": "A patient with seropositive rheumatoid arthritis", "start": 0, "end": 6}, {"entity_id": "2369419_1_Ent3", "role": "Treatment_Disorder", "text": "seropositive rheumatoid arthritis", "start": 3, "end": 6}, {"entity_id": "2369419_1_Ent1", "role": "Effect", "text": "ascites", "start": 7, "end": 8}, {"entity_id": "2369419_1_Ent2", "role": "Treatment", "text": "taking weekly doses of methotrexate ( MTX )", "start": 9, "end": 17}, {"entity_id": "2369419_1_Ent4", "role": "Treatment_Freq", "text": "weekly", "start": 10, "end": 11}, {"entity_id": "2369419_1_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2369419_1_Ent0", "text": "A patient with seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "2369419_1_Ent3", "text": "seropositive rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "2369419_1_Ent1", "text": "ascites", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2369419_1_Ent2", "text": "taking weekly doses of methotrexate ( MTX )", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "2369419_1_Ent4", "text": "weekly", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2369419_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2369419_3", "wnd_id": "2369419_3_1", "text": "This is the third report of reversible hepatic decompensation associated with prolonged MTX therapy in patients with rheumatoid arthritis .", "tokens": ["This", "is", "the", "third", "report", "of", "reversible", "hepatic", "decompensation", "associated", "with", "prolonged", "MTX", "therapy", "in", "patients", "with", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "2369419_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 9, "end": 10}, "arguments": [{"entity_id": "2369419_3_Ent1", "role": "Effect", "text": "reversible hepatic decompensation", "start": 6, "end": 9}, {"entity_id": "2369419_3_Ent2", "role": "Treatment", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent4", "role": "Treatment_Drug", "text": "MTX", "start": 12, "end": 13}, {"entity_id": "2369419_3_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 15, "end": 19}, {"entity_id": "2369419_3_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "2369419_3_Ent1", "text": "reversible hepatic decompensation", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2369419_3_Ent2", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent4", "text": "MTX", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2369419_3_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "2369419_3_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "23774436_1", "wnd_id": "23774436_1_1", "text": "Evaluation of initial and steady - state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations .", "tokens": ["Evaluation", "of", "initial", "and", "steady", "-", "state", "gatifloxacin", "pharmacokinetics", "and", "dose", "in", "pulmonary", "tuberculosis", "patients", "by", "using", "monte", "carlo", "simulations", "."], "event_mentions": [{"id": "23774436_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "in", "start": 11, "end": 12}, "arguments": [{"entity_id": "23774436_1_Ent1", "role": "Treatment", "text": "gatifloxacin", "start": 7, "end": 8}, {"entity_id": "23774436_1_Ent3", "role": "Treatment_Drug", "text": "gatifloxacin", "start": 7, "end": 8}, {"entity_id": "23774436_1_Ent2", "role": "Treatment_Disorder", "text": "pulmonary tuberculosis", "start": 12, "end": 14}, {"entity_id": "23774436_1_Ent0", "role": "Subject", "text": "pulmonary tuberculosis patients", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "23774436_1_Ent1", "text": "gatifloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "23774436_1_Ent3", "text": "gatifloxacin", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "23774436_1_Ent2", "text": "pulmonary tuberculosis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "23774436_1_Ent0", "text": "pulmonary tuberculosis patients", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "2378415_2", "wnd_id": "2378415_2_1", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and brainstem herniation after she received a single dose of intravenous methotrexate .", "tokens": ["A", "patient", "with", "intracranial", "osteosarcoma", "that", "arose", "16", "years", "after", "radiation", "therapy", "for", "hereditary", "retinoblastoma", "developed", "fatal", "cerebral", "edema", "and", "brainstem", "herniation", "after", "she", "received", "a", "single", "dose", "of", "intravenous", "methotrexate", "."], "event_mentions": [{"id": "2378415_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "2378415_2_Ent0", "role": "Subject", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma", "start": 0, "end": 15}, {"entity_id": "2378415_2_Ent4", "role": "Treatment_Disorder", "text": "intracranial osteosarcoma", "start": 3, "end": 5}, {"entity_id": "2378415_2_Ent1", "role": "Subject_Disorder", "text": "hereditary retinoblastoma", "start": 13, "end": 15}, {"entity_id": "2378415_2_Ent2", "role": "Effect", "text": "cerebral edema and brainstem herniation", "start": 17, "end": 22}, {"entity_id": "2378415_2_Ent5", "role": "Treatment_Freq", "text": "a single dose", "start": 25, "end": 28}, {"entity_id": "2378415_2_Ent3", "role": "Treatment", "text": "a single dose of intravenous methotrexate", "start": 25, "end": 31}, {"entity_id": "2378415_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 29, "end": 30}, {"entity_id": "2378415_2_Ent7", "role": "Treatment_Drug", "text": "methotrexate", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "2378415_2_Ent0", "text": "A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma", "entity_type": "Entity", "start": 0, "end": 15}, {"id": "2378415_2_Ent4", "text": "intracranial osteosarcoma", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2378415_2_Ent1", "text": "hereditary retinoblastoma", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "2378415_2_Ent2", "text": "cerebral edema and brainstem herniation", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "2378415_2_Ent5", "text": "a single dose", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "2378415_2_Ent3", "text": "a single dose of intravenous methotrexate", "entity_type": "Entity", "start": 25, "end": 31}, {"id": "2378415_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "2378415_2_Ent7", "text": "methotrexate", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "23970584_1", "wnd_id": "23970584_1_1", "text": "Raltegravir - induced Drug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome - implications for clinical practice and patient safety .", "tokens": ["Raltegravir", "-", "induced", "Drug", "Reaction", "with", "Eosinophilia", "and", "Systemic", "Symptoms", "(", "DRESS", ")", "syndrome", "-", "implications", "for", "clinical", "practice", "and", "patient", "safety", "."], "event_mentions": [{"id": "23970584_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "23970584_1_Ent1", "role": "Treatment", "text": "Raltegravir", "start": 0, "end": 1}, {"entity_id": "23970584_1_Ent2", "role": "Treatment_Drug", "text": "Raltegravir", "start": 0, "end": 1}, {"entity_id": "23970584_1_Ent0", "role": "Effect", "text": "Eosinophilia and Systemic Symptoms ( DRESS ) syndrome", "start": 6, "end": 14}]}], "entity_mentions": [{"id": "23970584_1_Ent1", "text": "Raltegravir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "23970584_1_Ent2", "text": "Raltegravir", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "23970584_1_Ent0", "text": "Eosinophilia and Systemic Symptoms ( DRESS ) syndrome", "entity_type": "Entity", "start": 6, "end": 14}], "lang": "en"}
{"doc_id": "23970584_4", "wnd_id": "23970584_4_1", "text": "Forty - one days later , she developed severe iatrogenic Cushing 's syndrome due to the drug - drug interaction between triamcinolone and her boosted protease inhibitor therapy .", "tokens": ["Forty", "-", "one", "days", "later", ",", "she", "developed", "severe", "iatrogenic", "Cushing", "'s", "syndrome", "due", "to", "the", "drug", "-", "drug", "interaction", "between", "triamcinolone", "and", "her", "boosted", "protease", "inhibitor", "therapy", "."], "event_mentions": [{"id": "23970584_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "23970584_4_Ent2", "role": "Effect", "text": "Forty - one days later", "start": 0, "end": 5}, {"entity_id": "23970584_4_Ent0", "role": "Subject", "text": "she", "start": 6, "end": 7}, {"entity_id": "23970584_4_Ent1", "role": "Subject_Gender", "text": "she", "start": 6, "end": 7}, {"entity_id": "23970584_4_Ent3", "role": "Effect", "text": "severe iatrogenic Cushing 's syndrome", "start": 8, "end": 13}, {"entity_id": "23970584_4_Ent5", "role": "Treatment_Drug", "text": "triamcinolone", "start": 21, "end": 22}, {"entity_id": "23970584_4_Ent7", "role": "Combination_Drug", "text": "triamcinolone", "start": 21, "end": 22}, {"entity_id": "23970584_4_Ent4", "role": "Treatment", "text": "triamcinolone and her boosted protease inhibitor", "start": 21, "end": 27}, {"entity_id": "23970584_4_Ent6", "role": "Treatment_Drug", "text": "protease inhibitor", "start": 25, "end": 27}, {"entity_id": "23970584_4_Ent8", "role": "Combination_Drug", "text": "protease inhibitor", "start": 25, "end": 27}]}], "entity_mentions": [{"id": "23970584_4_Ent2", "text": "Forty - one days later", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23970584_4_Ent0", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_4_Ent1", "text": "she", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "23970584_4_Ent3", "text": "severe iatrogenic Cushing 's syndrome", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "23970584_4_Ent5", "text": "triamcinolone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "23970584_4_Ent7", "text": "triamcinolone", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "23970584_4_Ent4", "text": "triamcinolone and her boosted protease inhibitor", "entity_type": "Entity", "start": 21, "end": 27}, {"id": "23970584_4_Ent6", "text": "protease inhibitor", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "23970584_4_Ent8", "text": "protease inhibitor", "entity_type": "Entity", "start": 25, "end": 27}], "lang": "en"}
{"doc_id": "23970584_6", "wnd_id": "23970584_6_1", "text": "Shortly after commencing the drug , the patient developed a severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome .", "tokens": ["Shortly", "after", "commencing", "the", "drug", ",", "the", "patient", "developed", "a", "severe", "adverse", "drug", "reaction", "manifesting", "as", "Drug", "Reaction", "(", "or", "Rash", ")", "with", "Eosinophilia", "and", "Systemic", "Symptoms", "(", "DRESS", ")", "syndrome", "."], "event_mentions": [{"id": "23970584_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "23970584_6_Ent3", "role": "Treatment_Time_elapsed", "text": "Shortly after", "start": 0, "end": 2}, {"entity_id": "23970584_6_Ent2", "role": "Treatment", "text": "Shortly after commencing the drug", "start": 0, "end": 5}, {"entity_id": "23970584_6_Ent0", "role": "Subject", "text": "the patient", "start": 6, "end": 8}, {"entity_id": "23970584_6_Ent1", "role": "Effect", "text": "severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome", "start": 10, "end": 31}]}], "entity_mentions": [{"id": "23970584_6_Ent3", "text": "Shortly after", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "23970584_6_Ent2", "text": "Shortly after commencing the drug", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "23970584_6_Ent0", "text": "the patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "23970584_6_Ent1", "text": "severe adverse drug reaction manifesting as Drug Reaction ( or Rash ) with Eosinophilia and Systemic Symptoms ( DRESS ) syndrome", "entity_type": "Entity", "start": 10, "end": 31}], "lang": "en"}
{"doc_id": "24163322_2", "wnd_id": "24163322_2_1", "text": "We report a case of an inadvertent increase in the international normalized ratio ( INR ) after the addition of bismuth subsalicylate for the treatment of diarrhea in an enterally fed patient receiving warfarin therapy .", "tokens": ["We", "report", "a", "case", "of", "an", "inadvertent", "increase", "in", "the", "international", "normalized", "ratio", "(", "INR", ")", "after", "the", "addition", "of", "bismuth", "subsalicylate", "for", "the", "treatment", "of", "diarrhea", "in", "an", "enterally", "fed", "patient", "receiving", "warfarin", "therapy", "."], "event_mentions": [{"id": "24163322_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "24163322_2_Ent1", "role": "Effect", "text": "inadvertent increase in the international normalized ratio ( INR )", "start": 6, "end": 16}, {"entity_id": "24163322_2_Ent2", "role": "Treatment", "text": "addition of bismuth subsalicylate", "start": 18, "end": 22}, {"entity_id": "24163322_2_Ent5", "role": "Treatment_Drug", "text": "bismuth subsalicylate", "start": 20, "end": 22}, {"entity_id": "24163322_2_Ent7", "role": "Combination_Drug", "text": "bismuth subsalicylate", "start": 20, "end": 22}, {"entity_id": "24163322_2_Ent4", "role": "Treatment_Disorder", "text": "diarrhea", "start": 26, "end": 27}, {"entity_id": "24163322_2_Ent0", "role": "Subject", "text": "an enterally fed patient", "start": 28, "end": 32}, {"entity_id": "24163322_2_Ent6", "role": "Treatment_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "24163322_2_Ent8", "role": "Combination_Drug", "text": "warfarin", "start": 33, "end": 34}, {"entity_id": "24163322_2_Ent3", "role": "Treatment", "text": "warfarin therapy", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "24163322_2_Ent1", "text": "inadvertent increase in the international normalized ratio ( INR )", "entity_type": "Entity", "start": 6, "end": 16}, {"id": "24163322_2_Ent2", "text": "addition of bismuth subsalicylate", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "24163322_2_Ent5", "text": "bismuth subsalicylate", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "24163322_2_Ent7", "text": "bismuth subsalicylate", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "24163322_2_Ent4", "text": "diarrhea", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "24163322_2_Ent0", "text": "an enterally fed patient", "entity_type": "Entity", "start": 28, "end": 32}, {"id": "24163322_2_Ent6", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "24163322_2_Ent8", "text": "warfarin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "24163322_2_Ent3", "text": "warfarin therapy", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "24163322_7", "wnd_id": "24163322_7_1", "text": "Bismuth subsalicylate 30 mL every 4 hours was prescribed for diarrhea .", "tokens": ["Bismuth", "subsalicylate", "30", "mL", "every", "4", "hours", "was", "prescribed", "for", "diarrhea", "."], "event_mentions": [{"id": "24163322_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prescribed", "start": 8, "end": 9}, "arguments": [{"entity_id": "24163322_7_Ent1", "role": "Treatment_Drug", "text": "Bismuth subsalicylate", "start": 0, "end": 2}, {"entity_id": "24163322_7_Ent0", "role": "Treatment", "text": "Bismuth subsalicylate 30 mL every 4 hours", "start": 0, "end": 7}, {"entity_id": "24163322_7_Ent2", "role": "Treatment_Dosage", "text": "30 mL", "start": 2, "end": 4}, {"entity_id": "24163322_7_Ent3", "role": "Treatment_Freq", "text": "every 4 hours", "start": 4, "end": 7}, {"entity_id": "24163322_7_Ent4", "role": "Treatment_Disorder", "text": "diarrhea", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "24163322_7_Ent1", "text": "Bismuth subsalicylate", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "24163322_7_Ent0", "text": "Bismuth subsalicylate 30 mL every 4 hours", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "24163322_7_Ent2", "text": "30 mL", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "24163322_7_Ent3", "text": "every 4 hours", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "24163322_7_Ent4", "text": "diarrhea", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "2429270_1", "wnd_id": "2429270_1_1", "text": "A patient with the Wolff - Parkinson - White syndrome presented with incessant orthodromic atrioventricular tachycardia following initiation of procainamide therapy .", "tokens": ["A", "patient", "with", "the", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "presented", "with", "incessant", "orthodromic", "atrioventricular", "tachycardia", "following", "initiation", "of", "procainamide", "therapy", "."], "event_mentions": [{"id": "2429270_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 16, "end": 17}, "arguments": [{"entity_id": "2429270_1_Ent0", "role": "Subject", "text": "A patient with the Wolff - Parkinson - White syndrome", "start": 0, "end": 10}, {"entity_id": "2429270_1_Ent3", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 4, "end": 10}, {"entity_id": "2429270_1_Ent1", "role": "Effect", "text": "incessant orthodromic atrioventricular tachycardia", "start": 12, "end": 16}, {"entity_id": "2429270_1_Ent2", "role": "Treatment", "text": "initiation of procainamide therapy", "start": 17, "end": 21}, {"entity_id": "2429270_1_Ent4", "role": "Treatment_Drug", "text": "procainamide", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "2429270_1_Ent0", "text": "A patient with the Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 0, "end": 10}, {"id": "2429270_1_Ent3", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "2429270_1_Ent1", "text": "incessant orthodromic atrioventricular tachycardia", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "2429270_1_Ent2", "text": "initiation of procainamide therapy", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "2429270_1_Ent4", "text": "procainamide", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "2429270_5", "wnd_id": "2429270_5_1", "text": "The pro - arrhythmic effects of procainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway .", "tokens": ["The", "pro", "-", "arrhythmic", "effects", "of", "procainamide", "may", "be", "explained", "on", "the", "basis", "of", "both", "its", "vagolytic", "action", "on", "the", "atrioventricular", "node", "as", "well", "as", "by", "prolongation", "of", "refractoriness", "in", "the", "accessory", "pathway", "."], "event_mentions": [{"id": "2429270_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 5, "end": 6}, "arguments": [{"entity_id": "2429270_5_Ent0", "role": "Effect", "text": "pro - arrhythmic effects", "start": 1, "end": 5}, {"entity_id": "2429270_5_Ent1", "role": "Treatment", "text": "procainamide", "start": 6, "end": 7}, {"entity_id": "2429270_5_Ent2", "role": "Treatment_Drug", "text": "procainamide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "2429270_5_Ent0", "text": "pro - arrhythmic effects", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "2429270_5_Ent1", "text": "procainamide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2429270_5_Ent2", "text": "procainamide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "24318743_14", "wnd_id": "24318743_14_1", "text": "Orally delivered PXD showed no evidence of clinical activity , when combined with weekly AUC2 - carboplatin in PROC .", "tokens": ["Orally", "delivered", "PXD", "showed", "no", "evidence", "of", "clinical", "activity", ",", "when", "combined", "with", "weekly", "AUC2", "-", "carboplatin", "in", "PROC", "."], "event_mentions": [{"id": "24318743_14_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "clinical activity", "start": 7, "end": 9}, "arguments": [{"entity_id": "24318743_14_Ent3", "role": "Treatment_Route", "text": "Orally", "start": 0, "end": 1}, {"entity_id": "24318743_14_Ent0", "role": "Treatment", "text": "Orally delivered PXD", "start": 0, "end": 3}, {"entity_id": "24318743_14_Ent4", "role": "Treatment_Drug", "text": "PXD", "start": 2, "end": 3}, {"entity_id": "24318743_14_Ent7", "role": "Combination_Drug", "text": "PXD", "start": 2, "end": 3}, {"entity_id": "24318743_14_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 13, "end": 14}, {"entity_id": "24318743_14_Ent1", "role": "Treatment", "text": "weekly AUC2 - carboplatin", "start": 13, "end": 17}, {"entity_id": "24318743_14_Ent5", "role": "Treatment_Drug", "text": "AUC2 - carboplatin", "start": 14, "end": 17}, {"entity_id": "24318743_14_Ent8", "role": "Combination_Drug", "text": "AUC2 - carboplatin", "start": 14, "end": 17}, {"entity_id": "24318743_14_Ent2", "role": "Treatment_Disorder", "text": "PROC", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "24318743_14_Ent3", "text": "Orally", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "24318743_14_Ent0", "text": "Orally delivered PXD", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24318743_14_Ent4", "text": "PXD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24318743_14_Ent7", "text": "PXD", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24318743_14_Ent6", "text": "weekly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "24318743_14_Ent1", "text": "weekly AUC2 - carboplatin", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "24318743_14_Ent5", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "24318743_14_Ent8", "text": "AUC2 - carboplatin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "24318743_14_Ent2", "text": "PROC", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "24318743_2", "wnd_id": "24318743_2_1", "text": "Platinum - resistant ovarian cancer ( PROC ) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic agents .", "tokens": ["Platinum", "-", "resistant", "ovarian", "cancer", "(", "PROC", ")", "constitutes", "a", "therapeutic", "dilemma", "with", "limited", "efficacy", "from", "traditional", "cytotoxic", "agents", "."], "event_mentions": [{"id": "24318743_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "from", "start": 15, "end": 16}, "arguments": [{"entity_id": "24318743_2_Ent2", "role": "Treatment_Disorder", "text": "Platinum - resistant ovarian cancer ( PROC )", "start": 0, "end": 8}, {"entity_id": "24318743_2_Ent0", "role": "Effect", "text": "limited efficacy", "start": 13, "end": 15}, {"entity_id": "24318743_2_Ent1", "role": "Treatment", "text": "traditional cytotoxic agents", "start": 16, "end": 19}, {"entity_id": "24318743_2_Ent3", "role": "Treatment_Drug", "text": "traditional cytotoxic agents", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "24318743_2_Ent2", "text": "Platinum - resistant ovarian cancer ( PROC )", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "24318743_2_Ent0", "text": "limited efficacy", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "24318743_2_Ent1", "text": "traditional cytotoxic agents", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "24318743_2_Ent3", "text": "traditional cytotoxic agents", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "2442958_1", "wnd_id": "2442958_1_1", "text": "Multicentric hepatocellular carcinoma following phosphate diethylstilbestrol therapy for prostatic cancer .", "tokens": ["Multicentric", "hepatocellular", "carcinoma", "following", "phosphate", "diethylstilbestrol", "therapy", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 3, "end": 4}, "arguments": [{"entity_id": "2442958_1_Ent0", "role": "Effect", "text": "Multicentric hepatocellular carcinoma", "start": 0, "end": 3}, {"entity_id": "2442958_1_Ent1", "role": "Treatment", "text": "phosphate diethylstilbestrol", "start": 4, "end": 6}, {"entity_id": "2442958_1_Ent2", "role": "Treatment_Drug", "text": "phosphate diethylstilbestrol", "start": 4, "end": 6}, {"entity_id": "2442958_1_Ent3", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "2442958_1_Ent0", "text": "Multicentric hepatocellular carcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2442958_1_Ent1", "text": "phosphate diethylstilbestrol", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2442958_1_Ent2", "text": "phosphate diethylstilbestrol", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2442958_1_Ent3", "text": "prostatic cancer", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "2442958_3", "wnd_id": "2442958_3_1", "text": "This paper reports an autopsy case of a 78 - year - old male with multiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( PDES ) for prostatic cancer .", "tokens": ["This", "paper", "reports", "an", "autopsy", "case", "of", "a", "78", "-", "year", "-", "old", "male", "with", "multiple", "nodules", "in", "the", "liver", "developed", "after", "long", "-", "termed", "administration", "of", "phosphate", "diethylstilbestrol", "(", "PDES", ")", "for", "prostatic", "cancer", "."], "event_mentions": [{"id": "2442958_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "2442958_3_Ent0", "role": "Subject", "text": "an autopsy case of a 78 - year - old male", "start": 3, "end": 14}, {"entity_id": "2442958_3_Ent2", "role": "Subject_Age", "text": "78 - year - old", "start": 8, "end": 13}, {"entity_id": "2442958_3_Ent3", "role": "Subject_Gender", "text": "male", "start": 13, "end": 14}, {"entity_id": "2442958_3_Ent4", "role": "Effect", "text": "multiple nodules in the liver", "start": 15, "end": 20}, {"entity_id": "2442958_3_Ent7", "role": "Treatment_Drug", "text": "phosphate diethylstilbestrol", "start": 27, "end": 29}, {"entity_id": "2442958_3_Ent5", "role": "Treatment", "text": "phosphate diethylstilbestrol ( PDES )", "start": 27, "end": 32}, {"entity_id": "2442958_3_Ent1", "role": "Subject", "text": "prostatic cancer", "start": 33, "end": 35}, {"entity_id": "2442958_3_Ent6", "role": "Treatment_Disorder", "text": "prostatic cancer", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "2442958_3_Ent0", "text": "an autopsy case of a 78 - year - old male", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "2442958_3_Ent2", "text": "78 - year - old", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "2442958_3_Ent3", "text": "male", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2442958_3_Ent4", "text": "multiple nodules in the liver", "entity_type": "Entity", "start": 15, "end": 20}, {"id": "2442958_3_Ent7", "text": "phosphate diethylstilbestrol", "entity_type": "Entity", "start": 27, "end": 29}, {"id": "2442958_3_Ent5", "text": "phosphate diethylstilbestrol ( PDES )", "entity_type": "Entity", "start": 27, "end": 32}, {"id": "2442958_3_Ent1", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}, {"id": "2442958_3_Ent6", "text": "prostatic cancer", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "24477376_5", "wnd_id": "24477376_5_1", "text": "While the patient was receiving both drugs , platelet aggregation studies revealed less platelet inhibition than would be expected in a patient not taking a concomitant inducer of ticagrelor metabolism .", "tokens": ["While", "the", "patient", "was", "receiving", "both", "drugs", ",", "platelet", "aggregation", "studies", "revealed", "less", "platelet", "inhibition", "than", "would", "be", "expected", "in", "a", "patient", "not", "taking", "a", "concomitant", "inducer", "of", "ticagrelor", "metabolism", "."], "event_mentions": [{"id": "24477376_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "revealed", "start": 11, "end": 12}, "arguments": [{"entity_id": "24477376_5_Ent1", "role": "Effect", "text": "less platelet inhibition than would be expected", "start": 12, "end": 19}, {"entity_id": "24477376_5_Ent0", "role": "Subject", "text": "a patient", "start": 20, "end": 22}, {"entity_id": "24477376_5_Ent2", "role": "Treatment", "text": "taking a concomitant inducer of ticagrelor metabolism .", "start": 23, "end": 31}, {"entity_id": "24477376_5_Ent4", "role": "Treatment_Drug", "text": "inducer of ticagrelor metabolism", "start": 26, "end": 30}, {"entity_id": "24477376_5_Ent5", "role": "Combination_Drug", "text": "inducer of ticagrelor metabolism", "start": 26, "end": 30}, {"entity_id": "24477376_5_Ent3", "role": "Treatment_Drug", "text": "ticagrelor", "start": 28, "end": 29}, {"entity_id": "24477376_5_Ent6", "role": "Combination_Drug", "text": "ticagrelor", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "24477376_5_Ent1", "text": "less platelet inhibition than would be expected", "entity_type": "Entity", "start": 12, "end": 19}, {"id": "24477376_5_Ent0", "text": "a patient", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "24477376_5_Ent2", "text": "taking a concomitant inducer of ticagrelor metabolism .", "entity_type": "Entity", "start": 23, "end": 31}, {"id": "24477376_5_Ent4", "text": "inducer of ticagrelor metabolism", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "24477376_5_Ent5", "text": "inducer of ticagrelor metabolism", "entity_type": "Entity", "start": 26, "end": 30}, {"id": "24477376_5_Ent3", "text": "ticagrelor", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "24477376_5_Ent6", "text": "ticagrelor", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "24477376_7", "wnd_id": "24477376_7_1", "text": "Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist following placement of coronary stents is critical to prevent stent thrombosis and subsequent myocardial infarction .", "tokens": ["Dual", "antiplatelet", "therapy", "with", "aspirin", "and", "a", "P2Y12", "receptor", "antagonist", "following", "placement", "of", "coronary", "stents", "is", "critical", "to", "prevent", "stent", "thrombosis", "and", "subsequent", "myocardial", "infarction", "."], "event_mentions": [{"id": "24477376_7_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "prevent", "start": 18, "end": 19}, "arguments": [{"entity_id": "24477376_7_Ent2", "role": "Treatment_Drug", "text": "aspirin", "start": 4, "end": 5}, {"entity_id": "24477376_7_Ent4", "role": "Combination_Drug", "text": "aspirin", "start": 4, "end": 5}, {"entity_id": "24477376_7_Ent0", "role": "Treatment", "text": "aspirin and a P2Y12 receptor antagonist following placement of coronary stents", "start": 4, "end": 15}, {"entity_id": "24477376_7_Ent3", "role": "Treatment_Drug", "text": "P2Y12 receptor antagonist", "start": 7, "end": 10}, {"entity_id": "24477376_7_Ent5", "role": "Combination_Drug", "text": "P2Y12 receptor antagonist", "start": 7, "end": 10}, {"entity_id": "24477376_7_Ent1", "role": "Treatment_Disorder", "text": "stent thrombosis and subsequent myocardial infarction", "start": 19, "end": 25}]}], "entity_mentions": [{"id": "24477376_7_Ent2", "text": "aspirin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "24477376_7_Ent4", "text": "aspirin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "24477376_7_Ent0", "text": "aspirin and a P2Y12 receptor antagonist following placement of coronary stents", "entity_type": "Entity", "start": 4, "end": 15}, {"id": "24477376_7_Ent3", "text": "P2Y12 receptor antagonist", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24477376_7_Ent5", "text": "P2Y12 receptor antagonist", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "24477376_7_Ent1", "text": "stent thrombosis and subsequent myocardial infarction", "entity_type": "Entity", "start": 19, "end": 25}], "lang": "en"}
{"doc_id": "24531907_1", "wnd_id": "24531907_1_1", "text": "Pharmacokinetics of etravirine in HIV - infected patients concomitantly treated with rifampin for tuberculosis .", "tokens": ["Pharmacokinetics", "of", "etravirine", "in", "HIV", "-", "infected", "patients", "concomitantly", "treated", "with", "rifampin", "for", "tuberculosis", "."], "event_mentions": [{"id": "24531907_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 12, "end": 13}, "arguments": [{"entity_id": "24531907_1_Ent1", "role": "Treatment", "text": "Pharmacokinetics of etravirine", "start": 0, "end": 3}, {"entity_id": "24531907_1_Ent3", "role": "Treatment_Drug", "text": "etravirine", "start": 2, "end": 3}, {"entity_id": "24531907_1_Ent7", "role": "Combination_Drug", "text": "etravirine", "start": 2, "end": 3}, {"entity_id": "24531907_1_Ent5", "role": "Treatment_Disorder", "text": "HIV", "start": 4, "end": 5}, {"entity_id": "24531907_1_Ent0", "role": "Subject", "text": "HIV - infected patients", "start": 4, "end": 8}, {"entity_id": "24531907_1_Ent2", "role": "Treatment", "text": "concomitantly treated with rifampin", "start": 8, "end": 12}, {"entity_id": "24531907_1_Ent4", "role": "Treatment_Drug", "text": "rifampin", "start": 11, "end": 12}, {"entity_id": "24531907_1_Ent8", "role": "Combination_Drug", "text": "rifampin", "start": 11, "end": 12}, {"entity_id": "24531907_1_Ent6", "role": "Treatment_Disorder", "text": "tuberculosis", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "24531907_1_Ent1", "text": "Pharmacokinetics of etravirine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "24531907_1_Ent3", "text": "etravirine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24531907_1_Ent7", "text": "etravirine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "24531907_1_Ent5", "text": "HIV", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "24531907_1_Ent0", "text": "HIV - infected patients", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "24531907_1_Ent2", "text": "concomitantly treated with rifampin", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "24531907_1_Ent4", "text": "rifampin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24531907_1_Ent8", "text": "rifampin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "24531907_1_Ent6", "text": "tuberculosis", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2461837_2", "wnd_id": "2461837_2_1", "text": "We report a case of hyperpigmentation due to bleomycin treatment in a patient with acquired immune deficiency syndrome ( AIDS ) .", "tokens": ["We", "report", "a", "case", "of", "hyperpigmentation", "due", "to", "bleomycin", "treatment", "in", "a", "patient", "with", "acquired", "immune", "deficiency", "syndrome", "(", "AIDS", ")", "."], "event_mentions": [{"id": "2461837_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 6, "end": 7}, "arguments": [{"entity_id": "2461837_2_Ent1", "role": "Effect", "text": "hyperpigmentation", "start": 5, "end": 6}, {"entity_id": "2461837_2_Ent2", "role": "Treatment", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "2461837_2_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 8, "end": 9}, {"entity_id": "2461837_2_Ent0", "role": "Subject", "text": "a patient with acquired immune deficiency syndrome ( AIDS )", "start": 11, "end": 21}, {"entity_id": "2461837_2_Ent4", "role": "Treatment_Disorder", "text": "acquired immune deficiency syndrome", "start": 14, "end": 18}]}], "entity_mentions": [{"id": "2461837_2_Ent1", "text": "hyperpigmentation", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2461837_2_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2461837_2_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2461837_2_Ent0", "text": "a patient with acquired immune deficiency syndrome ( AIDS )", "entity_type": "Entity", "start": 11, "end": 21}, {"id": "2461837_2_Ent4", "text": "acquired immune deficiency syndrome", "entity_type": "Entity", "start": 14, "end": 18}], "lang": "en"}
{"doc_id": "24755135_3", "wnd_id": "24755135_3_1", "text": "Study 202 was an open - label , add - on study in patients with partial or generalized epilepsy treated with valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy .", "tokens": ["Study", "202", "was", "an", "open", "-", "label", ",", "add", "-", "on", "study", "in", "patients", "with", "partial", "or", "generalized", "epilepsy", "treated", "with", "valproic", "acid", "(", "VPA", ")", ",", "carbamazepine", "(", "CBZ", ")", ",", "phenytoin", "(", "PHT", ")", ",", "or", "topiramate", "(", "TPM", ")", "as", "monotherapy", "."], "event_mentions": [{"id": "24755135_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 19, "end": 20}, "arguments": [{"entity_id": "24755135_3_Ent0", "role": "Subject", "text": "patients with partial or generalized epilepsy", "start": 13, "end": 19}, {"entity_id": "24755135_3_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 21, "end": 23}, {"entity_id": "24755135_3_Ent6", "role": "Combination_Drug", "text": "valproic acid", "start": 21, "end": 23}, {"entity_id": "24755135_3_Ent1", "role": "Treatment", "text": "valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy", "start": 21, "end": 44}, {"entity_id": "24755135_3_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 27, "end": 28}, {"entity_id": "24755135_3_Ent7", "role": "Combination_Drug", "text": "carbamazepine", "start": 27, "end": 28}, {"entity_id": "24755135_3_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 32, "end": 33}, {"entity_id": "24755135_3_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 32, "end": 33}, {"entity_id": "24755135_3_Ent5", "role": "Treatment_Drug", "text": "topiramate", "start": 38, "end": 39}, {"entity_id": "24755135_3_Ent9", "role": "Combination_Drug", "text": "topiramate", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "24755135_3_Ent0", "text": "patients with partial or generalized epilepsy", "entity_type": "Entity", "start": 13, "end": 19}, {"id": "24755135_3_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "24755135_3_Ent6", "text": "valproic acid", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "24755135_3_Ent1", "text": "valproic acid ( VPA ) , carbamazepine ( CBZ ) , phenytoin ( PHT ) , or topiramate ( TPM ) as monotherapy", "entity_type": "Entity", "start": 21, "end": 44}, {"id": "24755135_3_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24755135_3_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "24755135_3_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "24755135_3_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 32, "end": 33}, {"id": "24755135_3_Ent5", "text": "topiramate", "entity_type": "Entity", "start": 38, "end": 39}, {"id": "24755135_3_Ent9", "text": "topiramate", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "2483959_1", "wnd_id": "2483959_1_1", "text": "A typical case of dextran - 40 associated acute renal failure is presented .", "tokens": ["A", "typical", "case", "of", "dextran", "-", "40", "associated", "acute", "renal", "failure", "is", "presented", "."], "event_mentions": [{"id": "2483959_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "2483959_1_Ent1", "role": "Treatment", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent2", "role": "Treatment_Drug", "text": "dextran - 40", "start": 4, "end": 7}, {"entity_id": "2483959_1_Ent0", "role": "Effect", "text": "acute renal failure", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "2483959_1_Ent1", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent2", "text": "dextran - 40", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "2483959_1_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "25295553_3", "wnd_id": "25295553_3_1", "text": "Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off - label add - on treatment .", "tokens": ["Anxiety", "is", "common", "in", "patients", "with", "schizophrenia", "and", "pregabalin", "has", "been", "suggested", "as", "an", "off", "-", "label", "add", "-", "on", "treatment", "."], "event_mentions": [{"id": "25295553_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 20, "end": 21}, "arguments": [{"entity_id": "25295553_3_Ent4", "role": "Treatment_Disorder", "text": "Anxiety", "start": 0, "end": 1}, {"entity_id": "25295553_3_Ent0", "role": "Subject", "text": "patients with schizophrenia", "start": 4, "end": 7}, {"entity_id": "25295553_3_Ent1", "role": "Subject_Disorder", "text": "schizophrenia", "start": 6, "end": 7}, {"entity_id": "25295553_3_Ent3", "role": "Treatment_Drug", "text": "pregabalin", "start": 8, "end": 9}, {"entity_id": "25295553_3_Ent2", "role": "Treatment", "text": "pregabalin has been suggested as an off - label add - on treatment", "start": 8, "end": 21}]}], "entity_mentions": [{"id": "25295553_3_Ent4", "text": "Anxiety", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "25295553_3_Ent0", "text": "patients with schizophrenia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "25295553_3_Ent1", "text": "schizophrenia", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "25295553_3_Ent3", "text": "pregabalin", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25295553_3_Ent2", "text": "pregabalin has been suggested as an off - label add - on treatment", "entity_type": "Entity", "start": 8, "end": 21}], "lang": "en"}
{"doc_id": "2549018_6", "wnd_id": "2549018_6_1", "text": "Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .", "tokens": ["Three", "patients", "who", "had", "experienced", "neuroleptic", "-", "induced", "akathisia", "in", "the", "past", "reported", "that", "the", "symptoms", "of", "fluoxetine", "-", "induced", "akathisia", "were", "identical", ",", "although", "somewhat", "milder", "."], "event_mentions": [{"id": "2549018_6_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2549018_6_Ent8", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "2549018_6_Ent6", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "2549018_6_Ent10", "role": "Treatment", "text": "neuroleptic", "start": 5, "end": 6}, {"entity_id": "2549018_6_Ent11", "role": "Treatment_Drug", "text": "neuroleptic", "start": 5, "end": 6}, {"entity_id": "2549018_6_Ent7", "role": "Subject_Disorder", "text": "neuroleptic - induced akathisia", "start": 5, "end": 9}, {"entity_id": "2549018_6_Ent9", "role": "Effect", "text": "akathisia", "start": 8, "end": 9}]}, {"id": "2549018_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 19, "end": 20}, "arguments": [{"entity_id": "2549018_6_Ent2", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "2549018_6_Ent0", "role": "Subject", "text": "Three patients", "start": 0, "end": 2}, {"entity_id": "2549018_6_Ent1", "role": "Subject_Disorder", "text": "neuroleptic - induced akathisia", "start": 5, "end": 9}, {"entity_id": "2549018_6_Ent4", "role": "Treatment", "text": "fluoxetine", "start": 17, "end": 18}, {"entity_id": "2549018_6_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 17, "end": 18}, {"entity_id": "2549018_6_Ent3", "role": "Effect", "text": "akathisia", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2549018_6_Ent2", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_6_Ent8", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2549018_6_Ent0", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2549018_6_Ent6", "text": "Three patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2549018_6_Ent10", "text": "neuroleptic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2549018_6_Ent11", "text": "neuroleptic", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2549018_6_Ent1", "text": "neuroleptic - induced akathisia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2549018_6_Ent7", "text": "neuroleptic - induced akathisia", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "2549018_6_Ent9", "text": "akathisia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2549018_6_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2549018_6_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "2549018_6_Ent3", "text": "akathisia", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "25538343_3", "wnd_id": "25538343_3_1", "text": "Administration of thiazide diuretics also has been the cause of hyponatremia .", "tokens": ["Administration", "of", "thiazide", "diuretics", "also", "has", "been", "the", "cause", "of", "hyponatremia", "."], "event_mentions": [{"id": "25538343_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 8, "end": 9}, "arguments": [{"entity_id": "25538343_3_Ent1", "role": "Treatment", "text": "thiazide diuretics", "start": 2, "end": 4}, {"entity_id": "25538343_3_Ent2", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 2, "end": 4}, {"entity_id": "25538343_3_Ent0", "role": "Effect", "text": "hyponatremia", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "25538343_3_Ent1", "text": "thiazide diuretics", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "25538343_3_Ent2", "text": "thiazide diuretics", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "25538343_3_Ent0", "text": "hyponatremia", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "25538343_4", "wnd_id": "25538343_4_1", "text": "We report a case of duloxetine - induced hyponatremia in an elderly patient treated with thiazide diuretics .", "tokens": ["We", "report", "a", "case", "of", "duloxetine", "-", "induced", "hyponatremia", "in", "an", "elderly", "patient", "treated", "with", "thiazide", "diuretics", "."], "event_mentions": [{"id": "25538343_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "25538343_4_Ent3", "role": "Treatment", "text": "duloxetine", "start": 5, "end": 6}, {"entity_id": "25538343_4_Ent5", "role": "Treatment_Drug", "text": "duloxetine", "start": 5, "end": 6}, {"entity_id": "25538343_4_Ent8", "role": "Combination_Drug", "text": "duloxetine", "start": 5, "end": 6}, {"entity_id": "25538343_4_Ent2", "role": "Effect", "text": "hyponatremia", "start": 8, "end": 9}, {"entity_id": "25538343_4_Ent0", "role": "Subject", "text": "an elderly patient", "start": 10, "end": 13}, {"entity_id": "25538343_4_Ent1", "role": "Subject_Age", "text": "elderly", "start": 11, "end": 12}, {"entity_id": "25538343_4_Ent4", "role": "Treatment", "text": "thiazide diuretics", "start": 15, "end": 17}, {"entity_id": "25538343_4_Ent6", "role": "Treatment_Drug", "text": "thiazide diuretics", "start": 15, "end": 17}, {"entity_id": "25538343_4_Ent7", "role": "Combination_Drug", "text": "thiazide diuretics", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "25538343_4_Ent3", "text": "duloxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "25538343_4_Ent5", "text": "duloxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "25538343_4_Ent8", "text": "duloxetine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "25538343_4_Ent2", "text": "hyponatremia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "25538343_4_Ent0", "text": "an elderly patient", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "25538343_4_Ent1", "text": "elderly", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "25538343_4_Ent4", "text": "thiazide diuretics", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25538343_4_Ent6", "text": "thiazide diuretics", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "25538343_4_Ent7", "text": "thiazide diuretics", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "25540831_7", "wnd_id": "25540831_7_1", "text": "Most physicians are aware of serotonin syndrome secondary to antidepressants but do not think about other classes of medications such as analgesics .", "tokens": ["Most", "physicians", "are", "aware", "of", "serotonin", "syndrome", "secondary", "to", "antidepressants", "but", "do", "not", "think", "about", "other", "classes", "of", "medications", "such", "as", "analgesics", "."], "event_mentions": [{"id": "25540831_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 7, "end": 8}, "arguments": [{"entity_id": "25540831_7_Ent0", "role": "Effect", "text": "serotonin syndrome", "start": 5, "end": 7}, {"entity_id": "25540831_7_Ent1", "role": "Treatment", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent2", "role": "Treatment_Drug", "text": "antidepressants", "start": 9, "end": 10}, {"entity_id": "25540831_7_Ent3", "role": "Treatment_Drug", "text": "analgesics", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "25540831_7_Ent0", "text": "serotonin syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "25540831_7_Ent1", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent2", "text": "antidepressants", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "25540831_7_Ent3", "text": "analgesics", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "2554727_5", "wnd_id": "2554727_5_1", "text": "Peripheral nerve dysfunction is a potentially serious complication of high - dose cytosine arabinoside .", "tokens": ["Peripheral", "nerve", "dysfunction", "is", "a", "potentially", "serious", "complication", "of", "high", "-", "dose", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "2554727_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "2554727_5_Ent0", "role": "Effect", "text": "Peripheral nerve dysfunction", "start": 0, "end": 3}, {"entity_id": "2554727_5_Ent3", "role": "Treatment_Dosage", "text": "high - dose", "start": 9, "end": 12}, {"entity_id": "2554727_5_Ent1", "role": "Treatment", "text": "cytosine arabinoside", "start": 12, "end": 14}, {"entity_id": "2554727_5_Ent2", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "2554727_5_Ent0", "text": "Peripheral nerve dysfunction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2554727_5_Ent3", "text": "high - dose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2554727_5_Ent1", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2554727_5_Ent2", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "2568058_1", "wnd_id": "2568058_1_1", "text": "Nail - changes induced by penicillamine .", "tokens": ["Nail", "-", "changes", "induced", "by", "penicillamine", "."], "event_mentions": [{"id": "2568058_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "2568058_1_Ent0", "role": "Effect", "text": "Nail - changes", "start": 0, "end": 3}, {"entity_id": "2568058_1_Ent1", "role": "Treatment", "text": "penicillamine", "start": 5, "end": 6}, {"entity_id": "2568058_1_Ent2", "role": "Treatment_Drug", "text": "penicillamine", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "2568058_1_Ent0", "text": "Nail - changes", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2568058_1_Ent1", "text": "penicillamine", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2568058_1_Ent2", "text": "penicillamine", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "2568058_2", "wnd_id": "2568058_2_1", "text": "Peculiar nail - changes in a 70 - year - old woman with rheumatoid arthritis occurring after approximately 1 year of penicillamine treatment are described .", "tokens": ["Peculiar", "nail", "-", "changes", "in", "a", "70", "-", "year", "-", "old", "woman", "with", "rheumatoid", "arthritis", "occurring", "after", "approximately", "1", "year", "of", "penicillamine", "treatment", "are", "described", "."], "event_mentions": [{"id": "2568058_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 16, "end": 17}, "arguments": [{"entity_id": "2568058_2_Ent3", "role": "Effect", "text": "Peculiar nail - changes", "start": 0, "end": 4}, {"entity_id": "2568058_2_Ent0", "role": "Subject", "text": "a 70 - year - old woman with rheumatoid arthritis", "start": 5, "end": 15}, {"entity_id": "2568058_2_Ent1", "role": "Subject_Age", "text": "70 - year - old", "start": 6, "end": 11}, {"entity_id": "2568058_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 11, "end": 12}, {"entity_id": "2568058_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 13, "end": 15}, {"entity_id": "2568058_2_Ent6", "role": "Treatment_Time_elapsed", "text": "1 year", "start": 18, "end": 20}, {"entity_id": "2568058_2_Ent4", "role": "Treatment", "text": "penicillamine", "start": 21, "end": 22}, {"entity_id": "2568058_2_Ent7", "role": "Treatment_Drug", "text": "penicillamine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "2568058_2_Ent3", "text": "Peculiar nail - changes", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "2568058_2_Ent0", "text": "a 70 - year - old woman with rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "2568058_2_Ent1", "text": "70 - year - old", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "2568058_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "2568058_2_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "2568058_2_Ent6", "text": "1 year", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "2568058_2_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "2568058_2_Ent7", "text": "penicillamine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "2586773_2", "wnd_id": "2586773_2_1", "text": "We report a case of ibuprofen - induced meningitis in an otherwise healthy individual .", "tokens": ["We", "report", "a", "case", "of", "ibuprofen", "-", "induced", "meningitis", "in", "an", "otherwise", "healthy", "individual", "."], "event_mentions": [{"id": "2586773_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "2586773_2_Ent2", "role": "Treatment", "text": "ibuprofen", "start": 5, "end": 6}, {"entity_id": "2586773_2_Ent3", "role": "Treatment_Drug", "text": "ibuprofen", "start": 5, "end": 6}, {"entity_id": "2586773_2_Ent1", "role": "Effect", "text": "meningitis", "start": 8, "end": 9}, {"entity_id": "2586773_2_Ent0", "role": "Subject", "text": "an otherwise healthy individual", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "2586773_2_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2586773_2_Ent3", "text": "ibuprofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2586773_2_Ent1", "text": "meningitis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2586773_2_Ent0", "text": "an otherwise healthy individual", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "2621382_3", "wnd_id": "2621382_3_1", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of clofazimine , showed discoloration of nail plate , subungual hyperkeratosis and onycholysis .", "tokens": ["Two", "cases", "of", "lepromatous", "leprosy", "with", "erythema", "nodosum", "leprosum", "who", "were", "on", "high", "doses", "of", "clofazimine", ",", "showed", "discoloration", "of", "nail", "plate", ",", "subungual", "hyperkeratosis", "and", "onycholysis", "."], "event_mentions": [{"id": "2621382_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "showed", "start": 17, "end": 18}, "arguments": [{"entity_id": "2621382_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2621382_3_Ent0", "role": "Subject", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum", "start": 0, "end": 9}, {"entity_id": "2621382_3_Ent4", "role": "Treatment_Disorder", "text": "lepromatous leprosy with erythema nodosum leprosum", "start": 3, "end": 9}, {"entity_id": "2621382_3_Ent6", "role": "Treatment_Dosage", "text": "high doses", "start": 12, "end": 14}, {"entity_id": "2621382_3_Ent3", "role": "Treatment", "text": "high doses of clofazimine", "start": 12, "end": 16}, {"entity_id": "2621382_3_Ent5", "role": "Treatment_Drug", "text": "clofazimine", "start": 15, "end": 16}, {"entity_id": "2621382_3_Ent2", "role": "Effect", "text": "discoloration of nail plate , subungual hyperkeratosis and onycholysis", "start": 18, "end": 27}]}], "entity_mentions": [{"id": "2621382_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2621382_3_Ent0", "text": "Two cases of lepromatous leprosy with erythema nodosum leprosum", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "2621382_3_Ent4", "text": "lepromatous leprosy with erythema nodosum leprosum", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "2621382_3_Ent6", "text": "high doses", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "2621382_3_Ent3", "text": "high doses of clofazimine", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "2621382_3_Ent5", "text": "clofazimine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "2621382_3_Ent2", "text": "discoloration of nail plate , subungual hyperkeratosis and onycholysis", "entity_type": "Entity", "start": 18, "end": 27}], "lang": "en"}
{"doc_id": "2663536_1", "wnd_id": "2663536_1_1", "text": "Development of persistent late onset asthma following treatment with captopril .", "tokens": ["Development", "of", "persistent", "late", "onset", "asthma", "following", "treatment", "with", "captopril", "."], "event_mentions": [{"id": "2663536_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "2663536_1_Ent0", "role": "Effect", "text": "persistent late onset asthma", "start": 2, "end": 6}, {"entity_id": "2663536_1_Ent1", "role": "Treatment", "text": "captopril", "start": 9, "end": 10}, {"entity_id": "2663536_1_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2663536_1_Ent0", "text": "persistent late onset asthma", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "2663536_1_Ent1", "text": "captopril", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "2663536_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2663536_2", "wnd_id": "2663536_2_1", "text": "We describe the first case of de novo asthma following treatment with the angiotensin converting enzyme ( ACE ) inhibitor captopril .", "tokens": ["We", "describe", "the", "first", "case", "of", "de", "novo", "asthma", "following", "treatment", "with", "the", "angiotensin", "converting", "enzyme", "(", "ACE", ")", "inhibitor", "captopril", "."], "event_mentions": [{"id": "2663536_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treatment with", "start": 10, "end": 12}, "arguments": [{"entity_id": "2663536_2_Ent0", "role": "Effect", "text": "de novo asthma", "start": 6, "end": 9}, {"entity_id": "2663536_2_Ent1", "role": "Treatment", "text": "the angiotensin converting enzyme ( ACE ) inhibitor captopril", "start": 12, "end": 21}, {"entity_id": "2663536_2_Ent2", "role": "Treatment_Drug", "text": "captopril", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "2663536_2_Ent0", "text": "de novo asthma", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "2663536_2_Ent1", "text": "the angiotensin converting enzyme ( ACE ) inhibitor captopril", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "2663536_2_Ent2", "text": "captopril", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "2669373_1", "wnd_id": "2669373_1_1", "text": "A case report of a patient with probable cisplatin and bleomycin - induced TMA is presented .", "tokens": ["A", "case", "report", "of", "a", "patient", "with", "probable", "cisplatin", "and", "bleomycin", "-", "induced", "TMA", "is", "presented", "."], "event_mentions": [{"id": "2669373_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 12, "end": 13}, "arguments": [{"entity_id": "2669373_1_Ent0", "role": "Subject", "text": "a patient with probable cisplatin", "start": 4, "end": 9}, {"entity_id": "2669373_1_Ent4", "role": "Treatment_Disorder", "text": "probable cisplatin", "start": 7, "end": 9}, {"entity_id": "2669373_1_Ent2", "role": "Treatment", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "2669373_1_Ent3", "role": "Treatment_Drug", "text": "bleomycin", "start": 10, "end": 11}, {"entity_id": "2669373_1_Ent1", "role": "Effect", "text": "TMA", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "2669373_1_Ent0", "text": "a patient with probable cisplatin", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "2669373_1_Ent4", "text": "probable cisplatin", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "2669373_1_Ent2", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2669373_1_Ent3", "text": "bleomycin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2669373_1_Ent1", "text": "TMA", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "2719905_2", "wnd_id": "2719905_2_1", "text": "We report a case of long lasting respiratory depression after intravenous administration of morphine to a 7 year old girl with haemolytic uraemic syndrome .", "tokens": ["We", "report", "a", "case", "of", "long", "lasting", "respiratory", "depression", "after", "intravenous", "administration", "of", "morphine", "to", "a", "7", "year", "old", "girl", "with", "haemolytic", "uraemic", "syndrome", "."], "event_mentions": [{"id": "2719905_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 9, "end": 10}, "arguments": [{"entity_id": "2719905_2_Ent4", "role": "Effect", "text": "a case of long lasting respiratory depression", "start": 2, "end": 9}, {"entity_id": "2719905_2_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 10, "end": 11}, {"entity_id": "2719905_2_Ent5", "role": "Treatment", "text": "intravenous administration of morphine", "start": 10, "end": 14}, {"entity_id": "2719905_2_Ent7", "role": "Treatment_Drug", "text": "morphine", "start": 13, "end": 14}, {"entity_id": "2719905_2_Ent0", "role": "Subject", "text": "a 7 year old girl with haemolytic uraemic syndrome", "start": 15, "end": 24}, {"entity_id": "2719905_2_Ent1", "role": "Subject_Age", "text": "7 year old", "start": 16, "end": 19}, {"entity_id": "2719905_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 19, "end": 20}, {"entity_id": "2719905_2_Ent3", "role": "Subject_Disorder", "text": "haemolytic uraemic syndrome", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "2719905_2_Ent4", "text": "a case of long lasting respiratory depression", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "2719905_2_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "2719905_2_Ent5", "text": "intravenous administration of morphine", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "2719905_2_Ent7", "text": "morphine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "2719905_2_Ent0", "text": "a 7 year old girl with haemolytic uraemic syndrome", "entity_type": "Entity", "start": 15, "end": 24}, {"id": "2719905_2_Ent1", "text": "7 year old", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "2719905_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "2719905_2_Ent3", "text": "haemolytic uraemic syndrome", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "2738729_2", "wnd_id": "2738729_2_1", "text": "Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy .", "tokens": ["Withdrawal", "emergent", "syndrome", "in", "an", "infant", "associated", "with", "maternal", "haloperidol", "therapy", "."], "event_mentions": [{"id": "2738729_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 6, "end": 7}, "arguments": [{"entity_id": "2738729_2_Ent2", "role": "Effect", "text": "Withdrawal emergent syndrome", "start": 0, "end": 3}, {"entity_id": "2738729_2_Ent0", "role": "Subject", "text": "an infant", "start": 4, "end": 6}, {"entity_id": "2738729_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 5, "end": 6}, {"entity_id": "2738729_2_Ent5", "role": "Treatment_Route", "text": "maternal", "start": 8, "end": 9}, {"entity_id": "2738729_2_Ent3", "role": "Treatment", "text": "maternal haloperidol therapy", "start": 8, "end": 11}, {"entity_id": "2738729_2_Ent4", "role": "Treatment_Drug", "text": "haloperidol", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "2738729_2_Ent2", "text": "Withdrawal emergent syndrome", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2738729_2_Ent0", "text": "an infant", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "2738729_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2738729_2_Ent5", "text": "maternal", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "2738729_2_Ent3", "text": "maternal haloperidol therapy", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "2738729_2_Ent4", "text": "haloperidol", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "2743258_1", "wnd_id": "2743258_1_1", "text": "This report describes two patients who developed acute myelocytic leukemia only after exposure to cyclophosphamide , methotrexate , and 5 - fluorouracil adjuvant therapy .", "tokens": ["This", "report", "describes", "two", "patients", "who", "developed", "acute", "myelocytic", "leukemia", "only", "after", "exposure", "to", "cyclophosphamide", ",", "methotrexate", ",", "and", "5", "-", "fluorouracil", "adjuvant", "therapy", "."], "event_mentions": [{"id": "2743258_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "2743258_1_Ent1", "role": "Subject_Population", "text": "two", "start": 3, "end": 4}, {"entity_id": "2743258_1_Ent0", "role": "Subject", "text": "two patients", "start": 3, "end": 5}, {"entity_id": "2743258_1_Ent2", "role": "Effect", "text": "acute myelocytic leukemia", "start": 7, "end": 10}, {"entity_id": "2743258_1_Ent3", "role": "Treatment", "text": "exposure to cyclophosphamide , methotrexate , and 5 - fluorouracil adjuvant therapy", "start": 12, "end": 24}, {"entity_id": "2743258_1_Ent4", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 14, "end": 15}, {"entity_id": "2743258_1_Ent8", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 14, "end": 15}, {"entity_id": "2743258_1_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "2743258_1_Ent9", "role": "Combination_Drug", "text": "methotrexate", "start": 16, "end": 17}, {"entity_id": "2743258_1_Ent6", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 19, "end": 22}, {"entity_id": "2743258_1_Ent7", "role": "Combination_Drug", "text": "5 - fluorouracil", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "2743258_1_Ent1", "text": "two", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "2743258_1_Ent0", "text": "two patients", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2743258_1_Ent2", "text": "acute myelocytic leukemia", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "2743258_1_Ent3", "text": "exposure to cyclophosphamide , methotrexate , and 5 - fluorouracil adjuvant therapy", "entity_type": "Entity", "start": 12, "end": 24}, {"id": "2743258_1_Ent4", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2743258_1_Ent8", "text": "cyclophosphamide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2743258_1_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "2743258_1_Ent9", "text": "methotrexate", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "2743258_1_Ent6", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "2743258_1_Ent7", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "278642_1", "wnd_id": "278642_1_1", "text": "Acute myelogenous leukemia in patients receiving chlorambucil as long - term adjuvant chemotherapy for stage II breast cancer .", "tokens": ["Acute", "myelogenous", "leukemia", "in", "patients", "receiving", "chlorambucil", "as", "long", "-", "term", "adjuvant", "chemotherapy", "for", "stage", "II", "breast", "cancer", "."], "event_mentions": [{"id": "278642_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "278642_1_Ent1", "role": "Effect", "text": "Acute myelogenous leukemia", "start": 0, "end": 3}, {"entity_id": "278642_1_Ent0", "role": "Subject", "text": "patients", "start": 4, "end": 5}, {"entity_id": "278642_1_Ent2", "role": "Treatment", "text": "receiving chlorambucil as long - term adjuvant chemotherapy", "start": 5, "end": 13}, {"entity_id": "278642_1_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 6, "end": 7}, {"entity_id": "278642_1_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 12, "end": 13}, {"entity_id": "278642_1_Ent4", "role": "Treatment_Disorder", "text": "stage II breast cancer .", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "278642_1_Ent1", "text": "Acute myelogenous leukemia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "278642_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "278642_1_Ent2", "text": "receiving chlorambucil as long - term adjuvant chemotherapy", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "278642_1_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "278642_1_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "278642_1_Ent4", "text": "stage II breast cancer .", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "2811895_2", "wnd_id": "2811895_2_1", "text": "Life - threatening cranial dystonia following trihexyphenidyl withdrawal .", "tokens": ["Life", "-", "threatening", "cranial", "dystonia", "following", "trihexyphenidyl", "withdrawal", "."], "event_mentions": [{"id": "2811895_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 5, "end": 6}, "arguments": [{"entity_id": "2811895_2_Ent0", "role": "Effect", "text": "cranial dystonia", "start": 3, "end": 5}, {"entity_id": "2811895_2_Ent2", "role": "Treatment_Drug", "text": "trihexyphenidyl", "start": 6, "end": 7}, {"entity_id": "2811895_2_Ent1", "role": "Treatment", "text": "trihexyphenidyl withdrawal", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "2811895_2_Ent0", "text": "cranial dystonia", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "2811895_2_Ent2", "text": "trihexyphenidyl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "2811895_2_Ent1", "text": "trihexyphenidyl withdrawal", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "282937_2", "wnd_id": "282937_2_1", "text": "Paraplegia following intrathecal cytosine arabinoside .", "tokens": ["Paraplegia", "following", "intrathecal", "cytosine", "arabinoside", "."], "event_mentions": [{"id": "282937_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 1, "end": 2}, "arguments": [{"entity_id": "282937_2_Ent0", "role": "Effect", "text": "Paraplegia", "start": 0, "end": 1}, {"entity_id": "282937_2_Ent2", "role": "Treatment_Route", "text": "intrathecal", "start": 2, "end": 3}, {"entity_id": "282937_2_Ent1", "role": "Treatment", "text": "intrathecal cytosine arabinoside", "start": 2, "end": 5}, {"entity_id": "282937_2_Ent3", "role": "Treatment_Drug", "text": "cytosine arabinoside", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "282937_2_Ent0", "text": "Paraplegia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "282937_2_Ent2", "text": "intrathecal", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "282937_2_Ent1", "text": "intrathecal cytosine arabinoside", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "282937_2_Ent3", "text": "cytosine arabinoside", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "2857534_3", "wnd_id": "2857534_3_1", "text": "Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed lithium - responsive manic episodes .", "tokens": ["Two", "patients", "treated", "with", "alprazolam", "had", "histories", "suggestive", "of", "a", "bipolar", "disorder", "and", "developed", "lithium", "-", "responsive", "manic", "episodes", "."], "event_mentions": [{"id": "2857534_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "2857534_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "2857534_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "2857534_3_Ent4", "role": "Treatment", "text": "alprazolam", "start": 4, "end": 5}, {"entity_id": "2857534_3_Ent5", "role": "Treatment_Drug", "text": "alprazolam", "start": 4, "end": 5}, {"entity_id": "2857534_3_Ent2", "role": "Subject_Disorder", "text": "a bipolar disorder", "start": 9, "end": 12}, {"entity_id": "2857534_3_Ent3", "role": "Effect", "text": "lithium - responsive manic episodes", "start": 14, "end": 19}]}], "entity_mentions": [{"id": "2857534_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2857534_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "2857534_3_Ent4", "text": "alprazolam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2857534_3_Ent5", "text": "alprazolam", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "2857534_3_Ent2", "text": "a bipolar disorder", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "2857534_3_Ent3", "text": "lithium - responsive manic episodes", "entity_type": "Entity", "start": 14, "end": 19}], "lang": "en"}
{"doc_id": "2862137_1", "wnd_id": "2862137_1_1", "text": "A case is presented in which a 68 - year - old man became delirious after being withdrawn from a low dosage of alprazolam .", "tokens": ["A", "case", "is", "presented", "in", "which", "a", "68", "-", "year", "-", "old", "man", "became", "delirious", "after", "being", "withdrawn", "from", "a", "low", "dosage", "of", "alprazolam", "."], "event_mentions": [{"id": "2862137_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "2862137_1_Ent1", "role": "Subject_Age", "text": "68 - year - old", "start": 7, "end": 12}, {"entity_id": "2862137_1_Ent0", "role": "Subject", "text": "68 - year - old man", "start": 7, "end": 13}, {"entity_id": "2862137_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 12, "end": 13}, {"entity_id": "2862137_1_Ent3", "role": "Effect", "text": "delirious", "start": 14, "end": 15}, {"entity_id": "2862137_1_Ent4", "role": "Treatment", "text": "withdrawn from a low dosage of alprazolam", "start": 17, "end": 24}, {"entity_id": "2862137_1_Ent6", "role": "Treatment_Dosage", "text": "low dosage", "start": 20, "end": 22}, {"entity_id": "2862137_1_Ent5", "role": "Treatment_Drug", "text": "alprazolam", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "2862137_1_Ent1", "text": "68 - year - old", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "2862137_1_Ent0", "text": "68 - year - old man", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "2862137_1_Ent2", "text": "man", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "2862137_1_Ent3", "text": "delirious", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "2862137_1_Ent4", "text": "withdrawn from a low dosage of alprazolam", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "2862137_1_Ent6", "text": "low dosage", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "2862137_1_Ent5", "text": "alprazolam", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "2931445_1", "wnd_id": "2931445_1_1", "text": "L - Thyroxine - induced leukopenia in a patient with Hashimoto 's disease : involvement of suppressor - cytotoxic T cells .", "tokens": ["L", "-", "Thyroxine", "-", "induced", "leukopenia", "in", "a", "patient", "with", "Hashimoto", "'s", "disease", ":", "involvement", "of", "suppressor", "-", "cytotoxic", "T", "cells", "."], "event_mentions": [{"id": "2931445_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "2931445_1_Ent2", "role": "Treatment", "text": "L - Thyroxine", "start": 0, "end": 3}, {"entity_id": "2931445_1_Ent3", "role": "Treatment_Drug", "text": "L - Thyroxine", "start": 0, "end": 3}, {"entity_id": "2931445_1_Ent1", "role": "Effect", "text": "leukopenia", "start": 5, "end": 6}, {"entity_id": "2931445_1_Ent0", "role": "Subject", "text": "a patient with Hashimoto 's disease", "start": 7, "end": 13}, {"entity_id": "2931445_1_Ent4", "role": "Treatment_Disorder", "text": "Hashimoto 's disease", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "2931445_1_Ent2", "text": "L - Thyroxine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_1_Ent3", "text": "L - Thyroxine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "2931445_1_Ent1", "text": "leukopenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "2931445_1_Ent0", "text": "a patient with Hashimoto 's disease", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "2931445_1_Ent4", "text": "Hashimoto 's disease", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "2935070_3", "wnd_id": "2935070_3_1", "text": "In the following case report , a patient developed acute interstitial nephritis with renal failure and exfoliative dermatitis following ampicillin therapy .", "tokens": ["In", "the", "following", "case", "report", ",", "a", "patient", "developed", "acute", "interstitial", "nephritis", "with", "renal", "failure", "and", "exfoliative", "dermatitis", "following", "ampicillin", "therapy", "."], "event_mentions": [{"id": "2935070_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "2935070_3_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "2935070_3_Ent1", "role": "Effect", "text": "acute interstitial nephritis with renal failure and exfoliative dermatitis", "start": 9, "end": 18}, {"entity_id": "2935070_3_Ent3", "role": "Treatment_Drug", "text": "ampicillin", "start": 19, "end": 20}, {"entity_id": "2935070_3_Ent2", "role": "Treatment", "text": "ampicillin therapy", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "2935070_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "2935070_3_Ent1", "text": "acute interstitial nephritis with renal failure and exfoliative dermatitis", "entity_type": "Entity", "start": 9, "end": 18}, {"id": "2935070_3_Ent3", "text": "ampicillin", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "2935070_3_Ent2", "text": "ampicillin therapy", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "2937155_3", "wnd_id": "2937155_3_1", "text": "Vancomycin - induced vasculitis .", "tokens": ["Vancomycin", "-", "induced", "vasculitis", "."], "event_mentions": [{"id": "2937155_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "2937155_3_Ent1", "role": "Treatment", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "2937155_3_Ent2", "role": "Treatment_Drug", "text": "Vancomycin", "start": 0, "end": 1}, {"entity_id": "2937155_3_Ent0", "role": "Effect", "text": "vasculitis", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "2937155_3_Ent1", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2937155_3_Ent2", "text": "Vancomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2937155_3_Ent0", "text": "vasculitis", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "2979256_3", "wnd_id": "2979256_3_1", "text": "Nifedipine may induce , or aggravate , pre - existing , gastro - oesophageal reflux .", "tokens": ["Nifedipine", "may", "induce", ",", "or", "aggravate", ",", "pre", "-", "existing", ",", "gastro", "-", "oesophageal", "reflux", "."], "event_mentions": [{"id": "2979256_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce , or aggravate", "start": 2, "end": 6}, "arguments": [{"entity_id": "2979256_3_Ent1", "role": "Treatment", "text": "Nifedipine", "start": 0, "end": 1}, {"entity_id": "2979256_3_Ent2", "role": "Treatment_Drug", "text": "Nifedipine", "start": 0, "end": 1}, {"entity_id": "2979256_3_Ent0", "role": "Effect", "text": "gastro - oesophageal reflux", "start": 11, "end": 15}]}], "entity_mentions": [{"id": "2979256_3_Ent1", "text": "Nifedipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2979256_3_Ent2", "text": "Nifedipine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "2979256_3_Ent0", "text": "gastro - oesophageal reflux", "entity_type": "Entity", "start": 11, "end": 15}], "lang": "en"}
{"doc_id": "3030084_1", "wnd_id": "3030084_1_1", "text": "Transient phenytoin induced IgA deficiency and permanent IgE increase .", "tokens": ["Transient", "phenytoin", "induced", "IgA", "deficiency", "and", "permanent", "IgE", "increase", "."], "event_mentions": [{"id": "3030084_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3030084_1_Ent1", "role": "Treatment", "text": "phenytoin", "start": 1, "end": 2}, {"entity_id": "3030084_1_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 1, "end": 2}, {"entity_id": "3030084_1_Ent0", "role": "Effect", "text": "IgA deficiency and permanent IgE increase", "start": 3, "end": 9}]}], "entity_mentions": [{"id": "3030084_1_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3030084_1_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3030084_1_Ent0", "text": "IgA deficiency and permanent IgE increase", "entity_type": "Entity", "start": 3, "end": 9}], "lang": "en"}
{"doc_id": "3101617_2", "wnd_id": "3101617_2_1", "text": "When co - trimoxazole was stopped the red cell aplasia resolved .", "tokens": ["When", "co", "-", "trimoxazole", "was", "stopped", "the", "red", "cell", "aplasia", "resolved", "."], "event_mentions": [{"id": "3101617_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "stopped", "start": 5, "end": 6}, "arguments": [{"entity_id": "3101617_2_Ent1", "role": "Treatment", "text": "co - trimoxazole", "start": 1, "end": 4}, {"entity_id": "3101617_2_Ent2", "role": "Treatment_Drug", "text": "co - trimoxazole", "start": 1, "end": 4}, {"entity_id": "3101617_2_Ent0", "role": "Effect", "text": "red cell aplasia resolved", "start": 7, "end": 11}]}], "entity_mentions": [{"id": "3101617_2_Ent1", "text": "co - trimoxazole", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "3101617_2_Ent2", "text": "co - trimoxazole", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "3101617_2_Ent0", "text": "red cell aplasia resolved", "entity_type": "Entity", "start": 7, "end": 11}], "lang": "en"}
{"doc_id": "3136101_2", "wnd_id": "3136101_2_1", "text": "Two infants developed hyperkalemia shortly after cessation of prolonged ACTH therapy for infantile spasms .", "tokens": ["Two", "infants", "developed", "hyperkalemia", "shortly", "after", "cessation", "of", "prolonged", "ACTH", "therapy", "for", "infantile", "spasms", "."], "event_mentions": [{"id": "3136101_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "3136101_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "3136101_2_Ent0", "role": "Subject", "text": "Two infants", "start": 0, "end": 2}, {"entity_id": "3136101_2_Ent2", "role": "Subject_Age", "text": "infants", "start": 1, "end": 2}, {"entity_id": "3136101_2_Ent3", "role": "Effect", "text": "hyperkalemia", "start": 3, "end": 4}, {"entity_id": "3136101_2_Ent6", "role": "Treatment_Time_elapsed", "text": "shortly after", "start": 4, "end": 6}, {"entity_id": "3136101_2_Ent4", "role": "Treatment", "text": "shortly after cessation of prolonged ACTH therapy", "start": 4, "end": 11}, {"entity_id": "3136101_2_Ent7", "role": "Treatment_Dosage", "text": "cessation", "start": 6, "end": 7}, {"entity_id": "3136101_2_Ent8", "role": "Treatment_Drug", "text": "ACTH", "start": 9, "end": 10}, {"entity_id": "3136101_2_Ent5", "role": "Treatment_Disorder", "text": "infantile spasms", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3136101_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3136101_2_Ent0", "text": "Two infants", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3136101_2_Ent2", "text": "infants", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3136101_2_Ent3", "text": "hyperkalemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3136101_2_Ent6", "text": "shortly after", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3136101_2_Ent4", "text": "shortly after cessation of prolonged ACTH therapy", "entity_type": "Entity", "start": 4, "end": 11}, {"id": "3136101_2_Ent7", "text": "cessation", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3136101_2_Ent8", "text": "ACTH", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3136101_2_Ent5", "text": "infantile spasms", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3143551_2", "wnd_id": "3143551_2_1", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion , called camptocormia , during valproate monotherapy .", "tokens": ["A", "mentally", "retarded", "23", "-", "year", "-", "old", "woman", "with", "myoclonic", "astatic", "epilepsy", "developed", "an", "abnormal", "posture", "of", "extreme", "forward", "flexion", ",", "called", "camptocormia", ",", "during", "valproate", "monotherapy", "."], "event_mentions": [{"id": "3143551_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 25, "end": 26}, "arguments": [{"entity_id": "3143551_2_Ent0", "role": "Subject", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy", "start": 0, "end": 13}, {"entity_id": "3143551_2_Ent1", "role": "Subject_Disorder", "text": "mentally retarded", "start": 1, "end": 3}, {"entity_id": "3143551_2_Ent2", "role": "Subject_Age", "text": "23 - year - old", "start": 3, "end": 8}, {"entity_id": "3143551_2_Ent6", "role": "Treatment_Disorder", "text": "myoclonic astatic epilepsy", "start": 10, "end": 13}, {"entity_id": "3143551_2_Ent3", "role": "Effect", "text": "abnormal posture of extreme forward flexion , called camptocormia ,", "start": 15, "end": 25}, {"entity_id": "3143551_2_Ent4", "role": "Treatment", "text": "valproate", "start": 26, "end": 27}, {"entity_id": "3143551_2_Ent5", "role": "Treatment_Drug", "text": "valproate", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "3143551_2_Ent0", "text": "A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "3143551_2_Ent1", "text": "mentally retarded", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "3143551_2_Ent2", "text": "23 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3143551_2_Ent6", "text": "myoclonic astatic epilepsy", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3143551_2_Ent3", "text": "abnormal posture of extreme forward flexion , called camptocormia ,", "entity_type": "Entity", "start": 15, "end": 25}, {"id": "3143551_2_Ent4", "text": "valproate", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "3143551_2_Ent5", "text": "valproate", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "3149484_1", "wnd_id": "3149484_1_1", "text": "A 10 - year - old girl with Lennox - Gastaut syndrome who received intravenous lorazepam for atypical absence status seizures is reported .", "tokens": ["A", "10", "-", "year", "-", "old", "girl", "with", "Lennox", "-", "Gastaut", "syndrome", "who", "received", "intravenous", "lorazepam", "for", "atypical", "absence", "status", "seizures", "is", "reported", "."], "event_mentions": [{"id": "3149484_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "for", "start": 16, "end": 17}, "arguments": [{"entity_id": "3149484_1_Ent0", "role": "Subject", "text": "A 10 - year - old girl with Lennox - Gastaut syndrome", "start": 0, "end": 12}, {"entity_id": "3149484_1_Ent2", "role": "Subject_Age", "text": "10 - year - old", "start": 1, "end": 6}, {"entity_id": "3149484_1_Ent3", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "3149484_1_Ent1", "role": "Subject_Disorder", "text": "Lennox - Gastaut syndrome", "start": 8, "end": 12}, {"entity_id": "3149484_1_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 14, "end": 15}, {"entity_id": "3149484_1_Ent4", "role": "Treatment", "text": "intravenous lorazepam", "start": 14, "end": 16}, {"entity_id": "3149484_1_Ent7", "role": "Treatment_Drug", "text": "lorazepam", "start": 15, "end": 16}, {"entity_id": "3149484_1_Ent5", "role": "Treatment_Disorder", "text": "atypical absence status seizures", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "3149484_1_Ent0", "text": "A 10 - year - old girl with Lennox - Gastaut syndrome", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "3149484_1_Ent2", "text": "10 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3149484_1_Ent3", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3149484_1_Ent1", "text": "Lennox - Gastaut syndrome", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "3149484_1_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3149484_1_Ent4", "text": "intravenous lorazepam", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3149484_1_Ent7", "text": "lorazepam", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "3149484_1_Ent5", "text": "atypical absence status seizures", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "3156465_2", "wnd_id": "3156465_2_1", "text": "Isotretinoin teratogenicity .", "tokens": ["Isotretinoin", "teratogenicity", "."], "event_mentions": [{"id": "3156465_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Isotretinoin teratogenicity", "start": 0, "end": 2}, "arguments": [{"entity_id": "3156465_2_Ent1", "role": "Treatment", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_2_Ent2", "role": "Treatment_Drug", "text": "Isotretinoin", "start": 0, "end": 1}, {"entity_id": "3156465_2_Ent0", "role": "Effect", "text": "teratogenicity", "start": 1, "end": 2}]}], "entity_mentions": [{"id": "3156465_2_Ent1", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_2_Ent2", "text": "Isotretinoin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3156465_2_Ent0", "text": "teratogenicity", "entity_type": "Entity", "start": 1, "end": 2}], "lang": "en"}
{"doc_id": "3171334_1", "wnd_id": "3171334_1_1", "text": "A case of severe visual loss following a single dose of vincristine is described .", "tokens": ["A", "case", "of", "severe", "visual", "loss", "following", "a", "single", "dose", "of", "vincristine", "is", "described", "."], "event_mentions": [{"id": "3171334_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 6, "end": 7}, "arguments": [{"entity_id": "3171334_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "3171334_1_Ent1", "role": "Effect", "text": "severe visual loss", "start": 3, "end": 6}, {"entity_id": "3171334_1_Ent3", "role": "Treatment_Dosage", "text": "a single dose", "start": 7, "end": 10}, {"entity_id": "3171334_1_Ent2", "role": "Treatment", "text": "a single dose of vincristine", "start": 7, "end": 12}, {"entity_id": "3171334_1_Ent4", "role": "Treatment_Drug", "text": "vincristine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3171334_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3171334_1_Ent1", "text": "severe visual loss", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3171334_1_Ent3", "text": "a single dose", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3171334_1_Ent2", "text": "a single dose of vincristine", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "3171334_1_Ent4", "text": "vincristine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3171334_4", "wnd_id": "3171334_4_1", "text": "The literature of vincristine optic nerve toxicity is reviewed .", "tokens": ["The", "literature", "of", "vincristine", "optic", "nerve", "toxicity", "is", "reviewed", "."], "event_mentions": [{"id": "3171334_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 6, "end": 7}, "arguments": [{"entity_id": "3171334_4_Ent1", "role": "Treatment", "text": "vincristine", "start": 3, "end": 4}, {"entity_id": "3171334_4_Ent2", "role": "Treatment_Drug", "text": "vincristine", "start": 3, "end": 4}, {"entity_id": "3171334_4_Ent0", "role": "Effect", "text": "optic nerve toxicity", "start": 4, "end": 7}]}], "entity_mentions": [{"id": "3171334_4_Ent1", "text": "vincristine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3171334_4_Ent2", "text": "vincristine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3171334_4_Ent0", "text": "optic nerve toxicity", "entity_type": "Entity", "start": 4, "end": 7}], "lang": "en"}
{"doc_id": "3171334_5", "wnd_id": "3171334_5_1", "text": "Visual loss after a single small dose of vincristine has never been reported .", "tokens": ["Visual", "loss", "after", "a", "single", "small", "dose", "of", "vincristine", "has", "never", "been", "reported", "."], "event_mentions": [{"id": "3171334_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 2, "end": 3}, "arguments": [{"entity_id": "3171334_5_Ent0", "role": "Effect", "text": "Visual loss", "start": 0, "end": 2}, {"entity_id": "3171334_5_Ent1", "role": "Treatment", "text": "a single small dose of vincristine", "start": 3, "end": 9}, {"entity_id": "3171334_5_Ent3", "role": "Treatment_Duration", "text": "single", "start": 4, "end": 5}, {"entity_id": "3171334_5_Ent4", "role": "Treatment_Dosage", "text": "small dose", "start": 5, "end": 7}, {"entity_id": "3171334_5_Ent2", "role": "Treatment_Duration", "text": "dose", "start": 6, "end": 7}, {"entity_id": "3171334_5_Ent5", "role": "Treatment_Drug", "text": "vincristine", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3171334_5_Ent0", "text": "Visual loss", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3171334_5_Ent1", "text": "a single small dose of vincristine", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "3171334_5_Ent3", "text": "single", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3171334_5_Ent4", "text": "small dose", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3171334_5_Ent2", "text": "dose", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3171334_5_Ent5", "text": "vincristine", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3174043_1", "wnd_id": "3174043_1_1", "text": "Niacin causes a reversible toxic cystoid maculopathy that occurs in approximately 0.67 % of patients taking high doses of the drug .", "tokens": ["Niacin", "causes", "a", "reversible", "toxic", "cystoid", "maculopathy", "that", "occurs", "in", "approximately", "0.67", "%", "of", "patients", "taking", "high", "doses", "of", "the", "drug", "."], "event_mentions": [{"id": "3174043_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causes", "start": 1, "end": 2}, "arguments": [{"entity_id": "3174043_1_Ent3", "role": "Treatment", "text": "Niacin", "start": 0, "end": 1}, {"entity_id": "3174043_1_Ent5", "role": "Treatment_Drug", "text": "Niacin", "start": 0, "end": 1}, {"entity_id": "3174043_1_Ent2", "role": "Effect", "text": "reversible toxic cystoid maculopathy", "start": 3, "end": 7}, {"entity_id": "3174043_1_Ent0", "role": "Subject", "text": "approximately 0.67 % of patients", "start": 10, "end": 15}, {"entity_id": "3174043_1_Ent1", "role": "Subject_Population", "text": "0.67 %", "start": 11, "end": 13}, {"entity_id": "3174043_1_Ent4", "role": "Treatment", "text": "high doses", "start": 16, "end": 18}, {"entity_id": "3174043_1_Ent6", "role": "Treatment_Dosage", "text": "high doses", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "3174043_1_Ent3", "text": "Niacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3174043_1_Ent5", "text": "Niacin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3174043_1_Ent2", "text": "reversible toxic cystoid maculopathy", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "3174043_1_Ent0", "text": "approximately 0.67 % of patients", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "3174043_1_Ent1", "text": "0.67 %", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "3174043_1_Ent4", "text": "high doses", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "3174043_1_Ent6", "text": "high doses", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "3174043_3", "wnd_id": "3174043_3_1", "text": "The authors conclude that among patients taking high doses of oral niacin only those who experience visual symptoms need to be ophthalmologically evaluated .", "tokens": ["The", "authors", "conclude", "that", "among", "patients", "taking", "high", "doses", "of", "oral", "niacin", "only", "those", "who", "experience", "visual", "symptoms", "need", "to", "be", "ophthalmologically", "evaluated", "."], "event_mentions": [{"id": "3174043_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 6, "end": 7}, "arguments": [{"entity_id": "3174043_3_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "3174043_3_Ent3", "role": "Treatment_Dosage", "text": "high doses", "start": 7, "end": 9}, {"entity_id": "3174043_3_Ent2", "role": "Treatment", "text": "high doses of oral niacin", "start": 7, "end": 12}, {"entity_id": "3174043_3_Ent4", "role": "Treatment_Route", "text": "oral", "start": 10, "end": 11}, {"entity_id": "3174043_3_Ent5", "role": "Treatment_Drug", "text": "niacin", "start": 11, "end": 12}, {"entity_id": "3174043_3_Ent1", "role": "Effect", "text": "visual symptoms", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "3174043_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3174043_3_Ent3", "text": "high doses", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "3174043_3_Ent2", "text": "high doses of oral niacin", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "3174043_3_Ent4", "text": "oral", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "3174043_3_Ent5", "text": "niacin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3174043_3_Ent1", "text": "visual symptoms", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "3195622_1", "wnd_id": "3195622_1_1", "text": "A case report of the hypersensitivity syndrome occurring in a patient being treated with dapsone for a brown recluse spider bite is presented .", "tokens": ["A", "case", "report", "of", "the", "hypersensitivity", "syndrome", "occurring", "in", "a", "patient", "being", "treated", "with", "dapsone", "for", "a", "brown", "recluse", "spider", "bite", "is", "presented", "."], "event_mentions": [{"id": "3195622_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 12, "end": 13}, "arguments": [{"entity_id": "3195622_1_Ent1", "role": "Effect", "text": "hypersensitivity syndrome", "start": 5, "end": 7}, {"entity_id": "3195622_1_Ent0", "role": "Subject", "text": "a patient", "start": 9, "end": 11}, {"entity_id": "3195622_1_Ent2", "role": "Treatment", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "3195622_1_Ent3", "role": "Treatment_Drug", "text": "dapsone", "start": 14, "end": 15}, {"entity_id": "3195622_1_Ent4", "role": "Treatment_Disorder", "text": "brown recluse spider bite", "start": 17, "end": 21}]}], "entity_mentions": [{"id": "3195622_1_Ent1", "text": "hypersensitivity syndrome", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3195622_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3195622_1_Ent2", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3195622_1_Ent3", "text": "dapsone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "3195622_1_Ent4", "text": "brown recluse spider bite", "entity_type": "Entity", "start": 17, "end": 21}], "lang": "en"}
{"doc_id": "3290702_1", "wnd_id": "3290702_1_1", "text": "A clinically atypical , neuropathologically verified case of Creutzfeldt - Jakob disease is described in a 32 - year - old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence ( 1970 to 1973 ) with human growth hormone processed from pooled cadaveric pituitary glands .", "tokens": ["A", "clinically", "atypical", ",", "neuropathologically", "verified", "case", "of", "Creutzfeldt", "-", "Jakob", "disease", "is", "described", "in", "a", "32", "-", "year", "-", "old", "New", "Zealand", "woman", "with", "idiopathic", "hypopituitarism", "who", "had", "been", "treated", "in", "late", "adolescence", "(", "1970", "to", "1973", ")", "with", "human", "growth", "hormone", "processed", "from", "pooled", "cadaveric", "pituitary", "glands", "."], "event_mentions": [{"id": "3290702_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "described", "start": 13, "end": 14}, "arguments": [{"entity_id": "3290702_1_Ent4", "role": "Effect", "text": "Creutzfeldt - Jakob disease", "start": 8, "end": 12}, {"entity_id": "3290702_1_Ent0", "role": "Subject", "text": "a 32 - year - old New Zealand woman with idiopathic hypopituitarism", "start": 15, "end": 27}, {"entity_id": "3290702_1_Ent1", "role": "Subject_Age", "text": "32 - year - old", "start": 16, "end": 21}, {"entity_id": "3290702_1_Ent2", "role": "Subject_Race", "text": "New Zealand", "start": 21, "end": 23}, {"entity_id": "3290702_1_Ent3", "role": "Subject_Gender", "text": "woman", "start": 23, "end": 24}, {"entity_id": "3290702_1_Ent6", "role": "Treatment_Disorder", "text": "idiopathic hypopituitarism", "start": 25, "end": 27}, {"entity_id": "3290702_1_Ent5", "role": "Treatment", "text": "human growth hormone", "start": 40, "end": 43}, {"entity_id": "3290702_1_Ent7", "role": "Treatment_Drug", "text": "human growth hormone", "start": 40, "end": 43}]}], "entity_mentions": [{"id": "3290702_1_Ent4", "text": "Creutzfeldt - Jakob disease", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "3290702_1_Ent0", "text": "a 32 - year - old New Zealand woman with idiopathic hypopituitarism", "entity_type": "Entity", "start": 15, "end": 27}, {"id": "3290702_1_Ent1", "text": "32 - year - old", "entity_type": "Entity", "start": 16, "end": 21}, {"id": "3290702_1_Ent2", "text": "New Zealand", "entity_type": "Entity", "start": 21, "end": 23}, {"id": "3290702_1_Ent3", "text": "woman", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3290702_1_Ent6", "text": "idiopathic hypopituitarism", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "3290702_1_Ent5", "text": "human growth hormone", "entity_type": "Entity", "start": 40, "end": 43}, {"id": "3290702_1_Ent7", "text": "human growth hormone", "entity_type": "Entity", "start": 40, "end": 43}], "lang": "en"}
{"doc_id": "3290702_2", "wnd_id": "3290702_2_1", "text": "A new case of Creutzfeldt - Jakob disease associated with human growth hormone therapy in New Zealand .", "tokens": ["A", "new", "case", "of", "Creutzfeldt", "-", "Jakob", "disease", "associated", "with", "human", "growth", "hormone", "therapy", "in", "New", "Zealand", "."], "event_mentions": [{"id": "3290702_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "3290702_2_Ent0", "role": "Subject", "text": "A new case", "start": 0, "end": 3}, {"entity_id": "3290702_2_Ent1", "role": "Effect", "text": "Creutzfeldt - Jakob disease", "start": 4, "end": 8}, {"entity_id": "3290702_2_Ent2", "role": "Treatment", "text": "human growth hormone", "start": 10, "end": 13}, {"entity_id": "3290702_2_Ent3", "role": "Treatment_Drug", "text": "human growth hormone", "start": 10, "end": 13}]}], "entity_mentions": [{"id": "3290702_2_Ent0", "text": "A new case", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3290702_2_Ent1", "text": "Creutzfeldt - Jakob disease", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3290702_2_Ent2", "text": "human growth hormone", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "3290702_2_Ent3", "text": "human growth hormone", "entity_type": "Entity", "start": 10, "end": 13}], "lang": "en"}
{"doc_id": "3301251_1", "wnd_id": "3301251_1_1", "text": "A case of a 21 - year - old woman who had developed mild hepatotoxicity while receiving choline magnesium trisalicylate therapy is described .", "tokens": ["A", "case", "of", "a", "21", "-", "year", "-", "old", "woman", "who", "had", "developed", "mild", "hepatotoxicity", "while", "receiving", "choline", "magnesium", "trisalicylate", "therapy", "is", "described", "."], "event_mentions": [{"id": "3301251_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 16, "end": 17}, "arguments": [{"entity_id": "3301251_1_Ent0", "role": "Subject", "text": "a 21 - year - old woman", "start": 3, "end": 10}, {"entity_id": "3301251_1_Ent1", "role": "Subject_Age", "text": "21 - year - old", "start": 4, "end": 9}, {"entity_id": "3301251_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "3301251_1_Ent3", "role": "Effect", "text": "mild hepatotoxicity", "start": 13, "end": 15}, {"entity_id": "3301251_1_Ent4", "role": "Treatment", "text": "choline magnesium trisalicylate", "start": 17, "end": 20}, {"entity_id": "3301251_1_Ent5", "role": "Treatment_Drug", "text": "choline magnesium trisalicylate", "start": 17, "end": 20}]}], "entity_mentions": [{"id": "3301251_1_Ent0", "text": "a 21 - year - old woman", "entity_type": "Entity", "start": 3, "end": 10}, {"id": "3301251_1_Ent1", "text": "21 - year - old", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "3301251_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3301251_1_Ent3", "text": "mild hepatotoxicity", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "3301251_1_Ent4", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "3301251_1_Ent5", "text": "choline magnesium trisalicylate", "entity_type": "Entity", "start": 17, "end": 20}], "lang": "en"}
{"doc_id": "3301251_3", "wnd_id": "3301251_3_1", "text": "Salicylate - induced hepatotoxicity is reviewed .", "tokens": ["Salicylate", "-", "induced", "hepatotoxicity", "is", "reviewed", "."], "event_mentions": [{"id": "3301251_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "3301251_3_Ent1", "role": "Treatment", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent2", "role": "Treatment_Drug", "text": "Salicylate", "start": 0, "end": 1}, {"entity_id": "3301251_3_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "3301251_3_Ent1", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent2", "text": "Salicylate", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3301251_3_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "3310776_1", "wnd_id": "3310776_1_1", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria developed attacks of asthma when captopril was added to the nadolol and dyazide treatment for his high blood pressure .", "tokens": ["A", "51", "-", "yr", "-", "old", "nonsmoking", "male", "patient", "without", "any", "history", "of", "previous", "allergies", ",", "asthma", ",", "hay", "fever", ",", "or", "urticaria", "developed", "attacks", "of", "asthma", "when", "captopril", "was", "added", "to", "the", "nadolol", "and", "dyazide", "treatment", "for", "his", "high", "blood", "pressure", "."], "event_mentions": [{"id": "3310776_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 23, "end": 24}, "arguments": [{"entity_id": "3310776_1_Ent0", "role": "Subject", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria", "start": 0, "end": 23}, {"entity_id": "3310776_1_Ent1", "role": "Subject_Age", "text": "51 - yr - old", "start": 1, "end": 6}, {"entity_id": "3310776_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "3310776_1_Ent3", "role": "Effect", "text": "attacks of asthma", "start": 24, "end": 27}, {"entity_id": "3310776_1_Ent6", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}, {"entity_id": "3310776_1_Ent9", "role": "Combination_Drug", "text": "captopril", "start": 28, "end": 29}, {"entity_id": "3310776_1_Ent4", "role": "Treatment", "text": "captopril was added to the nadolol and dyazide", "start": 28, "end": 36}, {"entity_id": "3310776_1_Ent7", "role": "Treatment_Drug", "text": "nadolol", "start": 33, "end": 34}, {"entity_id": "3310776_1_Ent10", "role": "Combination_Drug", "text": "nadolol", "start": 33, "end": 34}, {"entity_id": "3310776_1_Ent8", "role": "Treatment_Drug", "text": "dyazide", "start": 35, "end": 36}, {"entity_id": "3310776_1_Ent11", "role": "Combination_Drug", "text": "dyazide", "start": 35, "end": 36}, {"entity_id": "3310776_1_Ent5", "role": "Treatment_Disorder", "text": "high blood pressure", "start": 39, "end": 42}]}], "entity_mentions": [{"id": "3310776_1_Ent0", "text": "A 51 - yr - old nonsmoking male patient without any history of previous allergies , asthma , hay fever , or urticaria", "entity_type": "Entity", "start": 0, "end": 23}, {"id": "3310776_1_Ent1", "text": "51 - yr - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "3310776_1_Ent2", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3310776_1_Ent3", "text": "attacks of asthma", "entity_type": "Entity", "start": 24, "end": 27}, {"id": "3310776_1_Ent6", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "3310776_1_Ent9", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "3310776_1_Ent4", "text": "captopril was added to the nadolol and dyazide", "entity_type": "Entity", "start": 28, "end": 36}, {"id": "3310776_1_Ent7", "text": "nadolol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "3310776_1_Ent10", "text": "nadolol", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "3310776_1_Ent8", "text": "dyazide", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3310776_1_Ent11", "text": "dyazide", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "3310776_1_Ent5", "text": "high blood pressure", "entity_type": "Entity", "start": 39, "end": 42}], "lang": "en"}
{"doc_id": "3359700_2", "wnd_id": "3359700_2_1", "text": "Based upon the observed fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria , we suggest that in this case the tubules and/or interstitium are the main targets for cyclosporine A nephrotoxicity .", "tokens": ["Based", "upon", "the", "observed", "fall", "of", "the", "filtration", "fraction", ",", "the", "rise", "in", "the", "relative", "clearance", "of", "99Tc", "-", "dimercaptosuccinic", "acid", "and", "the", "increase", "in", "proteinuria", ",", "we", "suggest", "that", "in", "this", "case", "the", "tubules", "and/or", "interstitium", "are", "the", "main", "targets", "for", "cyclosporine", "A", "nephrotoxicity", "."], "event_mentions": [{"id": "3359700_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "3359700_2_Ent0", "role": "Effect", "text": "fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria", "start": 4, "end": 26}, {"entity_id": "3359700_2_Ent1", "role": "Treatment", "text": "cyclosporine A", "start": 42, "end": 44}, {"entity_id": "3359700_2_Ent2", "role": "Treatment_Drug", "text": "cyclosporine A", "start": 42, "end": 44}]}], "entity_mentions": [{"id": "3359700_2_Ent0", "text": "fall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria", "entity_type": "Entity", "start": 4, "end": 26}, {"id": "3359700_2_Ent1", "text": "cyclosporine A", "entity_type": "Entity", "start": 42, "end": 44}, {"id": "3359700_2_Ent2", "text": "cyclosporine A", "entity_type": "Entity", "start": 42, "end": 44}], "lang": "en"}
{"doc_id": "3379435_3", "wnd_id": "3379435_3_1", "text": "Three senile patients developed fatal acute encephalopathy while receiving calcium hopantenate .", "tokens": ["Three", "senile", "patients", "developed", "fatal", "acute", "encephalopathy", "while", "receiving", "calcium", "hopantenate", "."], "event_mentions": [{"id": "3379435_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 3, "end": 4}, "arguments": [{"entity_id": "3379435_3_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "3379435_3_Ent0", "role": "Subject", "text": "Three senile patients", "start": 0, "end": 3}, {"entity_id": "3379435_3_Ent2", "role": "Subject_Age", "text": "senile", "start": 1, "end": 2}, {"entity_id": "3379435_3_Ent3", "role": "Effect", "text": "encephalopathy", "start": 6, "end": 7}, {"entity_id": "3379435_3_Ent4", "role": "Treatment", "text": "calcium hopantenate", "start": 9, "end": 11}, {"entity_id": "3379435_3_Ent5", "role": "Treatment_Drug", "text": "calcium hopantenate", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3379435_3_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3379435_3_Ent0", "text": "Three senile patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3379435_3_Ent2", "text": "senile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3379435_3_Ent3", "text": "encephalopathy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3379435_3_Ent4", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3379435_3_Ent5", "text": "calcium hopantenate", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3410226_2", "wnd_id": "3410226_2_1", "text": "We report a 46 - yr - old woman with ovarian carcinoma who developed porphyria cutanea tarda while undergoing treatment with cisplatin and cyclophosphamide .", "tokens": ["We", "report", "a", "46", "-", "yr", "-", "old", "woman", "with", "ovarian", "carcinoma", "who", "developed", "porphyria", "cutanea", "tarda", "while", "undergoing", "treatment", "with", "cisplatin", "and", "cyclophosphamide", "."], "event_mentions": [{"id": "3410226_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 13, "end": 14}, "arguments": [{"entity_id": "3410226_2_Ent0", "role": "Subject", "text": "a 46 - yr - old woman with ovarian carcinoma", "start": 2, "end": 12}, {"entity_id": "3410226_2_Ent1", "role": "Subject_Age", "text": "46 - yr - old", "start": 3, "end": 8}, {"entity_id": "3410226_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 8, "end": 9}, {"entity_id": "3410226_2_Ent7", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 10, "end": 12}, {"entity_id": "3410226_2_Ent3", "role": "Effect", "text": "porphyria cutanea tarda", "start": 14, "end": 17}, {"entity_id": "3410226_2_Ent5", "role": "Treatment_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent8", "role": "Combination_Drug", "text": "cisplatin", "start": 21, "end": 22}, {"entity_id": "3410226_2_Ent4", "role": "Treatment", "text": "cisplatin and cyclophosphamide", "start": 21, "end": 24}, {"entity_id": "3410226_2_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}, {"entity_id": "3410226_2_Ent9", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "3410226_2_Ent0", "text": "a 46 - yr - old woman with ovarian carcinoma", "entity_type": "Entity", "start": 2, "end": 12}, {"id": "3410226_2_Ent1", "text": "46 - yr - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3410226_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3410226_2_Ent7", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3410226_2_Ent3", "text": "porphyria cutanea tarda", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "3410226_2_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent8", "text": "cisplatin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "3410226_2_Ent4", "text": "cisplatin and cyclophosphamide", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "3410226_2_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "3410226_2_Ent9", "text": "cyclophosphamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "3417739_1", "wnd_id": "3417739_1_1", "text": "Acute renal failure in a patient treated by continuous povidone - iodine mediastinal irrigation .", "tokens": ["Acute", "renal", "failure", "in", "a", "patient", "treated", "by", "continuous", "povidone", "-", "iodine", "mediastinal", "irrigation", "."], "event_mentions": [{"id": "3417739_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "3417739_1_Ent1", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "3417739_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "3417739_1_Ent2", "role": "Treatment", "text": "continuous povidone - iodine mediastinal irrigation", "start": 8, "end": 14}, {"entity_id": "3417739_1_Ent3", "role": "Treatment_Drug", "text": "povidone", "start": 9, "end": 10}, {"entity_id": "3417739_1_Ent6", "role": "Combination_Drug", "text": "povidone", "start": 9, "end": 10}, {"entity_id": "3417739_1_Ent4", "role": "Treatment_Drug", "text": "iodine", "start": 11, "end": 12}, {"entity_id": "3417739_1_Ent7", "role": "Combination_Drug", "text": "iodine", "start": 11, "end": 12}, {"entity_id": "3417739_1_Ent5", "role": "Treatment_Route", "text": "irrigation", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "3417739_1_Ent1", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3417739_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "3417739_1_Ent2", "text": "continuous povidone - iodine mediastinal irrigation", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "3417739_1_Ent3", "text": "povidone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3417739_1_Ent6", "text": "povidone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3417739_1_Ent4", "text": "iodine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3417739_1_Ent7", "text": "iodine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3417739_1_Ent5", "text": "irrigation", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "3465489_1", "wnd_id": "3465489_1_1", "text": "Pharmacokinetic determinants of 6 - mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia .", "tokens": ["Pharmacokinetic", "determinants", "of", "6", "-", "mercaptopurine", "myelotoxicity", "and", "therapeutic", "failure", "in", "children", "with", "acute", "lymphoblastic", "leukemia", "."], "event_mentions": [{"id": "3465489_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "3465489_1_Ent3", "role": "Treatment", "text": "6 - mercaptopurine", "start": 3, "end": 6}, {"entity_id": "3465489_1_Ent4", "role": "Treatment_Drug", "text": "6 - mercaptopurine", "start": 3, "end": 6}, {"entity_id": "3465489_1_Ent2", "role": "Effect", "text": "myelotoxicity and therapeutic failure", "start": 6, "end": 10}, {"entity_id": "3465489_1_Ent1", "role": "Subject_Age", "text": "children", "start": 11, "end": 12}, {"entity_id": "3465489_1_Ent0", "role": "Subject", "text": "children with acute lymphoblastic leukemia", "start": 11, "end": 16}, {"entity_id": "3465489_1_Ent5", "role": "Treatment_Disorder", "text": "acute lymphoblastic leukemia", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "3465489_1_Ent3", "text": "6 - mercaptopurine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3465489_1_Ent4", "text": "6 - mercaptopurine", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "3465489_1_Ent2", "text": "myelotoxicity and therapeutic failure", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3465489_1_Ent1", "text": "children", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3465489_1_Ent0", "text": "children with acute lymphoblastic leukemia", "entity_type": "Entity", "start": 11, "end": 16}, {"id": "3465489_1_Ent5", "text": "acute lymphoblastic leukemia", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "3501467_2", "wnd_id": "3501467_2_1", "text": "Hypogammaglobulinemia associated with gold therapy : evidence for a partial maturation blockade of B cells .", "tokens": ["Hypogammaglobulinemia", "associated", "with", "gold", "therapy", ":", "evidence", "for", "a", "partial", "maturation", "blockade", "of", "B", "cells", "."], "event_mentions": [{"id": "3501467_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "3501467_2_Ent0", "role": "Effect", "text": "Hypogammaglobulinemia", "start": 0, "end": 1}, {"entity_id": "3501467_2_Ent3", "role": "Treatment_Drug", "text": "gold", "start": 3, "end": 4}, {"entity_id": "3501467_2_Ent2", "role": "Treatment", "text": "gold therapy", "start": 3, "end": 5}, {"entity_id": "3501467_2_Ent1", "role": "Effect", "text": "a partial maturation blockade of B cells", "start": 8, "end": 15}]}], "entity_mentions": [{"id": "3501467_2_Ent0", "text": "Hypogammaglobulinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3501467_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3501467_2_Ent2", "text": "gold therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3501467_2_Ent1", "text": "a partial maturation blockade of B cells", "entity_type": "Entity", "start": 8, "end": 15}], "lang": "en"}
{"doc_id": "3508194_1", "wnd_id": "3508194_1_1", "text": "Transient leucopenia and thrombocytopenia associated with sodium nitroprusside infusion .", "tokens": ["Transient", "leucopenia", "and", "thrombocytopenia", "associated", "with", "sodium", "nitroprusside", "infusion", "."], "event_mentions": [{"id": "3508194_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "3508194_1_Ent0", "role": "Effect", "text": "Transient leucopenia and thrombocytopenia", "start": 0, "end": 4}, {"entity_id": "3508194_1_Ent3", "role": "Treatment_Drug", "text": "sodium nitroprusside", "start": 6, "end": 8}, {"entity_id": "3508194_1_Ent1", "role": "Treatment", "text": "sodium nitroprusside infusion", "start": 6, "end": 9}, {"entity_id": "3508194_1_Ent2", "role": "Treatment_Route", "text": "infusion", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3508194_1_Ent0", "text": "Transient leucopenia and thrombocytopenia", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3508194_1_Ent3", "text": "sodium nitroprusside", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3508194_1_Ent1", "text": "sodium nitroprusside infusion", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "3508194_1_Ent2", "text": "infusion", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3513544_2", "wnd_id": "3513544_2_1", "text": "We report the first case of herpes esophagitis in a renal transplant patient treated with Cyclosporine A while on chronic steroid therapy .", "tokens": ["We", "report", "the", "first", "case", "of", "herpes", "esophagitis", "in", "a", "renal", "transplant", "patient", "treated", "with", "Cyclosporine", "A", "while", "on", "chronic", "steroid", "therapy", "."], "event_mentions": [{"id": "3513544_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "3513544_2_Ent1", "role": "Effect", "text": "herpes esophagitis", "start": 6, "end": 8}, {"entity_id": "3513544_2_Ent0", "role": "Subject", "text": "a renal transplant patient", "start": 9, "end": 13}, {"entity_id": "3513544_2_Ent5", "role": "Treatment_Disorder", "text": "renal transplant", "start": 10, "end": 12}, {"entity_id": "3513544_2_Ent3", "role": "Treatment_Drug", "text": "Cyclosporine A", "start": 15, "end": 17}, {"entity_id": "3513544_2_Ent6", "role": "Combination_Drug", "text": "Cyclosporine A", "start": 15, "end": 17}, {"entity_id": "3513544_2_Ent2", "role": "Treatment", "text": "Cyclosporine A while on chronic steroid therapy", "start": 15, "end": 22}, {"entity_id": "3513544_2_Ent4", "role": "Treatment_Drug", "text": "chronic steroid", "start": 19, "end": 21}, {"entity_id": "3513544_2_Ent7", "role": "Combination_Drug", "text": "chronic steroid", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "3513544_2_Ent1", "text": "herpes esophagitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "3513544_2_Ent0", "text": "a renal transplant patient", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "3513544_2_Ent5", "text": "renal transplant", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "3513544_2_Ent3", "text": "Cyclosporine A", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3513544_2_Ent6", "text": "Cyclosporine A", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "3513544_2_Ent2", "text": "Cyclosporine A while on chronic steroid therapy", "entity_type": "Entity", "start": 15, "end": 22}, {"id": "3513544_2_Ent4", "text": "chronic steroid", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "3513544_2_Ent7", "text": "chronic steroid", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "3528096_1", "wnd_id": "3528096_1_1", "text": "Administration of excessive insulin induced hypoglycemia within 4 to 8 hours , followed by rebound hyperglycemia .", "tokens": ["Administration", "of", "excessive", "insulin", "induced", "hypoglycemia", "within", "4", "to", "8", "hours", ",", "followed", "by", "rebound", "hyperglycemia", "."], "event_mentions": [{"id": "3528096_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "3528096_1_Ent2", "role": "Treatment", "text": "Administration of excessive insulin", "start": 0, "end": 4}, {"entity_id": "3528096_1_Ent4", "role": "Treatment_Dosage", "text": "excessive", "start": 2, "end": 3}, {"entity_id": "3528096_1_Ent3", "role": "Treatment_Drug", "text": "insulin", "start": 3, "end": 4}, {"entity_id": "3528096_1_Ent0", "role": "Effect", "text": "hypoglycemia", "start": 5, "end": 6}, {"entity_id": "3528096_1_Ent5", "role": "Treatment_Duration", "text": "4 to 8 hours", "start": 7, "end": 11}, {"entity_id": "3528096_1_Ent1", "role": "Effect", "text": "rebound hyperglycemia", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "3528096_1_Ent2", "text": "Administration of excessive insulin", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3528096_1_Ent4", "text": "excessive", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3528096_1_Ent3", "text": "insulin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3528096_1_Ent0", "text": "hypoglycemia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3528096_1_Ent5", "text": "4 to 8 hours", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "3528096_1_Ent1", "text": "rebound hyperglycemia", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "354311_1", "wnd_id": "354311_1_1", "text": "An 8 - year - old girl , who had been vaccinated with BCG without subsequent regional reactions , developed osteomyelitis in the left calcaneus 7 months later .", "tokens": ["An", "8", "-", "year", "-", "old", "girl", ",", "who", "had", "been", "vaccinated", "with", "BCG", "without", "subsequent", "regional", "reactions", ",", "developed", "osteomyelitis", "in", "the", "left", "calcaneus", "7", "months", "later", "."], "event_mentions": [{"id": "354311_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 19, "end": 20}, "arguments": [{"entity_id": "354311_1_Ent1", "role": "Subject_Age", "text": "8 - year - old", "start": 1, "end": 6}, {"entity_id": "354311_1_Ent0", "role": "Subject", "text": "8 - year - old girl", "start": 1, "end": 7}, {"entity_id": "354311_1_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "354311_1_Ent4", "role": "Treatment", "text": "BCG", "start": 13, "end": 14}, {"entity_id": "354311_1_Ent5", "role": "Treatment_Drug", "text": "BCG", "start": 13, "end": 14}, {"entity_id": "354311_1_Ent3", "role": "Effect", "text": "osteomyelitis", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "354311_1_Ent1", "text": "8 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "354311_1_Ent0", "text": "8 - year - old girl", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "354311_1_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "354311_1_Ent4", "text": "BCG", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "354311_1_Ent5", "text": "BCG", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "354311_1_Ent3", "text": "osteomyelitis", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3565435_2", "wnd_id": "3565435_2_1", "text": "Severe systemic hypersensitivity reaction to ibuprofen occurring after prolonged therapy .", "tokens": ["Severe", "systemic", "hypersensitivity", "reaction", "to", "ibuprofen", "occurring", "after", "prolonged", "therapy", "."], "event_mentions": [{"id": "3565435_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "3565435_2_Ent0", "role": "Effect", "text": "Severe systemic hypersensitivity reaction", "start": 0, "end": 4}, {"entity_id": "3565435_2_Ent1", "role": "Treatment", "text": "ibuprofen", "start": 5, "end": 6}, {"entity_id": "3565435_2_Ent3", "role": "Treatment_Drug", "text": "ibuprofen", "start": 5, "end": 6}, {"entity_id": "3565435_2_Ent2", "role": "Treatment", "text": "prolonged therapy", "start": 8, "end": 10}, {"entity_id": "3565435_2_Ent4", "role": "Treatment_Time_elapsed", "text": "prolonged therapy", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3565435_2_Ent0", "text": "Severe systemic hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3565435_2_Ent1", "text": "ibuprofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3565435_2_Ent3", "text": "ibuprofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3565435_2_Ent2", "text": "prolonged therapy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "3565435_2_Ent4", "text": "prolonged therapy", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3569037_2", "wnd_id": "3569037_2_1", "text": "Hypersensitivity reaction following chloramphenicol administration in a patient with typhoid fever .", "tokens": ["Hypersensitivity", "reaction", "following", "chloramphenicol", "administration", "in", "a", "patient", "with", "typhoid", "fever", "."], "event_mentions": [{"id": "3569037_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3569037_2_Ent1", "role": "Effect", "text": "Hypersensitivity reaction", "start": 0, "end": 2}, {"entity_id": "3569037_2_Ent2", "role": "Treatment", "text": "chloramphenicol", "start": 3, "end": 4}, {"entity_id": "3569037_2_Ent3", "role": "Treatment_Drug", "text": "chloramphenicol", "start": 3, "end": 4}, {"entity_id": "3569037_2_Ent0", "role": "Subject", "text": "a patient with typhoid fever", "start": 6, "end": 11}, {"entity_id": "3569037_2_Ent4", "role": "Treatment_Disorder", "text": "typhoid fever", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3569037_2_Ent1", "text": "Hypersensitivity reaction", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3569037_2_Ent2", "text": "chloramphenicol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3569037_2_Ent3", "text": "chloramphenicol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3569037_2_Ent0", "text": "a patient with typhoid fever", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3569037_2_Ent4", "text": "typhoid fever", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "3569037_4", "wnd_id": "3569037_4_1", "text": "We present a case report of a patient with typhoid fever who experienced a hypersensitivity reaction subsequent to the infusion of chloramphenicol sodium succinate .", "tokens": ["We", "present", "a", "case", "report", "of", "a", "patient", "with", "typhoid", "fever", "who", "experienced", "a", "hypersensitivity", "reaction", "subsequent", "to", "the", "infusion", "of", "chloramphenicol", "sodium", "succinate", "."], "event_mentions": [{"id": "3569037_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "subsequent to", "start": 16, "end": 18}, "arguments": [{"entity_id": "3569037_4_Ent0", "role": "Subject", "text": "a patient with typhoid fever", "start": 6, "end": 11}, {"entity_id": "3569037_4_Ent3", "role": "Treatment_Disorder", "text": "typhoid fever", "start": 9, "end": 11}, {"entity_id": "3569037_4_Ent1", "role": "Effect", "text": "hypersensitivity reaction", "start": 14, "end": 16}, {"entity_id": "3569037_4_Ent2", "role": "Treatment", "text": "the infusion of chloramphenicol sodium succinate", "start": 18, "end": 24}, {"entity_id": "3569037_4_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 19, "end": 20}, {"entity_id": "3569037_4_Ent4", "role": "Treatment_Drug", "text": "chloramphenicol sodium succinate", "start": 21, "end": 24}]}], "entity_mentions": [{"id": "3569037_4_Ent0", "text": "a patient with typhoid fever", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3569037_4_Ent3", "text": "typhoid fever", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "3569037_4_Ent1", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "3569037_4_Ent2", "text": "the infusion of chloramphenicol sodium succinate", "entity_type": "Entity", "start": 18, "end": 24}, {"id": "3569037_4_Ent5", "text": "infusion", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3569037_4_Ent4", "text": "chloramphenicol sodium succinate", "entity_type": "Entity", "start": 21, "end": 24}], "lang": "en"}
{"doc_id": "3579660_2", "wnd_id": "3579660_2_1", "text": "To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy , we conducted a retrospective survey of 25 additional patients with Wilson 's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine .", "tokens": ["To", "develop", "information", "on", "the", "relative", "rarity", "or", "frequency", "of", "neurologic", "worsening", "with", "the", "initiation", "of", "penicillamine", "therapy", ",", "we", "conducted", "a", "retrospective", "survey", "of", "25", "additional", "patients", "with", "Wilson", "'s", "disease", "who", "met", "the", "criteria", "of", "presenting", "with", "neurologic", "disease", "and", "having", "been", "treated", "with", "penicillamine", "."], "event_mentions": [{"id": "3579660_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presenting", "start": 37, "end": 38}, "arguments": [{"entity_id": "3579660_2_Ent1", "role": "Subject_Population", "text": "25", "start": 25, "end": 26}, {"entity_id": "3579660_2_Ent0", "role": "Subject", "text": "25 additional patients with Wilson 's disease", "start": 25, "end": 32}, {"entity_id": "3579660_2_Ent5", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 29, "end": 32}, {"entity_id": "3579660_2_Ent2", "role": "Effect", "text": "neurologic disease", "start": 39, "end": 41}, {"entity_id": "3579660_2_Ent3", "role": "Treatment", "text": "penicillamine", "start": 46, "end": 47}, {"entity_id": "3579660_2_Ent4", "role": "Treatment_Drug", "text": "penicillamine", "start": 46, "end": 47}]}], "entity_mentions": [{"id": "3579660_2_Ent1", "text": "25", "entity_type": "Entity", "start": 25, "end": 26}, {"id": "3579660_2_Ent0", "text": "25 additional patients with Wilson 's disease", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "3579660_2_Ent5", "text": "Wilson 's disease", "entity_type": "Entity", "start": 29, "end": 32}, {"id": "3579660_2_Ent2", "text": "neurologic disease", "entity_type": "Entity", "start": 39, "end": 41}, {"id": "3579660_2_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 46, "end": 47}, {"id": "3579660_2_Ent4", "text": "penicillamine", "entity_type": "Entity", "start": 46, "end": 47}], "lang": "en"}
{"doc_id": "3579660_4", "wnd_id": "3579660_4_1", "text": "Worsening of neurologic syndrome in patients with Wilson 's disease with initial penicillamine therapy .", "tokens": ["Worsening", "of", "neurologic", "syndrome", "in", "patients", "with", "Wilson", "'s", "disease", "with", "initial", "penicillamine", "therapy", "."], "event_mentions": [{"id": "3579660_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "3579660_4_Ent1", "role": "Effect", "text": "Worsening of neurologic syndrome", "start": 0, "end": 4}, {"entity_id": "3579660_4_Ent0", "role": "Subject", "text": "patients with Wilson 's disease", "start": 5, "end": 10}, {"entity_id": "3579660_4_Ent4", "role": "Treatment_Disorder", "text": "Wilson 's disease", "start": 7, "end": 10}, {"entity_id": "3579660_4_Ent3", "role": "Treatment_Drug", "text": "penicillamine", "start": 12, "end": 13}, {"entity_id": "3579660_4_Ent2", "role": "Treatment", "text": "penicillamine therapy", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "3579660_4_Ent1", "text": "Worsening of neurologic syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "3579660_4_Ent0", "text": "patients with Wilson 's disease", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "3579660_4_Ent4", "text": "Wilson 's disease", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "3579660_4_Ent3", "text": "penicillamine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "3579660_4_Ent2", "text": "penicillamine therapy", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "3620420_1", "wnd_id": "3620420_1_1", "text": "Cyclosporin therapy in Mooren 's ulcer .", "tokens": ["Cyclosporin", "therapy", "in", "Mooren", "'s", "ulcer", "."], "event_mentions": [{"id": "3620420_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "therapy", "start": 1, "end": 2}, "arguments": [{"entity_id": "3620420_1_Ent0", "role": "Treatment", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_1_Ent2", "role": "Treatment_Drug", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_1_Ent1", "role": "Treatment_Disorder", "text": "Mooren 's ulcer", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "3620420_1_Ent0", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_1_Ent2", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_1_Ent1", "text": "Mooren 's ulcer", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "3620420_6", "wnd_id": "3620420_6_1", "text": "Cyclosporin side effects included hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "tokens": ["Cyclosporin", "side", "effects", "included", "hirsutism", ",", "hypertension", ",", "increased", "blood", "levels", "of", "urea", "and", "creatinine", ",", "and", "abnormalities", "in", "liver", "function", "tests", "."], "event_mentions": [{"id": "3620420_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "side effects", "start": 1, "end": 3}, "arguments": [{"entity_id": "3620420_6_Ent1", "role": "Treatment", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_6_Ent2", "role": "Treatment_Drug", "text": "Cyclosporin", "start": 0, "end": 1}, {"entity_id": "3620420_6_Ent0", "role": "Effect", "text": "hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "start": 4, "end": 23}]}], "entity_mentions": [{"id": "3620420_6_Ent1", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_6_Ent2", "text": "Cyclosporin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3620420_6_Ent0", "text": "hirsutism , hypertension , increased blood levels of urea and creatinine , and abnormalities in liver function tests .", "entity_type": "Entity", "start": 4, "end": 23}], "lang": "en"}
{"doc_id": "3708949_1", "wnd_id": "3708949_1_1", "text": "After therapy with parenteral amiodarone ( 2300 mg in 3 days ) and other measures , signs of congestive heart failure disappeared ; subsequently the patient developed jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy .", "tokens": ["After", "therapy", "with", "parenteral", "amiodarone", "(", "2300", "mg", "in", "3", "days", ")", "and", "other", "measures", ",", "signs", "of", "congestive", "heart", "failure", "disappeared", ";", "subsequently", "the", "patient", "developed", "jaundice", ",", "marked", "increase", "in", "serum", "transaminase", "levels", "and", "fall", "in", "prothrombin", "time", ",", "and", "histologic", "changes", "of", "severe", "centrilobular", "necrosis", "were", "observed", "in", "hepatic", "biopsy", "."], "event_mentions": [{"id": "3708949_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "After", "start": 0, "end": 1}, "arguments": [{"entity_id": "3708949_1_Ent3", "role": "Treatment_Route", "text": "parenteral", "start": 3, "end": 4}, {"entity_id": "3708949_1_Ent1", "role": "Treatment", "text": "parenteral amiodarone ( 2300 mg in 3 days ) and other measures", "start": 3, "end": 15}, {"entity_id": "3708949_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 4, "end": 5}, {"entity_id": "3708949_1_Ent4", "role": "Treatment_Dosage", "text": "2300 mg in 3 days", "start": 6, "end": 11}, {"entity_id": "3708949_1_Ent5", "role": "Treatment_Disorder", "text": "congestive heart failure", "start": 18, "end": 21}, {"entity_id": "3708949_1_Ent0", "role": "Effect", "text": "jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy", "start": 27, "end": 53}]}], "entity_mentions": [{"id": "3708949_1_Ent3", "text": "parenteral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3708949_1_Ent1", "text": "parenteral amiodarone ( 2300 mg in 3 days ) and other measures", "entity_type": "Entity", "start": 3, "end": 15}, {"id": "3708949_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3708949_1_Ent4", "text": "2300 mg in 3 days", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "3708949_1_Ent5", "text": "congestive heart failure", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "3708949_1_Ent0", "text": "jaundice , marked increase in serum transaminase levels and fall in prothrombin time , and histologic changes of severe centrilobular necrosis were observed in hepatic biopsy", "entity_type": "Entity", "start": 27, "end": 53}], "lang": "en"}
{"doc_id": "3708949_2", "wnd_id": "3708949_2_1", "text": "A patient with acute changes suggesting acute hepatitis after parenteral amiodarone administration is described .", "tokens": ["A", "patient", "with", "acute", "changes", "suggesting", "acute", "hepatitis", "after", "parenteral", "amiodarone", "administration", "is", "described", "."], "event_mentions": [{"id": "3708949_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 8, "end": 9}, "arguments": [{"entity_id": "3708949_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "3708949_2_Ent1", "role": "Effect", "text": "acute changes suggesting acute hepatitis", "start": 3, "end": 8}, {"entity_id": "3708949_2_Ent2", "role": "Treatment", "text": "parenteral amiodarone administration", "start": 9, "end": 12}, {"entity_id": "3708949_2_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "3708949_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3708949_2_Ent1", "text": "acute changes suggesting acute hepatitis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "3708949_2_Ent2", "text": "parenteral amiodarone administration", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "3708949_2_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "3718111_1", "wnd_id": "3718111_1_1", "text": "He became hyperkalemic on rechallenge with timolol and normokalemic following its withdrawal .", "tokens": ["He", "became", "hyperkalemic", "on", "rechallenge", "with", "timolol", "and", "normokalemic", "following", "its", "withdrawal", "."], "event_mentions": [{"id": "3718111_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 9, "end": 10}, "arguments": [{"entity_id": "3718111_1_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "3718111_1_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "3718111_1_Ent2", "role": "Effect", "text": "hyperkalemic", "start": 2, "end": 3}, {"entity_id": "3718111_1_Ent3", "role": "Treatment", "text": "timolol", "start": 6, "end": 7}, {"entity_id": "3718111_1_Ent4", "role": "Treatment_Drug", "text": "timolol", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3718111_1_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3718111_1_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3718111_1_Ent2", "text": "hyperkalemic", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "3718111_1_Ent3", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3718111_1_Ent4", "text": "timolol", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3725284_1", "wnd_id": "3725284_1_1", "text": "Paroxysmal supraventricular tachycardia during treatment with cisplatin and etoposide combination .", "tokens": ["Paroxysmal", "supraventricular", "tachycardia", "during", "treatment", "with", "cisplatin", "and", "etoposide", "combination", "."], "event_mentions": [{"id": "3725284_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 3, "end": 4}, "arguments": [{"entity_id": "3725284_1_Ent0", "role": "Effect", "text": "Paroxysmal supraventricular tachycardia", "start": 0, "end": 3}, {"entity_id": "3725284_1_Ent2", "role": "Treatment_Drug", "text": "cisplatin", "start": 6, "end": 7}, {"entity_id": "3725284_1_Ent5", "role": "Combination_Drug", "text": "cisplatin", "start": 6, "end": 7}, {"entity_id": "3725284_1_Ent1", "role": "Treatment", "text": "cisplatin and etoposide combination", "start": 6, "end": 10}, {"entity_id": "3725284_1_Ent3", "role": "Treatment_Drug", "text": "etoposide", "start": 8, "end": 9}, {"entity_id": "3725284_1_Ent4", "role": "Combination_Drug", "text": "etoposide", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "3725284_1_Ent0", "text": "Paroxysmal supraventricular tachycardia", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3725284_1_Ent2", "text": "cisplatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3725284_1_Ent5", "text": "cisplatin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3725284_1_Ent1", "text": "cisplatin and etoposide combination", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3725284_1_Ent3", "text": "etoposide", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "3725284_1_Ent4", "text": "etoposide", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "3767790_1", "wnd_id": "3767790_1_1", "text": "Duodenal ulceration : a complication of tolazoline therapy .", "tokens": ["Duodenal", "ulceration", ":", "a", "complication", "of", "tolazoline", "therapy", "."], "event_mentions": [{"id": "3767790_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 4, "end": 5}, "arguments": [{"entity_id": "3767790_1_Ent0", "role": "Effect", "text": "Duodenal ulceration", "start": 0, "end": 2}, {"entity_id": "3767790_1_Ent1", "role": "Treatment", "text": "tolazoline", "start": 6, "end": 7}, {"entity_id": "3767790_1_Ent2", "role": "Treatment_Drug", "text": "tolazoline", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "3767790_1_Ent0", "text": "Duodenal ulceration", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3767790_1_Ent1", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3767790_1_Ent2", "text": "tolazoline", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "3767790_2", "wnd_id": "3767790_2_1", "text": "Two patients who were receiving Tolazoline by infusion developed duodenal ulceration and subsequent intestinal perforation .", "tokens": ["Two", "patients", "who", "were", "receiving", "Tolazoline", "by", "infusion", "developed", "duodenal", "ulceration", "and", "subsequent", "intestinal", "perforation", "."], "event_mentions": [{"id": "3767790_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "3767790_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "3767790_2_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "3767790_2_Ent3", "role": "Treatment", "text": "receiving Tolazoline by infusion", "start": 4, "end": 8}, {"entity_id": "3767790_2_Ent4", "role": "Treatment_Drug", "text": "Tolazoline", "start": 5, "end": 6}, {"entity_id": "3767790_2_Ent5", "role": "Treatment_Route", "text": "infusion", "start": 7, "end": 8}, {"entity_id": "3767790_2_Ent2", "role": "Effect", "text": "duodenal ulceration and subsequent intestinal perforation", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "3767790_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3767790_2_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3767790_2_Ent3", "text": "receiving Tolazoline by infusion", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "3767790_2_Ent4", "text": "Tolazoline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3767790_2_Ent5", "text": "infusion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3767790_2_Ent2", "text": "duodenal ulceration and subsequent intestinal perforation", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "3797173_1", "wnd_id": "3797173_1_1", "text": "Intravenous verapamil therapy in babies may cause apnea , hypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with \" familial seizure disorders \" may in fact have the long QT interval syndrome .", "tokens": ["Intravenous", "verapamil", "therapy", "in", "babies", "may", "cause", "apnea", ",", "hypotension", ",", "and", "bradycardia", ";", "continued", "episodes", "of", "atrial", "flutter", "in", "a", "child", "may", "cause", "sudden", "death", ";", "quinidine", "may", "be", "related", "to", "the", "death", ";", "children", "with", "\"", "familial", "seizure", "disorders", "\"", "may", "in", "fact", "have", "the", "long", "QT", "interval", "syndrome", "."], "event_mentions": [{"id": "3797173_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 6, "end": 7}, "arguments": [{"entity_id": "3797173_1_Ent4", "role": "Treatment_Route", "text": "Intravenous", "start": 0, "end": 1}, {"entity_id": "3797173_1_Ent3", "role": "Treatment", "text": "Intravenous verapamil", "start": 0, "end": 2}, {"entity_id": "3797173_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 1, "end": 2}, {"entity_id": "3797173_1_Ent0", "role": "Subject", "text": "babies", "start": 4, "end": 5}, {"entity_id": "3797173_1_Ent1", "role": "Subject_Age", "text": "babies", "start": 4, "end": 5}, {"entity_id": "3797173_1_Ent2", "role": "Effect", "text": "apnea , hypotension , and bradycardia", "start": 7, "end": 13}]}, {"id": "3797173_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 30, "end": 31}, "arguments": [{"entity_id": "3797173_1_Ent7", "role": "Treatment", "text": "quinidine", "start": 27, "end": 28}, {"entity_id": "3797173_1_Ent8", "role": "Treatment_Drug", "text": "quinidine", "start": 27, "end": 28}, {"entity_id": "3797173_1_Ent6", "role": "Effect", "text": "death", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "3797173_1_Ent4", "text": "Intravenous", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "3797173_1_Ent3", "text": "Intravenous verapamil", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3797173_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "3797173_1_Ent0", "text": "babies", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3797173_1_Ent1", "text": "babies", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3797173_1_Ent2", "text": "apnea , hypotension , and bradycardia", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "3797173_1_Ent7", "text": "quinidine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3797173_1_Ent8", "text": "quinidine", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "3797173_1_Ent6", "text": "death", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "3926849_2", "wnd_id": "3926849_2_1", "text": "Paradoxical pulmonary vasoconstriction induced by nitroglycerin in idiopathic pulmonary hypertension .", "tokens": ["Paradoxical", "pulmonary", "vasoconstriction", "induced", "by", "nitroglycerin", "in", "idiopathic", "pulmonary", "hypertension", "."], "event_mentions": [{"id": "3926849_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "3926849_2_Ent0", "role": "Effect", "text": "Paradoxical pulmonary vasoconstriction", "start": 0, "end": 3}, {"entity_id": "3926849_2_Ent1", "role": "Treatment", "text": "nitroglycerin", "start": 5, "end": 6}, {"entity_id": "3926849_2_Ent2", "role": "Treatment_Drug", "text": "nitroglycerin", "start": 5, "end": 6}, {"entity_id": "3926849_2_Ent3", "role": "Treatment_Disorder", "text": "idiopathic pulmonary hypertension", "start": 7, "end": 10}]}], "entity_mentions": [{"id": "3926849_2_Ent0", "text": "Paradoxical pulmonary vasoconstriction", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "3926849_2_Ent1", "text": "nitroglycerin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3926849_2_Ent2", "text": "nitroglycerin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "3926849_2_Ent3", "text": "idiopathic pulmonary hypertension", "entity_type": "Entity", "start": 7, "end": 10}], "lang": "en"}
{"doc_id": "3964363_1", "wnd_id": "3964363_1_1", "text": "A case of propranolol overdose complicated by esophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented .", "tokens": ["A", "case", "of", "propranolol", "overdose", "complicated", "by", "esophageal", "spasm", "preventing", "extrication", "of", "an", "orogastric", "lavage", "tube", "and", "relieved", "by", "intravenous", "glucagon", "is", "presented", "."], "event_mentions": [{"id": "3964363_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complicated", "start": 5, "end": 6}, "arguments": [{"entity_id": "3964363_1_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 3, "end": 4}, {"entity_id": "3964363_1_Ent1", "role": "Treatment", "text": "propranolol overdose", "start": 3, "end": 5}, {"entity_id": "3964363_1_Ent3", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "3964363_1_Ent0", "role": "Effect", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "start": 7, "end": 16}]}, {"id": "3964363_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "relieved", "start": 17, "end": 18}, "arguments": [{"entity_id": "3964363_1_Ent5", "role": "Treatment_Disorder", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "start": 7, "end": 16}, {"entity_id": "3964363_1_Ent6", "role": "Treatment_Route", "text": "intravenous", "start": 19, "end": 20}, {"entity_id": "3964363_1_Ent4", "role": "Treatment", "text": "intravenous glucagon", "start": 19, "end": 21}, {"entity_id": "3964363_1_Ent7", "role": "Treatment_Drug", "text": "glucagon", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "3964363_1_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3964363_1_Ent1", "text": "propranolol overdose", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3964363_1_Ent3", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "3964363_1_Ent0", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "3964363_1_Ent5", "text": "esophageal spasm preventing extrication of an orogastric lavage tube", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "3964363_1_Ent6", "text": "intravenous", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "3964363_1_Ent4", "text": "intravenous glucagon", "entity_type": "Entity", "start": 19, "end": 21}, {"id": "3964363_1_Ent7", "text": "glucagon", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "3969689_4", "wnd_id": "3969689_4_1", "text": "Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine .", "tokens": ["Careful", "observations", "on", "hepatotoxicity", "are", "suggested", "when", "acetaminophen", "is", "prescribed", "with", "caffeine", "."], "event_mentions": [{"id": "3969689_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 10, "end": 11}, "arguments": [{"entity_id": "3969689_4_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 3, "end": 4}, {"entity_id": "3969689_4_Ent1", "role": "Treatment", "text": "acetaminophen", "start": 7, "end": 8}, {"entity_id": "3969689_4_Ent3", "role": "Treatment_Drug", "text": "acetaminophen", "start": 7, "end": 8}, {"entity_id": "3969689_4_Ent2", "role": "Treatment", "text": "caffeine", "start": 11, "end": 12}, {"entity_id": "3969689_4_Ent4", "role": "Treatment_Drug", "text": "caffeine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "3969689_4_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3969689_4_Ent1", "text": "acetaminophen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3969689_4_Ent3", "text": "acetaminophen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "3969689_4_Ent2", "text": "caffeine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "3969689_4_Ent4", "text": "caffeine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "3982906_1", "wnd_id": "3982906_1_1", "text": "Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia .", "tokens": ["Cardiac", "decompensation", "following", "verapamil", "therapy", "in", "infants", "with", "supraventricular", "tachycardia", "."], "event_mentions": [{"id": "3982906_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "3982906_1_Ent2", "role": "Effect", "text": "Cardiac decompensation", "start": 0, "end": 2}, {"entity_id": "3982906_1_Ent5", "role": "Treatment_Drug", "text": "verapamil", "start": 3, "end": 4}, {"entity_id": "3982906_1_Ent3", "role": "Treatment", "text": "verapamil therapy", "start": 3, "end": 5}, {"entity_id": "3982906_1_Ent1", "role": "Subject_Age", "text": "infants", "start": 6, "end": 7}, {"entity_id": "3982906_1_Ent0", "role": "Subject", "text": "infants with supraventricular tachycardia", "start": 6, "end": 10}, {"entity_id": "3982906_1_Ent4", "role": "Treatment_Disorder", "text": "supraventricular tachycardia", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "3982906_1_Ent2", "text": "Cardiac decompensation", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "3982906_1_Ent5", "text": "verapamil", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3982906_1_Ent3", "text": "verapamil therapy", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "3982906_1_Ent1", "text": "infants", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "3982906_1_Ent0", "text": "infants with supraventricular tachycardia", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "3982906_1_Ent4", "text": "supraventricular tachycardia", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "3982906_2", "wnd_id": "3982906_2_1", "text": "However , each infant demonstrated hemodynamic decompensation shortly after verapamil administration and required cardiopulmonary resuscitation .", "tokens": ["However", ",", "each", "infant", "demonstrated", "hemodynamic", "decompensation", "shortly", "after", "verapamil", "administration", "and", "required", "cardiopulmonary", "resuscitation", "."], "event_mentions": [{"id": "3982906_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "demonstrated", "start": 4, "end": 5}, "arguments": [{"entity_id": "3982906_2_Ent0", "role": "Subject", "text": "each infant", "start": 2, "end": 4}, {"entity_id": "3982906_2_Ent1", "role": "Subject_Age", "text": "infant", "start": 3, "end": 4}, {"entity_id": "3982906_2_Ent2", "role": "Effect", "text": "hemodynamic decompensation", "start": 5, "end": 7}, {"entity_id": "3982906_2_Ent3", "role": "Treatment", "text": "verapamil", "start": 9, "end": 10}, {"entity_id": "3982906_2_Ent4", "role": "Treatment_Drug", "text": "verapamil", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "3982906_2_Ent0", "text": "each infant", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "3982906_2_Ent1", "text": "infant", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "3982906_2_Ent2", "text": "hemodynamic decompensation", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "3982906_2_Ent3", "text": "verapamil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3982906_2_Ent4", "text": "verapamil", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "3997294_1", "wnd_id": "3997294_1_1", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .", "tokens": ["Pneumonitis", "with", "pleural", "and", "pericardial", "effusion", "and", "neuropathy", "during", "amiodarone", "therapy", "."], "event_mentions": [{"id": "3997294_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 8, "end": 9}, "arguments": [{"entity_id": "3997294_1_Ent0", "role": "Effect", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "start": 0, "end": 8}, {"entity_id": "3997294_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 9, "end": 10}, {"entity_id": "3997294_1_Ent1", "role": "Treatment", "text": "amiodarone therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "3997294_1_Ent0", "text": "Pneumonitis with pleural and pericardial effusion and neuropathy", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "3997294_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "3997294_1_Ent1", "text": "amiodarone therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "4025011_1", "wnd_id": "4025011_1_1", "text": "Prolonged severe cholestasis induced by oxacillin derivatives .", "tokens": ["Prolonged", "severe", "cholestasis", "induced", "by", "oxacillin", "derivatives", "."], "event_mentions": [{"id": "4025011_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "4025011_1_Ent0", "role": "Effect", "text": "Prolonged severe cholestasis", "start": 0, "end": 3}, {"entity_id": "4025011_1_Ent2", "role": "Treatment_Drug", "text": "oxacillin", "start": 5, "end": 6}, {"entity_id": "4025011_1_Ent1", "role": "Treatment", "text": "oxacillin derivatives", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "4025011_1_Ent0", "text": "Prolonged severe cholestasis", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "4025011_1_Ent2", "text": "oxacillin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "4025011_1_Ent1", "text": "oxacillin derivatives", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "4051280_2", "wnd_id": "4051280_2_1", "text": "Propranolol - induced hypertension in treatment of cocaine intoxication .", "tokens": ["Propranolol", "-", "induced", "hypertension", "in", "treatment", "of", "cocaine", "intoxication", "."], "event_mentions": [{"id": "4051280_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "4051280_2_Ent1", "role": "Treatment", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "4051280_2_Ent2", "role": "Treatment_Drug", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "4051280_2_Ent0", "role": "Effect", "text": "hypertension", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "4051280_2_Ent1", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4051280_2_Ent2", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "4051280_2_Ent0", "text": "hypertension", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "4054170_3", "wnd_id": "4054170_3_1", "text": "EEG abnormalities were observed in two of the nine children during chlorambucil therapy .", "tokens": ["EEG", "abnormalities", "were", "observed", "in", "two", "of", "the", "nine", "children", "during", "chlorambucil", "therapy", "."], "event_mentions": [{"id": "4054170_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 3, "end": 4}, "arguments": [{"entity_id": "4054170_3_Ent3", "role": "Effect", "text": "EEG abnormalities", "start": 0, "end": 2}, {"entity_id": "4054170_3_Ent1", "role": "Subject_Population", "text": "two of the nine", "start": 5, "end": 9}, {"entity_id": "4054170_3_Ent0", "role": "Subject", "text": "two of the nine children", "start": 5, "end": 10}, {"entity_id": "4054170_3_Ent2", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "4054170_3_Ent4", "role": "Treatment", "text": "chlorambucil", "start": 11, "end": 12}, {"entity_id": "4054170_3_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "4054170_3_Ent3", "text": "EEG abnormalities", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "4054170_3_Ent1", "text": "two of the nine", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "4054170_3_Ent0", "text": "two of the nine children", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "4054170_3_Ent2", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "4054170_3_Ent4", "text": "chlorambucil", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "4054170_3_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "4095247_2", "wnd_id": "4095247_2_1", "text": "Subsequent in vivo / vitro studies clearly demonstrated that the neurological effects were due to a synergistic action of desferrioxamine and prochlorperazine , probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems .", "tokens": ["Subsequent", "in", "vivo", "/", "vitro", "studies", "clearly", "demonstrated", "that", "the", "neurological", "effects", "were", "due", "to", "a", "synergistic", "action", "of", "desferrioxamine", "and", "prochlorperazine", ",", "probably", "resulting", "in", "exceptional", "fluxes", "of", "intra", "/", "extra", "cellular", "iron", "/", "copper", "disturbing", "noradrenergic", "and", "serotonergic", "systems", "."], "event_mentions": [{"id": "4095247_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 13, "end": 14}, "arguments": [{"entity_id": "4095247_2_Ent0", "role": "Effect", "text": "neurological effects", "start": 10, "end": 12}, {"entity_id": "4095247_2_Ent2", "role": "Treatment_Drug", "text": "desferrioxamine", "start": 19, "end": 20}, {"entity_id": "4095247_2_Ent4", "role": "Combination_Drug", "text": "desferrioxamine", "start": 19, "end": 20}, {"entity_id": "4095247_2_Ent1", "role": "Treatment", "text": "desferrioxamine and prochlorperazine", "start": 19, "end": 22}, {"entity_id": "4095247_2_Ent3", "role": "Treatment_Drug", "text": "prochlorperazine", "start": 21, "end": 22}, {"entity_id": "4095247_2_Ent5", "role": "Combination_Drug", "text": "prochlorperazine", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "4095247_2_Ent0", "text": "neurological effects", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "4095247_2_Ent2", "text": "desferrioxamine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "4095247_2_Ent4", "text": "desferrioxamine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "4095247_2_Ent1", "text": "desferrioxamine and prochlorperazine", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "4095247_2_Ent3", "text": "prochlorperazine", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "4095247_2_Ent5", "text": "prochlorperazine", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "440873_4", "wnd_id": "440873_4_1", "text": "We have cared for three children in whom four episodes of dystonia proceeding to opisthotonus occurred in association with carbamazepine use .", "tokens": ["We", "have", "cared", "for", "three", "children", "in", "whom", "four", "episodes", "of", "dystonia", "proceeding", "to", "opisthotonus", "occurred", "in", "association", "with", "carbamazepine", "use", "."], "event_mentions": [{"id": "440873_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 15, "end": 16}, "arguments": [{"entity_id": "440873_4_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "440873_4_Ent0", "role": "Subject", "text": "three children", "start": 4, "end": 6}, {"entity_id": "440873_4_Ent2", "role": "Subject_Age", "text": "children", "start": 5, "end": 6}, {"entity_id": "440873_4_Ent3", "role": "Effect", "text": "four episodes of dystonia proceeding to opisthotonus", "start": 8, "end": 15}, {"entity_id": "440873_4_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 19, "end": 20}, {"entity_id": "440873_4_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "440873_4_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "440873_4_Ent0", "text": "three children", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "440873_4_Ent2", "text": "children", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "440873_4_Ent3", "text": "four episodes of dystonia proceeding to opisthotonus", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "440873_4_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "440873_4_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "448845_1", "wnd_id": "448845_1_1", "text": "Aplastic anemia and agranulocytosis in patients using methazolamide for glaucoma .", "tokens": ["Aplastic", "anemia", "and", "agranulocytosis", "in", "patients", "using", "methazolamide", "for", "glaucoma", "."], "event_mentions": [{"id": "448845_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 4, "end": 5}, "arguments": [{"entity_id": "448845_1_Ent2", "role": "Effect", "text": "Aplastic anemia and agranulocytosis", "start": 0, "end": 4}, {"entity_id": "448845_1_Ent0", "role": "Subject", "text": "patients", "start": 5, "end": 6}, {"entity_id": "448845_1_Ent3", "role": "Treatment", "text": "methazolamide", "start": 7, "end": 8}, {"entity_id": "448845_1_Ent4", "role": "Treatment_Drug", "text": "methazolamide", "start": 7, "end": 8}, {"entity_id": "448845_1_Ent1", "role": "Subject", "text": "glaucoma", "start": 9, "end": 10}, {"entity_id": "448845_1_Ent5", "role": "Treatment_Disorder", "text": "glaucoma", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "448845_1_Ent2", "text": "Aplastic anemia and agranulocytosis", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "448845_1_Ent0", "text": "patients", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "448845_1_Ent3", "text": "methazolamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "448845_1_Ent4", "text": "methazolamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "448845_1_Ent1", "text": "glaucoma", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "448845_1_Ent5", "text": "glaucoma", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "458006_1", "wnd_id": "458006_1_1", "text": "Squamous - cell carcinoma arising in a basal - cell epithelioma treated with 5 - fluorouracil .", "tokens": ["Squamous", "-", "cell", "carcinoma", "arising", "in", "a", "basal", "-", "cell", "epithelioma", "treated", "with", "5", "-", "fluorouracil", "."], "event_mentions": [{"id": "458006_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 11, "end": 12}, "arguments": [{"entity_id": "458006_1_Ent0", "role": "Effect", "text": "Squamous - cell carcinoma arising", "start": 0, "end": 5}, {"entity_id": "458006_1_Ent1", "role": "Treatment", "text": "5 - fluorouracil", "start": 13, "end": 16}, {"entity_id": "458006_1_Ent2", "role": "Treatment_Drug", "text": "5 - fluorouracil", "start": 13, "end": 16}]}], "entity_mentions": [{"id": "458006_1_Ent0", "text": "Squamous - cell carcinoma arising", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "458006_1_Ent1", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "458006_1_Ent2", "text": "5 - fluorouracil", "entity_type": "Entity", "start": 13, "end": 16}], "lang": "en"}
{"doc_id": "507889_1", "wnd_id": "507889_1_1", "text": "In two patients with mycosis fungoides , a squamous cell carcinoma developed during therapy with psoralens plus long - wave ultraviolet radiation ( PUVA ) .", "tokens": ["In", "two", "patients", "with", "mycosis", "fungoides", ",", "a", "squamous", "cell", "carcinoma", "developed", "during", "therapy", "with", "psoralens", "plus", "long", "-", "wave", "ultraviolet", "radiation", "(", "PUVA", ")", "."], "event_mentions": [{"id": "507889_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 11, "end": 12}, "arguments": [{"entity_id": "507889_1_Ent1", "role": "Subject_Population", "text": "two", "start": 1, "end": 2}, {"entity_id": "507889_1_Ent0", "role": "Subject", "text": "two patients with mycosis fungoides", "start": 1, "end": 6}, {"entity_id": "507889_1_Ent4", "role": "Treatment_Disorder", "text": "mycosis fungoides", "start": 4, "end": 6}, {"entity_id": "507889_1_Ent2", "role": "Effect", "text": "squamous cell carcinoma", "start": 8, "end": 11}, {"entity_id": "507889_1_Ent5", "role": "Treatment_Drug", "text": "psoralens", "start": 15, "end": 16}, {"entity_id": "507889_1_Ent3", "role": "Treatment", "text": "psoralens plus long - wave ultraviolet radiation ( PUVA )", "start": 15, "end": 25}]}], "entity_mentions": [{"id": "507889_1_Ent1", "text": "two", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "507889_1_Ent0", "text": "two patients with mycosis fungoides", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "507889_1_Ent4", "text": "mycosis fungoides", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "507889_1_Ent2", "text": "squamous cell carcinoma", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "507889_1_Ent5", "text": "psoralens", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "507889_1_Ent3", "text": "psoralens plus long - wave ultraviolet radiation ( PUVA )", "entity_type": "Entity", "start": 15, "end": 25}], "lang": "en"}
{"doc_id": "53128_2", "wnd_id": "53128_2_1", "text": "A patient is described with polycythemia vera who was taking anticoagulants and developed a spontaneous retropharyngeal hemorrhage after a violent sneezing episode .", "tokens": ["A", "patient", "is", "described", "with", "polycythemia", "vera", "who", "was", "taking", "anticoagulants", "and", "developed", "a", "spontaneous", "retropharyngeal", "hemorrhage", "after", "a", "violent", "sneezing", "episode", "."], "event_mentions": [{"id": "53128_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "53128_2_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "53128_2_Ent1", "role": "Effect", "text": "polycythemia vera", "start": 5, "end": 7}, {"entity_id": "53128_2_Ent3", "role": "Treatment", "text": "anticoagulants", "start": 10, "end": 11}, {"entity_id": "53128_2_Ent4", "role": "Treatment_Drug", "text": "anticoagulants", "start": 10, "end": 11}, {"entity_id": "53128_2_Ent2", "role": "Effect", "text": "a spontaneous retropharyngeal hemorrhage after a violent sneezing episode", "start": 13, "end": 22}]}], "entity_mentions": [{"id": "53128_2_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "53128_2_Ent1", "text": "polycythemia vera", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "53128_2_Ent3", "text": "anticoagulants", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "53128_2_Ent4", "text": "anticoagulants", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "53128_2_Ent2", "text": "a spontaneous retropharyngeal hemorrhage after a violent sneezing episode", "entity_type": "Entity", "start": 13, "end": 22}], "lang": "en"}
{"doc_id": "556126_1", "wnd_id": "556126_1_1", "text": "An infertile patient with amenorrhea - galactorrhea syndrome lost vision during a pregnancy occurring after Bromocryptine treatment .", "tokens": ["An", "infertile", "patient", "with", "amenorrhea", "-", "galactorrhea", "syndrome", "lost", "vision", "during", "a", "pregnancy", "occurring", "after", "Bromocryptine", "treatment", "."], "event_mentions": [{"id": "556126_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 14, "end": 15}, "arguments": [{"entity_id": "556126_1_Ent0", "role": "Subject", "text": "An infertile patient with amenorrhea - galactorrhea syndrome", "start": 0, "end": 8}, {"entity_id": "556126_1_Ent1", "role": "Subject_Disorder", "text": "infertile", "start": 1, "end": 2}, {"entity_id": "556126_1_Ent5", "role": "Treatment_Disorder", "text": "amenorrhea - galactorrhea syndrome", "start": 4, "end": 8}, {"entity_id": "556126_1_Ent2", "role": "Effect", "text": "lost vision", "start": 8, "end": 10}, {"entity_id": "556126_1_Ent3", "role": "Treatment", "text": "Bromocryptine", "start": 15, "end": 16}, {"entity_id": "556126_1_Ent4", "role": "Treatment_Drug", "text": "Bromocryptine", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "556126_1_Ent0", "text": "An infertile patient with amenorrhea - galactorrhea syndrome", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "556126_1_Ent1", "text": "infertile", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "556126_1_Ent5", "text": "amenorrhea - galactorrhea syndrome", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "556126_1_Ent2", "text": "lost vision", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "556126_1_Ent3", "text": "Bromocryptine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "556126_1_Ent4", "text": "Bromocryptine", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "566977_1", "wnd_id": "566977_1_1", "text": "Fatal acute tubular necrosis occurred in 1 patient in whom intravesical formalin was used to control massive persistent hemorrhage from radiation cystitis .", "tokens": ["Fatal", "acute", "tubular", "necrosis", "occurred", "in", "1", "patient", "in", "whom", "intravesical", "formalin", "was", "used", "to", "control", "massive", "persistent", "hemorrhage", "from", "radiation", "cystitis", "."], "event_mentions": [{"id": "566977_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 4, "end": 5}, "arguments": [{"entity_id": "566977_1_Ent2", "role": "Effect", "text": "acute tubular necrosis", "start": 1, "end": 4}, {"entity_id": "566977_1_Ent1", "role": "Subject_Population", "text": "1", "start": 6, "end": 7}, {"entity_id": "566977_1_Ent0", "role": "Subject", "text": "1 patient", "start": 6, "end": 8}, {"entity_id": "566977_1_Ent5", "role": "Treatment_Route", "text": "intravesical", "start": 10, "end": 11}, {"entity_id": "566977_1_Ent3", "role": "Treatment", "text": "intravesical formalin", "start": 10, "end": 12}, {"entity_id": "566977_1_Ent6", "role": "Treatment_Drug", "text": "formalin", "start": 11, "end": 12}, {"entity_id": "566977_1_Ent4", "role": "Treatment_Disorder", "text": "massive persistent hemorrhage from radiation cystitis", "start": 16, "end": 22}]}], "entity_mentions": [{"id": "566977_1_Ent2", "text": "acute tubular necrosis", "entity_type": "Entity", "start": 1, "end": 4}, {"id": "566977_1_Ent1", "text": "1", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "566977_1_Ent0", "text": "1 patient", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "566977_1_Ent5", "text": "intravesical", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "566977_1_Ent3", "text": "intravesical formalin", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "566977_1_Ent6", "text": "formalin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "566977_1_Ent4", "text": "massive persistent hemorrhage from radiation cystitis", "entity_type": "Entity", "start": 16, "end": 22}], "lang": "en"}
{"doc_id": "576675_2", "wnd_id": "576675_2_1", "text": "Edema associated with ibuprofen therapy .", "tokens": ["Edema", "associated", "with", "ibuprofen", "therapy", "."], "event_mentions": [{"id": "576675_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "576675_2_Ent0", "role": "Effect", "text": "Edema", "start": 0, "end": 1}, {"entity_id": "576675_2_Ent1", "role": "Treatment", "text": "ibuprofen", "start": 3, "end": 4}, {"entity_id": "576675_2_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 3, "end": 4}]}], "entity_mentions": [{"id": "576675_2_Ent0", "text": "Edema", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "576675_2_Ent1", "text": "ibuprofen", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "576675_2_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 3, "end": 4}], "lang": "en"}
{"doc_id": "576675_3", "wnd_id": "576675_3_1", "text": "It should be recognized that ibuprofen may be associated with salt and water retention in the same fashion as previously described with phenylbutazone and indomethacin .", "tokens": ["It", "should", "be", "recognized", "that", "ibuprofen", "may", "be", "associated", "with", "salt", "and", "water", "retention", "in", "the", "same", "fashion", "as", "previously", "described", "with", "phenylbutazone", "and", "indomethacin", "."], "event_mentions": [{"id": "576675_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "576675_3_Ent1", "role": "Treatment", "text": "ibuprofen", "start": 5, "end": 6}, {"entity_id": "576675_3_Ent2", "role": "Treatment_Drug", "text": "ibuprofen", "start": 5, "end": 6}, {"entity_id": "576675_3_Ent0", "role": "Effect", "text": "salt and water retention", "start": 10, "end": 14}, {"entity_id": "576675_3_Ent3", "role": "Treatment_Drug", "text": "phenylbutazone", "start": 22, "end": 23}, {"entity_id": "576675_3_Ent4", "role": "Treatment_Drug", "text": "indomethacin", "start": 24, "end": 25}]}], "entity_mentions": [{"id": "576675_3_Ent1", "text": "ibuprofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "576675_3_Ent2", "text": "ibuprofen", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "576675_3_Ent0", "text": "salt and water retention", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "576675_3_Ent3", "text": "phenylbutazone", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "576675_3_Ent4", "text": "indomethacin", "entity_type": "Entity", "start": 24, "end": 25}], "lang": "en"}
{"doc_id": "589261_3", "wnd_id": "589261_3_1", "text": "Minor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain , and none of the 16 who were receiving digoxin .", "tokens": ["Minor", "electrocardiographical", "changes", "were", "noted", "in", "five", "out", "of", "six", "patients", "who", "were", "not", "receiving", "a", "cardiac", "glycoside", "and", "four", "out", "of", "six", "who", "were", "receiving", "ouabain", ",", "and", "none", "of", "the", "16", "who", "were", "receiving", "digoxin", "."], "event_mentions": [{"id": "589261_3_Evt1", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 14, "end": 15}, "arguments": [{"entity_id": "589261_3_Ent6", "role": "Effect", "text": "electrocardiographical changes", "start": 1, "end": 3}, {"entity_id": "589261_3_Ent5", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "589261_3_Ent4", "role": "Subject", "text": "five out of six patients", "start": 6, "end": 11}, {"entity_id": "589261_3_Ent7", "role": "Treatment", "text": "cardiac glycoside", "start": 16, "end": 18}, {"entity_id": "589261_3_Ent8", "role": "Treatment_Drug", "text": "cardiac glycoside", "start": 16, "end": 18}]}, {"id": "589261_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 25, "end": 26}, "arguments": [{"entity_id": "589261_3_Ent1", "role": "Effect", "text": "electrocardiographical changes", "start": 1, "end": 3}, {"entity_id": "589261_3_Ent0", "role": "Subject", "text": "four out of six", "start": 19, "end": 23}, {"entity_id": "589261_3_Ent2", "role": "Treatment", "text": "ouabain", "start": 26, "end": 27}, {"entity_id": "589261_3_Ent3", "role": "Treatment_Drug", "text": "ouabain", "start": 26, "end": 27}]}], "entity_mentions": [{"id": "589261_3_Ent1", "text": "electrocardiographical changes", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "589261_3_Ent6", "text": "electrocardiographical changes", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "589261_3_Ent5", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "589261_3_Ent4", "text": "five out of six patients", "entity_type": "Entity", "start": 6, "end": 11}, {"id": "589261_3_Ent7", "text": "cardiac glycoside", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "589261_3_Ent8", "text": "cardiac glycoside", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "589261_3_Ent0", "text": "four out of six", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "589261_3_Ent2", "text": "ouabain", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "589261_3_Ent3", "text": "ouabain", "entity_type": "Entity", "start": 26, "end": 27}], "lang": "en"}
{"doc_id": "6093724_1", "wnd_id": "6093724_1_1", "text": "A healthy , 30 - year - old man , exposed to sulindac on two separate occasions , had an incapacitating isolated idential sensory neuropathy .", "tokens": ["A", "healthy", ",", "30", "-", "year", "-", "old", "man", ",", "exposed", "to", "sulindac", "on", "two", "separate", "occasions", ",", "had", "an", "incapacitating", "isolated", "idential", "sensory", "neuropathy", "."], "event_mentions": [{"id": "6093724_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposed", "start": 10, "end": 11}, "arguments": [{"entity_id": "6093724_1_Ent0", "role": "Subject", "text": "A healthy , 30 - year - old man", "start": 0, "end": 9}, {"entity_id": "6093724_1_Ent1", "role": "Subject_Age", "text": "30 - year - old", "start": 3, "end": 8}, {"entity_id": "6093724_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 8, "end": 9}, {"entity_id": "6093724_1_Ent4", "role": "Treatment", "text": "sulindac", "start": 12, "end": 13}, {"entity_id": "6093724_1_Ent5", "role": "Treatment_Drug", "text": "sulindac", "start": 12, "end": 13}, {"entity_id": "6093724_1_Ent3", "role": "Effect", "text": "incapacitating isolated idential sensory neuropathy", "start": 20, "end": 25}]}], "entity_mentions": [{"id": "6093724_1_Ent0", "text": "A healthy , 30 - year - old man", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6093724_1_Ent1", "text": "30 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "6093724_1_Ent2", "text": "man", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6093724_1_Ent4", "text": "sulindac", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6093724_1_Ent5", "text": "sulindac", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "6093724_1_Ent3", "text": "incapacitating isolated idential sensory neuropathy", "entity_type": "Entity", "start": 20, "end": 25}], "lang": "en"}
{"doc_id": "6142995_2", "wnd_id": "6142995_2_1", "text": "Sister chromatid exchanges ( SCEs ) , a sensitive measure of chromosome damage , were counted in peripheral - blood lymphocytes from 10 patients with Behcet 's syndrome receiving chlorambucil .", "tokens": ["Sister", "chromatid", "exchanges", "(", "SCEs", ")", ",", "a", "sensitive", "measure", "of", "chromosome", "damage", ",", "were", "counted", "in", "peripheral", "-", "blood", "lymphocytes", "from", "10", "patients", "with", "Behcet", "'s", "syndrome", "receiving", "chlorambucil", "."], "event_mentions": [{"id": "6142995_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 28, "end": 29}, "arguments": [{"entity_id": "6142995_2_Ent2", "role": "Effect", "text": "chromosome damage", "start": 11, "end": 13}, {"entity_id": "6142995_2_Ent1", "role": "Subject_Population", "text": "10", "start": 22, "end": 23}, {"entity_id": "6142995_2_Ent0", "role": "Subject", "text": "10 patients with Behcet 's syndrome", "start": 22, "end": 28}, {"entity_id": "6142995_2_Ent4", "role": "Treatment_Disorder", "text": "Behcet 's syndrome", "start": 25, "end": 28}, {"entity_id": "6142995_2_Ent3", "role": "Treatment", "text": "chlorambucil", "start": 29, "end": 30}, {"entity_id": "6142995_2_Ent5", "role": "Treatment_Drug", "text": "chlorambucil", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6142995_2_Ent2", "text": "chromosome damage", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "6142995_2_Ent1", "text": "10", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "6142995_2_Ent0", "text": "10 patients with Behcet 's syndrome", "entity_type": "Entity", "start": 22, "end": 28}, {"id": "6142995_2_Ent4", "text": "Behcet 's syndrome", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "6142995_2_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}, {"id": "6142995_2_Ent5", "text": "chlorambucil", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6149250_3", "wnd_id": "6149250_3_1", "text": "One of the patients had a dexamethasone dependent brain metastatic condition .", "tokens": ["One", "of", "the", "patients", "had", "a", "dexamethasone", "dependent", "brain", "metastatic", "condition", "."], "event_mentions": [{"id": "6149250_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "had", "start": 4, "end": 5}, "arguments": [{"entity_id": "6149250_3_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "6149250_3_Ent0", "role": "Subject", "text": "One of the patients", "start": 0, "end": 4}, {"entity_id": "6149250_3_Ent3", "role": "Treatment", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "6149250_3_Ent4", "role": "Treatment_Drug", "text": "dexamethasone", "start": 6, "end": 7}, {"entity_id": "6149250_3_Ent2", "role": "Effect", "text": "brain metastatic condition", "start": 8, "end": 11}, {"entity_id": "6149250_3_Ent5", "role": "Treatment_Disorder", "text": "brain metastatic condition", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "6149250_3_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6149250_3_Ent0", "text": "One of the patients", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6149250_3_Ent3", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6149250_3_Ent4", "text": "dexamethasone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6149250_3_Ent2", "text": "brain metastatic condition", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "6149250_3_Ent5", "text": "brain metastatic condition", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "6159523_3", "wnd_id": "6159523_3_1", "text": "Investigations suggested that the dextrose , rather than any additives , was responsible for the reaction .", "tokens": ["Investigations", "suggested", "that", "the", "dextrose", ",", "rather", "than", "any", "additives", ",", "was", "responsible", "for", "the", "reaction", "."], "event_mentions": [{"id": "6159523_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 12, "end": 13}, "arguments": [{"entity_id": "6159523_3_Ent1", "role": "Treatment", "text": "dextrose", "start": 4, "end": 5}, {"entity_id": "6159523_3_Ent2", "role": "Treatment_Drug", "text": "dextrose", "start": 4, "end": 5}, {"entity_id": "6159523_3_Ent0", "role": "Effect", "text": "the reaction", "start": 14, "end": 16}]}], "entity_mentions": [{"id": "6159523_3_Ent1", "text": "dextrose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6159523_3_Ent2", "text": "dextrose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6159523_3_Ent0", "text": "the reaction", "entity_type": "Entity", "start": 14, "end": 16}], "lang": "en"}
{"doc_id": "6197014_2", "wnd_id": "6197014_2_1", "text": "Two children with rheumatic fever developed anicteric hepatitis while on high - dose aspirin therapy .", "tokens": ["Two", "children", "with", "rheumatic", "fever", "developed", "anicteric", "hepatitis", "while", "on", "high", "-", "dose", "aspirin", "therapy", "."], "event_mentions": [{"id": "6197014_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "6197014_2_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6197014_2_Ent0", "role": "Subject", "text": "Two children with rheumatic fever", "start": 0, "end": 5}, {"entity_id": "6197014_2_Ent2", "role": "Subject_Age", "text": "children", "start": 1, "end": 2}, {"entity_id": "6197014_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatic fever", "start": 3, "end": 5}, {"entity_id": "6197014_2_Ent3", "role": "Effect", "text": "anicteric hepatitis", "start": 6, "end": 8}, {"entity_id": "6197014_2_Ent7", "role": "Treatment_Dosage", "text": "high - dose", "start": 10, "end": 13}, {"entity_id": "6197014_2_Ent4", "role": "Treatment", "text": "high - dose aspirin", "start": 10, "end": 14}, {"entity_id": "6197014_2_Ent6", "role": "Treatment_Drug", "text": "aspirin", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6197014_2_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6197014_2_Ent0", "text": "Two children with rheumatic fever", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6197014_2_Ent2", "text": "children", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6197014_2_Ent5", "text": "rheumatic fever", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "6197014_2_Ent3", "text": "anicteric hepatitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "6197014_2_Ent7", "text": "high - dose", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6197014_2_Ent4", "text": "high - dose aspirin", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "6197014_2_Ent6", "text": "aspirin", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6233326_2", "wnd_id": "6233326_2_1", "text": "Optic neuropathy developed in a patient with rheumatoid arthritis who had been receiving D - penicillamine for about 1 year .", "tokens": ["Optic", "neuropathy", "developed", "in", "a", "patient", "with", "rheumatoid", "arthritis", "who", "had", "been", "receiving", "D", "-", "penicillamine", "for", "about", "1", "year", "."], "event_mentions": [{"id": "6233326_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6233326_2_Ent1", "role": "Effect", "text": "Optic neuropathy", "start": 0, "end": 2}, {"entity_id": "6233326_2_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 4, "end": 9}, {"entity_id": "6233326_2_Ent3", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 7, "end": 9}, {"entity_id": "6233326_2_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 13, "end": 16}, {"entity_id": "6233326_2_Ent2", "role": "Treatment", "text": "D - penicillamine for about 1 year", "start": 13, "end": 20}, {"entity_id": "6233326_2_Ent5", "role": "Treatment_Duration", "text": "1 year", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "6233326_2_Ent1", "text": "Optic neuropathy", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6233326_2_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "6233326_2_Ent3", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6233326_2_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "6233326_2_Ent2", "text": "D - penicillamine for about 1 year", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "6233326_2_Ent5", "text": "1 year", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "6251941_2", "wnd_id": "6251941_2_1", "text": "Three cases of gold - related neuropathy are reported .", "tokens": ["Three", "cases", "of", "gold", "-", "related", "neuropathy", "are", "reported", "."], "event_mentions": [{"id": "6251941_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "6251941_2_Ent1", "role": "Subject_Population", "text": "Three", "start": 0, "end": 1}, {"entity_id": "6251941_2_Ent0", "role": "Subject", "text": "Three cases", "start": 0, "end": 2}, {"entity_id": "6251941_2_Ent3", "role": "Treatment", "text": "gold", "start": 3, "end": 4}, {"entity_id": "6251941_2_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 3, "end": 4}, {"entity_id": "6251941_2_Ent2", "role": "Effect", "text": "neuropathy", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6251941_2_Ent1", "text": "Three", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6251941_2_Ent0", "text": "Three cases", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6251941_2_Ent3", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6251941_2_Ent4", "text": "gold", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6251941_2_Ent2", "text": "neuropathy", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6311654_3", "wnd_id": "6311654_3_1", "text": "In six cases CT scans did not return to their original state after ACTH therapy .", "tokens": ["In", "six", "cases", "CT", "scans", "did", "not", "return", "to", "their", "original", "state", "after", "ACTH", "therapy", "."], "event_mentions": [{"id": "6311654_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "6311654_3_Ent1", "role": "Subject_Population", "text": "six", "start": 1, "end": 2}, {"entity_id": "6311654_3_Ent0", "role": "Subject", "text": "six cases", "start": 1, "end": 3}, {"entity_id": "6311654_3_Ent2", "role": "Effect", "text": "CT scans did not return to their original state", "start": 3, "end": 12}, {"entity_id": "6311654_3_Ent3", "role": "Treatment", "text": "ACTH", "start": 13, "end": 14}, {"entity_id": "6311654_3_Ent4", "role": "Treatment_Drug", "text": "ACTH", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "6311654_3_Ent1", "text": "six", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6311654_3_Ent0", "text": "six cases", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6311654_3_Ent2", "text": "CT scans did not return to their original state", "entity_type": "Entity", "start": 3, "end": 12}, {"id": "6311654_3_Ent3", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6311654_3_Ent4", "text": "ACTH", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "6329575_1", "wnd_id": "6329575_1_1", "text": "k bipolar manic - depressive patient , developed while on lithium prophylaxis , akathisia at therapeutic serum lithium levels and subsequently bucco - linguo - masticatory dyskinesia .", "tokens": ["k", "bipolar", "manic", "-", "depressive", "patient", ",", "developed", "while", "on", "lithium", "prophylaxis", ",", "akathisia", "at", "therapeutic", "serum", "lithium", "levels", "and", "subsequently", "bucco", "-", "linguo", "-", "masticatory", "dyskinesia", "."], "event_mentions": [{"id": "6329575_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6329575_1_Ent5", "role": "Treatment_Disorder", "text": "k bipolar manic - depressive", "start": 0, "end": 5}, {"entity_id": "6329575_1_Ent0", "role": "Subject", "text": "k bipolar manic - depressive patient", "start": 0, "end": 6}, {"entity_id": "6329575_1_Ent3", "role": "Treatment", "text": "lithium", "start": 10, "end": 11}, {"entity_id": "6329575_1_Ent6", "role": "Treatment_Drug", "text": "lithium", "start": 10, "end": 11}, {"entity_id": "6329575_1_Ent2", "role": "Effect", "text": "akathisia", "start": 13, "end": 14}, {"entity_id": "6329575_1_Ent4", "role": "Treatment", "text": "at therapeutic serum lithium levels", "start": 14, "end": 19}, {"entity_id": "6329575_1_Ent1", "role": "Effect", "text": "bucco - linguo - masticatory dyskinesia", "start": 21, "end": 27}]}], "entity_mentions": [{"id": "6329575_1_Ent5", "text": "k bipolar manic - depressive", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6329575_1_Ent0", "text": "k bipolar manic - depressive patient", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "6329575_1_Ent3", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6329575_1_Ent6", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "6329575_1_Ent2", "text": "akathisia", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "6329575_1_Ent4", "text": "at therapeutic serum lithium levels", "entity_type": "Entity", "start": 14, "end": 19}, {"id": "6329575_1_Ent1", "text": "bucco - linguo - masticatory dyskinesia", "entity_type": "Entity", "start": 21, "end": 27}], "lang": "en"}
{"doc_id": "6353252_1", "wnd_id": "6353252_1_1", "text": "Captopril - induced acute reversible renal failure .", "tokens": ["Captopril", "-", "induced", "acute", "reversible", "renal", "failure", "."], "event_mentions": [{"id": "6353252_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6353252_1_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "6353252_1_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "6353252_1_Ent0", "role": "Effect", "text": "acute reversible renal failure", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "6353252_1_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6353252_1_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6353252_1_Ent0", "text": "acute reversible renal failure", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "6353252_2", "wnd_id": "6353252_2_1", "text": "The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of captopril - induced acute renal failure .", "tokens": ["The", "5", "patients", "had", "severe", "renovascular", "disease", "which", "might", "thus", "represent", "a", "significant", "risk", "factor", "in", "the", "development", "of", "captopril", "-", "induced", "acute", "renal", "failure", "."], "event_mentions": [{"id": "6353252_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "6353252_2_Ent0", "role": "Subject", "text": "The 5 patients had severe renovascular disease", "start": 0, "end": 7}, {"entity_id": "6353252_2_Ent1", "role": "Subject_Population", "text": "5", "start": 1, "end": 2}, {"entity_id": "6353252_2_Ent2", "role": "Subject_Disorder", "text": "renovascular disease", "start": 5, "end": 7}, {"entity_id": "6353252_2_Ent4", "role": "Treatment", "text": "captopril", "start": 19, "end": 20}, {"entity_id": "6353252_2_Ent5", "role": "Treatment_Drug", "text": "captopril", "start": 19, "end": 20}, {"entity_id": "6353252_2_Ent3", "role": "Effect", "text": "acute renal failure", "start": 22, "end": 25}]}], "entity_mentions": [{"id": "6353252_2_Ent0", "text": "The 5 patients had severe renovascular disease", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6353252_2_Ent1", "text": "5", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6353252_2_Ent2", "text": "renovascular disease", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "6353252_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6353252_2_Ent5", "text": "captopril", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "6353252_2_Ent3", "text": "acute renal failure", "entity_type": "Entity", "start": 22, "end": 25}], "lang": "en"}
{"doc_id": "6362443_2", "wnd_id": "6362443_2_1", "text": "A depressed woman with no history of bipolar illness developed a manic episode during treatment with fluoxetine .", "tokens": ["A", "depressed", "woman", "with", "no", "history", "of", "bipolar", "illness", "developed", "a", "manic", "episode", "during", "treatment", "with", "fluoxetine", "."], "event_mentions": [{"id": "6362443_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 13, "end": 14}, "arguments": [{"entity_id": "6362443_2_Ent0", "role": "Subject", "text": "A depressed woman with no history of bipolar illness", "start": 0, "end": 9}, {"entity_id": "6362443_2_Ent5", "role": "Treatment_Disorder", "text": "depressed", "start": 1, "end": 2}, {"entity_id": "6362443_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 2, "end": 3}, {"entity_id": "6362443_2_Ent2", "role": "Effect", "text": "manic episode", "start": 11, "end": 13}, {"entity_id": "6362443_2_Ent3", "role": "Treatment", "text": "fluoxetine", "start": 16, "end": 17}, {"entity_id": "6362443_2_Ent4", "role": "Treatment_Drug", "text": "fluoxetine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "6362443_2_Ent0", "text": "A depressed woman with no history of bipolar illness", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "6362443_2_Ent5", "text": "depressed", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6362443_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "6362443_2_Ent2", "text": "manic episode", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "6362443_2_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "6362443_2_Ent4", "text": "fluoxetine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "6414095_3", "wnd_id": "6414095_3_1", "text": "A 52 - year - old Black woman on phenytoin therapy for post - traumatic epilepsy developed transient hemiparesis contralateral to the injury .", "tokens": ["A", "52", "-", "year", "-", "old", "Black", "woman", "on", "phenytoin", "therapy", "for", "post", "-", "traumatic", "epilepsy", "developed", "transient", "hemiparesis", "contralateral", "to", "the", "injury", "."], "event_mentions": [{"id": "6414095_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 16, "end": 17}, "arguments": [{"entity_id": "6414095_3_Ent0", "role": "Subject", "text": "A 52 - year - old Black woman", "start": 0, "end": 8}, {"entity_id": "6414095_3_Ent1", "role": "Subject_Age", "text": "52 - year - old", "start": 1, "end": 6}, {"entity_id": "6414095_3_Ent2", "role": "Subject_Race", "text": "Black", "start": 6, "end": 7}, {"entity_id": "6414095_3_Ent3", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "6414095_3_Ent5", "role": "Treatment", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent7", "role": "Treatment_Drug", "text": "phenytoin", "start": 9, "end": 10}, {"entity_id": "6414095_3_Ent6", "role": "Treatment_Disorder", "text": "post - traumatic epilepsy", "start": 12, "end": 16}, {"entity_id": "6414095_3_Ent4", "role": "Effect", "text": "transient hemiparesis contralateral to the injury", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "6414095_3_Ent0", "text": "A 52 - year - old Black woman", "entity_type": "Entity", "start": 0, "end": 8}, {"id": "6414095_3_Ent1", "text": "52 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "6414095_3_Ent2", "text": "Black", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6414095_3_Ent3", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6414095_3_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent7", "text": "phenytoin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "6414095_3_Ent6", "text": "post - traumatic epilepsy", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "6414095_3_Ent4", "text": "transient hemiparesis contralateral to the injury", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "6427463_1", "wnd_id": "6427463_1_1", "text": "Stroke - like syndrome after gold sodium thiomalate induced vasomotor reaction .", "tokens": ["Stroke", "-", "like", "syndrome", "after", "gold", "sodium", "thiomalate", "induced", "vasomotor", "reaction", "."], "event_mentions": [{"id": "6427463_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 4, "end": 5}, "arguments": [{"entity_id": "6427463_1_Ent1", "role": "Effect", "text": "Stroke - like syndrome", "start": 0, "end": 4}, {"entity_id": "6427463_1_Ent2", "role": "Treatment", "text": "gold sodium thiomalate", "start": 5, "end": 8}, {"entity_id": "6427463_1_Ent3", "role": "Treatment_Drug", "text": "gold sodium thiomalate", "start": 5, "end": 8}, {"entity_id": "6427463_1_Ent0", "role": "Effect", "text": "vasomotor reaction", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "6427463_1_Ent1", "text": "Stroke - like syndrome", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "6427463_1_Ent2", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6427463_1_Ent3", "text": "gold sodium thiomalate", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6427463_1_Ent0", "text": "vasomotor reaction", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "6484655_1", "wnd_id": "6484655_1_1", "text": "Although they had complex medical problems , the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy .", "tokens": ["Although", "they", "had", "complex", "medical", "problems", ",", "the", "high", "serum", "concentrations", "of", "ampicillin", "at", "the", "time", "of", "seizures", "without", "their", "recurrence", "after", "discontinuing", "the", "antibiotic", "suggest", "that", "the", "seizures", "were", "related", "to", "the", "ampicillin", "therapy", "."], "event_mentions": [{"id": "6484655_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 30, "end": 31}, "arguments": [{"entity_id": "6484655_1_Ent0", "role": "Effect", "text": "seizures", "start": 28, "end": 29}, {"entity_id": "6484655_1_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 33, "end": 34}, {"entity_id": "6484655_1_Ent1", "role": "Treatment", "text": "ampicillin therapy", "start": 33, "end": 35}]}], "entity_mentions": [{"id": "6484655_1_Ent0", "text": "seizures", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "6484655_1_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "6484655_1_Ent1", "text": "ampicillin therapy", "entity_type": "Entity", "start": 33, "end": 35}], "lang": "en"}
{"doc_id": "6484655_3", "wnd_id": "6484655_3_1", "text": "Two patients had ampicillin - associated seizures .", "tokens": ["Two", "patients", "had", "ampicillin", "-", "associated", "seizures", "."], "event_mentions": [{"id": "6484655_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6484655_3_Ent1", "role": "Treatment", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "6484655_3_Ent2", "role": "Treatment_Drug", "text": "ampicillin", "start": 3, "end": 4}, {"entity_id": "6484655_3_Ent0", "role": "Effect", "text": "seizures", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6484655_3_Ent1", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6484655_3_Ent2", "text": "ampicillin", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6484655_3_Ent0", "text": "seizures", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6498095_2", "wnd_id": "6498095_2_1", "text": "Pemphigus foliaceus induced by rifampicin .", "tokens": ["Pemphigus", "foliaceus", "induced", "by", "rifampicin", "."], "event_mentions": [{"id": "6498095_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "6498095_2_Ent0", "role": "Effect", "text": "Pemphigus foliaceus", "start": 0, "end": 2}, {"entity_id": "6498095_2_Ent1", "role": "Treatment", "text": "rifampicin", "start": 4, "end": 5}, {"entity_id": "6498095_2_Ent2", "role": "Treatment_Drug", "text": "rifampicin", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "6498095_2_Ent0", "text": "Pemphigus foliaceus", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6498095_2_Ent1", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6498095_2_Ent2", "text": "rifampicin", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "6507240_2", "wnd_id": "6507240_2_1", "text": "In eight patients , a mean decrease in serum Na+ of 8.25 + / - 3.2 mEq / L was observed after a single 200 mg intravenous dose of lorcainide .", "tokens": ["In", "eight", "patients", ",", "a", "mean", "decrease", "in", "serum", "Na+", "of", "8.25", "+", "/", "-", "3.2", "mEq", "/", "L", "was", "observed", "after", "a", "single", "200", "mg", "intravenous", "dose", "of", "lorcainide", "."], "event_mentions": [{"id": "6507240_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "observed", "start": 20, "end": 21}, "arguments": [{"entity_id": "6507240_2_Ent1", "role": "Subject_Population", "text": "eight", "start": 1, "end": 2}, {"entity_id": "6507240_2_Ent0", "role": "Subject", "text": "eight patients", "start": 1, "end": 3}, {"entity_id": "6507240_2_Ent2", "role": "Effect", "text": "mean decrease in serum Na+ of 8.25 + / - 3.2 mEq / L", "start": 5, "end": 19}, {"entity_id": "6507240_2_Ent4", "role": "Treatment_Dosage", "text": "a single 200 mg", "start": 22, "end": 26}, {"entity_id": "6507240_2_Ent3", "role": "Treatment", "text": "a single 200 mg intravenous dose of lorcainide", "start": 22, "end": 30}, {"entity_id": "6507240_2_Ent5", "role": "Treatment_Route", "text": "intravenous", "start": 26, "end": 27}, {"entity_id": "6507240_2_Ent6", "role": "Treatment_Drug", "text": "lorcainide", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "6507240_2_Ent1", "text": "eight", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6507240_2_Ent0", "text": "eight patients", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "6507240_2_Ent2", "text": "mean decrease in serum Na+ of 8.25 + / - 3.2 mEq / L", "entity_type": "Entity", "start": 5, "end": 19}, {"id": "6507240_2_Ent4", "text": "a single 200 mg", "entity_type": "Entity", "start": 22, "end": 26}, {"id": "6507240_2_Ent3", "text": "a single 200 mg intravenous dose of lorcainide", "entity_type": "Entity", "start": 22, "end": 30}, {"id": "6507240_2_Ent5", "text": "intravenous", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "6507240_2_Ent6", "text": "lorcainide", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "6507240_4", "wnd_id": "6507240_4_1", "text": "One patient developed severe hyponatremia with serum Na+ of 108 mEq / L when hydrochlorothiazide was given to control hypertension .", "tokens": ["One", "patient", "developed", "severe", "hyponatremia", "with", "serum", "Na+", "of", "108", "mEq", "/", "L", "when", "hydrochlorothiazide", "was", "given", "to", "control", "hypertension", "."], "event_mentions": [{"id": "6507240_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 2, "end": 3}, "arguments": [{"entity_id": "6507240_4_Ent1", "role": "Subject_Population", "text": "One", "start": 0, "end": 1}, {"entity_id": "6507240_4_Ent0", "role": "Subject", "text": "One patient", "start": 0, "end": 2}, {"entity_id": "6507240_4_Ent2", "role": "Effect", "text": "severe hyponatremia with serum Na+ of 108 mEq / L", "start": 3, "end": 13}, {"entity_id": "6507240_4_Ent3", "role": "Treatment", "text": "hydrochlorothiazide", "start": 14, "end": 15}, {"entity_id": "6507240_4_Ent5", "role": "Treatment_Drug", "text": "hydrochlorothiazide", "start": 14, "end": 15}, {"entity_id": "6507240_4_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "6507240_4_Ent1", "text": "One", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6507240_4_Ent0", "text": "One patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6507240_4_Ent2", "text": "severe hyponatremia with serum Na+ of 108 mEq / L", "entity_type": "Entity", "start": 3, "end": 13}, {"id": "6507240_4_Ent3", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6507240_4_Ent5", "text": "hydrochlorothiazide", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "6507240_4_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "6529939_4", "wnd_id": "6529939_4_1", "text": "This was accepted as evidence for propranolol being the cause of this conduction disorder .", "tokens": ["This", "was", "accepted", "as", "evidence", "for", "propranolol", "being", "the", "cause", "of", "this", "conduction", "disorder", "."], "event_mentions": [{"id": "6529939_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 9, "end": 10}, "arguments": [{"entity_id": "6529939_4_Ent1", "role": "Treatment", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "6529939_4_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 6, "end": 7}, {"entity_id": "6529939_4_Ent0", "role": "Effect", "text": "conduction disorder", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "6529939_4_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6529939_4_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6529939_4_Ent0", "text": "conduction disorder", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "6572542_4", "wnd_id": "6572542_4_1", "text": "Two patients treated for chronic myeloid leukemia with high doses of CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively ) developed a fatal pulmonary fibrosis .", "tokens": ["Two", "patients", "treated", "for", "chronic", "myeloid", "leukemia", "with", "high", "doses", "of", "CCNU", "(", "1100", "mg", "/", "m2", "and", "1240", "mg", "/", "m2", ",", "respectively", ")", "developed", "a", "fatal", "pulmonary", "fibrosis", "."], "event_mentions": [{"id": "6572542_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 25, "end": 26}, "arguments": [{"entity_id": "6572542_4_Ent2", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "6572542_4_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "6572542_4_Ent1", "role": "Subject", "text": "chronic myeloid leukemia", "start": 4, "end": 7}, {"entity_id": "6572542_4_Ent5", "role": "Treatment_Disorder", "text": "chronic myeloid leukemia", "start": 4, "end": 7}, {"entity_id": "6572542_4_Ent6", "role": "Treatment_Drug", "text": "CCNU", "start": 11, "end": 12}, {"entity_id": "6572542_4_Ent4", "role": "Treatment", "text": "CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively )", "start": 11, "end": 25}, {"entity_id": "6572542_4_Ent7", "role": "Treatment_Dosage", "text": "1100 mg / m2", "start": 13, "end": 17}, {"entity_id": "6572542_4_Ent8", "role": "Treatment_Dosage", "text": "1240 mg / m2", "start": 18, "end": 22}, {"entity_id": "6572542_4_Ent3", "role": "Effect", "text": "pulmonary fibrosis", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "6572542_4_Ent2", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6572542_4_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6572542_4_Ent1", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "6572542_4_Ent5", "text": "chronic myeloid leukemia", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "6572542_4_Ent6", "text": "CCNU", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6572542_4_Ent4", "text": "CCNU ( 1100 mg / m2 and 1240 mg / m2 , respectively )", "entity_type": "Entity", "start": 11, "end": 25}, {"id": "6572542_4_Ent7", "text": "1100 mg / m2", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "6572542_4_Ent8", "text": "1240 mg / m2", "entity_type": "Entity", "start": 18, "end": 22}, {"id": "6572542_4_Ent3", "text": "pulmonary fibrosis", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "6578007_1", "wnd_id": "6578007_1_1", "text": "Additive pulmonary toxicity with melphalan and busulfan therapy .", "tokens": ["Additive", "pulmonary", "toxicity", "with", "melphalan", "and", "busulfan", "therapy", "."], "event_mentions": [{"id": "6578007_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "with", "start": 3, "end": 4}, "arguments": [{"entity_id": "6578007_1_Ent0", "role": "Effect", "text": "Additive pulmonary toxicity", "start": 0, "end": 3}, {"entity_id": "6578007_1_Ent2", "role": "Treatment_Drug", "text": "melphalan", "start": 4, "end": 5}, {"entity_id": "6578007_1_Ent4", "role": "Combination_Drug", "text": "melphalan", "start": 4, "end": 5}, {"entity_id": "6578007_1_Ent1", "role": "Treatment", "text": "melphalan and busulfan therapy", "start": 4, "end": 8}, {"entity_id": "6578007_1_Ent3", "role": "Treatment_Drug", "text": "busulfan", "start": 6, "end": 7}, {"entity_id": "6578007_1_Ent5", "role": "Combination_Drug", "text": "busulfan", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6578007_1_Ent0", "text": "Additive pulmonary toxicity", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "6578007_1_Ent2", "text": "melphalan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6578007_1_Ent4", "text": "melphalan", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6578007_1_Ent1", "text": "melphalan and busulfan therapy", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "6578007_1_Ent3", "text": "busulfan", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6578007_1_Ent5", "text": "busulfan", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6614033_1", "wnd_id": "6614033_1_1", "text": "A major limitation in the use of amphotericin B is its potential to cause nephrotoxicity .", "tokens": ["A", "major", "limitation", "in", "the", "use", "of", "amphotericin", "B", "is", "its", "potential", "to", "cause", "nephrotoxicity", "."], "event_mentions": [{"id": "6614033_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 13, "end": 14}, "arguments": [{"entity_id": "6614033_1_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 7, "end": 9}, {"entity_id": "6614033_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6614033_1_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "6614033_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6693840_1", "wnd_id": "6693840_1_1", "text": "A 61 year - old male patient developed gynecomastia after starting theophylline .", "tokens": ["A", "61", "year", "-", "old", "male", "patient", "developed", "gynecomastia", "after", "starting", "theophylline", "."], "event_mentions": [{"id": "6693840_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_1_Ent0", "role": "Subject", "text": "A 61 year - old male patient", "start": 0, "end": 7}, {"entity_id": "6693840_1_Ent1", "role": "Subject_Age", "text": "61 year - old", "start": 1, "end": 5}, {"entity_id": "6693840_1_Ent2", "role": "Subject_Gender", "text": "male", "start": 5, "end": 6}, {"entity_id": "6693840_1_Ent3", "role": "Effect", "text": "gynecomastia", "start": 8, "end": 9}, {"entity_id": "6693840_1_Ent4", "role": "Treatment", "text": "theophylline", "start": 11, "end": 12}, {"entity_id": "6693840_1_Ent5", "role": "Treatment_Drug", "text": "theophylline", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "6693840_1_Ent0", "text": "A 61 year - old male patient", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "6693840_1_Ent1", "text": "61 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "6693840_1_Ent2", "text": "male", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_1_Ent3", "text": "gynecomastia", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "6693840_1_Ent4", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "6693840_1_Ent5", "text": "theophylline", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "6693840_4", "wnd_id": "6693840_4_1", "text": "The gynecomastia regressed when the theophylline was discontinued .", "tokens": ["The", "gynecomastia", "regressed", "when", "the", "theophylline", "was", "discontinued", "."], "event_mentions": [{"id": "6693840_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "discontinued", "start": 7, "end": 8}, "arguments": [{"entity_id": "6693840_4_Ent0", "role": "Effect", "text": "gynecomastia", "start": 1, "end": 2}, {"entity_id": "6693840_4_Ent1", "role": "Treatment", "text": "theophylline", "start": 5, "end": 6}, {"entity_id": "6693840_4_Ent2", "role": "Treatment_Drug", "text": "theophylline", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "6693840_4_Ent0", "text": "gynecomastia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "6693840_4_Ent1", "text": "theophylline", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "6693840_4_Ent2", "text": "theophylline", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "6725214_1", "wnd_id": "6725214_1_1", "text": "A case of priapism associated with trazodone is described .", "tokens": ["A", "case", "of", "priapism", "associated", "with", "trazodone", "is", "described", "."], "event_mentions": [{"id": "6725214_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "6725214_1_Ent0", "role": "Subject", "text": "A case", "start": 0, "end": 2}, {"entity_id": "6725214_1_Ent1", "role": "Effect", "text": "priapism", "start": 3, "end": 4}, {"entity_id": "6725214_1_Ent2", "role": "Treatment", "text": "trazodone", "start": 6, "end": 7}, {"entity_id": "6725214_1_Ent3", "role": "Treatment_Drug", "text": "trazodone", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "6725214_1_Ent0", "text": "A case", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6725214_1_Ent1", "text": "priapism", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6725214_1_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6725214_1_Ent3", "text": "trazodone", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "6725214_2", "wnd_id": "6725214_2_1", "text": "Priapism associated with trazodone therapy : case report .", "tokens": ["Priapism", "associated", "with", "trazodone", "therapy", ":", "case", "report", "."], "event_mentions": [{"id": "6725214_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "6725214_2_Ent0", "role": "Effect", "text": "Priapism", "start": 0, "end": 1}, {"entity_id": "6725214_2_Ent2", "role": "Treatment_Drug", "text": "trazodone", "start": 3, "end": 4}, {"entity_id": "6725214_2_Ent1", "role": "Treatment", "text": "trazodone therapy", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "6725214_2_Ent0", "text": "Priapism", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6725214_2_Ent2", "text": "trazodone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6725214_2_Ent1", "text": "trazodone therapy", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "6731466_2", "wnd_id": "6731466_2_1", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving zomepirac sodium for toothache .", "tokens": ["Anaphylactoid", "shock", ",", "disseminated", "intravascular", "coagulation", ",", "and", "anuric", "renal", "failure", "requiring", "dialysis", "occurred", "in", "a", "patient", "receiving", "zomepirac", "sodium", "for", "toothache", "."], "event_mentions": [{"id": "6731466_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 13, "end": 14}, "arguments": [{"entity_id": "6731466_2_Ent2", "role": "Effect", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis", "start": 0, "end": 13}, {"entity_id": "6731466_2_Ent0", "role": "Subject", "text": "a patient", "start": 15, "end": 17}, {"entity_id": "6731466_2_Ent3", "role": "Treatment", "text": "zomepirac sodium", "start": 18, "end": 20}, {"entity_id": "6731466_2_Ent4", "role": "Treatment_Drug", "text": "zomepirac sodium", "start": 18, "end": 20}, {"entity_id": "6731466_2_Ent1", "role": "Subject", "text": "toothache", "start": 21, "end": 22}, {"entity_id": "6731466_2_Ent5", "role": "Treatment_Disorder", "text": "toothache", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "6731466_2_Ent2", "text": "Anaphylactoid shock , disseminated intravascular coagulation , and anuric renal failure requiring dialysis", "entity_type": "Entity", "start": 0, "end": 13}, {"id": "6731466_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "6731466_2_Ent3", "text": "zomepirac sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "6731466_2_Ent4", "text": "zomepirac sodium", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "6731466_2_Ent1", "text": "toothache", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "6731466_2_Ent5", "text": "toothache", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "6794018_2", "wnd_id": "6794018_2_1", "text": "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy .", "tokens": ["Intrahepatic", "cholestasis", "and", "cutaneous", "bullae", "associated", "with", "glibenclamide", "therapy", "."], "event_mentions": [{"id": "6794018_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 5, "end": 6}, "arguments": [{"entity_id": "6794018_2_Ent0", "role": "Effect", "text": "Intrahepatic cholestasis and cutaneous bullae", "start": 0, "end": 5}, {"entity_id": "6794018_2_Ent2", "role": "Treatment_Drug", "text": "glibenclamide", "start": 7, "end": 8}, {"entity_id": "6794018_2_Ent1", "role": "Treatment", "text": "glibenclamide therapy", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "6794018_2_Ent0", "text": "Intrahepatic cholestasis and cutaneous bullae", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6794018_2_Ent2", "text": "glibenclamide", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6794018_2_Ent1", "text": "glibenclamide therapy", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "6833205_2", "wnd_id": "6833205_2_1", "text": "Desipramine - associated SIADH in an elderly woman : case report .", "tokens": ["Desipramine", "-", "associated", "SIADH", "in", "an", "elderly", "woman", ":", "case", "report", "."], "event_mentions": [{"id": "6833205_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "6833205_2_Ent4", "role": "Treatment", "text": "Desipramine", "start": 0, "end": 1}, {"entity_id": "6833205_2_Ent5", "role": "Treatment_Drug", "text": "Desipramine", "start": 0, "end": 1}, {"entity_id": "6833205_2_Ent3", "role": "Effect", "text": "SIADH", "start": 3, "end": 4}, {"entity_id": "6833205_2_Ent0", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "6833205_2_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "6833205_2_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "6833205_2_Ent4", "text": "Desipramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6833205_2_Ent5", "text": "Desipramine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "6833205_2_Ent3", "text": "SIADH", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "6833205_2_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "6833205_2_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "6833205_2_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "6865827_2", "wnd_id": "6865827_2_1", "text": "The patient was given methimazole instead of propylthiouracil but , 10 weeks later , agranulocytosis again occurred .", "tokens": ["The", "patient", "was", "given", "methimazole", "instead", "of", "propylthiouracil", "but", ",", "10", "weeks", "later", ",", "agranulocytosis", "again", "occurred", "."], "event_mentions": [{"id": "6865827_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 16, "end": 17}, "arguments": [{"entity_id": "6865827_2_Ent0", "role": "Subject", "text": "The patient", "start": 0, "end": 2}, {"entity_id": "6865827_2_Ent2", "role": "Treatment", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "6865827_2_Ent3", "role": "Treatment_Drug", "text": "methimazole", "start": 4, "end": 5}, {"entity_id": "6865827_2_Ent4", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 7, "end": 8}, {"entity_id": "6865827_2_Ent5", "role": "Treatment_Time_elapsed", "text": "10 weeks later", "start": 10, "end": 13}, {"entity_id": "6865827_2_Ent1", "role": "Effect", "text": "agranulocytosis", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "6865827_2_Ent0", "text": "The patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "6865827_2_Ent2", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6865827_2_Ent3", "text": "methimazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "6865827_2_Ent4", "text": "propylthiouracil", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "6865827_2_Ent5", "text": "10 weeks later", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "6865827_2_Ent1", "text": "agranulocytosis", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "6933231_1", "wnd_id": "6933231_1_1", "text": "Intracranial hemorrhage and focal seizures secondary to use of L - asparaginase during induction therapy of acute lymphocytic leukemia .", "tokens": ["Intracranial", "hemorrhage", "and", "focal", "seizures", "secondary", "to", "use", "of", "L", "-", "asparaginase", "during", "induction", "therapy", "of", "acute", "lymphocytic", "leukemia", "."], "event_mentions": [{"id": "6933231_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary to", "start": 5, "end": 7}, "arguments": [{"entity_id": "6933231_1_Ent0", "role": "Effect", "text": "Intracranial hemorrhage and focal seizures", "start": 0, "end": 5}, {"entity_id": "6933231_1_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 9, "end": 12}, {"entity_id": "6933231_1_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 9, "end": 12}]}], "entity_mentions": [{"id": "6933231_1_Ent0", "text": "Intracranial hemorrhage and focal seizures", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "6933231_1_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "6933231_1_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 9, "end": 12}], "lang": "en"}
{"doc_id": "7019786_2", "wnd_id": "7019786_2_1", "text": "The other woman had rheumatoid arthritis and developed acute tubular necrosis after treatment with gentamicin and cefoxitin .", "tokens": ["The", "other", "woman", "had", "rheumatoid", "arthritis", "and", "developed", "acute", "tubular", "necrosis", "after", "treatment", "with", "gentamicin", "and", "cefoxitin", "."], "event_mentions": [{"id": "7019786_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "7019786_2_Ent0", "role": "Subject", "text": "The other woman had rheumatoid arthritis", "start": 0, "end": 6}, {"entity_id": "7019786_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 2, "end": 3}, {"entity_id": "7019786_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 4, "end": 6}, {"entity_id": "7019786_2_Ent2", "role": "Effect", "text": "acute tubular necrosis", "start": 8, "end": 11}, {"entity_id": "7019786_2_Ent5", "role": "Treatment_Drug", "text": "gentamicin", "start": 14, "end": 15}, {"entity_id": "7019786_2_Ent7", "role": "Combination_Drug", "text": "gentamicin", "start": 14, "end": 15}, {"entity_id": "7019786_2_Ent3", "role": "Treatment", "text": "gentamicin and cefoxitin", "start": 14, "end": 17}, {"entity_id": "7019786_2_Ent6", "role": "Treatment_Drug", "text": "cefoxitin", "start": 16, "end": 17}, {"entity_id": "7019786_2_Ent8", "role": "Combination_Drug", "text": "cefoxitin", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "7019786_2_Ent0", "text": "The other woman had rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7019786_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7019786_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7019786_2_Ent2", "text": "acute tubular necrosis", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "7019786_2_Ent5", "text": "gentamicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7019786_2_Ent7", "text": "gentamicin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "7019786_2_Ent3", "text": "gentamicin and cefoxitin", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7019786_2_Ent6", "text": "cefoxitin", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7019786_2_Ent8", "text": "cefoxitin", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "7035691_1", "wnd_id": "7035691_1_1", "text": "Transient anuria following administration of angiotensin I - converting enzyme inhibitor ( SQ 14225 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation .", "tokens": ["Transient", "anuria", "following", "administration", "of", "angiotensin", "I", "-", "converting", "enzyme", "inhibitor", "(", "SQ", "14225", ")", "in", "a", "patient", "with", "renal", "artery", "stenosis", "of", "the", "solitary", "kidney", "successfully", "treated", "with", "renal", "autotransplantation", "."], "event_mentions": [{"id": "7035691_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 2, "end": 3}, "arguments": [{"entity_id": "7035691_1_Ent1", "role": "Effect", "text": "Transient anuria", "start": 0, "end": 2}, {"entity_id": "7035691_1_Ent4", "role": "Treatment_Drug", "text": "angiotensin I - converting enzyme inhibitor", "start": 5, "end": 11}, {"entity_id": "7035691_1_Ent2", "role": "Treatment", "text": "angiotensin I - converting enzyme inhibitor ( SQ 14225 )", "start": 5, "end": 15}, {"entity_id": "7035691_1_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis of the solitary kidney", "start": 16, "end": 26}, {"entity_id": "7035691_1_Ent3", "role": "Treatment_Disorder", "text": "renal artery stenosis of the solitary kidney", "start": 19, "end": 26}]}, {"id": "7035691_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 27, "end": 28}, "arguments": [{"entity_id": "7035691_1_Ent7", "role": "Treatment_Disorder", "text": "Transient anuria", "start": 0, "end": 2}, {"entity_id": "7035691_1_Ent5", "role": "Subject", "text": "a patient with renal artery stenosis of the solitary kidney", "start": 16, "end": 26}, {"entity_id": "7035691_1_Ent6", "role": "Treatment", "text": "renal autotransplantation", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "7035691_1_Ent1", "text": "Transient anuria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7035691_1_Ent7", "text": "Transient anuria", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7035691_1_Ent4", "text": "angiotensin I - converting enzyme inhibitor", "entity_type": "Entity", "start": 5, "end": 11}, {"id": "7035691_1_Ent2", "text": "angiotensin I - converting enzyme inhibitor ( SQ 14225 )", "entity_type": "Entity", "start": 5, "end": 15}, {"id": "7035691_1_Ent0", "text": "a patient with renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7035691_1_Ent5", "text": "a patient with renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7035691_1_Ent3", "text": "renal artery stenosis of the solitary kidney", "entity_type": "Entity", "start": 19, "end": 26}, {"id": "7035691_1_Ent6", "text": "renal autotransplantation", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "7035691_2", "wnd_id": "7035691_2_1", "text": "We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with transient anuria after the administration of captopril .", "tokens": ["We", "report", "on", "a", "patient", "with", "renal", "artery", "stenosis", "who", "had", "only", "1", "kidney", "and", "in", "whom", "acute", "renal", "impairment", "developed", "with", "transient", "anuria", "after", "the", "administration", "of", "captopril", "."], "event_mentions": [{"id": "7035691_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 24, "end": 25}, "arguments": [{"entity_id": "7035691_2_Ent0", "role": "Subject", "text": "a patient with renal artery stenosis who had only 1 kidney", "start": 3, "end": 14}, {"entity_id": "7035691_2_Ent1", "role": "Subject_Disorder", "text": "renal artery stenosis who had only 1 kidney", "start": 6, "end": 14}, {"entity_id": "7035691_2_Ent2", "role": "Effect", "text": "acute renal impairment developed with transient anuria", "start": 17, "end": 24}, {"entity_id": "7035691_2_Ent3", "role": "Treatment", "text": "the administration of captopril", "start": 25, "end": 29}, {"entity_id": "7035691_2_Ent4", "role": "Treatment_Drug", "text": "captopril", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7035691_2_Ent0", "text": "a patient with renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 3, "end": 14}, {"id": "7035691_2_Ent1", "text": "renal artery stenosis who had only 1 kidney", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "7035691_2_Ent2", "text": "acute renal impairment developed with transient anuria", "entity_type": "Entity", "start": 17, "end": 24}, {"id": "7035691_2_Ent3", "text": "the administration of captopril", "entity_type": "Entity", "start": 25, "end": 29}, {"id": "7035691_2_Ent4", "text": "captopril", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7056119_4", "wnd_id": "7056119_4_1", "text": "Because of a recurrence of paroxysmal atrial fibrillation , the dose of the drug was increased to 1.4 g / day ; 24 hours later AVT with syncope developed but responded promptly to atropine .", "tokens": ["Because", "of", "a", "recurrence", "of", "paroxysmal", "atrial", "fibrillation", ",", "the", "dose", "of", "the", "drug", "was", "increased", "to", "1.4", "g", "/", "day", ";", "24", "hours", "later", "AVT", "with", "syncope", "developed", "but", "responded", "promptly", "to", "atropine", "."], "event_mentions": [{"id": "7056119_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 28, "end": 29}, "arguments": [{"entity_id": "7056119_4_Ent0", "role": "Subject", "text": "paroxysmal atrial fibrillation", "start": 5, "end": 8}, {"entity_id": "7056119_4_Ent1", "role": "Subject_Disorder", "text": "paroxysmal atrial fibrillation", "start": 5, "end": 8}, {"entity_id": "7056119_4_Ent3", "role": "Treatment", "text": "the dose of the drug was increased to 1.4 g / day", "start": 9, "end": 21}, {"entity_id": "7056119_4_Ent6", "role": "Treatment_Drug", "text": "the drug", "start": 12, "end": 14}, {"entity_id": "7056119_4_Ent5", "role": "Treatment_Dosage", "text": "1.4 g / day", "start": 17, "end": 21}, {"entity_id": "7056119_4_Ent4", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 22, "end": 24}, {"entity_id": "7056119_4_Ent2", "role": "Effect", "text": "AVT with syncope", "start": 25, "end": 28}]}, {"id": "7056119_4_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "responded", "start": 30, "end": 31}, "arguments": [{"entity_id": "7056119_4_Ent8", "role": "Treatment_Disorder", "text": "AVT with syncope", "start": 25, "end": 28}, {"entity_id": "7056119_4_Ent7", "role": "Treatment", "text": "atropine", "start": 33, "end": 34}, {"entity_id": "7056119_4_Ent9", "role": "Treatment_Drug", "text": "atropine", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "7056119_4_Ent0", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7056119_4_Ent1", "text": "paroxysmal atrial fibrillation", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7056119_4_Ent3", "text": "the dose of the drug was increased to 1.4 g / day", "entity_type": "Entity", "start": 9, "end": 21}, {"id": "7056119_4_Ent6", "text": "the drug", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7056119_4_Ent5", "text": "1.4 g / day", "entity_type": "Entity", "start": 17, "end": 21}, {"id": "7056119_4_Ent4", "text": "24 hours", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "7056119_4_Ent2", "text": "AVT with syncope", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7056119_4_Ent8", "text": "AVT with syncope", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "7056119_4_Ent7", "text": "atropine", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "7056119_4_Ent9", "text": "atropine", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "7056119_5", "wnd_id": "7056119_5_1", "text": "Two years later , 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day , AVT with syncope occurred ; isoproterenol abolished the arrhythmia instantly .", "tokens": ["Two", "years", "later", ",", "24", "hours", "following", "an", "increase", "in", "the", "dose", "of", "disopyramide", "from", "300", "to", "600", "mg", "/", "day", ",", "AVT", "with", "syncope", "occurred", ";", "isoproterenol", "abolished", "the", "arrhythmia", "instantly", "."], "event_mentions": [{"id": "7056119_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 25, "end": 26}, "arguments": [{"entity_id": "7056119_5_Ent5", "role": "Treatment_Duration", "text": "Two years", "start": 0, "end": 2}, {"entity_id": "7056119_5_Ent1", "role": "Treatment", "text": "Two years later , 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day", "start": 0, "end": 21}, {"entity_id": "7056119_5_Ent2", "role": "Treatment_Time_elapsed", "text": "24 hours", "start": 4, "end": 6}, {"entity_id": "7056119_5_Ent4", "role": "Treatment_Drug", "text": "disopyramide", "start": 13, "end": 14}, {"entity_id": "7056119_5_Ent3", "role": "Treatment_Dosage", "text": "300 to 600 mg / day", "start": 15, "end": 21}, {"entity_id": "7056119_5_Ent0", "role": "Effect", "text": "AVT with syncope", "start": 22, "end": 25}]}, {"id": "7056119_5_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "abolished", "start": 28, "end": 29}, "arguments": [{"entity_id": "7056119_5_Ent6", "role": "Treatment", "text": "isoproterenol", "start": 27, "end": 28}, {"entity_id": "7056119_5_Ent8", "role": "Treatment_Drug", "text": "isoproterenol", "start": 27, "end": 28}, {"entity_id": "7056119_5_Ent7", "role": "Treatment_Disorder", "text": "arrhythmia", "start": 30, "end": 31}]}], "entity_mentions": [{"id": "7056119_5_Ent5", "text": "Two years", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7056119_5_Ent1", "text": "Two years later , 24 hours following an increase in the dose of disopyramide from 300 to 600 mg / day", "entity_type": "Entity", "start": 0, "end": 21}, {"id": "7056119_5_Ent2", "text": "24 hours", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7056119_5_Ent4", "text": "disopyramide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7056119_5_Ent3", "text": "300 to 600 mg / day", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "7056119_5_Ent0", "text": "AVT with syncope", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "7056119_5_Ent6", "text": "isoproterenol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7056119_5_Ent8", "text": "isoproterenol", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "7056119_5_Ent7", "text": "arrhythmia", "entity_type": "Entity", "start": 30, "end": 31}], "lang": "en"}
{"doc_id": "7067510_1", "wnd_id": "7067510_1_1", "text": "Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out , the sudden onset , prominent magnitude , and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event , possibly related to a transient coronary vasoconstriction induced by the dopamine infusion .", "tokens": ["Although", "the", "existence", "of", "an", "acute", "pericarditis", "or", "an", "acute", "myocarditis", "as", "possible", "causes", "of", "the", "ST", "elevation", "can", "not", "be", "fully", "ruled", "out", ",", "the", "sudden", "onset", ",", "prominent", "magnitude", ",", "and", "brief", "duration", "of", "the", "ST", "elevation", "are", "perhaps", "more", "indicative", "of", "an", "acute", "ischemic", "event", ",", "possibly", "related", "to", "a", "transient", "coronary", "vasoconstriction", "induced", "by", "the", "dopamine", "infusion", "."], "event_mentions": [{"id": "7067510_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 56, "end": 57}, "arguments": [{"entity_id": "7067510_1_Ent0", "role": "Effect", "text": "transient coronary vasoconstriction", "start": 53, "end": 56}, {"entity_id": "7067510_1_Ent1", "role": "Treatment", "text": "dopamine", "start": 59, "end": 60}, {"entity_id": "7067510_1_Ent2", "role": "Treatment_Drug", "text": "dopamine", "start": 59, "end": 60}]}], "entity_mentions": [{"id": "7067510_1_Ent0", "text": "transient coronary vasoconstriction", "entity_type": "Entity", "start": 53, "end": 56}, {"id": "7067510_1_Ent1", "text": "dopamine", "entity_type": "Entity", "start": 59, "end": 60}, {"id": "7067510_1_Ent2", "text": "dopamine", "entity_type": "Entity", "start": 59, "end": 60}], "lang": "en"}
{"doc_id": "7071645_2", "wnd_id": "7071645_2_1", "text": "We have described a man with classic rheumatoid arthritis who had membranous nephropathy associated with nephrotic syndrome not related to gold or penicillamine therapy .", "tokens": ["We", "have", "described", "a", "man", "with", "classic", "rheumatoid", "arthritis", "who", "had", "membranous", "nephropathy", "associated", "with", "nephrotic", "syndrome", "not", "related", "to", "gold", "or", "penicillamine", "therapy", "."], "event_mentions": [{"id": "7071645_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "not related", "start": 17, "end": 19}, "arguments": [{"entity_id": "7071645_2_Ent0", "role": "Subject", "text": "a man with classic rheumatoid arthritis", "start": 3, "end": 9}, {"entity_id": "7071645_2_Ent1", "role": "Subject_Gender", "text": "man", "start": 4, "end": 5}, {"entity_id": "7071645_2_Ent6", "role": "Treatment_Disorder", "text": "classic rheumatoid arthritis", "start": 6, "end": 9}, {"entity_id": "7071645_2_Ent2", "role": "Effect", "text": "membranous nephropathy associated with nephrotic syndrome", "start": 11, "end": 17}, {"entity_id": "7071645_2_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 20, "end": 21}, {"entity_id": "7071645_2_Ent3", "role": "Treatment", "text": "gold or penicillamine therapy", "start": 20, "end": 24}, {"entity_id": "7071645_2_Ent5", "role": "Treatment_Drug", "text": "penicillamine", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7071645_2_Ent0", "text": "a man with classic rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "7071645_2_Ent1", "text": "man", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7071645_2_Ent6", "text": "classic rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7071645_2_Ent2", "text": "membranous nephropathy associated with nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 17}, {"id": "7071645_2_Ent4", "text": "gold", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "7071645_2_Ent3", "text": "gold or penicillamine therapy", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "7071645_2_Ent5", "text": "penicillamine", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7081289_2", "wnd_id": "7081289_2_1", "text": "The case of an adult who developed both hepatic dysfunction and an impaired macrophage migration after exposure to cimetidine is discussed .", "tokens": ["The", "case", "of", "an", "adult", "who", "developed", "both", "hepatic", "dysfunction", "and", "an", "impaired", "macrophage", "migration", "after", "exposure", "to", "cimetidine", "is", "discussed", "."], "event_mentions": [{"id": "7081289_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "7081289_2_Ent0", "role": "Subject", "text": "an adult", "start": 3, "end": 5}, {"entity_id": "7081289_2_Ent1", "role": "Subject_Age", "text": "adult", "start": 4, "end": 5}, {"entity_id": "7081289_2_Ent2", "role": "Effect", "text": "hepatic dysfunction and an impaired macrophage migration", "start": 8, "end": 15}, {"entity_id": "7081289_2_Ent4", "role": "Treatment_Drug", "text": "cimetidine", "start": 18, "end": 19}, {"entity_id": "7081289_2_Ent3", "role": "Treatment", "text": "cimetidine is discussed", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "7081289_2_Ent0", "text": "an adult", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7081289_2_Ent1", "text": "adult", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7081289_2_Ent2", "text": "hepatic dysfunction and an impaired macrophage migration", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "7081289_2_Ent4", "text": "cimetidine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7081289_2_Ent3", "text": "cimetidine is discussed", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "7117795_1", "wnd_id": "7117795_1_1", "text": "Flucytosine - associated diarrhea has been previously described in 6% - 10 % of patients receiving the drug .", "tokens": ["Flucytosine", "-", "associated", "diarrhea", "has", "been", "previously", "described", "in", "6%", "-", "10", "%", "of", "patients", "receiving", "the", "drug", "."], "event_mentions": [{"id": "7117795_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7117795_1_Ent3", "role": "Treatment", "text": "Flucytosine", "start": 0, "end": 1}, {"entity_id": "7117795_1_Ent4", "role": "Treatment_Drug", "text": "Flucytosine", "start": 0, "end": 1}, {"entity_id": "7117795_1_Ent2", "role": "Effect", "text": "diarrhea", "start": 3, "end": 4}, {"entity_id": "7117795_1_Ent1", "role": "Subject_Population", "text": "6% - 10 %", "start": 9, "end": 13}, {"entity_id": "7117795_1_Ent0", "role": "Subject", "text": "6% - 10 % of patients", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "7117795_1_Ent3", "text": "Flucytosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7117795_1_Ent4", "text": "Flucytosine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7117795_1_Ent2", "text": "diarrhea", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7117795_1_Ent1", "text": "6% - 10 %", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "7117795_1_Ent0", "text": "6% - 10 % of patients", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "7139589_3", "wnd_id": "7139589_3_1", "text": "L - asparaginase - induced pancreatitis has been reported during or closely following administration of the drug .", "tokens": ["L", "-", "asparaginase", "-", "induced", "pancreatitis", "has", "been", "reported", "during", "or", "closely", "following", "administration", "of", "the", "drug", "."], "event_mentions": [{"id": "7139589_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7139589_3_Ent1", "role": "Treatment", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent2", "role": "Treatment_Drug", "text": "L - asparaginase", "start": 0, "end": 3}, {"entity_id": "7139589_3_Ent0", "role": "Effect", "text": "pancreatitis", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "7139589_3_Ent1", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent2", "text": "L - asparaginase", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7139589_3_Ent0", "text": "pancreatitis", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "7174620_1", "wnd_id": "7174620_1_1", "text": "Nine delirious patients suffering from lithium intoxication were examined with the Mini - Mental State Exam ( MMS ) to describe the clinical course of the disorder .", "tokens": ["Nine", "delirious", "patients", "suffering", "from", "lithium", "intoxication", "were", "examined", "with", "the", "Mini", "-", "Mental", "State", "Exam", "(", "MMS", ")", "to", "describe", "the", "clinical", "course", "of", "the", "disorder", "."], "event_mentions": [{"id": "7174620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering from", "start": 3, "end": 5}, "arguments": [{"entity_id": "7174620_1_Ent1", "role": "Subject_Population", "text": "Nine", "start": 0, "end": 1}, {"entity_id": "7174620_1_Ent0", "role": "Subject", "text": "Nine delirious patients", "start": 0, "end": 3}, {"entity_id": "7174620_1_Ent2", "role": "Subject_Disorder", "text": "delirious", "start": 1, "end": 2}, {"entity_id": "7174620_1_Ent4", "role": "Treatment", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "7174620_1_Ent5", "role": "Treatment_Drug", "text": "lithium", "start": 5, "end": 6}, {"entity_id": "7174620_1_Ent3", "role": "Effect", "text": "lithium intoxication", "start": 5, "end": 7}]}], "entity_mentions": [{"id": "7174620_1_Ent1", "text": "Nine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7174620_1_Ent0", "text": "Nine delirious patients", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7174620_1_Ent2", "text": "delirious", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7174620_1_Ent4", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7174620_1_Ent5", "text": "lithium", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7174620_1_Ent3", "text": "lithium intoxication", "entity_type": "Entity", "start": 5, "end": 7}], "lang": "en"}
{"doc_id": "71813_3", "wnd_id": "71813_3_1", "text": "Lichen planus and acne provoked by gold .", "tokens": ["Lichen", "planus", "and", "acne", "provoked", "by", "gold", "."], "event_mentions": [{"id": "71813_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "provoked", "start": 4, "end": 5}, "arguments": [{"entity_id": "71813_3_Ent0", "role": "Effect", "text": "Lichen planus and acne", "start": 0, "end": 4}, {"entity_id": "71813_3_Ent1", "role": "Treatment", "text": "gold", "start": 6, "end": 7}, {"entity_id": "71813_3_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "71813_3_Ent0", "text": "Lichen planus and acne", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "71813_3_Ent1", "text": "gold", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "71813_3_Ent2", "text": "gold", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7226916_2", "wnd_id": "7226916_2_1", "text": "Disopyramide - induced heart block .", "tokens": ["Disopyramide", "-", "induced", "heart", "block", "."], "event_mentions": [{"id": "7226916_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "7226916_2_Ent1", "role": "Treatment", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "7226916_2_Ent2", "role": "Treatment_Drug", "text": "Disopyramide", "start": 0, "end": 1}, {"entity_id": "7226916_2_Ent0", "role": "Effect", "text": "heart block", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "7226916_2_Ent1", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7226916_2_Ent2", "text": "Disopyramide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7226916_2_Ent0", "text": "heart block", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "7235792_3", "wnd_id": "7235792_3_1", "text": "In the second case , five cardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of bretylium maintenance therapy for complex ventricular ectopy .", "tokens": ["In", "the", "second", "case", ",", "five", "cardiac", "arrests", "due", "to", "ventricular", "tachycardia", "and", "fibrillation", "occurred", "during", "several", "hours", "after", "beginning", "a", "trial", "of", "bretylium", "maintenance", "therapy", "for", "complex", "ventricular", "ectopy", "."], "event_mentions": [{"id": "7235792_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 14, "end": 15}, "arguments": [{"entity_id": "7235792_3_Ent0", "role": "Subject", "text": "In the second case", "start": 0, "end": 4}, {"entity_id": "7235792_3_Ent1", "role": "Effect", "text": "five cardiac arrests due to ventricular tachycardia and fibrillation", "start": 5, "end": 14}, {"entity_id": "7235792_3_Ent4", "role": "Treatment_Time_elapsed", "text": "several hours after", "start": 16, "end": 19}, {"entity_id": "7235792_3_Ent2", "role": "Treatment", "text": "several hours after beginning a trial of bretylium maintenance therapy", "start": 16, "end": 26}, {"entity_id": "7235792_3_Ent5", "role": "Treatment_Drug", "text": "bretylium", "start": 23, "end": 24}, {"entity_id": "7235792_3_Ent3", "role": "Treatment_Disorder", "text": "complex ventricular ectopy", "start": 27, "end": 30}]}], "entity_mentions": [{"id": "7235792_3_Ent0", "text": "In the second case", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7235792_3_Ent1", "text": "five cardiac arrests due to ventricular tachycardia and fibrillation", "entity_type": "Entity", "start": 5, "end": 14}, {"id": "7235792_3_Ent4", "text": "several hours after", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "7235792_3_Ent2", "text": "several hours after beginning a trial of bretylium maintenance therapy", "entity_type": "Entity", "start": 16, "end": 26}, {"id": "7235792_3_Ent5", "text": "bretylium", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7235792_3_Ent3", "text": "complex ventricular ectopy", "entity_type": "Entity", "start": 27, "end": 30}], "lang": "en"}
{"doc_id": "7249424_1", "wnd_id": "7249424_1_1", "text": "Lithium is known to cause acute renal failure and tubulo - interstitial disease , but the recently described association with proteinuria or nephrotic syndrome is little recognized .", "tokens": ["Lithium", "is", "known", "to", "cause", "acute", "renal", "failure", "and", "tubulo", "-", "interstitial", "disease", ",", "but", "the", "recently", "described", "association", "with", "proteinuria", "or", "nephrotic", "syndrome", "is", "little", "recognized", "."], "event_mentions": [{"id": "7249424_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 18, "end": 19}, "arguments": [{"entity_id": "7249424_1_Ent2", "role": "Treatment", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "7249424_1_Ent3", "role": "Treatment_Drug", "text": "Lithium", "start": 0, "end": 1}, {"entity_id": "7249424_1_Ent0", "role": "Effect", "text": "acute renal failure and tubulo - interstitial disease", "start": 5, "end": 13}, {"entity_id": "7249424_1_Ent1", "role": "Effect", "text": "proteinuria or nephrotic syndrome", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "7249424_1_Ent2", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_1_Ent3", "text": "Lithium", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_1_Ent0", "text": "acute renal failure and tubulo - interstitial disease", "entity_type": "Entity", "start": 5, "end": 13}, {"id": "7249424_1_Ent1", "text": "proteinuria or nephrotic syndrome", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "7249424_3", "wnd_id": "7249424_3_1", "text": "Two patients on long - term lithium therapy developed the nephrotic syndrome .", "tokens": ["Two", "patients", "on", "long", "-", "term", "lithium", "therapy", "developed", "the", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "7249424_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 8, "end": 9}, "arguments": [{"entity_id": "7249424_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7249424_3_Ent0", "role": "Subject", "text": "Two patients", "start": 0, "end": 2}, {"entity_id": "7249424_3_Ent3", "role": "Treatment", "text": "long - term lithium therapy", "start": 3, "end": 8}, {"entity_id": "7249424_3_Ent4", "role": "Treatment_Drug", "text": "lithium", "start": 6, "end": 7}, {"entity_id": "7249424_3_Ent2", "role": "Effect", "text": "nephrotic syndrome", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7249424_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7249424_3_Ent0", "text": "Two patients", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7249424_3_Ent3", "text": "long - term lithium therapy", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7249424_3_Ent4", "text": "lithium", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7249424_3_Ent2", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "7282702_3", "wnd_id": "7282702_3_1", "text": "On the second day of hospitalization , it was noted that the patient 's dyspnea and sinus bradycardia could be related to a recent increase in his timolol dosage .", "tokens": ["On", "the", "second", "day", "of", "hospitalization", ",", "it", "was", "noted", "that", "the", "patient", "'s", "dyspnea", "and", "sinus", "bradycardia", "could", "be", "related", "to", "a", "recent", "increase", "in", "his", "timolol", "dosage", "."], "event_mentions": [{"id": "7282702_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 20, "end": 21}, "arguments": [{"entity_id": "7282702_3_Ent0", "role": "Subject", "text": "patient", "start": 12, "end": 13}, {"entity_id": "7282702_3_Ent1", "role": "Effect", "text": "dyspnea and sinus bradycardia", "start": 14, "end": 18}, {"entity_id": "7282702_3_Ent2", "role": "Treatment", "text": "a recent increase in his timolol dosage", "start": 22, "end": 29}, {"entity_id": "7282702_3_Ent3", "role": "Treatment_Drug", "text": "timolol", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7282702_3_Ent0", "text": "patient", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7282702_3_Ent1", "text": "dyspnea and sinus bradycardia", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "7282702_3_Ent2", "text": "a recent increase in his timolol dosage", "entity_type": "Entity", "start": 22, "end": 29}, {"id": "7282702_3_Ent3", "text": "timolol", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7304798_2", "wnd_id": "7304798_2_1", "text": "The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which L - dopa shortened the manic - depressive cycle length when administered in a double - blind trial .", "tokens": ["The", "authors", "report", "a", "longitudinal", "case", "study", "of", "a", "woman", "with", "a", "history", "of", "bipolar", "affective", "disorder", "in", "which", "L", "-", "dopa", "shortened", "the", "manic", "-", "depressive", "cycle", "length", "when", "administered", "in", "a", "double", "-", "blind", "trial", "."], "event_mentions": [{"id": "7304798_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "shortened", "start": 22, "end": 23}, "arguments": [{"entity_id": "7304798_2_Ent0", "role": "Subject", "text": "a woman with a history of bipolar affective disorder", "start": 8, "end": 17}, {"entity_id": "7304798_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 9, "end": 10}, {"entity_id": "7304798_2_Ent2", "role": "Subject_Disorder", "text": "bipolar affective disorder", "start": 14, "end": 17}, {"entity_id": "7304798_2_Ent4", "role": "Treatment", "text": "L - dopa", "start": 19, "end": 22}, {"entity_id": "7304798_2_Ent5", "role": "Treatment_Drug", "text": "L - dopa", "start": 19, "end": 22}, {"entity_id": "7304798_2_Ent3", "role": "Effect", "text": "shortened the manic - depressive cycle length", "start": 22, "end": 29}]}], "entity_mentions": [{"id": "7304798_2_Ent0", "text": "a woman with a history of bipolar affective disorder", "entity_type": "Entity", "start": 8, "end": 17}, {"id": "7304798_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7304798_2_Ent2", "text": "bipolar affective disorder", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7304798_2_Ent4", "text": "L - dopa", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7304798_2_Ent5", "text": "L - dopa", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7304798_2_Ent3", "text": "shortened the manic - depressive cycle length", "entity_type": "Entity", "start": 22, "end": 29}], "lang": "en"}
{"doc_id": "7321956_2", "wnd_id": "7321956_2_1", "text": "This paper reports a case of fatal perhexiline maleate liver injury .", "tokens": ["This", "paper", "reports", "a", "case", "of", "fatal", "perhexiline", "maleate", "liver", "injury", "."], "event_mentions": [{"id": "7321956_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "a case of", "start": 3, "end": 6}, "arguments": [{"entity_id": "7321956_2_Ent1", "role": "Treatment", "text": "perhexiline maleate", "start": 7, "end": 9}, {"entity_id": "7321956_2_Ent2", "role": "Treatment_Drug", "text": "perhexiline maleate", "start": 7, "end": 9}, {"entity_id": "7321956_2_Ent0", "role": "Effect", "text": "liver injury", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7321956_2_Ent1", "text": "perhexiline maleate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7321956_2_Ent2", "text": "perhexiline maleate", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7321956_2_Ent0", "text": "liver injury", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7351000_2", "wnd_id": "7351000_2_1", "text": "Acute non - lymphocytic leukemia occurred in eight women following long - term treatment with Treosulfan (= dihydroxybusulfan ) for ovarian carcinoma .", "tokens": ["Acute", "non", "-", "lymphocytic", "leukemia", "occurred", "in", "eight", "women", "following", "long", "-", "term", "treatment", "with", "Treosulfan", "(=", "dihydroxybusulfan", ")", "for", "ovarian", "carcinoma", "."], "event_mentions": [{"id": "7351000_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 5, "end": 6}, "arguments": [{"entity_id": "7351000_2_Ent3", "role": "Effect", "text": "Acute non - lymphocytic leukemia", "start": 0, "end": 5}, {"entity_id": "7351000_2_Ent1", "role": "Subject_Population", "text": "eight", "start": 7, "end": 8}, {"entity_id": "7351000_2_Ent0", "role": "Subject", "text": "eight women", "start": 7, "end": 9}, {"entity_id": "7351000_2_Ent2", "role": "Subject_Gender", "text": "women", "start": 8, "end": 9}, {"entity_id": "7351000_2_Ent5", "role": "Treatment_Drug", "text": "Treosulfan", "start": 15, "end": 16}, {"entity_id": "7351000_2_Ent4", "role": "Treatment", "text": "Treosulfan (= dihydroxybusulfan )", "start": 15, "end": 19}, {"entity_id": "7351000_2_Ent6", "role": "Treatment_Drug", "text": "dihydroxybusulfan", "start": 17, "end": 18}, {"entity_id": "7351000_2_Ent7", "role": "Treatment_Disorder", "text": "ovarian carcinoma", "start": 20, "end": 22}]}], "entity_mentions": [{"id": "7351000_2_Ent3", "text": "Acute non - lymphocytic leukemia", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7351000_2_Ent1", "text": "eight", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7351000_2_Ent0", "text": "eight women", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7351000_2_Ent2", "text": "women", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7351000_2_Ent5", "text": "Treosulfan", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7351000_2_Ent4", "text": "Treosulfan (= dihydroxybusulfan )", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "7351000_2_Ent6", "text": "dihydroxybusulfan", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7351000_2_Ent7", "text": "ovarian carcinoma", "entity_type": "Entity", "start": 20, "end": 22}], "lang": "en"}
{"doc_id": "7355327_2", "wnd_id": "7355327_2_1", "text": "Regardless of a negative history of asthma , therefore , life - threatening bronchospasm must be considered a possible complication of propranolol therapy .", "tokens": ["Regardless", "of", "a", "negative", "history", "of", "asthma", ",", "therefore", ",", "life", "-", "threatening", "bronchospasm", "must", "be", "considered", "a", "possible", "complication", "of", "propranolol", "therapy", "."], "event_mentions": [{"id": "7355327_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 19, "end": 20}, "arguments": [{"entity_id": "7355327_2_Ent0", "role": "Effect", "text": "life - threatening bronchospasm", "start": 10, "end": 14}, {"entity_id": "7355327_2_Ent1", "role": "Treatment", "text": "propranolol", "start": 21, "end": 22}, {"entity_id": "7355327_2_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 21, "end": 22}]}], "entity_mentions": [{"id": "7355327_2_Ent0", "text": "life - threatening bronchospasm", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "7355327_2_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7355327_2_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 21, "end": 22}], "lang": "en"}
{"doc_id": "7355327_3", "wnd_id": "7355327_3_1", "text": "Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy , the bronchospasm was believed to be caused by propranolol .", "tokens": ["Since", "the", "bronchospasm", "was", "relieved", "with", "discontinuation", "of", "propranolol", "and", "supportive", "bronchodilator", "therapy", ",", "the", "bronchospasm", "was", "believed", "to", "be", "caused", "by", "propranolol", "."], "event_mentions": [{"id": "7355327_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 20, "end": 21}, "arguments": [{"entity_id": "7355327_3_Ent2", "role": "Treatment_Drug", "text": "propranolol", "start": 8, "end": 9}, {"entity_id": "7355327_3_Ent0", "role": "Effect", "text": "bronchospasm", "start": 15, "end": 16}, {"entity_id": "7355327_3_Ent1", "role": "Treatment", "text": "propranolol", "start": 22, "end": 23}, {"entity_id": "7355327_3_Ent3", "role": "Treatment_Drug", "text": "propranolol", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "7355327_3_Ent2", "text": "propranolol", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7355327_3_Ent0", "text": "bronchospasm", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7355327_3_Ent1", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "7355327_3_Ent3", "text": "propranolol", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "7362333_1", "wnd_id": "7362333_1_1", "text": "Propranolol : an unrecognized cause of central nervous system dysfunction in patients undergoing cardiopulmonary bypass .", "tokens": ["Propranolol", ":", "an", "unrecognized", "cause", "of", "central", "nervous", "system", "dysfunction", "in", "patients", "undergoing", "cardiopulmonary", "bypass", "."], "event_mentions": [{"id": "7362333_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7362333_1_Ent3", "role": "Treatment", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent4", "role": "Treatment_Drug", "text": "Propranolol", "start": 0, "end": 1}, {"entity_id": "7362333_1_Ent2", "role": "Effect", "text": "central nervous system dysfunction", "start": 6, "end": 10}, {"entity_id": "7362333_1_Ent0", "role": "Subject", "text": "patients undergoing cardiopulmonary bypass", "start": 11, "end": 15}, {"entity_id": "7362333_1_Ent1", "role": "Subject_Disorder", "text": "cardiopulmonary bypass", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7362333_1_Ent3", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent4", "text": "Propranolol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7362333_1_Ent2", "text": "central nervous system dysfunction", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "7362333_1_Ent0", "text": "patients undergoing cardiopulmonary bypass", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7362333_1_Ent1", "text": "cardiopulmonary bypass", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7387219_1", "wnd_id": "7387219_1_1", "text": "Hepatotoxicity associated with use of D - penicillamine in rheumatoid arthritis .", "tokens": ["Hepatotoxicity", "associated", "with", "use", "of", "D", "-", "penicillamine", "in", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "7387219_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 1, "end": 2}, "arguments": [{"entity_id": "7387219_1_Ent0", "role": "Effect", "text": "Hepatotoxicity", "start": 0, "end": 1}, {"entity_id": "7387219_1_Ent1", "role": "Treatment", "text": "D - penicillamine", "start": 5, "end": 8}, {"entity_id": "7387219_1_Ent3", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 5, "end": 8}, {"entity_id": "7387219_1_Ent2", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7387219_1_Ent0", "text": "Hepatotoxicity", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7387219_1_Ent1", "text": "D - penicillamine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7387219_1_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "7387219_1_Ent2", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7387219_3", "wnd_id": "7387219_3_1", "text": "Two patients with rheumatoid arthritis developed evidence of hepatotoxicity while receiving D - penicillamine .", "tokens": ["Two", "patients", "with", "rheumatoid", "arthritis", "developed", "evidence", "of", "hepatotoxicity", "while", "receiving", "D", "-", "penicillamine", "."], "event_mentions": [{"id": "7387219_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 5, "end": 6}, "arguments": [{"entity_id": "7387219_3_Ent1", "role": "Subject_Population", "text": "Two", "start": 0, "end": 1}, {"entity_id": "7387219_3_Ent0", "role": "Subject", "text": "Two patients with rheumatoid arthritis", "start": 0, "end": 5}, {"entity_id": "7387219_3_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 3, "end": 5}, {"entity_id": "7387219_3_Ent2", "role": "Effect", "text": "hepatotoxicity", "start": 8, "end": 9}, {"entity_id": "7387219_3_Ent3", "role": "Treatment", "text": "D - penicillamine", "start": 11, "end": 14}, {"entity_id": "7387219_3_Ent4", "role": "Treatment_Drug", "text": "D - penicillamine", "start": 11, "end": 14}]}], "entity_mentions": [{"id": "7387219_3_Ent1", "text": "Two", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7387219_3_Ent0", "text": "Two patients with rheumatoid arthritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "7387219_3_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7387219_3_Ent2", "text": "hepatotoxicity", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7387219_3_Ent3", "text": "D - penicillamine", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "7387219_3_Ent4", "text": "D - penicillamine", "entity_type": "Entity", "start": 11, "end": 14}], "lang": "en"}
{"doc_id": "7397053_1", "wnd_id": "7397053_1_1", "text": "A patient developed papilloedema and hepatic dysfunction while being treated with perhexiline maleate .", "tokens": ["A", "patient", "developed", "papilloedema", "and", "hepatic", "dysfunction", "while", "being", "treated", "with", "perhexiline", "maleate", "."], "event_mentions": [{"id": "7397053_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "while", "start": 7, "end": 8}, "arguments": [{"entity_id": "7397053_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "7397053_1_Ent1", "role": "Effect", "text": "papilloedema and hepatic dysfunction", "start": 3, "end": 7}, {"entity_id": "7397053_1_Ent2", "role": "Treatment", "text": "perhexiline maleate", "start": 11, "end": 13}, {"entity_id": "7397053_1_Ent3", "role": "Treatment_Drug", "text": "perhexiline maleate", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "7397053_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7397053_1_Ent1", "text": "papilloedema and hepatic dysfunction", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7397053_1_Ent2", "text": "perhexiline maleate", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "7397053_1_Ent3", "text": "perhexiline maleate", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "7416268_1", "wnd_id": "7416268_1_1", "text": "Disulfiram encephalopathy as a cause of the catatonia syndrome .", "tokens": ["Disulfiram", "encephalopathy", "as", "a", "cause", "of", "the", "catatonia", "syndrome", "."], "event_mentions": [{"id": "7416268_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "7416268_1_Ent2", "role": "Treatment", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "7416268_1_Ent3", "role": "Treatment_Drug", "text": "Disulfiram", "start": 0, "end": 1}, {"entity_id": "7416268_1_Ent1", "role": "Effect", "text": "encephalopathy", "start": 1, "end": 2}, {"entity_id": "7416268_1_Ent0", "role": "Effect", "text": "catatonia syndrome", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "7416268_1_Ent2", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7416268_1_Ent3", "text": "Disulfiram", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7416268_1_Ent1", "text": "encephalopathy", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "7416268_1_Ent0", "text": "catatonia syndrome", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "7439122_3", "wnd_id": "7439122_3_1", "text": "Physicians should therefore be aware of its occurrence and carefully monitor serum levels of CPK , GOT and GPT during the treatment of diabetes insipidus with clofibrate , especially in patients with associated hypothyroidism , latent or overt , which possibly favors the development of myopathy .", "tokens": ["Physicians", "should", "therefore", "be", "aware", "of", "its", "occurrence", "and", "carefully", "monitor", "serum", "levels", "of", "CPK", ",", "GOT", "and", "GPT", "during", "the", "treatment", "of", "diabetes", "insipidus", "with", "clofibrate", ",", "especially", "in", "patients", "with", "associated", "hypothyroidism", ",", "latent", "or", "overt", ",", "which", "possibly", "favors", "the", "development", "of", "myopathy", "."], "event_mentions": [{"id": "7439122_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 43, "end": 44}, "arguments": [{"entity_id": "7439122_3_Ent6", "role": "Treatment_Disorder", "text": "diabetes insipidus", "start": 23, "end": 25}, {"entity_id": "7439122_3_Ent5", "role": "Treatment", "text": "clofibrate", "start": 26, "end": 27}, {"entity_id": "7439122_3_Ent7", "role": "Treatment_Drug", "text": "clofibrate", "start": 26, "end": 27}, {"entity_id": "7439122_3_Ent0", "role": "Subject", "text": "patients with associated hypothyroidism , latent or overt", "start": 30, "end": 38}, {"entity_id": "7439122_3_Ent1", "role": "Subject_Disorder", "text": "hypothyroidism", "start": 33, "end": 34}, {"entity_id": "7439122_3_Ent2", "role": "Subject_Disorder", "text": "latent", "start": 35, "end": 36}, {"entity_id": "7439122_3_Ent3", "role": "Subject_Disorder", "text": "overt", "start": 37, "end": 38}, {"entity_id": "7439122_3_Ent4", "role": "Effect", "text": "myopathy .", "start": 45, "end": 47}]}], "entity_mentions": [{"id": "7439122_3_Ent6", "text": "diabetes insipidus", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "7439122_3_Ent5", "text": "clofibrate", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7439122_3_Ent7", "text": "clofibrate", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7439122_3_Ent0", "text": "patients with associated hypothyroidism , latent or overt", "entity_type": "Entity", "start": 30, "end": 38}, {"id": "7439122_3_Ent1", "text": "hypothyroidism", "entity_type": "Entity", "start": 33, "end": 34}, {"id": "7439122_3_Ent2", "text": "latent", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "7439122_3_Ent3", "text": "overt", "entity_type": "Entity", "start": 37, "end": 38}, {"id": "7439122_3_Ent4", "text": "myopathy .", "entity_type": "Entity", "start": 45, "end": 47}], "lang": "en"}
{"doc_id": "7495990_1", "wnd_id": "7495990_1_1", "text": "Used injudiciously , naloxone can lead to withdrawal syndrome , return of severe pain , and other adverse effects .", "tokens": ["Used", "injudiciously", ",", "naloxone", "can", "lead", "to", "withdrawal", "syndrome", ",", "return", "of", "severe", "pain", ",", "and", "other", "adverse", "effects", "."], "event_mentions": [{"id": "7495990_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "lead", "start": 5, "end": 6}, "arguments": [{"entity_id": "7495990_1_Ent1", "role": "Treatment", "text": "Used injudiciously , naloxone", "start": 0, "end": 4}, {"entity_id": "7495990_1_Ent2", "role": "Treatment_Drug", "text": "naloxone", "start": 3, "end": 4}, {"entity_id": "7495990_1_Ent0", "role": "Effect", "text": "withdrawal syndrome , return of severe pain , and other adverse effects", "start": 7, "end": 19}]}], "entity_mentions": [{"id": "7495990_1_Ent1", "text": "Used injudiciously , naloxone", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "7495990_1_Ent2", "text": "naloxone", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7495990_1_Ent0", "text": "withdrawal syndrome , return of severe pain , and other adverse effects", "entity_type": "Entity", "start": 7, "end": 19}], "lang": "en"}
{"doc_id": "7526455_1", "wnd_id": "7526455_1_1", "text": "A 73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia developed an acute reversible encephalopathy within 15 days of initiation of flecainide .", "tokens": ["A", "73", "year", "-", "old", "patient", "with", "Wolff", "-", "Parkinson", "-", "White", "syndrome", "and", "paroxysmic", "supraventricular", "tachycardia", "developed", "an", "acute", "reversible", "encephalopathy", "within", "15", "days", "of", "initiation", "of", "flecainide", "."], "event_mentions": [{"id": "7526455_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "7526455_1_Ent1", "role": "Subject_Age", "text": "73 year - old", "start": 1, "end": 5}, {"entity_id": "7526455_1_Ent0", "role": "Subject", "text": "73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia", "start": 1, "end": 17}, {"entity_id": "7526455_1_Ent6", "role": "Treatment_Disorder", "text": "Wolff - Parkinson - White syndrome", "start": 7, "end": 13}, {"entity_id": "7526455_1_Ent7", "role": "Treatment_Disorder", "text": "paroxysmic supraventricular tachycardia", "start": 14, "end": 17}, {"entity_id": "7526455_1_Ent2", "role": "Effect", "text": "acute reversible encephalopathy", "start": 19, "end": 22}, {"entity_id": "7526455_1_Ent5", "role": "Treatment_Time_elapsed", "text": "within 15 days", "start": 22, "end": 25}, {"entity_id": "7526455_1_Ent3", "role": "Treatment", "text": "flecainide", "start": 28, "end": 29}, {"entity_id": "7526455_1_Ent4", "role": "Treatment_Drug", "text": "flecainide", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "7526455_1_Ent1", "text": "73 year - old", "entity_type": "Entity", "start": 1, "end": 5}, {"id": "7526455_1_Ent0", "text": "73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia", "entity_type": "Entity", "start": 1, "end": 17}, {"id": "7526455_1_Ent6", "text": "Wolff - Parkinson - White syndrome", "entity_type": "Entity", "start": 7, "end": 13}, {"id": "7526455_1_Ent7", "text": "paroxysmic supraventricular tachycardia", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7526455_1_Ent2", "text": "acute reversible encephalopathy", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7526455_1_Ent5", "text": "within 15 days", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "7526455_1_Ent3", "text": "flecainide", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "7526455_1_Ent4", "text": "flecainide", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "7577414_3", "wnd_id": "7577414_3_1", "text": "We report a 16 - year - old male who developed nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus after treatment with griseofulvin .", "tokens": ["We", "report", "a", "16", "-", "year", "-", "old", "male", "who", "developed", "nephrotic", "syndrome", "related", "to", "membranous", "glomerulopathy", "with", "clinical", "and", "serological", "evidence", "of", "systemic", "lupus", "erythematosus", "after", "treatment", "with", "griseofulvin", "."], "event_mentions": [{"id": "7577414_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 26, "end": 27}, "arguments": [{"entity_id": "7577414_3_Ent0", "role": "Subject", "text": "a 16 - year - old male", "start": 2, "end": 9}, {"entity_id": "7577414_3_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 3, "end": 8}, {"entity_id": "7577414_3_Ent2", "role": "Subject_Gender", "text": "male", "start": 8, "end": 9}, {"entity_id": "7577414_3_Ent3", "role": "Effect", "text": "nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus", "start": 11, "end": 26}, {"entity_id": "7577414_3_Ent4", "role": "Treatment", "text": "treatment with griseofulvin", "start": 27, "end": 30}, {"entity_id": "7577414_3_Ent5", "role": "Treatment_Drug", "text": "griseofulvin", "start": 29, "end": 30}]}], "entity_mentions": [{"id": "7577414_3_Ent0", "text": "a 16 - year - old male", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "7577414_3_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "7577414_3_Ent2", "text": "male", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7577414_3_Ent3", "text": "nephrotic syndrome related to membranous glomerulopathy with clinical and serological evidence of systemic lupus erythematosus", "entity_type": "Entity", "start": 11, "end": 26}, {"id": "7577414_3_Ent4", "text": "treatment with griseofulvin", "entity_type": "Entity", "start": 27, "end": 30}, {"id": "7577414_3_Ent5", "text": "griseofulvin", "entity_type": "Entity", "start": 29, "end": 30}], "lang": "en"}
{"doc_id": "7606071_2", "wnd_id": "7606071_2_1", "text": "CASE SUMMARIES : While conducting a protocol evaluating the efficacy of intraperitoneal cisplatin and hyperthermia in the treatment of recurrent ovarian cancer , 3 patients were noted to exhibit anaphylactoid reactions .", "tokens": ["CASE", "SUMMARIES", ":", "While", "conducting", "a", "protocol", "evaluating", "the", "efficacy", "of", "intraperitoneal", "cisplatin", "and", "hyperthermia", "in", "the", "treatment", "of", "recurrent", "ovarian", "cancer", ",", "3", "patients", "were", "noted", "to", "exhibit", "anaphylactoid", "reactions", "."], "event_mentions": [{"id": "7606071_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exhibit", "start": 28, "end": 29}, "arguments": [{"entity_id": "7606071_2_Ent5", "role": "Treatment_Route", "text": "intraperitoneal", "start": 11, "end": 12}, {"entity_id": "7606071_2_Ent3", "role": "Treatment", "text": "intraperitoneal cisplatin and hyperthermia", "start": 11, "end": 15}, {"entity_id": "7606071_2_Ent4", "role": "Treatment_Drug", "text": "cisplatin", "start": 12, "end": 13}, {"entity_id": "7606071_2_Ent6", "role": "Treatment_Disorder", "text": "recurrent ovarian cancer", "start": 19, "end": 22}, {"entity_id": "7606071_2_Ent1", "role": "Subject_Population", "text": "3", "start": 23, "end": 24}, {"entity_id": "7606071_2_Ent0", "role": "Subject", "text": "3 patients", "start": 23, "end": 25}, {"entity_id": "7606071_2_Ent2", "role": "Effect", "text": "anaphylactoid reactions", "start": 29, "end": 31}]}], "entity_mentions": [{"id": "7606071_2_Ent5", "text": "intraperitoneal", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7606071_2_Ent3", "text": "intraperitoneal cisplatin and hyperthermia", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "7606071_2_Ent4", "text": "cisplatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7606071_2_Ent6", "text": "recurrent ovarian cancer", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "7606071_2_Ent1", "text": "3", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "7606071_2_Ent0", "text": "3 patients", "entity_type": "Entity", "start": 23, "end": 25}, {"id": "7606071_2_Ent2", "text": "anaphylactoid reactions", "entity_type": "Entity", "start": 29, "end": 31}], "lang": "en"}
{"doc_id": "7647084_1", "wnd_id": "7647084_1_1", "text": "The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .", "tokens": ["The", "authors", "describe", "a", "case", "of", "neuroleptic", "malignant", "syndrome", "that", "occurred", "in", "a", "patient", "on", "amitriptyline", "and", "lithium", "carbonate", "."], "event_mentions": [{"id": "7647084_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 10, "end": 11}, "arguments": [{"entity_id": "7647084_1_Ent1", "role": "Effect", "text": "neuroleptic malignant syndrome", "start": 6, "end": 9}, {"entity_id": "7647084_1_Ent0", "role": "Subject", "text": "a patient", "start": 12, "end": 14}, {"entity_id": "7647084_1_Ent3", "role": "Treatment_Drug", "text": "amitriptyline", "start": 15, "end": 16}, {"entity_id": "7647084_1_Ent5", "role": "Combination_Drug", "text": "amitriptyline", "start": 15, "end": 16}, {"entity_id": "7647084_1_Ent2", "role": "Treatment", "text": "amitriptyline and lithium carbonate", "start": 15, "end": 19}, {"entity_id": "7647084_1_Ent4", "role": "Treatment_Drug", "text": "lithium carbonate", "start": 17, "end": 19}, {"entity_id": "7647084_1_Ent6", "role": "Combination_Drug", "text": "lithium carbonate", "start": 17, "end": 19}]}], "entity_mentions": [{"id": "7647084_1_Ent1", "text": "neuroleptic malignant syndrome", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7647084_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "7647084_1_Ent3", "text": "amitriptyline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7647084_1_Ent5", "text": "amitriptyline", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7647084_1_Ent2", "text": "amitriptyline and lithium carbonate", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "7647084_1_Ent4", "text": "lithium carbonate", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "7647084_1_Ent6", "text": "lithium carbonate", "entity_type": "Entity", "start": 17, "end": 19}], "lang": "en"}
{"doc_id": "7653281_8", "wnd_id": "7653281_8_1", "text": "These results suggest that the hepatoxicity of ethanol in alcoholic beverages is enhanced by interaction with its congeners and acetaldehyde ; they also suggest that alcoholic beverages are not equivalent in their potential to cause liver damage .", "tokens": ["These", "results", "suggest", "that", "the", "hepatoxicity", "of", "ethanol", "in", "alcoholic", "beverages", "is", "enhanced", "by", "interaction", "with", "its", "congeners", "and", "acetaldehyde", ";", "they", "also", "suggest", "that", "alcoholic", "beverages", "are", "not", "equivalent", "in", "their", "potential", "to", "cause", "liver", "damage", "."], "event_mentions": [{"id": "7653281_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "enhanced", "start": 12, "end": 13}, "arguments": [{"entity_id": "7653281_8_Ent0", "role": "Effect", "text": "hepatoxicity", "start": 5, "end": 6}, {"entity_id": "7653281_8_Ent1", "role": "Treatment", "text": "alcoholic", "start": 9, "end": 10}, {"entity_id": "7653281_8_Ent2", "role": "Treatment_Drug", "text": "alcoholic", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7653281_8_Ent0", "text": "hepatoxicity", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7653281_8_Ent1", "text": "alcoholic", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7653281_8_Ent2", "text": "alcoholic", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7673653_2", "wnd_id": "7673653_2_1", "text": "Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .", "tokens": ["Extrapyramidal", "side", "effects", "induced", "by", "some", "selective", "serotonin", "reuptake", "inhibitors", "(", "SSRIs", ")", ",", "i.e.", "fluoxetine", "and", "sertraline", ",", "have", "been", "previously", "reported", "in", "patients", "with", "depression", "and", "obsessive", "-", "compulsive", "disorder", "(", "OCD", ")", "."], "event_mentions": [{"id": "7673653_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced by", "start": 3, "end": 5}, "arguments": [{"entity_id": "7673653_2_Ent1", "role": "Effect", "text": "Extrapyramidal side effects", "start": 0, "end": 3}, {"entity_id": "7673653_2_Ent2", "role": "Treatment", "text": "some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline", "start": 5, "end": 18}, {"entity_id": "7673653_2_Ent7", "role": "Treatment_Drug", "text": "serotonin reuptake inhibitors", "start": 7, "end": 10}, {"entity_id": "7673653_2_Ent5", "role": "Treatment_Drug", "text": "fluoxetine", "start": 15, "end": 16}, {"entity_id": "7673653_2_Ent6", "role": "Treatment_Drug", "text": "sertraline", "start": 17, "end": 18}, {"entity_id": "7673653_2_Ent0", "role": "Subject", "text": "patients with depression and obsessive - compulsive disorder ( OCD )", "start": 24, "end": 35}, {"entity_id": "7673653_2_Ent3", "role": "Treatment_Disorder", "text": "depression", "start": 26, "end": 27}, {"entity_id": "7673653_2_Ent4", "role": "Treatment_Disorder", "text": "obsessive - compulsive disorder ( OCD )", "start": 28, "end": 35}]}], "entity_mentions": [{"id": "7673653_2_Ent1", "text": "Extrapyramidal side effects", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7673653_2_Ent2", "text": "some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline", "entity_type": "Entity", "start": 5, "end": 18}, {"id": "7673653_2_Ent7", "text": "serotonin reuptake inhibitors", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "7673653_2_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7673653_2_Ent6", "text": "sertraline", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "7673653_2_Ent0", "text": "patients with depression and obsessive - compulsive disorder ( OCD )", "entity_type": "Entity", "start": 24, "end": 35}, {"id": "7673653_2_Ent3", "text": "depression", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "7673653_2_Ent4", "text": "obsessive - compulsive disorder ( OCD )", "entity_type": "Entity", "start": 28, "end": 35}], "lang": "en"}
{"doc_id": "7679525_3", "wnd_id": "7679525_3_1", "text": "He recovered successfully after treatment with very high doses of corticosteroids and azathioprine .", "tokens": ["He", "recovered", "successfully", "after", "treatment", "with", "very", "high", "doses", "of", "corticosteroids", "and", "azathioprine", "."], "event_mentions": [{"id": "7679525_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recovered", "start": 1, "end": 2}, "arguments": [{"entity_id": "7679525_3_Ent0", "role": "Subject", "text": "He", "start": 0, "end": 1}, {"entity_id": "7679525_3_Ent1", "role": "Subject_Gender", "text": "He", "start": 0, "end": 1}, {"entity_id": "7679525_3_Ent3", "role": "Treatment_Dosage", "text": "very high doses", "start": 6, "end": 9}, {"entity_id": "7679525_3_Ent2", "role": "Treatment", "text": "very high doses of corticosteroids and azathioprine", "start": 6, "end": 13}, {"entity_id": "7679525_3_Ent4", "role": "Treatment_Drug", "text": "corticosteroids", "start": 10, "end": 11}, {"entity_id": "7679525_3_Ent6", "role": "Combination_Drug", "text": "corticosteroids", "start": 10, "end": 11}, {"entity_id": "7679525_3_Ent5", "role": "Treatment_Drug", "text": "azathioprine", "start": 12, "end": 13}, {"entity_id": "7679525_3_Ent7", "role": "Combination_Drug", "text": "azathioprine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7679525_3_Ent0", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7679525_3_Ent1", "text": "He", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7679525_3_Ent3", "text": "very high doses", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "7679525_3_Ent2", "text": "very high doses of corticosteroids and azathioprine", "entity_type": "Entity", "start": 6, "end": 13}, {"id": "7679525_3_Ent4", "text": "corticosteroids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7679525_3_Ent6", "text": "corticosteroids", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7679525_3_Ent5", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "7679525_3_Ent7", "text": "azathioprine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "7685228_1", "wnd_id": "7685228_1_1", "text": "Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .", "tokens": ["Reversal", "of", "gold", "-", "induced", "neutropenia", "with", "granulocyte", "colony", "-", "stimulating", "factor", "(", "G", "-", "CSF", ")", "."], "event_mentions": [{"id": "7685228_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 4, "end": 5}, "arguments": [{"entity_id": "7685228_1_Ent2", "role": "Treatment", "text": "gold", "start": 2, "end": 3}, {"entity_id": "7685228_1_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 2, "end": 3}, {"entity_id": "7685228_1_Ent1", "role": "Effect", "text": "neutropenia", "start": 5, "end": 6}, {"entity_id": "7685228_1_Ent0", "role": "Subject", "text": "granulocyte colony - stimulating factor", "start": 7, "end": 12}, {"entity_id": "7685228_1_Ent3", "role": "Treatment", "text": "granulocyte colony - stimulating factor ( G - CSF )", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "7685228_1_Ent2", "text": "gold", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7685228_1_Ent4", "text": "gold", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "7685228_1_Ent1", "text": "neutropenia", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7685228_1_Ent0", "text": "granulocyte colony - stimulating factor", "entity_type": "Entity", "start": 7, "end": 12}, {"id": "7685228_1_Ent3", "text": "granulocyte colony - stimulating factor ( G - CSF )", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "7712052_3", "wnd_id": "7712052_3_1", "text": "We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .", "tokens": ["We", "describe", "two", "cases", "that", "illustrate", "the", "use", "of", "lithium", "in", "the", "treatment", "of", "veterans", "with", "PTSD", "who", "complained", "of", "serious", "problems", "with", "irritability", "or", "angry", "outbursts", "."], "event_mentions": [{"id": "7712052_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained of", "start": 18, "end": 20}, "arguments": [{"entity_id": "7712052_3_Ent2", "role": "Treatment", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "7712052_3_Ent3", "role": "Treatment_Drug", "text": "lithium", "start": 9, "end": 10}, {"entity_id": "7712052_3_Ent0", "role": "Subject", "text": "veterans with PTSD", "start": 14, "end": 17}, {"entity_id": "7712052_3_Ent4", "role": "Treatment_Disorder", "text": "PTSD", "start": 16, "end": 17}, {"entity_id": "7712052_3_Ent1", "role": "Effect", "text": "serious problems with irritability or angry outbursts", "start": 20, "end": 27}]}], "entity_mentions": [{"id": "7712052_3_Ent2", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7712052_3_Ent3", "text": "lithium", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7712052_3_Ent0", "text": "veterans with PTSD", "entity_type": "Entity", "start": 14, "end": 17}, {"id": "7712052_3_Ent4", "text": "PTSD", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "7712052_3_Ent1", "text": "serious problems with irritability or angry outbursts", "entity_type": "Entity", "start": 20, "end": 27}], "lang": "en"}
{"doc_id": "7718983_1", "wnd_id": "7718983_1_1", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C.", "tokens": ["Graves", "'", "hyperthyroidism", "following", "transient", "thyrotoxicosis", "during", "interferon", "therapy", "for", "chronic", "hepatitis", "type", "C."], "event_mentions": [{"id": "7718983_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 6, "end": 7}, "arguments": [{"entity_id": "7718983_1_Ent0", "role": "Effect", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "start": 0, "end": 6}, {"entity_id": "7718983_1_Ent1", "role": "Treatment", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent2", "role": "Treatment_Drug", "text": "interferon", "start": 7, "end": 8}, {"entity_id": "7718983_1_Ent3", "role": "Treatment_Disorder", "text": "chronic hepatitis type C.", "start": 10, "end": 14}]}], "entity_mentions": [{"id": "7718983_1_Ent0", "text": "Graves ' hyperthyroidism following transient thyrotoxicosis", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "7718983_1_Ent1", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent2", "text": "interferon", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7718983_1_Ent3", "text": "chronic hepatitis type C.", "entity_type": "Entity", "start": 10, "end": 14}], "lang": "en"}
{"doc_id": "7720517_2", "wnd_id": "7720517_2_1", "text": "Budesonide is a synthetic glucocorticosteroid that is commonly used in topical treatment of asthma and rhinitis .", "tokens": ["Budesonide", "is", "a", "synthetic", "glucocorticosteroid", "that", "is", "commonly", "used", "in", "topical", "treatment", "of", "asthma", "and", "rhinitis", "."], "event_mentions": [{"id": "7720517_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "used in", "start": 8, "end": 10}, "arguments": [{"entity_id": "7720517_2_Ent0", "role": "Treatment", "text": "Budesonide", "start": 0, "end": 1}, {"entity_id": "7720517_2_Ent2", "role": "Treatment_Drug", "text": "Budesonide", "start": 0, "end": 1}, {"entity_id": "7720517_2_Ent1", "role": "Treatment_Disorder", "text": "asthma and rhinitis .", "start": 13, "end": 17}]}], "entity_mentions": [{"id": "7720517_2_Ent0", "text": "Budesonide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7720517_2_Ent2", "text": "Budesonide", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7720517_2_Ent1", "text": "asthma and rhinitis .", "entity_type": "Entity", "start": 13, "end": 17}], "lang": "en"}
{"doc_id": "7724306_7", "wnd_id": "7724306_7_1", "text": "RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .", "tokens": ["RESULTS", ":", "At", "our", "institution", ",", "no", "children", "appeared", "with", "acute", "INH", "neurotoxicity", "in", "the", "period", "1985", "through", "1990", ",", "whereas", "seven", "patients", "were", "treated", "from", "1991", "through", "1993", "."], "event_mentions": [{"id": "7724306_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appeared with", "start": 8, "end": 10}, "arguments": [{"entity_id": "7724306_7_Ent0", "role": "Subject", "text": "children", "start": 7, "end": 8}, {"entity_id": "7724306_7_Ent1", "role": "Subject_Age", "text": "children", "start": 7, "end": 8}, {"entity_id": "7724306_7_Ent3", "role": "Treatment", "text": "INH", "start": 11, "end": 12}, {"entity_id": "7724306_7_Ent4", "role": "Treatment_Drug", "text": "INH", "start": 11, "end": 12}, {"entity_id": "7724306_7_Ent2", "role": "Effect", "text": "neurotoxicity", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "7724306_7_Ent0", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_7_Ent1", "text": "children", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7724306_7_Ent3", "text": "INH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7724306_7_Ent4", "text": "INH", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7724306_7_Ent2", "text": "neurotoxicity", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "7748076_1", "wnd_id": "7748076_1_1", "text": "CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .", "tokens": ["CONCLUSION", ":", "Squamous", "metaplasia", "in", "these", "cases", "appears", "to", "be", "a", "consequence", "of", "progestin", "therapy", "."], "event_mentions": [{"id": "7748076_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "consequence", "start": 11, "end": 12}, "arguments": [{"entity_id": "7748076_1_Ent1", "role": "Effect", "text": "Squamous metaplasia", "start": 2, "end": 4}, {"entity_id": "7748076_1_Ent0", "role": "Subject", "text": "these cases", "start": 5, "end": 7}, {"entity_id": "7748076_1_Ent3", "role": "Treatment_Drug", "text": "progestin", "start": 13, "end": 14}, {"entity_id": "7748076_1_Ent2", "role": "Treatment", "text": "progestin therapy", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "7748076_1_Ent1", "text": "Squamous metaplasia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7748076_1_Ent0", "text": "these cases", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7748076_1_Ent3", "text": "progestin", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7748076_1_Ent2", "text": "progestin therapy", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "7752014_3", "wnd_id": "7752014_3_1", "text": "Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .", "tokens": ["Fever", "caused", "by", "the", "use", "of", "furosemide", "was", "proved", ";", "the", "fever", "resolved", "after", "discontinuation", "of", "this", "medication", "and", "recurred", "after", "its", "reintroduction", "."], "event_mentions": [{"id": "7752014_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 1, "end": 2}, "arguments": [{"entity_id": "7752014_3_Ent0", "role": "Effect", "text": "Fever", "start": 0, "end": 1}, {"entity_id": "7752014_3_Ent1", "role": "Treatment", "text": "furosemide", "start": 6, "end": 7}, {"entity_id": "7752014_3_Ent2", "role": "Treatment_Drug", "text": "furosemide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7752014_3_Ent0", "text": "Fever", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "7752014_3_Ent1", "text": "furosemide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7752014_3_Ent2", "text": "furosemide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "7776854_1", "wnd_id": "7776854_1_1", "text": "Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .", "tokens": ["Our", "cases", "constitute", "the", "most", "severe", "cases", "of", "benzarone", "hepatotoxicity", "reported", "so", "far", ",", "and", "comprise", "the", "first", "cases", "of", "(", "sub)fulminant", "hepatitis", "and", "cirrhosis", "related", "to", "benzarone", "."], "event_mentions": [{"id": "7776854_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 7, "end": 8}, "arguments": [{"entity_id": "7776854_1_Ent2", "role": "Treatment", "text": "benzarone", "start": 8, "end": 9}, {"entity_id": "7776854_1_Ent3", "role": "Treatment_Drug", "text": "benzarone", "start": 8, "end": 9}, {"entity_id": "7776854_1_Ent0", "role": "Effect", "text": "hepatotoxicity", "start": 9, "end": 10}, {"entity_id": "7776854_1_Ent1", "role": "Effect", "text": "( sub)fulminant hepatitis and cirrhosis", "start": 20, "end": 25}, {"entity_id": "7776854_1_Ent4", "role": "Treatment_Drug", "text": "benzarone", "start": 27, "end": 28}]}], "entity_mentions": [{"id": "7776854_1_Ent2", "text": "benzarone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7776854_1_Ent3", "text": "benzarone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7776854_1_Ent0", "text": "hepatotoxicity", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7776854_1_Ent1", "text": "( sub)fulminant hepatitis and cirrhosis", "entity_type": "Entity", "start": 20, "end": 25}, {"id": "7776854_1_Ent4", "text": "benzarone", "entity_type": "Entity", "start": 27, "end": 28}], "lang": "en"}
{"doc_id": "7787496_2", "wnd_id": "7787496_2_1", "text": "We present a case of sotalol - induced bradycardia reversed by glucagon .", "tokens": ["We", "present", "a", "case", "of", "sotalol", "-", "induced", "bradycardia", "reversed", "by", "glucagon", "."], "event_mentions": [{"id": "7787496_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 7, "end": 8}, "arguments": [{"entity_id": "7787496_2_Ent0", "role": "Subject", "text": "a case", "start": 2, "end": 4}, {"entity_id": "7787496_2_Ent2", "role": "Treatment", "text": "sotalol", "start": 5, "end": 6}, {"entity_id": "7787496_2_Ent3", "role": "Treatment_Drug", "text": "sotalol", "start": 5, "end": 6}, {"entity_id": "7787496_2_Ent1", "role": "Effect", "text": "bradycardia", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "7787496_2_Ent0", "text": "a case", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "7787496_2_Ent2", "text": "sotalol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7787496_2_Ent3", "text": "sotalol", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "7787496_2_Ent1", "text": "bradycardia", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7789881_1", "wnd_id": "7789881_1_1", "text": "Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .", "tokens": ["Secretory", "endometrial", "adenocarcinoma", "in", "a", "patient", "on", "tamoxifen", "for", "breast", "cancer", ":", "a", "report", "of", "a", "case", "."], "event_mentions": [{"id": "7789881_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "on", "start": 6, "end": 7}, "arguments": [{"entity_id": "7789881_1_Ent1", "role": "Effect", "text": "Secretory endometrial adenocarcinoma", "start": 0, "end": 3}, {"entity_id": "7789881_1_Ent0", "role": "Subject", "text": "a patient", "start": 4, "end": 6}, {"entity_id": "7789881_1_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "7789881_1_Ent2", "role": "Treatment", "text": "tamoxifen for breast cancer", "start": 7, "end": 11}, {"entity_id": "7789881_1_Ent3", "role": "Treatment_Disorder", "text": "breast cancer", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "7789881_1_Ent1", "text": "Secretory endometrial adenocarcinoma", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "7789881_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "7789881_1_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7789881_1_Ent2", "text": "tamoxifen for breast cancer", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "7789881_1_Ent3", "text": "breast cancer", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "7789881_4", "wnd_id": "7789881_4_1", "text": "Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .", "tokens": ["Well", "-", "differentiated", "endometrial", "adenocarcinoma", "of", "the", "secretory", "type", "(", "FIGO", "Grade", "1", ")", "with", "minimal", "myometrial", "invasion", "occurred", "in", "a", "postmenopausal", "patient", "on", "tamoxifen", "therapy", "5", "years", "after", "mastectomy", "for", "breast", "carcinoma", "."], "event_mentions": [{"id": "7789881_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurred", "start": 18, "end": 19}, "arguments": [{"entity_id": "7789881_4_Ent2", "role": "Effect", "text": "Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion", "start": 0, "end": 18}, {"entity_id": "7789881_4_Ent0", "role": "Subject", "text": "a postmenopausal patient", "start": 20, "end": 23}, {"entity_id": "7789881_4_Ent1", "role": "Subject_Disorder", "text": "postmenopausal", "start": 21, "end": 22}, {"entity_id": "7789881_4_Ent4", "role": "Treatment_Drug", "text": "tamoxifen", "start": 24, "end": 25}, {"entity_id": "7789881_4_Ent3", "role": "Treatment", "text": "tamoxifen therapy 5 years after mastectomy for breast carcinoma .", "start": 24, "end": 34}, {"entity_id": "7789881_4_Ent5", "role": "Treatment_Disorder", "text": "breast carcinoma", "start": 31, "end": 33}]}], "entity_mentions": [{"id": "7789881_4_Ent2", "text": "Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "7789881_4_Ent0", "text": "a postmenopausal patient", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "7789881_4_Ent1", "text": "postmenopausal", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "7789881_4_Ent4", "text": "tamoxifen", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "7789881_4_Ent3", "text": "tamoxifen therapy 5 years after mastectomy for breast carcinoma .", "entity_type": "Entity", "start": 24, "end": 34}, {"id": "7789881_4_Ent5", "text": "breast carcinoma", "entity_type": "Entity", "start": 31, "end": 33}], "lang": "en"}
{"doc_id": "7797283_2", "wnd_id": "7797283_2_1", "text": "Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .", "tokens": ["Esophageal", "candidiasis", "was", "diagnosed", "at", "endoscopy", "in", "two", "patients", "receiving", "omeprazole", "therapy", "."], "event_mentions": [{"id": "7797283_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 9, "end": 10}, "arguments": [{"entity_id": "7797283_2_Ent2", "role": "Effect", "text": "Esophageal candidiasis", "start": 0, "end": 2}, {"entity_id": "7797283_2_Ent1", "role": "Subject_Population", "text": "two", "start": 7, "end": 8}, {"entity_id": "7797283_2_Ent0", "role": "Subject", "text": "two patients", "start": 7, "end": 9}, {"entity_id": "7797283_2_Ent4", "role": "Treatment_Drug", "text": "omeprazole", "start": 10, "end": 11}, {"entity_id": "7797283_2_Ent3", "role": "Treatment", "text": "omeprazole therapy", "start": 10, "end": 12}]}], "entity_mentions": [{"id": "7797283_2_Ent2", "text": "Esophageal candidiasis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7797283_2_Ent1", "text": "two", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "7797283_2_Ent0", "text": "two patients", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "7797283_2_Ent4", "text": "omeprazole", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7797283_2_Ent3", "text": "omeprazole therapy", "entity_type": "Entity", "start": 10, "end": 12}], "lang": "en"}
{"doc_id": "788666_2", "wnd_id": "788666_2_1", "text": "Gentamicin - associated acute renal failure .", "tokens": ["Gentamicin", "-", "associated", "acute", "renal", "failure", "."], "event_mentions": [{"id": "788666_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "788666_2_Ent1", "role": "Treatment", "text": "Gentamicin", "start": 0, "end": 1}, {"entity_id": "788666_2_Ent2", "role": "Treatment_Drug", "text": "Gentamicin", "start": 0, "end": 1}, {"entity_id": "788666_2_Ent0", "role": "Effect", "text": "acute renal failure", "start": 3, "end": 6}]}], "entity_mentions": [{"id": "788666_2_Ent1", "text": "Gentamicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_2_Ent2", "text": "Gentamicin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "788666_2_Ent0", "text": "acute renal failure", "entity_type": "Entity", "start": 3, "end": 6}], "lang": "en"}
{"doc_id": "7900744_1", "wnd_id": "7900744_1_1", "text": "Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .", "tokens": ["Case", "report", ":", "mannitol", "nephrotoxicity", "syndrome", ":", "role", "of", "hemodialysis", "and", "postulate", "of", "mechanisms", "."], "event_mentions": [{"id": "7900744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "syndrome", "start": 5, "end": 6}, "arguments": [{"entity_id": "7900744_1_Ent1", "role": "Treatment", "text": "mannitol", "start": 3, "end": 4}, {"entity_id": "7900744_1_Ent2", "role": "Treatment_Drug", "text": "mannitol", "start": 3, "end": 4}, {"entity_id": "7900744_1_Ent0", "role": "Effect", "text": "nephrotoxicity", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "7900744_1_Ent1", "text": "mannitol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_1_Ent2", "text": "mannitol", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7900744_1_Ent0", "text": "nephrotoxicity", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "7937287_8", "wnd_id": "7937287_8_1", "text": "In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .", "tokens": ["In", "our", "patient", ",", "DIAN", "possibly", "was", "related", "to", "cefuroxime", ",", "but", "the", "patient", "did", "not", "experience", "associated", "allergic", "symptoms", "."], "event_mentions": [{"id": "7937287_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related to", "start": 7, "end": 9}, "arguments": [{"entity_id": "7937287_8_Ent0", "role": "Subject", "text": "our patient", "start": 1, "end": 3}, {"entity_id": "7937287_8_Ent1", "role": "Effect", "text": "DIAN", "start": 4, "end": 5}, {"entity_id": "7937287_8_Ent2", "role": "Treatment", "text": "cefuroxime", "start": 9, "end": 10}, {"entity_id": "7937287_8_Ent3", "role": "Treatment_Drug", "text": "cefuroxime", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "7937287_8_Ent0", "text": "our patient", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "7937287_8_Ent1", "text": "DIAN", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "7937287_8_Ent2", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "7937287_8_Ent3", "text": "cefuroxime", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "7946029_2", "wnd_id": "7946029_2_1", "text": "A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .", "tokens": ["A", "case", "of", "basilar", "invagination", "which", "is", "thought", "to", "have", "arisen", "from", "the", "patient", "'s", "intrauterine", "exposure", "to", "phenytoin", "is", "presented", "."], "event_mentions": [{"id": "7946029_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "exposure", "start": 16, "end": 17}, "arguments": [{"entity_id": "7946029_2_Ent0", "role": "Effect", "text": "basilar invagination", "start": 3, "end": 5}, {"entity_id": "7946029_2_Ent3", "role": "Treatment_Route", "text": "intrauterine", "start": 15, "end": 16}, {"entity_id": "7946029_2_Ent1", "role": "Treatment", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "7946029_2_Ent2", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "7946029_2_Ent0", "text": "basilar invagination", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "7946029_2_Ent3", "text": "intrauterine", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "7946029_2_Ent1", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "7946029_2_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "7978578_1", "wnd_id": "7978578_1_1", "text": "Response of a promethazine - induced coma to flumazenil .", "tokens": ["Response", "of", "a", "promethazine", "-", "induced", "coma", "to", "flumazenil", "."], "event_mentions": [{"id": "7978578_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Response", "start": 0, "end": 1}, "arguments": [{"entity_id": "7978578_1_Ent4", "role": "Treatment_Disorder", "text": "promethazine - induced coma", "start": 3, "end": 7}, {"entity_id": "7978578_1_Ent3", "role": "Treatment", "text": "flumazenil", "start": 8, "end": 9}, {"entity_id": "7978578_1_Ent5", "role": "Treatment_Drug", "text": "flumazenil", "start": 8, "end": 9}]}, {"id": "7978578_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "7978578_1_Ent1", "role": "Treatment", "text": "promethazine", "start": 3, "end": 4}, {"entity_id": "7978578_1_Ent2", "role": "Treatment_Drug", "text": "promethazine", "start": 3, "end": 4}, {"entity_id": "7978578_1_Ent0", "role": "Effect", "text": "coma", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "7978578_1_Ent1", "text": "promethazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7978578_1_Ent2", "text": "promethazine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "7978578_1_Ent4", "text": "promethazine - induced coma", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "7978578_1_Ent0", "text": "coma", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "7978578_1_Ent3", "text": "flumazenil", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "7978578_1_Ent5", "text": "flumazenil", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "7991279_1", "wnd_id": "7991279_1_1", "text": "Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .", "tokens": ["Actinomycin", "D", "associated", "hepatic", "veno", "-", "occlusive", "disease", "--", "a", "report", "of", "2", "cases", "."], "event_mentions": [{"id": "7991279_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "7991279_1_Ent1", "role": "Treatment", "text": "Actinomycin D", "start": 0, "end": 2}, {"entity_id": "7991279_1_Ent2", "role": "Treatment_Drug", "text": "Actinomycin D", "start": 0, "end": 2}, {"entity_id": "7991279_1_Ent0", "role": "Effect", "text": "hepatic veno - occlusive disease", "start": 3, "end": 8}]}], "entity_mentions": [{"id": "7991279_1_Ent1", "text": "Actinomycin D", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7991279_1_Ent2", "text": "Actinomycin D", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "7991279_1_Ent0", "text": "hepatic veno - occlusive disease", "entity_type": "Entity", "start": 3, "end": 8}], "lang": "en"}
{"doc_id": "7991279_2", "wnd_id": "7991279_2_1", "text": "There are now reports of liver failure following treatment of childhood cancers with AMD .", "tokens": ["There", "are", "now", "reports", "of", "liver", "failure", "following", "treatment", "of", "childhood", "cancers", "with", "AMD", "."], "event_mentions": [{"id": "7991279_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 7, "end": 8}, "arguments": [{"entity_id": "7991279_2_Ent2", "role": "Effect", "text": "liver failure", "start": 5, "end": 7}, {"entity_id": "7991279_2_Ent1", "role": "Subject_Age", "text": "childhood", "start": 10, "end": 11}, {"entity_id": "7991279_2_Ent0", "role": "Subject", "text": "childhood cancers", "start": 10, "end": 12}, {"entity_id": "7991279_2_Ent4", "role": "Treatment_Disorder", "text": "cancers", "start": 11, "end": 12}, {"entity_id": "7991279_2_Ent3", "role": "Treatment", "text": "AMD", "start": 13, "end": 14}, {"entity_id": "7991279_2_Ent5", "role": "Treatment_Drug", "text": "AMD", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "7991279_2_Ent2", "text": "liver failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "7991279_2_Ent1", "text": "childhood", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "7991279_2_Ent0", "text": "childhood cancers", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "7991279_2_Ent4", "text": "cancers", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "7991279_2_Ent3", "text": "AMD", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "7991279_2_Ent5", "text": "AMD", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8053440_4", "wnd_id": "8053440_4_1", "text": "This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .", "tokens": ["This", "is", "the", "first", "description", ",", "to", "our", "knowledge", ",", "of", "ductopenia", "apparently", "caused", "by", "clindamycin", "."], "event_mentions": [{"id": "8053440_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 13, "end": 14}, "arguments": [{"entity_id": "8053440_4_Ent0", "role": "Effect", "text": "ductopenia", "start": 11, "end": 12}, {"entity_id": "8053440_4_Ent1", "role": "Treatment", "text": "clindamycin", "start": 15, "end": 16}, {"entity_id": "8053440_4_Ent2", "role": "Treatment_Drug", "text": "clindamycin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8053440_4_Ent0", "text": "ductopenia", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8053440_4_Ent1", "text": "clindamycin", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "8053440_4_Ent2", "text": "clindamycin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8098286_3", "wnd_id": "8098286_3_1", "text": "We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .", "tokens": ["We", "report", "on", "a", "patient", "who", "developed", "hypersensitivity", "pneumonitis", "during", "treatment", "with", "the", "beta", "-", "blocker", ",", "celiprolol", "."], "event_mentions": [{"id": "8098286_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 6, "end": 7}, "arguments": [{"entity_id": "8098286_3_Ent0", "role": "Subject", "text": "a patient", "start": 3, "end": 5}, {"entity_id": "8098286_3_Ent1", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 7, "end": 9}, {"entity_id": "8098286_3_Ent2", "role": "Treatment", "text": "celiprolol", "start": 17, "end": 18}, {"entity_id": "8098286_3_Ent3", "role": "Treatment_Drug", "text": "celiprolol", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8098286_3_Ent0", "text": "a patient", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8098286_3_Ent1", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8098286_3_Ent2", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8098286_3_Ent3", "text": "celiprolol", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8120934_1", "wnd_id": "8120934_1_1", "text": "A 53 - year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .", "tokens": ["A", "53", "-", "year", "-", "old", "male", ",", "without", "any", "prior", "history", "of", "psychosis", ",", "developed", "schizophrenia", "4", "days", "after", "starting", "low", "-", "dose", "bromocriptine", "therapy", "for", "a", "macroprolactinoma", "."], "event_mentions": [{"id": "8120934_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "8120934_1_Ent0", "role": "Subject", "text": "A 53 - year - old male , without any prior history of psychosis", "start": 0, "end": 14}, {"entity_id": "8120934_1_Ent2", "role": "Subject_Age", "text": "53 - year - old", "start": 1, "end": 6}, {"entity_id": "8120934_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 6, "end": 7}, {"entity_id": "8120934_1_Ent4", "role": "Effect", "text": "schizophrenia", "start": 16, "end": 17}, {"entity_id": "8120934_1_Ent8", "role": "Treatment_Time_elapsed", "text": "4 days after", "start": 17, "end": 20}, {"entity_id": "8120934_1_Ent5", "role": "Treatment", "text": "4 days after starting low - dose bromocriptine therapy", "start": 17, "end": 26}, {"entity_id": "8120934_1_Ent9", "role": "Treatment_Dosage", "text": "low - dose", "start": 21, "end": 24}, {"entity_id": "8120934_1_Ent6", "role": "Treatment_Drug", "text": "bromocriptine", "start": 24, "end": 25}, {"entity_id": "8120934_1_Ent1", "role": "Subject", "text": "macroprolactinoma", "start": 28, "end": 29}, {"entity_id": "8120934_1_Ent7", "role": "Treatment_Disorder", "text": "macroprolactinoma", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "8120934_1_Ent0", "text": "A 53 - year - old male , without any prior history of psychosis", "entity_type": "Entity", "start": 0, "end": 14}, {"id": "8120934_1_Ent2", "text": "53 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8120934_1_Ent3", "text": "male", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8120934_1_Ent4", "text": "schizophrenia", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8120934_1_Ent8", "text": "4 days after", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "8120934_1_Ent5", "text": "4 days after starting low - dose bromocriptine therapy", "entity_type": "Entity", "start": 17, "end": 26}, {"id": "8120934_1_Ent9", "text": "low - dose", "entity_type": "Entity", "start": 21, "end": 24}, {"id": "8120934_1_Ent6", "text": "bromocriptine", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "8120934_1_Ent1", "text": "macroprolactinoma", "entity_type": "Entity", "start": 28, "end": 29}, {"id": "8120934_1_Ent7", "text": "macroprolactinoma", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "8124920_2", "wnd_id": "8124920_2_1", "text": "In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .", "tokens": ["In", "a", "patient", "suffering", "from", "rheumatoid", "arthritis", ",", "we", "report", "the", "first", "simultaneous", "occurrence", "of", "two", "side", "effects", "of", "low", "-", "dose", "methotrexate", ":", "an", "acute", "megaloblastic", "anaemia", "and", "a", "pneumonitis", "."], "event_mentions": [{"id": "8124920_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "an", "start": 24, "end": 25}, "arguments": [{"entity_id": "8124920_2_Ent0", "role": "Subject", "text": "patient suffering from rheumatoid arthritis", "start": 2, "end": 7}, {"entity_id": "8124920_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 5, "end": 7}, {"entity_id": "8124920_2_Ent4", "role": "Treatment_Dosage", "text": "low - dose", "start": 19, "end": 22}, {"entity_id": "8124920_2_Ent2", "role": "Treatment", "text": "low - dose methotrexate", "start": 19, "end": 23}, {"entity_id": "8124920_2_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "8124920_2_Ent1", "role": "Effect", "text": "acute megaloblastic anaemia and a pneumonitis", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "8124920_2_Ent0", "text": "patient suffering from rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8124920_2_Ent5", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8124920_2_Ent4", "text": "low - dose", "entity_type": "Entity", "start": 19, "end": 22}, {"id": "8124920_2_Ent2", "text": "low - dose methotrexate", "entity_type": "Entity", "start": 19, "end": 23}, {"id": "8124920_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8124920_2_Ent1", "text": "acute megaloblastic anaemia and a pneumonitis", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "8140860_2", "wnd_id": "8140860_2_1", "text": "We present the case of a woman undergoing treatment with acenocoumarol for deep vein thrombosis , who maintained an international normalized ratio ( INR ) of between 2.5 and 4 for 2 months .", "tokens": ["We", "present", "the", "case", "of", "a", "woman", "undergoing", "treatment", "with", "acenocoumarol", "for", "deep", "vein", "thrombosis", ",", "who", "maintained", "an", "international", "normalized", "ratio", "(", "INR", ")", "of", "between", "2.5", "and", "4", "for", "2", "months", "."], "event_mentions": [{"id": "8140860_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 8, "end": 9}, "arguments": [{"entity_id": "8140860_2_Ent0", "role": "Subject", "text": "a woman", "start": 5, "end": 7}, {"entity_id": "8140860_2_Ent1", "role": "Subject_Gender", "text": "woman", "start": 6, "end": 7}, {"entity_id": "8140860_2_Ent2", "role": "Treatment", "text": "acenocoumarol", "start": 10, "end": 11}, {"entity_id": "8140860_2_Ent3", "role": "Treatment_Drug", "text": "acenocoumarol", "start": 10, "end": 11}, {"entity_id": "8140860_2_Ent4", "role": "Treatment_Disorder", "text": "deep vein thrombosis", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "8140860_2_Ent0", "text": "a woman", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8140860_2_Ent1", "text": "woman", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8140860_2_Ent2", "text": "acenocoumarol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8140860_2_Ent3", "text": "acenocoumarol", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8140860_2_Ent4", "text": "deep vein thrombosis", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8145359_1", "wnd_id": "8145359_1_1", "text": "An 11 - year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .", "tokens": ["An", "11", "-", "year", "-", "old", "boy", "who", "was", "treated", "with", "a", "relatively", "high", "dose", "of", "methotrimeprazine", "meleate", "(", "Levemepromazine", ")", "a", "phenothiazine", "antipsychotic", "drug", ",", "was", "admitted", "to", "the", "pediatric", "intensive", "care", "unit", "suffering", "from", "respiratory", "distress", "syndrome", "."], "event_mentions": [{"id": "8145359_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suffering", "start": 34, "end": 35}, "arguments": [{"entity_id": "8145359_1_Ent0", "role": "Subject", "text": "An 11 - year - old boy", "start": 0, "end": 7}, {"entity_id": "8145359_1_Ent1", "role": "Subject_Age", "text": "11 - year - old", "start": 1, "end": 6}, {"entity_id": "8145359_1_Ent2", "role": "Subject_Gender", "text": "boy", "start": 6, "end": 7}, {"entity_id": "8145359_1_Ent5", "role": "Treatment_Dosage", "text": "relatively high dose", "start": 12, "end": 15}, {"entity_id": "8145359_1_Ent4", "role": "Treatment", "text": "relatively high dose of methotrimeprazine meleate ( Levemepromazine )", "start": 12, "end": 21}, {"entity_id": "8145359_1_Ent6", "role": "Treatment_Drug", "text": "methotrimeprazine meleate", "start": 16, "end": 18}, {"entity_id": "8145359_1_Ent3", "role": "Effect", "text": "respiratory distress syndrome", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "8145359_1_Ent0", "text": "An 11 - year - old boy", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8145359_1_Ent1", "text": "11 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8145359_1_Ent2", "text": "boy", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8145359_1_Ent5", "text": "relatively high dose", "entity_type": "Entity", "start": 12, "end": 15}, {"id": "8145359_1_Ent4", "text": "relatively high dose of methotrimeprazine meleate ( Levemepromazine )", "entity_type": "Entity", "start": 12, "end": 21}, {"id": "8145359_1_Ent6", "text": "methotrimeprazine meleate", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "8145359_1_Ent3", "text": "respiratory distress syndrome", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "8192712_1", "wnd_id": "8192712_1_1", "text": "Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .", "tokens": ["Based", "on", "our", "experience", "and", "on", "previously", "published", "data", ",", "serum", "ammonia", "levels", "appear", "to", "be", "indicated", "in", "all", "ED", "patients", "on", "valproic", "acid", "therapy", "who", "present", "with", "altered", "mental", "status", "."], "event_mentions": [{"id": "8192712_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 26, "end": 27}, "arguments": [{"entity_id": "8192712_1_Ent0", "role": "Subject", "text": "all ED patients", "start": 18, "end": 21}, {"entity_id": "8192712_1_Ent3", "role": "Treatment_Disorder", "text": "ED", "start": 19, "end": 20}, {"entity_id": "8192712_1_Ent4", "role": "Treatment_Drug", "text": "valproic acid", "start": 22, "end": 24}, {"entity_id": "8192712_1_Ent2", "role": "Treatment", "text": "valproic acid therapy", "start": 22, "end": 25}, {"entity_id": "8192712_1_Ent1", "role": "Effect", "text": "altered mental status", "start": 28, "end": 31}]}], "entity_mentions": [{"id": "8192712_1_Ent0", "text": "all ED patients", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8192712_1_Ent3", "text": "ED", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8192712_1_Ent4", "text": "valproic acid", "entity_type": "Entity", "start": 22, "end": 24}, {"id": "8192712_1_Ent2", "text": "valproic acid therapy", "entity_type": "Entity", "start": 22, "end": 25}, {"id": "8192712_1_Ent1", "text": "altered mental status", "entity_type": "Entity", "start": 28, "end": 31}], "lang": "en"}
{"doc_id": "8222875_3", "wnd_id": "8222875_3_1", "text": "Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .", "tokens": ["Pulmonary", "hemorrhage", "is", "an", "uncommon", "feature", "in", "the", "HUS", ",", "and", "seems", "to", "appear", "especially", "in", "the", "HUS", "associated", "with", "MMC", "therapy", "."], "event_mentions": [{"id": "8222875_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "appear", "start": 13, "end": 14}, "arguments": [{"entity_id": "8222875_3_Ent0", "role": "Effect", "text": "Pulmonary hemorrhage", "start": 0, "end": 2}, {"entity_id": "8222875_3_Ent1", "role": "Treatment", "text": "MMC", "start": 20, "end": 21}, {"entity_id": "8222875_3_Ent2", "role": "Treatment_Drug", "text": "MMC", "start": 20, "end": 21}]}], "entity_mentions": [{"id": "8222875_3_Ent0", "text": "Pulmonary hemorrhage", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8222875_3_Ent1", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8222875_3_Ent2", "text": "MMC", "entity_type": "Entity", "start": 20, "end": 21}], "lang": "en"}
{"doc_id": "8239963_3", "wnd_id": "8239963_3_1", "text": "Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .", "tokens": ["Though", "hypotension", ",", "dry", "mouth", ",", "and", "constipation", "are", "well", "-", "documented", "possible", "adverse", "effects", ",", "the", "possibility", "of", "clonidine", "-", "induced", "bradycardia", "is", "less", "well", "recognized", "and", "is", "rare", "."], "event_mentions": [{"id": "8239963_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 21, "end": 22}, "arguments": [{"entity_id": "8239963_3_Ent1", "role": "Treatment", "text": "clonidine", "start": 19, "end": 20}, {"entity_id": "8239963_3_Ent2", "role": "Treatment_Drug", "text": "clonidine", "start": 19, "end": 20}, {"entity_id": "8239963_3_Ent0", "role": "Effect", "text": "bradycardia", "start": 22, "end": 23}]}], "entity_mentions": [{"id": "8239963_3_Ent1", "text": "clonidine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8239963_3_Ent2", "text": "clonidine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8239963_3_Ent0", "text": "bradycardia", "entity_type": "Entity", "start": 22, "end": 23}], "lang": "en"}
{"doc_id": "8244201_1", "wnd_id": "8244201_1_1", "text": "A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .", "tokens": ["A", "high", "dose", "of", "cotrimoxazole", "induced", "hyperkalaemia", "with", "the", "elevation", "of", "serum", "creatinine", "and", "blood", "urea", ",", "and", "increased", "urinary", "N", "-", "acetyl", "glucosaminase", "after", "several", "days", "of", "the", "drug", "administration", "in", "these", "patients", ";", "one", "patient", "became", "unconscious", "."], "event_mentions": [{"id": "8244201_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "8244201_1_Ent2", "role": "Treatment", "text": "A high dose of cotrimoxazole", "start": 0, "end": 5}, {"entity_id": "8244201_1_Ent4", "role": "Treatment_Dosage", "text": "high dose", "start": 1, "end": 3}, {"entity_id": "8244201_1_Ent5", "role": "Treatment_Drug", "text": "cotrimoxazole", "start": 4, "end": 5}, {"entity_id": "8244201_1_Ent1", "role": "Effect", "text": "hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase", "start": 6, "end": 24}, {"entity_id": "8244201_1_Ent3", "role": "Treatment", "text": "after several days of the drug administration", "start": 24, "end": 31}, {"entity_id": "8244201_1_Ent6", "role": "Treatment_Time_elapsed", "text": "several days", "start": 25, "end": 27}, {"entity_id": "8244201_1_Ent0", "role": "Subject", "text": "these patients", "start": 32, "end": 34}]}, {"id": "8244201_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 37, "end": 38}, "arguments": [{"entity_id": "8244201_1_Ent10", "role": "Treatment", "text": "A high dose of cotrimoxazole", "start": 0, "end": 5}, {"entity_id": "8244201_1_Ent12", "role": "Treatment_Dosage", "text": "high dose", "start": 1, "end": 3}, {"entity_id": "8244201_1_Ent13", "role": "Treatment_Drug", "text": "cotrimoxazole", "start": 4, "end": 5}, {"entity_id": "8244201_1_Ent11", "role": "Treatment", "text": "after several days of the drug administration", "start": 24, "end": 31}, {"entity_id": "8244201_1_Ent14", "role": "Treatment_Time_elapsed", "text": "several days", "start": 25, "end": 27}, {"entity_id": "8244201_1_Ent8", "role": "Subject_Population", "text": "one", "start": 35, "end": 36}, {"entity_id": "8244201_1_Ent7", "role": "Subject", "text": "one patient", "start": 35, "end": 37}, {"entity_id": "8244201_1_Ent9", "role": "Effect", "text": "unconscious", "start": 38, "end": 39}]}], "entity_mentions": [{"id": "8244201_1_Ent2", "text": "A high dose of cotrimoxazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_1_Ent10", "text": "A high dose of cotrimoxazole", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "8244201_1_Ent4", "text": "high dose", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8244201_1_Ent12", "text": "high dose", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8244201_1_Ent5", "text": "cotrimoxazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8244201_1_Ent13", "text": "cotrimoxazole", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8244201_1_Ent1", "text": "hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase", "entity_type": "Entity", "start": 6, "end": 24}, {"id": "8244201_1_Ent3", "text": "after several days of the drug administration", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "8244201_1_Ent11", "text": "after several days of the drug administration", "entity_type": "Entity", "start": 24, "end": 31}, {"id": "8244201_1_Ent6", "text": "several days", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "8244201_1_Ent14", "text": "several days", "entity_type": "Entity", "start": 25, "end": 27}, {"id": "8244201_1_Ent0", "text": "these patients", "entity_type": "Entity", "start": 32, "end": 34}, {"id": "8244201_1_Ent8", "text": "one", "entity_type": "Entity", "start": 35, "end": 36}, {"id": "8244201_1_Ent7", "text": "one patient", "entity_type": "Entity", "start": 35, "end": 37}, {"id": "8244201_1_Ent9", "text": "unconscious", "entity_type": "Entity", "start": 38, "end": 39}], "lang": "en"}
{"doc_id": "8253700_1", "wnd_id": "8253700_1_1", "text": "BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .", "tokens": ["BACKGROUND", ":", "Fluoxetine", ",", "a", "highly", "specific", "serotonin", "reuptake", "inhibitor", ",", "has", "been", "reported", "to", "cause", "sexual", "dysfunction", "in", "a", "minority", "of", "patients", "."], "event_mentions": [{"id": "8253700_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 15, "end": 16}, "arguments": [{"entity_id": "8253700_1_Ent2", "role": "Treatment", "text": "Fluoxetine", "start": 2, "end": 3}, {"entity_id": "8253700_1_Ent3", "role": "Treatment_Drug", "text": "Fluoxetine", "start": 2, "end": 3}, {"entity_id": "8253700_1_Ent1", "role": "Effect", "text": "sexual dysfunction", "start": 16, "end": 18}, {"entity_id": "8253700_1_Ent0", "role": "Subject", "text": "minority of patients", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "8253700_1_Ent2", "text": "Fluoxetine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8253700_1_Ent3", "text": "Fluoxetine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8253700_1_Ent1", "text": "sexual dysfunction", "entity_type": "Entity", "start": 16, "end": 18}, {"id": "8253700_1_Ent0", "text": "minority of patients", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "8266863_1", "wnd_id": "8266863_1_1", "text": "Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .", "tokens": ["Four", "days", "after", "the", "initial", "injection", "of", "3.6", "mg", "of", "goserelin", "acetate", ",", "severe", "dyspnea", "developed", "due", "to", "worsening", "pleuritis", "carcinomatosa", ",", "which", "was", "considered", "as", "a", "flare", "-", "up", "."], "event_mentions": [{"id": "8266863_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 15, "end": 16}, "arguments": [{"entity_id": "8266863_1_Ent3", "role": "Treatment_Route", "text": "injection", "start": 5, "end": 6}, {"entity_id": "8266863_1_Ent2", "role": "Treatment", "text": "injection of 3.6 mg of goserelin acetate", "start": 5, "end": 12}, {"entity_id": "8266863_1_Ent4", "role": "Treatment_Dosage", "text": "3.6 mg", "start": 7, "end": 9}, {"entity_id": "8266863_1_Ent5", "role": "Treatment_Drug", "text": "goserelin acetate", "start": 10, "end": 12}, {"entity_id": "8266863_1_Ent0", "role": "Effect", "text": "severe dyspnea", "start": 13, "end": 15}, {"entity_id": "8266863_1_Ent1", "role": "Effect", "text": "worsening pleuritis carcinomatosa", "start": 18, "end": 21}]}], "entity_mentions": [{"id": "8266863_1_Ent3", "text": "injection", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8266863_1_Ent2", "text": "injection of 3.6 mg of goserelin acetate", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8266863_1_Ent4", "text": "3.6 mg", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "8266863_1_Ent5", "text": "goserelin acetate", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8266863_1_Ent0", "text": "severe dyspnea", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8266863_1_Ent1", "text": "worsening pleuritis carcinomatosa", "entity_type": "Entity", "start": 18, "end": 21}], "lang": "en"}
{"doc_id": "8276031_2", "wnd_id": "8276031_2_1", "text": "A 15 - month - old girl with rhinopharyngitis was treated with a nasal solution containing the imidazoline derivative naphazoline .", "tokens": ["A", "15", "-", "month", "-", "old", "girl", "with", "rhinopharyngitis", "was", "treated", "with", "a", "nasal", "solution", "containing", "the", "imidazoline", "derivative", "naphazoline", "."], "event_mentions": [{"id": "8276031_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treated", "start": 10, "end": 11}, "arguments": [{"entity_id": "8276031_2_Ent0", "role": "Subject", "text": "A 15 - month - old girl with rhinopharyngitis", "start": 0, "end": 9}, {"entity_id": "8276031_2_Ent1", "role": "Subject_Age", "text": "15 - month - old", "start": 1, "end": 6}, {"entity_id": "8276031_2_Ent2", "role": "Subject_Gender", "text": "girl", "start": 6, "end": 7}, {"entity_id": "8276031_2_Ent4", "role": "Treatment_Disorder", "text": "rhinopharyngitis", "start": 8, "end": 9}, {"entity_id": "8276031_2_Ent3", "role": "Treatment", "text": "a nasal solution containing the imidazoline derivative naphazoline", "start": 12, "end": 20}, {"entity_id": "8276031_2_Ent5", "role": "Treatment_Drug", "text": "imidazoline derivative", "start": 17, "end": 19}, {"entity_id": "8276031_2_Ent6", "role": "Treatment_Route", "text": "naphazoline", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "8276031_2_Ent0", "text": "A 15 - month - old girl with rhinopharyngitis", "entity_type": "Entity", "start": 0, "end": 9}, {"id": "8276031_2_Ent1", "text": "15 - month - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8276031_2_Ent2", "text": "girl", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8276031_2_Ent4", "text": "rhinopharyngitis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_2_Ent3", "text": "a nasal solution containing the imidazoline derivative naphazoline", "entity_type": "Entity", "start": 12, "end": 20}, {"id": "8276031_2_Ent5", "text": "imidazoline derivative", "entity_type": "Entity", "start": 17, "end": 19}, {"id": "8276031_2_Ent6", "text": "naphazoline", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "8276031_5", "wnd_id": "8276031_5_1", "text": "The symptomatology of 18 other paediatric cases of naphthylimidazoline exposure reported to the Belgian National Poison Centre , is also discussed .", "tokens": ["The", "symptomatology", "of", "18", "other", "paediatric", "cases", "of", "naphthylimidazoline", "exposure", "reported", "to", "the", "Belgian", "National", "Poison", "Centre", ",", "is", "also", "discussed", "."], "event_mentions": [{"id": "8276031_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "symptomatology", "start": 1, "end": 2}, "arguments": [{"entity_id": "8276031_5_Ent1", "role": "Subject_Population", "text": "18", "start": 3, "end": 4}, {"entity_id": "8276031_5_Ent0", "role": "Subject", "text": "18 other paediatric cases", "start": 3, "end": 7}, {"entity_id": "8276031_5_Ent2", "role": "Subject_Age", "text": "paediatric", "start": 5, "end": 6}, {"entity_id": "8276031_5_Ent4", "role": "Treatment", "text": "naphthylimidazoline", "start": 8, "end": 9}, {"entity_id": "8276031_5_Ent5", "role": "Treatment_Drug", "text": "naphthylimidazoline", "start": 8, "end": 9}, {"entity_id": "8276031_5_Ent3", "role": "Effect", "text": "naphthylimidazoline exposure", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8276031_5_Ent1", "text": "18", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8276031_5_Ent0", "text": "18 other paediatric cases", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8276031_5_Ent2", "text": "paediatric", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8276031_5_Ent4", "text": "naphthylimidazoline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_5_Ent5", "text": "naphthylimidazoline", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8276031_5_Ent3", "text": "naphthylimidazoline exposure", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8276031_6", "wnd_id": "8276031_6_1", "text": "Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .", "tokens": ["Imidazoline", "intoxication", "due", "to", "overdose", "or", "accidental", "ingestion", "but", "also", "after", "normal", "therapeutic", "usage", "is", "frequent", "in", "children", "."], "event_mentions": [{"id": "8276031_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "due", "start": 2, "end": 3}, "arguments": [{"entity_id": "8276031_6_Ent3", "role": "Treatment", "text": "Imidazoline", "start": 0, "end": 1}, {"entity_id": "8276031_6_Ent2", "role": "Effect", "text": "intoxication", "start": 1, "end": 2}, {"entity_id": "8276031_6_Ent6", "role": "Treatment_Dosage", "text": "overdose or accidental", "start": 4, "end": 7}, {"entity_id": "8276031_6_Ent4", "role": "Treatment", "text": "overdose or accidental ingestion but also after normal therapeutic usage", "start": 4, "end": 14}, {"entity_id": "8276031_6_Ent5", "role": "Treatment_Route", "text": "ingestion", "start": 7, "end": 8}, {"entity_id": "8276031_6_Ent7", "role": "Treatment_Dosage", "text": "but also after normal therapeutic usage", "start": 8, "end": 14}, {"entity_id": "8276031_6_Ent0", "role": "Subject", "text": "children", "start": 17, "end": 18}, {"entity_id": "8276031_6_Ent1", "role": "Subject_Age", "text": "children", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8276031_6_Ent3", "text": "Imidazoline", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8276031_6_Ent2", "text": "intoxication", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8276031_6_Ent6", "text": "overdose or accidental", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8276031_6_Ent4", "text": "overdose or accidental ingestion but also after normal therapeutic usage", "entity_type": "Entity", "start": 4, "end": 14}, {"id": "8276031_6_Ent5", "text": "ingestion", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8276031_6_Ent7", "text": "but also after normal therapeutic usage", "entity_type": "Entity", "start": 8, "end": 14}, {"id": "8276031_6_Ent0", "text": "children", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8276031_6_Ent1", "text": "children", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8305778_3", "wnd_id": "8305778_3_1", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease began taking amiodarone to suppress sustained ventricular tachycardia .", "tokens": ["A", "78", "-", "year", "-", "old", "man", "with", "a", "history", "of", "congestive", "heart", "failure", "and", "coronary", "artery", "disease", "began", "taking", "amiodarone", "to", "suppress", "sustained", "ventricular", "tachycardia", "."], "event_mentions": [{"id": "8305778_3_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "suppress", "start": 22, "end": 23}, "arguments": [{"entity_id": "8305778_3_Ent0", "role": "Subject", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "start": 0, "end": 18}, {"entity_id": "8305778_3_Ent1", "role": "Subject_Age", "text": "78 - year - old", "start": 1, "end": 6}, {"entity_id": "8305778_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "8305778_3_Ent3", "role": "Subject_Disorder", "text": "congestive heart failure", "start": 11, "end": 14}, {"entity_id": "8305778_3_Ent4", "role": "Subject_Disorder", "text": "coronary artery disease", "start": 15, "end": 18}, {"entity_id": "8305778_3_Ent5", "role": "Treatment", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent6", "role": "Treatment_Drug", "text": "amiodarone", "start": 20, "end": 21}, {"entity_id": "8305778_3_Ent7", "role": "Treatment_Disorder", "text": "sustained ventricular tachycardia", "start": 23, "end": 26}]}], "entity_mentions": [{"id": "8305778_3_Ent0", "text": "A 78 - year - old man with a history of congestive heart failure and coronary artery disease", "entity_type": "Entity", "start": 0, "end": 18}, {"id": "8305778_3_Ent1", "text": "78 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8305778_3_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8305778_3_Ent3", "text": "congestive heart failure", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8305778_3_Ent4", "text": "coronary artery disease", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8305778_3_Ent5", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent6", "text": "amiodarone", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8305778_3_Ent7", "text": "sustained ventricular tachycardia", "entity_type": "Entity", "start": 23, "end": 26}], "lang": "en"}
{"doc_id": "8305778_6", "wnd_id": "8305778_6_1", "text": "Amiodarone is a Class III antiarrhythmic with an adverse - effect profile involving many different organ systems .", "tokens": ["Amiodarone", "is", "a", "Class", "III", "antiarrhythmic", "with", "an", "adverse", "-", "effect", "profile", "involving", "many", "different", "organ", "systems", "."], "event_mentions": [{"id": "8305778_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "adverse - effect", "start": 8, "end": 11}, "arguments": [{"entity_id": "8305778_6_Ent1", "role": "Treatment", "text": "Amiodarone", "start": 0, "end": 1}, {"entity_id": "8305778_6_Ent0", "role": "Effect", "text": "an adverse - effect profile involving many different organ systems", "start": 7, "end": 17}]}], "entity_mentions": [{"id": "8305778_6_Ent1", "text": "Amiodarone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8305778_6_Ent0", "text": "an adverse - effect profile involving many different organ systems", "entity_type": "Entity", "start": 7, "end": 17}], "lang": "en"}
{"doc_id": "8308951_1", "wnd_id": "8308951_1_1", "text": "Cutaneous exposure to warfarin - like anticoagulant causing an intracerebral hemorrhage : a case report .", "tokens": ["Cutaneous", "exposure", "to", "warfarin", "-", "like", "anticoagulant", "causing", "an", "intracerebral", "hemorrhage", ":", "a", "case", "report", "."], "event_mentions": [{"id": "8308951_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "causing", "start": 7, "end": 8}, "arguments": [{"entity_id": "8308951_1_Ent2", "role": "Treatment", "text": "Cutaneous exposure to warfarin - like anticoagulant", "start": 0, "end": 7}, {"entity_id": "8308951_1_Ent3", "role": "Treatment_Drug", "text": "warfarin - like anticoagulant", "start": 3, "end": 7}, {"entity_id": "8308951_1_Ent1", "role": "Effect", "text": "an intracerebral hemorrhage", "start": 8, "end": 11}, {"entity_id": "8308951_1_Ent0", "role": "Subject", "text": "a case", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "8308951_1_Ent2", "text": "Cutaneous exposure to warfarin - like anticoagulant", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "8308951_1_Ent3", "text": "warfarin - like anticoagulant", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8308951_1_Ent1", "text": "an intracerebral hemorrhage", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8308951_1_Ent0", "text": "a case", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "8313300_9", "wnd_id": "8313300_9_1", "text": "The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .", "tokens": ["The", "exophthalmos", "improved", "dramatically", "within", "72", "hours", "of", "the", "withdrawal", "of", "lithium", "."], "event_mentions": [{"id": "8313300_9_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "improved", "start": 2, "end": 3}, "arguments": [{"entity_id": "8313300_9_Ent1", "role": "Treatment_Disorder", "text": "exophthalmos", "start": 1, "end": 2}, {"entity_id": "8313300_9_Ent3", "role": "Treatment_Time_elapsed", "text": "within 72 hours", "start": 4, "end": 7}, {"entity_id": "8313300_9_Ent0", "role": "Treatment", "text": "within 72 hours of the withdrawal of lithium", "start": 4, "end": 12}, {"entity_id": "8313300_9_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8313300_9_Ent1", "text": "exophthalmos", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8313300_9_Ent3", "text": "within 72 hours", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8313300_9_Ent0", "text": "within 72 hours of the withdrawal of lithium", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "8313300_9_Ent2", "text": "lithium", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8316494_1", "wnd_id": "8316494_1_1", "text": "Severe abdominal pain in low dosage clofazimine .", "tokens": ["Severe", "abdominal", "pain", "in", "low", "dosage", "clofazimine", "."], "event_mentions": [{"id": "8316494_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 3, "end": 4}, "arguments": [{"entity_id": "8316494_1_Ent0", "role": "Effect", "text": "abdominal pain", "start": 1, "end": 3}, {"entity_id": "8316494_1_Ent3", "role": "Treatment_Dosage", "text": "low dosage", "start": 4, "end": 6}, {"entity_id": "8316494_1_Ent1", "role": "Treatment", "text": "low dosage clofazimine", "start": 4, "end": 7}, {"entity_id": "8316494_1_Ent2", "role": "Treatment_Drug", "text": "clofazimine", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8316494_1_Ent0", "text": "abdominal pain", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8316494_1_Ent3", "text": "low dosage", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8316494_1_Ent1", "text": "low dosage clofazimine", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8316494_1_Ent2", "text": "clofazimine", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8329789_1", "wnd_id": "8329789_1_1", "text": "Amphotericin B overdose in pediatric patients with associated cardiac arrest .", "tokens": ["Amphotericin", "B", "overdose", "in", "pediatric", "patients", "with", "associated", "cardiac", "arrest", "."], "event_mentions": [{"id": "8329789_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "8329789_1_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 0, "end": 2}, {"entity_id": "8329789_1_Ent3", "role": "Treatment", "text": "Amphotericin B overdose", "start": 0, "end": 3}, {"entity_id": "8329789_1_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 2, "end": 3}, {"entity_id": "8329789_1_Ent1", "role": "Subject_Age", "text": "pediatric", "start": 4, "end": 5}, {"entity_id": "8329789_1_Ent0", "role": "Subject", "text": "pediatric patients", "start": 4, "end": 6}, {"entity_id": "8329789_1_Ent2", "role": "Effect", "text": "cardiac arrest", "start": 8, "end": 10}]}], "entity_mentions": [{"id": "8329789_1_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8329789_1_Ent3", "text": "Amphotericin B overdose", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8329789_1_Ent5", "text": "overdose", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8329789_1_Ent1", "text": "pediatric", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8329789_1_Ent0", "text": "pediatric patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8329789_1_Ent2", "text": "cardiac arrest", "entity_type": "Entity", "start": 8, "end": 10}], "lang": "en"}
{"doc_id": "8329789_2", "wnd_id": "8329789_2_1", "text": "OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .", "tokens": ["OBJECTIVE", ":", "To", "report", "the", "first", "five", "cases", "of", "amphotericin", "B", "overdose", "with", "secondary", "cardiac", "complications", "in", "a", "pediatric", "population", "."], "event_mentions": [{"id": "8329789_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "secondary", "start": 13, "end": 14}, "arguments": [{"entity_id": "8329789_2_Ent0", "role": "Subject", "text": "first five cases of", "start": 5, "end": 9}, {"entity_id": "8329789_2_Ent3", "role": "Subject_Population", "text": "five", "start": 6, "end": 7}, {"entity_id": "8329789_2_Ent6", "role": "Treatment_Drug", "text": "amphotericin B", "start": 9, "end": 11}, {"entity_id": "8329789_2_Ent5", "role": "Treatment", "text": "amphotericin B overdose", "start": 9, "end": 12}, {"entity_id": "8329789_2_Ent7", "role": "Treatment_Dosage", "text": "overdose", "start": 11, "end": 12}, {"entity_id": "8329789_2_Ent4", "role": "Effect", "text": "cardiac complications", "start": 14, "end": 16}, {"entity_id": "8329789_2_Ent1", "role": "Subject", "text": "a pediatric population", "start": 17, "end": 20}, {"entity_id": "8329789_2_Ent2", "role": "Subject_Age", "text": "pediatric", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8329789_2_Ent0", "text": "first five cases of", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8329789_2_Ent3", "text": "five", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8329789_2_Ent6", "text": "amphotericin B", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "8329789_2_Ent5", "text": "amphotericin B overdose", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_2_Ent7", "text": "overdose", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8329789_2_Ent4", "text": "cardiac complications", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8329789_2_Ent1", "text": "a pediatric population", "entity_type": "Entity", "start": 17, "end": 20}, {"id": "8329789_2_Ent2", "text": "pediatric", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "8329789_9", "wnd_id": "8329789_9_1", "text": "CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .", "tokens": ["CONCLUSIONS", ":", "Amphotericin", "B", "overdose", "can", "be", "fatal", "in", "children", "and", "infants", "."], "event_mentions": [{"id": "8329789_9_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 6, "end": 7}, "arguments": [{"entity_id": "8329789_9_Ent4", "role": "Treatment_Drug", "text": "Amphotericin B", "start": 2, "end": 4}, {"entity_id": "8329789_9_Ent3", "role": "Treatment", "text": "Amphotericin B overdose", "start": 2, "end": 5}, {"entity_id": "8329789_9_Ent5", "role": "Treatment_Dosage", "text": "overdose", "start": 4, "end": 5}, {"entity_id": "8329789_9_Ent1", "role": "Subject_Age", "text": "children", "start": 9, "end": 10}, {"entity_id": "8329789_9_Ent0", "role": "Subject", "text": "children and infants", "start": 9, "end": 12}, {"entity_id": "8329789_9_Ent2", "role": "Subject_Age", "text": "infants", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8329789_9_Ent4", "text": "Amphotericin B", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8329789_9_Ent3", "text": "Amphotericin B overdose", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8329789_9_Ent5", "text": "overdose", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8329789_9_Ent1", "text": "children", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8329789_9_Ent0", "text": "children and infants", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8329789_9_Ent2", "text": "infants", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8345435_2", "wnd_id": "8345435_2_1", "text": "L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .", "tokens": ["L", "-", "Carnitine", "supplementation", "has", "been", "recommended", "to", "prevent", "the", "fatal", "hepatotoxic", "effects", "associated", "with", "valproic", "acid", "."], "event_mentions": [{"id": "8345435_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "recommended", "start": 6, "end": 7}, "arguments": [{"entity_id": "8345435_2_Ent3", "role": "Treatment", "text": "L - Carnitine", "start": 0, "end": 3}, {"entity_id": "8345435_2_Ent4", "role": "Treatment_Drug", "text": "L - Carnitine", "start": 0, "end": 3}, {"entity_id": "8345435_2_Ent5", "role": "Treatment_Disorder", "text": "fatal hepatotoxic effects", "start": 10, "end": 13}]}, {"id": "8345435_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 13, "end": 14}, "arguments": [{"entity_id": "8345435_2_Ent0", "role": "Effect", "text": "hepatotoxic effects", "start": 11, "end": 13}, {"entity_id": "8345435_2_Ent1", "role": "Treatment", "text": "valproic acid", "start": 15, "end": 17}, {"entity_id": "8345435_2_Ent2", "role": "Treatment_Drug", "text": "valproic acid", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8345435_2_Ent3", "text": "L - Carnitine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8345435_2_Ent4", "text": "L - Carnitine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "8345435_2_Ent5", "text": "fatal hepatotoxic effects", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "8345435_2_Ent0", "text": "hepatotoxic effects", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8345435_2_Ent1", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}, {"id": "8345435_2_Ent2", "text": "valproic acid", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8360712_2", "wnd_id": "8360712_2_1", "text": "Delayed neurotoxicity of intraventricular interleukin - 2 : a case report .", "tokens": ["Delayed", "neurotoxicity", "of", "intraventricular", "interleukin", "-", "2", ":", "a", "case", "report", "."], "event_mentions": [{"id": "8360712_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 2, "end": 3}, "arguments": [{"entity_id": "8360712_2_Ent1", "role": "Effect", "text": "Delayed neurotoxicity", "start": 0, "end": 2}, {"entity_id": "8360712_2_Ent4", "role": "Treatment_Route", "text": "intraventricular", "start": 3, "end": 4}, {"entity_id": "8360712_2_Ent2", "role": "Treatment", "text": "intraventricular interleukin - 2", "start": 3, "end": 7}, {"entity_id": "8360712_2_Ent3", "role": "Treatment_Drug", "text": "interleukin - 2", "start": 4, "end": 7}, {"entity_id": "8360712_2_Ent0", "role": "Subject", "text": "a case report", "start": 8, "end": 11}]}], "entity_mentions": [{"id": "8360712_2_Ent1", "text": "Delayed neurotoxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8360712_2_Ent4", "text": "intraventricular", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8360712_2_Ent2", "text": "intraventricular interleukin - 2", "entity_type": "Entity", "start": 3, "end": 7}, {"id": "8360712_2_Ent3", "text": "interleukin - 2", "entity_type": "Entity", "start": 4, "end": 7}, {"id": "8360712_2_Ent0", "text": "a case report", "entity_type": "Entity", "start": 8, "end": 11}], "lang": "en"}
{"doc_id": "8384030_1", "wnd_id": "8384030_1_1", "text": "CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .", "tokens": ["CONCLUSIONS", ":", "It", "is", "probable", "that", "foscarnet", "contributed", "to", "the", "electrolyte", "disorders", "and", "symptomatology", "in", "this", "patient", "."], "event_mentions": [{"id": "8384030_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "contributed", "start": 7, "end": 8}, "arguments": [{"entity_id": "8384030_1_Ent2", "role": "Treatment", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_1_Ent3", "role": "Treatment_Drug", "text": "foscarnet", "start": 6, "end": 7}, {"entity_id": "8384030_1_Ent1", "role": "Effect", "text": "electrolyte disorders and symptomatology", "start": 10, "end": 14}, {"entity_id": "8384030_1_Ent0", "role": "Subject", "text": "this patient", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "8384030_1_Ent2", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_1_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8384030_1_Ent1", "text": "electrolyte disorders and symptomatology", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8384030_1_Ent0", "text": "this patient", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "8396491_2", "wnd_id": "8396491_2_1", "text": "The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .", "tokens": ["The", "results", "clearly", "demonstrate", "that", "CPH82", "was", "associated", "with", "suppression", "of", "the", "endogeneous", "production", "of", "ACTH", "and", "cortisol", "with", "a", "concomitant", "paradoxical", "picture", "of", "clinical", "hypercortisolism", "."], "event_mentions": [{"id": "8396491_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "8396491_2_Ent1", "role": "Treatment", "text": "CPH82", "start": 5, "end": 6}, {"entity_id": "8396491_2_Ent2", "role": "Treatment_Drug", "text": "CPH82", "start": 5, "end": 6}, {"entity_id": "8396491_2_Ent0", "role": "Effect", "text": "suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism", "start": 9, "end": 26}]}], "entity_mentions": [{"id": "8396491_2_Ent1", "text": "CPH82", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8396491_2_Ent2", "text": "CPH82", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8396491_2_Ent0", "text": "suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism", "entity_type": "Entity", "start": 9, "end": 26}], "lang": "en"}
{"doc_id": "8404753_2", "wnd_id": "8404753_2_1", "text": "A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .", "tokens": ["A", "variety", "of", "movement", "disorders", "are", "known", "to", "occur", "in", "association", "with", "carbamazepine", "(", "CBZ", ")", "therapy", "in", "adults", "and", "children", ",", "but", "development", "of", "tics", "has", "been", "described", "infrequently", "and", "only", "in", "patients", "with", "underlying", "Tourette", "'s", "syndrome", "or", "other", "movement", "disorders", "."], "event_mentions": [{"id": "8404753_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occur", "start": 8, "end": 9}, "arguments": [{"entity_id": "8404753_2_Ent3", "role": "Effect", "text": "movement disorders", "start": 3, "end": 5}, {"entity_id": "8404753_2_Ent5", "role": "Treatment_Drug", "text": "carbamazepine", "start": 12, "end": 13}, {"entity_id": "8404753_2_Ent4", "role": "Treatment", "text": "carbamazepine ( CBZ ) therapy", "start": 12, "end": 17}, {"entity_id": "8404753_2_Ent1", "role": "Subject_Age", "text": "adults", "start": 18, "end": 19}, {"entity_id": "8404753_2_Ent0", "role": "Subject", "text": "adults and children", "start": 18, "end": 21}, {"entity_id": "8404753_2_Ent2", "role": "Subject_Age", "text": "children", "start": 20, "end": 21}, {"entity_id": "8404753_2_Ent6", "role": "Treatment_Disorder", "text": "Tourette 's syndrome", "start": 36, "end": 39}]}], "entity_mentions": [{"id": "8404753_2_Ent3", "text": "movement disorders", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "8404753_2_Ent5", "text": "carbamazepine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8404753_2_Ent4", "text": "carbamazepine ( CBZ ) therapy", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8404753_2_Ent1", "text": "adults", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "8404753_2_Ent0", "text": "adults and children", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8404753_2_Ent2", "text": "children", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8404753_2_Ent6", "text": "Tourette 's syndrome", "entity_type": "Entity", "start": 36, "end": 39}], "lang": "en"}
{"doc_id": "8404753_3", "wnd_id": "8404753_3_1", "text": "We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .", "tokens": ["We", "report", "3", "children", "with", "epilepsy", "who", "developed", "facial", "motor", "tics", "after", "initiation", "of", "CBZ", "for", "complex", "partial", "seizures", "."], "event_mentions": [{"id": "8404753_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 11, "end": 12}, "arguments": [{"entity_id": "8404753_3_Ent1", "role": "Subject_Population", "text": "3", "start": 2, "end": 3}, {"entity_id": "8404753_3_Ent0", "role": "Subject", "text": "3 children with epilepsy", "start": 2, "end": 6}, {"entity_id": "8404753_3_Ent2", "role": "Subject_Age", "text": "children", "start": 3, "end": 4}, {"entity_id": "8404753_3_Ent5", "role": "Treatment_Disorder", "text": "epilepsy", "start": 5, "end": 6}, {"entity_id": "8404753_3_Ent3", "role": "Effect", "text": "facial motor tics", "start": 8, "end": 11}, {"entity_id": "8404753_3_Ent4", "role": "Treatment", "text": "CBZ", "start": 14, "end": 15}, {"entity_id": "8404753_3_Ent6", "role": "Treatment_Drug", "text": "CBZ", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8404753_3_Ent1", "text": "3", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8404753_3_Ent0", "text": "3 children with epilepsy", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8404753_3_Ent2", "text": "children", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8404753_3_Ent5", "text": "epilepsy", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8404753_3_Ent3", "text": "facial motor tics", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8404753_3_Ent4", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8404753_3_Ent6", "text": "CBZ", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "8435665_1", "wnd_id": "8435665_1_1", "text": "A 16 - year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .", "tokens": ["A", "16", "-", "year", "-", "old", "white", "male", "with", "acute", "biphenotypic", "leukemia", "developed", "evidence", "of", "the", "eosinophilia", "myalgia", "syndrome", "associated", "with", "total", "parenteral", "nutritional", "support", "with", "solutions", "containing", "tryptophan", ",", "which", "were", "given", "during", "his", "initial", "induction", "chemotherapy", "and", "also", "after", "autologous", "marrow", "transplantation", "."], "event_mentions": [{"id": "8435665_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 12, "end": 13}, "arguments": [{"entity_id": "8435665_1_Ent0", "role": "Subject", "text": "A 16 - year - old white male with acute biphenotypic leukemia", "start": 0, "end": 12}, {"entity_id": "8435665_1_Ent1", "role": "Subject_Age", "text": "16 - year - old", "start": 1, "end": 6}, {"entity_id": "8435665_1_Ent2", "role": "Subject_Race", "text": "white", "start": 6, "end": 7}, {"entity_id": "8435665_1_Ent3", "role": "Subject_Gender", "text": "male", "start": 7, "end": 8}, {"entity_id": "8435665_1_Ent4", "role": "Subject_Disorder", "text": "acute biphenotypic leukemia", "start": 9, "end": 12}, {"entity_id": "8435665_1_Ent5", "role": "Effect", "text": "eosinophilia myalgia syndrome", "start": 16, "end": 19}, {"entity_id": "8435665_1_Ent6", "role": "Treatment", "text": "total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation", "start": 21, "end": 44}, {"entity_id": "8435665_1_Ent8", "role": "Treatment_Route", "text": "parenteral", "start": 22, "end": 23}, {"entity_id": "8435665_1_Ent7", "role": "Treatment_Drug", "text": "tryptophan", "start": 28, "end": 29}]}], "entity_mentions": [{"id": "8435665_1_Ent0", "text": "A 16 - year - old white male with acute biphenotypic leukemia", "entity_type": "Entity", "start": 0, "end": 12}, {"id": "8435665_1_Ent1", "text": "16 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "8435665_1_Ent2", "text": "white", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8435665_1_Ent3", "text": "male", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "8435665_1_Ent4", "text": "acute biphenotypic leukemia", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "8435665_1_Ent5", "text": "eosinophilia myalgia syndrome", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "8435665_1_Ent6", "text": "total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation", "entity_type": "Entity", "start": 21, "end": 44}, {"id": "8435665_1_Ent8", "text": "parenteral", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8435665_1_Ent7", "text": "tryptophan", "entity_type": "Entity", "start": 28, "end": 29}], "lang": "en"}
{"doc_id": "8435665_3", "wnd_id": "8435665_3_1", "text": "Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .", "tokens": ["Thus", ",", "the", "eosinophilia", "myalgia", "syndrome", "can", "be", "associated", "with", "parenteral", "tryptophan", "administration", "."], "event_mentions": [{"id": "8435665_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 8, "end": 9}, "arguments": [{"entity_id": "8435665_3_Ent0", "role": "Effect", "text": "eosinophilia myalgia syndrome", "start": 3, "end": 6}, {"entity_id": "8435665_3_Ent3", "role": "Treatment_Route", "text": "parenteral", "start": 10, "end": 11}, {"entity_id": "8435665_3_Ent1", "role": "Treatment", "text": "parenteral tryptophan", "start": 10, "end": 12}, {"entity_id": "8435665_3_Ent2", "role": "Treatment_Drug", "text": "tryptophan", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "8435665_3_Ent0", "text": "eosinophilia myalgia syndrome", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8435665_3_Ent3", "text": "parenteral", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8435665_3_Ent1", "text": "parenteral tryptophan", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8435665_3_Ent2", "text": "tryptophan", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "8467620_1", "wnd_id": "8467620_1_1", "text": "Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .", "tokens": ["Lymphoma", "developing", "in", "a", "patient", "with", "rheumatoid", "arthritis", "taking", "methotrexate", "."], "event_mentions": [{"id": "8467620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 1, "end": 2}, "arguments": [{"entity_id": "8467620_1_Ent1", "role": "Effect", "text": "Lymphoma", "start": 0, "end": 1}, {"entity_id": "8467620_1_Ent0", "role": "Subject", "text": "a patient with rheumatoid arthritis", "start": 3, "end": 8}, {"entity_id": "8467620_1_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 6, "end": 8}, {"entity_id": "8467620_1_Ent2", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8467620_1_Ent3", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8467620_1_Ent1", "text": "Lymphoma", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8467620_1_Ent0", "text": "a patient with rheumatoid arthritis", "entity_type": "Entity", "start": 3, "end": 8}, {"id": "8467620_1_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8467620_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8467620_1_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8467620_2", "wnd_id": "8467620_2_1", "text": "The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .", "tokens": ["The", "mild", "immunosuppression", "that", "occurs", "with", "methotrexate", "therapy", "probably", "places", "patients", "with", "rheumatoid", "arthritis", "at", "added", "risk", "of", "developing", "lymphoproliferative", "diseases", ",", "but", "coincidence", "can", "not", "be", "excluded", "."], "event_mentions": [{"id": "8467620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developing", "start": 18, "end": 19}, "arguments": [{"entity_id": "8467620_2_Ent1", "role": "Effect", "text": "mild immunosuppression", "start": 1, "end": 3}, {"entity_id": "8467620_2_Ent3", "role": "Treatment", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8467620_2_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 6, "end": 7}, {"entity_id": "8467620_2_Ent0", "role": "Subject", "text": "patients with rheumatoid arthritis", "start": 10, "end": 14}, {"entity_id": "8467620_2_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 12, "end": 14}, {"entity_id": "8467620_2_Ent2", "role": "Effect", "text": "lymphoproliferative diseases", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "8467620_2_Ent1", "text": "mild immunosuppression", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8467620_2_Ent3", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8467620_2_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8467620_2_Ent0", "text": "patients with rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8467620_2_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "8467620_2_Ent2", "text": "lymphoproliferative diseases", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "8467620_3", "wnd_id": "8467620_3_1", "text": "We report one case of non - Hodgkin lymphoma in a patient , with a 30 - year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10 - month period .", "tokens": ["We", "report", "one", "case", "of", "non", "-", "Hodgkin", "lymphoma", "in", "a", "patient", ",", "with", "a", "30", "-", "year", "history", "of", "rheumatoid", "arthritis", ",", "taking", "low", "dose", "methotrexate", "weekly", "over", "a", "10", "-", "month", "period", "."], "event_mentions": [{"id": "8467620_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "taking", "start": 23, "end": 24}, "arguments": [{"entity_id": "8467620_3_Ent2", "role": "Effect", "text": "non - Hodgkin lymphoma", "start": 5, "end": 9}, {"entity_id": "8467620_3_Ent1", "role": "Subject_Population", "text": "a", "start": 10, "end": 11}, {"entity_id": "8467620_3_Ent0", "role": "Subject", "text": "a patient , with a 30 - year history of rheumatoid arthritis", "start": 10, "end": 22}, {"entity_id": "8467620_3_Ent4", "role": "Treatment_Disorder", "text": "rheumatoid arthritis", "start": 20, "end": 22}, {"entity_id": "8467620_3_Ent8", "role": "Treatment_Dosage", "text": "low dose", "start": 24, "end": 26}, {"entity_id": "8467620_3_Ent3", "role": "Treatment", "text": "low dose methotrexate weekly over a 10 - month period", "start": 24, "end": 34}, {"entity_id": "8467620_3_Ent5", "role": "Treatment_Drug", "text": "methotrexate", "start": 26, "end": 27}, {"entity_id": "8467620_3_Ent6", "role": "Treatment_Freq", "text": "weekly", "start": 27, "end": 28}, {"entity_id": "8467620_3_Ent7", "role": "Treatment_Duration", "text": "10 - month period .", "start": 30, "end": 35}]}], "entity_mentions": [{"id": "8467620_3_Ent2", "text": "non - Hodgkin lymphoma", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8467620_3_Ent1", "text": "a", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8467620_3_Ent0", "text": "a patient , with a 30 - year history of rheumatoid arthritis", "entity_type": "Entity", "start": 10, "end": 22}, {"id": "8467620_3_Ent4", "text": "rheumatoid arthritis", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8467620_3_Ent8", "text": "low dose", "entity_type": "Entity", "start": 24, "end": 26}, {"id": "8467620_3_Ent3", "text": "low dose methotrexate weekly over a 10 - month period", "entity_type": "Entity", "start": 24, "end": 34}, {"id": "8467620_3_Ent5", "text": "methotrexate", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "8467620_3_Ent6", "text": "weekly", "entity_type": "Entity", "start": 27, "end": 28}, {"id": "8467620_3_Ent7", "text": "10 - month period .", "entity_type": "Entity", "start": 30, "end": 35}], "lang": "en"}
{"doc_id": "8503421_1", "wnd_id": "8503421_1_1", "text": "Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .", "tokens": ["Although", "there", "is", "one", "case", "report", "of", "cholesterol", "crystal", "embolization", "following", "t", "-", "PA", "therapy", "with", "only", "extrarenal", "manifestations", "(", "N", "Engl", "J", "Med", "321:1270", ",", "1989", ")", ",", "this", "is", "the", "first", "reported", "case", "of", "atheroembolic", "acute", "renal", "failure", "following", "t", "-", "PA", "therapy", "."], "event_mentions": [{"id": "8503421_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 10, "end": 11}, "arguments": [{"entity_id": "8503421_1_Ent3", "role": "Effect", "text": "cholesterol crystal embolization", "start": 7, "end": 10}, {"entity_id": "8503421_1_Ent5", "role": "Treatment", "text": "t - PA", "start": 11, "end": 14}, {"entity_id": "8503421_1_Ent6", "role": "Treatment_Drug", "text": "t - PA", "start": 11, "end": 14}, {"entity_id": "8503421_1_Ent4", "role": "Effect", "text": "with only extrarenal manifestations", "start": 15, "end": 19}]}, {"id": "8503421_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 40, "end": 41}, "arguments": [{"entity_id": "8503421_1_Ent0", "role": "Effect", "text": "atheroembolic acute renal failure", "start": 36, "end": 40}, {"entity_id": "8503421_1_Ent2", "role": "Treatment_Drug", "text": "t - PA", "start": 41, "end": 44}, {"entity_id": "8503421_1_Ent1", "role": "Treatment", "text": "t - PA therapy", "start": 41, "end": 45}]}], "entity_mentions": [{"id": "8503421_1_Ent3", "text": "cholesterol crystal embolization", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8503421_1_Ent5", "text": "t - PA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8503421_1_Ent6", "text": "t - PA", "entity_type": "Entity", "start": 11, "end": 14}, {"id": "8503421_1_Ent4", "text": "with only extrarenal manifestations", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "8503421_1_Ent0", "text": "atheroembolic acute renal failure", "entity_type": "Entity", "start": 36, "end": 40}, {"id": "8503421_1_Ent2", "text": "t - PA", "entity_type": "Entity", "start": 41, "end": 44}, {"id": "8503421_1_Ent1", "text": "t - PA therapy", "entity_type": "Entity", "start": 41, "end": 45}], "lang": "en"}
{"doc_id": "8503421_3", "wnd_id": "8503421_3_1", "text": "We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .", "tokens": ["We", "report", "the", "occurrence", "of", "renal", "failure", "due", "to", "cholesterol", "crystal", "embolization", "following", "thrombolytic", "therapy", "with", "intravenous", "recombinant", "tissue", "-", "type", "plasminogen", "activator", "(", "t", "-", "PA", ")", "."], "event_mentions": [{"id": "8503421_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurrence", "start": 3, "end": 4}, "arguments": [{"entity_id": "8503421_3_Ent0", "role": "Effect", "text": "renal failure due to cholesterol crystal embolization", "start": 5, "end": 12}, {"entity_id": "8503421_3_Ent1", "role": "Treatment", "text": "thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA )", "start": 13, "end": 28}, {"entity_id": "8503421_3_Ent2", "role": "Treatment_Route", "text": "intravenous", "start": 16, "end": 17}, {"entity_id": "8503421_3_Ent3", "role": "Treatment_Drug", "text": "recombinant tissue - type plasminogen activator", "start": 17, "end": 23}]}], "entity_mentions": [{"id": "8503421_3_Ent0", "text": "renal failure due to cholesterol crystal embolization", "entity_type": "Entity", "start": 5, "end": 12}, {"id": "8503421_3_Ent1", "text": "thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA )", "entity_type": "Entity", "start": 13, "end": 28}, {"id": "8503421_3_Ent2", "text": "intravenous", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "8503421_3_Ent3", "text": "recombinant tissue - type plasminogen activator", "entity_type": "Entity", "start": 17, "end": 23}], "lang": "en"}
{"doc_id": "8513656_10", "wnd_id": "8513656_10_1", "text": "The efficacy of single - dose disulfiram as an inhibitor of human P450 2E1 suggests that this modality for manipulating clinical P450 2E1 activity may provide a useful probe for delineating P450 2E1 participation in human drug biotransformation or for the treatment of poisoning by P450 2E1 - activated toxins .", "tokens": ["The", "efficacy", "of", "single", "-", "dose", "disulfiram", "as", "an", "inhibitor", "of", "human", "P450", "2E1", "suggests", "that", "this", "modality", "for", "manipulating", "clinical", "P450", "2E1", "activity", "may", "provide", "a", "useful", "probe", "for", "delineating", "P450", "2E1", "participation", "in", "human", "drug", "biotransformation", "or", "for", "the", "treatment", "of", "poisoning", "by", "P450", "2E1", "-", "activated", "toxins", "."], "event_mentions": [{"id": "8513656_10_Evt0", "event_type": "Adverse_event", "trigger": {"text": "by", "start": 44, "end": 45}, "arguments": [{"entity_id": "8513656_10_Ent4", "role": "Treatment_Dosage", "text": "single - dose", "start": 3, "end": 6}, {"entity_id": "8513656_10_Ent2", "role": "Treatment_Drug", "text": "disulfiram", "start": 6, "end": 7}, {"entity_id": "8513656_10_Ent0", "role": "Effect", "text": "poisoning", "start": 43, "end": 44}, {"entity_id": "8513656_10_Ent1", "role": "Treatment", "text": "P450 2E1 - activated toxins", "start": 45, "end": 50}, {"entity_id": "8513656_10_Ent3", "role": "Treatment_Drug", "text": "P450 2E1 - activated toxins", "start": 45, "end": 50}]}], "entity_mentions": [{"id": "8513656_10_Ent4", "text": "single - dose", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8513656_10_Ent2", "text": "disulfiram", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8513656_10_Ent0", "text": "poisoning", "entity_type": "Entity", "start": 43, "end": 44}, {"id": "8513656_10_Ent1", "text": "P450 2E1 - activated toxins", "entity_type": "Entity", "start": 45, "end": 50}, {"id": "8513656_10_Ent3", "text": "P450 2E1 - activated toxins", "entity_type": "Entity", "start": 45, "end": 50}], "lang": "en"}
{"doc_id": "8523340_1", "wnd_id": "8523340_1_1", "text": "All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .", "tokens": ["All", "developed", "mucocutaneous", "side", "effects", "within", "20", "weeks", "of", "beginning", "i", "m", "gold", "therapy", ",", "at", "a", "time", "when", "RA", "had", "improved", "markedly", "compared", "to", "pretreatment", "status", "."], "event_mentions": [{"id": "8523340_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "beginning", "start": 9, "end": 10}, "arguments": [{"entity_id": "8523340_1_Ent0", "role": "Effect", "text": "mucocutaneous side effects", "start": 2, "end": 5}, {"entity_id": "8523340_1_Ent4", "role": "Treatment_Time_elapsed", "text": "within 20 weeks", "start": 5, "end": 8}, {"entity_id": "8523340_1_Ent3", "role": "Treatment_Route", "text": "i m", "start": 10, "end": 12}, {"entity_id": "8523340_1_Ent1", "role": "Treatment", "text": "i m gold therapy", "start": 10, "end": 14}, {"entity_id": "8523340_1_Ent2", "role": "Treatment_Drug", "text": "gold", "start": 12, "end": 13}, {"entity_id": "8523340_1_Ent5", "role": "Treatment_Disorder", "text": "RA", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "8523340_1_Ent0", "text": "mucocutaneous side effects", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "8523340_1_Ent4", "text": "within 20 weeks", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8523340_1_Ent3", "text": "i m", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "8523340_1_Ent1", "text": "i m gold therapy", "entity_type": "Entity", "start": 10, "end": 14}, {"id": "8523340_1_Ent2", "text": "gold", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8523340_1_Ent5", "text": "RA", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "8523340_2", "wnd_id": "8523340_2_1", "text": "How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .", "tokens": ["How", "low", "can", "you", "go", "?", "Use", "of", "very", "low", "dosage", "of", "gold", "in", "patients", "with", "mucocutaneous", "reactions", "."], "event_mentions": [{"id": "8523340_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "Use", "start": 6, "end": 7}, "arguments": [{"entity_id": "8523340_2_Ent3", "role": "Treatment_Dosage", "text": "very low dosage", "start": 8, "end": 11}, {"entity_id": "8523340_2_Ent2", "role": "Treatment", "text": "very low dosage of gold", "start": 8, "end": 13}, {"entity_id": "8523340_2_Ent4", "role": "Treatment_Drug", "text": "gold", "start": 12, "end": 13}, {"entity_id": "8523340_2_Ent0", "role": "Subject", "text": "patients with mucocutaneous reactions", "start": 14, "end": 18}, {"entity_id": "8523340_2_Ent1", "role": "Subject_Disorder", "text": "mucocutaneous reactions", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "8523340_2_Ent3", "text": "very low dosage", "entity_type": "Entity", "start": 8, "end": 11}, {"id": "8523340_2_Ent2", "text": "very low dosage of gold", "entity_type": "Entity", "start": 8, "end": 13}, {"id": "8523340_2_Ent4", "text": "gold", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8523340_2_Ent0", "text": "patients with mucocutaneous reactions", "entity_type": "Entity", "start": 14, "end": 18}, {"id": "8523340_2_Ent1", "text": "mucocutaneous reactions", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "8551001_2", "wnd_id": "8551001_2_1", "text": "Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .", "tokens": ["Azathioprine", "-", "induced", "myelosuppression", "due", "to", "thiopurine", "methyltransferase", "deficiency", "in", "a", "patient", "with", "autoimmune", "hepatitis", "."], "event_mentions": [{"id": "8551001_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "8551001_2_Ent2", "role": "Treatment", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "8551001_2_Ent5", "role": "Treatment_Drug", "text": "Azathioprine", "start": 0, "end": 1}, {"entity_id": "8551001_2_Ent1", "role": "Effect", "text": "myelosuppression", "start": 3, "end": 4}, {"entity_id": "8551001_2_Ent3", "role": "Treatment_Disorder", "text": "thiopurine methyltransferase deficiency", "start": 6, "end": 9}, {"entity_id": "8551001_2_Ent0", "role": "Subject", "text": "a patient with autoimmune hepatitis", "start": 10, "end": 15}, {"entity_id": "8551001_2_Ent4", "role": "Treatment_Disorder", "text": "autoimmune hepatitis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "8551001_2_Ent2", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8551001_2_Ent5", "text": "Azathioprine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8551001_2_Ent1", "text": "myelosuppression", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8551001_2_Ent3", "text": "thiopurine methyltransferase deficiency", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8551001_2_Ent0", "text": "a patient with autoimmune hepatitis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "8551001_2_Ent4", "text": "autoimmune hepatitis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "8570441_1", "wnd_id": "8570441_1_1", "text": "Nabumetone - associated interstitial nephritis .", "tokens": ["Nabumetone", "-", "associated", "interstitial", "nephritis", "."], "event_mentions": [{"id": "8570441_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8570441_1_Ent1", "role": "Treatment", "text": "Nabumetone", "start": 0, "end": 1}, {"entity_id": "8570441_1_Ent2", "role": "Treatment_Drug", "text": "Nabumetone", "start": 0, "end": 1}, {"entity_id": "8570441_1_Ent0", "role": "Effect", "text": "interstitial nephritis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "8570441_1_Ent1", "text": "Nabumetone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8570441_1_Ent2", "text": "Nabumetone", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8570441_1_Ent0", "text": "interstitial nephritis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "8597009_4", "wnd_id": "8597009_4_1", "text": "The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .", "tokens": ["The", "wide", "use", "of", "phenytoin", "during", "the", "recent", "tuberculosis", "epidemic", "makes", "it", "imperative", "to", "suspect", "this", "drug", "interaction", "in", "patients", "exhibiting", "clinical", "features", "that", "might", "be", "related", "to", "phenytoin", "toxicity", "."], "event_mentions": [{"id": "8597009_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "suspect", "start": 14, "end": 15}, "arguments": [{"entity_id": "8597009_4_Ent2", "role": "Treatment", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 4, "end": 5}, {"entity_id": "8597009_4_Ent3", "role": "Treatment_Duration", "text": "tuberculosis", "start": 8, "end": 9}, {"entity_id": "8597009_4_Ent0", "role": "Subject", "text": "patients", "start": 19, "end": 20}, {"entity_id": "8597009_4_Ent1", "role": "Effect", "text": "phenytoin toxicity", "start": 28, "end": 30}]}], "entity_mentions": [{"id": "8597009_4_Ent2", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8597009_4_Ent3", "text": "tuberculosis", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8597009_4_Ent0", "text": "patients", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "8597009_4_Ent1", "text": "phenytoin toxicity", "entity_type": "Entity", "start": 28, "end": 30}], "lang": "en"}
{"doc_id": "8604715_4", "wnd_id": "8604715_4_1", "text": "We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .", "tokens": ["We", "present", "a", "patient", "with", "human", "immunodeficiency", "virus", "infection", "under", "treatment", "with", "foscarnet", "for", "CMV", "retinitis", "who", "complained", "of", "thirst", "and", "polyuria", "."], "event_mentions": [{"id": "8604715_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complained", "start": 17, "end": 18}, "arguments": [{"entity_id": "8604715_4_Ent0", "role": "Subject", "text": "a patient with human immunodeficiency virus infection", "start": 2, "end": 9}, {"entity_id": "8604715_4_Ent1", "role": "Subject_Disorder", "text": "human immunodeficiency virus infection", "start": 5, "end": 9}, {"entity_id": "8604715_4_Ent3", "role": "Treatment", "text": "foscarnet", "start": 12, "end": 13}, {"entity_id": "8604715_4_Ent5", "role": "Treatment_Drug", "text": "foscarnet", "start": 12, "end": 13}, {"entity_id": "8604715_4_Ent4", "role": "Treatment_Disorder", "text": "CMV retinitis", "start": 14, "end": 16}, {"entity_id": "8604715_4_Ent2", "role": "Effect", "text": "thirst and polyuria", "start": 19, "end": 22}]}], "entity_mentions": [{"id": "8604715_4_Ent0", "text": "a patient with human immunodeficiency virus infection", "entity_type": "Entity", "start": 2, "end": 9}, {"id": "8604715_4_Ent1", "text": "human immunodeficiency virus infection", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "8604715_4_Ent3", "text": "foscarnet", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8604715_4_Ent5", "text": "foscarnet", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8604715_4_Ent4", "text": "CMV retinitis", "entity_type": "Entity", "start": 14, "end": 16}, {"id": "8604715_4_Ent2", "text": "thirst and polyuria", "entity_type": "Entity", "start": 19, "end": 22}], "lang": "en"}
{"doc_id": "8610807_2", "wnd_id": "8610807_2_1", "text": "CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .", "tokens": ["CONCLUSION", ":", "The", "administration", "of", "tissue", "plasminogen", "activator", "was", "responsible", "for", "the", "large", "extent", "of", "hemorrhage", "and", "should", "be", "considered", "in", "the", "differential", "diagnosis", "of", "hemorrhagic", "choroidal", "detachment", "."], "event_mentions": [{"id": "8610807_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "responsible", "start": 9, "end": 10}, "arguments": [{"entity_id": "8610807_2_Ent1", "role": "Treatment", "text": "tissue plasminogen activator", "start": 5, "end": 8}, {"entity_id": "8610807_2_Ent2", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 5, "end": 8}, {"entity_id": "8610807_2_Ent0", "role": "Effect", "text": "large extent of hemorrhage", "start": 12, "end": 16}]}], "entity_mentions": [{"id": "8610807_2_Ent1", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8610807_2_Ent2", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8610807_2_Ent0", "text": "large extent of hemorrhage", "entity_type": "Entity", "start": 12, "end": 16}], "lang": "en"}
{"doc_id": "8610807_3", "wnd_id": "8610807_3_1", "text": "PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67 - year - old man after a myocardial infarction and administration of tissue plasminogen activator .", "tokens": ["PURPOSE", ":", "To", "determine", "the", "cause", "of", "spontaneous", "choroidal", "hemorrhage", "in", "a", "67", "-", "year", "-", "old", "man", "after", "a", "myocardial", "infarction", "and", "administration", "of", "tissue", "plasminogen", "activator", "."], "event_mentions": [{"id": "8610807_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 10, "end": 11}, "arguments": [{"entity_id": "8610807_3_Ent3", "role": "Effect", "text": "spontaneous choroidal hemorrhage", "start": 7, "end": 10}, {"entity_id": "8610807_3_Ent1", "role": "Subject_Age", "text": "67 - year - old", "start": 12, "end": 17}, {"entity_id": "8610807_3_Ent0", "role": "Subject", "text": "67 - year - old man after a myocardial infarction", "start": 12, "end": 22}, {"entity_id": "8610807_3_Ent2", "role": "Subject_Gender", "text": "man", "start": 17, "end": 18}, {"entity_id": "8610807_3_Ent5", "role": "Treatment_Disorder", "text": "myocardial infarction", "start": 20, "end": 22}, {"entity_id": "8610807_3_Ent4", "role": "Treatment", "text": "tissue plasminogen activator", "start": 25, "end": 28}, {"entity_id": "8610807_3_Ent6", "role": "Treatment_Drug", "text": "tissue plasminogen activator", "start": 25, "end": 28}]}], "entity_mentions": [{"id": "8610807_3_Ent3", "text": "spontaneous choroidal hemorrhage", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "8610807_3_Ent1", "text": "67 - year - old", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "8610807_3_Ent0", "text": "67 - year - old man after a myocardial infarction", "entity_type": "Entity", "start": 12, "end": 22}, {"id": "8610807_3_Ent2", "text": "man", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8610807_3_Ent5", "text": "myocardial infarction", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8610807_3_Ent4", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 25, "end": 28}, {"id": "8610807_3_Ent6", "text": "tissue plasminogen activator", "entity_type": "Entity", "start": 25, "end": 28}], "lang": "en"}
{"doc_id": "8627446_1", "wnd_id": "8627446_1_1", "text": "Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .", "tokens": ["Accelerated", "nodulosis", "during", "methotrexate", "therapy", "for", "juvenile", "rheumatoid", "arthritis", "."], "event_mentions": [{"id": "8627446_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 2, "end": 3}, "arguments": [{"entity_id": "8627446_1_Ent0", "role": "Effect", "text": "Accelerated nodulosis", "start": 0, "end": 2}, {"entity_id": "8627446_1_Ent1", "role": "Treatment", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 3, "end": 4}, {"entity_id": "8627446_1_Ent3", "role": "Treatment_Disorder", "text": "juvenile rheumatoid arthritis", "start": 6, "end": 9}]}], "entity_mentions": [{"id": "8627446_1_Ent0", "text": "Accelerated nodulosis", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8627446_1_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8627446_1_Ent3", "text": "juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 6, "end": 9}], "lang": "en"}
{"doc_id": "8627446_2", "wnd_id": "8627446_2_1", "text": "We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .", "tokens": ["We", "describe", "two", "patients", "with", "rheumatoid", "factor", "-", "positive", ",", "polyarticular", "-", "onset", "juvenile", "rheumatoid", "arthritis", "in", "whom", "accelerated", "nodulosis", "developed", "during", "methotrexate", "therapy", "."], "event_mentions": [{"id": "8627446_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 20, "end": 21}, "arguments": [{"entity_id": "8627446_2_Ent1", "role": "Subject_Population", "text": "two", "start": 2, "end": 3}, {"entity_id": "8627446_2_Ent0", "role": "Subject", "text": "two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "start": 2, "end": 16}, {"entity_id": "8627446_2_Ent5", "role": "Treatment_Disorder", "text": "rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "start": 5, "end": 16}, {"entity_id": "8627446_2_Ent2", "role": "Effect", "text": "accelerated nodulosis", "start": 18, "end": 20}, {"entity_id": "8627446_2_Ent4", "role": "Treatment_Drug", "text": "methotrexate", "start": 22, "end": 23}, {"entity_id": "8627446_2_Ent3", "role": "Treatment", "text": "methotrexate therapy", "start": 22, "end": 24}]}], "entity_mentions": [{"id": "8627446_2_Ent1", "text": "two", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8627446_2_Ent0", "text": "two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 2, "end": 16}, {"id": "8627446_2_Ent5", "text": "rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis", "entity_type": "Entity", "start": 5, "end": 16}, {"id": "8627446_2_Ent2", "text": "accelerated nodulosis", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "8627446_2_Ent4", "text": "methotrexate", "entity_type": "Entity", "start": 22, "end": 23}, {"id": "8627446_2_Ent3", "text": "methotrexate therapy", "entity_type": "Entity", "start": 22, "end": 24}], "lang": "en"}
{"doc_id": "8645078_1", "wnd_id": "8645078_1_1", "text": "A patient with severe cholestatic jaundice induced by captopril is presented .", "tokens": ["A", "patient", "with", "severe", "cholestatic", "jaundice", "induced", "by", "captopril", "is", "presented", "."], "event_mentions": [{"id": "8645078_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 6, "end": 7}, "arguments": [{"entity_id": "8645078_1_Ent0", "role": "Subject", "text": "A patient", "start": 0, "end": 2}, {"entity_id": "8645078_1_Ent1", "role": "Effect", "text": "severe cholestatic jaundice", "start": 3, "end": 6}, {"entity_id": "8645078_1_Ent2", "role": "Treatment", "text": "captopril", "start": 8, "end": 9}, {"entity_id": "8645078_1_Ent3", "role": "Treatment_Drug", "text": "captopril", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8645078_1_Ent0", "text": "A patient", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8645078_1_Ent1", "text": "severe cholestatic jaundice", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "8645078_1_Ent2", "text": "captopril", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8645078_1_Ent3", "text": "captopril", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8645078_2", "wnd_id": "8645078_2_1", "text": "Captopril - associated \" pseudocholangitis ' .", "tokens": ["Captopril", "-", "associated", "\"", "pseudocholangitis", "'", "."], "event_mentions": [{"id": "8645078_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "8645078_2_Ent1", "role": "Treatment", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8645078_2_Ent2", "role": "Treatment_Drug", "text": "Captopril", "start": 0, "end": 1}, {"entity_id": "8645078_2_Ent0", "role": "Effect", "text": "pseudocholangitis", "start": 4, "end": 5}]}], "entity_mentions": [{"id": "8645078_2_Ent1", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_2_Ent2", "text": "Captopril", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8645078_2_Ent0", "text": "pseudocholangitis", "entity_type": "Entity", "start": 4, "end": 5}], "lang": "en"}
{"doc_id": "8651254_2", "wnd_id": "8651254_2_1", "text": "It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .", "tokens": ["It", "should", "be", "emphasized", "that", "the", "recurrence", "of", "nephrotic", "syndrome", "was", "observed", "after", "the", "following", "chemotherapy", ",", "including", "M", "-", "CSF", ",", "whereas", "the", "bone", "marrow", "still", "remained", "completely", "remitted", "."], "event_mentions": [{"id": "8651254_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 12, "end": 13}, "arguments": [{"entity_id": "8651254_2_Ent0", "role": "Effect", "text": "nephrotic syndrome", "start": 8, "end": 10}, {"entity_id": "8651254_2_Ent2", "role": "Treatment", "text": "chemotherapy , including M - CSF", "start": 15, "end": 21}, {"entity_id": "8651254_2_Ent3", "role": "Treatment_Drug", "text": "M - CSF", "start": 18, "end": 21}, {"entity_id": "8651254_2_Ent1", "role": "Effect", "text": "the bone marrow still remained completely remitted", "start": 23, "end": 30}]}], "entity_mentions": [{"id": "8651254_2_Ent0", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8651254_2_Ent2", "text": "chemotherapy , including M - CSF", "entity_type": "Entity", "start": 15, "end": 21}, {"id": "8651254_2_Ent3", "text": "M - CSF", "entity_type": "Entity", "start": 18, "end": 21}, {"id": "8651254_2_Ent1", "text": "the bone marrow still remained completely remitted", "entity_type": "Entity", "start": 23, "end": 30}], "lang": "en"}
{"doc_id": "8651254_3", "wnd_id": "8651254_3_1", "text": "The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .", "tokens": ["The", "possibility", "can", "be", "raised", "that", "M", "-", "CSF", "accelerated", "the", "underlying", "renal", "disease", "in", "this", "case", "through", "enhancing", "macrophage", "accumulation", "into", "the", "glomerulus", ",", "leading", "to", "the", "development", "of", "nephrotic", "syndrome", "."], "event_mentions": [{"id": "8651254_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "accelerated", "start": 9, "end": 10}, "arguments": [{"entity_id": "8651254_3_Ent1", "role": "Treatment", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent2", "role": "Treatment_Drug", "text": "M - CSF", "start": 6, "end": 9}, {"entity_id": "8651254_3_Ent0", "role": "Effect", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "start": 11, "end": 32}]}], "entity_mentions": [{"id": "8651254_3_Ent1", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent2", "text": "M - CSF", "entity_type": "Entity", "start": 6, "end": 9}, {"id": "8651254_3_Ent0", "text": "underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 32}], "lang": "en"}
{"doc_id": "8651254_5", "wnd_id": "8651254_5_1", "text": "We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .", "tokens": ["We", "describe", "a", "patient", "with", "acute", "myeloblastic", "leukemia", "(", "AML", ")", "who", "developed", "nephrotic", "syndrome", "after", "receiving", "several", "courses", "of", "chemotherapy", ",", "including", "macrophage", "-", "colony", "-", "stimulating", "factor", "(", "M", "-", "CSF", ")", "."], "event_mentions": [{"id": "8651254_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 15, "end": 16}, "arguments": [{"entity_id": "8651254_5_Ent0", "role": "Subject", "text": "a patient with acute myeloblastic leukemia ( AML )", "start": 2, "end": 11}, {"entity_id": "8651254_5_Ent3", "role": "Treatment_Disorder", "text": "acute myeloblastic leukemia", "start": 5, "end": 8}, {"entity_id": "8651254_5_Ent1", "role": "Effect", "text": "nephrotic syndrome", "start": 13, "end": 15}, {"entity_id": "8651254_5_Ent2", "role": "Treatment", "text": "several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF )", "start": 17, "end": 34}, {"entity_id": "8651254_5_Ent5", "role": "Treatment_Route", "text": "chemotherapy", "start": 20, "end": 21}, {"entity_id": "8651254_5_Ent4", "role": "Treatment_Drug", "text": "macrophage - colony - stimulating factor", "start": 23, "end": 29}]}], "entity_mentions": [{"id": "8651254_5_Ent0", "text": "a patient with acute myeloblastic leukemia ( AML )", "entity_type": "Entity", "start": 2, "end": 11}, {"id": "8651254_5_Ent3", "text": "acute myeloblastic leukemia", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "8651254_5_Ent1", "text": "nephrotic syndrome", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "8651254_5_Ent2", "text": "several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF )", "entity_type": "Entity", "start": 17, "end": 34}, {"id": "8651254_5_Ent5", "text": "chemotherapy", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8651254_5_Ent4", "text": "macrophage - colony - stimulating factor", "entity_type": "Entity", "start": 23, "end": 29}], "lang": "en"}
{"doc_id": "8672829_2", "wnd_id": "8672829_2_1", "text": "CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .", "tokens": ["CONCLUSIONS", ":", "There", "was", "a", "temporal", "relationship", "between", "the", "onset", "of", "nonconvulsive", "status", "epilepticus", "and", "initiation", "of", "ifosfamide", "infusion", "."], "event_mentions": [{"id": "8672829_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "relationship", "start": 6, "end": 7}, "arguments": [{"entity_id": "8672829_2_Ent0", "role": "Effect", "text": "onset of nonconvulsive status epilepticus", "start": 9, "end": 14}, {"entity_id": "8672829_2_Ent1", "role": "Treatment", "text": "initiation of ifosfamide infusion", "start": 15, "end": 19}, {"entity_id": "8672829_2_Ent2", "role": "Treatment_Drug", "text": "ifosfamide", "start": 17, "end": 18}, {"entity_id": "8672829_2_Ent3", "role": "Treatment_Route", "text": "infusion", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "8672829_2_Ent0", "text": "onset of nonconvulsive status epilepticus", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "8672829_2_Ent1", "text": "initiation of ifosfamide infusion", "entity_type": "Entity", "start": 15, "end": 19}, {"id": "8672829_2_Ent2", "text": "ifosfamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "8672829_2_Ent3", "text": "infusion", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "868978_2", "wnd_id": "868978_2_1", "text": "The ocular motor disturbances are probably an expression of regional 5 - FU neurotoxicity primarily affecting the brain stem .", "tokens": ["The", "ocular", "motor", "disturbances", "are", "probably", "an", "expression", "of", "regional", "5", "-", "FU", "neurotoxicity", "primarily", "affecting", "the", "brain", "stem", "."], "event_mentions": [{"id": "868978_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "expression", "start": 7, "end": 8}, "arguments": [{"entity_id": "868978_2_Ent0", "role": "Effect", "text": "The ocular motor disturbances", "start": 0, "end": 4}, {"entity_id": "868978_2_Ent2", "role": "Treatment", "text": "5 - FU", "start": 10, "end": 13}, {"entity_id": "868978_2_Ent3", "role": "Treatment_Drug", "text": "5 - FU", "start": 10, "end": 13}, {"entity_id": "868978_2_Ent1", "role": "Effect", "text": "neurotoxicity", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "868978_2_Ent0", "text": "The ocular motor disturbances", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "868978_2_Ent2", "text": "5 - FU", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "868978_2_Ent3", "text": "5 - FU", "entity_type": "Entity", "start": 10, "end": 13}, {"id": "868978_2_Ent1", "text": "neurotoxicity", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "8700794_3", "wnd_id": "8700794_3_1", "text": "When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .", "tokens": ["When", "vague", "symptoms", "develop", "during", "desmopressin", "therapy", ",", "hyponatremia", "must", "be", "considered", "as", "part", "of", "the", "differential", "diagnosis", "."], "event_mentions": [{"id": "8700794_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "during", "start": 4, "end": 5}, "arguments": [{"entity_id": "8700794_3_Ent0", "role": "Effect", "text": "vague symptoms", "start": 1, "end": 3}, {"entity_id": "8700794_3_Ent2", "role": "Treatment", "text": "desmopressin", "start": 5, "end": 6}, {"entity_id": "8700794_3_Ent3", "role": "Treatment_Drug", "text": "desmopressin", "start": 5, "end": 6}, {"entity_id": "8700794_3_Ent1", "role": "Effect", "text": "hyponatremia", "start": 8, "end": 9}]}], "entity_mentions": [{"id": "8700794_3_Ent0", "text": "vague symptoms", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8700794_3_Ent2", "text": "desmopressin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8700794_3_Ent3", "text": "desmopressin", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "8700794_3_Ent1", "text": "hyponatremia", "entity_type": "Entity", "start": 8, "end": 9}], "lang": "en"}
{"doc_id": "8739289_3", "wnd_id": "8739289_3_1", "text": "The association of central diabetes insipidus ( CDI ) with lithium use is rare .", "tokens": ["The", "association", "of", "central", "diabetes", "insipidus", "(", "CDI", ")", "with", "lithium", "use", "is", "rare", "."], "event_mentions": [{"id": "8739289_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "association", "start": 1, "end": 2}, "arguments": [{"entity_id": "8739289_3_Ent0", "role": "Effect", "text": "central diabetes insipidus ( CDI )", "start": 3, "end": 9}, {"entity_id": "8739289_3_Ent1", "role": "Treatment", "text": "lithium", "start": 10, "end": 11}, {"entity_id": "8739289_3_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "8739289_3_Ent0", "text": "central diabetes insipidus ( CDI )", "entity_type": "Entity", "start": 3, "end": 9}, {"id": "8739289_3_Ent1", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8739289_3_Ent2", "text": "lithium", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "8739289_5", "wnd_id": "8739289_5_1", "text": "To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .", "tokens": ["To", "the", "best", "of", "our", "knowledge", ",", "this", "is", "the", "first", "case", "of", "lithium", "-", "associated", "CDI", "and", "NDI", "presenting", "concurrently", "."], "event_mentions": [{"id": "8739289_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 15, "end": 16}, "arguments": [{"entity_id": "8739289_5_Ent1", "role": "Treatment", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_5_Ent2", "role": "Treatment_Drug", "text": "lithium", "start": 13, "end": 14}, {"entity_id": "8739289_5_Ent0", "role": "Effect", "text": "CDI and NDI", "start": 16, "end": 19}]}], "entity_mentions": [{"id": "8739289_5_Ent1", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_5_Ent2", "text": "lithium", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8739289_5_Ent0", "text": "CDI and NDI", "entity_type": "Entity", "start": 16, "end": 19}], "lang": "en"}
{"doc_id": "8749646_3", "wnd_id": "8749646_3_1", "text": "The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .", "tokens": ["The", "renal", "insufficiency", "of", "three", "patients", "and", "the", "timing", "of", "the", "seizures", "implicate", "accumulation", "of", "ofloxacin", "as", "a", "contributing", "factor", "."], "event_mentions": [{"id": "8749646_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "implicate", "start": 12, "end": 13}, "arguments": [{"entity_id": "8749646_3_Ent2", "role": "Effect", "text": "renal insufficiency", "start": 1, "end": 3}, {"entity_id": "8749646_3_Ent1", "role": "Subject_Population", "text": "three", "start": 4, "end": 5}, {"entity_id": "8749646_3_Ent0", "role": "Subject", "text": "three patients", "start": 4, "end": 6}, {"entity_id": "8749646_3_Ent3", "role": "Effect", "text": "seizures", "start": 11, "end": 12}, {"entity_id": "8749646_3_Ent4", "role": "Treatment", "text": "accumulation of ofloxacin", "start": 13, "end": 16}, {"entity_id": "8749646_3_Ent5", "role": "Treatment_Drug", "text": "ofloxacin", "start": 15, "end": 16}]}], "entity_mentions": [{"id": "8749646_3_Ent2", "text": "renal insufficiency", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "8749646_3_Ent1", "text": "three", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8749646_3_Ent0", "text": "three patients", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8749646_3_Ent3", "text": "seizures", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8749646_3_Ent4", "text": "accumulation of ofloxacin", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "8749646_3_Ent5", "text": "ofloxacin", "entity_type": "Entity", "start": 15, "end": 16}], "lang": "en"}
{"doc_id": "8749646_4", "wnd_id": "8749646_4_1", "text": "We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .", "tokens": ["We", "describe", "four", "patients", "who", "had", "seizures", "while", "receiving", "ofloxacin", ";", "no", "other", "causes", "were", "evident", "."], "event_mentions": [{"id": "8749646_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 8, "end": 9}, "arguments": [{"entity_id": "8749646_4_Ent1", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "8749646_4_Ent0", "role": "Subject", "text": "four patients", "start": 2, "end": 4}, {"entity_id": "8749646_4_Ent2", "role": "Effect", "text": "seizures", "start": 6, "end": 7}, {"entity_id": "8749646_4_Ent3", "role": "Treatment", "text": "ofloxacin", "start": 9, "end": 10}, {"entity_id": "8749646_4_Ent4", "role": "Treatment_Drug", "text": "ofloxacin", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8749646_4_Ent1", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8749646_4_Ent0", "text": "four patients", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8749646_4_Ent2", "text": "seizures", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8749646_4_Ent3", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8749646_4_Ent4", "text": "ofloxacin", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8771575_5", "wnd_id": "8771575_5_1", "text": "We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .", "tokens": ["We", "present", "a", "case", "of", "respiratory", "failure", "occurring", "in", "a", "woman", "at", "16", "weeks", "'", "gestation", "who", "was", "being", "treated", "with", "nitrofurantoin", "for", "a", "urinary", "tract", "infection", "."], "event_mentions": [{"id": "8771575_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 7, "end": 8}, "arguments": [{"entity_id": "8771575_5_Ent3", "role": "Effect", "text": "respiratory failure", "start": 5, "end": 7}, {"entity_id": "8771575_5_Ent0", "role": "Subject", "text": "a woman at 16 weeks ' gestation", "start": 9, "end": 16}, {"entity_id": "8771575_5_Ent1", "role": "Subject_Gender", "text": "woman", "start": 10, "end": 11}, {"entity_id": "8771575_5_Ent2", "role": "Subject_Disorder", "text": "16 weeks ' gestation", "start": 12, "end": 16}, {"entity_id": "8771575_5_Ent4", "role": "Treatment", "text": "being treated with nitrofurantoin for a urinary tract infection", "start": 18, "end": 27}, {"entity_id": "8771575_5_Ent5", "role": "Treatment_Drug", "text": "nitrofurantoin", "start": 21, "end": 22}, {"entity_id": "8771575_5_Ent6", "role": "Treatment_Disorder", "text": "urinary tract infection", "start": 24, "end": 27}]}], "entity_mentions": [{"id": "8771575_5_Ent3", "text": "respiratory failure", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "8771575_5_Ent0", "text": "a woman at 16 weeks ' gestation", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "8771575_5_Ent1", "text": "woman", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "8771575_5_Ent2", "text": "16 weeks ' gestation", "entity_type": "Entity", "start": 12, "end": 16}, {"id": "8771575_5_Ent4", "text": "being treated with nitrofurantoin for a urinary tract infection", "entity_type": "Entity", "start": 18, "end": 27}, {"id": "8771575_5_Ent5", "text": "nitrofurantoin", "entity_type": "Entity", "start": 21, "end": 22}, {"id": "8771575_5_Ent6", "text": "urinary tract infection", "entity_type": "Entity", "start": 24, "end": 27}], "lang": "en"}
{"doc_id": "8792511_2", "wnd_id": "8792511_2_1", "text": "Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .", "tokens": ["Methemoglobinemia", "is", "another", "common", "finding", "among", "patients", "receiving", "dapsone", "therapy", ",", "but", "rarely", "does", "it", "result", "in", "prominent", "symptoms", "other", "than", "transient", "pallor", "."], "event_mentions": [{"id": "8792511_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "receiving", "start": 7, "end": 8}, "arguments": [{"entity_id": "8792511_2_Ent1", "role": "Effect", "text": "Methemoglobinemia", "start": 0, "end": 1}, {"entity_id": "8792511_2_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "8792511_2_Ent4", "role": "Treatment_Drug", "text": "dapsone", "start": 8, "end": 9}, {"entity_id": "8792511_2_Ent3", "role": "Treatment", "text": "dapsone therapy", "start": 8, "end": 10}, {"entity_id": "8792511_2_Ent2", "role": "Effect", "text": "transient pallor", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "8792511_2_Ent1", "text": "Methemoglobinemia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8792511_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8792511_2_Ent4", "text": "dapsone", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8792511_2_Ent3", "text": "dapsone therapy", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8792511_2_Ent2", "text": "transient pallor", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "879939_2", "wnd_id": "879939_2_1", "text": "Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .", "tokens": ["Severe", "osteomalacia", "was", "present", "in", "two", "epileptic", "patients", "who", "were", "under", "long", "-", "term", "treatment", "with", "congeners", "of", "phenytoin", ",", "phenobarbital", ",", "and", "acetazolamide", "."], "event_mentions": [{"id": "879939_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "present", "start": 3, "end": 4}, "arguments": [{"entity_id": "879939_2_Ent2", "role": "Effect", "text": "osteomalacia", "start": 1, "end": 2}, {"entity_id": "879939_2_Ent1", "role": "Subject_Population", "text": "two", "start": 5, "end": 6}, {"entity_id": "879939_2_Ent0", "role": "Subject", "text": "two epileptic patients", "start": 5, "end": 8}, {"entity_id": "879939_2_Ent4", "role": "Treatment_Disorder", "text": "epileptic", "start": 6, "end": 7}, {"entity_id": "879939_2_Ent3", "role": "Treatment", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "start": 11, "end": 24}, {"entity_id": "879939_2_Ent5", "role": "Treatment_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent8", "role": "Combination_Drug", "text": "phenytoin", "start": 18, "end": 19}, {"entity_id": "879939_2_Ent6", "role": "Treatment_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent9", "role": "Combination_Drug", "text": "phenobarbital", "start": 20, "end": 21}, {"entity_id": "879939_2_Ent7", "role": "Treatment_Drug", "text": "acetazolamide", "start": 23, "end": 24}, {"entity_id": "879939_2_Ent10", "role": "Combination_Drug", "text": "acetazolamide", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "879939_2_Ent2", "text": "osteomalacia", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "879939_2_Ent1", "text": "two", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "879939_2_Ent0", "text": "two epileptic patients", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "879939_2_Ent4", "text": "epileptic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "879939_2_Ent3", "text": "long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide", "entity_type": "Entity", "start": 11, "end": 24}, {"id": "879939_2_Ent5", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent8", "text": "phenytoin", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "879939_2_Ent6", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent9", "text": "phenobarbital", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "879939_2_Ent7", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "879939_2_Ent10", "text": "acetazolamide", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "8832451_1", "wnd_id": "8832451_1_1", "text": "A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .", "tokens": ["A", "noninvasive", "method", "in", "the", "differential", "diagnosis", "of", "vecuronium", "-", "induced", "and", "magnesium", "-", "induced", "protracted", "neuromuscular", "block", "in", "a", "severely", "preeclamptic", "patient", "."], "event_mentions": [{"id": "8832451_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 10, "end": 11}, "arguments": [{"entity_id": "8832451_1_Ent3", "role": "Treatment", "text": "vecuronium", "start": 8, "end": 9}, {"entity_id": "8832451_1_Ent4", "role": "Treatment_Drug", "text": "vecuronium", "start": 8, "end": 9}, {"entity_id": "8832451_1_Ent2", "role": "Effect", "text": "protracted neuromuscular block", "start": 15, "end": 18}, {"entity_id": "8832451_1_Ent1", "role": "Subject_Disorder", "text": "severely preeclamptic", "start": 20, "end": 22}, {"entity_id": "8832451_1_Ent0", "role": "Subject", "text": "severely preeclamptic patient", "start": 20, "end": 23}]}, {"id": "8832451_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "8832451_1_Ent8", "role": "Treatment", "text": "magnesium", "start": 12, "end": 13}, {"entity_id": "8832451_1_Ent9", "role": "Treatment_Drug", "text": "magnesium", "start": 12, "end": 13}, {"entity_id": "8832451_1_Ent7", "role": "Effect", "text": "protracted neuromuscular block", "start": 15, "end": 18}, {"entity_id": "8832451_1_Ent6", "role": "Subject_Disorder", "text": "severely preeclamptic", "start": 20, "end": 22}, {"entity_id": "8832451_1_Ent5", "role": "Subject", "text": "severely preeclamptic patient", "start": 20, "end": 23}]}], "entity_mentions": [{"id": "8832451_1_Ent3", "text": "vecuronium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8832451_1_Ent4", "text": "vecuronium", "entity_type": "Entity", "start": 8, "end": 9}, {"id": "8832451_1_Ent8", "text": "magnesium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8832451_1_Ent9", "text": "magnesium", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "8832451_1_Ent2", "text": "protracted neuromuscular block", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8832451_1_Ent7", "text": "protracted neuromuscular block", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "8832451_1_Ent1", "text": "severely preeclamptic", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8832451_1_Ent6", "text": "severely preeclamptic", "entity_type": "Entity", "start": 20, "end": 22}, {"id": "8832451_1_Ent0", "text": "severely preeclamptic patient", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "8832451_1_Ent5", "text": "severely preeclamptic patient", "entity_type": "Entity", "start": 20, "end": 23}], "lang": "en"}
{"doc_id": "8862924_1", "wnd_id": "8862924_1_1", "text": "Keratitis in methamphetamine abusers .", "tokens": ["Keratitis", "in", "methamphetamine", "abusers", "."], "event_mentions": [{"id": "8862924_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 1, "end": 2}, "arguments": [{"entity_id": "8862924_1_Ent0", "role": "Effect", "text": "Keratitis", "start": 0, "end": 1}, {"entity_id": "8862924_1_Ent2", "role": "Treatment_Drug", "text": "methamphetamine", "start": 2, "end": 3}, {"entity_id": "8862924_1_Ent1", "role": "Treatment", "text": "methamphetamine abusers", "start": 2, "end": 4}]}], "entity_mentions": [{"id": "8862924_1_Ent0", "text": "Keratitis", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "8862924_1_Ent2", "text": "methamphetamine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8862924_1_Ent1", "text": "methamphetamine abusers", "entity_type": "Entity", "start": 2, "end": 4}], "lang": "en"}
{"doc_id": "8862924_2", "wnd_id": "8862924_2_1", "text": "Methamphetamine 's extensive physiologic effects , inconsistent street purity , and multiple routes of administration offer many possibilities for injury to the cornea .", "tokens": ["Methamphetamine", "'s", "extensive", "physiologic", "effects", ",", "inconsistent", "street", "purity", ",", "and", "multiple", "routes", "of", "administration", "offer", "many", "possibilities", "for", "injury", "to", "the", "cornea", "."], "event_mentions": [{"id": "8862924_2_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "offer", "start": 15, "end": 16}, "arguments": [{"entity_id": "8862924_2_Ent0", "role": "Treatment", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent2", "role": "Treatment_Drug", "text": "Methamphetamine 's", "start": 0, "end": 2}, {"entity_id": "8862924_2_Ent1", "role": "Treatment_Disorder", "text": "injury to the cornea", "start": 19, "end": 23}]}], "entity_mentions": [{"id": "8862924_2_Ent0", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent2", "text": "Methamphetamine 's", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "8862924_2_Ent1", "text": "injury to the cornea", "entity_type": "Entity", "start": 19, "end": 23}], "lang": "en"}
{"doc_id": "8862924_3", "wnd_id": "8862924_3_1", "text": "Potential causes of methamphetamine - related keratitis can be divided into four categories resulting from ( a ) direct pharmacologic and physical effects of methamphetamine ; ( b ) the toxic effects of diluting or \" cutting \" agents such as lidocaine and quinine ; ( c ) effects related to the route of drug administration ( intravenous , inhalation , smoking ) ; and ( d ) manufacture - related effects of exposure to unintentional caustic contaminants in the final product .", "tokens": ["Potential", "causes", "of", "methamphetamine", "-", "related", "keratitis", "can", "be", "divided", "into", "four", "categories", "resulting", "from", "(", "a", ")", "direct", "pharmacologic", "and", "physical", "effects", "of", "methamphetamine", ";", "(", "b", ")", "the", "toxic", "effects", "of", "diluting", "or", "\"", "cutting", "\"", "agents", "such", "as", "lidocaine", "and", "quinine", ";", "(", "c", ")", "effects", "related", "to", "the", "route", "of", "drug", "administration", "(", "intravenous", ",", "inhalation", ",", "smoking", ")", ";", "and", "(", "d", ")", "manufacture", "-", "related", "effects", "of", "exposure", "to", "unintentional", "caustic", "contaminants", "in", "the", "final", "product", "."], "event_mentions": [{"id": "8862924_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 5, "end": 6}, "arguments": [{"entity_id": "8862924_3_Ent1", "role": "Treatment", "text": "methamphetamine", "start": 3, "end": 4}, {"entity_id": "8862924_3_Ent2", "role": "Treatment_Drug", "text": "methamphetamine", "start": 3, "end": 4}, {"entity_id": "8862924_3_Ent0", "role": "Effect", "text": "keratitis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "8862924_3_Ent1", "text": "methamphetamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8862924_3_Ent2", "text": "methamphetamine", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "8862924_3_Ent0", "text": "keratitis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "8862924_4", "wnd_id": "8862924_4_1", "text": "The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of methamphetamine - related keratitis .", "tokens": ["The", "increasing", "prevalence", "of", "methamphetamine", "abuse", "and", "the", "severity", "of", "the", "associated", "ulcers", "should", "alert", "ophthalmologists", "to", "the", "problem", "of", "methamphetamine", "-", "related", "keratitis", "."], "event_mentions": [{"id": "8862924_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 22, "end": 23}, "arguments": [{"entity_id": "8862924_4_Ent4", "role": "Treatment_Drug", "text": "methamphetamine", "start": 4, "end": 5}, {"entity_id": "8862924_4_Ent2", "role": "Treatment", "text": "methamphetamine abuse", "start": 4, "end": 6}, {"entity_id": "8862924_4_Ent0", "role": "Effect", "text": "associated ulcers", "start": 11, "end": 13}, {"entity_id": "8862924_4_Ent3", "role": "Treatment", "text": "methamphetamine", "start": 20, "end": 21}, {"entity_id": "8862924_4_Ent5", "role": "Treatment_Drug", "text": "methamphetamine", "start": 20, "end": 21}, {"entity_id": "8862924_4_Ent1", "role": "Effect", "text": "keratitis", "start": 23, "end": 24}]}], "entity_mentions": [{"id": "8862924_4_Ent4", "text": "methamphetamine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8862924_4_Ent2", "text": "methamphetamine abuse", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "8862924_4_Ent0", "text": "associated ulcers", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "8862924_4_Ent3", "text": "methamphetamine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8862924_4_Ent5", "text": "methamphetamine", "entity_type": "Entity", "start": 20, "end": 21}, {"id": "8862924_4_Ent1", "text": "keratitis", "entity_type": "Entity", "start": 23, "end": 24}], "lang": "en"}
{"doc_id": "8862924_5", "wnd_id": "8862924_5_1", "text": "We report four cases of severe corneal ulceration in methamphetamine abusers .", "tokens": ["We", "report", "four", "cases", "of", "severe", "corneal", "ulceration", "in", "methamphetamine", "abusers", "."], "event_mentions": [{"id": "8862924_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 8, "end": 9}, "arguments": [{"entity_id": "8862924_5_Ent1", "role": "Subject_Population", "text": "four", "start": 2, "end": 3}, {"entity_id": "8862924_5_Ent0", "role": "Subject", "text": "four cases", "start": 2, "end": 4}, {"entity_id": "8862924_5_Ent2", "role": "Effect", "text": "corneal ulceration", "start": 6, "end": 8}, {"entity_id": "8862924_5_Ent3", "role": "Treatment", "text": "methamphetamine", "start": 9, "end": 10}, {"entity_id": "8862924_5_Ent4", "role": "Treatment_Drug", "text": "methamphetamine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8862924_5_Ent1", "text": "four", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8862924_5_Ent0", "text": "four cases", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "8862924_5_Ent2", "text": "corneal ulceration", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "8862924_5_Ent3", "text": "methamphetamine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8862924_5_Ent4", "text": "methamphetamine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8864370_1", "wnd_id": "8864370_1_1", "text": "BACKGROUND : Methotrexate ( MTX ) may induce liver damage , which in some psoriatics will lead to fibrosis or cirrhosis .", "tokens": ["BACKGROUND", ":", "Methotrexate", "(", "MTX", ")", "may", "induce", "liver", "damage", ",", "which", "in", "some", "psoriatics", "will", "lead", "to", "fibrosis", "or", "cirrhosis", "."], "event_mentions": [{"id": "8864370_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 7, "end": 8}, "arguments": [{"entity_id": "8864370_1_Ent2", "role": "Treatment_Drug", "text": "Methotrexate", "start": 2, "end": 3}, {"entity_id": "8864370_1_Ent1", "role": "Treatment", "text": "Methotrexate ( MTX )", "start": 2, "end": 6}, {"entity_id": "8864370_1_Ent0", "role": "Effect", "text": "liver damage , which in some psoriatics will lead to fibrosis or cirrhosis", "start": 8, "end": 21}, {"entity_id": "8864370_1_Ent3", "role": "Treatment_Disorder", "text": "psoriatics", "start": 14, "end": 15}]}], "entity_mentions": [{"id": "8864370_1_Ent2", "text": "Methotrexate", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "8864370_1_Ent1", "text": "Methotrexate ( MTX )", "entity_type": "Entity", "start": 2, "end": 6}, {"id": "8864370_1_Ent0", "text": "liver damage , which in some psoriatics will lead to fibrosis or cirrhosis", "entity_type": "Entity", "start": 8, "end": 21}, {"id": "8864370_1_Ent3", "text": "psoriatics", "entity_type": "Entity", "start": 14, "end": 15}], "lang": "en"}
{"doc_id": "889156_1", "wnd_id": "889156_1_1", "text": "The use of beclomethasone diproprionate inhaler complicated by the development of an eosinophilic pneumonia reaction .", "tokens": ["The", "use", "of", "beclomethasone", "diproprionate", "inhaler", "complicated", "by", "the", "development", "of", "an", "eosinophilic", "pneumonia", "reaction", "."], "event_mentions": [{"id": "889156_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 9, "end": 10}, "arguments": [{"entity_id": "889156_1_Ent3", "role": "Treatment_Drug", "text": "beclomethasone diproprionate", "start": 3, "end": 5}, {"entity_id": "889156_1_Ent1", "role": "Treatment", "text": "beclomethasone diproprionate inhaler", "start": 3, "end": 6}, {"entity_id": "889156_1_Ent2", "role": "Treatment_Route", "text": "inhaler", "start": 5, "end": 6}, {"entity_id": "889156_1_Ent0", "role": "Effect", "text": "eosinophilic pneumonia reaction", "start": 12, "end": 15}]}], "entity_mentions": [{"id": "889156_1_Ent3", "text": "beclomethasone diproprionate", "entity_type": "Entity", "start": 3, "end": 5}, {"id": "889156_1_Ent1", "text": "beclomethasone diproprionate inhaler", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "889156_1_Ent2", "text": "inhaler", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "889156_1_Ent0", "text": "eosinophilic pneumonia reaction", "entity_type": "Entity", "start": 12, "end": 15}], "lang": "en"}
{"doc_id": "8912599_6", "wnd_id": "8912599_6_1", "text": "Erosion of psoriatic plaques : an early sign of methotrexate toxicity .", "tokens": ["Erosion", "of", "psoriatic", "plaques", ":", "an", "early", "sign", "of", "methotrexate", "toxicity", "."], "event_mentions": [{"id": "8912599_6_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 8, "end": 9}, "arguments": [{"entity_id": "8912599_6_Ent0", "role": "Effect", "text": "Erosion of psoriatic plaques", "start": 0, "end": 4}, {"entity_id": "8912599_6_Ent1", "role": "Treatment", "text": "methotrexate", "start": 9, "end": 10}, {"entity_id": "8912599_6_Ent2", "role": "Treatment_Drug", "text": "methotrexate", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "8912599_6_Ent0", "text": "Erosion of psoriatic plaques", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "8912599_6_Ent1", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "8912599_6_Ent2", "text": "methotrexate", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "8936932_1", "wnd_id": "8936932_1_1", "text": "Acute esmolol toxicity may be self - limiting because of its extremely short half - life .", "tokens": ["Acute", "esmolol", "toxicity", "may", "be", "self", "-", "limiting", "because", "of", "its", "extremely", "short", "half", "-", "life", "."], "event_mentions": [{"id": "8936932_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "be", "start": 4, "end": 5}, "arguments": [{"entity_id": "8936932_1_Ent1", "role": "Treatment", "text": "esmolol", "start": 1, "end": 2}, {"entity_id": "8936932_1_Ent2", "role": "Treatment_Drug", "text": "esmolol", "start": 1, "end": 2}, {"entity_id": "8936932_1_Ent0", "role": "Effect", "text": "toxicity", "start": 2, "end": 3}]}], "entity_mentions": [{"id": "8936932_1_Ent1", "text": "esmolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8936932_1_Ent2", "text": "esmolol", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "8936932_1_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 2, "end": 3}], "lang": "en"}
{"doc_id": "8949576_1", "wnd_id": "8949576_1_1", "text": "A potential role for renal and hepatic impairment in the observed protracted course of amiodarone - induced thyrotoxicosis is suggested .", "tokens": ["A", "potential", "role", "for", "renal", "and", "hepatic", "impairment", "in", "the", "observed", "protracted", "course", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "is", "suggested", "."], "event_mentions": [{"id": "8949576_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 16, "end": 17}, "arguments": [{"entity_id": "8949576_1_Ent1", "role": "Treatment", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 14, "end": 15}, {"entity_id": "8949576_1_Ent0", "role": "Effect", "text": "thyrotoxicosis", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "8949576_1_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "8949576_1_Ent0", "text": "thyrotoxicosis", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "8949576_2", "wnd_id": "8949576_2_1", "text": "Failure of plasmapheresis , corticosteroids and thionamides to ameliorate a case of protracted amiodarone - induced thyroiditis .", "tokens": ["Failure", "of", "plasmapheresis", ",", "corticosteroids", "and", "thionamides", "to", "ameliorate", "a", "case", "of", "protracted", "amiodarone", "-", "induced", "thyroiditis", "."], "event_mentions": [{"id": "8949576_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "ameliorate", "start": 8, "end": 9}, "arguments": [{"entity_id": "8949576_2_Ent3", "role": "Treatment", "text": "plasmapheresis , corticosteroids and thionamides", "start": 2, "end": 7}, {"entity_id": "8949576_2_Ent5", "role": "Treatment_Drug", "text": "corticosteroids", "start": 4, "end": 5}, {"entity_id": "8949576_2_Ent6", "role": "Treatment_Drug", "text": "thionamides", "start": 6, "end": 7}, {"entity_id": "8949576_2_Ent4", "role": "Treatment_Disorder", "text": "amiodarone - induced thyroiditis", "start": 13, "end": 17}]}, {"id": "8949576_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "8949576_2_Ent1", "role": "Treatment", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "8949576_2_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "8949576_2_Ent0", "role": "Effect", "text": "thyroiditis", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "8949576_2_Ent3", "text": "plasmapheresis , corticosteroids and thionamides", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "8949576_2_Ent5", "text": "corticosteroids", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "8949576_2_Ent6", "text": "thionamides", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "8949576_2_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8949576_2_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "8949576_2_Ent4", "text": "amiodarone - induced thyroiditis", "entity_type": "Entity", "start": 13, "end": 17}, {"id": "8949576_2_Ent0", "text": "thyroiditis", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "897744_1", "wnd_id": "897744_1_1", "text": "Focal glomerulonephritis and interstitial nephritis in methicillin - treated , heroin - related infective endocarditis .", "tokens": ["Focal", "glomerulonephritis", "and", "interstitial", "nephritis", "in", "methicillin", "-", "treated", ",", "heroin", "-", "related", "infective", "endocarditis", "."], "event_mentions": [{"id": "897744_1_Evt1", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 8, "end": 9}, "arguments": [{"entity_id": "897744_1_Ent3", "role": "Effect", "text": "Focal glomerulonephritis and interstitial nephritis", "start": 0, "end": 5}, {"entity_id": "897744_1_Ent4", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent6", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "897744_1_Ent5", "role": "Treatment_Disorder", "text": "heroin - related infective endocarditis", "start": 10, "end": 15}]}, {"id": "897744_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 12, "end": 13}, "arguments": [{"entity_id": "897744_1_Ent1", "role": "Treatment", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent2", "role": "Treatment_Drug", "text": "heroin", "start": 10, "end": 11}, {"entity_id": "897744_1_Ent0", "role": "Effect", "text": "infective endocarditis", "start": 13, "end": 15}]}], "entity_mentions": [{"id": "897744_1_Ent3", "text": "Focal glomerulonephritis and interstitial nephritis", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "897744_1_Ent4", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent6", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "897744_1_Ent1", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent2", "text": "heroin", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "897744_1_Ent5", "text": "heroin - related infective endocarditis", "entity_type": "Entity", "start": 10, "end": 15}, {"id": "897744_1_Ent0", "text": "infective endocarditis", "entity_type": "Entity", "start": 13, "end": 15}], "lang": "en"}
{"doc_id": "8979664_1", "wnd_id": "8979664_1_1", "text": "METHODS / RESULTS : This paper presents a new case of rifabutin uveitis and a review of the various published reports to date .", "tokens": ["METHODS", "/", "RESULTS", ":", "This", "paper", "presents", "a", "new", "case", "of", "rifabutin", "uveitis", "and", "a", "review", "of", "the", "various", "published", "reports", "to", "date", "."], "event_mentions": [{"id": "8979664_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presents", "start": 6, "end": 7}, "arguments": [{"entity_id": "8979664_1_Ent0", "role": "Subject", "text": "new case", "start": 8, "end": 10}, {"entity_id": "8979664_1_Ent2", "role": "Treatment", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "8979664_1_Ent3", "role": "Treatment_Drug", "text": "rifabutin", "start": 11, "end": 12}, {"entity_id": "8979664_1_Ent1", "role": "Effect", "text": "uveitis", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "8979664_1_Ent0", "text": "new case", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "8979664_1_Ent2", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8979664_1_Ent3", "text": "rifabutin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "8979664_1_Ent1", "text": "uveitis", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9013348_2", "wnd_id": "9013348_2_1", "text": "Mesalamine - induced hypersensitivity pneumonitis .", "tokens": ["Mesalamine", "-", "induced", "hypersensitivity", "pneumonitis", "."], "event_mentions": [{"id": "9013348_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9013348_2_Ent1", "role": "Treatment", "text": "Mesalamine", "start": 0, "end": 1}, {"entity_id": "9013348_2_Ent2", "role": "Treatment_Drug", "text": "Mesalamine", "start": 0, "end": 1}, {"entity_id": "9013348_2_Ent0", "role": "Effect", "text": "hypersensitivity pneumonitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9013348_2_Ent1", "text": "Mesalamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9013348_2_Ent2", "text": "Mesalamine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9013348_2_Ent0", "text": "hypersensitivity pneumonitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9017913_1", "wnd_id": "9017913_1_1", "text": "Immunosuppression elicited by the extensive administration of prednisolone was suspected for the initiation of the generalized mite infestation .", "tokens": ["Immunosuppression", "elicited", "by", "the", "extensive", "administration", "of", "prednisolone", "was", "suspected", "for", "the", "initiation", "of", "the", "generalized", "mite", "infestation", "."], "event_mentions": [{"id": "9017913_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "generalized", "start": 15, "end": 16}, "arguments": [{"entity_id": "9017913_1_Ent1", "role": "Treatment", "text": "extensive administration of prednisolone", "start": 4, "end": 8}, {"entity_id": "9017913_1_Ent2", "role": "Treatment_Drug", "text": "prednisolone", "start": 7, "end": 8}, {"entity_id": "9017913_1_Ent0", "role": "Effect", "text": "mite infestation", "start": 16, "end": 18}]}], "entity_mentions": [{"id": "9017913_1_Ent1", "text": "extensive administration of prednisolone", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9017913_1_Ent2", "text": "prednisolone", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9017913_1_Ent0", "text": "mite infestation", "entity_type": "Entity", "start": 16, "end": 18}], "lang": "en"}
{"doc_id": "9022114_3", "wnd_id": "9022114_3_1", "text": "Delay of corneal wound healing in patients treated with colchicine .", "tokens": ["Delay", "of", "corneal", "wound", "healing", "in", "patients", "treated", "with", "colchicine", "."], "event_mentions": [{"id": "9022114_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "treated", "start": 7, "end": 8}, "arguments": [{"entity_id": "9022114_3_Ent1", "role": "Effect", "text": "Delay of corneal wound healing", "start": 0, "end": 5}, {"entity_id": "9022114_3_Ent0", "role": "Subject", "text": "patients", "start": 6, "end": 7}, {"entity_id": "9022114_3_Ent2", "role": "Treatment", "text": "colchicine", "start": 9, "end": 10}, {"entity_id": "9022114_3_Ent3", "role": "Treatment_Drug", "text": "colchicine", "start": 9, "end": 10}]}], "entity_mentions": [{"id": "9022114_3_Ent1", "text": "Delay of corneal wound healing", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9022114_3_Ent0", "text": "patients", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9022114_3_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9022114_3_Ent3", "text": "colchicine", "entity_type": "Entity", "start": 9, "end": 10}], "lang": "en"}
{"doc_id": "9022114_5", "wnd_id": "9022114_5_1", "text": "The authors suggest that in patients with corneal ulcers refractory to conventional treatment who are receiving colchicine , cessation of colchicine therapy should be considered .", "tokens": ["The", "authors", "suggest", "that", "in", "patients", "with", "corneal", "ulcers", "refractory", "to", "conventional", "treatment", "who", "are", "receiving", "colchicine", ",", "cessation", "of", "colchicine", "therapy", "should", "be", "considered", "."], "event_mentions": [{"id": "9022114_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "receiving", "start": 15, "end": 16}, "arguments": [{"entity_id": "9022114_5_Ent0", "role": "Subject", "text": "patients with corneal ulcers", "start": 5, "end": 9}, {"entity_id": "9022114_5_Ent3", "role": "Treatment_Disorder", "text": "corneal ulcers", "start": 7, "end": 9}, {"entity_id": "9022114_5_Ent1", "role": "Treatment", "text": "colchicine", "start": 16, "end": 17}, {"entity_id": "9022114_5_Ent2", "role": "Treatment_Drug", "text": "colchicine", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "9022114_5_Ent0", "text": "patients with corneal ulcers", "entity_type": "Entity", "start": 5, "end": 9}, {"id": "9022114_5_Ent3", "text": "corneal ulcers", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9022114_5_Ent1", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9022114_5_Ent2", "text": "colchicine", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "910864_1", "wnd_id": "910864_1_1", "text": "In one instance a systemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of acetohexamide for acetazolamide .", "tokens": ["In", "one", "instance", "a", "systemic", "hypoglycemic", "reaction", "resulting", "in", "head", "trauma", "and", "confusion", "ended", "in", "an", "emegency", "hospital", "admission", "following", "the", "substitution", "of", "acetohexamide", "for", "acetazolamide", "."], "event_mentions": [{"id": "910864_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "following", "start": 19, "end": 20}, "arguments": [{"entity_id": "910864_1_Ent0", "role": "Effect", "text": "systemic hypoglycemic reaction resulting in head trauma and confusion", "start": 4, "end": 13}, {"entity_id": "910864_1_Ent1", "role": "Treatment", "text": "acetohexamide", "start": 23, "end": 24}, {"entity_id": "910864_1_Ent2", "role": "Treatment_Drug", "text": "acetohexamide", "start": 23, "end": 24}, {"entity_id": "910864_1_Ent3", "role": "Treatment_Drug", "text": "acetazolamide", "start": 25, "end": 26}]}], "entity_mentions": [{"id": "910864_1_Ent0", "text": "systemic hypoglycemic reaction resulting in head trauma and confusion", "entity_type": "Entity", "start": 4, "end": 13}, {"id": "910864_1_Ent1", "text": "acetohexamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "910864_1_Ent2", "text": "acetohexamide", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "910864_1_Ent3", "text": "acetazolamide", "entity_type": "Entity", "start": 25, "end": 26}], "lang": "en"}
{"doc_id": "9149614_3", "wnd_id": "9149614_3_1", "text": "The probable proarrhythmic action of amiodarone , although rare , is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy .", "tokens": ["The", "probable", "proarrhythmic", "action", "of", "amiodarone", ",", "although", "rare", ",", "is", "reviewed", "along", "with", "a", "discussion", "of", "the", "novel", "use", "of", "intravenous", "magnesium", "sulfate", "therapy", "."], "event_mentions": [{"id": "9149614_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "action", "start": 3, "end": 4}, "arguments": [{"entity_id": "9149614_3_Ent0", "role": "Effect", "text": "proarrhythmic", "start": 2, "end": 3}, {"entity_id": "9149614_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 5, "end": 6}, {"entity_id": "9149614_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 5, "end": 6}]}], "entity_mentions": [{"id": "9149614_3_Ent0", "text": "proarrhythmic", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9149614_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9149614_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 5, "end": 6}], "lang": "en"}
{"doc_id": "9161656_1", "wnd_id": "9161656_1_1", "text": "Acute asthma associated with sustained - release verapamil .", "tokens": ["Acute", "asthma", "associated", "with", "sustained", "-", "release", "verapamil", "."], "event_mentions": [{"id": "9161656_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9161656_1_Ent0", "role": "Effect", "text": "Acute asthma", "start": 0, "end": 2}, {"entity_id": "9161656_1_Ent1", "role": "Treatment", "text": "sustained - release verapamil", "start": 4, "end": 8}, {"entity_id": "9161656_1_Ent2", "role": "Treatment_Drug", "text": "sustained - release verapamil", "start": 4, "end": 8}]}], "entity_mentions": [{"id": "9161656_1_Ent0", "text": "Acute asthma", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9161656_1_Ent1", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "9161656_1_Ent2", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 4, "end": 8}], "lang": "en"}
{"doc_id": "9161656_2", "wnd_id": "9161656_2_1", "text": "OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an acute asthma attack after receiving sustained - release verapamil .", "tokens": ["OBJECTIVE", ":", "To", "describe", "a", "patient", "with", "asymptomatic", "bronchial", "asthma", "and", "hypertension", "who", "developed", "an", "acute", "asthma", "attack", "after", "receiving", "sustained", "-", "release", "verapamil", "."], "event_mentions": [{"id": "9161656_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 18, "end": 19}, "arguments": [{"entity_id": "9161656_2_Ent0", "role": "Subject", "text": "a patient with asymptomatic bronchial asthma and hypertension", "start": 4, "end": 12}, {"entity_id": "9161656_2_Ent1", "role": "Subject_Disorder", "text": "asymptomatic bronchial asthma", "start": 7, "end": 10}, {"entity_id": "9161656_2_Ent4", "role": "Treatment_Disorder", "text": "hypertension", "start": 11, "end": 12}, {"entity_id": "9161656_2_Ent2", "role": "Effect", "text": "acute asthma attack", "start": 15, "end": 18}, {"entity_id": "9161656_2_Ent3", "role": "Treatment", "text": "sustained - release verapamil", "start": 20, "end": 24}, {"entity_id": "9161656_2_Ent5", "role": "Treatment_Drug", "text": "sustained - release verapamil", "start": 20, "end": 24}]}], "entity_mentions": [{"id": "9161656_2_Ent0", "text": "a patient with asymptomatic bronchial asthma and hypertension", "entity_type": "Entity", "start": 4, "end": 12}, {"id": "9161656_2_Ent1", "text": "asymptomatic bronchial asthma", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9161656_2_Ent4", "text": "hypertension", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9161656_2_Ent2", "text": "acute asthma attack", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "9161656_2_Ent3", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 20, "end": 24}, {"id": "9161656_2_Ent5", "text": "sustained - release verapamil", "entity_type": "Entity", "start": 20, "end": 24}], "lang": "en"}
{"doc_id": "9177620_1", "wnd_id": "9177620_1_1", "text": "A possible case of carbamazepine induced pancreatitis .", "tokens": ["A", "possible", "case", "of", "carbamazepine", "induced", "pancreatitis", "."], "event_mentions": [{"id": "9177620_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 5, "end": 6}, "arguments": [{"entity_id": "9177620_1_Ent0", "role": "Subject", "text": "A possible case", "start": 0, "end": 3}, {"entity_id": "9177620_1_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 4, "end": 5}, {"entity_id": "9177620_1_Ent3", "role": "Treatment_Drug", "text": "carbamazepine", "start": 4, "end": 5}, {"entity_id": "9177620_1_Ent1", "role": "Effect", "text": "pancreatitis", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9177620_1_Ent0", "text": "A possible case", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9177620_1_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9177620_1_Ent3", "text": "carbamazepine", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9177620_1_Ent1", "text": "pancreatitis", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9177620_2", "wnd_id": "9177620_2_1", "text": "The authors report a case of acute pancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( CBZ ) for post - traumatic petit mal epilepsy , and review the current literature of drug - induced AP .", "tokens": ["The", "authors", "report", "a", "case", "of", "acute", "pancreatitis", "(", "AP", ")", "occurring", "in", "a", "patient", "under", "treatment", "with", "carbamazepine", "(", "CBZ", ")", "for", "post", "-", "traumatic", "petit", "mal", "epilepsy", ",", "and", "review", "the", "current", "literature", "of", "drug", "-", "induced", "AP", "."], "event_mentions": [{"id": "9177620_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "occurring", "start": 11, "end": 12}, "arguments": [{"entity_id": "9177620_2_Ent1", "role": "Effect", "text": "acute pancreatitis", "start": 6, "end": 8}, {"entity_id": "9177620_2_Ent0", "role": "Subject", "text": "a patient", "start": 13, "end": 15}, {"entity_id": "9177620_2_Ent2", "role": "Treatment", "text": "carbamazepine", "start": 18, "end": 19}, {"entity_id": "9177620_2_Ent4", "role": "Treatment_Drug", "text": "carbamazepine", "start": 18, "end": 19}, {"entity_id": "9177620_2_Ent3", "role": "Treatment_Disorder", "text": "post - traumatic petit mal epilepsy", "start": 23, "end": 29}]}], "entity_mentions": [{"id": "9177620_2_Ent1", "text": "acute pancreatitis", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9177620_2_Ent0", "text": "a patient", "entity_type": "Entity", "start": 13, "end": 15}, {"id": "9177620_2_Ent2", "text": "carbamazepine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9177620_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9177620_2_Ent3", "text": "post - traumatic petit mal epilepsy", "entity_type": "Entity", "start": 23, "end": 29}], "lang": "en"}
{"doc_id": "9205466_1", "wnd_id": "9205466_1_1", "text": "Although its side effects are few , tamoxifen increases the incidence of proliferative lesions of the endometrium , which theoretically should be preventable with progestational agents .", "tokens": ["Although", "its", "side", "effects", "are", "few", ",", "tamoxifen", "increases", "the", "incidence", "of", "proliferative", "lesions", "of", "the", "endometrium", ",", "which", "theoretically", "should", "be", "preventable", "with", "progestational", "agents", "."], "event_mentions": [{"id": "9205466_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "increases", "start": 8, "end": 9}, "arguments": [{"entity_id": "9205466_1_Ent1", "role": "Treatment", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "9205466_1_Ent2", "role": "Treatment_Drug", "text": "tamoxifen", "start": 7, "end": 8}, {"entity_id": "9205466_1_Ent0", "role": "Effect", "text": "incidence of proliferative lesions of the endometrium", "start": 10, "end": 17}]}], "entity_mentions": [{"id": "9205466_1_Ent1", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9205466_1_Ent2", "text": "tamoxifen", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9205466_1_Ent0", "text": "incidence of proliferative lesions of the endometrium", "entity_type": "Entity", "start": 10, "end": 17}], "lang": "en"}
{"doc_id": "9211543_1", "wnd_id": "9211543_1_1", "text": "Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer .", "tokens": ["Bleomycin", "and", "cyclophosphamide", "toxicity", "simulating", "metastatic", "nodules", "to", "the", "lungs", "in", "childhood", "cancer", "."], "event_mentions": [{"id": "9211543_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "simulating", "start": 4, "end": 5}, "arguments": [{"entity_id": "9211543_1_Ent5", "role": "Treatment_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "9211543_1_Ent8", "role": "Combination_Drug", "text": "Bleomycin", "start": 0, "end": 1}, {"entity_id": "9211543_1_Ent3", "role": "Treatment", "text": "Bleomycin and cyclophosphamide toxicity", "start": 0, "end": 4}, {"entity_id": "9211543_1_Ent6", "role": "Treatment_Drug", "text": "cyclophosphamide", "start": 2, "end": 3}, {"entity_id": "9211543_1_Ent7", "role": "Combination_Drug", "text": "cyclophosphamide", "start": 2, "end": 3}, {"entity_id": "9211543_1_Ent2", "role": "Effect", "text": "metastatic nodules to the lungs", "start": 5, "end": 10}, {"entity_id": "9211543_1_Ent1", "role": "Subject_Age", "text": "childhood", "start": 11, "end": 12}, {"entity_id": "9211543_1_Ent0", "role": "Subject", "text": "childhood cancer", "start": 11, "end": 13}, {"entity_id": "9211543_1_Ent4", "role": "Treatment_Disorder", "text": "cancer", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9211543_1_Ent5", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9211543_1_Ent8", "text": "Bleomycin", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9211543_1_Ent3", "text": "Bleomycin and cyclophosphamide toxicity", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9211543_1_Ent6", "text": "cyclophosphamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9211543_1_Ent7", "text": "cyclophosphamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9211543_1_Ent2", "text": "metastatic nodules to the lungs", "entity_type": "Entity", "start": 5, "end": 10}, {"id": "9211543_1_Ent1", "text": "childhood", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9211543_1_Ent0", "text": "childhood cancer", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9211543_1_Ent4", "text": "cancer", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9215418_1", "wnd_id": "9215418_1_1", "text": "Clinical signs of hypermagnesemia are an uncommon complication following oral administration of magnesium sulfate .", "tokens": ["Clinical", "signs", "of", "hypermagnesemia", "are", "an", "uncommon", "complication", "following", "oral", "administration", "of", "magnesium", "sulfate", "."], "event_mentions": [{"id": "9215418_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 7, "end": 8}, "arguments": [{"entity_id": "9215418_1_Ent0", "role": "Effect", "text": "hypermagnesemia", "start": 3, "end": 4}, {"entity_id": "9215418_1_Ent3", "role": "Treatment_Route", "text": "oral", "start": 9, "end": 10}, {"entity_id": "9215418_1_Ent1", "role": "Treatment", "text": "oral administration of magnesium sulfate", "start": 9, "end": 14}, {"entity_id": "9215418_1_Ent2", "role": "Treatment_Drug", "text": "magnesium sulfate", "start": 12, "end": 14}]}], "entity_mentions": [{"id": "9215418_1_Ent0", "text": "hypermagnesemia", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9215418_1_Ent3", "text": "oral", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9215418_1_Ent1", "text": "oral administration of magnesium sulfate", "entity_type": "Entity", "start": 9, "end": 14}, {"id": "9215418_1_Ent2", "text": "magnesium sulfate", "entity_type": "Entity", "start": 12, "end": 14}], "lang": "en"}
{"doc_id": "9224230_1", "wnd_id": "9224230_1_1", "text": "These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients died of PCP occurring during the first month of treatment with prednisone .", "tokens": ["These", "cases", "were", "considered", "unusual", "in", "light", "of", "the", "short", "delay", "of", "their", "onset", "after", "initiation", "of", "immunosuppressive", "therapy", "and", "their", "fulminant", "course", ":", "3", "of", "these", "patients", "died", "of", "PCP", "occurring", "during", "the", "first", "month", "of", "treatment", "with", "prednisone", "."], "event_mentions": [{"id": "9224230_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "died", "start": 28, "end": 29}, "arguments": [{"entity_id": "9224230_1_Ent1", "role": "Subject_Population", "text": "3", "start": 24, "end": 25}, {"entity_id": "9224230_1_Ent0", "role": "Subject", "text": "3 of these patients", "start": 24, "end": 28}, {"entity_id": "9224230_1_Ent2", "role": "Effect", "text": "PCP", "start": 30, "end": 31}, {"entity_id": "9224230_1_Ent4", "role": "Treatment_Duration", "text": "first month", "start": 34, "end": 36}, {"entity_id": "9224230_1_Ent3", "role": "Treatment", "text": "first month of treatment with prednisone", "start": 34, "end": 40}, {"entity_id": "9224230_1_Ent5", "role": "Treatment_Drug", "text": "prednisone", "start": 39, "end": 40}]}], "entity_mentions": [{"id": "9224230_1_Ent1", "text": "3", "entity_type": "Entity", "start": 24, "end": 25}, {"id": "9224230_1_Ent0", "text": "3 of these patients", "entity_type": "Entity", "start": 24, "end": 28}, {"id": "9224230_1_Ent2", "text": "PCP", "entity_type": "Entity", "start": 30, "end": 31}, {"id": "9224230_1_Ent4", "text": "first month", "entity_type": "Entity", "start": 34, "end": 36}, {"id": "9224230_1_Ent3", "text": "first month of treatment with prednisone", "entity_type": "Entity", "start": 34, "end": 40}, {"id": "9224230_1_Ent5", "text": "prednisone", "entity_type": "Entity", "start": 39, "end": 40}], "lang": "en"}
{"doc_id": "9247841_1", "wnd_id": "9247841_1_1", "text": "Propylthiouracil - induced cutaneous vasculitis .", "tokens": ["Propylthiouracil", "-", "induced", "cutaneous", "vasculitis", "."], "event_mentions": [{"id": "9247841_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 2, "end": 3}, "arguments": [{"entity_id": "9247841_1_Ent1", "role": "Treatment", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "9247841_1_Ent2", "role": "Treatment_Drug", "text": "Propylthiouracil", "start": 0, "end": 1}, {"entity_id": "9247841_1_Ent0", "role": "Effect", "text": "cutaneous vasculitis", "start": 3, "end": 5}]}], "entity_mentions": [{"id": "9247841_1_Ent1", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9247841_1_Ent2", "text": "Propylthiouracil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9247841_1_Ent0", "text": "cutaneous vasculitis", "entity_type": "Entity", "start": 3, "end": 5}], "lang": "en"}
{"doc_id": "9253492_2", "wnd_id": "9253492_2_1", "text": "Children receiving zonisamide should be monitored for oligohidrosis and the development of neurological symptoms associated with an elevation of body temperature .", "tokens": ["Children", "receiving", "zonisamide", "should", "be", "monitored", "for", "oligohidrosis", "and", "the", "development", "of", "neurological", "symptoms", "associated", "with", "an", "elevation", "of", "body", "temperature", "."], "event_mentions": [{"id": "9253492_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "monitored", "start": 5, "end": 6}, "arguments": [{"entity_id": "9253492_2_Ent0", "role": "Subject", "text": "Children", "start": 0, "end": 1}, {"entity_id": "9253492_2_Ent1", "role": "Subject_Age", "text": "Children", "start": 0, "end": 1}, {"entity_id": "9253492_2_Ent4", "role": "Treatment", "text": "zonisamide", "start": 2, "end": 3}, {"entity_id": "9253492_2_Ent5", "role": "Treatment_Drug", "text": "zonisamide", "start": 2, "end": 3}, {"entity_id": "9253492_2_Ent2", "role": "Effect", "text": "oligohidrosis", "start": 7, "end": 8}, {"entity_id": "9253492_2_Ent3", "role": "Effect", "text": "development of neurological symptoms associated", "start": 10, "end": 15}]}], "entity_mentions": [{"id": "9253492_2_Ent0", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9253492_2_Ent1", "text": "Children", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9253492_2_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9253492_2_Ent5", "text": "zonisamide", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9253492_2_Ent2", "text": "oligohidrosis", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9253492_2_Ent3", "text": "development of neurological symptoms associated", "entity_type": "Entity", "start": 10, "end": 15}], "lang": "en"}
{"doc_id": "9253492_3", "wnd_id": "9253492_3_1", "text": "Heat stroke - like episode in a child caused by zonisamide .", "tokens": ["Heat", "stroke", "-", "like", "episode", "in", "a", "child", "caused", "by", "zonisamide", "."], "event_mentions": [{"id": "9253492_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "caused", "start": 8, "end": 9}, "arguments": [{"entity_id": "9253492_3_Ent2", "role": "Effect", "text": "Heat stroke - like episode", "start": 0, "end": 5}, {"entity_id": "9253492_3_Ent0", "role": "Subject", "text": "a child", "start": 6, "end": 8}, {"entity_id": "9253492_3_Ent1", "role": "Subject_Age", "text": "child", "start": 7, "end": 8}, {"entity_id": "9253492_3_Ent3", "role": "Treatment", "text": "zonisamide", "start": 10, "end": 11}, {"entity_id": "9253492_3_Ent4", "role": "Treatment_Drug", "text": "zonisamide", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9253492_3_Ent2", "text": "Heat stroke - like episode", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9253492_3_Ent0", "text": "a child", "entity_type": "Entity", "start": 6, "end": 8}, {"id": "9253492_3_Ent1", "text": "child", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9253492_3_Ent3", "text": "zonisamide", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9253492_3_Ent4", "text": "zonisamide", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9256906_2", "wnd_id": "9256906_2_1", "text": "Acute renal failure should be recognized as a potential complication of suramin treatment .", "tokens": ["Acute", "renal", "failure", "should", "be", "recognized", "as", "a", "potential", "complication", "of", "suramin", "treatment", "."], "event_mentions": [{"id": "9256906_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "complication", "start": 9, "end": 10}, "arguments": [{"entity_id": "9256906_2_Ent0", "role": "Effect", "text": "Acute renal failure", "start": 0, "end": 3}, {"entity_id": "9256906_2_Ent2", "role": "Treatment_Drug", "text": "suramin", "start": 11, "end": 12}, {"entity_id": "9256906_2_Ent1", "role": "Treatment", "text": "suramin treatment", "start": 11, "end": 13}]}], "entity_mentions": [{"id": "9256906_2_Ent0", "text": "Acute renal failure", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9256906_2_Ent2", "text": "suramin", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9256906_2_Ent1", "text": "suramin treatment", "entity_type": "Entity", "start": 11, "end": 13}], "lang": "en"}
{"doc_id": "9279731_1", "wnd_id": "9279731_1_1", "text": "When the disease recurred conventional amphotericin B was used again , but had to be stopped because of severe side effects .", "tokens": ["When", "the", "disease", "recurred", "conventional", "amphotericin", "B", "was", "used", "again", ",", "but", "had", "to", "be", "stopped", "because", "of", "severe", "side", "effects", "."], "event_mentions": [{"id": "9279731_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "of", "start": 17, "end": 18}, "arguments": [{"entity_id": "9279731_1_Ent1", "role": "Treatment", "text": "amphotericin B", "start": 5, "end": 7}, {"entity_id": "9279731_1_Ent2", "role": "Treatment_Drug", "text": "amphotericin B", "start": 5, "end": 7}, {"entity_id": "9279731_1_Ent0", "role": "Effect", "text": "side effects", "start": 19, "end": 21}]}], "entity_mentions": [{"id": "9279731_1_Ent1", "text": "amphotericin B", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9279731_1_Ent2", "text": "amphotericin B", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9279731_1_Ent0", "text": "side effects", "entity_type": "Entity", "start": 19, "end": 21}], "lang": "en"}
{"doc_id": "9302445_1", "wnd_id": "9302445_1_1", "text": "CONCLUSION : We believe this to be the first reported case of rhGH - induced hypercalcemia in an HIV - infected patient .", "tokens": ["CONCLUSION", ":", "We", "believe", "this", "to", "be", "the", "first", "reported", "case", "of", "rhGH", "-", "induced", "hypercalcemia", "in", "an", "HIV", "-", "infected", "patient", "."], "event_mentions": [{"id": "9302445_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9302445_1_Ent2", "role": "Treatment", "text": "rhGH", "start": 12, "end": 13}, {"entity_id": "9302445_1_Ent3", "role": "Treatment_Drug", "text": "rhGH", "start": 12, "end": 13}, {"entity_id": "9302445_1_Ent1", "role": "Effect", "text": "hypercalcemia", "start": 15, "end": 16}, {"entity_id": "9302445_1_Ent0", "role": "Subject", "text": "an HIV - infected patient", "start": 17, "end": 22}, {"entity_id": "9302445_1_Ent4", "role": "Treatment_Disorder", "text": "HIV", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9302445_1_Ent2", "text": "rhGH", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9302445_1_Ent3", "text": "rhGH", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9302445_1_Ent1", "text": "hypercalcemia", "entity_type": "Entity", "start": 15, "end": 16}, {"id": "9302445_1_Ent0", "text": "an HIV - infected patient", "entity_type": "Entity", "start": 17, "end": 22}, {"id": "9302445_1_Ent4", "text": "HIV", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9347384_2", "wnd_id": "9347384_2_1", "text": "During clarithromycin coadministration , four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and ataxia , which resolved within 5 days after clarithromycin discontinuation .", "tokens": ["During", "clarithromycin", "coadministration", ",", "four", "out", "of", "the", "seven", "patients", "developed", "moderate", "-", "to", "-", "severe", "toxic", "symptoms", "of", "carbamazepine", ",", "such", "as", "drowsiness", ",", "dizziness", ",", "and", "ataxia", ",", "which", "resolved", "within", "5", "days", "after", "clarithromycin", "discontinuation", "."], "event_mentions": [{"id": "9347384_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 10, "end": 11}, "arguments": [{"entity_id": "9347384_2_Ent5", "role": "Treatment_Time_elapsed", "text": "During", "start": 0, "end": 1}, {"entity_id": "9347384_2_Ent3", "role": "Treatment", "text": "During clarithromycin coadministration", "start": 0, "end": 3}, {"entity_id": "9347384_2_Ent6", "role": "Treatment_Drug", "text": "clarithromycin", "start": 1, "end": 2}, {"entity_id": "9347384_2_Ent8", "role": "Combination_Drug", "text": "clarithromycin", "start": 1, "end": 2}, {"entity_id": "9347384_2_Ent1", "role": "Subject_Population", "text": "four out of the seven", "start": 4, "end": 9}, {"entity_id": "9347384_2_Ent0", "role": "Subject", "text": "four out of the seven patients", "start": 4, "end": 10}, {"entity_id": "9347384_2_Ent2", "role": "Effect", "text": "moderate - to - severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and ataxia", "start": 11, "end": 29}, {"entity_id": "9347384_2_Ent4", "role": "Treatment", "text": "carbamazepine", "start": 19, "end": 20}, {"entity_id": "9347384_2_Ent7", "role": "Treatment_Drug", "text": "carbamazepine", "start": 19, "end": 20}, {"entity_id": "9347384_2_Ent9", "role": "Combination_Drug", "text": "carbamazepine", "start": 19, "end": 20}]}, {"id": "9347384_2_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "resolved", "start": 31, "end": 32}, "arguments": [{"entity_id": "9347384_2_Ent12", "role": "Treatment_Disorder", "text": "moderate - to - severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and ataxia", "start": 11, "end": 29}, {"entity_id": "9347384_2_Ent10", "role": "Treatment", "text": "5 days after clarithromycin discontinuation", "start": 33, "end": 38}, {"entity_id": "9347384_2_Ent11", "role": "Treatment_Drug", "text": "clarithromycin", "start": 36, "end": 37}]}], "entity_mentions": [{"id": "9347384_2_Ent5", "text": "During", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9347384_2_Ent3", "text": "During clarithromycin coadministration", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9347384_2_Ent6", "text": "clarithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9347384_2_Ent8", "text": "clarithromycin", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9347384_2_Ent1", "text": "four out of the seven", "entity_type": "Entity", "start": 4, "end": 9}, {"id": "9347384_2_Ent0", "text": "four out of the seven patients", "entity_type": "Entity", "start": 4, "end": 10}, {"id": "9347384_2_Ent2", "text": "moderate - to - severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and ataxia", "entity_type": "Entity", "start": 11, "end": 29}, {"id": "9347384_2_Ent12", "text": "moderate - to - severe toxic symptoms of carbamazepine , such as drowsiness , dizziness , and ataxia", "entity_type": "Entity", "start": 11, "end": 29}, {"id": "9347384_2_Ent4", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9347384_2_Ent7", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9347384_2_Ent9", "text": "carbamazepine", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9347384_2_Ent10", "text": "5 days after clarithromycin discontinuation", "entity_type": "Entity", "start": 33, "end": 38}, {"id": "9347384_2_Ent11", "text": "clarithromycin", "entity_type": "Entity", "start": 36, "end": 37}], "lang": "en"}
{"doc_id": "9352164_2", "wnd_id": "9352164_2_1", "text": "As far as we know , this is the first case report of acute hemorrhagic gastritis associated with AZ intoxication .", "tokens": ["As", "far", "as", "we", "know", ",", "this", "is", "the", "first", "case", "report", "of", "acute", "hemorrhagic", "gastritis", "associated", "with", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 16, "end": 17}, "arguments": [{"entity_id": "9352164_2_Ent0", "role": "Effect", "text": "acute hemorrhagic gastritis", "start": 13, "end": 16}, {"entity_id": "9352164_2_Ent2", "role": "Treatment", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_2_Ent3", "role": "Treatment_Drug", "text": "AZ", "start": 18, "end": 19}, {"entity_id": "9352164_2_Ent1", "role": "Effect", "text": "AZ intoxication", "start": 18, "end": 20}]}], "entity_mentions": [{"id": "9352164_2_Ent0", "text": "acute hemorrhagic gastritis", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9352164_2_Ent2", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_2_Ent3", "text": "AZ", "entity_type": "Entity", "start": 18, "end": 19}, {"id": "9352164_2_Ent1", "text": "AZ intoxication", "entity_type": "Entity", "start": 18, "end": 20}], "lang": "en"}
{"doc_id": "9352164_3", "wnd_id": "9352164_3_1", "text": "She was thus diagnosed as having AZ intoxication .", "tokens": ["She", "was", "thus", "diagnosed", "as", "having", "AZ", "intoxication", "."], "event_mentions": [{"id": "9352164_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "having", "start": 5, "end": 6}, "arguments": [{"entity_id": "9352164_3_Ent0", "role": "Subject", "text": "She", "start": 0, "end": 1}, {"entity_id": "9352164_3_Ent1", "role": "Subject_Gender", "text": "She", "start": 0, "end": 1}, {"entity_id": "9352164_3_Ent3", "role": "Treatment", "text": "AZ", "start": 6, "end": 7}, {"entity_id": "9352164_3_Ent4", "role": "Treatment_Drug", "text": "AZ", "start": 6, "end": 7}, {"entity_id": "9352164_3_Ent2", "role": "Effect", "text": "AZ intoxication", "start": 6, "end": 8}]}], "entity_mentions": [{"id": "9352164_3_Ent0", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9352164_3_Ent1", "text": "She", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9352164_3_Ent3", "text": "AZ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9352164_3_Ent4", "text": "AZ", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9352164_3_Ent2", "text": "AZ intoxication", "entity_type": "Entity", "start": 6, "end": 8}], "lang": "en"}
{"doc_id": "9399776_4", "wnd_id": "9399776_4_1", "text": "These case reports provide evidence that 5 - aminosalicylic acid may induce acute pancreatitis after long term treatment .", "tokens": ["These", "case", "reports", "provide", "evidence", "that", "5", "-", "aminosalicylic", "acid", "may", "induce", "acute", "pancreatitis", "after", "long", "term", "treatment", "."], "event_mentions": [{"id": "9399776_4_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induce", "start": 11, "end": 12}, "arguments": [{"entity_id": "9399776_4_Ent1", "role": "Treatment", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "9399776_4_Ent2", "role": "Treatment_Drug", "text": "5 - aminosalicylic acid", "start": 6, "end": 10}, {"entity_id": "9399776_4_Ent0", "role": "Effect", "text": "acute pancreatitis", "start": 12, "end": 14}, {"entity_id": "9399776_4_Ent3", "role": "Treatment_Duration", "text": "long term", "start": 15, "end": 17}]}], "entity_mentions": [{"id": "9399776_4_Ent1", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9399776_4_Ent2", "text": "5 - aminosalicylic acid", "entity_type": "Entity", "start": 6, "end": 10}, {"id": "9399776_4_Ent0", "text": "acute pancreatitis", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9399776_4_Ent3", "text": "long term", "entity_type": "Entity", "start": 15, "end": 17}], "lang": "en"}
{"doc_id": "9403220_2", "wnd_id": "9403220_2_1", "text": "Acute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with enalapril .", "tokens": ["Acute", "renal", "failure", "with", "severe", "tubulointerstitial", "changes", "in", "a", "patient", "with", "minimal", "change", "nephrotic", "syndrome", "treated", "with", "enalapril", "."], "event_mentions": [{"id": "9403220_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "in", "start": 7, "end": 8}, "arguments": [{"entity_id": "9403220_2_Ent1", "role": "Effect", "text": "Acute renal failure with severe tubulointerstitial changes", "start": 0, "end": 7}, {"entity_id": "9403220_2_Ent0", "role": "Subject", "text": "a patient with minimal change nephrotic syndrome", "start": 8, "end": 15}, {"entity_id": "9403220_2_Ent4", "role": "Treatment_Disorder", "text": "minimal change nephrotic syndrome", "start": 11, "end": 15}, {"entity_id": "9403220_2_Ent2", "role": "Treatment", "text": "enalapril", "start": 17, "end": 18}, {"entity_id": "9403220_2_Ent3", "role": "Treatment_Drug", "text": "enalapril", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9403220_2_Ent1", "text": "Acute renal failure with severe tubulointerstitial changes", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9403220_2_Ent0", "text": "a patient with minimal change nephrotic syndrome", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9403220_2_Ent4", "text": "minimal change nephrotic syndrome", "entity_type": "Entity", "start": 11, "end": 15}, {"id": "9403220_2_Ent2", "text": "enalapril", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9403220_2_Ent3", "text": "enalapril", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9407188_1", "wnd_id": "9407188_1_1", "text": "Early ritonavir - induced maculopapular eruption .", "tokens": ["Early", "ritonavir", "-", "induced", "maculopapular", "eruption", "."], "event_mentions": [{"id": "9407188_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 3, "end": 4}, "arguments": [{"entity_id": "9407188_1_Ent1", "role": "Treatment", "text": "ritonavir", "start": 1, "end": 2}, {"entity_id": "9407188_1_Ent2", "role": "Treatment_Drug", "text": "ritonavir", "start": 1, "end": 2}, {"entity_id": "9407188_1_Ent0", "role": "Effect", "text": "maculopapular eruption", "start": 4, "end": 6}]}], "entity_mentions": [{"id": "9407188_1_Ent1", "text": "ritonavir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9407188_1_Ent2", "text": "ritonavir", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9407188_1_Ent0", "text": "maculopapular eruption", "entity_type": "Entity", "start": 4, "end": 6}], "lang": "en"}
{"doc_id": "941054_2", "wnd_id": "941054_2_1", "text": "Review of the literature relating to methicillin - induced nephropathy suggests a hypersensitivity origin for this disorder , but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis .", "tokens": ["Review", "of", "the", "literature", "relating", "to", "methicillin", "-", "induced", "nephropathy", "suggests", "a", "hypersensitivity", "origin", "for", "this", "disorder", ",", "but", "immunologic", "and", "ultrastructural", "investigation", "to", "date", "has", "failed", "to", "elucidate", "pathogenesis", "."], "event_mentions": [{"id": "941054_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 8, "end": 9}, "arguments": [{"entity_id": "941054_2_Ent2", "role": "Treatment", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "941054_2_Ent3", "role": "Treatment_Drug", "text": "methicillin", "start": 6, "end": 7}, {"entity_id": "941054_2_Ent0", "role": "Effect", "text": "nephropathy", "start": 9, "end": 10}, {"entity_id": "941054_2_Ent1", "role": "Effect", "text": "hypersensitivity", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "941054_2_Ent2", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "941054_2_Ent3", "text": "methicillin", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "941054_2_Ent0", "text": "nephropathy", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "941054_2_Ent1", "text": "hypersensitivity", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9433539_1", "wnd_id": "9433539_1_1", "text": "A case is reported of an elderly woman who developed febrile agranulocytosis several weeks after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim .", "tokens": ["A", "case", "is", "reported", "of", "an", "elderly", "woman", "who", "developed", "febrile", "agranulocytosis", "several", "weeks", "after", "commencing", "ticlopidine", "but", "who", "had", "a", "favorable", "outcome", "after", "cessation", "of", "that", "drug", "and", "treatment", "with", "filgastrim", "."], "event_mentions": [{"id": "9433539_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 9, "end": 10}, "arguments": [{"entity_id": "9433539_1_Ent0", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "9433539_1_Ent1", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "9433539_1_Ent2", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "9433539_1_Ent3", "role": "Effect", "text": "febrile agranulocytosis", "start": 10, "end": 12}, {"entity_id": "9433539_1_Ent5", "role": "Treatment_Time_elapsed", "text": "several weeks", "start": 12, "end": 14}, {"entity_id": "9433539_1_Ent4", "role": "Treatment", "text": "several weeks after commencing ticlopidine", "start": 12, "end": 17}, {"entity_id": "9433539_1_Ent6", "role": "Treatment_Drug", "text": "ticlopidine", "start": 16, "end": 17}]}, {"id": "9433539_1_Evt1", "event_type": "Potential_therapeutic_event", "trigger": {"text": "after", "start": 23, "end": 24}, "arguments": [{"entity_id": "9433539_1_Ent7", "role": "Subject", "text": "an elderly woman", "start": 5, "end": 8}, {"entity_id": "9433539_1_Ent8", "role": "Subject_Age", "text": "elderly", "start": 6, "end": 7}, {"entity_id": "9433539_1_Ent9", "role": "Subject_Gender", "text": "woman", "start": 7, "end": 8}, {"entity_id": "9433539_1_Ent12", "role": "Treatment_Disorder", "text": "febrile agranulocytosis", "start": 10, "end": 12}, {"entity_id": "9433539_1_Ent10", "role": "Effect", "text": "a favorable outcome", "start": 20, "end": 23}, {"entity_id": "9433539_1_Ent11", "role": "Treatment", "text": "cessation of that drug and treatment with filgastrim", "start": 24, "end": 32}, {"entity_id": "9433539_1_Ent13", "role": "Treatment_Drug", "text": "filgastrim", "start": 31, "end": 32}]}], "entity_mentions": [{"id": "9433539_1_Ent0", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9433539_1_Ent7", "text": "an elderly woman", "entity_type": "Entity", "start": 5, "end": 8}, {"id": "9433539_1_Ent1", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9433539_1_Ent8", "text": "elderly", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9433539_1_Ent2", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9433539_1_Ent9", "text": "woman", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9433539_1_Ent3", "text": "febrile agranulocytosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9433539_1_Ent12", "text": "febrile agranulocytosis", "entity_type": "Entity", "start": 10, "end": 12}, {"id": "9433539_1_Ent5", "text": "several weeks", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9433539_1_Ent4", "text": "several weeks after commencing ticlopidine", "entity_type": "Entity", "start": 12, "end": 17}, {"id": "9433539_1_Ent6", "text": "ticlopidine", "entity_type": "Entity", "start": 16, "end": 17}, {"id": "9433539_1_Ent10", "text": "a favorable outcome", "entity_type": "Entity", "start": 20, "end": 23}, {"id": "9433539_1_Ent11", "text": "cessation of that drug and treatment with filgastrim", "entity_type": "Entity", "start": 24, "end": 32}, {"id": "9433539_1_Ent13", "text": "filgastrim", "entity_type": "Entity", "start": 31, "end": 32}], "lang": "en"}
{"doc_id": "9433539_3", "wnd_id": "9433539_3_1", "text": "Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression , typically aplastic anemia .", "tokens": ["Ticlopidine", "is", "an", "oral", "antiplatelet", "agent", "frequently", "utilized", "in", "the", "treatment", "of", "cerebrovascular", "disease", "and", "is", "rarely", "associated", "with", "severe", "bone", "marrow", "suppression", ",", "typically", "aplastic", "anemia", "."], "event_mentions": [{"id": "9433539_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 17, "end": 18}, "arguments": [{"entity_id": "9433539_3_Ent3", "role": "Treatment_Drug", "text": "Ticlopidine", "start": 0, "end": 1}, {"entity_id": "9433539_3_Ent1", "role": "Treatment", "text": "Ticlopidine is an oral antiplatelet agent", "start": 0, "end": 6}, {"entity_id": "9433539_3_Ent4", "role": "Treatment_Route", "text": "oral", "start": 3, "end": 4}, {"entity_id": "9433539_3_Ent2", "role": "Treatment_Disorder", "text": "cerebrovascular disease", "start": 12, "end": 14}, {"entity_id": "9433539_3_Ent0", "role": "Effect", "text": "severe bone marrow suppression , typically aplastic anemia", "start": 19, "end": 27}]}], "entity_mentions": [{"id": "9433539_3_Ent3", "text": "Ticlopidine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9433539_3_Ent1", "text": "Ticlopidine is an oral antiplatelet agent", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9433539_3_Ent4", "text": "oral", "entity_type": "Entity", "start": 3, "end": 4}, {"id": "9433539_3_Ent2", "text": "cerebrovascular disease", "entity_type": "Entity", "start": 12, "end": 14}, {"id": "9433539_3_Ent0", "text": "severe bone marrow suppression , typically aplastic anemia", "entity_type": "Entity", "start": 19, "end": 27}], "lang": "en"}
{"doc_id": "9494448_1", "wnd_id": "9494448_1_1", "text": "A MEDLINE search identified all the reported cases of hypersensitivity reactions to cyclosporine .", "tokens": ["A", "MEDLINE", "search", "identified", "all", "the", "reported", "cases", "of", "hypersensitivity", "reactions", "to", "cyclosporine", "."], "event_mentions": [{"id": "9494448_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "reactions", "start": 10, "end": 11}, "arguments": [{"entity_id": "9494448_1_Ent0", "role": "Effect", "text": "hypersensitivity reactions", "start": 9, "end": 11}, {"entity_id": "9494448_1_Ent1", "role": "Treatment", "text": "cyclosporine", "start": 12, "end": 13}, {"entity_id": "9494448_1_Ent2", "role": "Treatment_Drug", "text": "cyclosporine", "start": 12, "end": 13}]}], "entity_mentions": [{"id": "9494448_1_Ent0", "text": "hypersensitivity reactions", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9494448_1_Ent1", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9494448_1_Ent2", "text": "cyclosporine", "entity_type": "Entity", "start": 12, "end": 13}], "lang": "en"}
{"doc_id": "9494448_8", "wnd_id": "9494448_8_1", "text": "The literature search revealed 22 cases of hypersensitivity reaction to cyclosporine .", "tokens": ["The", "literature", "search", "revealed", "22", "cases", "of", "hypersensitivity", "reaction", "to", "cyclosporine", "."], "event_mentions": [{"id": "9494448_8_Evt0", "event_type": "Adverse_event", "trigger": {"text": "to", "start": 9, "end": 10}, "arguments": [{"entity_id": "9494448_8_Ent1", "role": "Subject_Population", "text": "22", "start": 4, "end": 5}, {"entity_id": "9494448_8_Ent0", "role": "Subject", "text": "22 cases", "start": 4, "end": 6}, {"entity_id": "9494448_8_Ent2", "role": "Effect", "text": "hypersensitivity reaction", "start": 7, "end": 9}, {"entity_id": "9494448_8_Ent3", "role": "Treatment", "text": "cyclosporine", "start": 10, "end": 11}, {"entity_id": "9494448_8_Ent4", "role": "Treatment_Drug", "text": "cyclosporine", "start": 10, "end": 11}]}], "entity_mentions": [{"id": "9494448_8_Ent1", "text": "22", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9494448_8_Ent0", "text": "22 cases", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9494448_8_Ent2", "text": "hypersensitivity reaction", "entity_type": "Entity", "start": 7, "end": 9}, {"id": "9494448_8_Ent3", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9494448_8_Ent4", "text": "cyclosporine", "entity_type": "Entity", "start": 10, "end": 11}], "lang": "en"}
{"doc_id": "9517515_1", "wnd_id": "9517515_1_1", "text": "Development of essential thrombocythemia in a patient treated with interferon alfa and pentostatin for hairy cell leukemia .", "tokens": ["Development", "of", "essential", "thrombocythemia", "in", "a", "patient", "treated", "with", "interferon", "alfa", "and", "pentostatin", "for", "hairy", "cell", "leukemia", "."], "event_mentions": [{"id": "9517515_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "Development", "start": 0, "end": 1}, "arguments": [{"entity_id": "9517515_1_Ent1", "role": "Effect", "text": "essential thrombocythemia", "start": 2, "end": 4}, {"entity_id": "9517515_1_Ent0", "role": "Subject", "text": "a patient", "start": 5, "end": 7}, {"entity_id": "9517515_1_Ent4", "role": "Treatment_Drug", "text": "interferon alfa", "start": 9, "end": 11}, {"entity_id": "9517515_1_Ent6", "role": "Combination_Drug", "text": "interferon alfa", "start": 9, "end": 11}, {"entity_id": "9517515_1_Ent2", "role": "Treatment", "text": "interferon alfa and pentostatin", "start": 9, "end": 13}, {"entity_id": "9517515_1_Ent5", "role": "Treatment_Drug", "text": "pentostatin", "start": 12, "end": 13}, {"entity_id": "9517515_1_Ent7", "role": "Combination_Drug", "text": "pentostatin", "start": 12, "end": 13}, {"entity_id": "9517515_1_Ent3", "role": "Treatment_Disorder", "text": "hairy cell leukemia", "start": 14, "end": 17}]}], "entity_mentions": [{"id": "9517515_1_Ent1", "text": "essential thrombocythemia", "entity_type": "Entity", "start": 2, "end": 4}, {"id": "9517515_1_Ent0", "text": "a patient", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9517515_1_Ent4", "text": "interferon alfa", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9517515_1_Ent6", "text": "interferon alfa", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9517515_1_Ent2", "text": "interferon alfa and pentostatin", "entity_type": "Entity", "start": 9, "end": 13}, {"id": "9517515_1_Ent5", "text": "pentostatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9517515_1_Ent7", "text": "pentostatin", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9517515_1_Ent3", "text": "hairy cell leukemia", "entity_type": "Entity", "start": 14, "end": 17}], "lang": "en"}
{"doc_id": "9545161_2", "wnd_id": "9545161_2_1", "text": "Administration of lamotrigine , especially in combination with valproic acid , may lead to the development of TEN .", "tokens": ["Administration", "of", "lamotrigine", ",", "especially", "in", "combination", "with", "valproic", "acid", ",", "may", "lead", "to", "the", "development", "of", "TEN", "."], "event_mentions": [{"id": "9545161_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "development", "start": 15, "end": 16}, "arguments": [{"entity_id": "9545161_2_Ent1", "role": "Treatment", "text": "Administration of lamotrigine", "start": 0, "end": 3}, {"entity_id": "9545161_2_Ent4", "role": "Treatment_Drug", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "9545161_2_Ent6", "role": "Combination_Drug", "text": "lamotrigine", "start": 2, "end": 3}, {"entity_id": "9545161_2_Ent2", "role": "Treatment", "text": "with valproic acid", "start": 7, "end": 10}, {"entity_id": "9545161_2_Ent3", "role": "Treatment_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "9545161_2_Ent5", "role": "Combination_Drug", "text": "valproic acid", "start": 8, "end": 10}, {"entity_id": "9545161_2_Ent0", "role": "Effect", "text": "TEN", "start": 17, "end": 18}]}], "entity_mentions": [{"id": "9545161_2_Ent1", "text": "Administration of lamotrigine", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9545161_2_Ent4", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9545161_2_Ent6", "text": "lamotrigine", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9545161_2_Ent2", "text": "with valproic acid", "entity_type": "Entity", "start": 7, "end": 10}, {"id": "9545161_2_Ent3", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9545161_2_Ent5", "text": "valproic acid", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9545161_2_Ent0", "text": "TEN", "entity_type": "Entity", "start": 17, "end": 18}], "lang": "en"}
{"doc_id": "9545161_5", "wnd_id": "9545161_5_1", "text": "To date , eight cases of TEN and one of SJS related to lamotrigine administration have been reported in the literature .", "tokens": ["To", "date", ",", "eight", "cases", "of", "TEN", "and", "one", "of", "SJS", "related", "to", "lamotrigine", "administration", "have", "been", "reported", "in", "the", "literature", "."], "event_mentions": [{"id": "9545161_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "related", "start": 11, "end": 12}, "arguments": [{"entity_id": "9545161_5_Ent0", "role": "Effect", "text": "TEN", "start": 6, "end": 7}, {"entity_id": "9545161_5_Ent1", "role": "Effect", "text": "SJS", "start": 10, "end": 11}, {"entity_id": "9545161_5_Ent2", "role": "Treatment", "text": "lamotrigine", "start": 13, "end": 14}, {"entity_id": "9545161_5_Ent3", "role": "Treatment_Drug", "text": "lamotrigine", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9545161_5_Ent0", "text": "TEN", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9545161_5_Ent1", "text": "SJS", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9545161_5_Ent2", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9545161_5_Ent3", "text": "lamotrigine", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9554064_1", "wnd_id": "9554064_1_1", "text": "Methanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies .", "tokens": ["Methanol", "toxicity", "can", "cause", "severe", "central", "nervous", "system", "insult", "in", "which", "a", "characteristic", "pattern", "of", "bilateral", "putaminal", "injury", "is", "noted", "on", "brain", "imaging", "studies", "."], "event_mentions": [{"id": "9554064_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 3, "end": 4}, "arguments": [{"entity_id": "9554064_1_Ent2", "role": "Treatment_Drug", "text": "Methanol", "start": 0, "end": 1}, {"entity_id": "9554064_1_Ent1", "role": "Treatment", "text": "Methanol toxicity", "start": 0, "end": 2}, {"entity_id": "9554064_1_Ent0", "role": "Effect", "text": "central nervous system insult", "start": 5, "end": 9}]}], "entity_mentions": [{"id": "9554064_1_Ent2", "text": "Methanol", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9554064_1_Ent1", "text": "Methanol toxicity", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "9554064_1_Ent0", "text": "central nervous system insult", "entity_type": "Entity", "start": 5, "end": 9}], "lang": "en"}
{"doc_id": "9554064_3", "wnd_id": "9554064_3_1", "text": "Theoretical basal ganglia toxicologic mechanisms of methanol poisoning are reviewed , and the role of brain imaging studies will regard to diagnosis , prognosis and impact on management is discussed .", "tokens": ["Theoretical", "basal", "ganglia", "toxicologic", "mechanisms", "of", "methanol", "poisoning", "are", "reviewed", ",", "and", "the", "role", "of", "brain", "imaging", "studies", "will", "regard", "to", "diagnosis", ",", "prognosis", "and", "impact", "on", "management", "is", "discussed", "."], "event_mentions": [{"id": "9554064_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "mechanisms", "start": 4, "end": 5}, "arguments": [{"entity_id": "9554064_3_Ent1", "role": "Treatment", "text": "methanol", "start": 6, "end": 7}, {"entity_id": "9554064_3_Ent2", "role": "Treatment_Drug", "text": "methanol", "start": 6, "end": 7}, {"entity_id": "9554064_3_Ent0", "role": "Effect", "text": "poisoning", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9554064_3_Ent1", "text": "methanol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9554064_3_Ent2", "text": "methanol", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9554064_3_Ent0", "text": "poisoning", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "95811_1", "wnd_id": "95811_1_1", "text": "A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of procainamide therapy .", "tokens": ["A", "61", "-", "year", "-", "old", "man", "developed", "clinical", "lupus", "syndrome", "with", "positive", "antinuclear", "antibody", ",", "positive", "lupus", "erythematosus", "(", "LE", ")", "cell", "preparation", ",", "and", "diffuse", "proliferative", "glomerulonephritis", "following", "26", "months", "of", "procainamide", "therapy", "."], "event_mentions": [{"id": "95811_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 7, "end": 8}, "arguments": [{"entity_id": "95811_1_Ent1", "role": "Subject_Age", "text": "61 - year - old", "start": 1, "end": 6}, {"entity_id": "95811_1_Ent0", "role": "Subject", "text": "61 - year - old man", "start": 1, "end": 7}, {"entity_id": "95811_1_Ent2", "role": "Subject_Gender", "text": "man", "start": 6, "end": 7}, {"entity_id": "95811_1_Ent3", "role": "Effect", "text": "clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis", "start": 8, "end": 29}, {"entity_id": "95811_1_Ent6", "role": "Treatment_Duration", "text": "26 months", "start": 30, "end": 32}, {"entity_id": "95811_1_Ent4", "role": "Treatment", "text": "26 months of procainamide therapy", "start": 30, "end": 35}, {"entity_id": "95811_1_Ent5", "role": "Treatment_Drug", "text": "procainamide", "start": 33, "end": 34}]}], "entity_mentions": [{"id": "95811_1_Ent1", "text": "61 - year - old", "entity_type": "Entity", "start": 1, "end": 6}, {"id": "95811_1_Ent0", "text": "61 - year - old man", "entity_type": "Entity", "start": 1, "end": 7}, {"id": "95811_1_Ent2", "text": "man", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "95811_1_Ent3", "text": "clinical lupus syndrome with positive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation , and diffuse proliferative glomerulonephritis", "entity_type": "Entity", "start": 8, "end": 29}, {"id": "95811_1_Ent6", "text": "26 months", "entity_type": "Entity", "start": 30, "end": 32}, {"id": "95811_1_Ent4", "text": "26 months of procainamide therapy", "entity_type": "Entity", "start": 30, "end": 35}, {"id": "95811_1_Ent5", "text": "procainamide", "entity_type": "Entity", "start": 33, "end": 34}], "lang": "en"}
{"doc_id": "961329_1", "wnd_id": "961329_1_1", "text": "A case of prolonged suxamethonium apnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported .", "tokens": ["A", "case", "of", "prolonged", "suxamethonium", "apnoea", "successfully", "terminated", "by", "the", "infusion", "of", "a", "commercial", "preparation", "of", "serumcholinesterase", "is", "reported", "."], "event_mentions": [{"id": "961329_1_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "terminated", "start": 7, "end": 8}, "arguments": [{"entity_id": "961329_1_Ent0", "role": "Effect", "text": "prolonged suxamethonium apnoea", "start": 3, "end": 6}, {"entity_id": "961329_1_Ent2", "role": "Treatment_Drug", "text": "suxamethonium", "start": 4, "end": 5}, {"entity_id": "961329_1_Ent1", "role": "Treatment", "text": "the infusion of a commercial preparation of serumcholinesterase", "start": 9, "end": 17}, {"entity_id": "961329_1_Ent4", "role": "Treatment_Route", "text": "infusion", "start": 10, "end": 11}, {"entity_id": "961329_1_Ent3", "role": "Treatment_Drug", "text": "serumcholinesterase", "start": 16, "end": 17}]}], "entity_mentions": [{"id": "961329_1_Ent0", "text": "prolonged suxamethonium apnoea", "entity_type": "Entity", "start": 3, "end": 6}, {"id": "961329_1_Ent2", "text": "suxamethonium", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "961329_1_Ent1", "text": "the infusion of a commercial preparation of serumcholinesterase", "entity_type": "Entity", "start": 9, "end": 17}, {"id": "961329_1_Ent4", "text": "infusion", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "961329_1_Ent3", "text": "serumcholinesterase", "entity_type": "Entity", "start": 16, "end": 17}], "lang": "en"}
{"doc_id": "9634122_1", "wnd_id": "9634122_1_1", "text": "Flutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate .", "tokens": ["Flutamide", "withdrawal", "syndrome", "is", "characterized", "by", "a", "decrease", "in", "prostate", "-", "specific", "antigen", "(", "PSA", ")", "after", "flutamide", "withdrawal", "in", "a", "subset", "of", "patients", "with", "progressing", "metastatic", "carcinoma", "of", "the", "prostate", "."], "event_mentions": [{"id": "9634122_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "withdrawal", "start": 18, "end": 19}, "arguments": [{"entity_id": "9634122_1_Ent1", "role": "Effect", "text": "decrease in prostate - specific antigen ( PSA )", "start": 7, "end": 16}, {"entity_id": "9634122_1_Ent2", "role": "Treatment", "text": "flutamide", "start": 17, "end": 18}, {"entity_id": "9634122_1_Ent4", "role": "Treatment_Drug", "text": "flutamide", "start": 17, "end": 18}, {"entity_id": "9634122_1_Ent0", "role": "Subject", "text": "subset of patients with progressing metastatic carcinoma of the prostate", "start": 21, "end": 31}, {"entity_id": "9634122_1_Ent3", "role": "Treatment_Disorder", "text": "progressing metastatic carcinoma of the prostate", "start": 25, "end": 31}]}], "entity_mentions": [{"id": "9634122_1_Ent1", "text": "decrease in prostate - specific antigen ( PSA )", "entity_type": "Entity", "start": 7, "end": 16}, {"id": "9634122_1_Ent2", "text": "flutamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9634122_1_Ent4", "text": "flutamide", "entity_type": "Entity", "start": 17, "end": 18}, {"id": "9634122_1_Ent0", "text": "subset of patients with progressing metastatic carcinoma of the prostate", "entity_type": "Entity", "start": 21, "end": 31}, {"id": "9634122_1_Ent3", "text": "progressing metastatic carcinoma of the prostate", "entity_type": "Entity", "start": 25, "end": 31}], "lang": "en"}
{"doc_id": "9653495_15", "wnd_id": "9653495_15_1", "text": "In the absence of an ideal dose - intense FU monotherapy regimen , monthly FU with low - dose LV provides a simple and economical means by which to achieve adequate FU efficacy in the treatment of advanced colorectal cancer .", "tokens": ["In", "the", "absence", "of", "an", "ideal", "dose", "-", "intense", "FU", "monotherapy", "regimen", ",", "monthly", "FU", "with", "low", "-", "dose", "LV", "provides", "a", "simple", "and", "economical", "means", "by", "which", "to", "achieve", "adequate", "FU", "efficacy", "in", "the", "treatment", "of", "advanced", "colorectal", "cancer", "."], "event_mentions": [{"id": "9653495_15_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "treatment", "start": 35, "end": 36}, "arguments": [{"entity_id": "9653495_15_Ent2", "role": "Treatment_Freq", "text": "monthly", "start": 13, "end": 14}, {"entity_id": "9653495_15_Ent0", "role": "Treatment", "text": "monthly FU with low - dose LV", "start": 13, "end": 20}, {"entity_id": "9653495_15_Ent3", "role": "Treatment_Drug", "text": "FU", "start": 14, "end": 15}, {"entity_id": "9653495_15_Ent6", "role": "Combination_Drug", "text": "FU", "start": 14, "end": 15}, {"entity_id": "9653495_15_Ent5", "role": "Treatment_Dosage", "text": "low - dose", "start": 16, "end": 19}, {"entity_id": "9653495_15_Ent4", "role": "Treatment_Drug", "text": "LV", "start": 19, "end": 20}, {"entity_id": "9653495_15_Ent7", "role": "Combination_Drug", "text": "LV", "start": 19, "end": 20}, {"entity_id": "9653495_15_Ent1", "role": "Treatment_Disorder", "text": "advanced colorectal cancer", "start": 37, "end": 40}]}], "entity_mentions": [{"id": "9653495_15_Ent2", "text": "monthly", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9653495_15_Ent0", "text": "monthly FU with low - dose LV", "entity_type": "Entity", "start": 13, "end": 20}, {"id": "9653495_15_Ent3", "text": "FU", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9653495_15_Ent6", "text": "FU", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9653495_15_Ent5", "text": "low - dose", "entity_type": "Entity", "start": 16, "end": 19}, {"id": "9653495_15_Ent4", "text": "LV", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9653495_15_Ent7", "text": "LV", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9653495_15_Ent1", "text": "advanced colorectal cancer", "entity_type": "Entity", "start": 37, "end": 40}], "lang": "en"}
{"doc_id": "9681092_13", "wnd_id": "9681092_13_1", "text": "Clinicians should be aware of the dysrhythmic potential of cyclobenzaprine and fluoxetine , monitor for other cytochrome P450 inhibitors , and avoid concomitant drugs known to prolong the QT interval .", "tokens": ["Clinicians", "should", "be", "aware", "of", "the", "dysrhythmic", "potential", "of", "cyclobenzaprine", "and", "fluoxetine", ",", "monitor", "for", "other", "cytochrome", "P450", "inhibitors", ",", "and", "avoid", "concomitant", "drugs", "known", "to", "prolong", "the", "QT", "interval", "."], "event_mentions": [{"id": "9681092_13_Evt0", "event_type": "Adverse_event", "trigger": {"text": "potential", "start": 7, "end": 8}, "arguments": [{"entity_id": "9681092_13_Ent0", "role": "Effect", "text": "dysrhythmic", "start": 6, "end": 7}, {"entity_id": "9681092_13_Ent2", "role": "Treatment_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent4", "role": "Combination_Drug", "text": "cyclobenzaprine", "start": 9, "end": 10}, {"entity_id": "9681092_13_Ent1", "role": "Treatment", "text": "cyclobenzaprine and fluoxetine", "start": 9, "end": 12}, {"entity_id": "9681092_13_Ent3", "role": "Treatment_Drug", "text": "fluoxetine", "start": 11, "end": 12}, {"entity_id": "9681092_13_Ent5", "role": "Combination_Drug", "text": "fluoxetine", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9681092_13_Ent0", "text": "dysrhythmic", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9681092_13_Ent2", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent4", "text": "cyclobenzaprine", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9681092_13_Ent1", "text": "cyclobenzaprine and fluoxetine", "entity_type": "Entity", "start": 9, "end": 12}, {"id": "9681092_13_Ent3", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}, {"id": "9681092_13_Ent5", "text": "fluoxetine", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9681092_5", "wnd_id": "9681092_5_1", "text": "Prior to surgery , the patient received droperidol , an agent known to prolong the QT interval .", "tokens": ["Prior", "to", "surgery", ",", "the", "patient", "received", "droperidol", ",", "an", "agent", "known", "to", "prolong", "the", "QT", "interval", "."], "event_mentions": [{"id": "9681092_5_Evt0", "event_type": "Potential_therapeutic_event", "trigger": {"text": "received", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681092_5_Ent2", "role": "Treatment", "text": "Prior to surgery", "start": 0, "end": 3}, {"entity_id": "9681092_5_Ent0", "role": "Subject", "text": "the patient", "start": 4, "end": 6}, {"entity_id": "9681092_5_Ent1", "role": "Treatment", "text": "droperidol", "start": 7, "end": 8}, {"entity_id": "9681092_5_Ent3", "role": "Treatment_Drug", "text": "droperidol", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9681092_5_Ent2", "text": "Prior to surgery", "entity_type": "Entity", "start": 0, "end": 3}, {"id": "9681092_5_Ent0", "text": "the patient", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9681092_5_Ent1", "text": "droperidol", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9681092_5_Ent3", "text": "droperidol", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9681211_1", "wnd_id": "9681211_1_1", "text": "Although this G - CSF - driven leucocytosis was alarming it did not appear to have adversely affected the patient 's prognosis .", "tokens": ["Although", "this", "G", "-", "CSF", "-", "driven", "leucocytosis", "was", "alarming", "it", "did", "not", "appear", "to", "have", "adversely", "affected", "the", "patient", "'s", "prognosis", "."], "event_mentions": [{"id": "9681211_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "driven", "start": 6, "end": 7}, "arguments": [{"entity_id": "9681211_1_Ent1", "role": "Treatment", "text": "G - CSF", "start": 2, "end": 5}, {"entity_id": "9681211_1_Ent2", "role": "Treatment_Drug", "text": "G - CSF", "start": 2, "end": 5}, {"entity_id": "9681211_1_Ent0", "role": "Effect", "text": "leucocytosis", "start": 7, "end": 8}]}], "entity_mentions": [{"id": "9681211_1_Ent1", "text": "G - CSF", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9681211_1_Ent2", "text": "G - CSF", "entity_type": "Entity", "start": 2, "end": 5}, {"id": "9681211_1_Ent0", "text": "leucocytosis", "entity_type": "Entity", "start": 7, "end": 8}], "lang": "en"}
{"doc_id": "9681211_3", "wnd_id": "9681211_3_1", "text": "We describe a patient with M4 AML treated with standard chemotherapy followed by G - CSF who developed marked monocytosis on day 8 of G - CSF therapy .", "tokens": ["We", "describe", "a", "patient", "with", "M4", "AML", "treated", "with", "standard", "chemotherapy", "followed", "by", "G", "-", "CSF", "who", "developed", "marked", "monocytosis", "on", "day", "8", "of", "G", "-", "CSF", "therapy", "."], "event_mentions": [{"id": "9681211_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "developed", "start": 17, "end": 18}, "arguments": [{"entity_id": "9681211_3_Ent0", "role": "Subject", "text": "a patient with M4 AML", "start": 2, "end": 7}, {"entity_id": "9681211_3_Ent3", "role": "Treatment_Disorder", "text": "M4 AML", "start": 5, "end": 7}, {"entity_id": "9681211_3_Ent2", "role": "Treatment", "text": "standard chemotherapy followed by G - CSF", "start": 9, "end": 16}, {"entity_id": "9681211_3_Ent4", "role": "Treatment_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "9681211_3_Ent7", "role": "Combination_Drug", "text": "chemotherapy", "start": 10, "end": 11}, {"entity_id": "9681211_3_Ent5", "role": "Treatment_Drug", "text": "G - CSF", "start": 13, "end": 16}, {"entity_id": "9681211_3_Ent8", "role": "Combination_Drug", "text": "G - CSF", "start": 13, "end": 16}, {"entity_id": "9681211_3_Ent1", "role": "Effect", "text": "marked monocytosis", "start": 18, "end": 20}, {"entity_id": "9681211_3_Ent6", "role": "Treatment_Time_elapsed", "text": "day 8", "start": 21, "end": 23}]}], "entity_mentions": [{"id": "9681211_3_Ent0", "text": "a patient with M4 AML", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "9681211_3_Ent3", "text": "M4 AML", "entity_type": "Entity", "start": 5, "end": 7}, {"id": "9681211_3_Ent2", "text": "standard chemotherapy followed by G - CSF", "entity_type": "Entity", "start": 9, "end": 16}, {"id": "9681211_3_Ent4", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9681211_3_Ent7", "text": "chemotherapy", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9681211_3_Ent5", "text": "G - CSF", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9681211_3_Ent8", "text": "G - CSF", "entity_type": "Entity", "start": 13, "end": 16}, {"id": "9681211_3_Ent1", "text": "marked monocytosis", "entity_type": "Entity", "start": 18, "end": 20}, {"id": "9681211_3_Ent6", "text": "day 8", "entity_type": "Entity", "start": 21, "end": 23}], "lang": "en"}
{"doc_id": "968449_7", "wnd_id": "968449_7_1", "text": "Case 2 demonstrated after 40 months on chlorambucil the presence of a balanced translocation , t ( 1;5 ) ( p36;q31 ) in 90 % of the cells .", "tokens": ["Case", "2", "demonstrated", "after", "40", "months", "on", "chlorambucil", "the", "presence", "of", "a", "balanced", "translocation", ",", "t", "(", "1;5", ")", "(", "p36;q31", ")", "in", "90", "%", "of", "the", "cells", "."], "event_mentions": [{"id": "968449_7_Evt0", "event_type": "Adverse_event", "trigger": {"text": "presence of", "start": 9, "end": 11}, "arguments": [{"entity_id": "968449_7_Ent0", "role": "Subject", "text": "Case 2", "start": 0, "end": 2}, {"entity_id": "968449_7_Ent4", "role": "Treatment_Time_elapsed", "text": "40 months", "start": 4, "end": 6}, {"entity_id": "968449_7_Ent2", "role": "Treatment", "text": "40 months on chlorambucil", "start": 4, "end": 8}, {"entity_id": "968449_7_Ent3", "role": "Treatment_Drug", "text": "chlorambucil", "start": 7, "end": 8}, {"entity_id": "968449_7_Ent1", "role": "Effect", "text": "a balanced translocation , t ( 1;5 ) ( p36;q31 ) in 90 % of the cells", "start": 11, "end": 28}]}], "entity_mentions": [{"id": "968449_7_Ent0", "text": "Case 2", "entity_type": "Entity", "start": 0, "end": 2}, {"id": "968449_7_Ent4", "text": "40 months", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "968449_7_Ent2", "text": "40 months on chlorambucil", "entity_type": "Entity", "start": 4, "end": 8}, {"id": "968449_7_Ent3", "text": "chlorambucil", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "968449_7_Ent1", "text": "a balanced translocation , t ( 1;5 ) ( p36;q31 ) in 90 % of the cells", "entity_type": "Entity", "start": 11, "end": 28}], "lang": "en"}
{"doc_id": "9695308_2", "wnd_id": "9695308_2_1", "text": "Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis associated with propylthiouracil therapy .", "tokens": ["Antineutrophil", "cytoplasmic", "antibody", "-", "positive", "crescentic", "glomerulonephritis", "associated", "with", "propylthiouracil", "therapy", "."], "event_mentions": [{"id": "9695308_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 7, "end": 8}, "arguments": [{"entity_id": "9695308_2_Ent0", "role": "Effect", "text": "Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis", "start": 0, "end": 7}, {"entity_id": "9695308_2_Ent2", "role": "Treatment_Drug", "text": "propylthiouracil", "start": 9, "end": 10}, {"entity_id": "9695308_2_Ent1", "role": "Treatment", "text": "propylthiouracil therapy", "start": 9, "end": 11}]}], "entity_mentions": [{"id": "9695308_2_Ent0", "text": "Antineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis", "entity_type": "Entity", "start": 0, "end": 7}, {"id": "9695308_2_Ent2", "text": "propylthiouracil", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9695308_2_Ent1", "text": "propylthiouracil therapy", "entity_type": "Entity", "start": 9, "end": 11}], "lang": "en"}
{"doc_id": "9701106_2", "wnd_id": "9701106_2_1", "text": "Attempts were made to stop and then restart the theophylline therapy at progressively lower doses ; however , with each attempt , the patient 's reaction to the drug became more toxic , with serum theophylline levels ranging between 99.9 and 149.9 micromol / L ( 18 and 27 microg / mL ) .", "tokens": ["Attempts", "were", "made", "to", "stop", "and", "then", "restart", "the", "theophylline", "therapy", "at", "progressively", "lower", "doses", ";", "however", ",", "with", "each", "attempt", ",", "the", "patient", "'s", "reaction", "to", "the", "drug", "became", "more", "toxic", ",", "with", "serum", "theophylline", "levels", "ranging", "between", "99.9", "and", "149.9", "micromol", "/", "L", "(", "18", "and", "27", "microg", "/", "mL", ")", "."], "event_mentions": [{"id": "9701106_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "became", "start": 29, "end": 30}, "arguments": [{"entity_id": "9701106_2_Ent3", "role": "Treatment_Drug", "text": "theophylline", "start": 9, "end": 10}, {"entity_id": "9701106_2_Ent2", "role": "Treatment", "text": "theophylline therapy", "start": 9, "end": 11}, {"entity_id": "9701106_2_Ent0", "role": "Subject", "text": "patient", "start": 23, "end": 24}, {"entity_id": "9701106_2_Ent1", "role": "Effect", "text": "reaction to the drug became more toxic", "start": 25, "end": 32}, {"entity_id": "9701106_2_Ent4", "role": "Treatment_Dosage", "text": "99.9 and 149.9 micromol / L", "start": 39, "end": 45}, {"entity_id": "9701106_2_Ent5", "role": "Treatment_Dosage", "text": "18 and 27 microg / mL", "start": 46, "end": 52}]}], "entity_mentions": [{"id": "9701106_2_Ent3", "text": "theophylline", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9701106_2_Ent2", "text": "theophylline therapy", "entity_type": "Entity", "start": 9, "end": 11}, {"id": "9701106_2_Ent0", "text": "patient", "entity_type": "Entity", "start": 23, "end": 24}, {"id": "9701106_2_Ent1", "text": "reaction to the drug became more toxic", "entity_type": "Entity", "start": 25, "end": 32}, {"id": "9701106_2_Ent4", "text": "99.9 and 149.9 micromol / L", "entity_type": "Entity", "start": 39, "end": 45}, {"id": "9701106_2_Ent5", "text": "18 and 27 microg / mL", "entity_type": "Entity", "start": 46, "end": 52}], "lang": "en"}
{"doc_id": "9704170_2", "wnd_id": "9704170_2_1", "text": "Clozapine is speculated to cause rhabdomyolysis in patients with defective calcium - activated K+ channels .", "tokens": ["Clozapine", "is", "speculated", "to", "cause", "rhabdomyolysis", "in", "patients", "with", "defective", "calcium", "-", "activated", "K+", "channels", "."], "event_mentions": [{"id": "9704170_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 4, "end": 5}, "arguments": [{"entity_id": "9704170_2_Ent3", "role": "Treatment", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9704170_2_Ent4", "role": "Treatment_Drug", "text": "Clozapine", "start": 0, "end": 1}, {"entity_id": "9704170_2_Ent2", "role": "Effect", "text": "rhabdomyolysis", "start": 5, "end": 6}, {"entity_id": "9704170_2_Ent0", "role": "Subject", "text": "patients with defective calcium - activated K+ channels", "start": 7, "end": 15}, {"entity_id": "9704170_2_Ent1", "role": "Subject_Disorder", "text": "defective calcium - activated K+ channels", "start": 9, "end": 15}]}], "entity_mentions": [{"id": "9704170_2_Ent3", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_2_Ent4", "text": "Clozapine", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9704170_2_Ent2", "text": "rhabdomyolysis", "entity_type": "Entity", "start": 5, "end": 6}, {"id": "9704170_2_Ent0", "text": "patients with defective calcium - activated K+ channels", "entity_type": "Entity", "start": 7, "end": 15}, {"id": "9704170_2_Ent1", "text": "defective calcium - activated K+ channels", "entity_type": "Entity", "start": 9, "end": 15}], "lang": "en"}
{"doc_id": "9726762_1", "wnd_id": "9726762_1_1", "text": "Gemfibrozil - warfarin drug interaction resulting in profound hypoprothrombinemia .", "tokens": ["Gemfibrozil", "-", "warfarin", "drug", "interaction", "resulting", "in", "profound", "hypoprothrombinemia", "."], "event_mentions": [{"id": "9726762_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "resulting", "start": 5, "end": 6}, "arguments": [{"entity_id": "9726762_1_Ent3", "role": "Treatment_Drug", "text": "Gemfibrozil", "start": 0, "end": 1}, {"entity_id": "9726762_1_Ent4", "role": "Combination_Drug", "text": "Gemfibrozil", "start": 0, "end": 1}, {"entity_id": "9726762_1_Ent1", "role": "Treatment", "text": "Gemfibrozil - warfarin drug interaction", "start": 0, "end": 5}, {"entity_id": "9726762_1_Ent2", "role": "Treatment_Drug", "text": "warfarin", "start": 2, "end": 3}, {"entity_id": "9726762_1_Ent5", "role": "Combination_Drug", "text": "warfarin", "start": 2, "end": 3}, {"entity_id": "9726762_1_Ent0", "role": "Effect", "text": "profound hypoprothrombinemia", "start": 7, "end": 9}]}], "entity_mentions": [{"id": "9726762_1_Ent3", "text": "Gemfibrozil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9726762_1_Ent4", "text": "Gemfibrozil", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9726762_1_Ent1", "text": "Gemfibrozil - warfarin drug interaction", "entity_type": "Entity", "start": 0, "end": 5}, {"id": "9726762_1_Ent2", "text": "warfarin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9726762_1_Ent5", "text": "warfarin", "entity_type": "Entity", "start": 2, "end": 3}, {"id": "9726762_1_Ent0", "text": "profound hypoprothrombinemia", "entity_type": "Entity", "start": 7, "end": 9}], "lang": "en"}
{"doc_id": "9760614_1", "wnd_id": "9760614_1_1", "text": "However , 1 eye had vitreous hemorrhage after repeated injections of tPA .", "tokens": ["However", ",", "1", "eye", "had", "vitreous", "hemorrhage", "after", "repeated", "injections", "of", "tPA", "."], "event_mentions": [{"id": "9760614_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 7, "end": 8}, "arguments": [{"entity_id": "9760614_1_Ent0", "role": "Effect", "text": "1 eye had vitreous hemorrhage", "start": 2, "end": 7}, {"entity_id": "9760614_1_Ent1", "role": "Treatment", "text": "repeated injections of tPA", "start": 8, "end": 12}, {"entity_id": "9760614_1_Ent2", "role": "Treatment_Route", "text": "injections", "start": 9, "end": 10}, {"entity_id": "9760614_1_Ent3", "role": "Treatment_Drug", "text": "tPA", "start": 11, "end": 12}]}], "entity_mentions": [{"id": "9760614_1_Ent0", "text": "1 eye had vitreous hemorrhage", "entity_type": "Entity", "start": 2, "end": 7}, {"id": "9760614_1_Ent1", "text": "repeated injections of tPA", "entity_type": "Entity", "start": 8, "end": 12}, {"id": "9760614_1_Ent2", "text": "injections", "entity_type": "Entity", "start": 9, "end": 10}, {"id": "9760614_1_Ent3", "text": "tPA", "entity_type": "Entity", "start": 11, "end": 12}], "lang": "en"}
{"doc_id": "9796135_3", "wnd_id": "9796135_3_1", "text": "In a postural challenge test after administration of isosorbide dinitrate ( 5 mg ) , blood pressure decreased from 120/67 to 65/35 mmHg , followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats / min .", "tokens": ["In", "a", "postural", "challenge", "test", "after", "administration", "of", "isosorbide", "dinitrate", "(", "5", "mg", ")", ",", "blood", "pressure", "decreased", "from", "120/67", "to", "65/35", "mmHg", ",", "followed", "by", "syncope", "with", "a", "sudden", "decrease", "in", "pulse", "rate", "from", "85", "to", "60", "beats", "/", "min", "."], "event_mentions": [{"id": "9796135_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "after", "start": 5, "end": 6}, "arguments": [{"entity_id": "9796135_3_Ent3", "role": "Treatment", "text": "administration of isosorbide dinitrate ( 5 mg )", "start": 6, "end": 14}, {"entity_id": "9796135_3_Ent4", "role": "Treatment_Drug", "text": "isosorbide dinitrate", "start": 8, "end": 10}, {"entity_id": "9796135_3_Ent5", "role": "Treatment_Dosage", "text": "5 mg", "start": 11, "end": 13}, {"entity_id": "9796135_3_Ent0", "role": "Effect", "text": "blood pressure decreased", "start": 15, "end": 18}, {"entity_id": "9796135_3_Ent1", "role": "Effect", "text": "syncope", "start": 26, "end": 27}, {"entity_id": "9796135_3_Ent2", "role": "Effect", "text": "a sudden decrease in pulse rate", "start": 28, "end": 34}]}], "entity_mentions": [{"id": "9796135_3_Ent3", "text": "administration of isosorbide dinitrate ( 5 mg )", "entity_type": "Entity", "start": 6, "end": 14}, {"id": "9796135_3_Ent4", "text": "isosorbide dinitrate", "entity_type": "Entity", "start": 8, "end": 10}, {"id": "9796135_3_Ent5", "text": "5 mg", "entity_type": "Entity", "start": 11, "end": 13}, {"id": "9796135_3_Ent0", "text": "blood pressure decreased", "entity_type": "Entity", "start": 15, "end": 18}, {"id": "9796135_3_Ent1", "text": "syncope", "entity_type": "Entity", "start": 26, "end": 27}, {"id": "9796135_3_Ent2", "text": "a sudden decrease in pulse rate", "entity_type": "Entity", "start": 28, "end": 34}], "lang": "en"}
{"doc_id": "9819544_1", "wnd_id": "9819544_1_1", "text": "Naproxen - associated sudden sensorineural hearing loss .", "tokens": ["Naproxen", "-", "associated", "sudden", "sensorineural", "hearing", "loss", "."], "event_mentions": [{"id": "9819544_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 2, "end": 3}, "arguments": [{"entity_id": "9819544_1_Ent1", "role": "Treatment", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_1_Ent2", "role": "Treatment_Drug", "text": "Naproxen", "start": 0, "end": 1}, {"entity_id": "9819544_1_Ent0", "role": "Effect", "text": "sudden sensorineural hearing loss", "start": 3, "end": 7}]}], "entity_mentions": [{"id": "9819544_1_Ent1", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_1_Ent2", "text": "Naproxen", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9819544_1_Ent0", "text": "sudden sensorineural hearing loss", "entity_type": "Entity", "start": 3, "end": 7}], "lang": "en"}
{"doc_id": "9855339_1", "wnd_id": "9855339_1_1", "text": "After 1 week of nefazodone therapy the patient experienced headache , confusion , and \" gray areas \" in her vision , without abnormal ophthalmologic findings .", "tokens": ["After", "1", "week", "of", "nefazodone", "therapy", "the", "patient", "experienced", "headache", ",", "confusion", ",", "and", "\"", "gray", "areas", "\"", "in", "her", "vision", ",", "without", "abnormal", "ophthalmologic", "findings", "."], "event_mentions": [{"id": "9855339_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "experienced", "start": 8, "end": 9}, "arguments": [{"entity_id": "9855339_1_Ent4", "role": "Treatment", "text": "After 1 week of nefazodone therapy", "start": 0, "end": 6}, {"entity_id": "9855339_1_Ent5", "role": "Treatment_Time_elapsed", "text": "1 week", "start": 1, "end": 3}, {"entity_id": "9855339_1_Ent6", "role": "Treatment_Drug", "text": "nefazodone", "start": 4, "end": 5}, {"entity_id": "9855339_1_Ent0", "role": "Subject", "text": "patient", "start": 7, "end": 8}, {"entity_id": "9855339_1_Ent3", "role": "Effect", "text": "headache , confusion , and \" gray areas \" in her vision , without abnormal ophthalmologic findings", "start": 9, "end": 26}, {"entity_id": "9855339_1_Ent1", "role": "Subject", "text": "her", "start": 19, "end": 20}, {"entity_id": "9855339_1_Ent2", "role": "Subject_Gender", "text": "her", "start": 19, "end": 20}]}], "entity_mentions": [{"id": "9855339_1_Ent4", "text": "After 1 week of nefazodone therapy", "entity_type": "Entity", "start": 0, "end": 6}, {"id": "9855339_1_Ent5", "text": "1 week", "entity_type": "Entity", "start": 1, "end": 3}, {"id": "9855339_1_Ent6", "text": "nefazodone", "entity_type": "Entity", "start": 4, "end": 5}, {"id": "9855339_1_Ent0", "text": "patient", "entity_type": "Entity", "start": 7, "end": 8}, {"id": "9855339_1_Ent3", "text": "headache , confusion , and \" gray areas \" in her vision , without abnormal ophthalmologic findings", "entity_type": "Entity", "start": 9, "end": 26}, {"id": "9855339_1_Ent1", "text": "her", "entity_type": "Entity", "start": 19, "end": 20}, {"id": "9855339_1_Ent2", "text": "her", "entity_type": "Entity", "start": 19, "end": 20}], "lang": "en"}
{"doc_id": "9876809_5", "wnd_id": "9876809_5_1", "text": "After ticlopidine was discontinued , the patient was rechallenged with the same dose of phenytoin without symptoms of toxicity .", "tokens": ["After", "ticlopidine", "was", "discontinued", ",", "the", "patient", "was", "rechallenged", "with", "the", "same", "dose", "of", "phenytoin", "without", "symptoms", "of", "toxicity", "."], "event_mentions": [{"id": "9876809_5_Evt0", "event_type": "Adverse_event", "trigger": {"text": "toxicity", "start": 18, "end": 19}, "arguments": [{"entity_id": "9876809_5_Ent1", "role": "Treatment", "text": "After ticlopidine was discontinued", "start": 0, "end": 4}, {"entity_id": "9876809_5_Ent3", "role": "Treatment_Drug", "text": "ticlopidine", "start": 1, "end": 2}, {"entity_id": "9876809_5_Ent2", "role": "Treatment", "text": "rechallenged with the same dose of phenytoin", "start": 8, "end": 15}, {"entity_id": "9876809_5_Ent4", "role": "Treatment_Drug", "text": "phenytoin", "start": 14, "end": 15}, {"entity_id": "9876809_5_Ent0", "role": "Effect", "text": "toxicity", "start": 18, "end": 19}]}], "entity_mentions": [{"id": "9876809_5_Ent1", "text": "After ticlopidine was discontinued", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9876809_5_Ent3", "text": "ticlopidine", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9876809_5_Ent2", "text": "rechallenged with the same dose of phenytoin", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9876809_5_Ent4", "text": "phenytoin", "entity_type": "Entity", "start": 14, "end": 15}, {"id": "9876809_5_Ent0", "text": "toxicity", "entity_type": "Entity", "start": 18, "end": 19}], "lang": "en"}
{"doc_id": "9883483_2", "wnd_id": "9883483_2_1", "text": "Thus , an immunological mechanism might be involved in the mechanism of pirmenol - induced QT prolongation and T wave inversion on the electrocardiogram .", "tokens": ["Thus", ",", "an", "immunological", "mechanism", "might", "be", "involved", "in", "the", "mechanism", "of", "pirmenol", "-", "induced", "QT", "prolongation", "and", "T", "wave", "inversion", "on", "the", "electrocardiogram", "."], "event_mentions": [{"id": "9883483_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 14, "end": 15}, "arguments": [{"entity_id": "9883483_2_Ent1", "role": "Treatment", "text": "pirmenol", "start": 12, "end": 13}, {"entity_id": "9883483_2_Ent2", "role": "Treatment_Drug", "text": "pirmenol", "start": 12, "end": 13}, {"entity_id": "9883483_2_Ent0", "role": "Effect", "text": "QT prolongation and T wave inversion", "start": 15, "end": 21}]}], "entity_mentions": [{"id": "9883483_2_Ent1", "text": "pirmenol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9883483_2_Ent2", "text": "pirmenol", "entity_type": "Entity", "start": 12, "end": 13}, {"id": "9883483_2_Ent0", "text": "QT prolongation and T wave inversion", "entity_type": "Entity", "start": 15, "end": 21}], "lang": "en"}
{"doc_id": "9920368_3", "wnd_id": "9920368_3_1", "text": "Since amiodarone was first marketed in 1992 in Japan , the incidence of amiodarone - induced thyrotoxicosis ( AIT ) has been increasing .", "tokens": ["Since", "amiodarone", "was", "first", "marketed", "in", "1992", "in", "Japan", ",", "the", "incidence", "of", "amiodarone", "-", "induced", "thyrotoxicosis", "(", "AIT", ")", "has", "been", "increasing", "."], "event_mentions": [{"id": "9920368_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "induced", "start": 15, "end": 16}, "arguments": [{"entity_id": "9920368_3_Ent3", "role": "Treatment_Drug", "text": "amiodarone", "start": 1, "end": 2}, {"entity_id": "9920368_3_Ent1", "role": "Treatment", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "9920368_3_Ent2", "role": "Treatment_Drug", "text": "amiodarone", "start": 13, "end": 14}, {"entity_id": "9920368_3_Ent0", "role": "Effect", "text": "thyrotoxicosis ( AIT )", "start": 16, "end": 20}]}], "entity_mentions": [{"id": "9920368_3_Ent3", "text": "amiodarone", "entity_type": "Entity", "start": 1, "end": 2}, {"id": "9920368_3_Ent1", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9920368_3_Ent2", "text": "amiodarone", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9920368_3_Ent0", "text": "thyrotoxicosis ( AIT )", "entity_type": "Entity", "start": 16, "end": 20}], "lang": "en"}
{"doc_id": "9934637_1", "wnd_id": "9934637_1_1", "text": "An unusual cause of burn injury : unsupervised use of drugs that contain psoralens .", "tokens": ["An", "unusual", "cause", "of", "burn", "injury", ":", "unsupervised", "use", "of", "drugs", "that", "contain", "psoralens", "."], "event_mentions": [{"id": "9934637_1_Evt0", "event_type": "Adverse_event", "trigger": {"text": "cause", "start": 2, "end": 3}, "arguments": [{"entity_id": "9934637_1_Ent0", "role": "Effect", "text": "burn injury", "start": 4, "end": 6}, {"entity_id": "9934637_1_Ent1", "role": "Treatment", "text": "use of drugs that contain psoralens .", "start": 8, "end": 15}, {"entity_id": "9934637_1_Ent2", "role": "Treatment_Drug", "text": "psoralens", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9934637_1_Ent0", "text": "burn injury", "entity_type": "Entity", "start": 4, "end": 6}, {"id": "9934637_1_Ent1", "text": "use of drugs that contain psoralens .", "entity_type": "Entity", "start": 8, "end": 15}, {"id": "9934637_1_Ent2", "text": "psoralens", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9972383_2", "wnd_id": "9972383_2_1", "text": "OBJECTIVE : To report a case of reversible nonthrombocytopenic palpable purpura associated with metoclopramide .", "tokens": ["OBJECTIVE", ":", "To", "report", "a", "case", "of", "reversible", "nonthrombocytopenic", "palpable", "purpura", "associated", "with", "metoclopramide", "."], "event_mentions": [{"id": "9972383_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 11, "end": 12}, "arguments": [{"entity_id": "9972383_2_Ent0", "role": "Effect", "text": "reversible nonthrombocytopenic palpable purpura", "start": 7, "end": 11}, {"entity_id": "9972383_2_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 13, "end": 14}, {"entity_id": "9972383_2_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9972383_2_Ent0", "text": "reversible nonthrombocytopenic palpable purpura", "entity_type": "Entity", "start": 7, "end": 11}, {"id": "9972383_2_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 13, "end": 14}, {"id": "9972383_2_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
{"doc_id": "9972383_3", "wnd_id": "9972383_3_1", "text": "Reversible nonthrombocytopenic palpable purpura associated with metoclopramide .", "tokens": ["Reversible", "nonthrombocytopenic", "palpable", "purpura", "associated", "with", "metoclopramide", "."], "event_mentions": [{"id": "9972383_3_Evt0", "event_type": "Adverse_event", "trigger": {"text": "associated", "start": 4, "end": 5}, "arguments": [{"entity_id": "9972383_3_Ent0", "role": "Effect", "text": "Reversible nonthrombocytopenic palpable purpura", "start": 0, "end": 4}, {"entity_id": "9972383_3_Ent1", "role": "Treatment", "text": "metoclopramide", "start": 6, "end": 7}, {"entity_id": "9972383_3_Ent2", "role": "Treatment_Drug", "text": "metoclopramide", "start": 6, "end": 7}]}], "entity_mentions": [{"id": "9972383_3_Ent0", "text": "Reversible nonthrombocytopenic palpable purpura", "entity_type": "Entity", "start": 0, "end": 4}, {"id": "9972383_3_Ent1", "text": "metoclopramide", "entity_type": "Entity", "start": 6, "end": 7}, {"id": "9972383_3_Ent2", "text": "metoclopramide", "entity_type": "Entity", "start": 6, "end": 7}], "lang": "en"}
{"doc_id": "9988365_2", "wnd_id": "9988365_2_1", "text": "Eosinophilia has been encountered from 0.2 to 61.7 % in clozapine - treated patients , mostly with a transient course and spontaneous remission .", "tokens": ["Eosinophilia", "has", "been", "encountered", "from", "0.2", "to", "61.7", "%", "in", "clozapine", "-", "treated", "patients", ",", "mostly", "with", "a", "transient", "course", "and", "spontaneous", "remission", "."], "event_mentions": [{"id": "9988365_2_Evt0", "event_type": "Adverse_event", "trigger": {"text": "encountered", "start": 3, "end": 4}, "arguments": [{"entity_id": "9988365_2_Ent1", "role": "Effect", "text": "Eosinophilia", "start": 0, "end": 1}, {"entity_id": "9988365_2_Ent2", "role": "Treatment", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent3", "role": "Treatment_Drug", "text": "clozapine", "start": 10, "end": 11}, {"entity_id": "9988365_2_Ent0", "role": "Subject", "text": "patients", "start": 13, "end": 14}]}], "entity_mentions": [{"id": "9988365_2_Ent1", "text": "Eosinophilia", "entity_type": "Entity", "start": 0, "end": 1}, {"id": "9988365_2_Ent2", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent3", "text": "clozapine", "entity_type": "Entity", "start": 10, "end": 11}, {"id": "9988365_2_Ent0", "text": "patients", "entity_type": "Entity", "start": 13, "end": 14}], "lang": "en"}
